{"docstore/ref_doc_info": {"5cc84e52-7fa7-489f-ac2a-32e2264395b6": {"node_ids": ["12bfbbf1-b9d5-44f1-944d-9eed91300535"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "e9e50c4d-d16f-49ae-b2b9-09ba12897637": {"node_ids": ["4d9a7f09-8021-4b65-81fb-f92c5eb5a98a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "74b4ccb3-3e13-406d-a0fa-4d5ccd8c88a4": {"node_ids": ["69c75384-b9ae-4a0c-baa1-487c554002cd"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "3a6176a7-7dc4-4217-b5b6-a6bbe28072bf": {"node_ids": ["0a0d989d-8975-432d-9617-efabfd1f5535"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "4a27b2b2-2241-49a9-83c1-d694a3b1b6cc": {"node_ids": ["abf5edef-6d14-4d7d-9154-16a245b01710"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "fa0add45-4478-4049-9f36-4bbbd72e5a51": {"node_ids": ["508afd52-7429-4cc9-ad2b-6e7f4d0547cf"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "a28b2b7e-71ff-40d9-8f3c-b240d46cd2ed": {"node_ids": ["eea7cf1c-2311-4850-b75a-e4ee23010280"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "ff781cfc-3bb3-494b-bffa-85c8326f8aa3": {"node_ids": ["bcc1cb49-9a5c-42c1-89d0-628f3300f107"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "12300e16-86fc-4720-9bf8-73091ef9103c": {"node_ids": ["8af70d71-cf6c-4d40-8360-358b919f08e1"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "04a585bb-270e-4507-9ebc-b0f80a58ceed": {"node_ids": ["acc47be9-b5a4-4619-b1b4-f7dc543bafbe"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "ba62259a-b46f-40dd-a519-ea084e24dde2": {"node_ids": ["e2572690-a2e6-4751-8833-d04843c1510d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "c04c6851-68de-43f7-afab-c2eef6af2d9a": {"node_ids": ["8f3ed4b4-9def-496d-8087-53ff1f75af8f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "be5bacf9-d850-4fbc-908e-4658119e1097": {"node_ids": ["7bef0868-211d-43a5-87b3-d307952a51d5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "d3bef375-4ec0-4365-b26b-69955c6cc073": {"node_ids": ["89403449-44ca-4fae-b241-812de9f15dec"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "637db76b-9865-4a56-9956-1f4a2c4e5875": {"node_ids": ["52c6dfe1-3eb2-43d5-bf09-217881d57809"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "66bd758f-415d-4fcb-9280-fa22df891619": {"node_ids": ["8cd8e432-af4c-4f3b-bd85-697502da4083"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "cc23d20b-1441-4e08-8377-88f08689f558": {"node_ids": ["6d6a63bc-4d10-4e90-8723-fe7e11cbcb89"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}}, "e6f43136-aa5d-49f5-b814-329a296da6f0": {"node_ids": ["bf48b5e2-88e4-446b-9013-2aab4d3111f5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d972c690-7fd4-4ee9-bc13-d0f769f68721": {"node_ids": ["976e1a38-35aa-4c2b-bef0-21bf9f3fc59e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "59e3d050-5d9f-4a77-94ed-a5f5fa109136": {"node_ids": ["f627f81b-721e-4dbe-9dcd-262751c0f88e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "af01b4e9-edb5-472c-93d8-894d4b32dffa": {"node_ids": ["dea046f4-632d-45b8-a4b9-61cb2b142024"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d2424e2f-847f-47dd-8c02-d4deb09e5710": {"node_ids": ["f68be336-28ad-4818-8848-df697737c1f2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "42911f43-0b70-4674-928c-fcccc1462c9d": {"node_ids": ["493561d0-3b31-403d-bca2-0b85c027f047"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "4ef0ff0f-c249-4d63-8acc-5c4df7b912bf": {"node_ids": ["51d2371a-b199-45f0-bef6-8912d7fcc563"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "4c8b0266-eb33-4241-bd0a-94456fbe6034": {"node_ids": ["1d091764-94cd-42be-b387-a2af886f46ac"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "01c17e6c-bbbc-47de-88f1-aa8c7b93cb62": {"node_ids": ["c5cacbcd-a282-43d4-a0cd-f0de9a5e7402"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "53ac8d95-8ed5-4398-8613-7d87e513363d": {"node_ids": ["ce874262-8e2e-4fbc-9f89-699bc6e8e889"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "cb1de74d-585b-4c20-886e-2081c3aa2c19": {"node_ids": ["ea39294d-6c99-4bb5-b4bd-3f999bfbd0d9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1def02ee-a12e-4e6d-96f4-7fcde7cbeadb": {"node_ids": ["2857959a-a3b6-4b63-95f0-707e4a52744a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6fa35e93-d004-4acd-98c0-ff8b44bfee13": {"node_ids": ["06eca883-e31c-4f1c-9687-b7215ea26427"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "acff764f-19de-4cd5-8013-acd83cda2667": {"node_ids": ["0fff3251-c4db-47a0-8088-4d24784bdb84"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "db8fa304-fee4-499c-ad1a-872980c85845": {"node_ids": ["aa0122f5-61e3-4b36-b156-04f126ea617c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a593f579-2bbf-4517-a269-b80d6aa6f111": {"node_ids": ["2d927dd5-1c23-4a06-aaed-603be3a12742", "bc8b3740-6791-468d-b088-cde0d5cf8e08", "7dbd2c33-0b0b-4f6f-b5d4-6d4b121bdf39", "3f0456b9-7b60-40b5-9a4a-5f82eca3fdc9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "0b0a029a-56bc-43b2-88d8-88a0c75b2527": {"node_ids": ["55e4e3c6-8615-49e7-b4c9-fb0dda0a0c63", "63db807c-c6fd-4a7d-828a-7aafcdae4d36"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "43fb8e82-07ae-4173-8391-dc4b0fd48669": {"node_ids": ["9f8b574d-b38d-4a56-8ec2-33adb1ce3ef5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d1be9396-079c-4b78-88bb-4fd37d811428": {"node_ids": ["aa6d3512-4ad8-4a0f-8027-0b4c8ae8d5f3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "512f94e0-dbed-48a1-afe7-dac48f9bfb30": {"node_ids": ["d8929ec1-a649-46ce-8cf0-c8a5aaa6eeeb", "75d823b4-f7fa-462b-b996-866c9cae4bcd", "148db91d-5de0-4e1f-846a-32c30e0498a5", "415d18b9-474b-4cfb-b9b0-8a2fee063e69", "af86ec6d-75e8-4291-b54c-35facc4607b9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "00c59cb8-b14e-4521-80a9-88414b8f18a2": {"node_ids": ["582f0cbb-99d4-4e24-b400-98b1cf3abb66", "2a761464-e219-4196-ba6e-f056757df3ce"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f3e0ce61-f519-4d4c-a4dd-a165c95cc1fa": {"node_ids": ["930ae542-8de8-4f45-b028-1d7e9d54d38e", "4b95ad8f-545f-4986-a89e-759479fccf46"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c5b6b360-beb5-4893-bec8-60f062a7cccd": {"node_ids": ["1726fdd5-a145-42c2-946e-eabd165612ce"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e9386ab6-405f-4079-90e3-ec21aba2fdf7": {"node_ids": ["e60365c9-1c38-4576-a509-98d144269e58"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c8c12c85-3c54-470d-9783-53f5cc8733a7": {"node_ids": ["b0cf5336-6072-4708-92eb-a50acf539895"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "0706e444-41ad-4d13-bb7f-c9ecdffd575b": {"node_ids": ["bc342e9a-f742-4fb6-acd6-0f4eaf5e3b61"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "50a7ec3f-9c6e-4759-b1d4-54fbf2b426e3": {"node_ids": ["3187a720-2c40-4d53-9f21-a0c47b623058", "e83811b2-7ce8-4dc9-a0cf-a74b47c01120"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "76d4ba1f-23ce-43f2-9743-0b6e3560c1e3": {"node_ids": ["8853035c-5944-4b75-a801-deaf4d3dffb3", "34d10113-81d5-4b44-882f-efeb66f169b4"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "007931ca-7497-4494-ae71-d1b69d701b45": {"node_ids": ["79c5a763-c636-4851-9f40-08fdad8429b3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "eeffd6c0-12f5-4a5e-a9e6-51fceeb60870": {"node_ids": ["1af0d2e5-9e93-4b98-aa34-dddadd8628c9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "567ac3f9-8160-429a-99bc-96b08904bc83": {"node_ids": ["5d20cd0e-395d-46ca-bd9e-9c3d990cba78"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "403755d6-e286-4e3c-b335-abf570a2f25d": {"node_ids": ["d4b0fa38-90ad-42fc-80d2-0c0223900d6c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "8674df02-31c5-48eb-bf7f-55eb9d17d8ac": {"node_ids": ["88c202f8-cac4-421b-a539-55cbe190522c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ddc59ad3-ef77-4c86-a2e9-513ac5d53697": {"node_ids": ["396cc111-a720-428b-92bf-4e96ff2a10b5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9f36b2a6-6d1f-4cc3-86eb-2a06ed41c1f2": {"node_ids": ["eba6571d-e975-457d-8190-230e4eaaed7b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "fe1fe893-f9d1-4f45-b093-1adc8c32e232": {"node_ids": ["0250f366-77d4-4972-b042-35ed862fbe30"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ade8b0cd-5fe2-4225-ace0-d88f8bd503e4": {"node_ids": ["bb454bdf-d7b4-4396-87cf-702f2fe28922"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "85db7d61-406e-4006-b6dd-63f8c027b04c": {"node_ids": ["d68205f4-24ed-4aaf-8154-830524857362"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "01ea736a-9c16-4c69-9ab9-3b2b7448815e": {"node_ids": ["53b66f95-aa2b-43d0-be2b-02b25082d8f7"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a9dcdda0-ff0e-4483-bfbb-7d83651a86ad": {"node_ids": ["5126dcfe-4b6b-4c51-a011-36621b0f1fce", "fba6cf3a-53c9-476b-86e8-c52d18972dc9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a81321a4-9e4a-441b-848f-8fc67c7466d5": {"node_ids": ["b27c6366-6ebf-4b5a-9737-df546dedc359"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f4ea5b2a-37fc-4a62-8b0e-c1249cfd2075": {"node_ids": ["32f225d5-84d6-4b06-bdf3-2cee403916a5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "fa86e237-7412-4906-b592-63e7774a6075": {"node_ids": ["4836db2d-7e2e-4b1c-9c28-2122125759b3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a459c278-cfb2-417d-a339-7c5ae3550b10": {"node_ids": ["f84b52d7-e639-4ac9-acee-29c42c56545a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a33d7137-d933-412e-b3b1-c53fc29004f9": {"node_ids": ["02d05981-5f0e-4aee-a651-15a0bd6bbf6a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "86e29a4c-8220-4a65-a6f1-222b9c54f25f": {"node_ids": ["eb84caf7-445f-4eeb-a5d7-8b4b1f38fc4f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c27d1392-fa30-4f92-be71-84a2a668245c": {"node_ids": ["68292c4a-41fb-4b9d-ba88-453a8d0dfd5c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "62f73e79-d0fa-41c0-8a3f-eb55f0ef6fb3": {"node_ids": ["eb0621d1-3b9f-4b0d-8276-0e153326daa3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "15ac59e7-059b-4429-ad1c-58d1c4a4233d": {"node_ids": ["a902bec2-0082-44b2-a7da-7b7e5aa6206c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "12009ceb-9cd7-452d-8dbc-e586beba08a0": {"node_ids": ["bf822dd0-5c24-4cbc-951e-a3d4b388cdf9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "48dc58f0-d511-452b-9110-e27041456e3c": {"node_ids": ["f9bd162e-3232-4b42-801c-016d3d4f1c6f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7068ead6-bff9-4210-bca9-e8ff5ec448d5": {"node_ids": ["23f18b3e-757b-4cfe-8ec5-6623dd7fd613"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3063a9fa-607b-4d2e-bc02-cbc66075c395": {"node_ids": ["f6a91855-338c-4a29-b0ee-69c60576b6f2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b3c225e0-4e56-44fc-9b33-4b4e5419adbb": {"node_ids": ["831b1cea-6418-42bb-adbf-c842904c9d98"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "5aa4cf96-662a-4d7d-940c-ea2af130484c": {"node_ids": ["b1779acc-465d-471b-8eff-721f3b33ceee"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "29ce36da-cfa6-4d5d-a2c6-0afb63511d0d": {"node_ids": ["bd39dde2-cfc8-4bd5-8617-dcdd690c52ff"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "731d0a10-87ef-4e01-8259-076ac86ad025": {"node_ids": ["cbbdde6c-3d0f-40ea-9194-f72a662a069c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "98996976-478a-457e-9906-40283f4b3b82": {"node_ids": ["468d8044-ac37-433c-aa0c-f2d67750fc5d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b29a5b4e-30af-44c9-bf34-1c068b9009a0": {"node_ids": ["94ecadfb-2398-4889-8be2-87430f62aa8c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1dfbd6c0-0b14-4489-9c38-599fa7edcf21": {"node_ids": ["e73afaee-4a88-4662-86d2-d66e1033842f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f26210d0-98de-4a96-bf3b-59ca2bb817bd": {"node_ids": ["30c54383-81ca-4567-a7de-cb201687dcda"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "489cc81f-ad58-44c3-9c60-97183ff4c076": {"node_ids": ["e102594c-5637-462d-8905-0f970ea0e04a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e9767c28-87a9-46de-b5c2-8050c7cf473f": {"node_ids": ["8a361c8b-6598-4e6e-8429-ce1356e77a1c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c09c7c3f-bdab-4052-be34-59c24509e7f2": {"node_ids": ["b5e196c5-c97a-4022-9658-0d3b2b5a0012"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1079c67f-84b7-489f-b08f-f0a27d3db911": {"node_ids": ["208aecd1-6596-4620-80ce-db068a4490cd"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "eb22fdff-fe5b-4595-9141-6d614228b3e0": {"node_ids": ["ed5aa648-d32c-4ae1-b5fb-11ab9ee7c1ab"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "72420c7d-b97f-4629-90d5-7707ebe04528": {"node_ids": ["9dd98725-cbc3-4230-a9e4-721ae0eec176"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "fb49db7e-8189-46db-bdeb-7fe0227c91fa": {"node_ids": ["9a79732b-d597-4866-9df1-ae5889296399"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "11f35436-25e2-4f7d-9c43-a3dce47996be": {"node_ids": ["292ba253-c450-47bb-aa99-8f8b44bc624e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "220da70b-77eb-4401-bd40-f07c9a039d58": {"node_ids": ["3b1fcf63-c013-4619-a89d-443aa21b3023"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "20b26d4c-6ad2-4b3f-9856-23e4656d8a23": {"node_ids": ["80ba2782-dd65-4974-8182-b7ff344dbe05"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b29aef51-944e-4fa2-a47a-eb3a4a09beaa": {"node_ids": ["2d995442-5846-4cd2-a2d5-e73bb0e86fb4"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f52c9fc1-53e6-4708-8b84-c2584dbb85a4": {"node_ids": ["8303726f-187f-423b-9609-f28144218107"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "43ab2c44-01f9-48bd-b692-2cc20871dfd1": {"node_ids": ["4aaa129a-a913-42c5-b0d6-3cb0797ca623"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "66ab9ff0-f98b-4030-b6d8-a64dbab51deb": {"node_ids": ["f3d25c71-e7a5-4625-a140-1c521d5aaff6"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "eb3b34c2-63f7-4d2b-8e5e-06da1bcb5b22": {"node_ids": ["3ee2e69d-c712-4592-bf4d-b82fb5542889"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ea94617c-964a-406e-94f1-f0fe9e985f32": {"node_ids": ["2f1257a2-32a1-4272-8582-16cdff15ae4b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "313a2366-cd6b-4063-901c-03a9e44ff0ef": {"node_ids": ["f0bbb000-0428-4e8b-b8cf-c94ca4fbb6fd"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ae26847e-8873-4011-889a-50acd7402270": {"node_ids": ["ec12dd59-5add-41d3-a44c-7ae672d20483"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "acb1c4fb-e545-47f0-ba4b-86b81c2ae6ce": {"node_ids": ["2693b941-0715-4834-aa6a-2cea3c53141c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "59327998-9b68-414e-b5cd-5acdf43c0ac0": {"node_ids": ["5c91ff1a-7b8c-430d-95f7-e8115e04bb75"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "00e23163-96f6-4f04-873a-979543754858": {"node_ids": ["69e59392-38ff-4578-9548-c5976a6f38e0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "90636f21-8a19-4c71-8608-76da9c30d726": {"node_ids": ["e277a41c-91bb-4aa0-bef1-dd5b233becd2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3a352d79-8f01-4f60-a2cb-ddb081454c0b": {"node_ids": ["c57eef32-13d2-4bb7-b3ad-4c03a91def6d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "cc3ca0f3-cd8c-4f5f-ae7a-82387eb8306a": {"node_ids": ["1e72d523-3df1-437e-bbdc-b70e8e3d7f07"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ad6a8f8b-7f16-4815-8932-6d98ff9c9312": {"node_ids": ["2752743f-bcc2-46dc-82ce-935b23f3dca0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "68b9230c-ee63-4cfb-9ad0-bfa985cbf8ce": {"node_ids": ["a6fd29f5-aab0-4fb5-a116-8dc773a81b41"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "855dd3d7-3a78-4d55-874e-12c4c38bc7f8": {"node_ids": ["465cfca3-3b44-4334-9e0e-ff14e3038c96"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9d9538dd-9ba6-4a7b-ae44-70338d4b63ce": {"node_ids": ["b3f47417-4767-47ab-82ac-ca67c5c00742"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7900954a-c796-4e35-9508-efd12118066b": {"node_ids": ["3417d99c-4acc-4367-8a9d-8f0fcf69aaa1"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d24614c8-16fe-439d-8707-6409d3ad2ea2": {"node_ids": ["2b002f52-0b24-4a75-b997-21442d8c2bd0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b32c7cf3-8bee-48a2-a66a-7c1c9d759abf": {"node_ids": ["4b0e758f-b2a4-4d2d-8f71-31dd4f774663"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6384ebff-8022-4289-abe2-9e08ea6db172": {"node_ids": ["85a4de42-a9ea-48b5-8ec1-36de138b5ad8"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b4f7b7c1-248e-4773-b69b-807db7d36bff": {"node_ids": ["6a8801bb-dd32-46cd-8a53-669512e0734b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c2f64ffa-deab-48ad-96a3-ba7a278e1670": {"node_ids": ["3d24e3f1-75ab-43d5-b7c4-9757ec72d0d5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "038be2f2-2613-4619-87ea-a10a0039510e": {"node_ids": ["4479bab3-8309-4b0e-8e2a-ec5f6dd49b87"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d76e6ea5-bc13-438c-9e6b-60206770cbaa": {"node_ids": ["49f4d782-47bd-4a62-9476-46196ec307c6"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "375d1d63-dcf4-4a27-983c-e1087a3fdf4c": {"node_ids": ["e5a55b4f-8f94-46fa-9821-2a4a80ef1b88"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1b7c47bd-533e-478b-9ad8-f00f0f20ca51": {"node_ids": ["2312d4fa-b8df-40b3-8352-b699ba518cb3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d5c26cf0-1296-4c1a-8df0-0f57a81a33de": {"node_ids": ["9ca77fa8-aafb-4098-910e-fea3bfd01a5f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3f6c49da-f89a-4070-b978-f8b29501a358": {"node_ids": ["a0bd5e49-5c5a-4d25-a7fa-665bcf7f270d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d1c4b196-8861-4274-a818-fec3b0be49a9": {"node_ids": ["35f097a8-4e0a-41d0-9d8e-79b3aa3d0394"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6fb4aca7-f879-4edd-9dca-60c982dfb96c": {"node_ids": ["60219114-1ee5-4c6a-8eea-a467dfa10f92"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "db5aac8e-d115-4e64-bf7f-4fd43fe9ca84": {"node_ids": ["2bb66447-d3e1-4a02-a687-ea0b1ed26e33"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "992614f7-f20c-4340-b618-20868edcbc3b": {"node_ids": ["0ec5c557-e863-44a9-92d3-d3cf0ec3bc4b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f3f090f0-17da-41dc-902a-e19b9693d59c": {"node_ids": ["406f687a-16d3-4655-876a-5fc585ffa03a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7c19bf4a-c6d7-4543-a778-6113d4bbd187": {"node_ids": ["79de6f11-dba2-44f4-9498-7f69ad5289ec"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "460807a3-82eb-4b47-a45b-940c6aad46cf": {"node_ids": ["d6195b68-94b0-4363-b9a0-1f92b1108085"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6cc29c47-5332-4726-beec-96dafa0a46be": {"node_ids": ["adbdc4e1-9064-4883-9c8a-cba21692ebfd"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ee453ded-3922-4b8b-b082-9a164373ed61": {"node_ids": ["3431e5eb-23cd-46b1-b13f-565a5671ef63"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "2613e220-cf71-42e7-bceb-47782bce63a2": {"node_ids": ["53b276da-1071-4669-94e0-20722cb94c74"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9463c141-aded-4652-ab3c-c4990daa2923": {"node_ids": ["d8d79ac3-29c4-440c-9543-8b2a1494d6b4"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "85ddc4ac-7e21-4bdd-82f1-a26b6bf446b9": {"node_ids": ["210f8336-be58-4c71-b23d-281f0f821e19"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7f635757-632d-4748-86ce-ae7609268a31": {"node_ids": ["40b43e3c-8c3e-46ce-98a0-d8c4dfeb99e8"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3edbb0c7-985b-41ed-869c-70d6a3ad1753": {"node_ids": ["76059695-a6fc-4d4e-8072-277af3e8f49a", "8bae01e0-c5c7-4af5-8538-1efedf85fbea"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b41b90f1-0078-4a2b-ae30-5306949207b3": {"node_ids": ["f7013c54-fa38-4b3e-a6cc-49636cf0db86", "d923e09a-d584-4103-b147-fa829a5beea0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c3d5e15b-3a2a-46db-8d47-33cb20f2779b": {"node_ids": ["00296e25-99e4-433f-a9aa-93b6f39c2202", "6611225f-f0b9-4364-bc02-73fad8398a8c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "0a1e5bb8-c01b-4f34-8b5b-9227b342f2a2": {"node_ids": ["537d976f-2b01-4126-b980-62762e2c4fd3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3b38f7eb-e40d-41ed-bbaf-f5fc2929d3d5": {"node_ids": ["ce8f9408-c81e-4dfd-be19-de7c64083a02"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "2d2acc2a-0840-4616-9ecb-f2ed5605f2d7": {"node_ids": ["0bcd0e6b-eb31-4b7f-9b9e-e388402b6ddd"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d7058f0d-1005-41c1-a902-b46c2e7be85b": {"node_ids": ["b5f2d3f7-7c51-47f1-8358-4e58bcab9d1a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "df452501-dee4-47cb-bf1c-85867286d2a5": {"node_ids": ["bbd1585b-68e0-4f41-bf79-aeb7fe52505c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1683fc9a-2286-462f-9476-593909d379d8": {"node_ids": ["9a485bb7-e5e0-4ad9-9416-c42737a8dfc8"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7de4552b-db33-4db6-afaa-79864b7b2384": {"node_ids": ["d4a57fba-858b-4498-8d5d-4d50dff123c7"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "cf8d35d4-4706-4368-9f93-6def7dab9980": {"node_ids": ["ab8098dc-a83d-4812-be9e-7f43a6d7aec5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "358e92cf-6cbf-46e9-94d9-1dd62d54dab1": {"node_ids": ["0113205c-6803-4fdb-9c03-8d499d191298", "be1a0711-0880-4610-86cb-af312eeb6233"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "255cff82-532f-46b0-8073-e321a2f14f82": {"node_ids": ["2c826dba-e412-4b47-b863-47a1764dd3da"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "679dfa8c-ab07-4e9d-9c8a-5595ebe0f0e7": {"node_ids": ["3d111f06-7bf8-4866-85a4-f23facab30e9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f4a80547-3a29-4741-97e7-acd81cd6079c": {"node_ids": ["5a17299c-de3a-452f-b353-d35ebe6eb8d2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "42444b4f-24e2-4bfe-9bc9-9ad3a7b95e48": {"node_ids": ["ed1967ad-ec71-4ad9-90fc-bf7980c40f78"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3fedaa4d-dbb0-46da-9109-cbac88a63cd6": {"node_ids": ["66d543d3-bcb5-4085-b49f-072bbc37a222"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7e679b46-87cb-4db8-ab40-6f03dd3cdf09": {"node_ids": ["a611ea6f-5795-4343-b978-5d4d28b32e0a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "66385e9f-6c2a-4929-9638-caa5f8ef824f": {"node_ids": ["e611ff35-a2cd-46a0-9b2b-c2f51fa6de97"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6e8bd49f-b7d2-439f-899f-63d871204d62": {"node_ids": ["203d003d-e414-4c84-94ed-2f02618a9d44"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e6ce08c5-59ca-49e6-a053-e81f5321e5c3": {"node_ids": ["2328d5d0-9a9b-4273-8e3d-6bc07710b1e0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c0de51ca-cab9-4299-9997-2a49d33a85dd": {"node_ids": ["8530d91c-c5f4-431b-b929-9e52657293cc"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "95f9918f-925c-4a2f-a198-b068ffe1140f": {"node_ids": ["9c223bfa-a549-4a10-8620-e00996a9d2c9", "7f70a74a-4ea8-4205-9262-87da14ad5f96", "513d3268-e6c7-4b6a-adc3-b67af432ad36", "2524e69f-355c-4000-8517-9c8a2cfa482c", "4f2c792e-676a-484e-b56b-7344fc16d2e4", "04f32862-4b40-462f-b6c5-bd0852ba7192"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7e313f4c-4894-4228-b2ff-25d5a6cf6c04": {"node_ids": ["25e3d104-0da5-4de7-8340-16559c6c79d4", "84892c70-e79e-4d64-ac4a-132d7904e776"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "db37cc98-edf6-4f92-9751-e2a87808f93a": {"node_ids": ["552f9b62-dad0-4fe7-9f9b-32475c5faeed", "b23510cb-ed6b-4ebf-b338-e88ce69a79a5", "f317cab3-8f90-4f1f-b17e-ce12bc01b097"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f876fa40-1b85-435d-a4ad-87b8ed0f7c6e": {"node_ids": ["80eeb05c-311e-4663-9f56-071539c09092", "48663510-780a-4688-98c5-8ffc91aee337"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "953b2c77-73ee-4ad3-bc18-c108f70e547f": {"node_ids": ["55504db7-97ef-48ff-b335-297cf972639a", "5384b178-2f6f-4b8a-ad34-993406afddf0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f28a947f-7736-489e-9265-01a1bec5a3e5": {"node_ids": ["d808fb79-a234-4b2a-b5b1-c6f960642db2", "adbd8b7d-06bc-4de2-a109-0d7bb26d28a9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3e41726d-dea7-4a5d-ade9-04f77a3809c9": {"node_ids": ["233ece1d-5b60-473f-8e7d-e288b6fe8341", "c600a6da-dbe8-4897-a233-e75e01731138"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3e900d67-ee0a-4cde-b62d-01837b4879fe": {"node_ids": ["bae81b8b-cc9a-47aa-907d-669f2e45b83f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f67be25f-680f-4aee-bc4a-a4f7ed02884a": {"node_ids": ["014b673d-9231-4075-910c-d36c3e75ea78"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d3ad766b-11f5-4fb3-83f0-95e555fb81ec": {"node_ids": ["b2b745dd-ae27-460a-a597-29802a049ea9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f37976c5-8a86-401f-abb4-e26489d3ab44": {"node_ids": ["2f640404-a5b3-428f-a4eb-36d56e4aa18e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e74e553d-7084-4ffe-b3f1-edcebe2e0242": {"node_ids": ["4a456271-4637-427b-8264-e08713edcd4e", "84a4a385-7593-4491-a0eb-b615db5f8716"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "8692462e-5b2f-47a8-abf6-b054f99557fc": {"node_ids": ["0c5a36c8-c046-44b2-9b12-9dcc10309220", "cd676445-c694-4e31-b664-3d546406d7d0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "715b650e-7245-4a0e-a13a-1912ad4f686d": {"node_ids": ["799d3667-0533-4178-a3d4-09e27c873624"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1de2cef1-d96e-4b89-a4bd-db7b12e14d54": {"node_ids": ["8f292219-0080-44e7-b639-d53c416483ba"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ebd2a808-21fb-44af-864f-e292f3c49b97": {"node_ids": ["cc6da427-fddc-4f19-ba96-cfd76fb5befb"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9148db7b-6a59-423a-87d0-0461afbc4fc6": {"node_ids": ["2b5acf84-c938-4712-9139-50f69eec4db6"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b0dba5c9-90c4-43b0-8a7e-80550665096a": {"node_ids": ["8f285835-3f2a-4f78-bb75-7fa0c05d8398"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "92c87418-61aa-4986-95b5-793c4cc07d98": {"node_ids": ["e7347695-0937-42d9-b760-e5d783976c17"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "41cfba3e-eafd-4c6d-86b5-880aa476c9c5": {"node_ids": ["fe92fffa-ba4a-4848-8725-4853cc961d7f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "29ed5b1b-e2e4-46b2-8abf-ef2646e29758": {"node_ids": ["5b777f47-9430-422a-a18e-ed6856e31e2a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "05e2b3a8-8a71-4b6d-9fa7-ebe3cca57788": {"node_ids": ["850ec10a-0b9b-4ecb-8852-e1d0dc3ff5ee"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "23f8e959-43bb-4f24-a05d-d168c96fdc02": {"node_ids": ["6692f1e9-bdb6-45bc-8207-c5c2f1830834"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6d6edacb-876a-4313-975e-7e621302ed0c": {"node_ids": ["29b8543b-76fc-4221-923c-bbee9f3086bb"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "994fb151-cf88-4e42-b7b4-38a2c1d1a993": {"node_ids": ["0e77ba2e-481c-4540-85f5-ec675ba6c005"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "777f4562-88a6-4a03-99f0-4537778d2a84": {"node_ids": ["ae99e7e6-21bc-47bb-a4f9-e247d4cbde7a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d9bec198-6f9b-423d-8c39-33ea89f68d87": {"node_ids": ["0612e6f9-36b4-4070-a628-602df130cfca"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "4246746e-22e3-44e7-9661-3446c77b5297": {"node_ids": ["e3b8a491-dac3-436b-bd31-2d701daa0566"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b9ad44e7-e6c5-4a1f-a619-cb07fb64cde2": {"node_ids": ["77eb6720-36c5-4c4d-a9ce-ddff1c1f6b29"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c4189724-3c6f-4ae3-8eb4-f7f4d06aff6e": {"node_ids": ["4a9863e9-1495-48f1-a6d8-6873615ec3eb"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "07bb7cfc-3693-4c9a-b022-bb8b4dd96b4b": {"node_ids": ["fbfe5ad0-46fa-4b1b-90b8-31943bb36701"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "45809fcb-6c1c-4861-b3f3-14430fea4a79": {"node_ids": ["0186137b-29ea-4e0e-a4b5-f45f69b2c951"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "64f19f01-feaf-47c9-a8ef-de66a2e7831e": {"node_ids": ["3ef56466-81ca-4160-b583-0079e360f5ae"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "489a460f-0d59-4296-921d-5d3a67e85f95": {"node_ids": ["e1cb826e-28ef-44fa-8203-60cb32ac568c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "064d57ce-11e3-41ac-9389-c95647d73d24": {"node_ids": ["c5246e1f-94eb-43ab-966b-3f53f4868ff0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "63d736b4-37f1-4b24-91d4-bda2321b2eb9": {"node_ids": ["1c0c58a4-0242-459e-bf26-c69f5832f262"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "53b930ad-d34e-4edd-9f51-7aae00760f1e": {"node_ids": ["ef852b94-00bc-4ded-982c-2a23b446762e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6ea854ad-6ce4-454d-b9b6-378b717f0820": {"node_ids": ["be84f6d7-a4f0-45f4-a851-a766e20043cf"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "2d491b58-f088-47fe-b5b5-7153eaca73d5": {"node_ids": ["aa7f9aed-a75e-46d0-a67d-784cc6cd9efb"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6efad591-ba4f-42f6-868a-5568347d9fab": {"node_ids": ["c58dae28-4861-4ac0-9e73-833bfa951707"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e50651fc-b850-4645-9f54-4204000f9d3a": {"node_ids": ["68da7bd6-1723-47da-beec-61e962085acd"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "cea97c02-6934-45f7-b113-abbda869e7f0": {"node_ids": ["9a3612c5-96ff-4e25-a2d9-4648eba181f1"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "15157e48-3d18-4b8d-86f5-1f7ed3860e2d": {"node_ids": ["4980f448-9bd1-4fc0-aea9-84b4a17c9049"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "4738a933-9e3d-4b0c-a047-8e5b85c0208c": {"node_ids": ["cc2f3579-5afb-4ed3-8945-a8f8b4648da3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "fabd0299-93dc-4a9b-a63a-24c619e5819c": {"node_ids": ["21ddf95a-fb2a-4f6f-8cf3-c7dabc0bb84e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "454128c7-fd52-4d5b-9e26-9d4a5eaa4f03": {"node_ids": ["7f908bfa-48a6-4105-859d-a090fe592818"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "45a301a9-4f00-4820-a448-bbfc58e8cd6b": {"node_ids": ["bf521a23-cc7d-4157-8bdd-2c1657e3d434"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "afc963e2-5fa0-4998-a7e0-64fcf93da6ab": {"node_ids": ["43277fd5-d3ff-46a9-87fa-504c58e37ad9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a8c5ca9f-0c9e-4615-b517-c07e84825a76": {"node_ids": ["607f4f6b-b250-49d8-82fd-d890df8c263f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "0c67c9dc-369b-43e8-acc7-2b5b5661f438": {"node_ids": ["1408b092-6278-4068-96cd-56ec682754d1"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d48d161c-6144-4a3f-a229-dc3afcc4a658": {"node_ids": ["60bf4709-29e8-4b8f-a1d2-f814499c80b4"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "164cb639-4aaf-4f1e-ace4-87caed5f234d": {"node_ids": ["ff2d6748-40a8-49db-8f83-1144106e4a2e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c6009284-b37a-4d94-bd3c-fdb883fcae19": {"node_ids": ["1a1ad8d8-52c6-4c13-b89a-c7d4a6c1f1e3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "88d3ccc3-78e6-4a3a-b212-0588eb650bd0": {"node_ids": ["5b56de18-ab46-4c12-b313-336ab970b3ef"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a3a3ccd1-8130-4ab1-a112-16f3ecc4e382": {"node_ids": ["47c25196-679b-4129-8afc-8e0ec11afd83"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "cf2127f9-c0fb-4e8f-97a0-8a14ae67e305": {"node_ids": ["a41a630c-4eae-4df1-aaa4-f2c451396a18"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "07cf93b7-7a75-4eba-b310-98aa31de4dc2": {"node_ids": ["93a33755-22eb-4192-8242-516f523b5beb"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "bc0dcb51-73de-4a08-a309-c44ecd5ad4f2": {"node_ids": ["9a3fcad9-6f27-4673-9d1e-ea331b4cfe5e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "673364d1-dae8-4197-8a80-1421b12b0bee": {"node_ids": ["eaf85fa1-18af-40f9-83a2-9f9d842b7810"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "5044a01e-72a1-4546-81f1-3399eea41f10": {"node_ids": ["67d9ad05-f86f-43ab-a861-3aa2b31d2181"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "39552474-c669-4f23-9aa1-894b50bcfad1": {"node_ids": ["2dded28f-04f2-434b-a0ba-4534cf625b51"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e371823b-dfd2-4370-ae31-050894bf10ed": {"node_ids": ["1a3cd8ef-0dfb-4620-a34f-abd8f3bc46f3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "bffa6e6b-338d-4a9f-a296-44cf332e21b4": {"node_ids": ["80004ae2-0808-4554-92ac-a8cc723763a1"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1ea880ea-49bd-4900-b1b9-49270b79604e": {"node_ids": ["2b8114a1-d710-4a41-948d-e536e30617a0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a71e27ee-9963-44f0-8c82-f806f976f893": {"node_ids": ["b335cdfd-c386-48b0-a9f3-4a224d5a4f53"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e8b65a57-b562-44e9-856a-abe3939013e5": {"node_ids": ["63e1c935-2ddc-4ac6-a5ec-2265170b048c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f4adfd8a-a0b0-427f-9292-21410c18f960": {"node_ids": ["a5523900-e787-4cb8-a14f-0eb36fd465af"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3c2cfe92-b8d3-490e-b763-9b71064c8ab0": {"node_ids": ["42007811-066c-4622-b636-bbdb7b1f938e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "cbbd9861-4751-4ed1-82c6-cac1ec6a487c": {"node_ids": ["fd13af9b-107c-4cbe-9759-bd3c8b944b08"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6aeb67bb-8858-45fe-abaf-bf53ab18a19d": {"node_ids": ["6c48f058-0a1e-44bd-b38d-ef478a601c98"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "318f2c95-d5d8-465b-a5d2-c4c61e4fe109": {"node_ids": ["7f821f97-a1b4-4b70-9385-34ce9b5e15b4"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c0349648-42ee-430c-8882-95e1240da141": {"node_ids": ["f47e5d59-9fd7-433e-9cdc-624cbc203499"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a64ab452-e6f6-4e8c-8ff4-7db12c8eafc6": {"node_ids": ["950061fa-fca2-4fa8-8f8c-44eb624f5645"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d716d36f-b51a-4e51-a9f3-1d40dcfad028": {"node_ids": ["7b423dce-121d-4448-b542-3a8b9a389864"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ff37c69d-66d3-467b-8aaf-7b5252751b93": {"node_ids": ["d6784c45-defb-4d35-a812-c2df9e6d0fe3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9926536b-7a39-4ac2-abc5-9a3392a7a534": {"node_ids": ["56cc54c1-34e7-480f-9984-4236c2369312"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9b8252ce-12d3-4f4a-90bc-f7be90418548": {"node_ids": ["b86ebc7f-15eb-4cc9-ba95-76b05f307044"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3703b5f4-67b1-4eaa-ae86-9d6bc002d241": {"node_ids": ["6b2c98b3-4949-420a-9b65-97ea56422940"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "95797838-538b-48c4-9324-5e0bb3dacea8": {"node_ids": ["b1e05b68-57e8-4cae-bef2-2cda85a98541"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ccdb31ca-832f-4bde-b973-073a70d97fbb": {"node_ids": ["ddbbc828-9dac-481c-8943-50cf0910f274"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "797ba812-d289-4fe5-a5e5-1291c9e653ba": {"node_ids": ["33cc0f41-75e9-45ad-8c2f-7a63382d551e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "5d778d96-ec95-4e96-aa35-d637ac9ab7d0": {"node_ids": ["91412d37-c240-4dff-bd16-0503f8e9a73f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1e1bcf58-c00b-4d67-be6a-43dc9b9b7b1a": {"node_ids": ["6e63ea0a-7a41-479c-aaf2-2ac788e9d436"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "423dd833-4f87-4dcd-a92b-2a77b2bc6c2b": {"node_ids": ["252d911d-b755-41b1-bbb9-0afc5be912e2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "43f8c93d-8ee0-4114-95cc-757bea57b286": {"node_ids": ["682a5002-dfbc-4bba-acb0-688493306cc1"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "0ead8a03-8eee-42bc-abee-04db89671c33": {"node_ids": ["a1fbfc5a-a004-4cfc-8974-8250ab255c15"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d6f9c3da-97ca-4fe3-a576-7850451de98a": {"node_ids": ["3465a8a7-08a7-48c1-9001-cd21149e8593"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e4800953-4c31-4030-a9a6-caad06701856": {"node_ids": ["bcddad49-a66e-472f-9601-756d0370afa6"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a978061c-778e-4e49-98e2-ead3d2d52681": {"node_ids": ["2198afb4-4e18-497b-b8fe-e2f3eb6c6b59"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6a97e2da-cc0a-4dd0-a334-b3debfbfc855": {"node_ids": ["19913956-bfd8-49a2-b4c7-ff7c59325a55"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "fabc46c3-44f5-4111-9178-6ea27d1811d0": {"node_ids": ["5359b077-9d9a-4c49-96ec-e31298b8676d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6953437c-594a-444b-a696-ca828b5318aa": {"node_ids": ["44ee6bbe-f91e-496b-a7b6-9e9146a80a22"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b2b8db5d-8435-4394-a011-02b228e36a42": {"node_ids": ["009fe699-dc35-46f1-98d4-b079858cdeea"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "50aed202-4de5-49d1-b26a-894a8a7faa0e": {"node_ids": ["260f19c6-6135-4325-9cb0-4f01ac85204b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e9fbffb5-7a7f-45f5-8081-41ca96fc99a5": {"node_ids": ["cd895e16-1798-4e03-8cb1-9006f9461b2f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1231cb79-529c-4a1f-a895-d4aeb82a877d": {"node_ids": ["9cd9c9ca-a643-46f7-a4d2-19c8bd0ff423"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b2f13e54-41bf-4dfd-9dd5-6cb81fecdfea": {"node_ids": ["6eb4466a-ca9a-45ca-830e-1472d9d86e2b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "aea7990d-ba6e-466b-ae12-d0614042f3be": {"node_ids": ["26b921ea-d590-4ee0-a844-c8a044f90f2b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "43e3b2d8-e28e-43c9-923c-cfb24866d9e6": {"node_ids": ["19dc683a-8c74-4b48-99e7-e6741bd20863"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a2c8925c-8d08-4749-a7f7-5c918a0fbc74": {"node_ids": ["9b6cd0f2-9bcd-40f3-8f0c-79e2bd38cd98"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "23c46d5b-c81d-4c48-a252-a4fb11894bc8": {"node_ids": ["863392cd-0830-4a93-a0f0-814f601f35c6"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "12dd2a24-0762-4adf-b421-0392af892bd2": {"node_ids": ["3ab104a5-fa0d-493d-9066-873ad5157a32"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "73179ac6-433c-4f0f-bbad-ddf1632199df": {"node_ids": ["9d59d589-db0c-472c-b48c-055b41a21278"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "268be36a-0e1c-4cf6-9d9f-22c9004a1972": {"node_ids": ["fb8722f1-d714-455f-9df1-b8684477f4de"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "31b6d4fd-ce37-43d5-8311-af0ba4be7f88": {"node_ids": ["98a2fd26-65a1-40cc-8b8e-0ef05b4869b3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1d82d2d4-4854-4cd3-8283-cb44458278ee": {"node_ids": ["03b4d968-0f14-4e03-b663-dcfe784551df"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7f04095d-dba7-4bc3-96a1-3222d45156e9": {"node_ids": ["96a7fa02-68cf-4b55-a4ae-1a8e246489ff"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "8bcbe2bb-893a-4f6a-9405-cb7a818569be": {"node_ids": ["15ba7f83-1625-425d-83d3-4da4ad0ea8f6"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "607e882b-239f-480a-a5c0-c33308a4ef83": {"node_ids": ["c8973ea1-23b4-4f03-833f-122c11a32854"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9d3ba01c-3ee6-4a5e-859b-fc4aa7bc6b29": {"node_ids": ["b5cf61d2-8a09-485b-bb5e-0f94094a75bc"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f25ac8e7-ba6d-46e4-804e-13bf8baeb649": {"node_ids": ["aea465cf-5501-4415-9d1a-7a5de52e2caa", "55832738-8e9f-42cd-a7cb-9dabd8f4c54e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "87ba7679-9f28-4feb-9c6e-832a400e7830": {"node_ids": ["a48ecaca-dcd0-49b7-b802-b882a7d1d2f5", "faaaf2eb-b1ed-41f3-969e-4b30b3519847"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "dc5ae1dc-9539-44a3-87af-6857c82af2c9": {"node_ids": ["4303fd47-f317-4df4-855a-63d0f685ab3f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "8a3d0930-fdd9-43a9-8e8a-588776d25810": {"node_ids": ["a277901a-e013-4cf4-a939-74a6eee2628a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d4d7637c-1d4c-4c68-805e-f6d676ce6264": {"node_ids": ["c0c54ec8-8284-41bd-a063-5804d4ba9780"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "5604776a-29fd-457d-bfb5-7fbfbb445b3f": {"node_ids": ["a7d7f928-7e39-487e-868d-e9d7edca5ce5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c2fbe436-9ea9-409f-8e34-1ede4b717f96": {"node_ids": ["f77be182-b170-4769-baed-8d42d31c86ec"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3e447a83-c0b6-4d82-bc24-8d14cd894e5b": {"node_ids": ["d85c2edb-14ab-45da-bd55-3e413112429a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "91c6d626-9e93-4226-896f-98ae7b6fc320": {"node_ids": ["c569053c-addc-45ef-be0a-6a7983c43161"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "846ce408-de2b-4b75-966d-4268f3ff976f": {"node_ids": ["7a16cce3-79b3-4ab5-ba1f-a82204c8dbdc"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "50b748bc-53ef-4655-a95a-9ebb2b65684a": {"node_ids": ["99439e92-ce6f-4713-a935-9180b12457ab"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7e7ec26b-b193-42a0-b4a8-240a10468094": {"node_ids": ["f2dc7c7c-2215-4e74-8375-fb1bce71bdab"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f5ca0ad5-036c-40d6-adca-4174073c8da6": {"node_ids": ["43217d89-3f41-43ee-8016-4cacf9f2b4dc"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ce12579e-a440-4f59-89b8-102b824da561": {"node_ids": ["a8757889-9907-40db-9227-805e1c3280c9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "23343146-0b3f-4fd3-a477-8e5956f6a55d": {"node_ids": ["187624ea-2e92-4c70-8a86-94473c633d59"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ca146124-b129-4adf-80de-954e3b05de7c": {"node_ids": ["a5241ea3-fc2f-4b96-8fb4-5bf6e2e7bb38"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b21a5dbd-a1ad-4f9f-9081-6d26efab3fe2": {"node_ids": ["5b57836f-7a8e-45e7-a941-3e4b14821e6f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1e084a08-16b2-4c53-9b15-5b34c93611f9": {"node_ids": ["c0dc152e-a7c1-4f38-acd8-17e813b1902c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "479d3835-57fb-4649-9d1c-8dd281619c71": {"node_ids": ["e9d5a0a5-d579-483c-b131-a193e90acecb"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c5c9801a-f2e1-48df-8e37-d0b11e88ce74": {"node_ids": ["126ff972-dbec-48d0-9e0d-d2c7a48fcbe5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "bfc3d096-4e75-4040-ae3b-5fe31b9ca5dd": {"node_ids": ["4cc171c5-e46c-475e-b257-8e557158b355"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a82ea8fe-50ad-49c7-bef1-ba913efc7765": {"node_ids": ["2ea2c762-6d65-482e-9db9-11ee70cca0d8"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "712e1ab1-ec96-4967-bdfa-caa5eed46331": {"node_ids": ["e2c5b170-6650-4890-a4a3-0fb15ff84e53"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f85d5b99-79ee-43d2-b53a-5ce2dc45058a": {"node_ids": ["8144e843-09c7-47f4-8e49-b5bc0872f729", "17e89ef4-9c6f-4c92-b6c0-986526a56416"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ab12cb30-c41d-4e73-8dd6-d9592785495b": {"node_ids": ["c30edf33-ee9c-4a86-a086-c9918c348a51"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d4674474-277d-4345-bdea-f1913af114dd": {"node_ids": ["1d2ca955-e0fc-458c-b568-9d38486c3048"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b236d035-357c-4162-b064-a5ce10cf0ed3": {"node_ids": ["428c9a34-c059-495f-92bb-730ddaebb762"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "29eaa3bc-be4b-458c-9eed-7d4c124a04a4": {"node_ids": ["b314a09d-7914-40e3-9a20-6192f713b920"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d694d9f1-3939-4a26-862a-4c86afc0cffe": {"node_ids": ["6059ff27-8333-46aa-9476-fd45c2a0a61c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f17e3d30-471b-4a48-9d18-c0be124343f6": {"node_ids": ["dde21d52-9097-4735-a9e7-3ff0d99e12c6"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7c73e8d7-d075-4b3d-aeef-845eac96e088": {"node_ids": ["e3c840f0-c948-4084-ba80-56fc585bde32"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6be67a9c-c963-4283-987d-48549eefbbef": {"node_ids": ["3b28c363-c445-4c77-b993-b2bbc32cb091"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d9cdcca0-72de-4ddb-a068-c479c7047b0e": {"node_ids": ["bda8f636-6e56-48bb-a548-90bd1755a80e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ba798995-6a97-4f3f-9327-3bccaa880282": {"node_ids": ["6b5f5eac-a719-4354-abae-2a8a2ae47064"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6188e219-02f4-4f5d-8fd5-5e337f4fd80e": {"node_ids": ["300107a2-dbaa-4dc6-8e88-52b65feff583"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "77ea3781-8665-4edb-a7ad-2ed535323528": {"node_ids": ["1f37b4cf-a04e-4f9c-b2c7-8daf5f8e4df4", "9796a46a-5a48-4e96-9bf6-c3b2cead242d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "af44db82-3e51-4411-bdba-e4ea99fa7f7e": {"node_ids": ["2c070022-d334-4756-9d28-ff0be1c32c5c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ded9dd90-e489-4c86-bcdb-03f2c3473267": {"node_ids": ["d4e84d2c-07ca-475d-ac3b-61f061eaf0bb"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c0a0778d-57ab-421a-b4f7-043f1dcbbe02": {"node_ids": ["f7045a10-75be-4c68-abd2-7e410458d9c9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ce88e2ff-70f3-4699-ac54-68cfc3f023a5": {"node_ids": ["ba43da52-0b82-40be-b761-89c40a7dec92"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ac68297a-1ade-4097-9e06-87fa33753b01": {"node_ids": ["9c4bea5e-b085-4ef5-8e50-8f24dff696f0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f6e84b8e-bc38-4d80-af84-cefa918ceffc": {"node_ids": ["9a4d17ce-1018-4911-aa83-be620c79e33b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d250e079-ddb8-41c9-b8a9-bfa9a5407e6e": {"node_ids": ["f4ddd6dd-e9f4-4aa0-b1c7-a5ad4b615bac"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "88041be1-d7e9-4f57-9380-7a44b9c6f5c5": {"node_ids": ["25cd7f3b-688a-4af2-bed3-e24f60e90d43"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "8c51711c-379d-4028-bbca-8baf3dcc8aca": {"node_ids": ["08a61b6c-ed7e-4dcb-a837-cb35abcbbd0e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "aa611b4d-839b-424b-9002-4056b4a3de67": {"node_ids": ["f6d5b80e-285f-4ab9-a07e-eb85eb3ceedb"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d8d87eac-4dc3-4dc0-81d7-a97468fd6537": {"node_ids": ["78c33e3d-ef08-4c08-b937-94a1fe60ee4d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9dec536e-02d8-4fbb-bfe9-f392a1780eac": {"node_ids": ["72e8cd01-55c8-4fdb-936f-8e31ac31b188"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "4fbf9320-532b-46de-8aed-e760b8511d1a": {"node_ids": ["45c79a6a-521e-44bc-abef-993c8966c293"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a66ec8e3-e13f-471d-8611-9d28a6b36708": {"node_ids": ["f76b8cb7-dc6f-4421-acb1-078ce9c73bc3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "80b496b8-4e7d-47ec-b9e7-5da6ac93832a": {"node_ids": ["b67b29cb-c68f-4b83-8898-99eb048f7fc8"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "440176be-bcc4-472c-a420-cf5c560891c5": {"node_ids": ["435a00c5-e076-4e7b-8477-611f9721f6d5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3296af08-1598-41ce-9a18-f5fbdc5bed59": {"node_ids": ["a69712d1-109f-472d-b224-c3884d7e98c8"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "0b5e5c3c-5e57-4e9d-8385-8fd6f4d013f6": {"node_ids": ["3c2fbe3d-e435-48ca-997e-dae5f44f321a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e17cfc69-74c7-4653-b900-1eedd06cca1f": {"node_ids": ["56625ac9-558b-4206-bf57-53494d2fdd68"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "911c1d1c-82dc-4e5c-bf18-d873eb296b56": {"node_ids": ["90e6a5b8-445a-474f-be08-6490b55566b1"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1eed5c54-a3c0-4d16-bb58-2c532bc9e63a": {"node_ids": ["59a70918-ef24-4f84-a25a-ec1c12867c54"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "03835053-efc3-4ed1-9212-ce8c2945d488": {"node_ids": ["fa4f0f0e-fb62-44e2-a460-84c4b24c95a3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "13eaa2aa-3e37-41c2-a904-141605e09909": {"node_ids": ["52c48bbb-aef7-499d-84ad-9d9199305f3e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7cbda0ab-1a95-41f6-bd72-e02f66302aa0": {"node_ids": ["ebe56182-5f1b-4ab5-9b2a-7f58728c899e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c9826e26-5728-4ba4-bb52-0a248552d1da": {"node_ids": ["f64f2099-50c5-4618-a81e-addcf249f0f6"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "678b4bba-729b-419d-88f8-23c62b64ae9d": {"node_ids": ["595c37d1-ddf5-4a1d-af28-571741604d8f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e6086451-a606-4296-981e-a3f5865ccb76": {"node_ids": ["aa10f33f-8b2a-4498-9e78-402d5806be1a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "745e20b2-a3b7-48d0-b9ca-4b1fc6b3261a": {"node_ids": ["9cf21bbb-0ed2-4a9c-a750-9dd42334fa17"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "982c64d8-51b7-4fc6-bd33-a6738b73b6f5": {"node_ids": ["661c1bd0-f5d5-4eb8-a712-558c54eb69d4"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "156468a8-a720-40de-b2d2-e6367caf47dc": {"node_ids": ["814152fb-00e5-4fc2-8cdd-7af6f5904a82"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ad5a96e3-03fe-441b-9c9c-8a93bf854db0": {"node_ids": ["6e5176bb-1a87-42e4-87d8-36baa97f2449"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "4f131185-fe75-4d19-b1ff-6284067ec09e": {"node_ids": ["587ed59d-a511-4073-a76d-9644dddb7bac"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "fc27cb4a-d82b-442d-94af-57c6746d7313": {"node_ids": ["f393c084-ea00-4e75-9cf3-14cfdae2677c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "de97da0f-d5f7-4be7-9409-8ff225902ab3": {"node_ids": ["37da712f-104d-4bca-b23b-3dd0fbdba72f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "cba30e59-e502-4833-a031-bc2d17d68b53": {"node_ids": ["d30cb208-7147-481f-ae87-b328a09f7f80"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "91014d5a-ca19-4e0a-ac4f-5759ffae1de3": {"node_ids": ["7cb33f51-b158-4fa3-9a16-a33ae1c731d9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "477898d4-ba08-4d4c-8390-2b71504d5310": {"node_ids": ["a5209975-58ea-4737-ac7f-f859a3a15246"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "79b8664e-f89e-476b-816d-5ca495703ddf": {"node_ids": ["7e309790-7784-4744-9eb5-1ca38f782c0c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "fb83bbc4-669d-422e-adb8-71dabe065e2d": {"node_ids": ["58e96070-8c92-4e82-89ec-dae0df84aa9e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "07a90ac3-ff97-465e-b15e-a5e732580a5f": {"node_ids": ["15c44524-3849-4c80-92f4-61c13b9b9d9f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "edb08ae8-f974-4bf0-9bac-4b13635d192d": {"node_ids": ["3b1a3ce1-4097-4dcb-a6c5-8229d93a9906"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "768faeeb-51f6-4fa8-8845-126c689f4bdd": {"node_ids": ["0e665d51-e018-47ce-bcf8-96a7252e8ef0", "d0346cd8-b164-49a8-9de9-69ebf09cca55", "10eef76f-d87b-4747-9e3b-9712f194653a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "4793ee5e-507e-4c61-b30f-6bc1f7757101": {"node_ids": ["eb01fe87-2186-4deb-8444-816f0f6f9ab0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c0c15dd3-3f26-4693-9fe7-969d902c6eff": {"node_ids": ["fa760af7-33b8-442c-89b1-7603b16b7fff"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3d4558b4-ceb5-4e3e-b65a-e4546e18bb7d": {"node_ids": ["6e90fbda-0081-4203-8dc1-8f3594b9df42"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "4b688342-6c7d-4f4d-b77c-616256675e92": {"node_ids": ["599b4230-e07d-4f94-83d2-231cf2ddf5a8"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "cd154823-2478-4ca3-9c43-819089866e6c": {"node_ids": ["db84cd80-7117-458e-b125-08cb2ad60bc7"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c3a3ac1e-bd91-4518-8875-6d5a5b90fede": {"node_ids": ["b45a730b-9ce4-4ace-be8e-d3a39cf86ef1"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "90ffe0c1-f750-450f-9ae1-69dcfa857132": {"node_ids": ["b52dfd36-b346-4d4d-8c38-f63b306532b1"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "69ee12e2-80f3-44f5-8e1e-c97eda47ad65": {"node_ids": ["cdd60fd5-c9b7-467e-80ad-c6efb4edb69f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9a0e2b60-7f40-4de3-8a17-29056de0eeb0": {"node_ids": ["05c51672-c1a7-4165-9bec-b1f9a9e2b4d4"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "15197f76-c69d-425e-86e9-1fcf9772d6fd": {"node_ids": ["1a6a4990-58a5-4d82-8e91-dab9c8455625"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "cc5ae223-c842-498d-a196-1d2b7c5e4c28": {"node_ids": ["98268bda-4022-4da5-8e76-3b2b0bfe5bcc"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6ce04762-f890-47bd-bf5d-d429a56a4baa": {"node_ids": ["818ce439-7251-4c5e-b4ce-cab1587be841"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "0694beca-8c13-4a9c-9ee8-69fdb9c0b75c": {"node_ids": ["eab4db7a-b6b9-49fd-b55b-5f68dbb0a950"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9f164476-ad69-4c91-8bad-b3ac4cb5d330": {"node_ids": ["8bfb2761-0860-4813-b609-75163039e02b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "8a8cdb8a-81c5-4f30-b917-4a4d0b375d81": {"node_ids": ["583e0d2b-1446-4682-864b-3deb156561c1"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7172c760-78df-4348-b7ec-369432b311f4": {"node_ids": ["9296035b-6d98-4413-8508-91e28dfacbf6"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d8e6ef44-3ebf-4aaf-96af-b61ed094a0d8": {"node_ids": ["3f221c45-2a61-42ae-87af-1fc12757b181"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "750d73e1-5de5-4f6b-a7f9-766b7354983a": {"node_ids": ["7b4bfffc-242b-4b69-a355-262db1fabf7e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e3af7681-ae9b-4af1-99f9-42f0dc14388c": {"node_ids": ["bacb60c3-5d2e-4581-b201-4417bc1e3e62"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c270651a-0705-48df-a8a6-524f5d9fc383": {"node_ids": ["66491d2e-215e-4968-9de2-57f2fce30145"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "8ff3b18f-aae9-478f-8bcf-3efd8b2cf1b9": {"node_ids": ["daac12a1-9017-49f2-ac69-0aea288b1e7c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "77d39405-1bdf-4c29-9c54-09acbce134f0": {"node_ids": ["5783214f-df83-430c-98b2-cf56cca6e8b2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "2f3c13cf-933a-4203-a879-a0ddef1d85fb": {"node_ids": ["159bd6e2-9e1b-4dff-b953-e9303f696045"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "acfd69af-093a-4130-a795-7f7905b20c5d": {"node_ids": ["01a7eb97-ad86-463a-97f2-6267c01c0f49"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "0d438650-5a0f-4ed0-8c3b-2f413414cbb3": {"node_ids": ["1b3768e4-6009-41e0-9592-0d27d433300c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "81311d6b-9222-4ab4-b9f7-34d95cb1d1d8": {"node_ids": ["5940d23b-8bb8-4643-8149-8ce16141ae76"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "36851490-a1a4-45e9-a718-ba8e0c7cb2c7": {"node_ids": ["67af3805-1da9-44d7-a08e-d6d0e0fd352e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "8425062e-980f-4c7d-bc7f-f1a34e3d6509": {"node_ids": ["eaf507ee-355c-4831-87a4-ac65a38ee87b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "fbc12338-3929-4053-8b50-8ceeab215833": {"node_ids": ["6231447c-3760-4e44-8628-91f398f87a4b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7c49a808-cbd3-439e-8511-979a53e74141": {"node_ids": ["678d53af-0e94-4115-ae34-a10415da6781"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "92504585-1f56-480d-9e2c-2227203564ea": {"node_ids": ["e416dc65-8a49-4e5c-bbab-5beb0d05bb9b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a1259d4b-bcf3-4edf-9735-fd462f450f9f": {"node_ids": ["030f56e0-5f0f-4f19-becd-1747066aa47b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "aa9fbcaf-0487-41a6-9653-c6b2607a0b5b": {"node_ids": ["c8f6dc8d-9808-4d57-b586-17dae0411e28"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "56d4e786-1d98-404d-9356-a97d6ba9629a": {"node_ids": ["b6337df0-0578-4f20-b652-2c760069fcfd"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9282ab04-e15f-4a72-9c37-fbee73cc3e4f": {"node_ids": ["ae6ab64a-ad08-44db-aa15-b14fca731fb0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "740ea1e7-c6e3-4dc3-b0a8-74acb449fcb6": {"node_ids": ["149641f1-4736-426e-9231-5ace0c4a7a2c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "06947c9e-2cae-4f6d-aefc-1ef66d3a0eb7": {"node_ids": ["d559304c-0b7d-45ef-81de-95212f0badb7"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "92cb6b14-d919-4cf8-96f7-f5acad5259a6": {"node_ids": ["46d31f3c-72de-4089-9b7c-688d73538298"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b0d49d83-b62b-4eb9-8426-4b6a52e20ed5": {"node_ids": ["6d51a858-c4fb-4648-b901-a12b09065353"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "279ad5f6-65c2-46cf-9e10-c5993fb029ee": {"node_ids": ["10803f36-f244-42f2-b5d8-2c590b423d92"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d221d6eb-35bb-4caa-aa55-698fb545035a": {"node_ids": ["d52ae396-fbba-4561-b987-c342c75203ea"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e4505c9e-afff-4481-8873-8f116b778807": {"node_ids": ["36110606-e3e8-417d-8b77-524aa8106672"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "298c7cea-d0d0-4511-bac3-5badcd7a0a24": {"node_ids": ["4c66a980-ed51-4237-aa08-94c041bb6997"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ce8c739d-be87-469f-b042-9a27b78245d5": {"node_ids": ["8dc80343-3cf9-4984-8c0b-2575cffcbcae"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d2748500-3ce0-4676-98c1-f45f4a9c6bfc": {"node_ids": ["359526ea-fc4b-4716-b7ec-3b6641eacbac"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7ea9b745-1be3-4603-b9d4-0eb8fba961e7": {"node_ids": ["440a8149-6a2f-4d40-8581-9095d19126d8"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "77a47a5d-ab45-44c0-aa14-ace7a2a19f61": {"node_ids": ["845f22ce-5c5c-4322-9384-b95e41e706bc"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6e4c6930-f6fe-4949-9049-4b495f602afd": {"node_ids": ["9b6b4be3-55ee-4928-8a88-a69e07131764"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6aa998ac-fef7-4557-b4ee-04e0308daef2": {"node_ids": ["64ec86eb-bfa7-4ccf-8024-416c911342ac"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "96db3495-0a4c-402a-8bb1-3a9db7de0477": {"node_ids": ["745dfb66-19ad-47a5-9ebf-0cfe4646c443"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ab33b7e3-1997-4b18-a024-d119d89e2537": {"node_ids": ["8ccbccb8-8b69-4c72-b680-8ecfcc971d82"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d829383f-25a7-461e-b803-078ee64d7668": {"node_ids": ["0f93b9f4-374d-450f-b40e-eefde8f23ff2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6320a82a-dd51-4d58-a25c-fa00227eec08": {"node_ids": ["f1301a21-0d44-40ea-a7ac-7e50ca174ec3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c0eb76d5-0a3c-444f-8000-a743edc835b6": {"node_ids": ["35fcc5b4-d6bb-4aa8-9384-dc6485835c8d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "25b628c3-67ee-42f9-9530-be6dd0d5cd72": {"node_ids": ["ca113084-8c42-4a50-a940-fe5c3195dd27"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "4c3df6ef-4c7d-43e8-9f4e-198a7cf16927": {"node_ids": ["e00b3890-8bab-482a-aef8-bd4c2fe093f5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f44eb63f-a431-4353-92f3-bff387dc257f": {"node_ids": ["2b9c01b2-bb80-4eab-9a14-0436f08dc7bd"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "766e8ebd-c590-4fe1-8e5d-5648b25dc01a": {"node_ids": ["bb4f85f3-088c-4c39-8d03-7c8f0869f202"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7fbe58f6-8d17-40e9-8a41-01d4323a803a": {"node_ids": ["fd9a5733-f7a2-4059-94d5-500c6c5819d2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a53700ce-a744-4d38-9abf-75d0a69e3bbd": {"node_ids": ["e20215cf-e2a3-470a-880e-1737ecbf75bc", "00735c34-2c69-4140-a2d6-07248c35a094"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "dcf35350-86dd-4402-993e-d6354cbb0e3b": {"node_ids": ["f9379dbd-ec25-40f9-b247-039e2dcefa3d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "98114f8d-a514-4ea3-a0b6-4065dccd1f47": {"node_ids": ["c3c6b60d-bfa8-48ee-a30e-492e10958ea3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c47a3081-3a7b-47db-ad02-d7f0d49c673e": {"node_ids": ["1be9a6d2-6dbf-4f36-a71b-687fc80fd101", "1509df48-ab6d-4182-b7b8-b4fbabe4b810"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "40c3afdd-ca38-4b69-b4f1-73886501d142": {"node_ids": ["d81dc526-60e8-4a93-9cc4-9024efc09160"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "01c08c97-1709-459f-a91e-9aa533a40b4e": {"node_ids": ["f1775753-d014-4eb9-9674-c312075d6c8f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f2b2c351-6e8a-456d-b4a9-4c0eec4ab980": {"node_ids": ["0bf4c050-954a-40ea-af2b-a4e4b5b62e65"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7b177ef4-3739-439f-b812-4b6c813e628e": {"node_ids": ["6c10267b-fa06-4c55-bbeb-702180432cad"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "dc2c524e-45c8-4523-bb87-bb6754e5563b": {"node_ids": ["51a78a97-47b6-46c2-bbf5-34dbf621746b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "9d8dcd36-9690-4abc-b014-4c84059a3fb1": {"node_ids": ["18abd514-ab82-4277-8246-8eeb7f7ccd15"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "48c8d820-b4be-4d3d-a72a-7b04834b25ca": {"node_ids": ["3da4be38-a3cc-4674-992f-c8c0c01cedf4"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "2e7d6875-6726-49d6-8733-a8ca6a06898c": {"node_ids": ["8adf1712-db17-44b3-b07c-b25888ef5954"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "39859c0f-4ffd-4908-9276-365eafd7cde2": {"node_ids": ["b4754450-ea23-41c3-ac50-72df885b422d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "79ce62ef-3b80-4a4f-89b1-c4e68d9b865b": {"node_ids": ["33d6f08f-790d-4c3d-b9ff-61e02c2f49c6"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f9c91904-8056-432e-aa0b-78afd13e5666": {"node_ids": ["2189e3e2-082b-4a7f-9af7-3c39c5c4eff5"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "3ca65200-48e4-48c9-b523-f6f57e6ca9a0": {"node_ids": ["52887db8-9151-4633-b416-9fd5069e66d4"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "fe9765f8-aa63-4457-b2ab-a7620c5657d6": {"node_ids": ["ecdd2daa-3958-4353-8de8-893bac524431"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "22261e96-ee27-495f-8185-2ff5179c50c5": {"node_ids": ["6d59bfac-1414-4117-9e8b-e46a259cc22c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1f012e1d-e5fa-48fe-a396-0a8575b93763": {"node_ids": ["eeb0fcff-d7cf-4291-906a-98d23d99e013"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "157c292c-1125-493e-899b-3db2e3cb0598": {"node_ids": ["19dd0a7a-5b45-47a0-9e3d-d369b9a6c24d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "b38f553d-7cbd-48f5-83d1-9eea563a41af": {"node_ids": ["aec53e9f-a6b7-48e8-bdba-9e42189580cd"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "61c3e6fa-bdc9-4dc5-8186-43c785244db2": {"node_ids": ["2fcf14dd-a2e6-4455-a4d0-1208444a8ec2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "6129b1ed-7eb1-4923-9e5d-b4ca6d2efffa": {"node_ids": ["d85e4ebc-90f9-4d37-b7a8-37b864e302f9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "7a77c3c8-2aef-44a8-9c8a-17a5163781c7": {"node_ids": ["f42268e7-f1f8-4aa8-8bb0-cadde78000f3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "0b182325-1de6-4f0d-a3eb-b1b6fcfc14de": {"node_ids": ["4cc55906-aabd-4413-b8e1-694f0c822236"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "008cddd8-aff9-414e-9be2-b23751bcba6b": {"node_ids": ["70173a99-205a-4db2-9494-f54061892aef"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "2cac1317-9e55-462a-95b8-0599ef76007e": {"node_ids": ["731d6df7-71bc-4ca5-a62a-6d85a41d48fc"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d3381f7e-7fc4-4e0c-acf4-0f52db886b2e": {"node_ids": ["2370d84c-304a-4901-8a94-220dd32ad52e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "a45fa8ef-aea5-4767-b137-6761b78a2701": {"node_ids": ["2c061279-5d38-4011-bbd2-40d5691be6b2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "cacd7cdf-c893-4812-a438-00507ee55a89": {"node_ids": ["0adb595c-88ff-4486-acb6-1e343c5ea243"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "c2c764e2-57db-4e01-b96c-928aaf1a5192": {"node_ids": ["a4d106d1-aad2-4aa2-8d2e-99a175ef1728"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d5850104-d5a1-41e0-b990-9ab47a319a35": {"node_ids": ["6ee6b166-38af-405a-a9a9-bf8eb77102a0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "aa7c31ae-e1b1-41f2-aad1-ed3e9bfe672d": {"node_ids": ["91e32d0f-4927-4140-aa03-56f248417b95"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "f2fa8fd5-6fce-46cd-bab7-6cf854651965": {"node_ids": ["6be66739-4dda-4c06-bb88-831f2ed6cf95"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "955739d3-0f70-48c7-8383-40f01e5d4a5b": {"node_ids": ["23a5e0d2-53cb-4ff5-9fc9-7fae636bba0e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "17f5606d-1e38-47c5-8b04-b2710958115c": {"node_ids": ["2c06e8bf-0f13-487e-a7fd-92c4caa1cc14"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "bcc91102-bcf6-416e-bd1a-2dc544d23d26": {"node_ids": ["e8147c24-c399-4b79-b799-bc291b2a6e3d", "6e495cf1-8f1f-4208-b17b-ab3fcc80c379"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "11151cf0-395d-46fb-9f20-490eba8b9b0f": {"node_ids": ["bbd74dcc-a594-48a6-bd61-fc5d301c9083"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ea8e34fb-1616-4ecf-9f91-c3f80fe06867": {"node_ids": ["3ddc2503-02cf-4c0c-b02d-6f7e77d7fac2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "76f93ae6-8028-4cee-9b6f-ff20fcf49d00": {"node_ids": ["f616cf1f-90dd-4315-9bec-47a11fb6c572"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d90af1c0-4e00-4557-b77a-4c516756f757": {"node_ids": ["457592c3-10c1-41e9-96ad-8662f6b3333b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "d7b16935-8249-4168-9e87-3817dcc67a69": {"node_ids": ["d3555915-5c9e-4ec5-8933-ddd80dc88a9e"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "1df9a4ef-ff0c-420a-be8f-a0fab197ca27": {"node_ids": ["4ac501ad-12c7-4f04-a9a7-13f23867a8d4"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "74f3e3a6-05b7-4584-8a58-deedb43a5be2": {"node_ids": ["04ceb7ba-a8f4-40a2-884c-470b40acdab9"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "e7bbfc7a-b432-40d7-b91e-cbcd2f90febb": {"node_ids": ["65d50cd9-1a6a-45e8-817c-489a811b5c90"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "41fe348a-fda1-4e46-af47-74ae1a64244c": {"node_ids": ["9c2e8bb0-0dd0-4ad0-99b7-97405050a56f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "85914d69-b362-42d3-b6a8-06ddd1453850": {"node_ids": ["1dec04f3-76a5-4857-99f6-fd81205ccd6f"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "ae541519-9682-4506-9959-f77e5c01436a": {"node_ids": ["a1a29f5a-8dca-47f3-b009-ca42b7424b0a"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}}, "45991a6d-db10-4bdc-b928-92b4c1b387b1": {"node_ids": ["da5d37e0-1128-4a75-aadb-f571de105424", "20fb55bb-489f-4b0b-8acf-a11379975154"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "1cbc38f2-56ea-4916-945b-5171710b2022": {"node_ids": ["168b9fc0-0c35-467e-81f7-61132150dba2"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "1e645bb1-4057-4de7-8dc9-6c04f579e578": {"node_ids": ["9481ac0b-bcc1-469a-a913-effce15d8a31", "fdf38bf1-621a-44ed-8122-6566af13619d"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "288cc7cd-18e8-41e1-9164-40b17a495ba2": {"node_ids": ["7003c701-7b41-4d3a-8aa8-f210a52abeec"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "d515bd6d-13cb-404a-b996-6012bb17f06d": {"node_ids": ["66357342-b047-4083-b831-94c9e245896e", "918f18d4-2f38-4876-8178-f5f56c228b44"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "6aa55cba-379c-41d6-90b0-01439bee8468": {"node_ids": ["e3049080-968d-4df7-81bf-64b5a4396197"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "4e63e548-649c-4c05-acd4-2e61ea7f049c": {"node_ids": ["372046f5-48f3-4d15-accc-415d26092e35", "4a4f1ae8-80f3-4cde-9256-218a559e6d21"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "d0d0ac07-6895-49ff-b546-3fa568811ddc": {"node_ids": ["8496d85d-c61f-48ee-a22c-9ddd5a38d0cf", "7fc6d2a1-e321-4e3a-9d48-56cd8f77945d", "a9bd3c95-f216-480b-b114-d43e343f33f2", "bab7ecc8-5078-4cf4-b92e-4aa2298c0436"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "78872d06-71da-4d71-8de7-35e2578ec81f": {"node_ids": ["26a462a8-52d7-4a3b-9f86-f5054d737f7d", "0af3d8a1-8b69-4d47-8017-50e6e49f9179"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "f3b49f9e-2822-4406-a716-d2d1618425b1": {"node_ids": ["8b2427b9-75f1-4a13-a3ac-f471fc75436b", "b7a0c283-7fdd-4d0b-89bd-49b1f60b0b6c"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "812560f0-129a-4f4f-a873-18407f47654d": {"node_ids": ["171f228c-c353-45aa-ab27-2bf576a49b91", "06f082e4-c6de-4192-ba72-c211acc799c3"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "7ae5bda9-3fc3-4f5e-9676-3e3a5b04ada3": {"node_ids": ["4be7f25d-a903-4266-bb05-6b94877242ba", "b8b98277-fd86-4384-b942-6a453fcd0e41"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "2cacf691-112c-49b8-917c-4b95010d0871": {"node_ids": ["49b0ae62-4ef7-49c3-83d2-8ed6e31719e5", "77b2e161-194b-4975-8bb8-f55d1e71101a", "827634ea-0225-4226-ae31-9d1a6190ef4b"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "f122079e-0696-43e7-954d-3c9ab0837715": {"node_ids": ["f38875ec-8395-4ee5-86b3-0510203e20ce", "2a10c853-f117-46c1-a02c-362a5f771083", "38bb7438-28de-4116-82bb-858ae992f43d", "41b160e8-3c5d-4fd5-af1f-cedffa097bd1"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "a0776b31-c3ac-4c62-b9e9-39ec3249ddb5": {"node_ids": ["28951f6e-67ce-44c5-89d6-f5e16fdeeff2", "31a64274-4d4e-4171-b86a-e2a192f7be00", "e39dcace-5031-47a8-be55-c6220ca61f55", "860f5b32-d621-4ae9-8170-87db736895d0"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "6d1b1009-9f31-49f1-b1ee-4f26dc589405": {"node_ids": ["72a2e743-a08d-4029-a42d-7cbef763d51e", "1a787cf3-587f-43ab-a92f-04834985d2c8", "75a1ecaf-4e1e-439d-b1b8-324643db379f", "a3639e37-007e-4971-bf01-3b76407111bf"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}, "042dc8e1-50a3-48aa-8025-e59c1e3d54f6": {"node_ids": ["6895513c-ddd0-43ba-8ade-7aa34d346c88"], "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}}}, "docstore/data": {"12bfbbf1-b9d5-44f1-944d-9eed91300535": {"__data__": {"id_": "12bfbbf1-b9d5-44f1-944d-9eed91300535", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5cc84e52-7fa7-489f-ac2a-32e2264395b6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "2b35c2857b584033a0340f50169a89031544b54cef5b7a65f29f681b0580ec7e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Supplementary Appendix\n\nThis appendix has been provided by the authors to give readers additional information about their work.\n\nSupplement to: Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008;359:229-41.\n\n(PDF updated October 24, 2008.)", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 317, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4d9a7f09-8021-4b65-81fb-f92c5eb5a98a": {"__data__": {"id_": "4d9a7f09-8021-4b65-81fb-f92c5eb5a98a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e9e50c4d-d16f-49ae-b2b9-09ba12897637", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "58f8a2814295a09ee46ee7117c8e4bba0bec423067ee05a921d6bbe56771b9c5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Appendix 1. Topics and content of dietary education sessions \u2014 the DIRECT Study\n\n# Background\n\nEach dietary education session started with weighing and attaching stickers on shirts with the current weight as well as the weight change since the previous meeting. The dietician solicited feedback and led a problem-solving discussion, provided more examples of daily menus, and specific targets according to weight loss phase and upcoming events (holidays, etc). The second part of each dietary session was dedicated to a specific topic, as described in detail below. Most sessions concluded by discussing the \"Myth of the Day\" (a common misconception or unproven notion about food, diet and health). Dietitians met with their groups in the workplace during weeks 1, 3, 5, 7, and then at 6 week intervals, for a total of 18 90-minute sessions. The exact same workshop format and Power Point slides were used by each of the dietitians coordinating the 3 intervention arms, apart from the instructions that were specific to each diet strategy. These workshops were periodically monitored by the primary investigator to ensure equal intensity of intervention. Additional diet recipes, notes (prior to holidays) and notifications about upcoming measurements / electronic questionnaires and reminders for the monthly visit date in the nurse clinic were delivered via the workplace's intranet system. Six times during the two-year intervention, a different dietitian than the one in charge of the intervention arm conducted 10-15 minute motivational telephone calls, and provided a written summary.\n\nAt the end of the study after data analysis, each participant was provided, as guaranteed, all of their individual data and figures of trends and normal range values of the nutritional and health parameters assessed during the 2-year intervention, accompanied by comments from a physician.\n\n# 1. Introduction, basic concepts of each diet\n\nParticipants were introduced to the aims of the study: weight loss and improvement in health parameters in a long\u2013term project. Furthermore, participants were introduced to their assigned diet strategy (detailed below), and its apparent advantages. Each group was given initial examples of menus. In all diets, the participants were encouraged to avoid trans fat.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2295, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "69c75384-b9ae-4a0c-baa1-487c554002cd": {"__data__": {"id_": "69c75384-b9ae-4a0c-baa1-487c554002cd", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "74b4ccb3-3e13-406d-a0fa-4d5ccd8c88a4", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "ae41a7f940064db667908e60f78cb4c5b422af062888b082a199b647a1c4ac36", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Low Fat Diet\n\nParticipants were counseled to consume low-fat grains, vegetables, fruits, and legumes and to limit added fats, sweets, and high-fat snacks. For the low-fat, restricted-calorie diet we aimed at up to 30% of calories from fat, 10% from saturated fat and up to 300mg cholesterol/day, with 1500kcal for women and 1800kcal/day for men.\n\n# Mediterranean Diet\n\nThe moderate-fat, calorie-restricted diet is rich in vegetables and low in meat, with poultry and fish replacing beef and lamb. We aimed to have 35% of calories from fat; the main sources of added fat were from 30-45 grams of olive oil and a handful of nuts (5-7, less than 20 grams) per day. We restricted energy to 1500kcal for women and 1800kcal/day for men.\n\n# Low Carbohydrate Diet\n\nThis low-carb, non-calorie restricted diet aimed to provide 20g/day of carbohydrates during the induction phase (first 2 months), and returned to this level of severe carb restriction after each religious holiday. At other times participants were instructed to increase carbs gradually up to maximum of 120g/day to maintain the weight loss. Total calories, protein and fat intake from any source (except industrial- trans fats) were not limited.\n\n# 2. The Food Pyramid for each diet\n\nParticipants learned more about their diet strategy through specific diet food pyramids, the history of the specific dietary approach, and the food sources of each food group. They further learned how to choose their food items in the cafeteria by following their specific color food labels.\n\nMyth of the day: \u201cMixing vegetables and fruits with water cause stomach ache.\u201d", "mimetype": "text/plain", "start_char_idx": 3, "end_char_idx": 1617, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0a0d989d-8975-432d-9617-efabfd1f5535": {"__data__": {"id_": "0a0d989d-8975-432d-9617-efabfd1f5535", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3a6176a7-7dc4-4217-b5b6-a6bbe28072bf", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "2dad72a18b4fd283e3e16d3c0a98ccfd6c4f0734e8fc635970bcdf6ed5c8ed19", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Principles of low-fat diet strategy\n\n| Fats, Oils & Sweets                               | KEY                                 |\n| ------------------------------------------------- | ----------------------------------- |\n| USE SPARINGLY                                     | Fat (naturally occurring and added) |\n| Those symbols show fats and added sugars in foods |                                     |\n\n# Milk, Yogurt &#x26; Cheese Group\n\n2-3 SERVINGS\n\n# Meat, Poultry, Fish, Dry Beans, Eggs &#x26; Nuts Group\n\n2-3 SERVINGS\n\n# Vegetable Group\n\n3-5 SERVINGS\n\n# Fruit Group\n\n4 SERVINGS\n\n# Bread, Cereal, Rice &#x26; Pasta Group\n\n6-11 SERVINGS\n\nSource: USDA, public domain", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 675, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "abf5edef-6d14-4d7d-9154-16a245b01710": {"__data__": {"id_": "abf5edef-6d14-4d7d-9154-16a245b01710", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4a27b2b2-2241-49a9-83c1-d694a3b1b6cc", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "29d04832f2e862c9569c78fb8805e5e2b321fc70a8a78f72a12266cb5d9f7f4f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Principles of Mediterranean diet strategy\n\n# USE SPARINGLY:\n\n- RED MEAT &#x26; BUTTER\n- REFINED GRAINS: WHITE RICE, BREAD &#x26; PASTA\n- POTATOES\n- SUGARY DRINKS &#x26; SWEETS\n- SALT\n\n# DAIRY (1-2 servings a day) OR VITAMIN D/CALCIUM SUPPLEMENTS\n\n| NUTS, SEEDS, BEANS & TOFU | FISH, POULTRY & EGGS                      | HEALTHY FATS/OILS:   |\n| ------------------------- | ----------------------------------------- | -------------------- |\n| OLIVE, CANOLA, SOY, CORN  | SUNFLOWER, PEANUT & OTHER VEGETABLE OILS; | TRANS-FREE MARGARINE |\n| WHOLE GRAINS:             | BROWN RICE, WHOLE WHEAT PASTA             | OATS, ETC.           |\n| VEGETABLES & FRUITS       | HEALTHY FATS/OILS                         | WHOLE GRAINS         |\n\nAdapted from The Healthy Eating Pyramid, Department of Nutrition, Harvard School of Public Health. Copyright \u00a9 2008, Harvard University. For more information, see The Nutrition Source, www.THENUTRITIONSOURCE.ORG and Eat, Drink, and Be Healthy, by Walter C. Willett, M.D. and Patrick J. Skerrett (2005), Free Press/Simon &#x26; Schuster.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1072, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "508afd52-7429-4cc9-ad2b-6e7f4d0547cf": {"__data__": {"id_": "508afd52-7429-4cc9-ad2b-6e7f4d0547cf", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fa0add45-4478-4049-9f36-4bbbd72e5a51", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "98a479a24581dbbdcb60fd6f21e07d003a0a5f55e5a368afa05ff2d48b1e6a3a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Principles of low-carbohydrate diet strategy\n\nReprinted with permission,\n\nAtkins Nutritionals, Inc. Center for Research &#x26; Development. Reference # 0000570580\n\n# Food Categories\n\n| Whole grain foods                            | Vegetable and seed oils, cheese and dairy, nuts and legumes |\n| -------------------------------------------- | ----------------------------------------------------------- |\n| Fruits                                       | Vegetables                                                  |\n| Blueberries, raspberries, pears and avocados | Salad greens, broccoli, cauliflower, asparagus and spinach  |\n| Protein sources                              | Poultry, fish, beef, pork and soy products                  |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 740, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eea7cf1c-2311-4850-b75a-e4ee23010280": {"__data__": {"id_": "eea7cf1c-2311-4850-b75a-e4ee23010280", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a28b2b7e-71ff-40d9-8f3c-b240d46cd2ed", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "d396b1dcaf8f8feccd9a574fa00bb229cbdb7413d0dc0ae8155785e4cff69bd9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "EXAMPLES OF EACH DIET ARE PRESENTED HERE\n\n# Low fat diet, day 1\n\n| Ingredient                     | Quantity         |\n| ------------------------------ | ---------------- |\n| Light whole-wheat bread        | 2 slices         |\n| Cottage Cheese (5% fat)        | 75 g             |\n| Tomato                         | 1 medium (160 g) |\n| Peach                          | 1 medium (160 g) |\n| Roast chicken breast           | 150 g            |\n| Roast potatoes                 | 2 medium (240 g) |\n| Cabbage salad                  | 100 g            |\n| Low fat yogurt (1.5% fat)      | 150 g            |\n| Energy bar                     | 1 bar (43 g)     |\n| Whole-wheat bread              | 2 slices         |\n| Hard cheese (9% fat)           | 1 slice (20 g)   |\n| Carrot salad, low-fat dressing | 200 g            |\n| Watermelon                     | 250 g            |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 875, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bcc1cb49-9a5c-42c1-89d0-628f3300f107": {"__data__": {"id_": "bcc1cb49-9a5c-42c1-89d0-628f3300f107", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ff781cfc-3bb3-494b-bffa-85c8326f8aa3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "a21319aa5e88bac1b648939bf091c5c608a085212fd6584b6315054df268134d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Low fat diet, day 2\n\n| Ingredient              | Quantity        |\n| ----------------------- | --------------- |\n| Low fat yogurt (0% fat) | 150g            |\n| Grapes                  | 6 medium (42 g) |\n\n# Breakfast\n\n| Plum                          | 1 medium (70 g) |\n| ----------------------------- | --------------- |\n| Granola                       | 2 spoons (30 g) |\n| Chicken legs, baked, w/o skin | 2 units         |\n| Spaghetti in tomato sauce     | 1 cup (200 g)   |\n\n# Lunch\n\n| Mixed vegetable salad, low-fat dressing | 1 cup (150 g) |\n| --------------------------------------- | ------------- |\n\n# PM Snack\n\n| Whole-wheat cracker  | 2 crackers        |\n| -------------------- | ----------------- |\n| Strawberry jam       | 2 teaspoon (12 g) |\n| Whole-wheat bread    | 2 slices          |\n| Low fat cream-cheese | 35 g              |\n| Smoked salmon        | 50 g              |\n\n# Dinner\n\n| Tomato                  | 1 medium (90 g)  |\n| ----------------------- | ---------------- |\n| Low fat yogurt (0% fat) | 150g             |\n| Banana                  | 1 medium (100 g) |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1093, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8af70d71-cf6c-4d40-8360-358b919f08e1": {"__data__": {"id_": "8af70d71-cf6c-4d40-8360-358b919f08e1", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "12300e16-86fc-4720-9bf8-73091ef9103c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "fa2caee0a7fecb72656af68d336da505f8221e4286c96bc451f565e9d55a9bf7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Mediterranean diet, day 1\n\n# Breakfast\n\n| Coffee with 1% fat milk   |                 |\n| ------------------------- | --------------- |\n| Light whole wheat bread   | 2 slices        |\n| With low fat white cheese | 2 TB            |\n| Cucumber and tomato       | few slices each |\n| Fruit, anything           | 1 unit          |\n\n# Lunch\n\n| Grilled fish                     | 1 portion, 150 gr |\n| -------------------------------- | ----------------- |\n| Cooked chickpeas                 | 1 cup             |\n| Fresh and cooked vegetable salad | 1 cup             |\n| + olive oil                      | 1.5 TB            |\n| Low-fat yogurt                   | 1, 150cc          |\n\n# PM Snack\n\n| Fruit+                  | 1 unit     |\n| ----------------------- | ---------- |\n| Fresh vegetables        | few slices |\n| Light whole wheat bread | 2 slices   |\n| Low fat white cheese    | 3 TB       |\n| Fresh vegetable salad   | 1 cup      |\n| + olive oil             | 1 TB       |\n\n# Dinner\n\n| + walnuts        | 5 units    |\n| ---------------- | ---------- |\n| Fruit            | 1 unit     |\n| Fresh vegetables | few slices |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1129, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "acc47be9-b5a4-4619-b1b4-f7dc543bafbe": {"__data__": {"id_": "acc47be9-b5a4-4619-b1b4-f7dc543bafbe", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "04a585bb-270e-4507-9ebc-b0f80a58ceed", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "575f7e14763099c6fcd62d632295c52f625b4cac3624a9878160bdf209e11b1c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Mediterranean diet, day 2\n\n# Breakfast\n\n| Coffee with 1% fat milk              |          |\n| ------------------------------------ | -------- |\n| Low-fat yogurt                       | 150cc    |\n| Fruits                               | 2 units  |\n| Greek salad with low-fat feta cheese | big bowl |\n| Olive oil                            | 1.5 TB   |\n| Cooked peas                          | 1/2 cup  |\n\n# Lunch\n\n| Whole wheat rice        | 1/2 cup |\n| ----------------------- | ------- |\n| Light whole wheat bread | 1 slice |\n| Low-fat white cheese    | 2 TB    |\n\n# PM Snack\n\n| Fruit                   | 1 unit     |\n| ----------------------- | ---------- |\n| Fresh vegetables        | few slices |\n| Light whole wheat bread | 1 slice    |\n| Low fat white cheese    | 3 TB       |\n| Fresh vegetable salad   | big bowl   |\n| Olive oil               | 1 TB       |\n| Walnuts                 | 5 units    |\n\n# Dinner\n\n| Hard boiled egg   | 1 unit     |\n| ----------------- | ---------- |\n| Chickpeas, cooked | 1/2 cup    |\n| Fruit             | 1 unit     |\n| Fresh vegetables  | few slices |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1095, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e2572690-a2e6-4751-8833-d04843c1510d": {"__data__": {"id_": "e2572690-a2e6-4751-8833-d04843c1510d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ba62259a-b46f-40dd-a519-ea084e24dde2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "ffef36d7cb111ebf946e03e67266957c3d94efd679e2064d60ce8f3f837bc69f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Low-carb, initiation phase\n\n# Ingredient\n\n| Ingredient                    | Quantity         |\n| ----------------------------- | ---------------- |\n| walnut                        | 1 (6 g)          |\n| High fat cream cheese         | 100 g            |\n| Fried chicken breast          | Liberal          |\n| cucumber                      | 1 small (82 g)   |\n| tomato                        | 1 small (80 g)   |\n| Tachini (sesame based spread) | 2T (7 g)         |\n| Turkey pastrami               | 2 slice (64 g)   |\n| Tuna fish preserved in oil    | Liberal          |\n| Fried Eggs                    | Liberal          |\n| Avocado                       | Liberal          |\n| cucumber                      | 2 medium (160 g) |\n| lettuce                       | 1 cup (55 g)     |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 786, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8f3ed4b4-9def-496d-8087-53ff1f75af8f": {"__data__": {"id_": "8f3ed4b4-9def-496d-8087-53ff1f75af8f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c04c6851-68de-43f7-afab-c2eef6af2d9a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "c22b01fa797b861bf74460eed7ff5d3f2986b3b841260b32dc988553bef5c64a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Low-carb, maintenance phase\n\n# Ingredient\n\n| Ingredient                                                                       | Quantity |\n| -------------------------------------------------------------------------------- | -------- |\n| Sour cream 15% fat                                                               | Liberal  |\n| Fish or chicken/or beef, fried or roasted                                        | Liberal  |\n| Stir fried zucchini with herbs                                                   | 1/2 cup  |\n| Roasted eggplants                                                                | 1/2 cup  |\n| Fresh vegetable salad with 2 tablespoons (17 g) of Tachini (sesame based spread) | 2 cup    |\n\n# Lunch\n\n| Almond cookies (based on eggs, almonds and sugar substitute) | 2 small (12 g) |\n| ------------------------------------------------------------ | -------------- |\n| Cream cheese                                                 | 250g           |\n| Broccoli and mushrooms coated with eggs, no flour            | 1/2 cup        |\n| Tuna                                                         | Liberal        |\n| Olives                                                       |                |\n\n# Dinner\n\n| Fruit flavor diet yogurt | 150 g           |\n| ------------------------ | --------------- |\n| Walnuts                  | 5 (28 g)        |\n| Apple                    | 1 small (100 g) |", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 1419, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7bef0868-211d-43a5-87b3-d307952a51d5": {"__data__": {"id_": "7bef0868-211d-43a5-87b3-d307952a51d5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "be5bacf9-d850-4fbc-908e-4658119e1097", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "ca891eb268faf6b88c9c553c87bfd7208e58ae705254a1b31d54be6b5047c66b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 3. Lipids and Fats\n\nParticipants learned about the chemical structure of dietary saturated, unsaturated and trans fats and omega 3, about their distribution in food sources and their effects on HDL, LDL and TG. They further learned about cooking with fats and oils.\n\nMyth of the day: \"One central huge meal a day is better than smaller spread meals for weight loss.\"\n\n# 4. Energy Balance\n\nParticipants learned about overweight, the meaning of calories, basal metabolic rate and energy expenditure, and examples of food items and their caloric values.\n\nMyth of the day: \"Consuming dietetic foods prevents you from gaining weight.\"\n\n# 5. Physical activity\n\nParticipants learned about the role of physical activity in energy balance, its benefits for general health and weight loss maintenance, the guidelines for a moderate activity and the difference between fat and muscle tissue.\n\nMyth of the day: \"I am busy, so I don't have time for physical activity.\"\n\n# 6. Dining out\n\nParticipants were introduced to the principles of dining out: planning, assertiveness, controlling and choosing. The dietitians suggested examples of appropriate restaurant food dishes, according to the specific diet intervention arms, and discussed the risks when eating in restaurants and further issues of eating in social meetings and during travels.\n\nMyth of the day: \"You can only gain weight when dining out.\"\n\n# 7. Environmental distraction and extra eating\n\nParticipants were provided examples of environmental distractions (e.g., watching TV, eating with kids, shopping near a bakery, traveling, getting back home very hungry, etc) and possible ways of overcoming the potential for extra eating due to distraction.\n\nMyth of the day: \"It is not me, blame him.\"\n\n# 8. Scientific background \u2013 dietary arm specific\n\nIn this session, each diet group was provided scientific background and historical perspective about what was published in the literature regarding their designated type of diet.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1977, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "89403449-44ca-4fae-b241-812de9f15dec": {"__data__": {"id_": "89403449-44ca-4fae-b241-812de9f15dec", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d3bef375-4ec0-4365-b26b-69955c6cc073", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "30adf5c32f50265a10a2acdcba3cecf66bb34924843d0036f8f8db4c7c7ccb1e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 9. Subcutaneous vs. visceral fat\n\nParticipants learned about abdominal fat, waist circumference, fat distribution, and what is known about differences between subcutaneous and visceral fat.\n\n# 10. Weight maintenance\n\nParticipants learned about adaptation of basal metabolic rate to changes in energy intake, and further metabolic and behavioral explanations for weight regain. They learned about successful strategies that were found for weight maintenance and were exposed to personal successful stories, including pictures before and few years after weight loss.\n\nMyth of the day: \"You need to be highly disciplined in order to maintain your body weight, and I have such a weak character\u2026\"\n\n# 11. Atherosclerosis\n\nThe participants learned about the development of arterial plaques, their pathogenesis and stages, and risks for development of coronary heart disease and stroke.\n\nMyth of the day: \"My cholesterol level is OK- I am safe.\"\n\n# 12. Physical activity\n\nParticipants were encouraged to be physically active, 30 minutes, at least 3 times per week. They learned about the role of exercising in the weight loss process, types of aerobic and anaerobic activities, and how to cope with excuses for \"not exercising.\u201d The subjects were advised to use a pedometer.\n\nMyth of the day: \"We can lose weight and maintain weight loss without exercising.\"\n\n# 13. Glycemic index\n\nIn this session the subjects learned about the glycemic response and about the role of insulin. They learned about the glycemic index and glycemic load and what is known about its association with health parameters. They learned about further factors modifying the glycemic index (e.g., degree of fruit maturity, cooking method, mixture with other ingredients) and the limitations of this approach. Finally, they were provided a food list with their glycemic index values.", "mimetype": "text/plain", "start_char_idx": 3, "end_char_idx": 1851, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "52c6dfe1-3eb2-43d5-bf09-217881d57809": {"__data__": {"id_": "52c6dfe1-3eb2-43d5-bf09-217881d57809", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "637db76b-9865-4a56-9956-1f4a2c4e5875", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "10821803b04979a476c4d1648e4405c3e27fb90d7ec5d570e77c8eb7ec387385", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 14. More perspectives on lipids and proteins\n\nParticipants learned about the biochemistry of lipid particles (chylomicrons, VLDL, LDL, HDL, TG) in the body and target levels according to the NCEP-ATP guidelines.\n\nMyth of the day: \"If you already lost enough weight you can stop dieting.\"\n\n# 15. Sugar substitutes\n\nParticipants were taught about natural and artificial sweeteners and sugar substitutes, and about the controversies related to their impact on health. They were specifically provided information regarding aspartame (avoid cooking/boiling), sucralose, and cyclamate.\n\n# 16. Childhood obesity\n\nIn this session we discussed the family perspective on dieting, and the standard obesity definitions, and focused on childhood obesity. We described the epidemic, discussed possible explanations for it, the associated risks, and the cycle of gaining weight. We concluded with the role of parents in their children\u2019s obesity and the importance of providing good role models, taking the DIRECT study as a platform.\n\nMyth of the day: \"A child is a child. Don't worry about his weight when he is young \u2013 he will grow out of it.\"\n\n# 17. Food labels\n\nParticipants learned about the rules and laws related to food labels, their components, and how to read them and were encouraged to look carefully at food labels, as well as the ingredients list. They learned about the meaning of \"health food declarations\" (for example, in Israel, declaration of \"light\" means up to 2/3 of nutrient component compared with the original food item; \u201clow-sodium\u201d means up to 100mg sodium/100grams, etc.).\n\nMyth of the day: \"What I don't know can't harm me.\"", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1642, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8cd8e432-af4c-4f3b-bd85-697502da4083": {"__data__": {"id_": "8cd8e432-af4c-4f3b-bd85-697502da4083", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66bd758f-415d-4fcb-9280-fa22df891619", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "c53cc3c8f82838a63e3246c9d9665b8dd7db29365e596d1a8d668929519b3650", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 18. Long-term weight maintenance\n\nAt the final dietary session of the DIRECT, we summarized some take-home messages for life. We started by reviewing the DIRECT objectives, and emphasized that weight loss is just part of the overall health benefit of switching to healthy regimens. We summarized the group achievements, warned about risks of weight regain and the future use of \"magic diets\", and highly recommended that participants continue to follow their diet strategies, keep weighing themselves, eat breakfast, keep exercising, and keep following their health parameters. We thanked the DIRECT participants for their active involvement.\n\nMyth of the day: \"If the DIRECT is over, there is no chance I could keep my achievements.\"", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 737, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6d6a63bc-4d10-4e90-8723-fe7e11cbcb89": {"__data__": {"id_": "6d6a63bc-4d10-4e90-8723-fe7e11cbcb89", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cc23d20b-1441-4e08-8377-88f08689f558", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejm_shai_229sa1.pdf", "file_name": "nejm_shai_229sa1.pdf", "file_type": "application/haansoftpdf", "file_size": 226099, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejm_shai_229sa1.pdf", "source_type": "medical_document"}, "hash": "9f7b74ec097380326dc61415c50a73e313375ef6555b3849eda6752ccee6aad0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Appendix 2. Dietary intervention\n\n# 2a. diet protocols\n\n|                                                                 | Low Fat                                                                                  | Mediterranean                            | Low Carb                                                                                                        |\n| --------------------------------------------------------------- | ---------------------------------------------------------------------------------------- | ---------------------------------------- | --------------------------------------------------------------------------------------------------------------- |\n| Energy                                                          | restricted                                                                               | restricted                               | Non-restricted                                                                                                  |\n| Total fat                                                       | \u2264 30%                                                                                    | \u2264 35%                                    | Non-restricted                                                                                                  |\n| Saturated fat                                                   | \u2264 10%                                                                                    | \u2264 10%                                    | not specifically restricted, but moderation recommended, as well                                                |\n| Dietary cholesterol                                             | \u2264 300 mg                                                                                 | \u2264 300 mg                                 | as reduced trans fat not specifically restricted                                                                |\n| Carbohydrates                                                   | Not restricted, whole grains recommended                                                 | Not restricted, whole grains recommended | Restricted \u2264 20gr in induction phases, Gradually added to maximum of 120gr/day to maintain achieved weight loss |\n| Specific food items added                                       | a. 30-45gr extra virgin olive oil/day b. a handful (5-7) of nuts /day c. 2 fish meals/wk |                                          |                                                                                                                 |\n| No specific recommendations for alcohol and vitamin supplements |                                                                                          |                                          |                                                                                                                 |\n\n# 2b. Daily food color labeling in the cafeteria\n\n| Low-fat              | Med                   | Low-carb |\n| -------------------- | --------------------- | -------- |\n| Feel free to consume | Consume in moderation |          |\n\nFood labels: Energy (kcal), total fat (gr), saturated fat (gr), carbohydrates (gr) per portion size", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 3235, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bf48b5e2-88e4-446b-9013-2aab4d3111f5": {"__data__": {"id_": "bf48b5e2-88e4-446b-9013-2aab4d3111f5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e6f43136-aa5d-49f5-b814-329a296da6f0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fc409045b25ada4edbbe8b98ec351e0e0301322829cc9e1111fea1436a729308", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Protocol\n\n# Protocol for: Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity.\n\nN Engl J Med 2022;387:205-16. DOI: 10.1056/NEJMoa2206038\n\nThis trial protocol has been provided by the authors to give readers additional information about the work.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 290, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "976e1a38-35aa-4c2b-bef0-21bf9f3fc59e": {"__data__": {"id_": "976e1a38-35aa-4c2b-bef0-21bf9f3fc59e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d972c690-7fd4-4ee9-bc13-d0f769f68721", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "dcde74ee6d5c5fe7047cf81b119ad3114281a19486231736c61de402dff80df3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# This supplement contains the following items:\n\n1. Protocol:\n1. Original protocol, dated 09 September 2019\n2. Final protocol version (b), dated 04 October 2021, including summary of changes and amendment history\n3. Original protocol addendum I8F\u2011MC\u2011GPHK (1), dated 10 September 2019\n4. Original protocol addendum I8F\u2011MC\u2011GPHK HR Addendum (2), dated 11 September 2019\n5. Final protocol addendum I8F\u2011MC\u2011GPHK HR Addendum (2.1), dated 24 January 2020\n2. Statistical analysis plan:\n1. Original statistical analysis plan, dated 05 September 2020\n2. Final statistical analysis plan with revision history, dated 28 September 2021", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 623, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f627f81b-721e-4dbe-9dcd-262751c0f88e": {"__data__": {"id_": "f627f81b-721e-4dbe-9dcd-262751c0f88e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "59e3d050-5d9f-4a77-94ed-a5f5fa109136", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b1a0d67cfb6699f167d5aab95fbc08ca8530ac809bcf158ae7fa95597b475305", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# CONFIDENTIAL\n\n# Protocol I8F\u2011MC\u2011GPHK\n\n# Title Page\n\nConfidential Information\n\nThe information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of tirzepatide (LY3298176) unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries.\n\nNote to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.\n\n# Protocol Title:\n\nEfficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight\u2011Related Comorbidities: A Randomized, Double\u2011Blind, Placebo\u2011Controlled Trial (SURMOUNT\u20111)\n\n# Protocol Number:\n\nI8F-MC-GPHK\n\n# Compound Number:\n\nLY3298176\n\n# Study Phase:\n\nPhase 3\n\n# Short Title:\n\nEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who are either Obese or Overweight with Weight\u2011Related Comorbidities (SURMOUNT\u20111)\n\n# Acronym:\n\nSURMOUNT\u20111\n\n# Sponsor Name:\n\nEli Lilly and Company\n\n# Legal Registered Address:\n\nIndianapolis, Indiana, USA 46285\n\n# Regulatory Agency Identifier Number(s)\n\nIND: Preassigned IND # 139721\n\n# Approval Date:\n\nProtocol Electronically Signed and Approved by Lilly on date provided below.\n\n# Approval Date:\n\n09-Sep-2019 GMT\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 1826, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dea046f4-632d-45b8-a4b9-61cb2b142024": {"__data__": {"id_": "dea046f4-632d-45b8-a4b9-61cb2b142024", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "af01b4e9-edb5-472c-93d8-894d4b32dffa", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1fb7ac605623c55384b44e0c1e69863470eb5b39d64bb59f40f646d137532155", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Table of Contents\n\n1. Protocol Summary\n1. Synopsis\n2. Schema\n3. Schedule of Activities\n1. Schedule of Activities covering visits to primary study endpoint\n2. Schedule of Activities for continued follow\u2011up in participants with prediabetes at randomization\n2. Introduction\n1. Study Rationale\n2. Background\n3. Benefit/Risk Assessment\n3. Objectives and Endpoints\n4. Study Design\n1. Overall Design\n1. Overview of Study Periods\n2. Study Procedures\n2. Scientific Rationale for Study Design\n3. Justification for Dose\n4. End of Study Definition\n5. Study Population\n1. Inclusion Criteria\n2. Exclusion Criteria\n3. Lifestyle Considerations\n1. Meals and Dietary Restrictions\n2. Physical Activity\n4. Screen Failures\n6. Study Intervention\n1. Study Interventions Administered\n1. Medical Devices\n2. Preparation/Handling/Storage/Accountability\n3. Measures to Minimize Bias: Randomization and Blinding\n4. Study Intervention Compliance\n5. Concomitant Therapy\n6. Dose Modification\n1. Tirzepatide\n2. Management of Participants with Gastrointestinal Symptoms\n7. Intervention after the End of the Study\n1. Treatment after Study Completion\n7. Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\n1. Discontinuation of Study Intervention\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1291, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f68be336-28ad-4818-8848-df697737c1f2": {"__data__": {"id_": "f68be336-28ad-4818-8848-df697737c1f2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d2424e2f-847f-47dd-8c02-d4deb09e5710", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e0a4f38505b9dbe89318c3f88931baca5c9ca8787a4844133a6cfb929a8271b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                               Protocol I8F\u2011MC\u2011GPHK\n\n# 7.1.1. Temporary Study Drug Discontinuation\n\n55\n\n# 7.2. Participant Discontinuation/Withdrawal from the Study\n\n56\n\n# 7.2.1. Participant disposition and timing of safety follow\u2011up for the primary endpoint (72 weeks)\n\n57\n\n# 7.2.2. Participant disposition and timing of safety follow\u2011up for those with prediabetes undergoing 176 week follow\u2011up\n\n58\n\n# 7.2.3. Discontinuation of Inadvertently Enrolled Participants\n\n59\n\n# 7.3. Lost to Follow\u2011up\n\n59\n\n# 8. Study Assessments and Procedures\n\n60\n\n# 8.1. Efficacy Assessments\n\n60\n\n# 8.1.1. Primary Efficacy Assessments\n\n60\n\n# 8.1.2. Secondary Efficacy Assessments\n\n60\n\n# 8.1.3. Patient\u2011Reported Outcomes Assessments\n\n60\n\n# 8.1.4. Short Form 36 version 2, acute, 1 week recall version\n\n61\n\n# 8.1.5. Impact of Weight on Quality of Life\u2011Lite Clinical Trials Version\n\n61\n\n# 8.1.6. EQ\u20115D\u20115L\n\n61\n\n# 8.1.7. Patient Global Impression of Status for Physical Activity\n\n62\n\n# 8.2. Safety Assessments\n\n62\n\n# 8.2.1. Physical Examinations\n\n62\n\n# 8.2.2. Vital Signs\n\n62\n\n# 8.2.3. Electrocardiograms\n\n62\n\n# 8.2.4. Clinical Safety Laboratory Assessments\n\n63\n\n# 8.2.5. Safety Monitoring\n\n64\n\n# 8.2.6. Depression, Suicidal Ideation, and Behavior Risk Monitoring\n\n64\n\n# 8.3. Adverse Events and Serious Adverse Events\n\n65\n\n# 8.3.1. Time Period and Frequency for Collecting AE and SAE Information\n\n67\n\n# 8.3.2. Follow\u2011up of AEs and SAEs\n\n67\n\n# 8.3.3. Regulatory Reporting Requirements for SAEs\n\n67\n\n# 8.3.4. Pregnancy\n\n68\n\n# 8.3.5. Medical Device Incidents (Including Malfunctions)\n\n68\n\n# 8.3.6. Complaint Handling\n\n69\n\n# 8.4. Treatment of Overdose\n\n69\n\n# 8.5. Pharmacokinetics\n\n70\n\n# 8.6. Pharmacodynamics\n\n70\n\n# 8.7. Genetics\n\n70\n\n# 8.7.1. Whole Blood Sample(s) for Pharmacogenetic Research\n\n70\n\n# 8.8. Biomarkers\n\n71\n\n# 8.9. Health Economics\n\n71\n\n# 9. Statistical Considerations\n\n72\n\n# 9.1. Statistical Hypotheses\n\n72\n\n# 9.2. Sample Size Determination\n\n73\n\n# 9.3. Populations for Analyses\n\n75\n\n# 9.4. Statistical Analyses\n\n75\n\n# 9.4.1. General Statistical Considerations\n\n75\n\nLY3298176    3", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2111, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "493561d0-3b31-403d-bca2-0b85c027f047": {"__data__": {"id_": "493561d0-3b31-403d-bca2-0b85c027f047", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "42911f43-0b70-4674-928c-fcccc1462c9d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7c8c724fabf1ee58deb72c2e3e5890190f82cf83736703346a7aa96fdae9951b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                        Protocol I8F\u2011MC\u2011GPHK\n\n# 9.4.2. Treatment Group Comparability\n\n# 9.4.3. Efficacy Analyses\n\n# 9.4.4. Safety Analyses\n\n# 9.4.5. Pharmacokinetic/Pharmacodynamic Analyses\n\n# 9.4.6. Evaluation of Immunogenicity\n\n# 9.4.7. Other Analyses\n\n# 9.5. Interim Analyses\n\n# 10. Supporting Documentation and Operational Considerations\n\n# 10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations\n\n# 10.1.1. Regulatory and Ethical Considerations\n\n# 10.1.2. Informed Consent Process\n\n# 10.1.3. Data Protection\n\n# 10.1.4. Committees Structure\n\n# 10.1.5. Dissemination of Clinical Study Data\n\n# 10.1.6. Data Quality Assurance\n\n# 10.1.7. Data Capture System\n\n# 10.1.8. Source Documents\n\n# 10.1.9. Study and Site Closure\n\n# 10.1.10. Publication Policy\n\n# 10.2. Appendix 2: Clinical Laboratory Tests\n\n# 10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow\u2011Up, and Reporting\n\n# 10.3.1. Special Safety Topics\n\n# 10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information\n\n# 10.5. Appendix 5: Liver Safety: Suggested Actions and Follow\u2011Up Assessments\n\n# 10.6. Appendix 6: Medical Device Incidents: Definition and Procedures for Recording, Evaluating, Follow\u2011Up, and Reporting\n\n# 10.7. Appendix 7: Protocol GPHK Standardized Protocols for the Measurement of Height, Weight, Waist Circumference, Vital Signs, Electrocardiogram, and Oral Glucose Tolerance Test\n\n# 10.8. Appendix 8: Suggested Visit Structure\n\n# 10.9. Appendix 9: Management of Gastrointestinal Symptoms\n\n# 10.10. Appendix 10: Abbreviations\n\n# 11. References\n\nLY3298176    4", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1658, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "51d2371a-b199-45f0-bef6-8912d7fcc563": {"__data__": {"id_": "51d2371a-b199-45f0-bef6-8912d7fcc563", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4ef0ff0f-c249-4d63-8acc-5c4df7b912bf", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "65883541eaa41f9f295f8f5d0a1137cf54b7fc9714faaae21480d3db389140a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 1. Protocol Summary\n\n# 1.1. Synopsis\n\nProtocol Title:\n\nEfficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight\u2011Related Comorbidities: A Randomized, Double\u2011Blind, Placebo\u2011Controlled Trial (SURMOUNT\u20111)\n\nShort Title:\n\nEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who are either Obese or Overweight with Weight\u2011Related Comorbidities (SURMOUNT\u20111)\n\nRationale:\n\nObesity is a chronic disease and its increasing prevalence is a public health concern associated with the rising incidence of type 2 diabetes mellitus (T2DM), increased risk for premature death and increased risk for some cancers (Allison et al. 2008; AMA 2013; Council on Science and Public Health 2013). Although loss of 5% to 10% body weight has been shown to reduce complications related to obesity and improve quality of life (Mertens and Van Gaal 2000; Knowler et al. 2002; Jensen et al. 2014; Li et al. 2014; Warkentin et al. 2014), lifestyle therapies fail to achieve sustainable weight loss in the majority of patients with obesity (Dombrowski et al. 2014).\n\nThe gut incretin hormones, glucose\u2011dependent insulinotropic polypeptide (GIP) and glucagon\u2011like peptide\u20111 (GLP\u20111), are secreted after meal ingestion and mediate the incretin effect. Both hormones have effects on endocrine cells in the pancreas, increasing insulin biosynthesis and secretion, and modifying glucagon secretion (Skow et al. 2016). Based on these properties, several GLP\u20111 receptor (GLP\u20111R) agonists have been approved for pharmacological treatment of T2DM (Tomlinson et al. 2016).\n\nIn addition to its pancreatic effects, GLP\u20111R activation decreases gut motility, slows gastric emptying, and promotes satiety (presumably through a combination of GLP\u20111R activation in the central and peripheral nervous systems), thereby regulating food intake and body weight (Baggio and Drucker 2007). The US Food and Drug Administration and the European Medicines Agency approved the GLP\u20111R agonist liraglutide for the treatment of overweight and obesity (SAXENDA\u00ae package insert, 2014; SAXENDA\u00ae SmPc, 2015).\n\nPreclinical data indicate that GIP also exerts effects on appetite regulation and food intake, adipose tissue, and on peripheral energy metabolism. Although studies evaluating effects of GIP on body weight have yielded equivocal results, GIP receptor (GIPR) activation may play a role in body weight regulation and targeting both the GLP\u20111R and the GIPR simultaneously may result in additive or synergistic effects of the 2 incretins on body weight (Coskun et al. 2018).\n\nTirzepatide is a 39\u2011amino acid synthetic peptide dual GIP and GLP\u20111 receptor agonist. Its structure is based on the GIP sequence and includes a C20 fatty diacid moiety. It is administered once\u2011weekly (QW) by subcutaneous (SC) injection (Coskun et al. 2018).\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2923, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1d091764-94cd-42be-b387-a2af886f46ac": {"__data__": {"id_": "1d091764-94cd-42be-b387-a2af886f46ac", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c8b0266-eb33-4241-bd0a-94456fbe6034", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1d972990d39cc1d9af4a3bd2022c748e7e471d1b75ec34fb836b40d4a97b7ec2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL           Protocol I8F\u2011MC\u2011GPHK\n\nAs a dual GIP/GLP\u20111R agonist, tirzepatide could exceed the efficacy of selective GLP\u20111R agonists by recruiting metabolically active tissues not targeted by selective GLP\u20111R agonists (for example, adipose tissue as indicated by the observation of increased energy utilization) (Baggio and Drucker 2007) and has the potential to reach higher efficacy in target tissues, such as insulin\u2011producing pancreatic beta cells that express both GIPR and GLP\u20111R, before reaching its therapeutic limitation.\n\n# Study I8F\u2011MC\u2011GPHK (GPHK; SURMOUNT\u20111)\n\nis a Phase 3, multicenter, randomized, placebo\u2011controlled, double\u2011blinded study of the safety and efficacy of 5\u2011mg, 10\u2011mg and 15\u2011mg tirzepatide QW, compared with placebo, when used in conjunction with a reduced\u2011calorie diet and increased physical activity for weight management, in participants who do not have T2DM, and have obesity (BMI \u226530 kg/m\u00b2) or are overweight (BMI \u226527 kg/m\u00b2) with at least one weight\u2011related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). All participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction. Participants who have prediabetes will be studied for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to detect potential differences in progression to T2DM.\n\nLY3298176    6", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1401, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c5cacbcd-a282-43d4-a0cd-f0de9a5e7402": {"__data__": {"id_": "c5cacbcd-a282-43d4-a0cd-f0de9a5e7402", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "01c17e6c-bbbc-47de-88f1-aa8c7b93cb62", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "41233d8240f2590607af7faf0931893f71725958cecb0f4072222f7c81c873fb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Objectives and Endpoints\n\n# Objectives\n\n| Primary                                                              | at 72 weeks, by dose analysis                                                               |   |\n| -------------------------------------------------------------------- | ------------------------------------------------------------------------------------------- | - |\n| To demonstrate that tirzepatide 10 mg QW is superior to placebo for: |                                                                                             |   |\n| \u2022 percent change in body weight AND                                  | \u2022 mean percent change in body weight from randomization                                     |   |\n| \u2022 percentage of participants with \u22655% body weight reduction          | \u2022 percentage of study participants who achieve \u22655% body weight reduction from randomization |   |\n| AND/OR                                                               |                                                                                             |   |\n| To demonstrate that tirzepatide 15 mg QW is superior to placebo for: |                                                                                             |   |\n| \u2022 percent change in body weight AND                                  |                                                                                             |   |\n| \u2022 percentage of participants with \u22655% body weight reduction          |                                                                                             |   |\n\n# Key secondary (controlled for Type I error)\n\n| at 20 weeks, by dose analysis                                                                  |                                                      |   |\n| ---------------------------------------------------------------------------------------------- | ---------------------------------------------------- | - |\n| For tirzepatide 5\u2011mg, 10\u2011mg, and/or 15\u2011mg QW doses, to demonstrate superiority to placebo for: |                                                      |   |\n| \u2022 body weight                                                                                  | \u2022 mean change in body weight (kg) from randomization |   |\n\n# Key secondary (controlled for Type I error)\n\n| at 72 weeks, by dose analysis                                       |                                                                                             |   |\n| ------------------------------------------------------------------- | ------------------------------------------------------------------------------------------- | - |\n| To demonstrate that tirzepatide 5 mg QW is superior to placebo for: |                                                                                             |   |\n| \u2022 percent change in body weight AND                                 | \u2022 mean percent change in body weight from randomization                                     |   |\n| \u2022 percentage of participants with \u22655% body weight reduction         | \u2022 percentage of study participants who achieve \u22655% body weight reduction from randomization |   |\n\nLY3298176    7", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3213, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ce874262-8e2e-4fbc-9f89-699bc6e8e889": {"__data__": {"id_": "ce874262-8e2e-4fbc-9f89-699bc6e8e889", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "53ac8d95-8ed5-4398-8613-7d87e513363d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ee6bd1bef91e5dd8717a68d11d3f0f26c7a63ae9b6154fb97fb8f5c824ce7f93", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Objectives\n\nFor tirzepatide 10\u2011mg and/or 15\u2011mg QW doses, to demonstrate superiority to placebo for:\n\n- body weight\n- waist circumference\n- patient reported outcomes (SF\u201136v2 acute form Physical Functioning)\n\n# Endpoints\n\n- percentage of participants who achieve;\n- \u226510% body weight reduction from randomization\n- \u226515% body weight reduction from randomization\n- mean change in waist circumference (cm) from randomization\n- mean change in SF\u201136v2 acute form Physical Functioning domain score from randomization\n\n# Key secondary (controlled for Type I error) at 72 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo for:\n\n- mean change from randomization in lipid parameters\n- triglycerides (mg/dL)\n- LDL (mg/dL)\n- total cholesterol (mg/dL)\n- mean change in SBP (mmHg) from randomization\n- mean change in fasting insulin (pmol/L) from randomization\n\n# Key secondary (controlled for Type I error) at 176 weeks, by dose analysis\n\nFor tirzepatide 10\u2011mg and/or 15\u2011mg QW doses, to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- mean percent change in body weight from randomization\n\n# Key secondary (controlled for Type I error) at 176 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo (for participants with prediabetes at randomization) in:\n\nLY3298176    8", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1455, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ea39294d-6c99-4bb5-b4bd-3f999bfbd0d9": {"__data__": {"id_": "ea39294d-6c99-4bb5-b4bd-3f999bfbd0d9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cb1de74d-585b-4c20-886e-2081c3aa2c19", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0046556afdd0d66a6ea44b1ca0c7b09b050cf014654048ba23e738f890f8af2b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Objectives\n\n- delayed progression to T2DM\n\n# Endpoints\n\n- time to onset of T2DM\n\n# Additional secondary at 72 weeks, by dose analysis\n\nFor tirzepatide 5\u2011mg QW dose, to demonstrate superiority to placebo for:\n\n- body weight\n- percentage of participants who achieve:\n- \u226510% body weight reduction from randomization\n- \u226515% body weight reduction from randomization\n- waist circumference\n- mean change in waist circumference (cm) from randomization\n- patient\u2011reported outcomes (SF\u201136v2 Physical Functioning)\n- mean change in SF\u201136v2 acute form Physical Functioning domain score from randomization\n\n# For tirzepatide 5\u2011mg, 10\u2011mg, and/or 15\u2011mg QW doses, to demonstrate superiority to placebo for:\n\n- body weight\n- mean change in body weight (kg) from randomization\n- mean change in BMI (kg/m\u00b2) from randomization\n- glycemic control\n- mean change in HbA1c (%, mmol/mol) from randomization\n- mean change in fasting glucose (mg/dL) from randomization\n- patient\u2011reported outcomes\n- mean change in IWQOL\u2011Lite\u2011CT Physical Function composite score from randomization\n\n# Additional secondary at 72 weeks, pooled analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo for:\n\n- DBP\n- mean change in DBP (mmHg) from randomization\n\nLY3298176    9", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1301, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2857959a-a3b6-4b63-95f0-707e4a52744a": {"__data__": {"id_": "2857959a-a3b6-4b63-95f0-707e4a52744a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1def02ee-a12e-4e6d-96f4-7fcde7cbeadb", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "55b1b79b077dfc65160162b9ba50a94f76017f5fccf207cae8b9c0d6be36321c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Objectives\n\n- lipid parameters\n\n# Endpoints\n\n- mean change from randomization in:\n- HDL\u2011cholesterol (mg/dL)\n- VLDL\u2011cholesterol (mg/dL)\n- free fatty acids (mg/dL)\n\n# Additional secondary at 176 weeks, by dose analysis\n\nFor tirzepatide 5\u2011mg QW dose, to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- body weight\n- mean percent change in body weight from randomization\n\nFor tirzepatide 5 mg, 10 mg and/or 15 mg QW doses, to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- body weight\n- percentage of study participants who achieve \u22655% body weight reduction from randomization\n\n# Additional Secondary at 176 weeks, pooled analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- Patient\u2011reported outcomes\n- mean change in SF\u201136v2 acute form Physical Functioning domain score from randomization\n- mean change in IWQOL\u2011Lite\u2011CT Physical Function composite score from randomization\n\n# Additional Secondary\n\n# Pharmacokinetics/Pharmacodynamics\n\n- To characterize the population PK of tirzepatide and explore the relationships between the tirzepatide concentration and efficacy, safety and tolerability measures\n\n- population PK and PD parameters\n\nLY3298176    10", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1384, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "06eca883-e31c-4f1c-9687-b7215ea26427": {"__data__": {"id_": "06eca883-e31c-4f1c-9687-b7215ea26427", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6fa35e93-d004-4acd-98c0-ff8b44bfee13", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1e510d58297d63354fae19fe5be8dc41b1e951e34e0119ebf29d4c4072a8e8b4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\nAbbreviations: AUC= area under curve; BMI = body mass index; DBP = diastolic blood pressure; HbA1c = hemoglobin A1c; HDL = high\u2011density lipoprotein; IWQOL\u2011Lite\u2011CT = Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version; LDL = low\u2011density lipoprotein; PK = pharmacokinetics; QW = once\u2011weekly; SF\u201136v2 = Short Form survey\u201136 version 2; SBP = systolic blood pressure; T2DM = type 2 diabetes mellitus; VLDL = very low\u2011density lipoprotein.\n\nLY3298176    11", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 501, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0fff3251-c4db-47a0-8088-4d24784bdb84": {"__data__": {"id_": "0fff3251-c4db-47a0-8088-4d24784bdb84", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "acff764f-19de-4cd5-8013-acd83cda2667", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ad64943f5494b517a63687d4f10744f815ddc25e6ea849a55496c57fe0f7d80a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                        Protocol I8F\u2011MC\u2011GPHK\n\n# Overall Design:\n\nStudy I8F\u2011MC\u2011GPHK is a Phase 3, multicenter, randomized, placebo\u2011controlled, double\u2011blinded study of the safety and efficacy of 5\u2011mg, 10\u2011mg, and 15\u2011mg tirzepatide QW compared with placebo for weight management when used in conjunction with a reduced\u2011calorie diet and increased physical activity, in participants who have obesity (BMI \u226530 kg/m\u00b2) or are overweight (BMI \u226527 kg/m\u00b2) with weight\u2011related comorbidities (excluding T2DM). Eligible participants will be stratified based on prediabetes status to either 72 (no prediabetes) or 176 weeks (prediabetes), follow\u2011up for endpoints of weight loss, and delay of diabetes onset.\n\n# Disclosure Statement:\n\nThis is a parallel group\u2011treatment study with 4 arms that is participant and investigator blinded.\n\n# Number of Participants:\n\nApproximately 2400 participants will be randomized in a 1:1:1:1 ratio to 5\u2011mg tirzepatide (600 participants), 10\u2011mg tirzepatide (600 participants), 15\u2011mg tirzepatide (600 participants), and placebo (600 participants). An upper limit of 70% enrollment of women will be used to ensure a sufficiently large sample of men.\n\n# Intervention Groups and Duration:\n\nStudy participants will be randomized in a 1:1:1:1 ratio (tirzepatide 5 mg QW, tirzepatide 10 mg QW, tirzepatide 15 mg QW, and placebo QW), stratified by country, sex, and prediabetes status. All participants will undergo a 2\u2011week screening period and a 72\u2011week treatment period including a 20\u2011week dose escalation. Participants with prediabetes at randomization who remain on study drug during the first 72 weeks will undergo a further 104\u2011week treatment period (total treatment duration of 176 weeks). The safety follow\u2011up period will be 4 weeks (for those completing or discontinuing study drug during the first 72 weeks) or 12 weeks (for participants completing or discontinuing study drug between weeks 72\u2011176).\n\n# Data Monitoring Committee:\n\nAn independent data monitoring committee (DMC) will review unblinded interim\u2011analysis results.\n\nLY3298176    12", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2106, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "aa0122f5-61e3-4b36-b156-04f126ea617c": {"__data__": {"id_": "aa0122f5-61e3-4b36-b156-04f126ea617c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "db8fa304-fee4-499c-ad1a-872980c85845", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "283e6e273ff2090ba98c4314f12d7b1448da31ee3c133cef15a3056979f34df9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 1.2. Schema\n\nAbbreviations: QW= once weekly; T= telephone visit.\n\nAll participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction.\n\nParticipants who have prediabetes will be studied for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to detect potential differences in progression to T2DM. The safety follow\u2011up visit will occur after 4 weeks in participants discontinuing (or completing) the study within the first 72 weeks. Those discontinuing (or completing) the study after 72 weeks will undergo safety follow\u2011up after 12 weeks.\n\nLY3298176    13", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 664, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2d927dd5-1c23-4a06-aaed-603be3a12742": {"__data__": {"id_": "2d927dd5-1c23-4a06-aaed-603be3a12742", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a593f579-2bbf-4517-a269-b80d6aa6f111", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "82ef09249ee0b38057e8f1dd9adc58a3bfdecce5d01a53468a635a8c17d0142f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc8b3740-6791-468d-b088-cde0d5cf8e08", "node_type": "1", "metadata": {}, "hash": "27e6aa8beb95d8ec417f401ae862c061291ee6d6e1a87d138af3d05862c19ae5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 1.3.  Schedule of Activities\n\n# 1.3.1. Schedule of Activities covering visits to primary study endpoint\n\n| Visit\\*                               | 1  | 2  | 3\\* | 4  | 5  | 6                    | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 99\\* | ED\\*  | 801\\* |   |   |   |\n| ------------------------------------- | -- | -- | --- | -- | -- | -------------------- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ---- | ----- | ----- | - | - | - |\n| Week of Treatment                     | -2 | -1 | 0   | 4  | 8  | 12                   | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 52 | 56 | 60 | 64 | 68 | 72 | 72   | 4 wks |       |   |   |   |\n| Allowable Deviation (days)\\*          |    | \u00b13 | \u00b13  | \u00b13 | +7 | \u00b13                   | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b17   | \u00b13    |       |   |   |   |\n| Fasting Visit\\*                       | X  | X  | X   | X  | X  | X                    | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X    | X     |       |   |   |   |\n| Telephone Visit                       |    |    |     |    |    | X                    | X  |    | X  | X  |    | X  | X  |    | X  | X  |    | X  |    | X  |    | X    |       | X     |   |   |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1347, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bc8b3740-6791-468d-b088-cde0d5cf8e08": {"__data__": {"id_": "bc8b3740-6791-468d-b088-cde0d5cf8e08", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a593f579-2bbf-4517-a269-b80d6aa6f111", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "82ef09249ee0b38057e8f1dd9adc58a3bfdecce5d01a53468a635a8c17d0142f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d927dd5-1c23-4a06-aaed-603be3a12742", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "78940f586290237b5b6ee758e98661907a19881b2727b69ce7fbfa40857bf0c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dbd2c33-0b0b-4f6f-b5d4-6d4b121bdf39", "node_type": "1", "metadata": {}, "hash": "60b911cd9a27d3508ebd432f1677665bef4a0f78636c0fdca6e7b63a10010c78", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "|    |    |     |    |    | X                    | X  |    | X  | X  |    | X  | X  |    | X  | X  |    | X  |    | X  |    | X    |       | X     |   |   |   |\n| Informed consent                      | X  |    |     |    |    |                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |       |       |   |   |   |\n| Randomization                         |    | X  |     |    |    |                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |       |       |   |   |   |\n|                                       |    |    |     |    |    | Clinical Assessments |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |       |       |   |   |   |\n| Medical history\\*                     | X  |    |     |    |    |                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |       |       |   |   |   |\n| Physical examination                  | X  |    |     |    |    |", "mimetype": "text/plain", "start_char_idx": 1191, "end_char_idx": 2223, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7dbd2c33-0b0b-4f6f-b5d4-6d4b121bdf39": {"__data__": {"id_": "7dbd2c33-0b0b-4f6f-b5d4-6d4b121bdf39", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a593f579-2bbf-4517-a269-b80d6aa6f111", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "82ef09249ee0b38057e8f1dd9adc58a3bfdecce5d01a53468a635a8c17d0142f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc8b3740-6791-468d-b088-cde0d5cf8e08", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b8872429f26d326d4efa9b51a3047cec3a96e22b1d47607c03ae5b43cfd1f26d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f0456b9-7b60-40b5-9a4a-5f82eca3fdc9", "node_type": "1", "metadata": {}, "hash": "ca96482d2cee2ab9e5ae8ca87c2e5f1b355bbcd18f2523bbf61eb89537e826ff", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "|    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |       |       |   |   |   |\n| Physical examination                  | X  |    |     |    |    |                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |       |       |   |   |   |\n| Height                                | X  |    |     |    |    |                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |       |       |   |   |   |\n| Weight\\*                              | X  | X  | X   | X  | X  | X                    | X  | X  |    | X  |    | X  | X  | X  | X  |    | X  |    | X  |    |    |      |       |       |   |   |   |\n| Waist circumference                   |    | X  | X   | X  | X  | X                    | X  |    | X  |    | X  | X  | X  | X  | X  |    | X  |    | X  |    |    |      |       |       |   |   |   |\n| Electrocardiogram\\*                   |    | X  | X   |    | X  |                      | X  |    | X  |    | X  |    | X  |    | X  |    |    |", "mimetype": "text/plain", "start_char_idx": 2049, "end_char_idx": 3105, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3f0456b9-7b60-40b5-9a4a-5f82eca3fdc9": {"__data__": {"id_": "3f0456b9-7b60-40b5-9a4a-5f82eca3fdc9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a593f579-2bbf-4517-a269-b80d6aa6f111", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "82ef09249ee0b38057e8f1dd9adc58a3bfdecce5d01a53468a635a8c17d0142f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dbd2c33-0b0b-4f6f-b5d4-6d4b121bdf39", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "40596239ae0cac578b6125b6f21207a3adfeb0e5a6b1c3b1450bef43f2109bbe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "|       |       |   |   |   |\n| Electrocardiogram\\*                   |    | X  | X   |    | X  |                      | X  |    | X  |    | X  |    | X  |    | X  |    |    |    |    |    |    |      |       |       |   |   |   |\n| Vital signs (3 sitting BP and HR)\\*   | X  | X  | X   | X  | X  | X                    | X  |    | X  |    | X  |    | X  | X  | X  |    | X  |    | X  |    |    |      |       |       |   |   |   |\n| Adverse events and product complaints | X  | X  | X   | X  | X  | X                    | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  |      |       |       |   |   |   |\n| Concomitant medications               | X  | X  | X   | X  | X  | X                    | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  |      |       |       |   |   |   |\n\n# Participant Education and Assessment\n\n| Hand out diary, instruct in use\\*                                 | X |   | X |   | X |   | X |   |   |   |   |   |   |   |   |   |   |   |   |   |   |\n| ----------------------------------------------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| Review study participant diary, including study\u2011drug compliance\\* |   | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |   |   |\n| Lifestyle Program instructions\\*                                  | X | X | X |   | X |   | X |   | X |   | X |   | X |   | X |   | X |   | X |   |   |\n\nLY3298176    14", "mimetype": "text/plain", "start_char_idx": 2930, "end_char_idx": 4437, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "55e4e3c6-8615-49e7-b4c9-fb0dda0a0c63": {"__data__": {"id_": "55e4e3c6-8615-49e7-b4c9-fb0dda0a0c63", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0b0a029a-56bc-43b2-88d8-88a0c75b2527", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "94147f9c85ead6ac97d51c4acf9ae9800803f8bbf261129d3e1dfcb121643b73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63db807c-c6fd-4a7d-828a-7aafcdae4d36", "node_type": "1", "metadata": {}, "hash": "1f1a077d30faa0792ab7c32b17c7bdcef66b1293a9fd0dcd83ca3c4f8b4e2369", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Visit*\n\n| 1                 | 2  | 3\\* | 4 | 5 | 6 | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 99\\* | ED\\* | 801\\* |\n| ----------------- | -- | --- | - | - | - | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ---- | ---- | ----- |\n| Week of Treatment | -2 | -1  | 0 | 4 | 8 | 12 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 52 | 56 | 60 | 64 | 68 | 72   | 72   | 4 wks |\n\n# Allowable Deviation\n\n| (days)\\* | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b17 | \u00b13 |\n| -------- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |\n\n# Fasting Visit*\n\n| X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Telephone Visit\n\n|   |   | X | X |   | X |   | X |   | X |   |\n| - | - | - | - | - | - | - | - | - | - | - |\n\n# Review diet and exercise goals*\n\n| X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Injection training with autoinjector demonstration device*\n\nX\n\n# Dispense study drug\n\n| X | X | X | X | X | X |   | X |   | X |   | X\\* |\n| - | - | - | - | - | - | - | - | - | - | - | --- |\n\n# Observe participant administer study drug*\n\nX\n\n# Participant returns study drugs and injection supplies\n\n| X | X | X | X | X | X |   | X |   | X |   | X |   | X |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Laboratory Tests\n\n| Serum pregnancy test\\*", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1668, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "63db807c-c6fd-4a7d-828a-7aafcdae4d36": {"__data__": {"id_": "63db807c-c6fd-4a7d-828a-7aafcdae4d36", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0b0a029a-56bc-43b2-88d8-88a0c75b2527", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "94147f9c85ead6ac97d51c4acf9ae9800803f8bbf261129d3e1dfcb121643b73", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55e4e3c6-8615-49e7-b4c9-fb0dda0a0c63", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7157cb0e01cf0e64c53f961eef2b249e248f1a8c53f426212474436de75dabb4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "drug*\n\nX\n\n# Participant returns study drugs and injection supplies\n\n| X | X | X | X | X | X |   | X |   | X |   | X |   | X |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Laboratory Tests\n\n| Serum pregnancy test\\*                                                                        | X |   |   |   |   |   |   |   |   |   |\n| --------------------------------------------------------------------------------------------- | - | - | - | - | - | - | - | - | - | - |\n| Urine pregnancy test\\*                                                                        |   | X |   | X |   | X |   | X | X | X |\n| Follicle\u2011stimulating hormone test\\*                                                           | X |   |   |   |   |   |   |   |   |   |\n| 2\u2011hour oral glucose tolerance test (includes glucose, insulin, c\u2011peptide at each timepoint)\\* | X |   |   |   |   | X |   | X |   |   |\n| Chemistry panel (include Cr for eGFR calculation and glucose)\\*                               | X |   | X |   | X |   | X |   | X | X |\n| Lipid panel                                                                                   | X |   | X |   |   | X |   | X |   |   |\n| Fasting insulin                                                                               |   | X | X | X | X | X |   | X | X |   |\n\nLY3298176    15", "mimetype": "text/plain", "start_char_idx": 1439, "end_char_idx": 2764, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9f8b574d-b38d-4a56-8ec2-33adb1ce3ef5": {"__data__": {"id_": "9f8b574d-b38d-4a56-8ec2-33adb1ce3ef5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "43fb8e82-07ae-4173-8391-dc4b0fd48669", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6321b538ac3a2fdcd8a7a7239fd8ff43c99aceb8d42105a0ec607cafc42c85af", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n| Visit\\*                      | 1  | 2  | 3\\* | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 99\\* | ED\\*  | 801\\*    |\n| ---------------------------- | -- | -- | --- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ---- | ----- | -------- |\n| Week of Treatment            | -2 | -1 | 0   | 4  | 8  | 12 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 52 | 56 | 60 | 64 | 68 | 72 | 72   | 4 wks | Post TxP |\n| Allowable Deviation (days)\\* | \u00b13 | \u00b13 | \u00b13  | +7 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b17 | \u00b13 |      |       |          |\n\n| Fasting Visit\\* | Telephone Visit | C\u2011peptide | Free fatty acids | Urinary albumin/creatinine | Cystatin\u2011c | Calcitonin | Hematology | HbA1c | Pancreatic amylase, lipase | Thyroid\u2011stimulating hormone | Immunogenicity (includes PK sample)\\* | TZP PK\\* | Pharmacogenetic stored sample | Nonpharmacogenetic stored sample |\n| --------------- | --------------- | --------- | ---------------- | -------------------------- | ---------- | ---------- | ---------- | ----- | -------------------------- | --------------------------- | ------------------------------------- | -------- | ----------------------------- | -------------------------------- |\n| X               |                 | X         | X                | X\\*                        | X\\*        | X\\*        | X\\*        | X     | X                          | X\\*                         | X                                     | X        | X                             | X                                |\n| X               | X               | X         |                  |                            |            |            | X          | X     | X                          |                             |                                       |          |                               | X                                |\n| X               | X               | X         | X                | X                          | X          | X          | X          | X     | X                          | X                           | X                                     | X        | X                             | X                                |\n\n| Mental Health Questionnaires | PHQ\u20119\\* | C\u2011SSRS (Baseline/Screening Version)\\* | C\u2011SSRS (Since Last Visit Version)\\* |\n| ---------------------------- | ------- | ------------------------------------- | ----------------------------------- |\n|                              | X       | X                                     | X                                   |\n|                              | X       |                                       | X                                   |\n|                              | X       |                                       | X                                   |\n|                              | X       |                                       | X                                   |\n|                              | X       |                                       | X                                   |\n|                              | X       |                                       | X                                   |\n|                              | X       |                                       | X                                   |\n|                              | X       |                                       | X                                   |\n|                              | X       |                                       | X                                   |\n|                              | X       |                                       | X                                   |\n\nLY3298176    16", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3779, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "aa6d3512-4ad8-4a0f-8027-0b4c8ae8d5f3": {"__data__": {"id_": "aa6d3512-4ad8-4a0f-8027-0b4c8ae8d5f3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d1be9396-079c-4b78-88bb-4fd37d811428", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a2f0640a9a179a1406b020d2a7dc403343ab4069949b2fda5e532396a4cb15db", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n| Visit\\*                      | 1  | 2  | 3\\* | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 99\\* | ED\\*  | 801\\* |\n| ---------------------------- | -- | -- | --- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ---- | ----- | ----- |\n| Week of Treatment            | -2 | -1 | 0   | 4  | 8  | 12 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 52 | 56 | 60 | 64 | 68 | 72 | 72   | 4 wks |       |\n| Allowable Deviation (days)\\* | \u00b13 | \u00b13 | \u00b13  | +7 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 | +7 | \u00b13   |       |       |\n\n| Fasting Visit\\*             | X | X | X | X | X | X | X | X |   | X |   | X |   | X |   | X |   | X |   | X |   | X |   |\n| --------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| Telephone Visit             |   |   | X | X | X | X | X | X | X |   |   |   |   |   |   |   |   |   |   |   |   |   |   |\n| Self\u2011Harm Supplement Form\\* | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |   |\n| Self\u2011Harm Follow\u2011up Form\\*  | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |   |\n\n# Patient Reported Outcomes\n\n| PGIS                         | X |   |   |   |   |   |   |   |   | X |   | X |\n| ---------------------------- | - | - | - | - | - | - | - | - | - | - | - | - |\n| SF\u201136, version 2, acute form | X |   |   |   |   |   |   |   |   | X |   | X |\n| IWQOL\u2011Lite CT                | X |   |   |   |   |   |   |   |   | X |   | X |\n| EQ\u20115D\u20115L                     | X |   |   |   |   |   |   |   |   | X |   | X |\n\nLY3298176    17", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1759, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d8929ec1-a649-46ce-8cf0-c8a5aaa6eeeb": {"__data__": {"id_": "d8929ec1-a649-46ce-8cf0-c8a5aaa6eeeb", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "512f94e0-dbed-48a1-afe7-dac48f9bfb30", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "57c3c46ee046601916dadad9f060937a3482477247254132d16351839adae7df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75d823b4-f7fa-462b-b996-866c9cae4bcd", "node_type": "1", "metadata": {}, "hash": "1dd7fc36212154b1e4da26c15215dce7dbba7f6dbc5ba4383ea5cd496a5ba9f1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 1.3.2. Schedule of Activities for continued follow-up in participants with prediabetes at randomization\n\n| Visit\\*                                                           | 101 | 102 | 103 | 104                                  | 105 | 106 | 107 | 108 | 109    | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 199\\* | ED\\*     | 802\\* |   |   |   |\n| ----------------------------------------------------------------- | --- | --- | --- | ------------------------------------ | --- | --- | --- | --- | ------ | --- | --- | --- | --- | --- | --- | --- | ----- | -------- | ----- | - | - | - |\n| Week of                                                           |     |     |     |                                      |     |     |     |     | 12 wks |     |     |     |     |     |     |     |       |          |       |   |   |   |\n| Treatment                                                         | 78  | 85  | 91  | 98                                   | 104 | 111 | 117 | 124 | 130    | 137 | 143 | 150 | 156 | 163 | 169 | 176 | 176   | Post TxP |       |   |   |   |\n| Allowable Deviation (days)\\*                                      | \u00b17  | \u00b17  | \u00b17  | \u00b17                                   | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17     | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17    | \u00b13", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1322, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "75d823b4-f7fa-462b-b996-866c9cae4bcd": {"__data__": {"id_": "75d823b4-f7fa-462b-b996-866c9cae4bcd", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "512f94e0-dbed-48a1-afe7-dac48f9bfb30", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "57c3c46ee046601916dadad9f060937a3482477247254132d16351839adae7df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8929ec1-a649-46ce-8cf0-c8a5aaa6eeeb", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ff4edb63c6c3a9ea93ec991fe3a226141b6b7e5b9f309e09090f1b5ae2905754", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "148db91d-5de0-4e1f-846a-32c30e0498a5", "node_type": "1", "metadata": {}, "hash": "fff65df44f5a975649d2bbe13fda1155e8f3b04a0ce3c93060ac3731fa4db05c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| \u00b17  | \u00b17  | \u00b17  | \u00b17                                   | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17     | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17    | \u00b13       |       |   |   |   |\n| Fasting Visit\\*                                                   | X   |     | X   | X                                    |     | X   | X   | X   | X      | X   | X   | X   | X   | X   | X   | X   |       | X        |       |   |   |   |\n| Telephone Visit                                                   | X   | X   |     | X                                    | X   |     | X   | X   |        |     |     |     |     |     |     |     |       |          |       |   |   |   |\n|                                                                   |     |     |     | Clinical Assessments                 |     |     |     |     |        |     |     |     |     |     |     |     |       |          |       |   |   |   |\n| Weight\\*                                                          |", "mimetype": "text/plain", "start_char_idx": 1178, "end_char_idx": 2143, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "148db91d-5de0-4e1f-846a-32c30e0498a5": {"__data__": {"id_": "148db91d-5de0-4e1f-846a-32c30e0498a5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "512f94e0-dbed-48a1-afe7-dac48f9bfb30", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "57c3c46ee046601916dadad9f060937a3482477247254132d16351839adae7df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75d823b4-f7fa-462b-b996-866c9cae4bcd", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "5fe5bce264db9db5329b1e25c42b50b0546254db48fd2ebe91ccb2ac874aa1cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "415d18b9-474b-4cfb-b9b0-8a2fee063e69", "node_type": "1", "metadata": {}, "hash": "c6af3eb4dd90ee7bacfd66544a445eda38a3545b6408ecc4ce30ea0f9fcbc0d6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "|     |     |     |     |     |     |       |          |       |   |   |   |\n| Weight\\*                                                          | X   |     | X   | X                                    |     | X   | X   | X   | X      | X   | X   | X   | X   | X   | X   | X   |       | X        |       |   |   |   |\n| Waist circumference                                               | X   |     | X   | X                                    |     | X   | X   | X   |        | X   |     |     |     |     |     |     |       | X        |       |   |   |   |\n| Electrocardiogram\\*                                               |     |     |     | X                                    |     |     | X   |     | X      |     |     |     |     |     |     |     |       |          |       |   |   |   |\n| Vital signs (3 sitting BP and HR)\\*                               | X   |     | X   | X                                    |     | X   | X   | X   |        | X   |     |     |     |     |     |", "mimetype": "text/plain", "start_char_idx": 1997, "end_char_idx": 2992, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "415d18b9-474b-4cfb-b9b0-8a2fee063e69": {"__data__": {"id_": "415d18b9-474b-4cfb-b9b0-8a2fee063e69", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "512f94e0-dbed-48a1-afe7-dac48f9bfb30", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "57c3c46ee046601916dadad9f060937a3482477247254132d16351839adae7df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "148db91d-5de0-4e1f-846a-32c30e0498a5", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "30adf915dc36ba7912ba4886fbf04cc7c5d9a36d72fb5cab9385426cfc13b319", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af86ec6d-75e8-4291-b54c-35facc4607b9", "node_type": "1", "metadata": {}, "hash": "280d4e700141437e34cc32e26ae889f9435b7f68e82d6e517c3729e25e3fb7cd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| X   |     | X   | X                                    |     | X   | X   | X   |        | X   |     |     |     |     |     |     |       | X        |       |   |   |   |\n| Adverse events/Product Complaints                                 | X   | X   | X   | X                                    | X   | X   | X   | X   | X      | X   | X   | X   | X   | X   | X   | X   | X     | X        |       |   |   |   |\n| Concomitant medications                                           | X   | X   | X   | X                                    | X   | X   | X   | X   | X      | X   | X   | X   | X   | X   | X   | X   | X     | X        |       |   |   |   |\n|                                                                   |     |     |     | Participant Education and Assessment |     |     |     |     |        |     |     |     |     |     |     |     |       |          |       |   |   |   |\n| Hand out diary, instruct in use\\*                                 | X   |     | X   | X                                    |     | X   | X   |     |        |     |     |     |     |     |     |     |       |          |       |   |   |   |\n| Review study participant diary,", "mimetype": "text/plain", "start_char_idx": 2865, "end_char_idx": 4035, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "af86ec6d-75e8-4291-b54c-35facc4607b9": {"__data__": {"id_": "af86ec6d-75e8-4291-b54c-35facc4607b9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "512f94e0-dbed-48a1-afe7-dac48f9bfb30", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "57c3c46ee046601916dadad9f060937a3482477247254132d16351839adae7df", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "415d18b9-474b-4cfb-b9b0-8a2fee063e69", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "61eb06aefc35b00ea0c143e3cdf6af1f0656ada59eca0b972294d00e4dcdad33", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "|     |     |     |     |     |       |          |       |   |   |   |\n| Hand out diary, instruct in use\\*                                 | X   |     | X   | X                                    |     | X   | X   |     |        |     |     |     |     |     |     |     |       |          |       |   |   |   |\n| Review study participant diary, including study drug compliance\\* | X   | X   | X   | X                                    | X   | X   | X   | X   | X      | X   | X   | X   | X   | X   | X   |     | X     |          |       |   |   |   |\n| Lifestyle Program instructions\\*                                  | X   |     | X   | X                                    |     | X   | X   | X   |        | X   |     |     |     |     |     |     |       | X        |       |   |   |   |\n| Review diet and exercise goals\\*                                  | X   | X   | X   | X                                    |     | X   | X   | X   | X      | X   | X   | X   | X   | X   | X   |     | X     |          |       |   |   |   |\n| Dispense study drug                                               | X   |     | X   | X                                    |     | X   | X   |     |        |     |     |     |     |     |     |     |       |          |       |   |   |   |\n| Participant returns study drugs and injection supplies            | X   |     | X   | X                                    |     | X   | X   | X   |        |     |     |     |     |     |     |     |       | X        |       |   |   |   |\n\nLY3298176    18", "mimetype": "text/plain", "start_char_idx": 3690, "end_char_idx": 5223, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "582f0cbb-99d4-4e24-b400-98b1cf3abb66": {"__data__": {"id_": "582f0cbb-99d4-4e24-b400-98b1cf3abb66", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "00c59cb8-b14e-4521-80a9-88414b8f18a2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ea8afdcef56a374fef832861b02c40bf09ae8ea7db0961f629efd7988789c002", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a761464-e219-4196-ba6e-f056757df3ce", "node_type": "1", "metadata": {}, "hash": "31fac13cb162ed76613434329b2f19c6d0fd478b019698b4096ddb2341039a56", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Visit*\n\n|                     | 101 | 102    | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 199\\* | ED\\* | 802\\* |\n| ------------------- | --- | ------ | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ----- | ---- | ----- |\n| Week of             |     | 12 wks |     |     |     |     |     |     |     |     |     |     |     |     |     |     |       |      |       |\n| Treatment           | 78  | 85     | 91  | 98  | 104 | 111 | 117 | 124 | 130 | 137 | 143 | 150 | 156 | 163 | 169 | 176 | 176   | Post | TxP   |\n| Allowable Deviation | \u00b17  | \u00b17     | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17    | \u00b13   |       |\n| (days)\\*            |     |        |     |     |     |     |     |     |     |     |     |     |     |     |     |     |       |      |       |\n| Fasting Visit\\*     | X   | X      | X   | X   | X   |     | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   |       |      |       |\n| Telephone Visit     | X   | X      | X   | X   | X   |     | X   | X   |     |     |     |     |     |     |     |     |       |      |       |\n\n# Laboratory Tests\n\n| Urine pregnancy test\\*                                                      | X | X | X | X | X |   | X | X |   |   |   |   |   |   |   |   |   |   |   |\n| --------------------------------------------------------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| 2 hour oral glucose tolerance test (includes glucose, insulin,", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1614, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2a761464-e219-4196-ba6e-f056757df3ce": {"__data__": {"id_": "2a761464-e219-4196-ba6e-f056757df3ce", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "00c59cb8-b14e-4521-80a9-88414b8f18a2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ea8afdcef56a374fef832861b02c40bf09ae8ea7db0961f629efd7988789c002", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "582f0cbb-99d4-4e24-b400-98b1cf3abb66", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "befa0e1f08a01fd84c8e95b84fbdd98456a1fe59febf7864f8197322e83a5834", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "insulin, c\u2011peptide)\\* |   |   | X |   |   | X | X | X |   |   |   |   |   |   |   |   |   |   |   |\n| Chemistry panel (includes Cr for eGFR calculation and glucose)\\*            | X | X | X | X | X |   | X | X |   | X |   |   |   |   |   |   |   |   |   |\n| Lipid panel                                                                 |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n| Free fatty acids                                                            |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n| Urinary albumin/creatinine ratio                                            |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n| Cystatin\u2011c                                                                  |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n| Calcitonin                                                                  |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n| Hematology                                                                  |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n| HbA1c                                                                       | X | X | X | X | X |   | X | X |   | X |   |   |   |   |   |   |   |   |   |\n| Pancreatic amylase, lipase                                                  |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n| Immunogenicity (includes PK sample)\\*                                       | X |   | X |   | X |   | X | X |   |   |   |   |   |   |   |   |   |   |   |\n| Nonpharmacogenetic stored sample                                            |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n\n# Mental Health Questionnaires\n\n| PHQ\u20119\\*                             | X | X | X | X | X |   | X | X | X | X |   |   |   |   |   |   |   |   |   |\n| ----------------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| C\u2011SSRS (Since Last Visit Version)\\* | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |\n\nLY3298176    19", "mimetype": "text/plain", "start_char_idx": 1606, "end_char_idx": 3819, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "930ae542-8de8-4f45-b028-1d7e9d54d38e": {"__data__": {"id_": "930ae542-8de8-4f45-b028-1d7e9d54d38e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f3e0ce61-f519-4d4c-a4dd-a165c95cc1fa", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d51c17abc6ffd2de659c8251e86c8274418833210fdc8afcb9dbe74c4fe2e80d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b95ad8f-545f-4986-a89e-759479fccf46", "node_type": "1", "metadata": {}, "hash": "c0e8a87cac54fa469f46c296040ba9b19b797305869935395e4809fea40c1ef8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n| Visit\\*                     | 101 | 102 | 103 | 104    | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 199\\* | ED\\* | 802\\* |\n| --------------------------- | --- | --- | --- | ------ | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ----- | ---- | ----- |\n| Week of                     |     |     |     | 12 wks |     |     |     |     |     |     |     |     |     |     |     |     |       |      |       |\n| Treatment                   | 78  | 85  | 91  | 98     | 104 | 111 | 117 | 124 | 130 | 137 | 143 | 150 | 156 | 163 | 169 | 176 | 176   | Post | TxP   |\n| Allowable Deviation         | \u00b17  | \u00b17  | \u00b17  | \u00b17     | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17    | \u00b13   |       |\n| Fasting Visit\\*             | X   |     | X   |        | X   |     | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X     |      |       |\n| Telephone Visit             | X   | X   | X   | X      |     | X   | X   | X   |     |     |     |     |     |     |     |     |       |      |       |\n| Self\u2011Harm Supplement Form\\* | X   | X   | X   | X      | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X     | X    |       |\n| Self\u2011Harm Follow\u2011up Form\\*  | X   | X   | X   | X      | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X     | X    |       |\n\n# PROs\n\n| PGIS                   | X |   |   |   | X |   | X |\n| ---------------------- | - | - | - | - | - | - | - |\n| SF\u201136, version 2 acute | X |   |   |   | X |   | X |\n| IWQOL\u2011Lite \u2011CT         | X |   |   |   | X |   | X |\n| EQ\u20115D\u20115L               | X |   |   |   | X |   | X |\n\n*Please see table below for corresponding additional information\n\nAbbreviations: BP = blood pressure; Cr= creatinine; C\u2011SSRS = Columbia\u2011Suicide Severity Rating Scale; ED= early discontinuation of treatment; eGFR = estimated glomerular filtration rate; HbA1c = hemoglobin A1c; HR = heart rate; IWQOL\u2011Lite\u2011CT = Impact of Weight on Quality of Life\u2011Lite Clinical trials; PGIS = Patient Global Impression of status for physical activity; PHQ\u20119 = Patient Health Questionnaire\u20119;", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2182, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4b95ad8f-545f-4986-a89e-759479fccf46": {"__data__": {"id_": "4b95ad8f-545f-4986-a89e-759479fccf46", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f3e0ce61-f519-4d4c-a4dd-a165c95cc1fa", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d51c17abc6ffd2de659c8251e86c8274418833210fdc8afcb9dbe74c4fe2e80d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "930ae542-8de8-4f45-b028-1d7e9d54d38e", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1429123864096965b56fde0744e84a104f3c40e3a8d6c2f630a328f69f2ae651", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cr= creatinine; C\u2011SSRS = Columbia\u2011Suicide Severity Rating Scale; ED= early discontinuation of treatment; eGFR = estimated glomerular filtration rate; HbA1c = hemoglobin A1c; HR = heart rate; IWQOL\u2011Lite\u2011CT = Impact of Weight on Quality of Life\u2011Lite Clinical trials; PGIS = Patient Global Impression of status for physical activity; PHQ\u20119 = Patient Health Questionnaire\u20119; PK = pharmacokinetics; SF\u201136 = Short\u2011Form\u201136 Health Survey version 2, acute form; TxP = treatment period; TZP = tirzepatide.\n\nLY3298176    20", "mimetype": "text/plain", "start_char_idx": 1812, "end_char_idx": 2324, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1726fdd5-a145-42c2-946e-eabd165612ce": {"__data__": {"id_": "1726fdd5-a145-42c2-946e-eabd165612ce", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c5b6b360-beb5-4893-bec8-60f062a7cccd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1f0f2e5b374efa57bd15b03e79957e959032cd1e156e929fc65971048819f7ad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Additional Information Regarding Activities Described in Schedule of Activities\n\n| Activity      | Notes                                                                                                                                                                                                                                                                                                                                                                        |\n| ------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Visit         | On all office visits, study participants should be reminded to report to the site                                                                                                                                                                                                                                                                                            |\n| Fasting Visit | before taking study drug (s) in a fasting condition, after a period of approximately 8 hours without eating, drinking (except water), or any significant physical activity. Since some screening procedures need to be completed in the fasting state, Visit 1 may be conducted over more than 1 day to ensure necessary conditions are met.                                 |\n| Visit 3       | Baseline assessments must be completed before processing in the IWRS.                                                                                                                                                                                                                                                                                                        |\n| Visit 99      | Participants wanting to discontinue the study before Week 72 will be asked to return for Visit 99 at 72 weeks \u00b1 7 days after randomization primarily for body weight measurement and assessment of adverse events. If the participant is unwilling to attend Visit 99, it should be documented in the participant medical record that the participant has refused to attend. |\n| Visit 199     | Participants wanting to discontinue the study after Week 72 but before Week 176 will be asked to return for Visit 199 primarily for the body weight measurement and assessment of adverse events. Refusal to attend should be documented.                                                                                                                                    |\n\nLY3298176    21", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2833, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e60365c9-1c38-4576-a509-98d144269e58": {"__data__": {"id_": "e60365c9-1c38-4576-a509-98d144269e58", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e9386ab6-405f-4079-90e3-ec21aba2fdf7", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c9fabb70efbea387972cc72133f79b189736e5786d03166ae3efa9a80764e122", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\nParticipants who are unable or unwilling to continue the study treatment for any reason will perform an ED visit. If the participant is discontinuing during an unscheduled visit or a scheduled visit, that visit should be performed as the ED visit.\n\n# Safety Follow\u2011up Visits\n\nFor participants who discontinue or complete the study within the first 72 weeks, Visit 801 (safety follow\u2011up visit) should be performed 4 weeks after the last visit during the 72\u2011week treatment period. Participants with prediabetes continuing to Week 78 should not perform Visit 801. For participants with prediabetes who complete the 176 weeks or discontinue after Week 72, Visit 802 should be performed 12 weeks after the last visit during the 2\u2011year extension period.\n\n# Allowable Deviation (days)\n\nThe visit date is determined in relation to the date of the randomization visit (\u00b1 the allowed visit window).\n\n# Medical History\n\nMedical history includes assessment of preexisting conditions (for example, history of gallbladder disease, cardiovascular disease, and medullary thyroid carcinoma) and substance usage (such as alcohol and tobacco).\n\n# Weight\n\nWeight measurements should be obtained per the instructions in Section 10.7. Body weight must be measured in fasting state. If the participant is not fasting, the participant should be called in for a new visit within the visit window to have the fasting body weight measured.\n\n# Electrocardiogram\n\nECG measurements should be obtained per the instructions in Section 10.7. ECGs will be performed in triplicate at Weeks 0 and 36. All other ECGs will be single measurements. ECGs should be collected at least 30 minutes prior to collection of blood samples for laboratory testing, including PK samples.\n\n# Vital signs (3 sitting BP and HR)\n\nVital\u2011sign measurements should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing, per the instruction in Section 10.7.\n\n# Hand out diary, instruct in use\n\nAll training should be repeated as needed to ensure participant compliance.\n\n# Review study participant diary and study\u2011drug compliance\n\nData from diary, as well as study drug compliance, should be reviewed.\n\nLY3298176    22", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2246, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b0cf5336-6072-4708-92eb-a50acf539895": {"__data__": {"id_": "b0cf5336-6072-4708-92eb-a50acf539895", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c8c12c85-3c54-470d-9783-53f5cc8733a7", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "44cae5a8ddd3845d68282e8b06e38c8f3c26e9ffe663d7953fa3dad2d336875f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Lifestyle Program instructions\n\nCounselling on diet and exercise, to be performed by a dietician or equivalent qualified delegate, to include calculation of individualized energy requirement and methods to change dietary composition and amount of physical activity. The Lifestyle Program Instruction may be delivered on a separate day from the rest of that visit\u2019s study procedures but must occur within the visit window. Beginning at Week 8, the Lifestyle Program Instruction may be delivered by phone.\n\n# Review diet and exercise goals\n\nAll training should be repeated as needed to ensure participant compliance. Study personnel to provide reinforcement and encouragement for lifestyle modifications.\n\n# Injection training with Autoinjector demonstration device\n\nAll training should be repeated as needed to ensure participant compliance.\n\n# Dispense study drug Visit 72\n\nThis applies only to those participants going into the extension.\n\n# Observe participant administer study drug\n\nParticipants should administer their first dose of study drug at the end of the Visit 3, after other study procedures are completed.\n\n# Serum pregnancy test\n\nA serum pregnancy test will be performed at Visit 1 for women of childbearing potential only.\n\n# Urine pregnancy test\n\nA urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy tests (beyond those required per the Schedule of Activities) should be performed at any time during the trial if a menstrual period is missed, there is clinical suspicion of pregnancy, or as required by local law or regulation.\n\n# Follicle\u2011stimulating hormone test\n\nFollicle\u2011stimulating hormone test performed at Visit 1 for postmenopausal women at least 40 years of age with an intact uterus, not on hormone therapy, and who have had spontaneous amenorrhea for more than 1 year without an alternative medical cause.\n\n# 2\u2011hour oral glucose tolerance test (includes glucose, insulin, c\u2011peptide)\n\n2\u2011hour OGTT testing should be omitted at visits following a protocol\u2011defined diabetes diagnosis.\n\nLY3298176    23", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2213, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bc342e9a-f742-4fb6-acd6-0f4eaf5e3b61": {"__data__": {"id_": "bc342e9a-f742-4fb6-acd6-0f4eaf5e3b61", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0706e444-41ad-4d13-bb7f-c9ecdffd575b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "494444ac3886c9e9fdcc4561fee2d5ae365f06febd476258cfe135a326d9ebb1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Urinary albumin/creatinine ratio\n\nScreening visit assessment will be used to confirm eligibility. If calcitonin results are not available, a final review of eligibility will occur at Visit 3 before randomization can proceed.\n\n# Cystatin\u2011c\n\n# Calcitonin\n\n# Hematology\n\n# Thyroid\u2011stimulating hormone (TSH)\n\n# Chemistry panel (include Cr for eGFR calculation)\n\nThe CKD\u2011EPI equation will be used by the central lab to estimate and report eGFR.\n\n# Immunogenicity (includes PK sample)\n\nPK samples for immunogenicity must be taken prior to drug administration at these visits. In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and exploratory biomarker samples.\n\n# TZP PK\n\nPK samples will be collected at these visits at time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours post dose, as assigned by IWRS at randomization. Dependent on the time windows to which a participant is assigned, they may be required to come to site for PK\u2011specific visits.\n\n# PHQ\u20119\n\nThe C\u2011SSRS, Self\u2011Harm Supplement Form and PHQ\u20119 should be administered after assessment of adverse events. For this study, the C\u2011SSRS is adapted for the assessment of the ideation and behavior categories only. The Intensity of Ideation and Lethality of Behavior sections are removed.\n\n# C\u2011SSRS (Baseline/Screening Version)\n\n# C\u2011SSRS (Since last Visit Version)\n\n# Self\u2011Harm Supplement Form\n\nSelf\u2011Harm Follow\u2011up Form is only required if triggered by the Self\u2011Harm Supplement Form, per instructions in the form.\n\n# Abbreviations:\n\nADA = antidrug antibody; BP = blood pressure; CKD\u2011EPI = Chronic Kidney Disease\u2011Epidemiology; Cr = creatinine; C\u2011SSRS = Columbia\u2011Suicide Severity Rating Scale; ECG = electrocardiogram; ED = early discontinuation of treatment; eGFR = estimated glomerular filtration rate; HR = heart rate; IWRS = interactive web\u2011response system; OGTT = oral glucose tolerance test; PHQ\u20119 = Patient Health Questionnaire\u20119; PK = pharmacokinetic; TSH = thyroid\u2011stimulating hormone; TZP = tirzepatide.\n\nLY3298176    24", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2129, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3187a720-2c40-4d53-9f21-a0c47b623058": {"__data__": {"id_": "3187a720-2c40-4d53-9f21-a0c47b623058", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "50a7ec3f-9c6e-4759-b1d4-54fbf2b426e3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "bfb7c8bddb55ab688ea005e9b79bd122f9f516a796ae664bed78429ba5d625f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e83811b2-7ce8-4dc9-a0cf-a74b47c01120", "node_type": "1", "metadata": {}, "hash": "051343917f27fcbd879e8efa15a05ce6fd8e284c76a36ae4bbee4e2f1f93db0f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 2. Introduction\n\nObesity is a chronic disease whose increasing prevalence is a public\u2011health concern associated with rising incidence of type 2 diabetes mellitus (T2DM), increased risk for premature death and increased risk for some cancers (Allison et al. 2008; AMA 2013; Council on Science and Public Health 2013). Although loss of 5% to 10% body weight has been shown to reduce complications related to obesity and improve quality of life (Mertens and Van Gaal 2000; Knowler et al. 2002; Jensen et al. 2014; Li et al. 2014; Warkentin et al. 2014), lifestyle therapies fail to achieve sustainable weight loss in the majority of patients with obesity (Dombrowski et al. 2014).\n\n# 2.1. Study Rationale\n\nThe gut incretin hormones, glucose\u2011dependent insulinotropic polypeptide (GIP) and glucagon\u2011like peptide\u20111 (GLP\u20111), are secreted after meal ingestion and mediate the incretin effect. Both hormones have effects on endocrine cells in the pancreas, increasing insulin biosynthesis and secretion, stimulating beta\u2011cell neogenesis and proliferation, and protecting beta cells from apoptosis. They also exert actions on alpha cells, modifying glucagon secretion (Skow et al. 2016). Based on these properties, several GLP\u20111 receptor (GLP\u20111R) agonists have been approved for pharmacological treatment of T2DM (Tomlinson et al. 2016).\n\nIn addition to its pancreatic effects, GLP\u20111R activation decreases gut motility, slows gastric emptying, and promotes satiety (presumably through a combination of GLP\u20111R activation in the central and peripheral nervous system), thereby regulating food intake and body weight (Baggio and Drucker 2007). The US Food and Drug Administration and the European Medicines Agency approved the GLP\u20111R agonist liraglutide for the treatment of overweight and obesity (SAXENDA\u00ae package insert, 2014; SAXENDA\u00ae SmPc, 2015).\n\nPreclinical data indicate that GIP exerts effects on appetite regulation and food intake, on adipose tissue and on peripheral energy metabolism. Although studies evaluating effects of GIP on body weight have yielded equivocal results, GIP receptor (GIPR) activation may play a role in body weight regulation and targeting both the GLP\u20111R and the GIPR simultaneously may result in additive or synergistic effects of the 2 incretins on body weight (Coskun et al. 2018).\n\nTirzepatide is a 39\u2011amino acid synthetic peptide with agonist activity at both the GIPR and GLP\u20111R. Its structure is based on the GIP sequence and includes a C20 fatty di\u2011acid moiety (Coskun et al. 2018). It is administered once weekly (QW) by subcutaneous (SC) injection. As a dual GIP/GLP\u20111R agonist, tirzepatide could exceed the efficacy of selective GLP\u20111R agonists by recruiting metabolically active tissues not targeted by selective GLP\u20111R agonists (for example, adipose tissue as indicated by the observation of increased energy utilization) (Baggio and Drucker 2007) and has the potential to reach higher efficacy in target tissues that express both GIPR and GLP1R.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3023, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e83811b2-7ce8-4dc9-a0cf-a74b47c01120": {"__data__": {"id_": "e83811b2-7ce8-4dc9-a0cf-a74b47c01120", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "50a7ec3f-9c6e-4759-b1d4-54fbf2b426e3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "bfb7c8bddb55ab688ea005e9b79bd122f9f516a796ae664bed78429ba5d625f8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3187a720-2c40-4d53-9f21-a0c47b623058", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0bc680266062c3171ae17a6ddc9071e13a48f375269871fc74f764d692256eb2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2018). It is administered once weekly (QW) by subcutaneous (SC) injection. As a dual GIP/GLP\u20111R agonist, tirzepatide could exceed the efficacy of selective GLP\u20111R agonists by recruiting metabolically active tissues not targeted by selective GLP\u20111R agonists (for example, adipose tissue as indicated by the observation of increased energy utilization) (Baggio and Drucker 2007) and has the potential to reach higher efficacy in target tissues that express both GIPR and GLP1R.\n\nStudy I8F\u2011MC\u2011GPHK (GPHK, SURMOUNT\u20111) is a Phase 3, multicenter, randomized, placebo\u2011controlled, double\u2011blinded study, to investigate the safety and efficacy of 5\u2011mg, 10\u2011mg, and 15\u2011mg tirzepatide QW, compared with placebo, when used in conjunction with a reduced\u2011calorie diet and increased physical activity for body weight management in participants who do not have T2DM and have obesity (BMI \u226530 kg/m\u00b2) or are overweight (BMI \u226527 kg/m\u00b2) with at least one weight\u2011related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular).\n\nLY3298176                                                                                        25", "mimetype": "text/plain", "start_char_idx": 2548, "end_char_idx": 3677, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8853035c-5944-4b75-a801-deaf4d3dffb3": {"__data__": {"id_": "8853035c-5944-4b75-a801-deaf4d3dffb3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "76d4ba1f-23ce-43f2-9743-0b6e3560c1e3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0e679cd43adb7e8f4595c6a15e8e6cc5752becdf28576f467f3e3e5f12d1e33b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34d10113-81d5-4b44-882f-efeb66f169b4", "node_type": "1", "metadata": {}, "hash": "ab4127f43c99786718122deb4792cde543364b25a70a3c4f28b03cdad54f71bf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                   Protocol I8F\u2011MC\u2011GPHK\n\ndisease). All participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction. Participants who have prediabetes at randomization will be studied for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to assess the effects of tirzepatide on progression to T2D and on long\u2011term body weight changes.\n\n# 2.2. Background\n\nThere remains an unmet need in the pharmacologic treatment of obesity for drugs that are safe, efficacious and well tolerated. With the exception of orlistat, a drug that blocks absorption of dietary fat, many current obesity treatments work primarily by stimulating regions of the brain to promote satiety. Weight loss induced by GLP\u20111R agonists appears to be mediated through a combination of hormonal inputs to satiety centers (van Bloemendaal et al. 2014) and has not been consistently associated with changes in mental health or with potential for addiction in long\u2011term studies conducted to establish cardiovascular safety in patients with diabetes (Marso et al. 2016a, Marso et al. 2016b, Gerstein et al. 2019). Tirzepatide, which is both a GLP\u20111R and GIPR agonist, has been associated with significant dose\u2011dependent weight loss at 5\u2011, 10\u2011 and 15\u2011 mg doses in Phase 2 studies (Frias et al. 2018).\n\nDose selection for obesity treatment has been informed by 3 clinical trials: a Phase 1 study, Study I8F\u2011MC\u2011GPGA (GPGA), and two Phase 2 studies, Study I8F\u2011MC\u2011GPGB (GPGB) and I8F\u2011MC\u2011GPGF (GPGF).\n\nPhase 1 Study GPGA was a combination of single ascending dose (SAD) and multiple ascending dose (MAD) studies in healthy subjects and a multiple dose study in patients with T2DM. A total of 142 participants (89 healthy subjects and 53 patients with T2DM) received at least 1 dose of treatment. Doses of tirzepatide ranged from:\n\n- 0.25 mg to 8 mg in the SAD (with maximum tolerated dose achieved at 5 mg)\n- multiple doses from 0.5 mg to 4.5 mg QW and titrated doses up to 10 mg QW for 4 weeks in healthy subjects\n- multiple doses at 0.5 mg and 5 mg QW and titrated up to 15 mg QW for 4 weeks in patients with T2DM in the MAD\n\nThe safety and tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profiles of tirzepatide at doses and escalation regimens administered in this Phase 1 study supported further development of tirzepatide for QW dosing in patients with T2DM.\n\nPhase 2 studies GPGB and GPGF studies provided initial safety, tolerability and efficacy data in the tirzepatide 1\u2011to\u201115\u2011mg dose range when used in treatment of patients with T2DM. In the dose range of 5 to 15 mg, tirzepatide provided significantly greater reductions in hemoglobin A1c (HbA1c) and body weight compared with dulaglutide 1.5 mg QW. The most common AEs, which were also dose dependent, were mild to moderate nausea, vomiting, and diarrhea.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2899, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "34d10113-81d5-4b44-882f-efeb66f169b4": {"__data__": {"id_": "34d10113-81d5-4b44-882f-efeb66f169b4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "76d4ba1f-23ce-43f2-9743-0b6e3560c1e3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0e679cd43adb7e8f4595c6a15e8e6cc5752becdf28576f467f3e3e5f12d1e33b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8853035c-5944-4b75-a801-deaf4d3dffb3", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b61f98505b35e62e83c3e61ba26aeeefbe6f68c82d7b3591bbaa6fd7105660b9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Phase 2 studies GPGB and GPGF studies provided initial safety, tolerability and efficacy data in the tirzepatide 1\u2011to\u201115\u2011mg dose range when used in treatment of patients with T2DM. In the dose range of 5 to 15 mg, tirzepatide provided significantly greater reductions in hemoglobin A1c (HbA1c) and body weight compared with dulaglutide 1.5 mg QW. The most common AEs, which were also dose dependent, were mild to moderate nausea, vomiting, and diarrhea. Study GPGF showed that adjustments in the tirzepatide dose\u2011escalation algorithm resulted in additional reductions in the frequency of GI AEs and reduced the frequency of treatment discontinuations due to GI AEs.\n\n# 2.3. Benefit/Risk Assessment\n\nMore information about the known and expected benefits, risks, serious AEs (SAEs) and reasonably anticipated AEs of tirzepatide are to be found in the Investigator\u2019s Brochure (IB).\n\nLY3298176                                                                                        26", "mimetype": "text/plain", "start_char_idx": 2446, "end_char_idx": 3426, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "79c5a763-c636-4851-9f40-08fdad8429b3": {"__data__": {"id_": "79c5a763-c636-4851-9f40-08fdad8429b3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "007931ca-7497-4494-ae71-d1b69d701b45", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "57894187a188c9d68aa33d3a8aec70ebeea0ddbceacd7933caa1a3fcd2c39148", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 3. Objectives and Endpoints\n\n| **Objectives**                                                                                                                                                                                     | **Endpoints**                                                                                                                                       |\n| -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------- |\n| **Primary**                                                                                                                                                                                        |                                                                                                                                                     |\n| at 72 weeks, by dose analysis To demonstrate that tirzepatide 10 mg QW is superior to placebo for: \u2022 percent change in body weight AND \u2022 percentage of participants with \u22655% body weight reduction | \u2022 mean percent change in body weight from randomization \u2022 percentage of study participants who achieve \u22655% body weight reduction from randomization |\n| AND/OR                                                                                                                                                                                             |                                                                                                                                                     |\n| To demonstrate that tirzepatide 15 mg QW is superior to placebo for: \u2022 percent change in body weight AND \u2022 percentage of participants with \u22655% body weight reduction                               |                                                                                                                                                     |\n| **Key Secondary (controlled for Type I error)**                                                                                                                                                    |                                                                                                                                                     |\n| at 20 weeks, by dose analysis For tirzepatide 5 mg, 10 mg, and/or 15 mg QW doses, to demonstrate superiority to placebo for: \u2022 body weight                                                         | \u2022 mean change in body weight (kg) from randomization                                                                                                |\n| **Key Secondary (controlled for Type I error)**                                                                                                                                                    |                                                                                                                                                     |\n| at 72 weeks, by dose analysis To demonstrate that tirzepatide 5 mg QW is superior to placebo for: \u2022 percent change in body weight AND \u2022 percentage of participants with \u22655% body weight reduction  | \u2022 mean percent change in body weight from randomization \u2022 percentage of study participants who achieve \u22655% body weight reduction from randomization |\n\nLY3298176    27", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3576, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1af0d2e5-9e93-4b98-aa34-dddadd8628c9": {"__data__": {"id_": "1af0d2e5-9e93-4b98-aa34-dddadd8628c9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "eeffd6c0-12f5-4a5e-a9e6-51fceeb60870", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "230bcc13e8a4d474c298954dd00f905d37a2e8e6768e581b9d9196514ff44f9e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Objectives\n\nFor tirzepatide 10 mg and/or 15 mg QW doses, to demonstrate superiority to placebo for:\n\n- body weight\n- waist circumference\n- Patient reported outcomes (SF\u201136v2 acute form Physical Functioning domain score)\n\n# Endpoints\n\n- percentage of participants who achieve;\n- \u226510% body weight reduction from randomization\n- \u226515% body weight reduction from randomization\n- mean change in waist circumference (cm) from randomization\n- mean change in SF\u201136v2 acute form Physical Functioning domain score from randomization\n\n# Key Secondary (controlled for Type I error) at 72 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo for:\n\n- lipid parameters\n- mean change from randomization in\n- triglycerides (mg/dL)\n- LDL (mg/dL)\n- total cholesterol (mg/dL)\n- SBP\n- mean change in SBP (mmHg) from randomization\n- insulin\n- mean change in fasting insulin (pmol/L) from randomization\n\n# Key Secondary (controlled for Type I error) at 176 weeks, by dose analysis\n\nFor tirzepatide 10 mg and/or 15 mg QW doses, to demonstrate superiority to placebo for:\n\n- mean percent change in body weight from randomization\n\n# Key Secondary (controlled for Type I error) at 176 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo (for participants with prediabetes at randomization) in:\n\n- delayed progression to T2DM\n- time to onset of T2DM\n\nLY3298176    28", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1489, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5d20cd0e-395d-46ca-bd9e-9c3d990cba78": {"__data__": {"id_": "5d20cd0e-395d-46ca-bd9e-9c3d990cba78", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "567ac3f9-8160-429a-99bc-96b08904bc83", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "464ec7a7dd458790633d1b2980192d108bf6360d6ef31a9c3be84b57f99c87dc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Objectives\n\n# Endpoints\n\n# Efficacy\n\nFor tirzepatide 5 mg QW dose, to demonstrate superiority to placebo at 72 weeks for:\n\n- body weight\n- percentage of participants who achieve\n- \u226510% body weight reduction from randomization\n- \u226515% body weight reduction from randomization\n- waist circumference\n- mean change in waist circumference (cm) from randomization\n- patient reported outcomes (SF\u201136v2 Physical Functioning)\n- mean change in SF\u201136 v2 acute form Physical Functioning domain score from randomization\n\nFor tirzepatide 5 mg, 10 mg, and/or 15 mg QW doses, to demonstrate superiority to placebo for:\n\n- body weight\n- mean change in body weight (kg) from randomization\n- mean change in BMI (kg/m\u00b2) from randomization\n- glycemic control\n- mean change in HbA1c (%, mmol/mol) from randomization\n- mean change in fasting glucose (mg/dL) from randomization\n- Patient\u2011reported outcomes\n- Mean change in IWQOL\u2011Lite\u2011CT Physical Function composite score from randomization\n\n# Additional secondary at 72 weeks, pooled analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo at 72 weeks for:\n\n- DBP\n- mean change in DBP (mmHg) from randomization\n\nLY3298176    29", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1226, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d4b0fa38-90ad-42fc-80d2-0c0223900d6c": {"__data__": {"id_": "d4b0fa38-90ad-42fc-80d2-0c0223900d6c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "403755d6-e286-4e3c-b335-abf570a2f25d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "f4639ac30f2bbc63fe22a4400a24fb58d53c9ec791d56d8ceb604db204096775", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Objectives\n\n- lipid parameters\n\n# Endpoints\n\n- mean change from randomization in:\n\n# Additional secondary at 176 weeks, by dose analysis\n\nFor tirzepatide 5 mg QW dose, to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- body weight\n\n- mean percent change in body weight from randomization\n\nFor tirzepatide 5 mg, 10 mg, and/or 15 mg QW doses, to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- body weight\n\n- percentage of study participants who achieve \u22655% body weight reduction from randomization\n\n# Additional Secondary at 176 weeks, pooled analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- Patient reported outcomes\n\n- mean change in SF\u201136v2 acute form Physical Functioning domain score from randomization\n- mean change in IWQOL\u2011Lite\u2011CT Physical Function composite score from randomization\n\n# Additional Secondary\n\n# Pharmacokinetics/Pharmacodynamics\n\n- To characterize the population PK of tirzepatide and explore the relationships between the tirzepatide concentration and efficacy, safety and tolerability measures\n\n- population PK and PD parameters\n\n# Abbreviations:\n\n- AUC = area under the curve\n- BMI = body mass index\n- DBP = diastolic blood pressure\n- HbA1c = hemoglobin A1c\n- HDL = high\u2011density lipoprotein\n- IWQOL\u2011Lite\u2011CT = Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version\n- LDL = low\u2011density lipoprotein\n- PD = pharmacodynamics\n- PK = pharmacokinetics\n- QW = once\u2011weekly\n- SAP = statistical analysis plan\n- SBP = systolic blood pressure\n- SF\u201136v2 = Short Form survey\u201136 version 2\n- T2DM = type 2 diabetes mellitus\n- VLDL = very low\u2011density lipoprotein.\n\nLY3298176    30", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1835, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "88c202f8-cac4-421b-a539-55cbe190522c": {"__data__": {"id_": "88c202f8-cac4-421b-a539-55cbe190522c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8674df02-31c5-48eb-bf7f-55eb9d17d8ac", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a9ab11d107ac8767c3d245e8193214fb66d356a860eb47b6987b864c45a4d18a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 4. Study Design\n\n# 4.1. Overall Design\n\nStudy GPHK (SURMOUNT\u20111) is a Phase 3, multicenter, randomized, double\u2011blinded, placebo\u2011controlled study that will investigate the effects of treatment with tirzepatide 5 mg, 10 mg, and 15 mg QW compared with placebo on weight loss in study participants without T2DM who are either obese (BMI \u226530 kg/m\u00b2) or overweight (\u226527 kg/m\u00b2) with at least one weight\u2011related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). The coprimary endpoints will be mean percent change in weight and percentage of participants reaching \u22655% total body weight loss, measured from randomization to Week 72.\n\nStudy participants will be randomized in a 1:1:1:1 ratio (tirzepatide 5 mg QW, tirzepatide 10 mg QW, tirzepatide 15 mg QW, and placebo). An upper limit of 70% enrollment of women will be used to ensure a sufficiently large sample of men.\n\nAll participants will undergo a 2\u2011week screening period and a 72\u2011week treatment period including a 20\u2011week dose escalation. Participants who have prediabetes will be studied for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to detect potential differences in progression to T2DM.\n\nThe safety follow\u2011up period will be 4 weeks (for participants completing or discontinuing study drug during the first 72 weeks) or 12 weeks (for participants completing or discontinuing study drug between weeks 72\u2011176).\n\n# 4.1.1. Overview of Study Periods\n\n# 4.1.1.1. Visit Structure for all Office Visits\n\nOn all designated fasting office visits, study participants are required to report to the site in a fasting condition, after approximately 8 hours without eating, drinking (except water), or performing any significant physical activity. If a participant is adversely affected by the fasting condition, they are allowed to eat, however, specific study procedures need to be completed while fasting. See Section 10.8 for a suggested order of activities that occurs at office visits.\n\n# 4.1.1.2. Main Study Period\n\n# 4.1.1.2.1. Screening Period\n\nVisit 1\n\nThe purpose of screening procedures at Visit 1 is to establish initial eligibility, and to obtain blood samples for laboratory assessments needed to confirm eligibility and classify glycemic status (Section 4.1.2.1). The participant must sign the informed consent form (ICF) before the study procedures are performed, as outlined in the Schedule of Activities, Section 1.3. Since some screening procedures need to be completed in the fasting state (approximately 8 hours without eating, drinking [except water], or any significant physical activity), Visit 1 may be conducted over more than 1 day to ensure necessary conditions are met. Participants who have no glycemic assessments suggestive of T2DM (Section 4.1.2.1) and meet all other applicable\n\nLY3298176    31", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2873, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "396cc111-a720-428b-92bf-4e96ff2a10b5": {"__data__": {"id_": "396cc111-a720-428b-92bf-4e96ff2a10b5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ddc59ad3-ef77-4c86-a2e9-513ac5d53697", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8e96d800e58824b9e03f4f12b92e10e7cece74ddfaa421294ecb0bea595a1ea9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                    Protocol I8F\u2011MC\u2011GPHK\n\ninclusion criteria and none of the applicable exclusion criteria (Sections 5.1 and 5.2) at Visit 1 will continue to Visit 2.\n\n# Visit 2\n\nParticipants should arrive to the clinic in the fasting state (approximately 8 hours without eating, drinking [except water], or any significant physical activity). At Visit 2, the screening laboratory results will be reviewed. For those participants without glycemic evidence of T2DM (Section 4.1.2.1), and meeting all other eligibility requirements, a 2\u2011hour oral glucose tolerance test (OGTT) will be performed. The 2\u2011hour OGTT consists of assessment of glucose, insulin, and c\u2011peptide at time 0, 30, 60, 90, and 120 minutes (Sections 4.1.2.2 and 10.7). If calcitonin results are not available, Visit 2 can proceed. A final review of eligibility will occur at Visit 3 before randomization can proceed.\n\nThe mental health questionnaires (Columbia\u2011Suicide Severity Rating Scale [C\u2011SSRS] and Self\u2011Harm Form) should be completed after the assessment for AEs.\n\n# 4.1.1.2.2.  Treatment Period\n\n# Randomization (Visit 3)\n\nAt Visit 3, eligible participants will perform all required baseline study procedures (including the collection of all baseline laboratory measures and questionnaires) prior to randomization and prior to taking the first dose of study drug. Participants should arrive to the clinic in the fasting state (after a period of approximately 8 hours without eating, drinking [except water], or any significant physical activity). Patient\u2011reported outcomes (PROs) questionnaires should be administered as early as possible, as per Suggested Visit Structure (Section 10.8). Preferred administration order is: Patient Global Impression of status for physical activity (PGIS), Short Form survey\u201136 version 2 (SF\u201136v2) acute form, Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version (IWQOL\u2011Lite\u2011CT), and EQ\u20115D\u20115L. The mental health questionnaires (Patient Health Questionnaire\u20119 [PHQ\u20119], C\u2011SSRS, and Self\u2011Harm Form) should be completed after the assessment for AEs.\n\nParticipants will receive an initial consultation with a qualified dietician, according to local standards, to set lifestyle goals for caloric intake and physical activity (Sections 5.3.1 and 5.3.2). Following randomization, study site personnel will demonstrate use of the autoinjector (also referred to as single\u2011dose pen) using the provided demonstration device and observe the study participant inject the first dose of tirzepatide or placebo. The date, time, and location of the first dose of study drug will be recorded on the electronic case report form (eCRF). Beginning at randomization, all participants will receive study drug according to the randomized treatment arm for the duration of the 72\u2011week treatment period including a 20\u2011week dose escalation. Participants will be provided diaries and be trained to record key study information, as appropriate.\n\n# Treatment Period (End of Visit 3 to Visit 21)\n\nDuring the treatment period, office visits will occur monthly through 24 weeks and then every 12 weeks thereafter, to 72 weeks. The participant should be fasting for all office visits. Telephone visits will occur at 4\u2011week intervals between the office visits starting at Week 28.\n\nLY3298176    32", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3325, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eba6571d-e975-457d-8190-230e4eaaed7b": {"__data__": {"id_": "eba6571d-e975-457d-8190-230e4eaaed7b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9f36b2a6-6d1f-4cc3-86eb-2a06ed41c1f2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9cd16bccb033c3573e3ca8aed24403b7a33d95deb7af05e3646eb7dc01721e49", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                          Protocol I8F\u2011MC\u2011GPHK\n\nOffice visit procedures should be conducted according to the Schedule of Activities (Section 1.3), and will include:\n\n- weight, waist circumference, and vital signs measurements\n- review of participant diary information (to include reinforcement and compliance assessments for study drug administration and lifestyle goals)\n- administration of questionnaires\n- laboratory testing\n- drug dispensing\n- collect AEs, product complaints and concomitant medications\n\nMental Health Questionnaires should be completed after the assessment of AEs.\n\nDietician consultations continue at Weeks 4, 8, 12, and then every 12 weeks thereafter, to Week 72. Study drug and injection supplies will be returned per the Schedule of Activities (Section 1.3) and according to local requirements. New supplies will be dispensed as needed.\n\nStudy drug dose escalation is double\u2011blinded and will be managed via the interactive web\u2011response system (IWRS). The starting dose is 2.5 mg QW (or matching placebo) for 4 weeks, then the dose is increased by 2.5 mg (or matching placebo) every 4 weeks:  2.5 to 5 mg for those randomized to 5 mg, 2.5 to 5 to 7.5 to 10 mg for those randomized to 10 mg, and continuing to 12.5 to 15 mg for those randomized to 15 mg. The dose is then maintained up to 72 weeks.\n\nAt each of the 8 scheduled telephone visits, procedures will include:\n\n- reinforcement and compliance assessments for study drug administration and lifestyle goals,\n- listing of concomitant medications\n- AE and Product Complaints (PCs) assessment (see Schedule of Activities Section 1.3.1)\n- administration of questionnaires\n\nParticipants should be instructed to contact the investigative site for assistance as soon as possible if they experience any difficulties administering their study medication. Participants should also be advised about the appropriate course of action in the event that study drug is not taken at the required time (late/missing doses).\n\nStudy participants will be permitted to use concomitant medications that they require during the study, except certain excluded medications (see Section 5.2) that may interfere with the assessment of efficacy and safety characteristics of the study treatments.\n\nFor those participants without glycemic evidence of T2DM (Section 4.1.2.1), a 2\u2011hour oral OGTT will be performed at Visit 21.\n\n# Visit 99\n\nVisit 99 is only applicable to participants who discontinue the study treatment prematurely (before Week 72). Participants will be asked to return for Visit 99 at 72 weeks \u00b1 7 days after\n\nLY3298176                                                                                         33", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2722, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0250f366-77d4-4972-b042-35ed862fbe30": {"__data__": {"id_": "0250f366-77d4-4972-b042-35ed862fbe30", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fe1fe893-f9d1-4f45-b093-1adc8c32e232", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "20bd3be44d09bbd7a56008bd6ba2b73b13227e6ec609e8f9ebd7d9bf6461f336", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK\n\nrandomization. This visit is critical to ensure complete data collection for the primary weight\u2011loss endpoint.\n\nParticipants should attend this visit in the fasting state. Procedures to be completed are:\n\n- measurement of weight and waist circumference\n- listing of concomitant medications\n- assessment of AEs\n- completion of the mental health questionnaires (after the AE assessment)\n\nFor participants unwilling to attend this visit, their refusal to attend should be documented in the participant medical record.\n\n# 4.1.1.2.3. Continued Follow-up for Participants with Prediabetes (Visits 101 through 116)\n\nParticipants classified as having prediabetes at randomization and who remain on study drug through Week 72, will continue follow\u2011up for an additional 104 weeks (total study duration 176 weeks). Subsequent visits will occur approximately every 1.5 months, alternating between telephone and office visits.\n\nOffice visit procedures should be conducted according to the Schedule of Activities (Section 1.3), and will include:\n\n- weight, waist circumference, and vital signs measurements\n- review of participant diary information (to include reinforcement and compliance assessments for drug administration and lifestyle goals)\n- administration of questionnaires\n- laboratory testing\n- drug dispensing\n- collection of AEs, product complaints, and concomitant medications\n\nPatient\u2011reported outcomes questionnaires should be administered as early as possible, as per Suggested Visit Structure (Appendix 8). Mental Health Questionnaires should be completed after the assessment of AEs.\n\nDietician consultations continue approximately every 3 months after Visit 21 to Visit 116. At Visits 108 and 116, participants will undergo 2 hour OGTTs (Sections 4.1.2.2 and 10.7). Study drug and injection supplies will be returned per the Schedule of Activities (Section 1.3) and according to local requirements. New supplies will be dispensed as needed.\n\nAt each of the 8 scheduled telephone visits, procedures will include:\n\n- reinforcement and compliance assessments for study drug administration and lifestyle goals\n- listing of concomitant medications\n- AE and PC assessment (see Schedule of Activities [Section 1.3])\n\nLY3298176 34", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2263, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bb454bdf-d7b4-4396-87cf-702f2fe28922": {"__data__": {"id_": "bb454bdf-d7b4-4396-87cf-702f2fe28922", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ade8b0cd-5fe2-4225-ace0-d88f8bd503e4", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0e7e70ac680aae3a6c131d90793eaab92128e1648d7d61bd1095f22ae38552df", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK\n\n\u2022 administration of questionnaires Participants should be instructed to contact the investigative site for assistance as soon as possible if they experience any difficulties administering their study medication. Participants should also be advised about the appropriate course of action in the event that study drug is not taken at the required time (late/missing doses).\n\n# Visit 199\n\nVisit 199 is only applicable to participants who discontinue the study treatment prematurely (between Week 72 and Week 176). Participants will be asked to return for Visit 199 at 176 weeks \u00b1 7 days after randomization. This visit is critical to ensure complete data collection for the weight\u2011loss and progression\u2011to\u2011diabetes endpoints. Participants should attend this visit in the fasting state. Procedures to be completed are:\n\n- measurement of weight\n- listing of concomitant medications\n- assessment of AEs\n- completion of the mental health questionnaires (after the AE assessment)\n- 2\u2011hour OGTT\n\nFor participants unwilling to attend this visit, their refusal to attend should be documented in the participant medical record.\n\n# 4.1.1.2.4. Early Discontinuation of Treatment Visit\n\nParticipants unable or unwilling to continue the study treatment for any reason will perform an early discontinuation of treatment (ED) visit. If the participant is discontinuing during an unscheduled visit, that visit should be performed as the ED visit. If the participant is discontinuing during a scheduled visit, that visit should be performed as an ED visit. Procedures should be completed according to the Schedule of Activities (Section 1.3). Patient\u2011reported outcomes questionnaires should be administered as early as possible, as per Suggested Visit Structure (Section 10.8). Administration of mental health questionnaires should follow assessment for AEs (see Section 7.2).\n\n# 4.1.1.2.5. Safety Follow-up Period\n\n# Visit 801 or Visit 802\n\nAll participants are required to complete a safety follow\u2011up visit (Visit 801 or Visit 802), according to the Schedule of Activities (Section 1.3). Participants discontinuing the study early and performing an ED visit will also be asked to perform the safety follow\u2011up visit. During the safety follow\u2011up period, participants will not receive study drug. Participants are also required to return any remaining study diaries to the study site at the end of this period.\n\nFor participants who discontinue or complete the study within the first 72 weeks, Visit 801 (safety follow\u2011up visit) should be performed 4 weeks after the last treatment visit (Visit 21 or 99) or 4 weeks after the ED visit for those who decline to return for Visit 99. Participants with prediabetes continuing to Week 78 should not perform Visit 801.\n\nLY3298176    35", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2847, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d68205f4-24ed-4aaf-8154-830524857362": {"__data__": {"id_": "d68205f4-24ed-4aaf-8154-830524857362", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "85db7d61-406e-4006-b6dd-63f8c027b04c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2089af1ef1482e02b0805e84be96700c90f124dc54d5aea4c14ef821e159f678", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                    Protocol I8F\u2011MC\u2011GPHK\n\nPrediabetes continuing in the 2\u2011year extension, Visit 802 should be performed 12 weeks after the last visit (Visit 116 or 199) or 12 weeks after the ED visit for those who decline to return for Visit 199 during the 2\u2011year extension period.\n\nFor those participants without glycemic evidence of T2DM (Section 4.1.2.1), a 2\u2011hour oral OGTT will be performed at Visit 802.\n\n# 4.1.2. Study Procedures\n\nParticipants will perform study procedures listed in the Schedule of Activities (Section 1.3). Participants will be permitted to use concomitant medications that they require during the study, except certain medications that may interfere with the assessment of efficacy and safety characteristics of the study treatments (Section 5.2). Study governance considerations are described in detail in Section 10.1 (Appendix 1).\n\n# 4.1.2.1. Definition of Prediabetes\n\nThe duration of treatment in Study GPHK (SURMOUNT\u20111) is determined by glycemic status at randomization, categorized into those with prediabetes or normoglycemia (participants with T2DM are excluded), as defined by the 2019 American Diabetes Association Standards of Medical Care in Diabetes (American Diabetes Association 2019b). The following populations are defined:\n\n|                 | Normoglycemia                                | Prediabetes       | Diabetes       |\n| --------------- | -------------------------------------------- | ----------------- | -------------- |\n| Fasting glucose | Obtained alone or at time = 0 during an OGTT |                   |                |\n|                 | <100 mg/dL                                   | (<5.6 mmol/L)     |                |\n|                 | <140 mg/dL                                   | 140\u2011mg\u2011199 mg/dL  | \u2265200 mg/dL     |\n| 2H glucose      | Obtained at time = 120 min during an OGTT    |                   |                |\n|                 | (<7.8 mmol/L)                                | (7.8\u201111.0 mmol/L) | (\u226511.1 mmol/L) |\n| HbA1c           | <5.7%                                        | 5.7%\u20116.4%         | \u22656.5%          |\n|                 | (<39 mmol/mol)                               | (39\u201147 mmol/mol)  | (\u226548 mmol/mol) |\n\nAbbreviations: H = hour; HbA1c = hemoglobin A1c; OGTT = 2\u2011hour oral glucose tolerance test.\n\nScreening to determine randomization glycemic status will occur in 2 visits:\n\n# Screening Visit 1\n\nParticipants will have a fasting glucose (FG) and HbA1c test. Results of these tests determine eligibility to proceed to Screening Visit 2.\n\n- FG \u2265126 mg/dL (7.0 mmol/L) OR HbA1c \u22656.5% (48 mmol/mol) suggests DM. These participants are excluded from the study and should be referred to their primary care physician for further work\u2011up to confirm the diagnosis.\n\nLY3298176    36", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2820, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "53b66f95-aa2b-43d0-be2b-02b25082d8f7": {"__data__": {"id_": "53b66f95-aa2b-43d0-be2b-02b25082d8f7", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "01ea736a-9c16-4c69-9ab9-3b2b7448815e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e4e628c4f10c44aed8914346e4003d6b68bff18cc506dcd8460307482db0d682", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                        Protocol I8F\u2011MC\u2011GPHK\n\n\u2022 All participants otherwise eligible and without FG or HbA1c values suggestive of diabetes will proceed to Screening Visit 2\n\n# Screening Visit 2\n\nAll participants attending Screening Visit 2 will undergo a 2\u2011hour OGTT test. These results, in combination with those obtained from Screening Visit 1, will be used to determine study eligibility and randomization glycemic status.\n\n- 2\u2011hour OGTT results: FG \u2265126 mg/dL (\u22657.0 mmol/L) OR 2\u2011hour OGTT \u2265200 mg/dL (\u226511.1 mmol/L) suggests diabetes mellitus. These participants are excluded from the study and should be referred to their primary care physician for further work\u2011up to confirm the diagnosis.\n\n# Glycemic Classification\n\nAll participants without laboratory tests suggestive of diabetes will be classified as having either normoglycemia or prediabetes. In keeping with American Diabetes Association guidelines (American Diabetes Association 2019b), at least 2 abnormal tests are required to diagnose prediabetes. For example:\n\n- Both 0 AND 2\u2011hour values during the 2\u2011hour OGTT values are in the prediabetes range.\n- FG at Screening Visit 1 AND Visit 2 are in the prediabetes range.\n- FG at Screening Visit 1 AND 2\u2011hour values during 2\u2011hour OGTT are in the prediabetes range.\n- HbA1c AND 1 of either the FG or 2\u2011hour OGTT values are in the prediabetes range.\n\n# 4.1.2.2. Oral Glucose Tolerance Test\n\nParticipants should attend visits requiring a 2\u2011hour OGTT in the fasting state. Samples will be collected at 0, 30, 60, 90, and 120 minutes during the 2\u2011hour OGTT. For glycemic classification, the values at time = 0 min (FG) and 120 minutes (2\u2011hour OGTT) will be used.\n\nTwo\u2011hour OGTTs should be performed per the Schedule of Activities (Section 1.3) and as described in Section 10.7, until such time as a protocol\u2011defined diagnosis of diabetes is confirmed (see Section 4.1.2.3). Two\u2011hour OGTT testing should be omitted at visits following a protocol\u2011defined diabetes diagnosis.\n\n# 4.1.2.3. Definition and Management of Incident Diabetes\n\n# Definition of incident diabetes\n\nIncident diabetes is defined when any 1 of the following occur after randomization (American Diabetes Association 2019b):\n\n- unequivocal hyperglycemia (random glucose \u2265200 mg/dL) with signs or symptoms of hyperglycemia\n- within a 4\u2011week period, any 2 of the following criteria are observed or 1 abnormal value is observed and confirmed:\n\nLY3298176    37", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2471, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5126dcfe-4b6b-4c51-a011-36621b0f1fce": {"__data__": {"id_": "5126dcfe-4b6b-4c51-a011-36621b0f1fce", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a9dcdda0-ff0e-4483-bfbb-7d83651a86ad", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8dcf793d448146a261d312e9db4d4c78665752bbc0707c9d3c00d581107729d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fba6cf3a-53c9-476b-86e8-c52d18972dc9", "node_type": "1", "metadata": {}, "hash": "895de177d6fae53f5d1ca2a30a16ac957cca63281c04da31501f7dac93efa821", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                         Protocol I8F\u2011MC\u2011GPHK\n\no  FG or 0\u2011hour serum glucose from 2\u2011hour OGTT \u2265126 mg/dL (7.0 mmol/L)\n\no  2\u2011hour glucose \u2265200 mg/dL (11.1 mmol/L) by a 2\u2011hour OGTT\n\n- initiation of any medication for the treatment of diabetes\n\n# Management of incident diabetes\n\nParticipants who develop diabetes during the study will be\n\n- provided and trained to use a glucometer\n- educated on the signs and symptoms of hypoglycemia and its treatment, and\n- provided a diary to record hypoglycemic episodes per Section 10.3.1.1.\n\nParticipants will be referred to their usual care provider and provided with a letter showing the study results indicative of diabetes. The decision to further evaluate, to initiate antihyperglycemic therapy, and the choice of antihyperglycemic medication will be at the discretion of the participant\u2019s usual care provider, with the exception of use of dipeptidyl\u2011peptidase\u20114 (DPP\u20114) inhibitors and open\u2011label GLP\u20111R agonists, which are prohibited in the study. Monitoring for hypoglycemia includes capture of events as defined in Section 10.3 (Appendix 3). Date of diagnosis of diabetes will be captured in the eCRF.\n\n# 4.2. Scientific Rationale for Study Design\n\nTirzepatide is a 39\u2011amino acid synthetic peptide with agonist activity at both the GIPR and GLP\u20111R. Its structure is based on the GIP sequence and includes a C20 fatty di\u2011acid moiety (Coskun et al. 2018). It is administered QW by SC injection.\n\nAs a dual GIP/GLP\u20111R agonist, tirzepatide could exceed the efficacy of selective GLP\u20111R agonists by recruiting metabolically active tissues not targeted by selective GLP\u20111R agonists (for example, adipose tissue as indicated by the observation of increased energy utilization) (Baggio and Drucker 2007) and has the potential to reach higher efficacy in target tissues, such as insulin\u2011producing pancreatic beta cells that express both GIPR and GLP\u20111R, before reaching its therapeutic limitation. Results from a Phase 2 study (GPGB) demonstrated that tirzepatide use in participants with T2DM was associated with a substantial, dose\u2011dependent weight loss, greater than the weight change observed with dulaglutide, a specific GLP\u20111R agonist. General safety characteristics of all studied doses of tirzepatide were similar to that of the GLP\u20111R agonist class, consisting mainly of nausea, vomiting, and diarrhea. In general, these events were transient and mild or moderate in severity, with few severe episodes. Although GI AEs were more common at the 15\u2011mg arm of tirzepatide, this dose demonstrated the highest efficacy in terms of weight loss. This suggests that tirzepatide has the potential to become a medication for chronic weight management. An optimized dose escalation regimen, proposed in the Study GPHK (SURMOUNT\u20111) to improve tolerability (and supported by a dose\u2011escalation algorithm from study GPGF), should enable a use of higher doses to maximize effects on body weight. Study GPHK (SURMOUNT\u20111) is designed to determine the comparative benefits and risks of tirzepatide 5 mg, 10 mg or 15 mg QW versus placebo in participants who have obesity or are overweight.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3159, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fba6cf3a-53c9-476b-86e8-c52d18972dc9": {"__data__": {"id_": "fba6cf3a-53c9-476b-86e8-c52d18972dc9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a9dcdda0-ff0e-4483-bfbb-7d83651a86ad", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8dcf793d448146a261d312e9db4d4c78665752bbc0707c9d3c00d581107729d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5126dcfe-4b6b-4c51-a011-36621b0f1fce", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "5c85a133091100898cfb67dd906398268d01d9752a95c995e12b6eb2a417b6b5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This suggests that tirzepatide has the potential to become a medication for chronic weight management. An optimized dose escalation regimen, proposed in the Study GPHK (SURMOUNT\u20111) to improve tolerability (and supported by a dose\u2011escalation algorithm from study GPGF), should enable a use of higher doses to maximize effects on body weight. Study GPHK (SURMOUNT\u20111) is designed to determine the comparative benefits and risks of tirzepatide 5 mg, 10 mg or 15 mg QW versus placebo in participants who have obesity or are overweight. A double\u2011blind design was selected to minimize participant and investigator bias in assessments for efficacy, safety, and study drug tolerability.\n\nLY3298176    38", "mimetype": "text/plain", "start_char_idx": 2629, "end_char_idx": 3323, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b27c6366-6ebf-4b5a-9737-df546dedc359": {"__data__": {"id_": "b27c6366-6ebf-4b5a-9737-df546dedc359", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a81321a4-9e4a-441b-848f-8fc67c7466d5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9e0a8a47effeb873a9ff1a7dfccd56eb9494d657f95b54e5005c201918de595d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK\n\nA placebo comparator was selected for this trial in accordance with regulatory guidance (FDA 2007; EMA 2016). In addition, all participants, regardless of treatment assignment, will receive lifestyle modification counselling consistent with current guidelines for weight management (Jensen et al. 2013). Specifically, participants will consult with a dietician, or equivalent qualified delegate, throughout the study to achieve at least a 500 kcal/day energy deficit through a combination of caloric restriction and increased physical activity (Section 5.3.1). The planned duration of treatment for the primary endpoint at 72 weeks allows for at least a 52\u2011week treatment period at the dose achieved following dose escalation to either 5, 10, or 15 mg. This duration is considered appropriate to assess the full effects and benefit/risk of each maintenance dose of tirzepatide compared with placebo on body weight and is consistent with regulatory guidelines (FDA 2007; EMA 2016).\n\nThe effects of drug cessation will be assessed in the 4\u2011week and in the 12\u2011week safety follow\u2011up/observational periods. Another objective of the study is to evaluate the effect of tirzepatide on the risk of new\u2011onset diabetes. Obesity is associated with an increased risk of developing T2DM and diabetes prevention is of great importance in obese subjects to protect them from complications of the disease. Several studies have shown that interventions leading to weight loss may help prevent diabetes (Adams et al. 2017, le Roux et al. 2017).\n\nTo obtain additional information regarding the rate of conversion to diabetes on tirzepatide, participants with prediabetes diagnosed at the beginning of the study (being at increased risk of diabetes), will be treated and observed for an additional 2 years. Based on available literature, the 3 years of treatment with tirzepatide should be sufficient to demonstrate the risk reduction of developing T2DM compared to placebo. This additional treatment period would also permit collecting data on the durability of weight changes with long\u2011term therapy and safety of long\u2011term tirzepatide treatment.\n\nTo minimize the potential confounding effect of changes to concomitant medications, participants will be permitted to use concomitant medications that do not interfere with the assessment of efficacy or safety characteristics of the study treatments.\n\n# 4.3. Justification for Dose\n\nTirzepatide doses of 5 mg, 10 mg, and 15 mg QW will be evaluated in this study. These doses and associated escalation schemes were selected based on assessment of safety, efficacy (weight loss), and GI tolerability data, followed by exposure\u2011response modeling of data in patients in Phase 1 and 2 studies that predicted weight loss in obese and overweight patients without T2DM. Dosing algorithms starting at a low dose of 2.5 mg accompanied by dose escalation of 2.5\u2011mg increments every 4 weeks should permit time for development of tolerance to GI events and are predicted to minimize GI tolerability concerns. The maximum proposed dose of 15 mg maintains an exposure multiple of 1.6 to 2.4 to the no\u2011observed adverse\u2011effect level doses in 6\u2011month monkey and rat toxicology studies.\n\n# 4.4. End of Study Definition\n\nSection 7.2 describes the criteria used to determine if a participant has completed the study.\n\nLY3298176    39", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3430, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "32f225d5-84d6-4b06-bdf3-2cee403916a5": {"__data__": {"id_": "32f225d5-84d6-4b06-bdf3-2cee403916a5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f4ea5b2a-37fc-4a62-8b0e-c1249cfd2075", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9a04c3e92ff4a5a9482d6f2ee0698b0e2066801a836c98dd11436554d16e24b0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\nThe end of the study is defined as the date of the last visit of the last participant in the study or the last scheduled procedure shown in the Schedule of Activities (Section 1.3.1 or 1.3.2 based on randomization glycemic status), for the last participant in the trial globally.\n\nLY3298176    40", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 334, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4836db2d-7e2e-4b1c-9c28-2122125759b3": {"__data__": {"id_": "4836db2d-7e2e-4b1c-9c28-2122125759b3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fa86e237-7412-4906-b592-63e7774a6075", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d9f227416755c7ea59c2466ab943f1a31dd96ae1ab44fb4000417d0c16588c98", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 5. Study Population\n\nProspective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.\n\n# 5.1. Inclusion Criteria\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n# Type of Participant and Disease Characteristics\n\n1. Have a BMI\n- \u226530 kg/m\u00b2 or\n- \u226527 kg/m\u00b2 and previously diagnosed with at least one of the following weight related comorbidities:\n1. hypertension: treated or with systolic blood pressure (SBP) \u2265130 mmHg or diastolic blood pressure \u226580 mmHg\n2. dyslipidemia: treated or with low\u2011density lipoprotein (LDL) \u2265160 mg/dL (4.1 mmol/L) or triglycerides \u2265150 mg/dL (1.7 mmol/L), or high\u2011density lipoprotein (HDL) &#x3C;40 mg/dL (1.0 mmol/L) for men or HDL&#x3C;50 mg/dL (1.3 mmol/L) for women\n3. obstructive sleep apnea\n4. cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I\u2011III heart failure)\n2. Have a history of at least one self\u2011reported unsuccessful dietary effort to lose body weight\n3. In the investigator\u2019s opinion, are well\u2011motivated, capable, and willing to\n- learn how to self\u2011inject study drug, as required for this protocol (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject study drug; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject study drug)\n- inject study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)\n- follow study procedures for the duration of the study, including, but not limited to: follow lifestyle advice (for example, dietary restrictions and exercise plan), maintain a study diary, and complete required questionnaires\n\nLY3298176    41", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1952, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f84b52d7-e639-4ac9-acee-29c42c56545a": {"__data__": {"id_": "f84b52d7-e639-4ac9-acee-29c42c56545a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a459c278-cfb2-417d-a339-7c5ae3550b10", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "359c8b78551cbc0e5506199f6a4a99cb04d9426f0f76c58656aebd9cbc0a039f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK\n\n# Participant Characteristics\n\n1. Are 18 years or older\n1. male participants:\n- Male participants with partners of childbearing potential should be willing to use reliable contraceptive methods throughout the study and for 5 half-lives of study drug plus 90 days, corresponding to 4 months after the last injection.\n2. female participants:\n- Female participants not of childbearing potential may participate and include those who are:\n- infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy or tubal ligation), congenital anomaly such as Mullerian agenesis\n- postmenopausal, defined as either\n- a woman at least 40 years of age with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, AND a follicle-stimulating hormone \u226540mIU/mL; women in this category must test negative in pregnancy test prior to study entry\n- or a woman 55 or older not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea\n- or a woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy\n- Female participants of child-bearing potential (not surgically sterilized and between menarche and 1-year postmenopausal) must:\n- test negative for pregnancy at Visit 1 based on a serum pregnancy test\n- and if sexually active, agree to use 2 forms of effective contraception, where at least 1 form is highly effective, for the duration of the trial and for 30 days thereafter\n- not be breastfeeding\n\n# Informed Consent\n\n1. Have given written informed consent to participate in this study in accordance with local regulations and the ethical review board (ERB) governing the study site\n\n# Exclusion Criteria\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nLY3298176\n\n42", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1875, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "02d05981-5f0e-4aee-a651-15a0bd6bbf6a": {"__data__": {"id_": "02d05981-5f0e-4aee-a651-15a0bd6bbf6a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a33d7137-d933-412e-b3b1-c53fc29004f9", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a01cf8b766f25940c437a70eaefee6a9b10b7c739de4723e0f56ecc219be38ef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Medical Conditions\n\n# Diabetes-related\n\n1. Have type 1 diabetes mellitus (T1DM) or T2DM, history of ketoacidosis, or hyperosmolar state/coma\n2. Have laboratory evidence diagnostic of diabetes mellitus during screening, including 1 or more of: HbA1c \u22656.5% (\u226548 mmol/mol), FG \u2265126 mg/dL (\u22657.0 mmol/L), random glucose or 2\u2011hour glucose measurement from a 2\u2011hour OGTT \u2265200 mg/dL (\u226511.1 mmol/L)\n\n# Obesity-related\n\nHave a self\u2011reported change in body weight >5 kg within 3 months prior to screening\nHave a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)\nHave or plan to have endoscopic and/or device\u2011based therapy for obesity or have had device removal within the last 6 months (for example, mucosal ablation, gastric artery embolization, intragastric balloon and duodenal\u2011jejunal bypass sleeve)\n\n# Other medical\n\nHave renal impairment measured as estimated glomerular filtration rate (eGFR) &#x3C;30 mL/min/1.73 m\u00b2, calculated by Chronic Kidney Disease\u2011Epidemiology as determined by central laboratory during screening\nHave a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility\nHave had a history of chronic or acute pancreatitis\nHave thyroid\u2011stimulating hormone (TSH) outside of the range of 0.4 to 6.0 mIU/L at screening visit\n- Note: Patients receiving treatment for hypothyroidism may be included, provided their thyroid hormone replacement dose has been stable for at least 3 months.\n- Note: TSH values above the normal range can, in some patients, suggest subclinical hypothyroidism. If, in the investigator\u2019s opinion, the participant has subclinical hypothyroidism and may require initiation of thyroid hormone replacement during the course of the study, the patient should be excluded from the study.\n\nHave obesity induced by other endocrinologic disorders (for example, Cushing Syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome)\n\nLY3298176    43", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2202, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eb84caf7-445f-4eeb-a5d7-8b4b1f38fc4f": {"__data__": {"id_": "eb84caf7-445f-4eeb-a5d7-8b4b1f38fc4f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "86e29a4c-8220-4a65-a6f1-222b9c54f25f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c20422124839b0ce2f438098c25f3d879b788f13e76f36e63ac37902fc9b6251", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                    Protocol I8F\u2011MC\u2011GPHK\n\n# 16.\n\nHave a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years\n\nNote: Patients with MDD or generalized anxiety disorder whose disease state is considered stable and expected to remain stable throughout the course of the study, in the opinion of the investigator, may be considered for inclusion if they are not on excluded medications\n\n# 17.\n\nHave any lifetime history of a suicide attempt\n\n# 18.\n\nHave a Patient Health Questionnaire\u20119 (PHQ\u20119) score of 15 or more at Visit 1 or 3, prior to randomization\n\n# 19.\n\nOn the C\u2011SSRS at Visits 1, 2, or 3, prior to randomization:\n\n- a \u201cyes\u201d answer to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or\n- a \u201cyes\u201d answer to Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the \"Suicidal Ideation\" portion of the C\u2011SSRS or\n- a \u201cyes\u201d answer to any of the suicide\u2011related behaviors (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Act or Behavior) on the \"Suicidal Behavior\" portion of the C\u2011SSRS and\n- the ideation or behavior occurred within the past month\n\n# 20.\n\nHave uncontrolled hypertension (SBP above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)\n\n# 21.\n\nHave any of the following cardiovascular conditions within 3 months prior to randomization: acute myocardial infarction (MI), cerebrovascular accident (stroke), unstable angina, or hospitalization due to congestive heart failure (CHF)\n\n# 22.\n\nHave NYHA Functional Classification IV CHF\n\n# 23.\n\nHave acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease, or any of the following, as determined by the central laboratory during screening:\n\n- alanine aminotransferase (ALT) level >3.0X the upper limit of normal (ULN) for the reference range or\n- alkaline phosphatase (ALP) level >1.5X the ULN for the reference range or\n- total bilirubin (TBL) level >1.2X the ULN for the reference range (except for cases of known Gilbert\u2019s Syndrome)\n\nLY3298176    44", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2295, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "68292c4a-41fb-4b9d-ba88-453a8d0dfd5c": {"__data__": {"id_": "68292c4a-41fb-4b9d-ba88-453a8d0dfd5c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c27d1392-fa30-4f92-be71-84a2a668245c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3c8fc5311b997852984e9ac6f4c9da2da532aee8ba09e1bb2d58d7c8d98f46a1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                  Protocol I8F\u2011MC\u2011GPHK\n\nNote: Participants with nonalcoholic fatty liver disease are eligible to participate in this trial if their ALT level is \u22643.0X the ULN for the reference range.\n\n1. Have a calcitonin level (at Visit 1) of:\n- \u226520 ng/L at Visit 1, if eGFR \u226560 mL/min/1.73 m\u00b2\n- \u226535 ng/L at Visit 1, if eGFR &#x3C;60 mL/min/1.73 m\u00b2\n2. Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2.\n3. Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal\u2011 or squamous\u2011cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.\n4. Have any other condition not listed in this section (for example, hypersensitivity or intolerance) that is a contraindication to GLP\u20111R agonists.\n5. Have a history of any other condition (such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder) that, in the opinion of the investigator, may preclude the participant from following and completing the protocol.\n6. Have history of use of marijuana within 3 months of enrollment and unwillingness to abstain from marijuana use during the trial. Participants should also refrain from use of cannabidiol oil for the duration of the study.\n7. Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or awaiting an organ transplant.\n8. Have any hematological condition that may interfere with HbA1c measurement (for example, hemolytic anemias, sickle cell disease).\n\n# Prior/Concomitant Therapy\n\nAre receiving or have received within 3 months prior to screening chronic (>2 weeks or 14 days) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra\u2011articular, or inhaled preparations) or have evidence of a significant, active autoimmune abnormality (for example, lupus or rheumatoid arthritis) that has required (within the last 3 months) or is likely to require, in the opinion of the investigator, concurrent treatment with systemic glucocorticoids (excluding topical, intraocular, intranasal, intra\u2011articular or inhaled preparations) in the next 12 months.\nHave current or history of (within 3 months prior to randomization) treatment with medications that may cause significant weight gain, including but not limited to: tricyclic antidepressants, atypical antipsychotic and mood stabilizers for example:\n- imipramine\n- amitriptyline\n- mirtazapine\n\nLY3298176    45", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2572, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eb0621d1-3b9f-4b0d-8276-0e153326daa3": {"__data__": {"id_": "eb0621d1-3b9f-4b0d-8276-0e153326daa3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "62f73e79-d0fa-41c0-8a3f-eb55f0ef6fb3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "abb97f99e4740213fc458e0729d4ad4ee5d35f79963b52fa83cf0bb82d63abc8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK\n\n- paroxetine\n- phenelzine\n- chlorpromazine\n- thioridazine\n- clozapine\n- olanzapine\n- valproic acid and its derivatives\n- lithium\n\nNote: Selective serotonin reuptake inhibitors other than paroxetine are permitted.\n\n34. Have taken within 3 months prior to randomization, medications (prescribed or over\u2011the\u2011counter) or alternative remedies intended to promote weight loss. Examples include, but are not limited to:\n\n- Saxenda\u00ae (liraglutide 3.0 mg)\n- Xenical\u00ae/Alli\u00ae (orlistat)\n- Meridia\u00ae (sibutramine)\n- Acutrim\u00ae (phenylpropanolamine)\n- Sanorex\u00ae (mazindol)\n- Adipex\u00ae (phentermine)\n- BELVIQ\u00ae (lorcaserin)\n- Qsymia\u00ae (phentermine/topiramate combination)\n- Contrave\u00ae (naltrexone/bupropion)\n\nNote: Use of metformin or any other glucose\u2011lowering medication, whether prescribed for polycystic ovary syndrome or diabetes prevention is not permitted.\n\n35. Have started implantable or injectable contraceptives (such as Depo\u2011Provera\u00ae) within 18 months prior to screening.\n\n# Prior/Concurrent Clinical Study Experience\n\n36. Are currently enrolled in any other clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study.\n\n37. Within the last 30 days, have participated in a clinical study and received treatment, whether active or placebo. If the study involved an IP, 5 half\u2011lives or 30 days, whichever is longer, should have passed.\n\n# Other Exclusions\n\n38. Are investigator site personnel directly affiliated with this study and/or their immediate family. Immediate family is defined as a spouse, legal partner, parent, child, or sibling, whether biological or legally adopted.\n\n39. Are Eli Lilly and Company (Lilly) employees.\n\nLY3298176 46", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1775, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a902bec2-0082-44b2-a7da-7b7e5aa6206c": {"__data__": {"id_": "a902bec2-0082-44b2-a7da-7b7e5aa6206c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "15ac59e7-059b-4429-ad1c-58d1c4a4233d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7dd3ce5e62be9adc84597508876f4103990ebd2721dee3f93d34f9967151ceb6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                          Protocol I8F\u2011MC\u2011GPHK\n\n# 5.3. Lifestyle Considerations\n\nPer the Schedule of Activities (Section 1.3), participants will consult with a dietician, or equivalent qualified delegate, according to local standards, to receive lifestyle management counseling at Weeks 0, 4, 8 and 12 during dose escalation and then at Week 24 and every 12 weeks thereafter through 72 weeks. Participants in the 104\u2011week extension will continue to receive lifestyle management counseling at 3\u2011month intervals as defined in the Schedule of Activities (Section 1.3). Diet and exercise goals established during the lifestyle consultation and the importance of adherence to the lifestyle component of the trial will be reinforced at each trial contact by study staff.\n\n# 5.3.1. Meals and Dietary Restrictions\n\nAt Visit 3 and subsequent visits, study participants will receive diet counselling by a dietician/nutritionist, or equivalent qualified delegate, according to local standard. Dietary counseling will consist of advice on healthy food choices and focus on calorie restriction using a hypocaloric diet with macronutrient composition of:\n\n- maximum 30% of energy from fat\n- approximately 20% of energy from protein\n- approximately 50% of energy from carbohydrates\n- an energy deficit of approximately 500 kcal/day compared to the participant\u2019s estimated total energy expenditure (TEE)\n\nTo encourage adherence, it is recommended that a 3\u2011day diet and exercise diary be completed prior to each counseling visit. During each visit, the participant\u2019s diet is reviewed and advice to maximize adherence is provided if needed.\n\nThe hypocaloric diet is continued after randomization and throughout the treatment period. If a BMI \u226422 kg/m2 is reached, the recommended energy intake should be recalculated with no kcal deficit for the remainder of the trial.\n\nTotal energy expenditure (TEE) is calculated by multiplying the estimated Basal Metabolic Rate (BMR) (see table below) with a Physical Activity Level value of 1.3 (FAO/WHO/UNU 2004), which reflects an inactive lifestyle. This calculation provides a conservative estimate of caloric requirements:\n\nTEE (kcal/day) = BMR X 1.3\n\nLY3298176    47", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2222, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bf822dd0-5c24-4cbc-951e-a3d4b388cdf9": {"__data__": {"id_": "bf822dd0-5c24-4cbc-951e-a3d4b388cdf9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "12009ceb-9cd7-452d-8dbc-e586beba08a0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0342c9ae5c46738163791b5990e68aa09b79cee9d3384eaaad0b5e048bc80c51", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                               Protocol I8F\u2011MC\u2011GPHK\n\n# Equations for estimating BMR in kcal/day*\n\n| Sex       | Age         | BMR (kcal/day)                       |   |\n| --------- | ----------- | ------------------------------------ | - |\n| Men       | 18\u201130 years | 15.057 X actual weight in kg + 692.2 |   |\n|           | 31\u201160 years | 11.472 X actual weight in kg + 873.1 |   |\n| >60 years |             | 11.711 X actual weight in kg + 587.7 |   |\n| Women     | 18\u201130 years | 14.818 X actual weight in kg + 486.6 |   |\n|           | 31\u201160 years | 8.126 X actual weight in kg + 845.6  |   |\n| >60 years |             | 9.082 X actual weight in kg + 658.5  |   |\n\nAbbreviations: BMR = basal metabolic rate; WHO = World Health Organization.\n\n*Revised WHO equations (adapted from: FAO/WHO/UNU 2004).\n\n# 5.3.2. Physical Activity\n\nAt Visit 3 and all subsequent visits, participants will be advised to increase their physical activity to at least 150 minutes per week.\n\n# 5.4. Screen Failures\n\nScreen failures are defined as participants who consent to participate in the clinical study but are not subsequently randomly assigned to the study intervention. A minimal set of screen\u2011failure information should be collected to ensure transparent reporting of screen\u2011failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any SAE. Individuals who do not meet the criteria for participation in this study (screen failure) may not be rescreened.\n\nLY3298176    48", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1700, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f9bd162e-3232-4b42-801c-016d3d4f1c6f": {"__data__": {"id_": "f9bd162e-3232-4b42-801c-016d3d4f1c6f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "48dc58f0-d511-452b-9110-e27041456e3c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cf076649442aaabd0dd230655c353859b43006f45a179988b9c9ad7a68797573", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 6. Study Intervention\n\nStudy intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.\n\n# 6.1. Study Interventions Administered\n\n| ARM Name                | Tirzepatide 5 mg                                                                                                                                                                                     | Tirzepatide 10 mg | Tirzepatide 15 mg | Placebo |\n| ----------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------- | ----------------- | ------- |\n| Dose                    | 5 mg QW                                                                                                                                                                                              | 10 mg QW          | 15 mg QW          | N/A     |\n| Route of Administration | SC                                                                                                                                                                                                   | SC                | SC                | SC      |\n| Sourcing                | Provided centrally by the Sponsor and dispensed via IWRS                                                                                                                                             |                   |                   |         |\n| Packaging and Labeling  | Study Intervention will be provided in autoinjectors (single\u2011dose pens), packaged in cartons to be dispensed. Clinical study materials will be labeled according to country regulatory requirements. |                   |                   |         |\n\nAbbreviations: IWRS = interactive web response service; N/A = not available; QW = once\u2011weekly; SC = subcutaneous.\n\nThere are no restrictions on the time of day each weekly dose of study drug is given, but it is advisable to administer the SC injections on the same day and same time each week. The actual date, time and injection site location of all dose administrations will be recorded in the diary by the participant. If a dose of study drug is missed, the participant should take it as soon as possible unless it is within 72 hours of the next dose, in which case that dose should be skipped, and the next dose should be taken at the appropriate time. The day of weekly administration can be changed if necessary, as long as the last dose was administered 72 or more hours before.\n\nAll participants will inject study drug subcutaneously in the abdomen or thigh using the injection supplies provided; a caregiver may administer the injection in the participant\u2019s upper arm. The injection site location of all dose administrations will be recorded by the participant. A new autoinjector will be used for each injection. If study drug is to always be injected in the same body region, participants should be advised to rotate injection sites each week.\n\n# 6.1.1. Medical Devices\n\nThe combination products provided for use in the study are tirzepatide investigational autoinjector (or matching placebo). Any medical\u2011device incidents, including those resulting from malfunctions of the device, must be detected, documented, and reported by the investigator throughout the study (see Section 10.6).\n\nLY3298176    49", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3588, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "23f18b3e-757b-4cfe-8ec5-6623dd7fd613": {"__data__": {"id_": "23f18b3e-757b-4cfe-8ec5-6623dd7fd613", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7068ead6-bff9-4210-bca9-e8ff5ec448d5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a15b56c7bfb55d9aaafaf3ca2c8ff3402082fafca21d45bd70bbb9fcf37704a4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK\n\n# 6.2.  Preparation/Handling/Storage/Accountability\n\n- The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study intervention received and any discrepancies are reported and resolved before use of the study intervention.\n- Only participants enrolled in the study may receive study intervention and only authorized site staff may supply study intervention.\n- All study intervention must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.\n- The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention (includes study drug and autoinjector or single\u2011dose pen) accountability, reconciliation, and record maintenance (for example, receipt, reconciliation, and final disposition of records).\n- Study site staff must regularly assess whether the participant is correctly administering the assigned study drug and storing study drug according to the provided instructions.\n\n# 6.3.  Measures to Minimize Bias: Randomization and Blinding\n\nThis is a double\u2011blind study. Participants who meet all criteria for enrollment will be randomized to one of the study treatment groups at Visit 3. Assignment to treatment groups will be determined by a computer\u2011generated, random sequence using an IWRS. Participants will be randomized in a 1:1:1:1 ratio to receive tirzepatide 5 mg, tirzepatide 10 mg, tirzepatide 15 mg, or placebo.\n\nThe randomization will be stratified by prediabetes status, country, and sex (female, male). Investigators, site staff, clinical monitors and participants will remain blinded to the treatment assignments until the study is complete. To preserve the blinding of the study, a limited number of preidentified individuals from the Sponsor will be unblinded to treatment assignments as needed for the interim analysis and for the primary endpoint (Week 72) database lock (see Section 9.5).\n\nEmergency unblinding may be performed through the IWRS. This option may be used ONLY if the participant\u2019s wellbeing requires knowledge of the participant\u2019s treatment assignment. All emergency unblinding events are recorded and reported by the IWRS.\n\nIf an investigator, site personnel performing assessments, or participant is unblinded, the participant must be discontinued from the study. In cases where there are ethical reasons to have the participant remain in the study, the investigator must obtain specific approval from a Lilly clinical research physician (CRP) for the participant to continue in the study.\n\nIn case of an emergency, the investigator has the sole responsibility for determining if unblinding of a participant\u2019s treatment assignment is warranted for medical management of the event. The participant safety must always be the first consideration in making such a determination. If a participant\u2019s treatment assignment is unblinded, Lilly must be notified immediately. If the investigator decides that unblinding is warranted, it is the responsibility of the investigator to promptly document the decision and rationale and notify Lilly as soon as possible.\n\nLY3298176    50", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3381, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f6a91855-338c-4a29-b0ee-69c60576b6f2": {"__data__": {"id_": "f6a91855-338c-4a29-b0ee-69c60576b6f2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3063a9fa-607b-4d2e-bc02-cbc66075c395", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1d8b299a027b8bc2f6e3f94c95381bf7deaef925cc1fbe103e4e03e22a645ed8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                              Protocol I8F\u2011MC\u2011GPHK\n\n# 6.4. Study Intervention Compliance\n\nParticipant compliance with study intervention will be assessed at each visit. Compliance will be assessed by direct questioning and counting of unused study drug and/or empty cartons returned. Study drug compliance will be determined by the following:\n\n- Study drug administration data will be recorded by the participant and reviewed by the investigator at each study visit.\n- The participants will be instructed to return any unused study drug and/or empty cartons at the next visit to the study site for the purpose of performing drug accountability.\n\nTreatment compliance for each visit interval is defined as taking at least 75% of the required doses of study drug. Similarly, a participant will be considered significantly noncompliant if he or she is judged by the investigator to have intentionally or repeatedly taken more than the prescribed amount of medication (more than 125%).\n\nIn addition to the assessment of a participant\u2019s compliance with study drug administration, other aspects of compliance with the study treatments will be assessed at each visit based on the participant\u2019s adherence to the visit schedule, completion of study diaries, and any other parameters the investigator considers necessary.\n\nParticipants considered to be poorly compliant with their medication and/or the study procedures will receive additional training and instruction, as required, and will be reminded of the importance of complying with the protocol.\n\n# 6.5. Concomitant Therapy\n\nParticipants will be permitted to use concomitant medications that they require during the study, except certain medications (for example; other medications for weight management) that may interfere with the assessment of efficacy and safety characteristics of the study treatments. Participants who develop diabetes during the study may initiate medication for glucose control, with the exception of DPP\u20114 inhibitors or GLP\u20111R agonists (Section 4.1.2.3). Initiation of metformin for the treatment of diabetes is permitted, but metformin should not be initiated during the study for the treatment of other metabolic conditions (for example, polycystic ovary syndrome, diabetes prevention).\n\nInvestigative\u2011site staff will inform participants that they must consult with the investigator or a designated site staff member upon being prescribed any new medications during the study. This may not be possible when initiated for treatment of medical emergencies, in which case, the participant will inform the investigator or a designated site staff member as soon as possible.\n\nNonstudy medications taken by participants who are screened but not randomized will not be reported to Lilly unless an SAE or AE occurs that the investigator believes may have been caused by a study procedure.\n\nLY3298176    51", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2902, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "831b1cea-6418-42bb-adbf-c842904c9d98": {"__data__": {"id_": "831b1cea-6418-42bb-adbf-c842904c9d98", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b3c225e0-4e56-44fc-9b33-4b4e5419adbb", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3d9a58844b1c672452fabd47c1623296fc91588174926631b5c2aa9696ccafec", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK\n\n# 6.6. Dose Modification\n\n# 6.6.1. Tirzepatide\n\nTirzepatide is given once weekly by SC injection. There are no restrictions on the time of day each weekly dose of tirzepatide is given, but it is advisable to administer the SC injections on the same day of the week and similar time each week. If a dose of tirzepatide is missed, the participant should take it as soon as possible unless it is within 72 hours of the next dose, in which case, that dose should be skipped, and the next dose should be taken at the appropriate time. Study drug dose modification is not permitted, except for management of intolerable GI symptoms (see Section 6.6.2).\n\n# 6.6.2. Management of Participants with Gastrointestinal Symptoms\n\nParticipants who experience intolerable GI symptoms (for example, nausea, vomiting, or diarrhea) at any time during the study, should first be counselled on dietary behaviors that may help mitigate nausea and vomiting, (for example, eating smaller meals, splitting 3 daily meals into 4 or more smaller ones, and stopping eating when they feel full). If symptoms persist, the participant should be prescribed, at the investigator\u2019s discretion, symptomatic medication (for example, antiemetic or antidiarrheal medication). A temporary interruption of study drug for 1 dose is permitted, provided the participant has taken the last 3 weekly doses. Study treatment should be resumed at the assigned dose immediately, either alone or in combination with symptomatic medication, which can also be utilized to manage symptoms (Section 10.9). Management of study drug after interruptions >1 dose is discussed in Section 7.1.1.\n\nIf intolerable GI symptoms (for example, nausea, vomiting, or diarrhea) persist despite the above measures, the investigator should contact Lilly to consider reinitiating study drug at the next\u2011lowest maintenance dose in a blinded fashion (for example, 15 mg reduced to 10 mg, 10 mg reduced to 5 mg, or 5 mg reduced to placebo) (Section 10.9). If intolerable GI symptoms persist despite symptomatic treatment, temporary drug interruption, and resumption at a lower dose of study drug, the participant should be discontinued from study drug. Only 1 dose reduction per participant will be permitted during the course of the study. All participants who discontinue study drug should continue to attend scheduled study visits. All dose adjustments will be managed through IWRS.\n\n# 6.7. Intervention after the End of the Study\n\n# 6.7.1. Treatment after Study Completion\n\nTirzepatide will not be made available to participants after conclusion of the study.\n\nLY3298176 52", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2637, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b1779acc-465d-471b-8eff-721f3b33ceee": {"__data__": {"id_": "b1779acc-465d-471b-8eff-721f3b33ceee", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5aa4cf96-662a-4d7d-940c-ea2af130484c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "39ac5d6491184088926cd0c474330b7533dd0f62f4a25b5842389a45202329e3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 7. Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\n\n# 7.1. Discontinuation of Study Intervention\n\nPossible reasons leading to permanent discontinuation of IP:\n\n- participant decision\n- the participant requests to discontinue IP.\n- clinical considerations\n- initiation of open\u2011label GLP\u20111R agonist or DPP\u20114 inhibitor, if participants will not or cannot discontinue them\n- intolerable GI symptoms despite management as described in Section 6.6.2\n- BMI \u226418.5 kg/m2 is reached at any time during the treatment period\nNote: The investigator should contact the Sponsor CRP to discuss whether it is medically appropriate for the participant to continue study treatment.\n- diagnosis of T1DM\n- diagnosis of MTC after randomization\n- significant elevation of calcitonin (Section 10.3.1.4)\n- diagnosis of acute or chronic pancreatitis\n- diagnosis of an active or untreated malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) after randomization\n- development of any significant study drug\u2011related hypersensitivity reaction\n- onset of pregnancy in a female participant\n- occurrence of any other treatment\u2011emergent AE (TEAE), SAE, or clinically significant finding for which the investigator believes that permanent study drug discontinuation is the appropriate measure to be taken\n- inadvertent enrollment if continued treatment with study drug would not be medically appropriate (Section 7.2.3)\n- PHQ\u20119 score \u226515\n\nLY3298176    53", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1561, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bd39dde2-cfc8-4bd5-8617-dcdd690c52ff": {"__data__": {"id_": "bd39dde2-cfc8-4bd5-8617-dcdd690c52ff", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "29ce36da-cfa6-4d5d-a2c6-0afb63511d0d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "948fab59ac6fc99e3dbf4c8ad88daa654245bd4d67b24a8ad193ce29c86340c7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                   Protocol I8F\u2011MC\u2011GPHK\n\nParticipants should be referred to a Mental Health Professional (MHP) to assist in deciding whether the subject should be discontinued from study drug. If a participant\u2019s psychiatric disorder can be adequately treated with psycho\u2011 and/or pharmacotherapy, then the subject, at the discretion of the Investigator (in agreement with the MHP), may be continued in the trial on randomized therapy.\n\nIn addition, study drug may be discontinued if participants:\n\n- answered \u201cyes\u201d to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) on the \"Suicidal Ideation\" portion of the C\u2011SSRS\n- or answered \u201cyes\u201d to Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the \"Suicidal Ideation\" portion of the C\u2011SSRS\n- or answered \u201cyes\u201d to any of the suicide\u2011related behaviors (Actual attempt, Interrupted attempt, Aborted attempt, Preparatory act or behavior) on the \u201cSuicidal Behavior\u201d portion of the C\u2011SSRS.\n\nNote: A psychiatrist or appropriately trained professional may assist in the decision to discontinue the participant.\n\nDiscontinuation due to a hepatic event or liver test abnormality:\n\n- Participants who are discontinued from IP due to a hepatic event or liver test abnormality should have additional hepatic safety data collected via eCRF.\n- Discontinuation of the IP for abnormal liver tests should be considered by the investigator when a participant meets one of the following conditions after consultation with the Lilly designated medical monitor:\n\nLY3298176    54", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1609, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cbbdde6c-3d0f-40ea-9194-f72a662a069c": {"__data__": {"id_": "cbbdde6c-3d0f-40ea-9194-f72a662a069c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "731d0a10-87ef-4e01-8259-076ac86ad025", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "263099caf1fab68ec5cd68c23d35df3c1547355030e40f11b8099390b45b01fa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                             Protocol I8F\u2011MC\u2011GPHK\n\n\u25aa ALP >2.5X ULN with the appearance of fatigue, nausea, vomiting, right\u2011quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) Participants who stop study drug permanently should continue to attend all scheduled study visits to collect all planned efficacy and safety measurements. Participants who are unwilling to attend all scheduled visits and stop the study prior to 72 weeks, should return for a final weight measurement (Visit 99). If participants are unwilling to attend Visit 99, their refusal to attend should be documented in the patient medical record. Participants with prediabetes who stop study drug after 72 weeks should return for a final assessment of weight and glycemic status (Visit 199). Refusal to attend should be documented in the patient medical record. Participants discontinuing from the IP prematurely for any reason should complete AE and other follow\u2011up procedures per Section 1.3 (Schedule of Activities), Section 8.3 (Adverse Events and Serious Adverse Events), and Section 8.2 (Safety Assessments) of the protocol.\n\n# 7.1.1. Temporary Study Drug Discontinuation\n\nIn certain situations, after randomization, the investigator may need to temporarily interrupt study drug. Every effort should be made by the investigator to maintain participants on study drug and to restart study drug after any temporary interruption, as soon as it is safe to do so. Distribution of study medication at the correct dose will be per IWRS instructions.\n\n| If study drug interruption is\u2026      | then\u2026                                                                                                   |\n| ----------------------------------- | ------------------------------------------------------------------------------------------------------- |\n| 2 consecutive doses or less         | participant restarts study drug at last administered dose, as per escalation schedule.                  |\n| 3 consecutive doses or more         | participant restarts study drug (at 5 mg, managed by IWRS) and repeats dose escalation scheme.          |\n| due to an AE                        | the event is to be documented and followed according to the procedures in Section 8.3 of this protocol. |\n| due to intolerable persistent GI AE | participants should be treated as suggested in Section 6.6.2.                                           |\n\nAbbreviations: AE = adverse event; GI = gastrointestinal; IWRS = interactive web response service. Investigators should inform Lilly that study drug has been temporarily interrupted. The data related to temporary interruption of study treatment will be documented in source documents and entered on the eCRF.\n\nLY3298176    55", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2763, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "468d8044-ac37-433c-aa0c-f2d67750fc5d": {"__data__": {"id_": "468d8044-ac37-433c-aa0c-f2d67750fc5d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "98996976-478a-457e-9906-40283f4b3b82", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ef458d358c9c709e0994994ccc2331607149f6bd49c9af1195245fa2dd8dc7e9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                   Protocol I8F\u2011MC\u2011GPHK\n\n# 7.2. Participant Discontinuation/Withdrawal from the Study\n\nTo minimize the amount of missing data and to enable assessment of study objectives as planned in the study protocol, every attempt will be made to keep participants in the study irrespective of the following:\n\n- adherence to or discontinuation from study drug\n- adherence to visit schedule\n- missing assessments\n- study drug discontinuation due to AE\n- development of comorbidities\n- development of clinical outcomes\n\nThe circumstances listed above are not valid reasons for discontinuation from the study. Participants will be withdrawn from the study in the following circumstances:\n\n- enrollment in any other clinical study involving an IP or enrollment in any other type of medical research judged not to be scientifically or medically compatible with this study\n- participation in the study needs to be stopped for medical, safety, regulatory, or other reasons consistent with applicable laws, regulations, and good clinical practice (GCP)\n- participant requests to be withdrawn from the study and clearly indicates that there will be no further contact of any kind with the site\n\nParticipants who agree to provide information relevant to any trial endpoint at the end of the study are not considered to have discontinued from the study. Participants discontinuing from the study prematurely for any reason should complete AE and other safety follow\u2011up per Section 1.3 (Schedule of Activities), Section 8.3 (Adverse Events and Serious Adverse Events), and Section 8.2 (Safety Assessments) of this protocol.\n\nLY3298176    56", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1677, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "94ecadfb-2398-4889-8be2-87430f62aa8c": {"__data__": {"id_": "94ecadfb-2398-4889-8be2-87430f62aa8c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b29a5b4e-30af-44c9-bf34-1c068b9009a0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1c3f72577c4c1ca633b9ab4ef9f05cb6e665b9fb1f7f516fa8a0e5e17ec7b530", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 7.2.1.  Participant disposition and timing of safety follow-up for the primary endpoint (72 weeks)\n\nAbbreviations: ED = early discontinuation of treatment; Pt = participant; wks = weeks.\n\nLY3298176    57", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 245, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e73afaee-4a88-4662-86d2-d66e1033842f": {"__data__": {"id_": "e73afaee-4a88-4662-86d2-d66e1033842f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1dfbd6c0-0b14-4489-9c38-599fa7edcf21", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "12abcde3ea62dd8d9c38d829e29cac42dd779c2a12223b8d25d1272cf9bc992a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 7.2.2. Participant disposition and timing of safety follow-up for those with prediabetes undergoing 176 week follow-up\n\nAbbreviations: ED = early discontinuation of treatment; wks = weeks.\n\nNote: Participants with prediabetes who discontinue study drug on or before Week 72 are not eligible to continue follow\u2011up after Visit 21 (Week 72)\n\n| LY3298176 | 58 |\n| --------- | -- |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 417, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "30c54383-81ca-4567-a7de-cb201687dcda": {"__data__": {"id_": "30c54383-81ca-4567-a7de-cb201687dcda", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f26210d0-98de-4a96-bf3b-59ca2bb817bd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "da216bdbaf97fac1cd03de960aea480a9a7275482c47dfe8a0877c753a5898f1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                      Protocol I8F\u2011MC\u2011GPHK\n\n# 7.2.3. Discontinuation of Inadvertently Enrolled Participants\n\nIf the Sponsor or investigator identify a participant who did not meet enrollment criteria and was inadvertently enrolled, the investigator and the Sponsor CRP must agree whether continuing the study treatment is medically appropriate. Continuation of inadvertently enrolled participants in the study, with or without study drug treatment, requires documented approval from the Sponsor CRP. Safety follow up is as outlined in Section 1.3 (Schedule of Activities), Section 8.3 (Adverse Events and Serious Adverse Events), and Section 8.2 (Safety Assessments) of the protocol.\n\n# 7.3. Lost to Follow-up\n\nA participant will be considered lost to follow\u2011up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site. Site personnel are expected to make diligent attempts to contact participants who fail to return for a scheduled visit or were otherwise unable to be followed up by the site.\n\nSite personnel, or an independent third party, will attempt to collect the vital status of the participant within legal and ethical boundaries for all participants randomized, including those who did not get IP. Public sources may be searched for vital status information. If vital status is determined, this will be documented, and the participant will not be considered lost to follow\u2011up. Eli Lilly and Company personnel will not be involved in any attempts to collect vital status information.\n\nDiscontinuation of specific sites or of the study as a whole are handled as part of Section 10.1.9.\n\nLY3298176    59", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1707, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e102594c-5637-462d-8905-0f970ea0e04a": {"__data__": {"id_": "e102594c-5637-462d-8905-0f970ea0e04a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "489cc81f-ad58-44c3-9c60-97183ff4c076", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0b4685b7266aa2888eea82904b541b0fabeb07c2064b4d05c58a3f09e3773146", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 8. Study Assessments and Procedures</h8>\n- Section 10.2 (Appendix 2) lists the laboratory tests that will be performed for this study. Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the samples.\n- Unless otherwise stated in the subsections below, all samples collected for specified laboratory tests will be destroyed within 60 days of receipt of confirmed test results. Certain samples may be retained for a longer period, if necessary, to comply with applicable laws, regulations, or laboratory certification standards.\n\n# Efficacy Assessments</h8>\n\n# Primary Efficacy Assessments</h8>\nThe primary efficacy assessment in this study is the body weight. Body weight measurements will be collected at specific clinic visits as summarized in the Schedule of Activities (Section 1.3). Methods for measuring body weight are described in Section 10.7 (Appendix 7).\n\n# Secondary Efficacy Assessments</h8>\nThe following secondary efficacy assessments will also be collected according to the Schedule of Activities:\n\n- waist circumference (measuring method is described in Section 10.7 [Appendix 7]).\n- fasting insulin (measured through central lab)\n- onset of T2DM (definition is described Section 4.1.2.3)\n- HbA1c (%, mmol/mol) (measured through central lab)\n- fasting glucose (measured through central lab)\n- BMI (derived using body weight in kilograms divided by the square of height in meters)\n- blood pressure\n- lipids\n\n# Patient-Reported Outcomes Assessments</h8>\nThe self\u2011reported questionnaires will be translated into the native language of the region, linguistically validated and administered according to the Schedule of Activities (Section 1.3). At these visits, the questionnaires should be completed before the participant has discussed their medical condition or progress in the study with the investigator and/or site staff, if the participant is not adversely affected by their fasting condition.\n\nLY3298176    60", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2009, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8a361c8b-6598-4e6e-8429-ce1356e77a1c": {"__data__": {"id_": "8a361c8b-6598-4e6e-8429-ce1356e77a1c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e9767c28-87a9-46de-b5c2-8050c7cf473f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "44bd6b2794d5215f0ed3faf151f5cd952986d9cfc1b877dfd70b5dd5fbf4c687", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                      Protocol I8F\u2011MC\u2011GPHK\n\n# 8.1.4. Short Form 36 version 2, acute, 1 week recall version\n\nThe SF\u201136v2 acute, 1\u2011week recall version is a 36\u2011item, generic, patient\u2011administered measure designed to assess the following 8 domains:\n\n- Physical Functioning\n- Role\u2011Physical\n- Bodily Pain\n- General Health\n- Vitality\n- Social Functioning\n- Role\u2011Emotional\n- Mental Health\n\nThe Physical\u2011Functioning domain assesses limitations due to health \u201cnow\u201d while the remaining domains assess functioning \u201cin the past week.\u201d Each domain is scored individually and information from these 8 domains are further aggregated into 2 health\u2011component summary scores: Physical\u2011Component Summary and Mental\u2011Component Summary. Items are answered on Likert scales of varying lengths (3\u2011, 5\u2011, or 6\u2011 point scales). Scoring of each domain and both summary scores are norm\u2011based and presented in the form of T\u2011scores, with a mean of 50 and standard deviation (SD) of 10; higher scores indicate better levels of function and/or better health (Maruish 2011).\n\n# 8.1.5. Impact of Weight on Quality of Life-Lite Clinical Trials Version\n\nThe IWQOL\u2011Lite\u2011CT is a 20\u2011item, obesity\u2011specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity\u2011related health\u2011related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5\u2011item subset of the physical domain, the physical\u2011function composite is also supported. Items in the physical\u2011function composite describe physical impacts related to general and specific physical activities. All items are rated on either a 5\u2011point frequency (\u201cnever\u201d to \u201calways\u201d) scale or a 5\u2011point truth (\u201cnot at all true\u201d to \u201ccompletely true\u201d) scale (Kolotkin et al. 2017, 2018).\n\n# 8.1.6. EQ-5D-5L\n\nGeneric health\u2011related quality of life will be assessed using the EQ\u20115D\u20115L (EQ\u20115D; EuroQoL Group 2015). The EQ\u20115D\u20115L is a standardized 5\u2011item instrument for use as a measure of health outcome. It provides a simple descriptive profile and a single index value for health status that can be used in the clinical and economic evaluation of health care as well as population health surveys. The EQ\u20115D\u20115L comprises 5 dimensions of health (mobility, self\u2011care, usual activities, pain/discomfort, and anxiety/depression). The 5L version, introduced in 2005, scores each dimension at 5 levels (no problems, slight problems, moderate problems, severe problems, unable to perform/extreme problems), for a total of 3125 possible health states. In addition to the health profile, a single health\u2011state index value can be derived based on a formula that attaches weights to each of the levels in each dimension. This index value ranges between \u02c20 (where 0 is\n\nLY3298176    61", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2775, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b5e196c5-c97a-4022-9658-0d3b2b5a0012": {"__data__": {"id_": "b5e196c5-c97a-4022-9658-0d3b2b5a0012", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c09c7c3f-bdab-4052-be34-59c24509e7f2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6da0e8d2cfe33e27dfafbf14e0507e015694a9c586cd590fd268f01e0a5d7094", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK\n\na health\u2011state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health) (Dolan 1997). In addition, the EQ Visual Analog Scale records the respondent\u2019s self\u2011rated health status on a vertical graduated (0 to 100) scale. In conjunction with the health\u2011state data, it provides a composite picture of the respondent\u2019s health status.\n\nThe EQ\u20115D\u20115L is used worldwide and is available in more than 170 different languages. Details on the instrument, and scoring, organizing, and presenting the data collected can be found in the EQ\u20115D\u20115L User Guide (EuroQoL Group 2015).\n\n# 8.1.7. Patient Global Impression of Status for Physical Activity\n\nStudy participants will be asked to complete a PGIS item specifically developed for this study. This is a patient\u2011rated assessment of current health limitation and is rated on a 5\u2011point scale ranging from \u201c1\u2011 not at all limited\u201d to \u201c5\u2011 extremely limited.\u201d\n\n# 8.2. Safety Assessments\n\nPlanned time points for all safety assessments are provided in the Schedule of Activities (Section 1.3).\n\n# 8.2.1. Physical Examinations\n\n- A complete physical examination will include, at a minimum, assessments of the cardiovascular, respiratory, GI and neurological systems, as well as a thyroid exam. Height, weight, and waist circumference will also be measured and recorded, per Section 10.7.\n- Investigators should pay special attention to clinical signs related to previous serious illnesses.\n\n# 8.2.2. Vital Signs\n\nFor each participant, vital signs should be measured according to the Schedule of Activities (Section 1.3) and Section 10.7. Any clinically significant findings from vital\u2011signs measurement that result in a diagnosis and that occur after the participant receives the first dose of study treatment should be reported to Lilly or its designee as an AE via the eCRF.\n\n# 8.2.3. Electrocardiograms\n\nFor each participant, 12\u2011Lead electrocardiograms (ECGs) should be collected according to the Schedule of Activities (Section 1.3) and Section 10.7. Electrocardiograms will initially be interpreted by a qualified physician (the investigator or qualified designee) at the site as soon after the time of ECG collection as possible, and ideally while the participant is still present, for immediate subject management, should any clinically relevant findings be identified. Any clinically significant findings from ECGs that result in a diagnosis and that occur after the participant receives the first dose of the investigational treatment should be reported to Lilly or its designee as an AE via the eCRF. All digital ECGs will be obtained using centrally provided ECG machines and will be electronically transmitted to a designated central ECG laboratory. ECGs will be performed in\n\nLY3298176                                                                                         62", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2938, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "208aecd1-6596-4620-80ce-db068a4490cd": {"__data__": {"id_": "208aecd1-6596-4620-80ce-db068a4490cd", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1079c67f-84b7-489f-b08f-f0a27d3db911", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "5eabfae6a3840f35bcc9679271d802310fa1eda5aa5ce416f1992e8c0ac544d7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK\n\ntriplicate at Weeks 0 and 36. The central ECG laboratory will perform a basic quality control check (for example, demographics and study details) and then store the ECGs in a database. At a future time, the stored ECG data may be overread by a cardiologist at the central ECG laboratory for further evaluation of machine\u2011read measurements or to meet regulatory requirements. The machine\u2011read ECG intervals and heart rate (HR) may be used for data analysis and report\u2011writing purposes, unless a cardiologist overreading of the ECGs is conducted prior to completion of the final study report (in which case, the overread data would be used).\n\n# 8.2.4. Clinical Safety Laboratory Assessments\n\n- For each participant, laboratory tests detailed in (Section 10.2) should be conducted according to the Schedule of Activities (Section 1.3).\n- With the exception of laboratory test results that may unblind the study, Lilly or its designee will provide the investigator with the results of laboratory tests analyzed by a central vendor, if a central vendor is used for the clinical trial.\n- Any clinically significant findings from laboratory tests that result in a diagnosis and that occur after the participant receives the first dose of IP should be reported to Lilly or its designee as an AE via eCRF.\n\n# 8.2.4.1. Immunogenicity Assessment\n\nWhere local regulations and ERBs allow, blood samples for immunogenicity testing will be collected to determine antibody production against tirzepatide as specified in the Schedule of Activities (Section 1.3). At the visits and times specified in the Schedule of Activities (Section 1.3), venous blood samples will be collected to determine antibody production against tirzepatide. To interpret the results of immunogenicity, a PK sample will be collected at the same time points as the immunogenicity sample. All samples for immunogenicity should be taken predose when applicable and possible. In the event of systemic drug\u2011hypersensitivity reactions (immediate or nonimmediate), additional samples will be collected (including antidrug antibodies [ADAs], PK, and exploratory biomarker samples) as close to the onset of the event as possible, at the resolution of the event, and 30 days following the event. Instructions for the collection and handling of blood samples will be provided by the Sponsor. The actual date and time (24\u2011hour clock time) of each sampling will be recorded. Immunogenicity will be assessed by a validated assay designed to detect ADAs in the presence of tirzepatide at a laboratory approved by the Sponsor. Antibodies may be further characterized and/or evaluated for their ability to neutralize the activity of tirzepatide. Sample collected at Visit 801 or Visit 802 will assess immunogenicity at washout of tirzepatide (5 half\u2011lives post end of treatment).\n\nSamples with tirzepatide ADA detected will be titered and evaluated for their ability to neutralize the activity of assigned treatment (tirzepatide\u2011neutralizing antibodies). Samples with tirzepatide ADA detected will also be tested for cross\u2011reactive binding to native GIP and GLP\u20111, and if such is detected, then for neutralizing antibodies against native GIP and GLP\u20111, respectively. Treatment\u2011emergent ADAs are defined in Section 9.4.6. Samples will be retained for a maximum of 15 years after the last participant visit, or for a shorter period if local regulations and ERBs allow, at a facility selected by the Sponsor.\n\nLY3298176 63", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3497, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ed5aa648-d32c-4ae1-b5fb-11ab9ee7c1ab": {"__data__": {"id_": "ed5aa648-d32c-4ae1-b5fb-11ab9ee7c1ab", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "eb22fdff-fe5b-4595-9141-6d614228b3e0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "f4691947398e51df1c427b44dd7fc30a2aa140f6b528f85b632e18dcd5fe5fc7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK\n\nduration allows the Sponsor to respond to future regulatory requests related to tirzepatide. Any samples remaining after 15 years will be destroyed.\n\n# 8.2.5. Safety Monitoring\n\nLilly will periodically review evolving aggregate safety data within the study by appropriate methods. The study team will review safety reports in a blinded fashion according to the schedule provided in the Trial\u2011Level Safety Review plan. Lilly will also review SAEs within time frames mandated by company procedures. The Lilly CRP will, as appropriate, consult with the functionally independent Global Patient Safety therapeutic area physician or clinical scientist.\n\n# 8.2.5.1. Hepatic Safety Monitoring\n\nIf a study participant experiences elevated ALT \u22653X ULN, ALP \u22652X ULN, or elevated TBL \u22652X ULN, liver testing (Section 10.5) should be repeated within 3 to 5 days including ALT, AST, ALP, TBL, direct bilirubin, gamma\u2011glutamyl transferase, and creatine kinase to confirm the abnormality and to determine if it is increasing or decreasing. If the abnormality persists or worsens, clinical and laboratory monitoring should be initiated by the investigator and in consultation with the study medical monitor. Monitoring of ALT, AST, TBL, and ALP should continue until levels normalize or return to approximate baseline levels.\n\nAdditional safety data should be collected via the eCRF if 1 or more of the following conditions occur:\n\n- elevation of serum ALT to \u22655X ULN on 2 or more consecutive blood tests\n- elevated serum TBL to \u22652X ULN (except for cases of known Gilbert\u2019s syndrome)\n- elevation of serum ALP to \u22652X ULN on 2 or more consecutive blood tests\n- participant discontinued from treatment due to a hepatic event or abnormality of liver tests\n- hepatic event considered to be an SAE\n\n# 8.2.6. Depression, Suicidal Ideation, and Behavior Risk Monitoring\n\nOverweight and obese patients are at increased risk for depression (Luppino et al. 2010). Depression can increase the risk for suicidal ideation and behavior. Therefore, study participants will be screened at trial entry and monitored during the study for depression, and suicidal ideation and behavior.\n\nParticipants should be monitored appropriately and observed closely for suicidal ideation and behavior or any other unusual changes in behavior, especially at the beginning and end of the course of treatment, or at the time of dose changes, either increases or decreases. Consideration should be given to discontinuing study medication in subjects who experience signs of suicidal ideation or behavior, following a risk assessment (Section 7.1).\n\nBaseline and treatment emergent assessment of depression, suicidal ideation and behavior will be monitored during the study using the C\u2011SSRS and PHQ\u20119 (Section 8.3.1.1).\n\nLY3298176 64", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2818, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9dd98725-cbc3-4230-a9e4-721ae0eec176": {"__data__": {"id_": "9dd98725-cbc3-4230-a9e4-721ae0eec176", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "72420c7d-b97f-4629-90d5-7707ebe04528", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "31a26db898fa3873a8e80b8f2b274e0112f0ba488dd56d1f24d1ed1ae6027f26", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                  Protocol I8F\u2011MC\u2011GPHK\n\n# 8.3. Adverse Events and Serious Adverse Events\n\nPlease refer to Section 10.3 Appendix 3 Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow\u2011up, and Reporting.\n\nInvestigators are responsible for monitoring the safety of participants who have entered this study and for alerting Lilly or its designee to any event that seems unusual, even if this event may be considered an unanticipated benefit to the participant.\n\nThe investigator is responsible for the appropriate medical care of participants during the study. Investigators must document their review of each laboratory safety report.\n\nThe investigator remains responsible for following, through an appropriate health care option, AEs that are serious or otherwise medically important, considered related to the IP or the study, or that caused the participant to discontinue the IP before completing the study. The participant should be followed until the event resolves, stabilizes with appropriate diagnostic evaluation, or is reasonably explained. The frequency of follow\u2011up evaluations of the AE is left to the discretion of the investigator.\n\nLack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to establish treatment effect.\n\nAfter the ICF is signed, study site personnel will record via eCRF the occurrence and nature of each participant\u2019s preexisting conditions, including clinically significant signs and symptoms of the disease under treatment in the study. In addition, site personnel will record any change in the condition(s) and any new conditions as AEs. Investigators should record their assessment of the potential relatedness of each AE to protocol procedure and IP via eCRF.\n\nThe investigator will interpret and document whether or not an AE has a reasonable possibility of being related to study treatment, study device, or a study procedure, taking into account the disease, concomitant treatment, or pathologies.\n\nA \u201creasonable possibility\u201d means that there is a cause and effect relationship between the IP, study device, and/or study procedure and the AE.\n\nThe investigator answers yes/no when making this assessment.\n\nPlanned surgeries and nonsurgical interventions should not be reported as AEs unless the underlying medical condition has worsened during the course of the study.\n\nIf a participant\u2019s IP is discontinued as a result of an AE, study\u2011site personnel must report this to Lilly or its designee via eCRF, clarifying if possible, the circumstances leading to any dosage modifications or discontinuations of treatment.\n\n# Serious Adverse Events\n\nAll AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious criteria. An SAE is any AE from this study that results in one of the following outcomes:\n\n- death\n- initial or prolonged inpatient hospitalization\n- a life\u2011threatening experience (that is, immediate risk of dying)\n\nLY3298176                                                                                            65", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3101, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9a79732b-d597-4866-9df1-ae5889296399": {"__data__": {"id_": "9a79732b-d597-4866-9df1-ae5889296399", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fb49db7e-8189-46db-bdeb-7fe0227c91fa", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a97908c4585a0d654b0219ae8767a817c187e7217d81946ea571fcd9ca3a0e60", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK\n\n- persistent or significant disability/incapacity\n- congenital anomaly/birth defect\n- important medical events that may not be immediately life\u2011threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent 1 of the other outcomes listed in the definition above. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.\n- when a condition related to the drug delivery system necessitates medical or surgical intervention to preclude either permanent impairment of a body function or permanent damage to a body structure, the serious outcome of \u201crequired intervention\u201d will be assigned.\n\nAll AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious criteria. The SAE reporting to the Sponsor begins after the participant has signed the ICF and has received IP. However, if an SAE occurs after signing the ICF, but prior to receiving IP, the SAE should be reported to the Sponsor per SAE\u2011reporting requirements and timelines (see Section 8.3.1) if it is considered reasonably possibly related to study procedure.\n\nStudy\u2011site personnel must alert Lilly or its designee of any SAE within 24 hours of investigator awareness of the event via a sponsor\u2011approved method. If alerts are issued via telephone, they are to be immediately followed with official notification on study\u2011specific SAE forms. This 24\u2011hour notification requirement refers to the initial SAE information and all follow\u2011up SAE information. Participants with a serious hepatic AE should have additional data collected using the eCRF.\n\nPregnancy (during maternal or paternal exposure to IP) does not meet the definition of an AE. However, to fulfill regulatory requirements any pregnancy should be reported following the SAE process to collect data on the outcome for both mother and fetus.\n\nInvestigators are not obligated to actively seek AEs or SAEs in subjects once they have discontinued and/or completed the study (the participant disposition case report form [CRF] has been completed). However, if the investigator learns of any SAE, including a death, at any time after a subject has been discharged from the study, and he or she considers the event reasonably possibly related to the study treatment or study participation, the investigator must promptly notify Lilly.\n\n# Suspected Unexpected Serious Adverse Reactions\n\nSuspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed in the IB and that the investigator identifies as related to IP or procedure. United States 21 CFR 312.32, European Union Clinical Trial Directive 2001/20/EC, and the associated detailed guidance or national regulatory requirements in participating countries require the reporting of SUSARs. Lilly has procedures that will be followed for the identification, recording, and expedited reporting of SUSARs that are consistent with global regulations and the associated detailed guidance.\n\nLY3298176 66", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3213, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "292ba253-c450-47bb-aa99-8f8b44bc624e": {"__data__": {"id_": "292ba253-c450-47bb-aa99-8f8b44bc624e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "11f35436-25e2-4f7d-9c43-a3dce47996be", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "63c4017b973f8e09497dc17bc2fb426eadf0781f1f651d9328bf12c0431bfea1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK\n\n# 8.3.1. Time Period and Frequency for Collecting AE and SAE Information\n\nAll AE data will be collected from the signing of the ICF until the time points specified in the Schedule of Activities (Section 1.3). Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open\u2011ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrences.\n\n# 8.3.1.1. Adverse Event Monitoring with a Systematic Questionnaire\n\nBefore administering the C\u2011SSRS or the PHQ\u20119, study site personnel will question the participant about any change in the preexisting condition(s) and the occurrence and nature of any AEs. Nonserious AEs obtained through the questionnaire are recorded and analyzed separately. Only serious AEs elicited through the C\u2011SSRS or PHQ\u20119 are to be recorded as AEs via the eCRF and reported to Lilly or its designee within 24 hours as SAEs. For this study, the C\u2011SSRS is adapted for the assessment of the ideation and behavior categories only. The Intensity of Ideation and Lethality of Behavior sections are removed.\n\nThe C\u2011SSRS is a scale that captures the occurrence, severity, and frequency of suicidal ideation and/or behavior during the assessment period. The scale includes suggested questions to solicit the type of information needed to determine if suicidal ideation and/or behavior occurred. The tool was developed by the National Institute of Mental Health trial group for the purpose of being a counterpart to the Columbia Classification Algorithm of Suicide Assessment categorization of suicidal events.\n\nThe PHQ\u20119 is a validated self\u2011report screening tool that assesses the presence and intensity of depressive symptoms. The PHQ\u20119, which incorporates the 9 Diagnostic and Statistical Manual\u2011IV depression criteria as \u201c0\u201d (not at all) to \u201c3\u201d (nearly every day), was developed for use in primary care settings (Kroenke et al. 2001).\n\n# 8.3.2. Follow-up of AEs and SAEs\n\nAfter the initial AE or SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow\u2011up (as defined in Section 1.3).\n\n# 8.3.3. Regulatory Reporting Requirements for SAEs\n\n- Prompt notification by the investigator to the Sponsor of a SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.\n- The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The Sponsor will comply with country\u2011specific regulatory requirements relating to safety reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and investigators.\n\nLY3298176 67", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3001, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3b1fcf63-c013-4619-a89d-443aa21b3023": {"__data__": {"id_": "3b1fcf63-c013-4619-a89d-443aa21b3023", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "220da70b-77eb-4401-bd40-f07c9a039d58", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0ff6ad7a089ab4f662b59fa114e77340ac92a84466962416abdff87f9a865b33", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                    Protocol I8F\u2011MC\u2011GPHK\n\n\u2022  Investigator safety reports must be prepared for SUSARs according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary.\n\n\u2022  An investigator who receives an investigator safety report describing an SAE or other specific safety information (for example, summary or listing of SAEs) from the Sponsor will review and then file it along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.\n\n# 8.3.4. Pregnancy\n\n\u2022  Details of all pregnancies in female participants and female partners of male participants will be collected after the start of study intervention and the participant will be followed to determine the outcome of the pregnancy for mother and neonate.\n\n\u2022  If a pregnancy is reported, the investigator should inform the Sponsor within 24 hours of learning of the pregnancy and should follow the procedures outlined in Section 10.4 (Appendix 4).\n\n\u2022  Abnormal pregnancy outcomes (for example, spontaneous abortion, fetal death, stillbirth, congenital anomalies, and ectopic pregnancy) are considered SAEs.\n\n# 8.3.5. Medical Device Incidents (Including Malfunctions)\n\nMedical devices are being used in this study for the purposes of administering tirzepatide.  In order to fulfill regulatory reporting obligations worldwide, the investigator is responsible for the detection and documentation of events meeting the definitions of incident or malfunction that occur during the study with such devices.\n\nThe definition of a medical device incident can be found in Section 10.6 Appendix 6.\n\nNote:     Incidents fulfilling the definition of an AE/SAE will also follow the processes outlined in Section 8.3.2.\n\n# 8.3.5.1. Time Period for Detecting Medical Device Incidents\n\n\u2022  Medical device incidents, or malfunctions of the device that result in an incident, will be detected, documented, and reported to the Sponsor during all periods of the study in which the medical device is used.\n\n\u2022  If the investigator learns of any incident at any time after a participant has been discharged from the study, and such incident is considered reasonably related to a medical device used during the study, the investigator will promptly notify the Sponsor through the complaints process.\n\nThe method of documenting medical device incidents is provided in Section 10.6 (Appendix 6).\n\n# 8.3.5.2. Follow-up of Medical Device Incidents\n\n\u2022  All medical device incidents involving an AE will be followed and reported in the same manner as other AEs (see Section 8.3.2). This applies to all participants, including those who discontinue study intervention.\n\nLY3298176    68", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2724, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "80ba2782-dd65-4974-8182-b7ff344dbe05": {"__data__": {"id_": "80ba2782-dd65-4974-8182-b7ff344dbe05", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "20b26d4c-6ad2-4b3f-9856-23e4656d8a23", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c646256e28f9049b8cc2cc19e3e9a14d6858ba171dc829d2e8862d1ea9136c34", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                    Protocol I8F\u2011MC\u2011GPHK\n\nThe investigator is responsible for ensuring that follow\u2011up includes any supplemental investigations as indicated to elucidate the nature and/or causality of the incident.\n\nNew or updated information will be recorded on the originally completed form with all changes signed and dated by the investigator.\n\n# 8.3.5.3. Prompt Reporting of Medical Device Incidents and Malfunctions to Sponsor\n\n- Medical device incidents or malfunctions will be reported to the Sponsor within a business day or as determined for the study, after the investigator determines that the event or issue meets the protocol definition of a medical device incident or malfunction.\n- Medical device incidents or malfunctions that result in an SAE will be reported to the Sponsor within 24 hours, in the same manner as other (S)AEs.\n- Malfunctions will be reported via the Product Complaint Form and sent to the Sponsor per training and per instructions provided on the Product Complaint Form.\n- The same individual at the site will be the contact for the receipt of medical device reports and SAE.\n\n# 8.3.5.4. Regulatory Reporting Requirements for Medical Device Incidents\n\n- The investigator will promptly report to the Sponsor all incidents occurring with any medical device provided for use in the study in order for the Sponsor to fulfill the legal responsibility to notify appropriate regulatory authorities and other entities about certain safety information relating to medical devices being used in clinical studies.\n- The investigator, or responsible person according to local requirements (for example; the head of the medical institution), will comply with the applicable local regulatory requirements relating to the reporting of incidents to the IRB/IEC.\n\n# 8.3.6. Complaint Handling\n\nLilly collects product complaints on all IPs (drugs/medical devices, inclusive of packaging, labeling, instructions for use, or other component) used in clinical studies, inclusive of comparators, in order to ensure the safety of study participants, monitor product quality, and facilitate process and product improvements.\n\nParticipants will be instructed to contact the investigator as soon as possible if he or she has a complaint or problem with the investigational drug or medical device, so that the situation can be assessed.\n\nInvestigators will provide complete and timely reports to the Sponsor as instructed for the study, and per the Product Complaint Form.\n\n# 8.4. Treatment of Overdose\n\nStudy drug overdose (more than the specified number of injections) will be reported as an AE. In the event of overdose, refer to the IB for tirzepatide.\n\nLY3298176    69", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2725, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2d995442-5846-4cd2-a2d5-e73bb0e86fb4": {"__data__": {"id_": "2d995442-5846-4cd2-a2d5-e73bb0e86fb4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b29aef51-944e-4fa2-a47a-eb3a4a09beaa", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "27b40f3a21ab2e5ee086842c6a5d021b1cd4c45535e8a7c6c1db88e2323817a2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK\n\n# 8.5. Pharmacokinetics\n\nPharmacokinetic samples will be collected from all randomized participants. Plasma tirzepatide concentrations will only be determined from blood samples obtained from participants receiving tirzepatide treatment. Blood samples for PK assessment will be collected at Weeks 8, 16, and 36 following tirzepatide treatment per the Schedule of Activities or at ED (Section 1.3). At each visit prior to a PK assessment, each participant will be assigned via IWRS to one of the sampling PK time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose. In addition, plasma tirzepatide concentration will be determined on immunogenicity visits up to and including Week 176.\n\nThe date and time of the most recent tirzepatide SC injection administered prior to collecting the PK sample must be recorded on the eCRF from the study diaries. The date and time at which each sample was drawn must be recorded on the laboratory accession page. Concentrations of tirzepatide will be assayed using a validated liquid chromatography mass spectrometry method. Bioanalytical samples collected to measure tirzepatide concentration will be retained for a maximum of 1 year following last participant visit for the study. During this time, samples remaining after the bioanalyses may be used for exploratory analyses such as metabolism work, protein binding, and/or bioanalytical method cross\u2011validation.\n\n# 8.6. Pharmacodynamics\n\nSamples to assess the PD properties of tirzepatide are included in the efficacy measures and not applicable in this section.\n\n# 8.7. Genetics\n\n# 8.7.1. Whole Blood Sample(s) for Pharmacogenetic Research\n\nA whole blood sample will be collected for pharmacogenetic analysis as specified in the Schedule of Activities (Section 1.3) where local regulations allow. Samples will not be used to conduct unspecified disease or population genetic research either now or in the future. Samples will be used to investigate variable response to tirzepatide and to investigate genetic variants thought to play a role in obesity. Assessment of variable response may include evaluation of AEs or differences in efficacy.\n\nAll samples will be coded with the participant number. These samples and any data generated can be linked back to the patient only by the investigator site personnel. Samples will be retained at a facility selected by Lilly or its designee for a maximum of 15 years after the last participant visit for the study, or for a shorter period if local regulations and/or ERBs/ IRBs impose shorter time limits. This retention period enables use of new technologies, response to regulatory questions, and investigation of variable response that may not be observed until later in the development of tirzepatide or after tirzepatide become(s) commercially available.\n\nLY3298176                                                                                           70", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3005, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8303726f-187f-423b-9609-f28144218107": {"__data__": {"id_": "8303726f-187f-423b-9609-f28144218107", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f52c9fc1-53e6-4708-8b84-c2584dbb85a4", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c0e7a86d23207f2991e006ca9005d04c2c1f9ab084473bf629e032da194a5b5c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK\n\nMolecular technologies are expected to improve during the 15\u2011year storage period and therefore cannot be specifically named. However, existing approaches include whole genome or exome sequencing, genome wide association studies, and candidate gene studies. Regardless of technology utilized, genotyping data generated will be used only for the specific research scope described in this section.\n\n# 8.8. Biomarkers\n\nBiomarker research is performed to address questions of relevance to drug disposition, target engagement, PD, mechanism of action, variability of participant response (including safety), and clinical outcome. Sample collection is incorporated into clinical studies to enable examination of these questions through measurement of biomolecules including deoxyribonucleic acid (DNA), proteins, lipids, and other cellular elements.\n\nSerum, and plasma samples for biomarker research will be collected at the times specified in the Schedule of Activities (Section 1.3) where local regulations allow.\n\nSamples will be used for research on the drug target, disease process, variable response to tirzepatide, pathways associated with obesity, mechanism of action of tirzepatide, and/or research method or in validating diagnostic tools or assay(s) related to obesity.\n\nAll samples will be coded with the participant number. These samples and any data generated can be linked back to the participant only by the investigator site personnel.\n\nSamples will be retained at a facility selected by Lilly or its designee for a maximum 15 years after the last participant visit for the study, or for a shorter period if local regulations and ERBs/IRBs impose shorter time limits. This retention period enables use of new technologies, response to regulatory questions, and investigation of variable response that may not be observed until later in the development of tirzepatide or after tirzepatide become(s) commercially available.\n\n# 8.9. Health Economics\n\nHealth Economics and Medical Resource Utilization Parameters are not evaluated in this study.\n\nLY3298176    71", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2158, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4aaa129a-a913-42c5-b0d6-3cb0797ca623": {"__data__": {"id_": "4aaa129a-a913-42c5-b0d6-3cb0797ca623", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "43ab2c44-01f9-48bd-b692-2cc20871dfd1", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e8b21a14eac64c714e4593e1a4b4dc72e311556159742885ddbd93d4b3d51cc3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 9. Statistical Considerations</h9>\n\n# 9.1. Statistical Hypotheses</h9>\nThe alternative hypotheses for the primary objective are the following:\n\n- H10,1: QW tirzepatide 10 mg is superior to placebo for percent change in body weight from randomization AND percentage of participants who achieve \u22655% body weight reduction at 72 weeks.\n- H15,1: QW tirzepatide 15 mg is superior to placebo for percent change in body weight from randomization AND percentage of participants who achieve \u22655% body weight reduction at 72 weeks.\n\nThe above two hypotheses will be tested in parallel, each at a 2\u2011sided significance level of 0.025.\n\nThe alternative hypotheses for the key secondary objective controlling for type 1 error rate are the following:\n\n- H5,2: tirzepatide 5 mg QW is superior to placebo for change in body weight (kg) from randomization at 20 weeks.\n- H10,2: tirzepatide 10 mg QW is superior to placebo for change in body weight (kg) from randomization at 20 weeks.\n- H15,2: tirzepatide 15 mg QW is superior to placebo for change in body weight (kg) from randomization at 20 weeks.\n- H5,3: tirzepatide 5 mg QW is superior to placebo for percent change in body weight from randomization AND percentage of participants who achieve \u22655% body weight reduction at 72 weeks.\n- H10,4: tirzepatide 10 mg QW is superior to placebo for percentage of participants who achieve \u226510% body weight reduction at 72 weeks.\n- H15,4: tirzepatide 15 mg QW is superior to placebo for percentage of participants who achieve \u226510% body weight reduction at 72 weeks.\n- H10,5: tirzepatide 10 mg QW is superior to placebo for percentage of participants who achieve \u226515% body weight reduction at 72 weeks.\n- H15,5: tirzepatide 15 mg QW is superior to placebo for percentage of participants who achieve \u226515% body weight reduction at 72 weeks.\n- H10,6: tirzepatide 10 mg QW is superior to placebo for change from randomization in waist circumference (cm) at 72 weeks.\n- H15,6: tirzepatide 15 mg QW is superior to placebo for change from randomization in waist circumference (cm) at 72 weeks.\n- H10,7: tirzepatide 10 mg QW is superior to placebo for change in SF\u201136v2 acute form physical functioning domain score from randomization at 72 weeks.\n\nLY3298176    72", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2268, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f3d25c71-e7a5-4625-a140-1c521d5aaff6": {"__data__": {"id_": "f3d25c71-e7a5-4625-a140-1c521d5aaff6", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66ab9ff0-f98b-4030-b6d8-a64dbab51deb", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9b3655f7faf673cc6e85f79089aad9edd97a4e1213e427c776fd757cde8ac82b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK\n\n- H15,7: tirzepatide 15 mg QW is superior to placebo for change in SF\u201136v2 acute form physical functioning domain score from randomization at 72 weeks.\n- Hp,8: tirzepatide (all doses combined) is superior to placebo for change in triglycerides (mg/dL) from randomization at 72 weeks.\n- Hp,9: tirzepatide (all doses combined) is superior to placebo for change in LDL cholesterol (mg/dL) from randomization at 72 weeks.\n- Hp,10: tirzepatide (all doses combined) is superior to placebo for change in total cholesterol (mg/dL) from randomization at 72 weeks.\n- Hp,11: tirzepatide (all doses combined) is superior to placebo for change in SBP (mmHg) from randomization at 72 weeks.\n- Hp,12: tirzepatide (all doses combined) is superior to placebo for change in fasting insulin (pmol/L) from randomization at 72 weeks.\n- H10,13: tirzepatide 10 mg QW is superior to placebo for change in percent body weight from randomization at 176 weeks (for participants with prediabetes at randomization).\n- H15,13: tirzepatide 15 mg QW is superior to placebo for change in percent body weight from randomization at 176 weeks (for participants with prediabetes at randomization).\n- Hp, 14: tirzepatide (all doses combined) is superior to placebo for delaying the onset of diabetes during 176 weeks (for participants with prediabetes at randomization).\n\nThe details of family\u2011wise type I error rate control strategy and methods for the aforementioned hypotheses will be provided in the statistical analysis plan (SAP).\n\n# 9.2. Sample Size Determination\n\nApproximately 3429 participants will be screened to achieve 2400 randomly assigned to study intervention (600 participants per intervention group).\n\nThe sample size determination assumes that evaluation of superiority of 10\u2011mg tirzepatide and tirzepatide 15 mg to placebo will be conducted in parallel, each at a 2\u2011sided significance level of 0.025 using a 2\u2011sample t\u2011test. Additionally, a difference of at least 11% mean body weight percentage reduction from randomization at 72 weeks for 10\u2011mg tirzepatide and/or tirzepatide 15 mg compared with placebo, a common SD of 10%, and a dropout rate of 25% are assumed for statistical power calculations. Under the assumptions above, randomizing 2400 participants in a 1:1:1:1 ratio to tirzepatide 5 mg (600), tirzepatide 10 mg (600), tirzepatide 15 mg (600), and placebo (600) provides more than 90% power to demonstrate superiority of tirzepatide 10 mg and/or 15 mg to placebo.\n\nThe chosen sample size and randomization ratio also provides >90% power to establish superiority of 10\u2011mg tirzepatide and 15\u2011mg tirzepatide doses to placebo in term of percentage of participants achieving at least 5% body weight reduction at 72 weeks, conducted in parallel using a Fisher\u2019s exact test, each at a 2\u2011sided significance level of 0.025, assuming 25% placebo\u2011treated.\n\nLY3298176    73", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2946, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3ee2e69d-c712-4592-bf4d-b82fb5542889": {"__data__": {"id_": "3ee2e69d-c712-4592-bf4d-b82fb5542889", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "eb3b34c2-63f7-4d2b-8e5e-06da1bcb5b22", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6151f0e72f6374869967d91a7dff75761ba0d5ed47aa639168d512aa0ed97c48", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                               Protocol I8F\u2011MC\u2011GPHK\n\nparticipants and 90% tirzepatide\u2011treated participants achieving the goal and a dropout rate of 25%.\n\nIn addition, assuming that approximately 60% of the randomized population will have prediabetes, the study sample size will also provide more than 90% power to demonstrate superiority of tirzepatide (all doses combined) over placebo in terms of delaying the onset of diabetes for participants with prediabetes at study entry. It is based on the following assumptions:\n\n1. 1.6% (corresponding to annual hazard rate of 0.54%) of participants randomized to tirzepatide and 6% of participants randomized to placebo (corresponding to annual hazard rate of 2.1%) will progress to diabetes during the 3\u2011year period;\n2. 49% of participants will drop out (corresponding to annual drop\u2011out rate of 22%) during the same period;\n3. and the test will be conducted at a 2\u2011sided significance level of 0.05.\n\nLY3298176    74", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 991, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2f1257a2-32a1-4272-8582-16cdff15ae4b": {"__data__": {"id_": "2f1257a2-32a1-4272-8582-16cdff15ae4b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ea94617c-964a-406e-94f1-f0fe9e985f32", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "80c3b27f8a792434bd23a3a2638d2c32629e3d7e10d967d4c25a722484f7c0d3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK\n\n# 9.3. Populations for Analyses\n\nFor purposes of analysis, the following analysis sets are defined:\n\n| Analysis Set                        | Description                                                                                                                                                       |\n| ----------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Entered Participants                | all participants who sign informed consent                                                                                                                        |\n| Randomized Participants             | all participants who are randomly assigned a study treatment                                                                                                      |\n| Modified Intent\u2011to\u2011Treat (mITT) Set | all randomly assigned participants who are exposed to at least 1 dose of study drug; participants will be included in the treatment group they were randomized to |\n| Efficacy Analysis Set (EAS)         | data obtained during treatment period from mITT, excluding data after discontinuation of study drug (last dose date + 7 days)                                     |\n| Full analysis set (FAS)             | data obtained during treatment period from mITT, regardless of adherence to study drug.                                                                           |\n| Safety Analysis Set (SS)            | data obtained during the treatment period plus safety follow\u2011up period from mITT, regardless of adherence to study drug                                           |\n\n# 9.4. Statistical Analyses\n\n# 9.4.1. General Statistical Considerations\n\nStatistical analysis of this study will be the responsibility of Lilly or its designee. Any change to the data analysis methods described in the protocol will require an amendment ONLY if it changes a principal feature of the protocol. Any other change to the data analysis methods described in the protocol, and the justification for making the change, will be described in the SAP or the Clinical Study Report (CSR). Additional exploratory data analyses may be conducted as deemed appropriate.\n\nUnless otherwise noted, all tests of treatment effects will be conducted at a 2\u2011sided alpha level of 0.05, and the confidence interval will be calculated at 95%, 2\u2011sided. In statistical summaries and analyses, data will be analyzed as randomized.\n\nUnless specified otherwise, efficacy and safety will be assessed using the modified intention\u2011to\u2011treat (mITT) population. Baseline is defined as the last nonmissing data collected at randomization (prior to first dosing of study drug). Unless specified otherwise, safety assessments will be guided by an estimand comparing safety of tirzepatide doses with placebo irrespective of adherence to study drug. Thus, safety analysis will be conducted using safety analysis set (SS).\n\nSummary statistics for continuous measures will include sample size, mean, SD, median, minimum, and maximum. The analysis model to make comparisons among treatment groups relative to continuous measurements assessed over time will be a mixed model for repeated measures (MMRM), with terms of treatment, visit, and treatment\u2011by\u2011visit interaction, stratification factors, and baseline measurement as a covariate.\n\nKaplan\u2011Meier method will be used for estimation of cumulative event\u2011free survival rates over time, and Cox proportional hazards regression analysis will be used to compare hazard rates among treatments.\n\nSummary statistics for categorical measures (including categorized continuous measures) will include sample size, frequency, and percentages. Logistic regression will be used to examine the\n\nLY3298176 75", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3886, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f0bbb000-0428-4e8b-b8cf-c94ca4fbb6fd": {"__data__": {"id_": "f0bbb000-0428-4e8b-b8cf-c94ca4fbb6fd", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "313a2366-cd6b-4063-901c-03a9e44ff0ef", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "555e3d3b8f94c901bf7ef46be0c8f717cf49b0d13f71adeb58c3474cbf24778b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK\n\nTreatment difference in binary efficacy outcomes if there is a need to adjust for covariates. Otherwise, Fisher\u2019s exact test will be used to examine the treatment difference in categorical outcomes. Summary statistics for discrete count measures will include sample size, mean, SD, median, minimum, and maximum. The negative binomial regression model will be used for the treatment comparison of discrete count measures. Other statistical methods may be used, as appropriate, and details will be described in the SAP.\n\n# 9.4.2. Treatment Group Comparability\n\n# 9.4.2.1. Participant Disposition\n\nA detailed description of participant disposition will be provided at the end of the study. Frequency counts and percentages of all participants screened, randomized, and receiving at least 1 dose of study drug will be presented by treatment groups. Of the participants in the mITT set, frequency counts and percentages of participants who completed the study, prematurely discontinued the study (and/or study drug), including reason for premature discontinuation, will be presented by treatment groups. A Kaplan\u2011Meier analysis of time from randomization to premature discontinuation from study by treatment group will be provided.\n\n# 9.4.2.2. Participant Characteristics\n\nDemographics and other baseline characteristics (including years of education) will be summarized by treatment group for all randomized participants.\n\n# 9.4.2.3. Concomitant Therapy\n\nConcomitant medications, including previous therapy, will be summarized by treatment arm for SS.\n\n# 9.4.2.4. Treatment Compliance\n\nFrequency counts and percentages of participants compliant to study drug will be summarized by treatment groups and visits for full analysis set (FAS).\n\n# 9.4.3. Efficacy Analyses\n\n# 9.4.3.1. Primary Analyses\n\nThere will be 2 estimands of interest in comparing efficacy of tirzepatide doses with placebo. First estimand, the \u201cefficacy\u201d estimand, represents efficacy prior to discontinuation of study drug. Second estimand, the \u201ctreatment\u2011regimen\u201d estimand, represents the efficacy irrespective of adherence to study drug. For the Food and Drug Administration, the primary efficacy analysis will be guided by the \u201ctreatment\u2011regimen\u201d estimand and conducted using the FAS. This assessment will analyze percent change in body weight obtained at the 72\u2011week visit using an analysis of covariance (ANCOVA) and the percentage of participants achieving at least 5% body weight reduction obtained at the 72\u2011week visit using a logistic regression model. Both models will include terms.\n\nLY3298176 76", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2609, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ec12dd59-5add-41d3-a44c-7ae672d20483": {"__data__": {"id_": "ec12dd59-5add-41d3-a44c-7ae672d20483", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ae26847e-8873-4011-889a-50acd7402270", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0439083414fea619770d4c4914df30e462c4ec8b9f62e04813bfa9f88c458399", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                         Protocol I8F\u2011MC\u2011GPHK\n\nof treatment, stratification factors, and baseline body weight as a covariate. Missing value of change in body weight at the 72\u2011week visit will be imputed based on observed body weight change from baseline values at the visit from participants in the same treatment group who had their efficacy assessed after early discontinuation of study drug. In cases where there are not enough retrieved dropouts to provide a reliable imputation model (for example, the model implemented by the SAS program does not converge), an alternative multiple imputation method with reference to the placebo group (placebo multiple imputation) will be used. Analysis will be conducted with multiple imputations. Since the mean percent change in body weight and percentage of participants with \u22655% body weight reduction need to be achieved at the same time, no multiplicity adjustment is planned for these 2 tests.\n\nFor all other purposes, the primary efficacy analysis will be guided by the \u201cefficacy\u201d estimand and conducted using the efficacy analysis set (EAS). The primary analysis model will be a MMRM for body weight percent change over time and longitudinal logistic regression for percentage of participants achieving at least 5% body weight reduction over time. The response variable of MMRM will be the percent change in body weight from baseline values obtained at each scheduled post baseline visit. The response variable of longitudinal logistic regression will be the percentage of participants achieving at least 5% body weight reduction at each scheduled postbaseline visit. The independent variables of both analysis models are treatment group (tirzepatide 5 mg, tirzepatide 10 mg, tirzepatide 15 mg, and placebo), visit, and treatment\u2011by\u2011visit interaction, stratification factors, and baseline body weight as a covariate. An unstructured covariance structure will model relationship of within\u2011patient errors. If the analysis fails to converge, the following variance\u2011covariance matrices will be used (in order) until convergence is achieved: heterogeneous compound symmetry, compound symmetry, and first\u2011order autoregressive. The Kenward\u2011Roger approximation will be used to estimate denominator degrees of freedom.\n\n# 9.4.3.2. Key Secondary Analyses\n\n- superiority of each tirzepatide dose (5 mg, 10 mg and 15 mg) to placebo for change from randomization in change of body weight (kg) at 20 weeks visit\n- superiority of QW tirzepatide 5 mg to placebo for percent change in body weight from randomization AND percentage of participants who achieve \u22655% body weight reduction at 72 weeks visit\n- superiority of each tirzepatide dose (10 mg and 15 mg) to placebo for the percentage of study participants who achieve \u226510% body weight reduction at 72 weeks visit\n- superiority of each tirzepatide dose (10 mg and 15 mg) to placebo for the percentage of study participants who achieve \u226515% body weight reduction at 72 weeks visit\n- superiority of each tirzepatide dose (10 mg and 15 mg) to placebo for change from randomization in waist circumference (cm) at 72 weeks visit\n- superiority of each tirzepatide dose (10 mg and 15 mg) to placebo for change from randomization in SF\u201136v2 acute form physical functioning domain score at 72 weeks visit\n- superiority of tirzepatide (all doses combined) to placebo for change from randomization in triglycerides (mg/dL) at 72 weeks visit\n\nLY3298176                                                                                       77", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3561, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2693b941-0715-4834-aa6a-2cea3c53141c": {"__data__": {"id_": "2693b941-0715-4834-aa6a-2cea3c53141c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "acb1c4fb-e545-47f0-ba4b-86b81c2ae6ce", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e01cd8d25829f0f71881591bb43ebd00458a2eee63c365d63fc1247fa58fc4a6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                            Protocol I8F\u2011MC\u2011GPHK\n\n\u2022  superiority of tirzepatide (all doses combined) to placebo for change from randomization in LDL cholesterol (mg/dL) at 72 weeks visit\n\n\u2022  superiority of tirzepatide (all doses combined) to placebo for change from randomization in total cholesterol (mg/dL) at 72 weeks visit\n\n\u2022  superiority of tirzepatide (all doses combined) to placebo for change from randomization in SBP (mmHg) at 72 weeks visit\n\n\u2022  superiority of tirzepatide (all doses combined) to placebo for change from randomization in fasting insulin (pmol/L) at 72 weeks visit\n\n\u2022  superiority of tirzepatide (10 mg and 15 mg) to placebo for change from randomization in percent change of body weight at 176 weeks visit (for participants with prediabetes at randomization)\n\n\u2022  superiority of tirzepatide (all doses combined) to placebo in delaying the onset of diabetes during 176 weeks (for participants with prediabetes at randomization)\n\nAdditional details, including analysis methods for key secondary endpoints and the strategy for controlling overall type 1 error rate at a 2\u2011sided alpha of 0.05 of primary and key secondary endpoint evaluation, will be provided in the SAP.\n\n# 9.4.4. Safety Analyses\n\nUnless specified otherwise, safety assessments will be guided by an estimand comparing safety of tirzepatide doses with placebo irrespective of adherence to study drug. Thus, safety analysis will be conducted using SS.\n\n# 9.4.4.1. Study Drug Exposure\n\nExposure to each study treatment will be calculated for each participant and summarized by treatment group.\n\n# 9.4.4.2. Adverse Events\n\nAdverse events will be coded from the actual term using the Medical Dictionary for Regulatory Activities (MedDRA) and reported with preferred terms and system organ class. Counts and percentages of participants experiencing events will be reported for each treatment group, and Fisher\u2019s exact test will be used to compare the treatment groups.\n\nThe percentage of participants experiencing TEAE, SAE, discontinuation due to AE will be summarized by treatment group.\n\n# 9.4.4.3. Adverse Event of Special Interest\n\nThis section includes areas of interest whether due to observed safety findings, potential findings based on drug class, and agreed upon consultation with regulatory agencies for the reasons previously mentioned.\n\nThe following AEs are AEs of special interest (AESI) for this study:\n\n- severe hypoglycemia\n\nLY3298176    78", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2488, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5c91ff1a-7b8c-430d-95f7-e8115e04bb75": {"__data__": {"id_": "5c91ff1a-7b8c-430d-95f7-e8115e04bb75", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "59327998-9b68-414e-b5cd-5acdf43c0ac0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e3bd17a0ea1c3529ebd1179874347f039ec1917ca86c9ced4c140c022678a7d7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                      Protocol I8F\u2011MC\u2011GPHK\n\n- major adverse cardiovascular events (adjudicated); includes, but not limited to cardiovascular death, nonfatal MI, nonfatal stroke, and hospitalization for heart failure\n- treatment\u2011emergent supraventricular arrhythmias and cardiac conduction disorders\n- hepatobiliary disorders; includes biliary colic, cholecystitis, and other gallbladder disease\n- severe GI events\n- acute renal events\n- MDD/suicidal behavior and ideation\n- pancreatitis (adjudicated)\n- c\u2011cell hyperplasia and thyroid malignancies\n- allergic/hypersensitivity reactions; includes injection site reactions and ADA formation.\n\nSummaries and analyses for incidence of AESIs will be provided by treatment. The details of analysis of AESI will be provided in the SAP.\n\n# 9.4.4.4. Other Adverse Event Assessments\n\n# 9.4.4.4.1. Gastrointestinal Events\n\nSummaries and analyses for incidence and severity of nausea, vomiting, and diarrhea will be provided by each treatment.\n\n# 9.4.4.4.2. Events Related to Potential Abuse Liability\n\nTwo clusters of preferred terms for AEs suggestive of abuse liability will be analyzed. The first cluster includes the Standardized MedDRA Queries (SMQ) \u201cDrug abuse and dependence\u201d [20000101]. The second cluster is a Lilly Search Cluster composed of \u201cadditional abuse potential\u201d terms, which are additional terms suggestive of abuse liability that are not listed under Drug abuse and dependence SMQ [20000101].\n\nSummaries and analyses for incidence of potential abuse liability terms will be provided by treatment. The details will be provided in the SAP.\n\n# 9.4.4.4.3. Depression, Suicidal Ideation, and Behavior\n\nIn addition to the summary of TEAEs, suicidal ideation and behavior will be assessed by C\u2011SSRS, and depression\u2011related symptoms will be assessed using PHQ\u20119.\n\nThe analysis details will be provided in the SAP.\n\n# 9.4.4.4.4. Central Laboratory Measures, Vital Signs, and Electrocardiograms\n\nActual values and change from randomization to postrandomization values of central laboratory measures, vital signs, and selected ECG parameters will be summarized at each scheduled visit. Change from randomization to postrandomization value will be summarized for participants who have both a randomization and at least 1 postrandomization result.\n\nLY3298176                                                                                          79", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2440, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "69e59392-38ff-4578-9548-c5976a6f38e0": {"__data__": {"id_": "69e59392-38ff-4578-9548-c5976a6f38e0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "00e23163-96f6-4f04-873a-979543754858", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c87a1d6ab00ae30e78110e7afb57b6c1a2bd8d37af24fa2ba92609b9b7fad487", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                        Protocol I8F\u2011MC\u2011GPHK\n\nThe percentages of participants with treatment\u2011emergent (TE) abnormal, high, or low measures (including laboratory, vital, and ECG parameters) will be summarized and compared between treatment groups using Fisher\u2019s exact test. The analysis details will be provided in the SAP.\n\n# 9.4.5. Pharmacokinetic/Pharmacodynamic Analyses\n\nTirzepatide concentration data will be analyzed using a population PK approach using nonlinear mixed\u2011effects modeling techniques implemented on the NONMEM\u00ae software. The relationships between tirzepatide dose and/or concentration and selected efficacy, tolerability, and safety endpoints will be characterized. Additionally, the impact of intrinsic and extrinsic participant factors such as age, weight, gender, and renal function on tirzepatide PK and/or PD parameters may be examined. If ADA titers are detected from immunogenicity testing, then the impact of immunogenicity titers on tirzepatide PK or any relevant PD parameters may also be examined.\n\n# 9.4.6. Evaluation of Immunogenicity\n\nThe frequency and percentage of participants with preexisting ADA and with TE ADA+ to tirzepatide will be tabulated. Treatment\u2011emergent ADAs are defined as those with a titer 2\u2011fold (1 dilution) greater than the minimum required dilution (1:10) of the ADA assay if no ADAs were detected at baseline (treatment\u2011induced ADA) or those with a 4\u2011fold (2 dilutions) increase in titer compared with baseline if ADAs were detected at baseline (treatment\u2011boosted ADA). For the TE ADA+ participants, the distribution of maximum titers will be described. The frequency of neutralizing antibodies will also be tabulated in TE ADA+ participants.\n\n# 9.4.7. Other Analyses\n\n# 9.4.7.1. Subgroup Analyses for Primary Outcome\n\nDetails of the subgroup analyses will be shown in the SAP. The following subgroup variables will be considered (but not limited to):\n\n- age (&#x3C;65 years and \u226565 years);\n- sex (female and male)\n- baseline BMI (&#x3C;30, \u226530 and &#x3C;35, \u226535 and &#x3C;40, \u226540 kg/m\u00b2)\n- race\n- ethnicity\n- glycemic status at randomization (normoglycemia vs prediabetes)\n\nThe outcome measures for the subgroup analyses will include:\n\n- percent change in body weight from randomization at 72 weeks\n- percentage of participants achieving at least 5% body weight reduction at 72 weeks\n\nLY3298176    80", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2404, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e277a41c-91bb-4aa0-bef1-dd5b233becd2": {"__data__": {"id_": "e277a41c-91bb-4aa0-bef1-dd5b233becd2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "90636f21-8a19-4c71-8608-76da9c30d726", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "bffd5547bf71467dcc5b0751817b134dab7c5adcb4176ae23cd34afb977969f0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                           Protocol I8F\u2011MC\u2011GPHK\n\n# 9.5. Interim Analyses\n\nAn interim analysis is planned to assess the effect of 5\u2011, 10\u2011, and 15\u2011mg doses of tirzepatide compared to placebo on HR in GPHK (SURMOUNT\u20111) participants. The timing of the interim analysis will be triggered by the completion of a 24\u2011hour ambulatory monitoring sub\u2011study; specifically, after approximately 576 randomized participants in GPHK who agree to perform ambulatory monitoring and have either completed 36 weeks of treatment or discontinued earlier.\n\nAn independent data monitoring committee (DMC) will have the responsibility to review unblinded interim analysis results. A statistical analysis center independent from the Sponsor will perform the data analysis for the DMC.\n\nFollowing the interim analysis specified above, the primary database lock will occur after all randomized participants complete the 72\u2011week treatment period or discontinue the study early. The primary objective of the study will be assessed following the primary database lock.\n\nThe final database lock will occur after participants classified with prediabetes have completed a 176\u2011week treatment period and the safety follow\u2011up visit or discontinued the study early.\n\nA limited number of preidentified individuals will have access to the unblinded data from the interim and/or primary database lock prior to the final database lock (after all randomized participants complete the entire study). Information that may unblind the study after the interim or primary database lock will not be communicated to study sites or blinded study team prior to final database lock, unless it is deemed necessary for participant safety. Details will be specified in the blinding/unblinding plan and in the DMC charter.\n\nLY3298176    81", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1811, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c57eef32-13d2-4bb7-b3ad-4c03a91def6d": {"__data__": {"id_": "c57eef32-13d2-4bb7-b3ad-4c03a91def6d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3a352d79-8f01-4f60-a2cb-ddb081454c0b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cf05144a9fae3c5a6700efb418ea6e07428105dfbe32eafc13ecfa056f6bf06b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 10. Supporting Documentation and Operational Considerations\n\n# 10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations\n\n# 10.1.1. Regulatory and Ethical Considerations\n\n- This study will be conducted in accordance with the protocol and with the following:\n- Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines\n- Applicable The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines\n- Applicable laws and regulations\n- The protocol, protocol amendments, ICF, investigator\u2019s brochure, and other relevant documents (for example, advertisements) must be submitted to an IRB/IEC by the investigator and reviewed and approved by the IRB/IEC before the study is initiated.\n- Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.\n- The investigator will be responsible for the following:\n- Providing written summaries of the status of the study to the ERB annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC\n- Notifying the IRB/IEC of SAEs or other significant safety findings as required by ERB procedures\n- Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations\n\n# 10.1.2. Informed Consent Process\n\n- The investigator or his or her representative will explain the nature of the study, including risks and benefits, to the study participant or his/her legally authorized representative and answer all questions regarding the study.\n\nLY3298176    82", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2050, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1e72d523-3df1-437e-bbdc-b70e8e3d7f07": {"__data__": {"id_": "1e72d523-3df1-437e-bbdc-b70e8e3d7f07", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cc3ca0f3-cd8c-4f5f-ae7a-82387eb8306a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0c7f432cb159e481c1ed963132aa7af9a395fa67df52aef3c6893a031c0cddd6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                             Protocol I8F\u2011MC\u2011GPHK\n\n\u2022  Study participants must be informed that their participation is voluntary. Study participants or their legally authorized representative will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.\n\n\u2022  The medical record must include a statement that written informed consent was obtained before the study participant was entered into the trial and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF.\n\n\u2022  Study participants must be reconsented to the most current version of the ICF(s) during their participation in the trial.\n\n\u2022  A copy of the ICF(s) must be provided to the study participant or the study participant\u2019s legally authorized representative.\n\n# 10.1.3. Data Protection\n\n\u2022  Study participants will be assigned a unique identifier by the investigator. Any study participant records, datasets, or tissue samples that are transferred to the Sponsor will contain the identifier only; study participant names or any information which would make the study participant identifiable will not be transferred.\n\n\u2022  The study participant must be informed that his/her personal trial\u2011related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the study participant.\n\n\u2022  The study participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.\n\n# 10.1.4. Committees Structure\n\nProspective adjudication of major adverse cardiovascular events and pancreatic AEs will be performed for this study. Section 10.3 Appendix 3 outlines additional information on pancreatic and cardiovascular adjudication committees.\n\nAn independent DMC for the interim analysis (Section 9.5) will include members with no conflict of financial interest.\n\n# 10.1.5. Dissemination of Clinical Study Data\n\nRequired clinical trial registries (for example, ClinicalTrials.gov) will be updated with the results from registered clinical trials regardless of the research outcome in accordance with local laws and regulations.\n\nAll CSRs, amendments, and addenda will be submitted to external regulatory authorities, external partners (as applicable), and sites.\n\nLY3298176    83", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2671, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2752743f-bcc2-46dc-82ce-935b23f3dca0": {"__data__": {"id_": "2752743f-bcc2-46dc-82ce-935b23f3dca0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ad6a8f8b-7f16-4815-8932-6d98ff9c9312", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ba28002e919f5139f47bf2ef28d3e48a4c2dd2fac3931c93b3c967481aea76b8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK\n\nThe publication policy for Study I8F\u2011MC\u2011GPHK (SURMOUNT\u20111) is outlined in Section 10.1.10 and further described in the Clinical Trial Agreement.\n\n# 10.1.6. Data Quality Assurance\n\nTo ensure accurate, complete, and reliable data, Lilly or its representatives will:\n\n- provide instructional material to the study sites, as appropriate\n- provide sponsor start\u2011up training to instruct the investigators and study coordinators. This training will provide instruction on the protocol, the completion of the eCRFs, and study procedures\n- make periodic visits to the study site\n- be available for consultation and stay in contact with the study site personnel by mail, telephone, and/or fax\n- review and verify data reported to detect potential errors.\n\nIn addition, Lilly or its representatives will periodically check a sample of the participant data recorded against source documents at the study site. The study may be audited by Lilly or its representatives and/or regulatory agencies at any time. Investigators will be given notice before an audit occurs.\n\nThe investigator will keep records of all original source data. This might include laboratory tests, medical records, and clinical notes. If requested, the investigator will provide the Sponsor, applicable regulatory agencies, and applicable ERBs with direct access to original source documents.\n\n# 10.1.7. Data Capture System\n\nThe investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported to the Sponsor.\n\nAn electronic data capture (EDC) system will be used in this study for the collection of CRF data. The investigator maintains a separate source for the data entered by the investigator or designee into the sponsor\u2011provided EDC system. The investigator is responsible for the identification of any data to be considered source and for the confirmation that data reported are accurate and complete by signing the eCRF.\n\nAdditionally, clinical outcome assessment data (scales, self\u2011reported diary data) will be collected by the subject/investigator site personnel via a paper source document and will be transcribed by the investigator site personnel into the EDC system.\n\nData collected via the sponsor\u2011provided data capture systems will be stored at third parties. The investigator will have continuous access to the data during the study and until decommissioning of the data capture systems. Prior to decommissioning, the investigator will receive an archival copy of pertinent data for retention.\n\nData managed by a central vendor, such as laboratory test data, will be stored electronically in the central vendor\u2019s database system and electronic transfers will be provided to the investigator.\n\nLY3298176 84", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2766, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a6fd29f5-aab0-4fb5-a116-8dc773a81b41": {"__data__": {"id_": "a6fd29f5-aab0-4fb5-a116-8dc773a81b41", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "68b9230c-ee63-4cfb-9ad0-bfa985cbf8ce", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "42bebddf94566076dc415797232df653fa1778dd39d06b774b31831b18255346", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                    Protocol I8F\u2011MC\u2011GPHK\n\nfor review and retention. Data will subsequently be transferred from the central vendor to the Lilly data warehouse. Data from complaint forms submitted to Lilly will be encoded and stored in the global product complaint management system.\n\n# 10.1.8. Source Documents\n\n- Source documents provide evidence for the existence of the study participant and substantiate the integrity of the data collected. Source documents are filed at the investigator\u2019s site.\n- Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the trial. Also, current medical records must be available.\n\n# 10.1.9. Study and Site Closure\n\n# 10.1.9.1. Discontinuation of Study\n\nThe study will be discontinued if Lilly or its designee judges it necessary for medical, safety, regulatory, or other reasons consistent with applicable laws, regulations, and GCP.\n\n# 10.1.9.2. Discontinuation of Study Sites\n\nStudy site participation may be discontinued if Lilly or its designee, the investigator, or the ERB of the study site judges it necessary for medical, safety, regulatory, or other reasons consistent with applicable laws, regulations, and GCP.\n\n# 10.1.10. Publication Policy\n\n- The Sponsor will comply with the requirements for publication of study results.\n- Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.\n- The publication policy for Study I8F\u2011MC\u2011GPHK (SURMOUNT\u20111) is described in the Clinical Trial Agreement.\n\nLY3298176    85", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1801, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "465cfca3-3b44-4334-9e0e-ff14e3038c96": {"__data__": {"id_": "465cfca3-3b44-4334-9e0e-ff14e3038c96", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "855dd3d7-3a78-4d55-874e-12c4c38bc7f8", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3b26d7ba41305c6012a917709137fdd23a5467c8fce8abeb3bd8774802a66876", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                  Protocol I8F\u2011MC\u2011GPHK\n\n# 10.2.  Appendix 2: Clinical Laboratory Tests\n\n- The tests detailed below will be performed by the central laboratory unless otherwise stated.\n- Local laboratory results are only required in the event that the central laboratory results are not available in time for response evaluation. If a local sample is required, it is important that the sample for central analysis is obtained at the same time. Additionally, if the local laboratory results are used to make either a study intervention decision or response evaluation, the results must be entered into the eCRF.\n- Protocol\u2011specific requirements for inclusion or exclusion of participants are detailed in Section 5 of the protocol.\n- Additional tests may be performed at any time during the study as determined necessary by the investigator or required by local regulations.\n- Refer to Section 5.1 (Inclusion Criteria) for screening pregnancy criteria.\n\nInvestigators must document their review of each laboratory safety report. Laboratory/analyte results that could unblind the study will not be reported to investigative sites or other blinded personnel until the study has been unblinded.\n\nLY3298176    86", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1250, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b3f47417-4767-47ab-82ac-ca67c5c00742": {"__data__": {"id_": "b3f47417-4767-47ab-82ac-ca67c5c00742", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9d9538dd-9ba6-4a7b-ae44-70338d4b63ce", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "f05ff909f754929a0af43f250c6a4c2fe0618d5760334c96ef3ff9f0aec3b239", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK\n\n# Clinical Laboratory Tests\n\n# Hematology\u1d43\n\n- Hemoglobin\n- Hematocrit\n- Erythrocyte count (RBC)\n- Mean cell volume\n- Mean cell hemoglobin concentration\n- Leukocytes (WBC)\n- Neutrophils, segmented\n- Lymphocytes\n- Monocytes\n- Eosinophils\n- Basophils\n- Platelets\n\n# Urine Chemistries\u1d43\n\n- Albumin\n- Creatinine\n\n# Clinical Chemistry\u1d43\n\n- Sodium\n- Potassium\n- Bicarbonate\n- Total bilirubin\n- Direct bilirubin\n- Alkaline phosphatase\n- Alanine aminotransferase (ALT)\n- Aspartate aminotransferase (AST)\n- Blood urea nitrogen (BUN)\n- Creatinine\n- Uric acid\n- Calcium\n- Glucose, fasting\n- Albumin\n- Total Cholesterol\n- Triglycerides\n- Creatine kinase (CK)\n\n# Nonpharmacogenetic Stored Samples\n\n- Serum\n- EDTA plasma\n- P800 plasma\n\n# Hormones (females)\n\n- Pregnancy Test a, serum and/or urineb\n- Follicle\u2011stimulating hormone (FSH)\u1d48\n\n# Calculations\n\n- eGFR (calculated by CKD\u2011EPI equation)a,c\n- UACR (urine albumin mg/dL/creatinine g/dL=UACR mg/g)\n\n# Pharmacokinetics samplesa,e,f,g\n\n- Whole blood (EDTA)\n\n# Pancreas (exocrine) a\n\n- Pancreatic amylase\n- Lipase\n\n# Oral Glucose Tolerance Test\n\n- glucose, insulin, c\u2011peptide\n\n# Cystatin-C\u1d43\n\n# HbA1c\u1d43\n\n# Immunogenicitya,e,g\n\n- Anti\u2011tirzepatide antibodies\n- Anti\u2011tirzepatide antibody neutralization\n\n# Endocrine\u1d43\n\n- Calcitonin\n- Thyroid\u2011stimulating hormone (TSH)\n- Insulin\n- C-peptide\n\n# Lipid Panel\u1d43\n\n- LDL\u2011C\n- HDL\u2011C\n- VLDL\u2011C\n- Free Fatty Acids\n\nLY3298176 87", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1427, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3417d99c-4acc-4367-8a9d-8f0fcf69aaa1": {"__data__": {"id_": "3417d99c-4acc-4367-8a9d-8f0fcf69aaa1", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7900954a-c796-4e35-9508-efd12118066b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ffeb08dba13fab96d0287e436ef47be2d875b5d41cb88afc473daa07428d8897", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\nAbbreviations: ADA = antidrug antibody; ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; CK = creatinine kinase, CKD\u2011EPI = Chronic Kidney Disease\u2011Epidemiology; eGFR = estimated glomerular filtration rate; EDTA = ethylenediaminetetraacetic acid; FSH = follicle\u2011stimulating hormone; HbA1c = hemoglobin A1c; HDL = high\u2011density lipoprotein; IWRS = interactive web\u2011response system; LDL = low\u2011density lipoprotein; PK = pharmacokinetics; RBC = red blood cells; TSH = thyroid\u2011stimulating hormone; UACR = urine albumin/creatinine ratio; VLDL = very low\u2011density lipoprotein; WBC = white blood cells.\n\na All tests will be performed by a Lilly\u2011designated central laboratory, unless otherwise noted.\n\nb A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only.\n\nA urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy tests (beyond those required per the Schedule of Activities [Section 1.3]) should be performed at any time during the trial if a menstrual period is missed, there is clinical suspicion of pregnancy, or as required by local law or regulation.\n\nc Estimated glomerular filtration rate will be calculated by the central laboratory at all visits and included in lab result reports.\n\nd Follicle\u2011stimulating hormone test performed at Visit 1 for postmenopausal women at least 40 years of age with an intact uterus, not on hormone therapy, and who have had spontaneous amenorrhea for more than 1 year without an alternative medical cause.\n\ne Results will not be provided to the investigative sites.\n\nf PK samples will be collected at these visits at time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose, as assigned by IWRS. Dependent on the time\u2011windows to which a participant gets assigned, they may be required to come to site for PK\u2011specific visits.\n\ng In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and exploratory biomarker samples. PK samples for immunogenicity must be taken prior to drug administration.\n\nLY3298176    88", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2342, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2b002f52-0b24-4a75-b997-21442d8c2bd0": {"__data__": {"id_": "2b002f52-0b24-4a75-b997-21442d8c2bd0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d24614c8-16fe-439d-8707-6409d3ad2ea2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "519b832d85bf448f86e407c5d583e58a7c7b0b094fe025daecec66b1d7a04f64", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\nSelected tests may be obtained in the event of anaphylaxis or systemic allergic/hypersensitivity reactions.\n\n# Hypersensitivity Tests\u1d43\n\nAnti\u2011LY antibodies (immunogenicity)\nLY concentration (PK)\nTryptase\u1d47\nN\u2011methylhistamine\u1d47\nDrug Specific IgE\u1d47\nBasophil Activation Test\u1d47\nComplements\nCytokine Panel\n\nAbbreviations: LY = LY3298176; IgE = immunoglobulin E; PK = pharmacokinetics.\n\na  Assayed by Lilly\u2011designated laboratory.\n\nb  Will be performed if a validated assay is available.\n\nLY3298176    89", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 530, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4b0e758f-b2a4-4d2d-8f71-31dd4f774663": {"__data__": {"id_": "4b0e758f-b2a4-4d2d-8f71-31dd4f774663", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b32c7cf3-8bee-48a2-a66a-7c1c9d759abf", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "de81614341ff1419d101eac2fd1900c3e4e013785a6f7d8cdd9b5cff3b515e26", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                            Protocol I8F\u2011MC\u2011GPHK\n\n# 10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-Up, and Reporting\n\nPlease refer to Section 8.3 Adverse Events and Serious Adverse Events.\n\n# 10.3.1. Special Safety Topics\n\n# 10.3.1.1. Hypoglycemia\n\nUpon ICF signing, all participants will be educated about signs and symptoms of hypoglycemia, how to treat hypoglycemia, and how to collect appropriate information for each episode of hypoglycemia.\n\nHypoglycemia may be identified by spontaneous reporting of symptoms from participants (whether confirmed or unconfirmed by simultaneous glucose values) or by blood glucose (BG) samples collected during study visits.\n\nAll participants who develop diabetes during the study will be provided with glucometers. Participants without diabetes may, at the investigator\u2019s discretion, be given glucometers to assist in the evaluation of reported symptoms consistent with hypoglycemia. Participants receiving glucometers will be provided a diary to record relevant information (for example, glucose values, symptoms).\n\nHypoglycemic episodes will be recorded on a specific eCRF and should not be recorded as AEs unless the event meets serious criteria. If a hypoglycemic event meets severe criteria (see definition below), it should be recorded as serious on the AE and SAE eCRFs, and reported to Lilly as an SAE.\n\nInvestigators should use the following definitions and criteria when diagnosing and categorizing an episode considered to be related to hypoglycemia (the plasma Glucose values in this section refer to values determined by a laboratory or International Federation of Clinical Chemistry and Laboratory Medicine blood\u2011equivalent glucose meters and strips) in accordance with the 2019 American Diabetes Association position statement on glycemic targets (American Diabetes Association 2019a):\n\n# Glucose Alert Value (Level 1):\n\n- Documented symptomatic hypoglycemia is defined as any time a patient feels that he or she is experiencing symptoms and/or signs associated with hypoglycemia and has a PG level of \u226470 mg/dL (\u22643.9 mmol/L).\n- Documented asymptomatic hypoglycemia is defined as any event not accompanied by typical symptoms of hypoglycemia, but with a measured PG \u226470 mg/dL (\u22643.9 mmol/L).\n- Documented unspecified hypoglycemia is defined as any event with no information about symptoms of hypoglycemia available, but with a measured PG \u226470 mg/dL (\u22643.9 mmol/L).\n\nLY3298176    90", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2511, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "85a4de42-a9ea-48b5-8ec1-36de138b5ad8": {"__data__": {"id_": "85a4de42-a9ea-48b5-8ec1-36de138b5ad8", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6384ebff-8022-4289-abe2-9e08ea6db172", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "25f0aff30e4fc353af208841448eaea083e0e998077ec1ec695669a8b61916e3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                        Protocol I8F\u2011MC\u2011GPHK\n\n# Clinically Significant Hypoglycemia (Level 2):\n\n- Documented symptomatic hypoglycemia is defined as any time a participant feels that he or she is experiencing symptoms and/or signs associated with hypoglycemia and has a BG level of &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n- Documented asymptomatic hypoglycemia is defined as any event not accompanied by typical symptoms of hypoglycemia but with a measured BG &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n- Documented unspecified hypoglycemia is defined as any event with no information about symptoms of hypoglycemia available but with a measured BG &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n\n# Severe hypoglycemia (Level 3):\n\n- Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. Blood glucose measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration.\n\nTo avoid duplicate reporting, all consecutive BG values \u226470mg/dL (3.9 mmol/L) occurring within a 1\u2011hour period may be considered to be a single hypoglycemic event (Weinberg et al. 2010; Danne et al. 2013).\n\n# 10.3.1.2. Pancreatitis\n\nAcute pancreatitis is defined as an AE of interest in all trials with tirzepatide, including this trial. Acute pancreatitis is an acute inflammatory process of the pancreas that may also involve peripancreatic tissues and/or remote organ systems (Banks and Freeman 2006). The diagnosis of acute pancreatitis requires 2 of the following 3 features:\n\n- abdominal pain, characteristic of acute pancreatitis (generally located in the epigastrium and radiates to the back in approximately half the cases) (Banks and Freeman 2006; Koizumi et al. 2006); the pain is often associated with nausea and vomiting);\n- serum amylase (total and/or pancreatic) and/or lipase \u22653X ULN\n- characteristic findings of acute pancreatitis on computed tomography (CT) scan or magnetic resonance imaging (MRI).\n\nIf acute pancreatitis is suspected, appropriate laboratory tests (including levels of pancreatic amylase and lipase) should be obtained via the central laboratory (and locally, if needed). Imaging studies, such as abdominal CT scan with or without contrast, MRI, or gallbladder ultrasound, should be performed. Abdominal ultrasound may be used as an alternative method only if CT and MRI cannot be performed. If laboratory values and/or abdominal imaging support the diagnosis of acute pancreatitis, the participant must discontinue therapy with\n\nLY3298176\n\n91", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2856, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6a8801bb-dd32-46cd-8a53-669512e0734b": {"__data__": {"id_": "6a8801bb-dd32-46cd-8a53-669512e0734b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b4f7b7c1-248e-4773-b69b-807db7d36bff", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e51613a294998adce8f1415df5b033779ca61fdf267364b94b6abc694839d1e2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                      Protocol I8F\u2011MC\u2011GPHK\n\ntirzepatide, but will continue in the study. A review of the participant\u2019s concomitant medications should be conducted to assess any potential causal relationship with pancreatitis.\n\nEach AE of pancreatitis must be reported. If typical signs and/or symptoms of pancreatitis are present and confirmed by laboratory values (lipase or amylase [total and/or pancreatic]) and imaging studies, the event must be reported as an SAE. For a potential case that does not meet all of these criteria, it is up to the investigator to determine the seriousness of the case (AE or SAE) and the relatedness of the event to study drug(s).\n\nEach participant will have measurements of p\u2011amylase and lipase (assessed at the central laboratory) as shown on the Schedule of Activities (Section 1.3) to assess the effects of the investigational doses of tirzepatide on pancreatic enzyme levels. Serial measurements of pancreatic enzymes have limited clinical value for predicting episodes of acute pancreatitis in asymptomatic participants (Nauck et al. 2017; Steinberg et al. 2017a, 2017b). Thus, further diagnostic follow\u2011up of cases of asymptomatic pancreatic hyperenzymemia (lipase and/or pancreatic amylase \u22653X ULN) is not mandated but may be performed based on the investigator\u2019s clinical judgment and assessment of the participant\u2019s overall clinical condition. Only cases of pancreatic hyperenzymemia that undergo additional diagnostic follow\u2011up and/or are accompanied by symptoms suggestive of pancreatitis will be submitted for adjudication.\n\nAll suspected cases of acute or chronic pancreatitis will be adjudicated by an independent clinical endpoint committee. In addition, AEs of severe or serious abdominal pain of unknown etiology will also be submitted to the adjudication committee to assess for possible pancreatitis or other pancreatic disease. Relevant data from participants with acute or chronic pancreatitis and those with severe or serious abdominal pain will be entered into a specifically designed eCRF page. The adjudication committee representative will enter the results of adjudication in a corresponding eCRF page.\n\n# 10.3.1.3.  Thyroid Malignancies and C-Cell Hyperplasia\n\nIndividuals with personal or family history of MTC and/or MEN\u20112 will be excluded from the study. Participants who are diagnosed with MTC and/or MEN\u20112 during the study will have study drug stopped and should continue follow\u2011up with an endocrinologist.\n\nThe assessment of thyroid safety during the trial will include reporting of any case of thyroid malignancy (including MTC and papillary carcinoma) and measurements of calcitonin. This data will be captured in specific eCRFs. The purpose of calcitonin measurements is to assess the potential of tirzepatide to affect thyroid C\u2011cell function, which may indicate development of C\u2011cell hyperplasia and neoplasms.\n\n# 10.3.1.4.  Calcitonin Measurements\n\nIf an increased calcitonin value (see definitions below) is observed in a participant who has been administered a medication that is known to increase serum calcitonin, then this medication should be stopped and calcitonin levels should be measured after an appropriate washout period. For participants who require additional endocrine assessment because of increased calcitonin concentration as defined in this section, data from the follow\u2011up assessment will be collected in the specific section of the eCRF.\n\nLY3298176    92", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3497, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3d24e3f1-75ab-43d5-b7c4-9757ec72d0d5": {"__data__": {"id_": "3d24e3f1-75ab-43d5-b7c4-9757ec72d0d5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c2f64ffa-deab-48ad-96a3-ba7a278e1670", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6689e54dff227c4afb1a4a6eb9d76a9de0d0f03a14cb0b254789c79157f2acd4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                   Protocol I8F\u2011MC\u2011GPHK\n\n# Calcitonin Measurements in Participants with eGFR \u226560 mL/min/1.73m\u00b2\n\nA significant increase in calcitonin for participants with eGFR \u226560 mL/min is defined below. If a participant\u2019s laboratory results meet these criteria, these clinically significant laboratory results should be recorded as an AE.\n\n- calcitonin value \u226520 ng/L and &#x3C;35 ng/L AND \u226550% increase from the screening value. These participants will be asked to repeat the measurement within 1 month. If this repeat value is increasing (\u226510% increase), study drug should be stopped, and the participant encouraged to undergo additional endocrine assessment and longer\u2011term follow\u2011up by an endocrinologist to exclude any serious adverse effect on the thyroid.\n- calcitonin value \u226535 ng/L AND \u226550% over the screening value. In these participants, study drug should be stopped, and the participant recommended to immediately undergo additional endocrine assessments and longer\u2011term follow\u2011up by an endocrinologist.\n\n# Calcitonin Measurement in Participants with eGFR &#x3C;60 mL/min/1.73m\u00b2\n\nA significant increase in calcitonin for participants with eGFR &#x3C;60 mL/min/1.73m\u00b2 is defined as a calcitonin value \u226535 ng/L AND \u226550% over the screening value. If a participant\u2019s labs meet these criteria, these clinically significant labs should be recorded as an AE.\n\nIn these participants, study drug should be discontinued (after first confirming the value) and the participant recommended to immediately undergo additional endocrine assessments and longer\u2011term follow\u2011up by an endocrinologist to exclude any serious adverse effect on the thyroid.\n\n# 10.3.1.5. Major Adverse Cardiovascular Events\n\nDeaths and nonfatal cardiovascular AEs will be adjudicated by a committee of physicians external to Lilly with cardiology expertise. This committee will be blinded to treatment assignment. The nonfatal cardiovascular AEs to be adjudicated include:\n\n- myocardial infarction\n- hospitalization for unstable angina\n- hospitalization for heart failure\n- coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and\n- cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack.\n\n# 10.3.1.6. Supraventricular Arrhythmias and Cardiac Conduction Disorders\n\nTreatment\u2011emergent cardiac conduction disorders will be further evaluated. Participants who develop any event from these groups of disorders should undergo an ECG, which should be submitted to the central reading center. The specific diagnosis will be recorded as an AE.\n\nEvents that meet criteria for serious conditions as described in Section 8.3 must be reported as SAEs.\n\nLY3298176    93", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2766, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4479bab3-8309-4b0e-8e2a-ec5f6dd49b87": {"__data__": {"id_": "4479bab3-8309-4b0e-8e2a-ec5f6dd49b87", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "038be2f2-2613-4619-87ea-a10a0039510e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e227246a1a9a604048eda8aca17f667e0deb2cf45987a7df3fb43e2e3fd70e4f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK\n\n# 10.3.1.7. Hypersensitivity Events\n\nAll allergic or hypersensitivity reactions will be reported by the investigator as either AEs, or if any serious criterion is met, as SAEs.\n\nIn the event of suspected drug hypersensitivity reactions (immediate or nonimmediate) in subjects who experience moderate\u2011to\u2011severe injection reactions as assessed by the investigator, unscheduled blood samples will be collected for PK and ADA analyses at the following time points:\n\n- as close as possible to the onset of the event\n- at the resolution of the event\n- 30 (\u00b13) days following the event.\n\nAdditionally, unscheduled serum samples for immune safety laboratory testing (including, but not limited to \u03b2 tryptase, total IgE, complement and cytokine panel testing) should also be collected at approximately 60 to 120 minutes and 4 to 6 weeks after the onset of the event in these subjects.\n\nAdditional data, such as type of reaction and treatment received, will be collected on any AEs or SAEs that the investigator deems related to study drug(s) via the eCRF created for this purpose. Study drug(s) should be temporarily interrupted in any individual suspected of having a severe or serious allergic reaction to study drug(s). Study drug(s) may be restarted when/if it is safe to do so, in the opinion of the investigator.\n\n# 10.3.1.8. Injection Site Reactions\n\nInjection site reactions will be collected on the eCRF separate from the hypersensitivity reaction eCRF. At the time of AE occurrence, samples will be collected for measurement of tirzepatide ADA and tirzepatide concentration.\n\n# 10.3.1.9. Antidrug Antibodies\n\nThe occurrence of ADA formation will be assessed as outlined in Section 8.7.\n\n# 10.3.1.10. Hepatobiliary Disorders\n\nAll events of TE biliary colic, cholecystitis, or other suspected events related to gallbladder disease should be evaluated and additional diagnostic tests performed, as needed. In cases of elevated liver markers, hepatic monitoring should be initiated as outlined in Section 7.\n\n# 10.3.1.11. Severe Gastrointestinal Adverse Events\n\nTirzepatide may cause severe GI AEs, such as nausea, vomiting, and diarrhea. Information about severe GI AEs as well as antiemetic/antidiarrheal use will be collected in the eCRF/AE form. For detailed information concerning the management of GI AEs, please refer to Section 6.6.2.\n\n# 10.3.1.12. Acute Renal Events\n\nRenal safety will be assessed based on repeated renal functional assessment as well as assessment of AEs suggestive of acute or worsening of chronic renal failure. Gastrointestinal\n\nLY3298176 94", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2606, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "49f4d782-47bd-4a62-9476-46196ec307c6": {"__data__": {"id_": "49f4d782-47bd-4a62-9476-46196ec307c6", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d76e6ea5-bc13-438c-9e6b-60206770cbaa", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "71d4649456985b7a18e9155dc95f29e033a488f15fe39447c2a6d56a3500f921", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                     Protocol I8F\u2011MC\u2011GPHK\n\nAEs have been reported with tirzepatide, including nausea, diarrhea, and vomiting. This is consistent with other GLP\u20111R agonists (Aroda and Ratner 2011). The events may lead to dehydration, which could cause a deterioration in renal function, including acute renal failure. Participants should be advised to notify investigators in case of severe nausea, frequent vomiting, or symptoms of dehydration.\n\n# 10.3.1.13.  Depression, Suicidal Ideation, or Behavior Monitoring\n\nParticipants will be monitored for depression and suicidal ideation or behavior through AE collection and by using the C\u2011SSRS and the PHQ\u20119. Participants will be referred to an MHP if, in the opinion of the investigator, it is necessary for the safety of the participant, or if the participant had any of the following:\n\n- a PHQ\u20119 score \u226515\n- C\u2011SSRS responses of\n\nLY3298176    95", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 939, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e5a55b4f-8f94-46fa-9821-2a4a80ef1b88": {"__data__": {"id_": "e5a55b4f-8f94-46fa-9821-2a4a80ef1b88", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "375d1d63-dcf4-4a27-983c-e1087a3fdf4c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "819bb992de51d1114494bcd2275d79d469d1f9209b998f00e6a97546f19b6d0e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                        Protocol I8F\u2011MC\u2011GPHK\n\n# 10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information\n\n# Definitions:\n\n# Woman of Childbearing Potential\n\nA woman is considered fertile following menarche and until becoming postmenopausal unless permanently sterile (see below). If fertility is unclear (for example; amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered.\n\nWomen in the following categories are not considered women of childbearing potential:\n\n- Article I. Premenarchal\n- Article II. Premenopausal female with 1 of the following:\n- Documented hysterectomy\n- Documented bilateral salpingectomy\n- Documented bilateral oophorectomy\n\nFor individuals with permanent infertility due to an alternate medical cause other than the above, (for example; Mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry. Note: Documentation can come from the site personnel\u2019s review of the participant\u2019s medical records, medical examination, or medical history interview.\n- Article III. Postmenopausal female\n- A postmenopausal state is defined as either\n- A woman at least 40 years of age with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, AND a follicle\u2011stimulating hormone (FSH) \u226540 mIU/mL; or\n- A woman 55 or older not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea; or\n- A woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy.\n\nNote: A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than 1 FSH measurement (\u226540 mIU/mL) is required.\n- Females on HRT and whose menopausal status is in doubt will be required to use one of the nonestrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.\n\nLY3298176    96", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2365, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2312d4fa-b8df-40b3-8352-b699ba518cb3": {"__data__": {"id_": "2312d4fa-b8df-40b3-8352-b699ba518cb3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1b7c47bd-533e-478b-9ad8-f00f0f20ca51", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a596dc4539eece47e2167f2c88b792f83b8878c2352859070652446921ccff3c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                         Protocol I8F\u2011MC\u2011GPHK\n\n# Contraception Guidance:\n\nContraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Two forms of effective contraception, where at least 1 form is highly effective, will be used. Effective contraception may be used as the second therapy. Barrier protection methods without concomitant use of a spermicide are not a reliable or acceptable method. The use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these methods are combined.\n\n# Highly Effective Methods of Contraception:\n\n- Combined oral contraceptive pill and mini pill\n- NuvaRing\n- Implantable contraceptives\n- Injectable contraceptives (such as Depo\u2011Provera\u00ae)\n- Intrauterine device (such as Mirena\u00ae and ParaGard\u00ae)\n- Contraceptive patch \u2013 ONLY women &#x3C;198 pounds or 90 kg\n- Total abstinence (if this is their preferred and usual lifestyle) or in a same\u2011sex relationship with no sexual relationship with males (as part of their preferred and usual lifestyle), and agrees to maintain this status throughout trial follow\u2011up\n\nNote: periodic abstinence (for example, calendar, ovulation, symptothermal, and postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception.\n\n- Vasectomy \u2013 for men in clinical studies\n\nNote: Implantable contraceptives and injectable contraceptives (such as Depo Provera) are only permitted if started prior to screening. Participants should not start these methods of contraception after being enrolled in the study.\n\n# Effective Methods of Contraception (must use combination of 2 methods):\n\n- Male condom with spermicide\n- Female condom with spermicide\n- Diaphragm with spermicide\n- Cervical sponge\n- Cervical cap with spermicide\n\nMen, regardless of their fertility status, with nonpregnant women of childbearing potential partners must agree to either remain abstinent (if this is their preferred and usual lifestyle) or use condoms plus 1 additional highly effective (less than 1% failure rate) method of contraception (such as combination oral contraceptives, implanted contraceptives, or intrauterine device) or\n\nLY3298176    97", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2367, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9ca77fa8-aafb-4098-910e-fea3bfd01a5f": {"__data__": {"id_": "9ca77fa8-aafb-4098-910e-fea3bfd01a5f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d5c26cf0-1296-4c1a-8df0-0f57a81a33de", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "18ff5bf698bc0f33c8faa82ece2d5bcaa5f36746c6efcc71bc07b30a51fa7f53", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                      Protocol I8F\u2011MC\u2011GPHK\n\n# Effective Method of Contraception\n\nMen must use an effective method of contraception (such as diaphragms with spermicide or cervical sponge) for the duration of the study and for 5 half\u2011lives of study drug plus 90 days, which is approximately 4 months after the last injection. Periodic abstinence (for example, calendar, ovulation, symptothermal, and postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception.\n\nMen with pregnant partners should use condoms during intercourse for the duration of the study and until the end of estimated relevant potential exposure in women of childbearing potential. Men who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same\u2011sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same\u2011sex relationship without sexual relationships with females (usual lifestyle). In these situations, men are not required to use contraception.\n\nMen should refrain from sperm donation for the duration of the study and for 5 half\u2011lives of study drug plus 90 days after the last dose of study drug, corresponding to 4 months after the last injection.\n\n# Collection of Pregnancy Information\n\n# Male Participants with Partners Who Become Pregnant\n\n- The investigator will attempt to collect pregnancy information on any male participant\u2019s female partner who becomes pregnant while the male participant is in this study.\n- After obtaining the necessary signed informed consent from the pregnant female partner directly, the investigator will record pregnancy information on the appropriate form and submit it to the Sponsor within 24 hours of learning of the partner\u2019s pregnancy. The female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow\u2011up will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.\n\n# Female Participants Who Become Pregnant\n\n- The investigator will collect pregnancy information on any female participant who becomes pregnant while participating in this study. Information will be recorded on the appropriate form and submitted to the Sponsor within 24 hours of learning of a participant\u2019s pregnancy.\n- The participant will be followed to determine the outcome of the pregnancy. The investigator will collect follow\u2011up information on the participant and the neonate and the information will be forwarded to the Sponsor. Generally, follow\u2011up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.\n\nLY3298176    98", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3098, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a0bd5e49-5c5a-4d25-a7fa-665bcf7f270d": {"__data__": {"id_": "a0bd5e49-5c5a-4d25-a7fa-665bcf7f270d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3f6c49da-f89a-4070-b978-f8b29501a358", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c131e1bbbe0337660607d183ba1288363921406bb1d9cde2a057d21252f5c5f9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL      Protocol I8F\u2011MC\u2011GPHK\n\n\u2022  While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion is always considered to be an SAE and will be reported as such. Any poststudy pregnancy\u2011related SAE considered reasonably related to the study intervention by the investigator will be reported to the Sponsor as described in Section 8.3.2. While the investigator is not obligated to actively seek this information in former study participants, he or she may learn of an SAE through spontaneous reporting.\n\n\u2022  Any female participant who becomes pregnant while participating in the study will discontinue study intervention or be withdrawn from the study.\n\nLY3298176    99", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 797, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "35f097a8-4e0a-41d0-9d8e-79b3aa3d0394": {"__data__": {"id_": "35f097a8-4e0a-41d0-9d8e-79b3aa3d0394", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d1c4b196-8861-4274-a818-fec3b0be49a9", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "dff85c64351684a239a27ae8ba6f2f21fb55d5112e4fe32011aa367a4298387f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 10.5. Appendix 5: Liver Safety: Suggested Actions and Follow-Up Assessments\n\n# Hepatic Monitoring Tests\n\n| Hepatic Hematology     | Haptoglobin |\n| ---------------------- | ----------- |\n| Hemoglobin             |             |\n| Hematocrit             |             |\n| RBC                    |             |\n| WBC                    |             |\n| Neutrophils, segmented |             |\n| Lymphocytes            |             |\n| Monocytes              |             |\n| Eosinophils            |             |\n| Basophils              |             |\n| Platelets              |             |\n\n# Hepatic Coagulation\n\n| Prothrombin Time | Prothrombin Time, INR |\n| ---------------- | --------------------- |\n\n# Hepatic Serologies\n\n| Hepatitis A antibody, total  |   |\n| ---------------------------- | - |\n| Hepatitis A antibody, IgM    |   |\n| Hepatitis B surface antigen  |   |\n| Hepatitis B surface antibody |   |\n| Hepatitis B Core antibody    |   |\n| Hepatitis C antibody         |   |\n| Hepatitis E antibody, IgG    |   |\n| Hepatitis E antibody, IgM    |   |\n\n# Hepatic Chemistry\n\n| Total bilirubin      |   |\n| -------------------- | - |\n| Direct bilirubin     |   |\n| Alkaline phosphatase |   |\n| ALT                  |   |\n| AST                  |   |\n| GGT                  |   |\n| CPK                  |   |\n\n# Abbreviations:\n\nALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatinine phosphokinase; GGT = gamma\u2011glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red blood cells; WBC = white blood cells.\n\na Assayed by Lilly\u2011designated or local laboratory.\n\nb Reflex/confirmation dependent on regulatory requirements and/or testing availability.\n\nLY3298176    100", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1778, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "60219114-1ee5-4c6a-8eea-a467dfa10f92": {"__data__": {"id_": "60219114-1ee5-4c6a-8eea-a467dfa10f92", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6fb4aca7-f879-4edd-9dca-60c982dfb96c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "4a569b0fd514885f37ec995821785b1e096c64d0cc21fc68ee54c206d73b8269", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                Protocol I8F\u2011MC\u2011GPHK\n\n# 10.6. Appendix 6: Medical Device Incidents: Definition and Procedures for Recording, Evaluating, Follow-Up, and Reporting\n\n# Definitions of a Medical Device Incident\n\nThe detection and documentation procedures described in this protocol apply to all sponsor medical devices provided for use in the study.\n\n# Medical Device Incident Definition\n\n- A medical device incident is any malfunction or deterioration in the characteristics and/or performance of a device as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to a serious injury, death of a participant/user/other person, or to a serious deterioration in his/her state of health.\n- Not all incidents lead to death or serious deterioration in health. The nonoccurrence of such a result might have been due to other fortunate circumstances or to the intervention of health care personnel.\n\nIt is sufficient that:\n\n- An incident associated with a device happened.\n- AND\n- The incident was such that, if it occurred again, might lead to death or a serious deterioration in health.\n\n# A serious deterioration in state of health can include any of the following:\n\n- Life\u2011threatening illness\n- Permanent impairment of body function or permanent damage to body structure\n- Condition necessitating medical or surgical intervention to prevent one of the above\n- Fetal distress, fetal death, or any congenital abnormality or birth defects\n\n# Examples of Incidents\n\n- A participant, user, caregiver, or health care professional is injured as a result of a medical device failure or its misuse.\n- A participant\u2019s study intervention is interrupted or compromised by a medical device failure.\n- A misdiagnosis due to a medical device failure leads to inappropriate treatment.\n- A participant\u2019s health deteriorates due to a medical device failure.\n\nLY3298176    101", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1970, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2bb66447-d3e1-4a02-a687-ea0b1ed26e33": {"__data__": {"id_": "2bb66447-d3e1-4a02-a687-ea0b1ed26e33", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "db5aac8e-d115-4e64-bf7f-4fd43fe9ca84", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "dbcb4f44663ac9043d4d88ed1ddfb41d6a70256e287bdbd242b4c84cf37e74a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                      Protocol I8F\u2011MC\u2011GPHK\n\n# Documenting Medical Device Incidents\n\nMedical Device Incident Documenting\n\n- Any medical device incident occurring during the study will be documented in the participant\u2019s medical records, in accordance with the investigator\u2019s normal clinical practice, and on the appropriate form of the eCRF.\n- For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE eCRF page will be completed as described in Section 8.3.\n- A product complaint must be submitted describing the issue or deficiency that may have led to the incident or AE.\n- The eCRF will be completed as thoroughly as possible and signed by the investigator before transmittal to the Sponsor or designee.\n- It is very important that the investigator provides his/her assessment of causality (relationship to the medical device provided by the Sponsor) at the time of the initial AE or SAE report and describes any corrective or remedial actions taken to prevent recurrence of the incident.\n\nLY3298176    102", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1078, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0ec5c557-e863-44a9-92d3-d3cf0ec3bc4b": {"__data__": {"id_": "0ec5c557-e863-44a9-92d3-d3cf0ec3bc4b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "992614f7-f20c-4340-b618-20868edcbc3b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "18a280830bf9d412c4d163e8439d565595f98a931edd2f0aa4e4bdb89e9bd2ee", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                              Protocol I8F\u2011MC\u2011GPHK\n\n# 10.7. Appendix 7: Protocol GPHK Standardized Protocols for the Measurement of Height, Weight, Waist Circumference, Vital Signs, Electrocardiogram, and Oral Glucose Tolerance Test\n\nThe following information has been adapted from standardized physical measurement protocols for the World Health Organization\u2019s STEPwise approach to Surveillance (STEPS) (WHO 2008) (Available at: https://www.who.int/ncds/surveillance/steps/Section%204%20Step%202%20Physical%20Measurements.pdf) Accessed January 17, 2019.\n\n# Measuring Height\n\n1. Ask the participant to remove their footwear and any headgear (light headgear worn for religious reasons can remain, but this should be worn by the participant at every clinic visit when their height is measured).\n2. Ask the participant to stand on the calibrated height measuring board (stadiometer) or against a wall with their feet together and their knees straight with their heels against the backboard, the stadiometer, or the wall.\n3. Ask the participant to look straight ahead without tilting their head up.\n4. Ask the participant to breathe in and stand tall. Measure and record the participant\u2019s height in centimeters (cm) to 1 decimal place.\n\n# Measuring Weight\n\n- Body weight measurements should be done in a consistent manner using a calibrated electronic scale capable of measuring weight in kilograms (kg) to 1 decimal place.\n- All weights for a given participant should be measured using the same scale, whenever possible, at approximately the same time in the morning after evacuation of bladder contents.\n- Body weight must be measured in fasting state. If the participant is not fasting, the participant should be called in for a new visit within the visit window to have the fasting body weight measured.\n\n1. Ask the participant to empty their pockets, remove their footwear, outerwear (coat, jacket, etc.), and any headgear (light headgear worn for religious reasons can remain, but this should be worn by the participant at every clinic visit when weight is measured).\n2. Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a sloping surface, or a rough, uneven surface).\n3. Ask the participant to step onto the scale with 1 foot on each side of the scale.\n4. Ask the participant to stand still with arms by sides and then record weight in kilograms (kg) to the nearest one\u2011tenth kg.\n\nLY3298176    103", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2458, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "406f687a-16d3-4655-876a-5fc585ffa03a": {"__data__": {"id_": "406f687a-16d3-4655-876a-5fc585ffa03a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f3f090f0-17da-41dc-902a-e19b9693d59c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9322c642c3dcec1c2c1b885b719817153f8e426d7db29625bd4a22535efdb20c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                              Protocol I8F\u2011MC\u2011GPHK\n\n# Measuring Waist Circumference\n\n- Waist circumference should be measured in the horizontal plane and at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest.\n- Measurements should be taken at the end of a normal expiration using a nonstretchable measuring tape. The tape should lie flat against the skin without compressing the soft tissue.\n- The waist circumference should be measured twice, rounded to the nearest 0.5 cm. The measuring tape should be removed between the 2 measurements. Both measurements will be recorded in the eCRF. If the difference between the 2 measurements exceeds 1 cm, this set of measurements should be discarded and the 2 measurements repeated.\n\n1. Ask the participant to wear light clothing (if available, patient gowns could also be used).\n2. Ask the participant to stand with their feet close together, arms at their side, body weight evenly distributed.\n3. Ask the participant to relax and measure the participant\u2019s waist circumference.\n\n# Vital Sign Measurements (blood pressure and heart rate)\n\n- Vital sign measurements (blood pressure and heart rate, measured by pulse) should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing.\n- The participant should sit quietly for 5 minutes before vital signs measurements are taken.\n- For each parameter, 3 measurements will be taken using the same arm, preferably the nondominant arm.\n- The recordings should be taken at least 1 minute apart. Each measurement of sitting pulse and BP needs to be recorded in the eCRF.\n- Blood pressure must be taken with an automated blood pressure instrument.\n- If blood pressure and pulse measurements are taken separately, pulse should be taken prior to blood pressure.\n\nNote: In the event pulse measurement cannot be taken via an automated blood pressure instrument, the preferred location for measurement of pulse is the radial artery.\n\n# Electrocardiogram\n\n- All digital ECGs will be obtained using centrally provided ECG machines and will be electronically transmitted to a designated central ECG laboratory.\n- 12\u2011lead ECGs should be obtained after the subject has rested in a supine position for at least 10 minutes.\n\nLY3298176                                                                                         104", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2413, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "79de6f11-dba2-44f4-9498-7f69ad5289ec": {"__data__": {"id_": "79de6f11-dba2-44f4-9498-7f69ad5289ec", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7c19bf4a-c6d7-4543-a778-6113d4bbd187", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d0d9e4d099843dafa9d538011fdcab17ed5383e89721762a8973dd79bf784b6d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                      Protocol I8F\u2011MC\u2011GPHK\n\n\u2022  Electrocardiograms should be collected at least 30 minutes prior to collection of blood samples for laboratory testing, including PK samples.\n\n\u2022  Triplicate ECGs (obtained at Week 0 and Week 36) should be obtained approximately 1 minute apart, with all 3 tracings to be obtained within approximately 5 minutes.  Measurements that deviate substantially from previous readings should be repeated immediately.\n\n# 2-Hour Oral Glucose Tolerance Test\n\n\u2022  Participants should maintain adequate carbohydrate intake for 3 days prior to the scheduled 2\u2011hour OGTT.\n\n\u2022  In the 24 hours preceding the test, patients should refrain from drinking any alcohol or performing any extreme physical activity.\n\n\u2022  Participants should fast for approximately 8 hours before the administration of the test and should not eat until the test is complete.\n\n\u2022  Placement of a venous cannula, preferably in an antecubital vein, is recommended to simplify collection of multiple blood samples for glucose, insulin, and C\u2011peptide at time 0, 30, 60, 90, and 120 minutes.\n\n\u2022  Immediately after collection of the time 0 sample, a 75\u2011gram glucose dose will be given orally, using a commercial product approved for this use (and in a total volume of not more than 350 mL).\n\n\u2022  The participant should consume the glucose load within 5 minutes.\n\n\u2022  The patient should remain minimally active for the duration of the test.\n\nLY3298176    105", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1477, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d6195b68-94b0-4363-b9a0-1f92b1108085": {"__data__": {"id_": "d6195b68-94b0-4363-b9a0-1f92b1108085", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "460807a3-82eb-4b47-a45b-940c6aad46cf", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7e068f13c7163c21647a928110c305390f79ce41e7944790dec6a6a5c45e0781", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 10.8.  Appendix 8: Suggested Visit Structure\n\nAbbreviations: AEs = adverse events; ECG = electrocardiogram; OGTT = 2\u2011hour oral glucose tolerance test; PK = pharmacokinetics; PRO = patient\u2011reported outcomes; SOA = schedule of activities.\n\nLY3298176    106", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 295, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "adbdc4e1-9064-4883-9c8a-cba21692ebfd": {"__data__": {"id_": "adbdc4e1-9064-4883-9c8a-cba21692ebfd", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6cc29c47-5332-4726-beec-96dafa0a46be", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "48e9a2ba1a141d608e637f23fa1bb4186098f4721a707ecdf61ab1c1f758feac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 10.9. Appendix 9: Management of Gastrointestinal Symptoms\n\nAbbreviations: GI = gastrointestinal; IWRS = interactive web\u2011response system.\n\nLY3298176                                                                    107", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 259, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3431e5eb-23cd-46b1-b13f-565a5671ef63": {"__data__": {"id_": "3431e5eb-23cd-46b1-b13f-565a5671ef63", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ee453ded-3922-4b8b-b082-9a164373ed61", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "10f61ffc354708c635998eebb2e3ccebbb311f917fc9fb09d0d8c75cce12dee5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 10.10. Appendix 10: Abbreviations\n\n| Term       | Definition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n| ---------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| ADA        | antidrug antibodies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| AE         | adverse event: Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. |\n| AESI       | adverse events (AEs) of special interest                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| ALP        | alkaline phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| ALT        | alanine aminotransferase                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| AST        | aspartate aminotransferase                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n| BG         | blood glucose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| BMI        | body mass index                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| BMR        | basal metabolic rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| BP         | blood pressure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |\n| CHF        | congestive heart failure                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| complaint  | A complaint is any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, purity, durability, reliability, safety or effectiveness, or performance of a drug or drug delivery system.                                                                                                                                                                                                                                                               |\n| compliance | Adherence to all study\u2011related, good clinical practice (GCP), and applicable regulatory requirements.                                                                                                                                                                                                                                                                                                                                                                                               |\n| CONSORT    | Consolidated Standards of Reporting Trials                                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n| CRF        | case report form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n| CRP        | clinical research physician: Individual responsible for the medical conduct of the study. Responsibilities of the CRP may be performed by a physician, clinical research scientist, global safety physician or other medical officer.                                                                                                                                                                                                                                                               |\n| CSR        | Clinical Study Report                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| C-SSRS     | Columbia\u2011Suicide Severity Rating Scale                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| CT         | computed tomography                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| DMC        | data monitoring committee                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |\n| LY3298176  | 108                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 11598, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "53b276da-1071-4669-94e0-20722cb94c74": {"__data__": {"id_": "53b276da-1071-4669-94e0-20722cb94c74", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2613e220-cf71-42e7-bceb-47782bce63a2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fcb10196f8dcf1cb32ddec08430edaa2294c8978fe5ea3ce820c5f2c75a25fd3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Abbreviations\n\n| DPP-4             | dipeptidyl\u2011peptidase\u20114                                                                                                                   |\n| ----------------- | ---------------------------------------------------------------------------------------------------------------------------------------- |\n| EAS               | efficacy analysis set                                                                                                                    |\n| ECG               | electrocardiogram                                                                                                                        |\n| ED                | early discontinuation of treatment                                                                                                       |\n| EDC               | electronic data capture                                                                                                                  |\n| eCRF              | electronic case report form                                                                                                              |\n| eGFR              | estimated glomerular filtration rate                                                                                                     |\n| enroll            | The act of assigning a patient to a treatment. Patients who are enrolled in the study are those who have been assigned to a treatment.   |\n| enter             | Patients entered into a study are those who sign the informed consent form directly or through their legally acceptable representatives. |\n| ERB               | ethical review board                                                                                                                     |\n| FAS               | full analysis set                                                                                                                        |\n| FG                | fasting glucose                                                                                                                          |\n| FSH               | follicle\u2011stimulating hormone                                                                                                             |\n| GCP               | good clinical practice                                                                                                                   |\n| GI                | gastrointestinal                                                                                                                         |\n| GIP               | glucose\u2011dependent insulinotropic polypeptide                                                                                             |\n| GIPR              | glucose\u2011dependent insulinotropic polypeptide receptor                                                                                    |\n| GLP-1             | glucagon\u2011like peptide\u20111                                                                                                                  |\n| GLP-1R            | glucagon\u2011like peptide\u20111 receptor                                                                                                         |\n| GPGA              | Study I8F\u2011MC\u2011GPGA                                                                                                                        |\n| GPGB              | Study I8F\u2011MC\u2011GPGB                                                                                                                        |\n| GPGF              | Study I8F\u2011MC\u2011GPGF                                                                                                                        |\n| GPHK (SURMOUNT-1) | Study I8F\u2011MC\u2011GPHK                                                                                                                        |\n| HbA1c             | hemoglobin A1c                                                                                                                           |\n| HDL               | high\u2011density lipoprotein                                                                                                                 |\n| HR                | heart rate                                                                                                                               |\n| LY3298176         | 109                                                                                                                                      |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4563, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d8d79ac3-29c4-440c-9543-8b2a1494d6b4": {"__data__": {"id_": "d8d79ac3-29c4-440c-9543-8b2a1494d6b4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9463c141-aded-4652-ab3c-c4990daa2923", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "240aaa6af9cf277d43ee7a15fa889d951809523870ebb1e42762875ff4c81245", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Glossary of Terms\n\n| **HRT**              | hormonal replacement therapy                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| -------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| **IB**               | Investigator\u2019s Brochure                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| **ICF**              | informed consent form                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| **ICH**              | The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use                                                                                                                                                                                                                                                                                                                                                                   |\n| **Informed consent** | A process by which a patient voluntarily confirms his or her willingness to participate in a particular study, after having been informed of all aspects of the study that are relevant to the patient\u2019s decision to participate. Informed consent is documented by means of a written, signed, and dated informed consent form.                                                                                                                                          |\n| **interim analysis** | An interim analysis is an analysis of clinical study data, separated into treatment groups, that is conducted before the final reporting database is created/locked.                                                                                                                                                                                                                                                                                                      |\n| **INR**              | international normalized ratio                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| **IP**               | investigational product: A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including products already on the market when used or assembled (formulated or packaged) in a way different from the authorized form, or marketed products used for an unauthorized indication, or marketed products used to gain further information about the authorized form.                                               |\n| **IRB/IEC**          | Institutional Review Boards/Independent Ethics Committees                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| **ITT**              | intention to treat: The principle that asserts that the effect of a treatment policy can be best assessed by evaluating on the basis of the intention to treat a patient (that is, the planned treatment regimen) rather than the actual treatment given. It has the consequence that patients allocated to a treatment group should be followed up, assessed, and analyzed as members of that group irrespective of their compliance to the planned course of treatment. |\n| **IWQOL-Lite-CT**    | Impact of Weight on Quality of Life\u2011Lite\u2011Clinical trials                                                                                                                                                                                                                                                                                                                                                                                                                  |\n| **IWRS**             | interactive voice\u2011response system/interactive web\u2011response system                                                                                                                                                                                                                                                                                                                                                                                                         |\n| **LDL**              | low\u2011density lipoprotein                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| **Lilly**            | Eli Lilly and Company                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| **MAD**              | multiple ascending dose                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| **MDD**              | Major Depressive Disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| **MedDRA**           | Medical Dictionary for Regulatory Activities                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| **MEN**              | multiple endocrine neoplasia                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| **MHP**              | mental health professional                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| **MI**               | myocardial infarction                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| **LY3298176**        | 110                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 10729, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "210f8336-be58-4c71-b23d-281f0f821e19": {"__data__": {"id_": "210f8336-be58-4c71-b23d-281f0f821e19", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "85ddc4ac-7e21-4bdd-82f1-a26b6bf446b9", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1eb95be3eb9389348ef01d790ad933871055e0c31d36682ef7b4fd2caf093172", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\nmITT\nmodified intention\u2011to\u2011treat\n\nMMRM\nmixed\u2011model for repeated measures\n\nMRI\nmagnetic resonance imaging\n\nMTC\nmedullary thyroid carcinoma\n\nNYHA\nNew York Heart Association\n\nOGTT\noral glucose tolerance test\n\nPC\nProduct Complaints\n\nPGIS\nPatient Global Impression of status for physical activity\n\nPHQ-9\nPatient Health Questionnaire\u20119\n\nPK/PD\npharmacokinetics/pharmacodynamics\n\nPROs/ePRO\npatient\u2011reported outcomes\n\nQW\nonce weekly\n\nSAD\nsingle ascending dose\n\nSAE\nserious adverse event\n\nSAP\nStatistical Analysis Plan\n\nSBP\nsystolic blood pressure\n\nSC\nsubcutaneous\n\nscreen\nThe act of determining if an individual meets minimum requirements to become part of a pool of potential candidates for participation in a clinical study.\n\nSD\nstandard deviation\n\nSF-36v2\nShort\u2011Form\u201136 Health Survey (SF\u201136), version 2\n\nSMQ\nstandardized MedDRA queries\n\nSS\nsafety analysis set\n\nSUSARs\nsuspected unexpected serious adverse reactions\n\nT1DM\ntype 1 diabetes mellitus\n\nT2DM\ntype 2 diabetes mellitus\n\nTBL\ntotal bilirubin level\n\nLY3298176\n111", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1051, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "40b43e3c-8c3e-46ce-98a0-d8c4dfeb99e8": {"__data__": {"id_": "40b43e3c-8c3e-46ce-98a0-d8c4dfeb99e8", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7f635757-632d-4748-86ce-ae7609268a31", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "917a7bd88a7b7015eb5baaac0212c2eee4e0cf4d43863ea68fd81a1b1beca05b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# Abbreviations\n\nTE       treatment emergent\n\nTEAE     treatment\u2011emergent adverse event: An untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment.\n\nTEE      total energy exposure\n\nTSH      thyroid\u2011stimulating hormone\n\nULN      upper limit of normal\n\nLY3298176    112", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 487, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "76059695-a6fc-4d4e-8072-277af3e8f49a": {"__data__": {"id_": "76059695-a6fc-4d4e-8072-277af3e8f49a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3edbb0c7-985b-41ed-869c-70d6a3ad1753", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8a2edf90c1c397366a9f8934916fbdfdf80b62ff6b621d80cfc444a0da8e3bc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bae01e0-c5c7-4af5-8538-1efedf85fbea", "node_type": "1", "metadata": {}, "hash": "55c62c39b99589fa200c2d0a2e8e1721ea001c326615132c7822a600e046b594", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK\n\n# 11. References\n\nAdams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, Gutierrez JM, Frogley SJ, Ibele AR, Brinton EA, Hopkins PN, McKinlay RM., Simper SC, Hunt SC. Weight and metabolic outcomes 12 years after gastric bypass. N Eng J Med. 2017;377(12):1143\u20111155.\n\nAllison DB, Downey M, Atkinson RL, Billington CJ, Bray GA, Eckel RH, Finkelstein EA, Jensen MD, Tremblay A. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of The Obesity Society. Obesity (Silver Spring). 2008;16(6):1161\u20111177.\n\nAmerican Diabetes Association. In Standards of Medical Care in Diabetes\u20112019. Glycemic Targets: Standards of Medical Care in Diabetes\u20112019. Diabetes Care. 2019a;42(suppl 1):S61\u2011S70.\n\nAmerican Diabetes Association. In Standards of Medical Care in Diabetes\u20112019. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes\u20112019. Diabetes Care 2019b; 42(suppl 1): S 13\u2011S28.\n\n[AMA] American Medical Association. American Medical Association House of Delegates Resolution: 420 (A\u201113) Recognition of Obesity as a Disease, 2013 pp 1\u20117. Available at: https://www.npr.org/documents/2013/jun/ama\u2011resolution\u2011obesity.pdf Accessed August 30, 2019.\n\nAroda VR, Ratner R. The safety and tolerability of GLP\u20111 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev. 2011;27(6):528\u2011542.\n\nBaggio LL, Drucker DJ. Biology of incretins: GLP\u20111 and GIP. Gastroenterol. 2007;132(6):2131\u20112157.\n\nBanks PA, Freeman ML; Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379\u20112400.\n\nCoskun T, Sloop KW, Loghin C, Alsina\u2011Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D\u2019Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP\u20111 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201114.\n\nCouncil on Science and Public Health. Report of the Council on Science and Public Health. Is obesity a disease? (Resolution 115\u2011A\u201112). Council on Science and Public Health. Report number: 3\u2011A\u201113, 2013.\n\nDanne T, Philotheou A, Goldman D, Guo X, Ping L, Cali A, Johnston P. A randomized trial comparing the rate of hypoglycemia \u2013 assessed using continuous glucose monitoring \u2013 in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Pediatr Diabetes. 2013;14(8):593\u2011601.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2572, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8bae01e0-c5c7-4af5-8538-1efedf85fbea": {"__data__": {"id_": "8bae01e0-c5c7-4af5-8538-1efedf85fbea", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3edbb0c7-985b-41ed-869c-70d6a3ad1753", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8a2edf90c1c397366a9f8934916fbdfdf80b62ff6b621d80cfc444a0da8e3bc5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76059695-a6fc-4d4e-8072-277af3e8f49a", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "eb3406c6ab767861d789be4129604a2273f6f5756be718ea23c4846b9bd78dfd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Is obesity a disease? (Resolution 115\u2011A\u201112). Council on Science and Public Health. Report number: 3\u2011A\u201113, 2013.\n\nDanne T, Philotheou A, Goldman D, Guo X, Ping L, Cali A, Johnston P. A randomized trial comparing the rate of hypoglycemia \u2013 assessed using continuous glucose monitoring \u2013 in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Pediatr Diabetes. 2013;14(8):593\u2011601. Erratum in: Pediatr Diabetes. 2015;16(6):462.\n\nDolan P. Modeling valuations for EuroQol Health States. Medical Care 1997; 35(11):1095\u20111108.\n\nLY3298176    113", "mimetype": "text/plain", "start_char_idx": 2135, "end_char_idx": 2730, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f7013c54-fa38-4b3e-a6cc-49636cf0db86": {"__data__": {"id_": "f7013c54-fa38-4b3e-a6cc-49636cf0db86", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b41b90f1-0078-4a2b-ae30-5306949207b3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8c930c21c4a6d82039f3d09615e6ccd7e8fab5e592898aafd746ad8d35f38a55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d923e09a-d584-4103-b147-fa829a5beea0", "node_type": "1", "metadata": {}, "hash": "6ff34b70c94b352c6ff66ff2fd69c57c14f354077648db311169d1d641b8d98e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK\n\nDombrowski SU, Knittle K, Avenell A, Ara\u00fajo\u2011Soares V, Sniehotta FF. Long term maintenance of weight loss with non\u2011surgical interventions in obese adults: systematic review and meta\u2011analyses of randomized controlled trials. BMJ. 2014;348:g2646.\n\n[EMA] European Medicines Agency. Guideline on clinical evaluation of medicinal products used in weight management. Committee for Medicinal Products for Human Use. June 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500209942.pdf Accessed November 19, 2018.\n\nEuroQoL Group. EQ\u20115D\u20115L User guide: basic information on how to use the EQ\u20115D\u20115L instrument. Version 2.1. Available at: https://euroqol.org/wp\u2011content/uploads/2016/09/EQ\u20115D\u20115L_UserGuide_2015.pdf. Published April 2015. Accessed January 22, 2019.\n\nFAO/WHO/UNU. Human energy requirements. Report of a joint FAO/WHO/UNU expert, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WHH, Temelkova\u2011Kurktschiev T, for the REWIMND consultation. FAO: food and nutrition technical report series 1. Rome: FAO/WHO/UNU; 2004.\n\n[FDA] Food and Drug Administration. Guidance for Industry. Developing products for weight management. February 2007. Available at: https://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf. Accessed November 19, 2018.\n\nFrias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A. Efficacy and safety of LY3298176, a novel dual GIP and GLP\u20111 receptor agonist, in patients with type 2 diabetes: a randomised, placebo\u2011controlled and active comparator\u2011controlled phase 2 trial. Lancet. 2018;392(10160):2180\u20112193.\n\nGerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Pobstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao\u2011Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez\u2011Jaramillo P, Munoz EGC, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH\u2011H, Temelkova\u2011Kurktschiev T, for the REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double\u2011blind, randomized placebo\u2011controlled trial. Lancet 2019;394(10193):121\u2011130.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2249, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d923e09a-d584-4103-b147-fa829a5beea0": {"__data__": {"id_": "d923e09a-d584-4103-b147-fa829a5beea0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b41b90f1-0078-4a2b-ae30-5306949207b3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8c930c21c4a6d82039f3d09615e6ccd7e8fab5e592898aafd746ad8d35f38a55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7013c54-fa38-4b3e-a6cc-49636cf0db86", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6c3c6f6bf452df20d3c547ab09f1cd1fa64bcd857cf022bc6d5051a2fc158f74", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double\u2011blind, randomized placebo\u2011controlled trial. Lancet 2019;394(10193):121\u2011130.\n\nJensen MD, Ryan DH, Donato KA, Aprovian, CM, Arrd, JD, Comuzzie AG, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi\u2011Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Uanovski SZ. Executive summary: guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the Obesity Expert Panel, 2013. Obesity. 2014;22:(suppl 2):S5\u2011S39.\n\nKnowler WC, Barrett\u2011Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2011403.\n\nLY3298176 114", "mimetype": "text/plain", "start_char_idx": 2096, "end_char_idx": 3187, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "00296e25-99e4-433f-a9aa-93b6f39c2202": {"__data__": {"id_": "00296e25-99e4-433f-a9aa-93b6f39c2202", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c3d5e15b-3a2a-46db-8d47-33cb20f2779b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2f0025aa31aad5d11e8908ac2b70d92ab062f0447883dfe073f3443a0b18c78a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6611225f-f0b9-4364-bc02-73fad8398a8c", "node_type": "1", "metadata": {}, "hash": "b153d25ff81c4b579f04f2ef8bf9fe2a40af0501b8945cd632964d6d94088008", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                      Protocol I8F\u2011MC\u2011GPHK\n\nKoizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, Kimura Y, Takeda K, Isaji S, Otsuki M, Matsuno S; JPN. JPN Guidelines for the management of acute pancreatitis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg. 2006;13(1):25\u201132.\n\nKolotkin RL, Ervin CM, Meincke HH, Hojbjerre L, Fehnel SE. Development of a clinical trials version of the Impact of Weight on Quality of Life\u2011Lite questionnaire (IWQoL\u2011Lite Clinicial Trials Version): results from two qualitative studies. Clin Obes. 2017;7(5):290\u2011299.\n\nKolotkin RL, Williams V, Ervin, CM, Meincke HH, Qin S, Smith LvH, Fehnel SE. Validation of a new measure of quality of life in obesity trials: IWQOL \u2013 Lite Clinical Trials Version. Poster presented at: Obesity Week 2018; November 13, 2018; Nashville, TN.\n\nKroenke K, Spitzer RL, Williams JB. The PHQ\u20119: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u2011616.\n\nle Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjoth TV, Manning LS, Pi\u2011Sunyer X for the SCALE Obesity Prediabetes NN8022\u20111839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomized, double\u2011blind trial. Lancet. 2017;389(10077):1399\u20111409.\n\nLi G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, Yang W, Zhang B, Shuai Y, Hong J, Engelgau MM, Li H, Roglic G, Hu Y, Bennett PH. Cardiovascular mortality, all\u2011cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23\u2011year follow\u2011up study. Lancet Diabetes Endocrinol. 2014;2(6):474\u2011480.\n\nLuppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: a systematic review and meta\u2011analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220\u2011229.\n\nMarso SP, Daniels GH, Brown\u2011Frandsen K, Kirstensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Tavn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. For the LEADER Steering Committee. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016a; 375:311\u2011322.\n\nMarso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren M, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T, for the SUSTAIN\u20116 Investigators.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2534, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6611225f-f0b9-4364-bc02-73fad8398a8c": {"__data__": {"id_": "6611225f-f0b9-4364-bc02-73fad8398a8c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c3d5e15b-3a2a-46db-8d47-33cb20f2779b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2f0025aa31aad5d11e8908ac2b70d92ab062f0447883dfe073f3443a0b18c78a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00296e25-99e4-433f-a9aa-93b6f39c2202", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "5e30f22ff8d58c2a011a01e6f5c92b8d3de272028a57a58e081b1fc66914b884", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "For the LEADER Steering Committee. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016a; 375:311\u2011322.\n\nMarso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren M, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T, for the SUSTAIN\u20116 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016b; 375:1834\u20111844.\n\nMaruish ME, ed. User\u2019s manual for the SF\u201136v2 Health Survey. 3rd ed. Lincoln, RI: Quality Metric Incorporated; 2011.\n\nMertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8(3):270\u2011278.\n\nNauck MA, Meier JJ, Schmidt WE. Incretin\u2011based glucose\u2011lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio\u2011vascular outcome trials. Diabetes Obes Metab. 2017;19(9):1327\u20111328.\n\nLY3298176    115", "mimetype": "text/plain", "start_char_idx": 2207, "end_char_idx": 3149, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "537d976f-2b01-4126-b980-62762e2c4fd3": {"__data__": {"id_": "537d976f-2b01-4126-b980-62762e2c4fd3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0a1e5bb8-c01b-4f34-8b5b-9227b342f2a2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0a418094eba973267aa15f9e4e17f143b4950db96eb9516b23d5bc8371f1278e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                          Protocol I8F\u2011MC\u2011GPHK\n\nSAXENDA\u00ae [EMA summary of product characteristics (SmPC)]. Novo Nordisk, Bagsvaerd, Denmark. Available at: https://ec.europa.eu/health/documents/community-register/2015/20150323131125/anx_131125_en.pdf. Accessed April 10, 2019.\n\nSAXENDA\u00ae [package insert] Novo Nordisk, Bagsvaerd, Denmark. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf. Accessed March 2, 2019.\n\nSkow MA, Bergmann, NC, Knop FK. Diabetes and obesity treatment based on dual incretin receptor activation: \u201ctwincretins\u201d. Diabetes Obes Metab. 2016;18(9):847\u2011854.\n\nSteinberg WM, Buse JB, Ghorbani MLM, \u00d8rsted DD, Nauck MA; LEADER Steering Committee; LEADER Trial Investigators. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER Randomized Trial. Diabetes Care. 2017a;40(7):966\u2011972.\n\nSteinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program. Diabetes Care. 2017b;40(7):839\u2011848.\n\nTomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. An overview of new GLP\u20111 receptor agonists for type 2 diabetes. Expert Opin Investig Drugs. 2016;25(2):145\u2011158.\n\nvan Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon\u2011like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221(1):T1\u2011T16.\n\nWarkentin LM, Das D, Majumdar SR, Johnson JA, Padwal RS. The effect of weight loss on health\u2011related quality of life: systematic review and meta\u2011analysis of randomized trials. Obes Rev. 2014;15(3):169\u2011182.\n\nWeinberg ME, Bacchetti P, Rushakoff RJ. Frequently repeated glucose measurements overestimate the incidence of inpatient hypoglycemia and severe hyperglycemia. J Diabetes Sci Technol. 2010;4(3):577\u2011582.\n\nLY3298176    116", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 2058, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ce8f9408-c81e-4dfd-be19-de7c64083a02": {"__data__": {"id_": "ce8f9408-c81e-4dfd-be19-de7c64083a02", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3b38f7eb-e40d-41ed-bbaf-f5fc2929d3d5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "4db345babb3c55cde243078478d4fdef60703a7ce26dffa15c1bb7ffa28f4157", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Leo Document ID = 99a89d7e-3883-4654-aae4-4490a2c0ceac\n\nApprover: PPD\n\nApproval Date &#x26; Time: 09-Sep-2019 13:58:42 GMT\n\nSignature meaning: Approved\n\nApprover: PPD\n\nApproval Date &#x26; Time: 09-Sep-2019 14:09:12 GMT\n\nSignature meaning: Approved", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 250, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0bcd0e6b-eb31-4b7f-9b9e-e388402b6ddd": {"__data__": {"id_": "0bcd0e6b-eb31-4b7f-9b9e-e388402b6ddd", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2d2acc2a-0840-4616-9ecb-f2ed5605f2d7", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "eccfef7630ae640c11eb508b6f54297886eaee72dd94e69204b3a00cfa149bc6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Title Page\n\n# Confidential Information\n\nThe information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of tirzepatide (LY3298176), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries.\n\nNote to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.\n\n# Protocol Title\n\nEfficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight\u2011Related Comorbidities: A Randomized, Double\u2011Blind, Placebo\u2011Controlled Trial (SURMOUNT\u20111)\n\n# Protocol Number\n\nI8F-MC-GPHK(b)\n\n# Compound Number\n\nLY3298176\n\n# Study Phase\n\nPhase 3\n\n# Short Title\n\nEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who are either Obese or Overweight with Weight\u2011Related Comorbidities (SURMOUNT\u20111)\n\n# Acronym\n\nSURMOUNT\u20111\n\n# Sponsor Name\n\nEli Lilly and Company\n\n# Legal Registered Address\n\nIndianapolis, Indiana, USA 46285\n\n# Regulatory Agency Identifier Number(s)\n\nIND: 139721\n\n# Approval Date\n\nProtocol Amendment (b) Electronically Signed and Approved by Lilly on date provided below.\n\n# Approval Date\n\n04-Oct-2021 GMT\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 1819, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b5f2d3f7-7c51-47f1-8358-4e58bcab9d1a": {"__data__": {"id_": "b5f2d3f7-7c51-47f1-8358-4e58bcab9d1a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d7058f0d-1005-41c1-a902-b46c2e7be85b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a5f0c499cc513e474e9177741966e09efc01d4858ff19a901bb0cd291e4e8260", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                               Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Protocol Amendment Summary of Changes Table\n\n# DOCUMENT HISTORY\n\n| Document          | Date        |\n| ----------------- | ----------- |\n| Amendment (a)     | 24\u2011Jul\u20112020 |\n| Original Protocol | 09\u2011Sep\u20112019 |\n\n# Overall Rationale for Amendment (b):\n\nThe overall rationale for the current GPHK protocol amendment is to update the key study objectives and endpoints in Section 3; clarify the definition of incident diabetes, add guidance for retesting, confirmation, recording, and adjudication of incident diabetes in Section 4.1.2.3; add guidance in Sections 6.6.1 and 6.6.3 for study drug dose modification during the additional 2\u2011year treatment period in participants with perceived excessive weight loss; and to update information relevant to statistical analyses in Section 9 to align with recent updates to the SAP. These and other changes are listed in the below table.\n\n| Section # and Name | Description of Change                                                                                                                                                           | Brief Rationale                                                                                                                                                                                                |\n| ------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| 1.1. Synopsis      | Key secondary objective at 20 weeks was modified, changing heading from \u201cby dose\u201d to \u201cpooled dose\u201d analysis, and editing objective to reflect the pooled 10 mg and 15 mg doses. | Analysis of pooled data from participants on different tirzepatide doses is more appropriate as participants randomized to the 15\u2011mg dose of tirzepatide will not be exposed to that dose until after Week 20. |\n| 1.1. Synopsis      | Key secondary objective at 72 weeks, by dose analysis, was modified: For the body weight objective, added the endpoint \u201c\u226520% body weight reduction from randomization\u201d.         | To better inform clinical decisions in management of people living with obesity.                                                                                                                               |\n|                    | Deleted the objective and associated endpoint for SF\u201136v2 acute form Physical Functioning domain score for 10 mg and 15 mg separately.                                          | Objective and associated endpoint were moved to Key secondary at 72 weeks, pooled dose analysis.                                                                                                               |\n\nLY3298176    2", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3013, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bbd1585b-68e0-4f41-bf79-aeb7fe52505c": {"__data__": {"id_": "bbd1585b-68e0-4f41-bf79-aeb7fe52505c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "df452501-dee4-47cb-bf1c-85867286d2a5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d491179728c2a9fbf4cbc4fc4fd103cd2ad17093f3ef52a011e365e45f8365d3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Section # and Name\n\n# Description of Change\n\n# Brief Rationale\n\n| 1.1. Synopsis                                                                                                             | Revised key secondary objective at 72 weeks from \u201cby dose\u201d to \u201cpooled dose\u201d analysis to demonstrate that the pooled 10 mg and 15 mg QW tirzepatide is superior to placebo for SF\u201136v2 acute form Physical Functioning domain score.                                                     | To reduce the number of key secondary objectives.                                                                                                                  |\n| ------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------ |\n| 1.1. Synopsis                                                                                                             | In the key secondary objective at 72 weeks, pooled dose analysis for tirzepatide (all doses combined) to demonstrate superiority to placebo for lipid parameters, the endpoint was modified to replace \u201cLDL\u201d with \u201cnon\u2011HDL cholesterol\u201d, and to replace \u201ctotal\u201d with \u201cHDL\u201d cholesterol. | Emerging science indicates assessing HDL\u2011cholesterol in addition to non\u2011HDL cholesterol should provide more valuable data on CVD risk in this specific population. |\n| 1.1. Synopsis                                                                                                             | Additional secondary objective at 72 weeks, pooled dose analysis, the endpoint associated with lipid parameters was modified to replace \u201cHDL\u201d with \u201cLDL\u201d cholesterol, and to add \u201ctotal cholesterol\u201d.                                                                                   | For consistency and to reflect the changes to the key secondary objectives.                                                                                        |\n| 4.1.1.2.3. Additional 2\u2011Year Treatment Period for Participants with Prediabetes at Randomization (Visits 101 through 116) | Added wording \u201cunless diabetes had been diagnosed prior to the visits\u201d.                                                                                                                                                                                                                 | For clarity.                                                                                                                                                       |\n| 4.1.2.2. Oral Glucose Tolerance Test                                                                                      | Added wording regarding use of OGTT for confirming diagnosis of diabetes.                                                                                                                                                                                                               | For clarity and consistency with new text related to confirmation of diabetes diagnosis in Section 4.1.2.3.                                                        |\n| 4.1.2.3. Definition and Management of Incident Diabetes                                                                   | Revised definition of incident diabetes and added subsections containing clarifying information related to \u201cConfirmation of diabetes diagnosis\u201d and \u201cRecording of incident diabetes events\u201d.                                                                                            | Definition of incident diabetes was revised to clarify the criteria regarding the requirement for 2 abnormal test results to confirm the diagnosis.                |\n\nLY3298176 3", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4128, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9a485bb7-e5e0-4ad9-9416-c42737a8dfc8": {"__data__": {"id_": "9a485bb7-e5e0-4ad9-9416-c42737a8dfc8", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1683fc9a-2286-462f-9476-593909d379d8", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9823ef5dcd109152193fe6b0d191a1dd58284538424dcbe5d39d4d84406fefed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n| Section # and Name                                                                                                                                                      | Description of Change                                                                                                                                                                                           | Brief Rationale                                                                                                                                                                                                 |\n| ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| 6.6.1. Tirzepatide                                                                                                                                                      | Added sentence allowing dose modification for management of participants with perceived excessive weight loss during the additional 2\u2011year treatment period for participants with prediabetes at randomization. | To support patient management and retention in the additional 2\u2011year treatment period.                                                                                                                          |\n| 6.6.3. Management of Participants with Perceived Excessive Weight Loss During the Additional 2\u2011year Treatment Period for Participants with Prediabetes at Randomization | Added this subsection containing information for managing participants with perceived excessive weight loss during the additional 2\u2011year treatment period for participants with prediabetes at randomization.   | Provide clear, detailed information for managing and retaining participants in the additional 2\u2011year treatment period.                                                                                          |\n| 7.2. Participant Discontinuation/Withdrawal from the Study                                                                                                              | Added bullet point \u201cFemale participants will be withdrawn from the study if the participant becomes pregnant.\u201d                                                                                                  | For clarity in participant management.                                                                                                                                                                          |\n| 9.1. Statistical Hypotheses                                                                                                                                             | Updated to reflect the changes specified in the key secondary objectives and endpoints in Section 3.                                                                                                            | For consistency.                                                                                                                                                                                                |\n| 9.4.3.1. Primary Analyses                                                                                                                                               | Updated information on estimands and related analyses.                                                                                                                                                          | To address and align with FDA feedback.                                                                                                                                                                         |\n| 9.4.3.2. Key Secondary Analyses                                                                                                                                         | Updated to reflect the changes specified in the key objectives and endpoints in Section 3.                                                                                                                      | For consistency.                                                                                                                                                                                                |\n| 9.4.4.4.2. Events Related to Potential Abuse Liability                                                                                                                  | Updated to replace current information with \u201cTo identify AE terms suggestive of potential abuse liability, narrow terms from SMQ of Drug abuse and dependence (20000101) will be used.\u201d                         | Based on mechanism of action of tirzepatide, anticipated gastrointestinal adverse events, and low likelihood for abuse potential/psychoactive effects, it is reasonable to narrow the list of abuse terms used. |\n| 10.1.4. Committee Structure                                                                                                                                             | Added wording pertaining to adjudication of incident diabetes events and cross\u2011reference to related details in Section 4.1.2.3.                                                                                 | For clarity and consistency.                                                                                                                                                                                    |\n\nLY3298176 4", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 5973, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d4a57fba-858b-4498-8d5d-4d50dff123c7": {"__data__": {"id_": "d4a57fba-858b-4498-8d5d-4d50dff123c7", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7de4552b-db33-4db6-afaa-79864b7b2384", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "044c26536f19444323e73934d103d6f84edd2d2c0c26dee336479a16862d4636", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n| Section # and Name                                                                                                                                                                 | Description of Change                                                                                                                                                                                                                                        | Brief Rationale                                                      |\n| ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | -------------------------------------------------------------------- |\n| 10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information                                                                                                   | In subsection for \u201cFemale Participants who become pregnant\u201d, modified final sentence to indicate that if a study participant becomes pregnant, the participant will discontinue study intervention \u201cand\u201d will be withdrawn from the study.                   | For clarity and to align with other changes in protocol Section 7.2. |\n| 10.7. Appendix 7: Protocol GPHK Standardized Protocols for the Measurement of Height, Weight, Waist Circumference, Vital Signs, Electrocardiogram, and Oral Glucose Tolerance Test | Added note in the text stating that placement of a venous cannula may not be required when a 2\u2011hour OGTT is repeated to confirm the diagnosis of diabetes during the study, and only samples at 0 and 120 minutes for glucose measurement will be collected. | For clarity and to align with changes in Section 4.1.2.2.            |\n| Throughout                                                                                                                                                                         | Used the term \u201cadditional 2\u2011year treatment period for participants with prediabetes at randomization\u201d to replace similar but inconsistently used terms when referring to the study period following primary outcome at Visit 21 (Week 72).                   | For clarity and consistency.                                         |\n| Throughout                                                                                                                                                                         | Minor, editorial and document formatting revisions.                                                                                                                                                                                                          | Minor, therefore have not been summarized.                           |\n\nLY3298176 5", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3107, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ab8098dc-a83d-4812-be9e-7f43a6d7aec5": {"__data__": {"id_": "ab8098dc-a83d-4812-be9e-7f43a6d7aec5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cf8d35d4-4706-4368-9f93-6def7dab9980", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "262ec064c21aa6147fe9b2bf60a3588932cbfdff41600165b735520849aacdf4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Table of Contents\n\n1. Protocol Summary\n- Synopsis\n- Schema\n- Schedule of Activities\n- Schedule of Activities covering visits to primary study endpoint\n- Schedule of Activities for additional 2\u2011year treatment period for participants with prediabetes at randomization\n2. Introduction\n- Study Rationale\n- Background\n- Benefit/Risk Assessment\n3. Objectives and Endpoints\n4. Study Design\n- Overall Design\n- Overview of Study Periods\n- Study Procedures\n- Scientific Rationale for Study Design\n- Justification for Dose\n- End of Study Definition\n5. Study Population\n- Inclusion Criteria\n- Exclusion Criteria\n- Lifestyle Considerations\n- Meals and Dietary Restrictions\n- Physical Activity\n- Screen Failures\n6. Study Intervention\n- Study Interventions Administered\n- Medical Devices\n- Preparation/Handling/Storage/Accountability\n- Measures to Minimize Bias: Randomization and Blinding\n- Study Intervention Compliance\n- Concomitant Therapy\n- Dose Modification\n- Tirzepatide\n- Management of Participants with Gastrointestinal Symptoms\n- Management of Participants with Perceived Excessive Weight Loss During the Additional 2\u2011year Treatment Period for Participants with Prediabetes at Randomization\n- Intervention after the End of the Study\n- Treatment after Study Completion\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1317, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0113205c-6803-4fdb-9c03-8d499d191298": {"__data__": {"id_": "0113205c-6803-4fdb-9c03-8d499d191298", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "358e92cf-6cbf-46e9-94d9-1dd62d54dab1", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0d2be62bd39b5c9ced9c96f7a413e8e766a20d591e4594d904a164570e7e6c80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be1a0711-0880-4610-86cb-af312eeb6233", "node_type": "1", "metadata": {}, "hash": "59d19f7869991b7c9f9bfb35ac80b3c71fd83d854b94c043152b26f7386dfefb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 7. Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal</h7>\n61\n\n# 7.1. Discontinuation of Study Intervention</h7>\n61\n\n# 7.1.1. Temporary Study Drug Discontinuation</h7>\n63\n\n# 7.2. Participant Discontinuation/Withdrawal from the Study</h7>\n64\n\n# 7.2.1. Participant Disposition and Timing of Safety Follow\u2011up for the Primary Endpoint (72 Weeks)</h7>\n65\n\n# 7.2.2. Participant Disposition and Timing of Safety Follow\u2011up for those with Prediabetes at Randomization Continuing in Additional 2\u2011year Treatment Period</h7>\n66\n\n# 7.2.3. Discontinuation of Inadvertently Enrolled Participants</h7>\n67\n\n# 7.3. Lost to Follow\u2011up</h7>\n67\n\n# 8. Study Assessments and Procedures</h7>\n68\n\n# 8.1. Efficacy Assessments</h7>\n68\n\n# 8.1.1. Primary Efficacy Assessments</h7>\n68\n\n# 8.1.2. Secondary Efficacy Assessments</h7>\n68\n\n# 8.1.3. Patient\u2011Reported Outcomes Assessments</h7>\n68\n\n# 8.1.4. Short Form 36 version 2, acute, 1 week recall version</h7>\n69\n\n# 8.1.5. Impact of Weight on Quality of Life\u2011Lite Clinical Trials Version</h7>\n69\n\n# 8.1.6. EQ\u20115D\u20115L</h7>\n69\n\n# 8.1.7. Patient Global Impression of Status for Physical Activity</h7>\n70\n\n# 8.2. Safety Assessments</h7>\n70\n\n# 8.2.1. Physical Examinations</h7>\n70\n\n# 8.2.2. Vital Signs</h7>\n70\n\n# 8.2.3. Electrocardiograms</h7>\n70\n\n# 8.2.4. Clinical Safety Laboratory Assessments</h7>\n71\n\n# 8.2.5. Safety Monitoring</h7>\n72\n\n# 8.2.6. Depression, Suicidal Ideation, and Behavior Risk Monitoring</h7>\n72\n\n# 8.3. Adverse Events and Serious Adverse Events</h7>\n73\n\n# 8.3.1. Time Period and Frequency for Collecting AE and SAE Information</h7>\n75\n\n# 8.3.2. Follow\u2011up of AEs and SAEs</h7>\n75\n\n# 8.3.3. Regulatory Reporting Requirements for SAEs</h7>\n75\n\n# 8.3.4. Pregnancy</h7>\n76\n\n# 8.3.5. Medical Device Incidents (Including Malfunctions)</h7>\n76\n\n# 8.3.6. Complaint Handling</h7>\n77\n\n# 8.4. Treatment of Overdose</h7>\n77\n\n# 8.5. Pharmacokinetics</h7>\n78\n\n# 8.6. Pharmacodynamics</h7>\n78\n\n# 8.7. Genetics</h7>\n78\n\n# 8.7.1.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2017, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "be1a0711-0880-4610-86cb-af312eeb6233": {"__data__": {"id_": "be1a0711-0880-4610-86cb-af312eeb6233", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "358e92cf-6cbf-46e9-94d9-1dd62d54dab1", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0d2be62bd39b5c9ced9c96f7a413e8e766a20d591e4594d904a164570e7e6c80", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0113205c-6803-4fdb-9c03-8d499d191298", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0bf4e1f6a82e5e474f1563d9365bd0c56030177942d4e64d3886cfa243b24533", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pregnancy</h7>\n76\n\n# 8.3.5. Medical Device Incidents (Including Malfunctions)</h7>\n76\n\n# 8.3.6. Complaint Handling</h7>\n77\n\n# 8.4. Treatment of Overdose</h7>\n77\n\n# 8.5. Pharmacokinetics</h7>\n78\n\n# 8.6. Pharmacodynamics</h7>\n78\n\n# 8.7. Genetics</h7>\n78\n\n# 8.7.1. Whole Blood Sample(s) for Pharmacogenetic Research</h7>\n78\n\n# 8.8. Biomarkers</h7>\n79\n\n# 8.9. Health Economics</h7>\n79\n\n# 9. Statistical Considerations</h7>\n80\n\n# 9.1. Statistical Hypotheses</h7>\n80\n\nLY3298176 7", "mimetype": "text/plain", "start_char_idx": 1756, "end_char_idx": 2229, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2c826dba-e412-4b47-b863-47a1764dd3da": {"__data__": {"id_": "2c826dba-e412-4b47-b863-47a1764dd3da", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "255cff82-532f-46b0-8073-e321a2f14f82", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a2badd9d8520fac4d5e1cf5868b2f116b24e0f5f2f8051e3bf4de061dcf8cd9c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 9. Sample Size Determination\n\n# 9.3. Populations for Analyses\n\n# 9.4. Statistical Analyses\n\n# 9.4.1. General Statistical Considerations\n\n# 9.4.2. Treatment Group Comparability\n\n# 9.4.3. Efficacy Analyses\n\n# 9.4.4. Safety Analyses\n\n# 9.4.5. Pharmacokinetic/Pharmacodynamic Analyses\n\n# 9.4.6. Evaluation of Immunogenicity\n\n# 9.4.7. Other Analyses\n\n# 9.5. Interim Analyses\n\n# 10. Supporting Documentation and Operational Considerations\n\n# 10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations\n\n# 10.1.1. Regulatory and Ethical Considerations\n\n# 10.1.2. Informed Consent Process\n\n# 10.1.3. Data Protection\n\n# 10.1.4. Committees Structure\n\n# 10.1.5. Dissemination of Clinical Study Data\n\n# 10.1.6. Data Quality Assurance\n\n# 10.1.7. Data Capture System\n\n# 10.1.8. Source Documents\n\n# 10.1.9. Study and Site Closure\n\n# 10.1.10. Publication Policy\n\n# 10.2. Appendix 2: Clinical Laboratory Tests\n\n# 10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow\u2011Up, and Reporting\n\n# 10.3.1. Special Safety Topics\n\n# 10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information\n\n# 10.5. Appendix 5: Liver Safety: Suggested Actions and Follow\u2011Up Assessments\n\n# 10.6. Appendix 6: Medical Device Incidents: Definition and Procedures for Recording, Evaluating, Follow\u2011Up, and Reporting\n\n# 10.7. Appendix 7: Protocol GPHK Standardized Protocols for the Measurement of Height, Weight, Waist Circumference, Vital Signs, Electrocardiogram, and Oral Glucose Tolerance Test\n\n# 10.8. Appendix 8: Suggested Visit Structure\n\n# 10.9. Appendix 9: Management of Gastrointestinal Symptoms\n\n# 10.10. Appendix 10: Provisions for Changes in Study Conduct During Exceptional Circumstances\n\n# 10.11. Appendix 11: Abbreviations\n\n# 10.12. Appendix 12: Protocol Amendment History\n\n# 11. References\n\nLY3298176 8", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1888, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3d111f06-7bf8-4866-85a4-f23facab30e9": {"__data__": {"id_": "3d111f06-7bf8-4866-85a4-f23facab30e9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "679dfa8c-ab07-4e9d-9c8a-5595ebe0f0e7", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ccda4804eeaa3880ce57b652577dd047d682cc66b24684d4e200a05ff077785f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 1. Protocol Summary\n\n# 1.1. Synopsis\n\nProtocol Title:\n\nEfficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight\u2011Related Comorbidities: A Randomized, Double\u2011Blind, Placebo\u2011Controlled Trial (SURMOUNT\u20111)\n\nShort Title:\n\nEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who are either Obese or Overweight with Weight\u2011Related Comorbidities (SURMOUNT\u20111)\n\nRationale:\n\nObesity is a chronic disease and its increasing prevalence is a public health concern associated with the rising incidence of type 2 diabetes mellitus (T2DM), increased risk for premature death and increased risk for some cancers (Allison et al. 2008; AMA 2013; Council on Science and Public Health 2013). Although loss of 5% to 10% body weight has been shown to reduce complications related to obesity and improve quality of life (Mertens and Van Gaal 2000; Knowler et al. 2002; Jensen et al. 2014; Li et al. 2014; Warkentin et al. 2014), lifestyle therapies fail to achieve sustainable weight loss in the majority of patients with obesity (Dombrowski et al. 2014).\n\nThe gut incretin hormones, glucose\u2011dependent insulinotropic polypeptide (GIP) and glucagon\u2011like peptide\u20111 (GLP\u20111), are secreted after meal ingestion and mediate the incretin effect. Both hormones have effects on endocrine cells in the pancreas, increasing insulin biosynthesis and secretion, and modifying glucagon secretion (Skow et al. 2016). Based on these properties, several GLP\u20111 receptor (GLP\u20111R) agonists have been approved for pharmacological treatment of T2DM (Tomlinson et al. 2016).\n\nIn addition to its pancreatic effects, GLP\u20111R activation decreases gut motility, slows gastric emptying, and promotes satiety (presumably through a combination of GLP\u20111R activation in the central and peripheral nervous systems), thereby regulating food intake and body weight (Baggio and Drucker 2007). The US Food and Drug Administration and the European Medicines Agency approved the GLP\u20111R agonist liraglutide for the treatment of overweight and obesity (SAXENDA\u00ae package insert, 2014; SAXENDA\u00ae SmPc, 2015).\n\nPreclinical data indicate that GIP also exerts effects on appetite regulation and food intake, adipose tissue, and on peripheral energy metabolism. Although studies evaluating effects of GIP on body weight have yielded equivocal results, GIP receptor (GIPR) activation may play a role in body weight regulation and targeting both the GLP\u20111R and the GIPR simultaneously may result in additive or synergistic effects of the 2 incretins on body weight (Coskun et al. 2018).\n\nTirzepatide is a 39\u2011amino acid synthetic peptide dual GIP and GLP\u20111 receptor agonist. Its structure is based on the GIP sequence and includes a C20 fatty diacid moiety. It is administered once\u2011weekly (QW) by subcutaneous (SC) injection (Coskun et al. 2018).\n\nLY3298176                                                                                        9", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3015, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5a17299c-de3a-452f-b353-d35ebe6eb8d2": {"__data__": {"id_": "5a17299c-de3a-452f-b353-d35ebe6eb8d2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f4a80547-3a29-4741-97e7-acd81cd6079c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3a6d4aa9daabd04ff0c6d163247da388078212d00b24a14e2ab84e7162014694", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nAs a dual GIP/GLP\u20111R agonist, tirzepatide could exceed the efficacy of selective GLP\u20111R agonists by recruiting metabolically active tissues not targeted by selective GLP\u20111R agonists (for example, adipose tissue as indicated by the observation of increased energy utilization) (Baggio and Drucker 2007) and has the potential to reach higher efficacy in target tissues, such as insulin\u2011producing pancreatic beta cells that express both GIPR and GLP\u20111R, before reaching its therapeutic limitation.\n\nStudy I8F\u2011MC\u2011GPHK (GPHK; SURMOUNT\u20111) is a Phase 3, multicenter, randomized, placebo\u2011controlled, double\u2011blinded study of the safety and efficacy of 5\u2011mg, 10\u2011mg and 15\u2011mg tirzepatide QW, compared with placebo, when used in conjunction with a reduced\u2011calorie diet and increased physical activity for weight management, in participants who do not have T2DM, and have obesity (BMI \u226530 kg/m\u00b2) or are overweight (BMI \u226527 kg/m\u00b2) with at least one weight\u2011related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). All participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction. Participants who have prediabetes will be studied for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to detect potential differences in progression to T2DM.\n\nLY3298176    10", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1394, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ed1967ad-ec71-4ad9-90fc-bf7980c40f78": {"__data__": {"id_": "ed1967ad-ec71-4ad9-90fc-bf7980c40f78", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "42444b4f-24e2-4bfe-9bc9-9ad3a7b95e48", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3dc9f9d1f3d6260a12f9788582eebaad84686366de404d229d6b58fad9226476", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Objectives and Endpoints\n\n# Objectives\n\n# Primary\n\nTo demonstrate that tirzepatide 10 mg QW is superior to placebo for:\n\n- percent change in body weight AND\n- percentage of participants with \u22655% body weight reduction\n\nAND/OR\n\nTo demonstrate that tirzepatide 15 mg QW is superior to placebo for:\n\n- percent change in body weight AND\n- percentage of participants with \u22655% body weight reduction\n\n# Key secondary (controlled for Type I error)\n\n# at 20 weeks, pooled dose analysis\n\nFor pooled tirzepatide 10 mg and 15 mg QW doses, to demonstrate superiority to placebo for:\n\n- body weight\n\nmean change in body weight (kg) from randomization\n\n# Key secondary (controlled for Type I error)\n\n# at 72 weeks, by dose analysis\n\nTo demonstrate that tirzepatide 5 mg QW is superior to placebo for:\n\n- percent change in body weight AND\n- percentage of participants with \u22655% body weight reduction\n\nLY3298176    11", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 942, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "66d543d3-bcb5-4085-b49f-072bbc37a222": {"__data__": {"id_": "66d543d3-bcb5-4085-b49f-072bbc37a222", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3fedaa4d-dbb0-46da-9109-cbac88a63cd6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "86b61026d29cf14604ec58cf98df7acaf3c317ef6c9c57af6765766d5008ff12", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Objectives\n\nFor tirzepatide 10\u2011mg and/or 15\u2011mg QW doses, to demonstrate superiority to placebo for:\n\n- body weight\n- waist circumference\n\n# Endpoints\n\nPercentage of participants who achieve:\n\n- \u226510% body weight reduction from randomization\n- \u226515% body weight reduction from randomization\n- \u226520% body weight reduction from randomization\n\nMean change in waist circumference (cm) from randomization\n\n# Key secondary (controlled for Type I error) at 72 weeks, pooled dose analysis\n\nTo demonstrate that pooled tirzepatide 10 mg and 15 mg QW is superior to placebo for:\n\n- patient\u2011reported outcomes (SF\u201136v2 acute form Physical Functioning domain score)\n\n# Endpoints\n\nMean change in SF\u201136v2 acute form Physical Functioning domain score from randomization\n\n# Key secondary (controlled for Type I error) at 72 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo for:\n\n- lipid parameters\n- SBP\n- insulin\n\n# Endpoints\n\nMean change from randomization in:\n\n- triglycerides (mg/dL)\n- non\u2011HDL cholesterol (mg/dL)\n- HDL cholesterol (mg/dL)\n\nMean change in SBP (mmHg) from randomization\n\nMean change in fasting insulin (pmol/L) from randomization\n\nLY3298176    12", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1247, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a611ea6f-5795-4343-b978-5d4d28b32e0a": {"__data__": {"id_": "a611ea6f-5795-4343-b978-5d4d28b32e0a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7e679b46-87cb-4db8-ab40-6f03dd3cdf09", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "430e79ef59552b5237190bcbcb511a3fb47927b43a3da888cc09b334922dad2c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Objectives\n\n# Endpoints\n\n# Key secondary (controlled for Type I error) at 176 weeks, by dose analysis\n\nFor tirzepatide 10\u2011mg and/or 15\u2011mg QW doses, to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- body weight\n\n\u2022 mean percent change in body weight from randomization\n\n# Key secondary (controlled for Type I error) at 176 or 193 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo (for participants with prediabetes at randomization) in:\n\n- delayed progression to T2DM at 176 weeks\n- time to onset of T2DM during 176 weeks treatment period\n- delayed progression to T2DM at 193 weeks\n- time to onset of T2DM during entire study including safety follow up period\n\n# Additional secondary at 72 weeks, by dose analysis\n\nFor tirzepatide 5\u2011mg QW dose, to demonstrate superiority to placebo for:\n\n- body weight\n- percentage of participants who achieve:\n- - \u226510% body weight reduction from randomization\n- \u226515% body weight reduction from randomization\n\nwaist circumference\n- mean change in waist circumference (cm) from randomization\n- patient\u2011reported outcomes (SF\u201136v2 Physical Functioning)\n- mean change in SF\u201136v2 acute form Physical Functioning domain score from randomization\n\nFor tirzepatide 5\u2011mg, 10\u2011mg, and/or 15\u2011mg QW doses, to demonstrate superiority to placebo for:\n\n- body weight\n- mean change in body weight (kg) from randomization\n- mean change in BMI (kg/m\u00b2) from randomization\n- glycemic control\n- mean change in HbA1c (%, mmol/mol) from randomization\n- mean change in fasting glucose (mg/dL) from randomization\n\nLY3298176    13", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1685, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e611ff35-a2cd-46a0-9b2b-c2f51fa6de97": {"__data__": {"id_": "e611ff35-a2cd-46a0-9b2b-c2f51fa6de97", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "66385e9f-6c2a-4929-9638-caa5f8ef824f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c8ab6541051645fe768ead3d9fb72e0952490e287570196257fa0f58d8013058", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Objectives\n\n# Endpoints\n\n- patient\u2011reported outcomes\n- mean change in IWQOL\u2011Lite\u2011CT Physical Function composite score from randomization\n\n# Additional secondary at 72 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo for:\n\n- DBP\n- mean change in DBP (mmHg) from randomization\n- lipid parameters\n- mean change from randomization in:\n- LDL\u2011cholesterol (mg/dL)\n- total cholesterol (mg/dL)\n- VLDL\u2011cholesterol (mg/dL)\n- free fatty acids (mg/dL)\n\n# Additional secondary at 176 weeks, by dose analysis\n\nFor tirzepatide 5\u2011mg QW dose, to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- body weight\n- mean percent change in body weight from randomization\n\nFor tirzepatide 5 mg, 10 mg and/or 15 mg QW doses, to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- body weight\n- percentage of study participants who achieve \u22655% body weight reduction from randomization\n\n# Additional Secondary at 176 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- Patient\u2011reported outcomes\n- mean change in SF\u201136v2 acute form Physical Functioning domain score from randomization\n- mean change in IWQOL\u2011Lite\u2011CT Physical Function composite score from randomization\n\nLY3298176    14", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1465, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "203d003d-e414-4c84-94ed-2f02618a9d44": {"__data__": {"id_": "203d003d-e414-4c84-94ed-2f02618a9d44", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6e8bd49f-b7d2-439f-899f-63d871204d62", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a0834237954f3ccca49a737301bbc5cac9c0ead2033af7bf33c159adb2326b3e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Objectives\n\n# Endpoints\n\n# Additional Secondary\n\n# Pharmacokinetics/Pharmacodynamics\n\n- To characterize the population PK of tirzepatide and explore the relationships between the tirzepatide concentration and efficacy, safety and tolerability measures\n\n# Endpoints\n\n- population PK and PD parameters\n\n# Abbreviations:\n\nAUC= area under curve; BMI = body mass index; DBP = diastolic blood pressure; HbA1c = hemoglobin A1c; HDL = high\u2011density lipoprotein; IWQOL\u2011Lite\u2011CT = Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version; LDL = low\u2011density lipoprotein; PK = pharmacokinetics; QW = once\u2011weekly; SF\u201136v2 = Short Form survey\u201136 version 2; SBP = systolic blood pressure; T2DM = type 2 diabetes mellitus; VLDL = very low\u2011density lipoprotein.\n\n# LY3298176\n\n15", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 811, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2328d5d0-9a9b-4273-8e3d-6bc07710b1e0": {"__data__": {"id_": "2328d5d0-9a9b-4273-8e3d-6bc07710b1e0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e6ce08c5-59ca-49e6-a053-e81f5321e5c3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ce82b1be649ca2cab35334dd31f8ae11b34cd7b433309eeb8dd5646548e6c054", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Overall Design:\n\nStudy I8F\u2011MC\u2011GPHK is a Phase 3, multicenter, randomized, placebo\u2011controlled, double\u2011blinded study of the safety and efficacy of 5\u2011mg, 10\u2011mg, and 15\u2011mg tirzepatide QW compared with placebo for weight management when used in conjunction with a reduced\u2011calorie diet and increased physical activity, in participants who have obesity (BMI \u226530 kg/m\u00b2) or are overweight (BMI \u226527 kg/m\u00b2) with weight\u2011related comorbidities (excluding T2DM). Eligible participants will be stratified based on prediabetes status to either 72 (no prediabetes) or 176 weeks (prediabetes), follow\u2011up for endpoints of weight loss, and delay of diabetes onset.\n\nDisclosure Statement: This is a parallel group\u2011treatment study with 4 arms that is participant and investigator blinded.\n\n# Number of Participants:\n\nApproximately 2400 participants will be randomized in a 1:1:1:1 ratio to 5\u2011mg tirzepatide (600 participants), 10\u2011mg tirzepatide (600 participants), 15\u2011mg tirzepatide (600 participants), and placebo (600 participants). An upper limit of 70% enrollment of women will be used to ensure a sufficiently large sample of men.\n\n# Intervention Groups and Duration:\n\nStudy participants will be randomized in a 1:1:1:1 ratio (tirzepatide 5 mg QW, tirzepatide 10 mg QW, tirzepatide 15 mg QW, and placebo QW), stratified by country, sex, and prediabetes status. All participants will undergo a 2\u2011week screening period and a 72\u2011week treatment period including a 20\u2011week dose escalation. Participants with prediabetes at randomization who remain on study drug during the first 72 weeks will undergo a further 104\u2011week treatment period (total treatment duration of 176 weeks). The safety follow\u2011up period will be 4 weeks (for those completing or discontinuing study drug during the first 72 weeks) or 17 weeks (for participants completing or discontinuing study drug between Weeks 72 through 176).\n\n# Data Monitoring Committee:\n\nAn independent data monitoring committee (DMC) will review unblinded interim\u2011analysis results.\n\nLY3298176    16", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2061, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8530d91c-c5f4-431b-b929-9e52657293cc": {"__data__": {"id_": "8530d91c-c5f4-431b-b929-9e52657293cc", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c0de51ca-cab9-4299-9997-2a49d33a85dd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "bbcb3cff005442f7e5fc3e7c6482db0e45f0144df9b95b544342a14557c5bb9d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 1.2. Schema\n\nAbbreviations: QW= once weekly; T= telephone visit\n\nAll participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction.\n\nParticipants who have prediabetes will be studied for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to detect potential differences in progression to T2DM. The safety follow\u2011up visit will occur after 4 weeks in participants discontinuing (or completing) the study within the first 72 weeks. Those discontinuing (or completing) the study after 72 weeks will undergo safety follow\u2011up after 17 weeks.\n\nLY3298176    17", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 666, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9c223bfa-a549-4a10-8620-e00996a9d2c9": {"__data__": {"id_": "9c223bfa-a549-4a10-8620-e00996a9d2c9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "95f9918f-925c-4a2f-a198-b068ffe1140f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2d7132eb48eb82d37c9d67ac496af184e3dc03738d8ac57438c2cb5c9f633c21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f70a74a-4ea8-4205-9262-87da14ad5f96", "node_type": "1", "metadata": {}, "hash": "200430f1e9001acf0ee9bedc625e9f6cf56f36637313b021c8cfc8072d6efc6d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 1.3. Schedule of Activities\n\nThe Schedule of Activities described below should be followed for all participants enrolled in Study GPHK. However, for those participants whose participation in this study is affected by exceptional circumstances (such as pandemics or natural disasters), please refer to Section 10.10 Appendix 10 for additional guidance.\n\n# 1.3.1. Schedule of Activities covering visits to primary study endpoint\n\n| Visit\\*                               | 1  | 2  | 3\\* | 4  | 5                                    | 6                    | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 99\\* | ED\\*           | 801\\* |   |   |   |\n| ------------------------------------- | -- | -- | --- | -- | ------------------------------------ | -------------------- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ---- | -------------- | ----- | - | - | - |\n| Week of Treatment                     | -2 | -1 | 0   | 4  | 8                                    | 12                   | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 52 | 56 | 60 | 64 | 68 | 72 | 72   | 4 wks Post TxP |       |   |   |   |\n| Allowable Deviation (days)\\*          |    | \u00b13 | \u00b13  | \u00b13 | +7                                   | \u00b13                   | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b17   | \u00b17             | \u00b13    |   |   |   |\n| Fasting Visit\\*                       | X  | X  | X   | X  | X                                    | X", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1551, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7f70a74a-4ea8-4205-9262-87da14ad5f96": {"__data__": {"id_": "7f70a74a-4ea8-4205-9262-87da14ad5f96", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "95f9918f-925c-4a2f-a198-b068ffe1140f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2d7132eb48eb82d37c9d67ac496af184e3dc03738d8ac57438c2cb5c9f633c21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c223bfa-a549-4a10-8620-e00996a9d2c9", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e6e097ec12f9284ee97ad1896387c59ef7ba53002b4329746d1e3011edebdeba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "513d3268-e6c7-4b6a-adc3-b67af432ad36", "node_type": "1", "metadata": {}, "hash": "4987448ba56992c687a8042397fb9cda08fa81818cd56788af67e58d0ce9c769", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| \u00b17             | \u00b13    |   |   |   |\n| Fasting Visit\\*                       | X  | X  | X   | X  | X                                    | X                    | X  | X  | X  |    | X  |    | X  | X  | X  | X  |    | X  | X  |    |    |      |                |       |   |   |   |\n| Telephone Visit                       |    |    |     |    |                                      | X                    | X  |    | X  | X  |    | X  | X  |    | X  | X  |    | X  | X  |    |    |      |                |       |   |   |   |\n| Informed consent                      | X  |    |     |    |                                      |                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |                |       |   |   |   |\n| Randomization                         |    | X  |     |    |                                      |                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |                |", "mimetype": "text/plain", "start_char_idx": 1409, "end_char_idx": 2403, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "513d3268-e6c7-4b6a-adc3-b67af432ad36": {"__data__": {"id_": "513d3268-e6c7-4b6a-adc3-b67af432ad36", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "95f9918f-925c-4a2f-a198-b068ffe1140f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2d7132eb48eb82d37c9d67ac496af184e3dc03738d8ac57438c2cb5c9f633c21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f70a74a-4ea8-4205-9262-87da14ad5f96", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ae12ed10ff8c3ec65d9ca55ecb1fe85cfee3ed427883e58e8300fe6419f4c3bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2524e69f-355c-4000-8517-9c8a2cfa482c", "node_type": "1", "metadata": {}, "hash": "dfbec41f65ef2a448cf60771df1d124f40408bd18a47ef544faf30f4ee81675c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "|                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |                |       |   |   |   |\n| Register study visit in IWRS          | X  | X  | X   | X  | X                                    | X                    | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X    |                |       |   |   |   |\n|                                       |    |    |     |    |                                      | Clinical Assessments |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |                |       |   |   |   |\n| Medical history\\*                     | X  |    |     |    |                                      |                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |                |       |   |   |   |\n| Physical examination                  | X  |    |     |    |                                      |", "mimetype": "text/plain", "start_char_idx": 2280, "end_char_idx": 3257, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2524e69f-355c-4000-8517-9c8a2cfa482c": {"__data__": {"id_": "2524e69f-355c-4000-8517-9c8a2cfa482c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "95f9918f-925c-4a2f-a198-b068ffe1140f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2d7132eb48eb82d37c9d67ac496af184e3dc03738d8ac57438c2cb5c9f633c21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "513d3268-e6c7-4b6a-adc3-b67af432ad36", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0f5e4c432c11a7f254c259fe34b5c4fc2fc5d2c60bc7ccb87cd0d695a59d4da5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f2c792e-676a-484e-b56b-7344fc16d2e4", "node_type": "1", "metadata": {}, "hash": "3e3b05f1a0815de38af14f4f1a49712c45587e3c1fab3dd8941fbb67fb8958bc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "|                |       |   |   |   |\n| Physical examination                  | X  |    |     |    |                                      |                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |                |       |   |   |   |\n| Height                                | X  |    |     |    |                                      |                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |                |       |   |   |   |\n| Weight\\*                              | X  |    | X   | X  | X                                    | X                    | X  | X  |    | X  |    | X  | X  | X  | X  |    | X  | X  |    |    |    |      |                |       |   |   |   |\n| Waist circumference                   |    | X  | X   | X  | X                                    | X                    | X  |    |    | X  |    | X  | X  | X  | X  |    | X  | X  |    |    |    |      |", "mimetype": "text/plain", "start_char_idx": 3117, "end_char_idx": 4094, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4f2c792e-676a-484e-b56b-7344fc16d2e4": {"__data__": {"id_": "4f2c792e-676a-484e-b56b-7344fc16d2e4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "95f9918f-925c-4a2f-a198-b068ffe1140f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2d7132eb48eb82d37c9d67ac496af184e3dc03738d8ac57438c2cb5c9f633c21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2524e69f-355c-4000-8517-9c8a2cfa482c", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7dab113e974058c9c3d658d2f967d36f3cd2267abf26ee2b5e082896ff446262", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04f32862-4b40-462f-b6c5-bd0852ba7192", "node_type": "1", "metadata": {}, "hash": "b95f64326aafb53ed2b041f4f23ecdcf09564abf085f67613fd580a6ccf64e57", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| X                                    | X                    | X  |    |    | X  |    | X  | X  | X  | X  |    | X  | X  |    |    |    |      |                |       |   |   |   |\n| Electrocardiogram\\*                   |    | X  |     | X  |                                      | X                    |    | X  |    |    |    | X  |    | X  |    |    |    |    |    |    |    |      |                |       |   |   |   |\n| Vital signs (3 sitting BP and HR)\\*   | X  | X  | X   | X  | X                                    | X                    | X  |    |    | X  |    | X  |    | X  |    | X  |    | X  |    |    |    |      |                |       |   |   |   |\n| Adverse events and product complaints | X  | X  | X   | X  | X                                    | X                    | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  |    |      |                |       |   |   |   |\n| Concomitant medications               | X  | X  | X   | X  | X                                    | X                    | X  | X  | X  | X  | X  | X  | X  | X  | X", "mimetype": "text/plain", "start_char_idx": 3949, "end_char_idx": 5030, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "04f32862-4b40-462f-b6c5-bd0852ba7192": {"__data__": {"id_": "04f32862-4b40-462f-b6c5-bd0852ba7192", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "95f9918f-925c-4a2f-a198-b068ffe1140f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2d7132eb48eb82d37c9d67ac496af184e3dc03738d8ac57438c2cb5c9f633c21", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f2c792e-676a-484e-b56b-7344fc16d2e4", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "45d79b4e4ee1d73f9f512113c12ec962ccbd5b3a545bfb90ff135895deac3067", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "|   |   |   |\n| Concomitant medications               | X  | X  | X   | X  | X                                    | X                    | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  |    |      |                |       |   |   |   |\n|                                       |    |    |     |    | Participant Education and Assessment |                      |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |                |       |   |   |   |\n| Hand out diary, instruct in use\\*     | X  |    | X   |    | X                                    |                      | X  |    | X  |    | X  |    | X  |    | X  |    | X  |    |    |    |    |      |                |       |   |   |   |\n\nLY3298176    18", "mimetype": "text/plain", "start_char_idx": 4850, "end_char_idx": 5612, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "25e3d104-0da5-4de7-8340-16559c6c79d4": {"__data__": {"id_": "25e3d104-0da5-4de7-8340-16559c6c79d4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7e313f4c-4894-4228-b2ff-25d5a6cf6c04", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "66ccdff900f994b80208f40e98f6256e9291304249a1fa711794dea939bb091b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84892c70-e79e-4d64-ac4a-132d7904e776", "node_type": "1", "metadata": {}, "hash": "67f9d2dd4af5972e48a1b337c5e95fc342c529a644ccb49b2d053347a1b84777", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n| Visit\\*                                                           | 1  | 2  | 3\\* | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 99\\* | ED\\*  | 801\\* |\n| ----------------------------------------------------------------- | -- | -- | --- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ---- | ----- | ----- |\n| Week of Treatment                                                 | -2 | -1 | 0   | 4  | 8  | 12 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 52 | 56 | 60 | 64 | 68 | 72 | 72   | 4 wks |       |\n| Allowable Deviation                                               | \u00b13 | \u00b13 | \u00b13  | +7 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b17 | \u00b17 | \u00b13   |       |       |\n| Fasting Visit\\*                                                   | X  | X  | X   | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X    |       |       |\n| Telephone Visit                                                   |    |    | X   | X  |    | X  | X  |    | X  | X  | X  | X  |    |    |    |    |    |    |    |    |    |      |       |       |\n| Review study participant diary,", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1269, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "84892c70-e79e-4d64-ac4a-132d7904e776": {"__data__": {"id_": "84892c70-e79e-4d64-ac4a-132d7904e776", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7e313f4c-4894-4228-b2ff-25d5a6cf6c04", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "66ccdff900f994b80208f40e98f6256e9291304249a1fa711794dea939bb091b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25e3d104-0da5-4de7-8340-16559c6c79d4", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b417c14b1b6e80dc229b8f9b0f20776b8c3eecdacd1a72e19f0a0c1d1cad2ab8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "including study-drug compliance\\* | X  | X  | X   | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  |      |       |       |\n| Lifestyle Program instructions\\*                                  | X  | X  | X   | X  |    | X  |    | X  |    | X  |    | X  |    |    |    |    |    |    |    |    |    |      |       |       |\n| Review diet and exercise goals\\*                                  | X  | X  | X   | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  | X  |    |      |       |       |\n| Injection training with autoinjector demonstration device\\*       | X  |    |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |       |       |\n| Dispense study drug                                               | X  | X  | X   | X  | X  | X  |    | X  |    | X  |    | X  |    |    |    |    |    |    |    |    |    |      |       |       |\n| Observe participant administer study drug\\*                       | X  |    |     |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |      |       |       |\n| Participant returns study drugs and injection supplies            | X  | X  | X   | X  | X  | X  |    | X  |    | X  |    | X  |    |    |    |    |    |    |    |    |    |      |       |       |\n\n# Laboratory Tests\n\n| Serum pregnancy test\\*              | X |   |   |   |   |   |   |   |   |\n| ----------------------------------- | - | - | - | - | - | - | - | - | - |\n| Urine pregnancy test\\*              | X |   | X |   | X |   | X | X | X |\n| Follicle-stimulating hormone test\\* | X |   |   |   |   |   |   |   |   |\n\nLY3298176    19", "mimetype": "text/plain", "start_char_idx": 1270, "end_char_idx": 2970, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "552f9b62-dad0-4fe7-9f9b-32475c5faeed": {"__data__": {"id_": "552f9b62-dad0-4fe7-9f9b-32475c5faeed", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "db37cc98-edf6-4f92-9751-e2a87808f93a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "aeb0dc13224a174166a5cd683ef26fb6e3096985fa6eb5fbfc3fff8b7cd8b92c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b23510cb-ed6b-4ebf-b338-e88ce69a79a5", "node_type": "1", "metadata": {}, "hash": "2d3cbb1ae8fc4378673f3c1f4908dabe76ee80b9a4eb91d7572b929ad8e8e3c4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Visit\n\n| 1                          | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 99 | ED | 801   |\n| -------------------------- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ----- |\n| Week of Treatment          | -2 | -1 | 0  | 4  | 8  | 12 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 52 | 56 | 60 | 64 | 68 | 72 | 72 | 4 wks |\n| Allowable Deviation (days) | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b17 | \u00b17 | \u00b13    |\n\n# Fasting Visit\n\n| X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Telephone Visit\n\n|   |   | X | X |   | X | X |   | X | X |   | X | X |   | X | X |   | X |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# 2-hour oral glucose tolerance test (includes glucose, insulin, c-peptide at each timepoint)\n\n| X |   |   |   | X |   | X |   | X |   |   |   |   |   |   |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Chemistry panel (include Cr for eGFR calculation and glucose)\n\n| X |   | X |   | X |   | X |   | X |   | X |   | X |   | X |   | X |   | X |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Lipid panel\n\n| X |   | X |   |   | X |   | X |   |   | X |   |   |   |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Fasting insulin\n\n|   |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1676, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b23510cb-ed6b-4ebf-b338-e88ce69a79a5": {"__data__": {"id_": "b23510cb-ed6b-4ebf-b338-e88ce69a79a5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "db37cc98-edf6-4f92-9751-e2a87808f93a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "aeb0dc13224a174166a5cd683ef26fb6e3096985fa6eb5fbfc3fff8b7cd8b92c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "552f9b62-dad0-4fe7-9f9b-32475c5faeed", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6ea6dc1fd927be7514418734555a69e18fcc845e5d5f7ad49d11ca43906f1fd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f317cab3-8f90-4f1f-b17e-ce12bc01b097", "node_type": "1", "metadata": {}, "hash": "55a8268ff96aea184585c4cfa167e1491e795963b956f74ece5000f265ede1d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Lipid panel\n\n| X |   | X |   |   | X |   | X |   |   | X |   |   |   |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Fasting insulin\n\n|   | X | X | X | X | X | X | X | X |   |   |   |   |   |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# C-peptide\n\n|   | X | X | X | X | X | X | X | X |   |   |   |   |   |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Free fatty acids\n\n| X | X |   | X |   | X |   | X |   |   | X |   |   |   |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Urinary albumin/creatinine\n\n| X |   |   | X |   | X |   | X |   |   | X |   |   |   |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Cystatin-c\n\n| X |   |   | X |   | X |   | X |   |   | X |   |   |   |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Calcitonin\n\n| X |   |   | X |   | X |   | X |   |   | X |   |   |   |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Hematology\n\n| X |   |   | X |   | X |   | X |   |   | X |   |   |   |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# HbA1c\n\n| X | X |   | X |   | X |   | X |   | X | X | X |", "mimetype": "text/plain", "start_char_idx": 1429, "end_char_idx": 2877, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f317cab3-8f90-4f1f-b17e-ce12bc01b097": {"__data__": {"id_": "f317cab3-8f90-4f1f-b17e-ce12bc01b097", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "db37cc98-edf6-4f92-9751-e2a87808f93a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "aeb0dc13224a174166a5cd683ef26fb6e3096985fa6eb5fbfc3fff8b7cd8b92c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b23510cb-ed6b-4ebf-b338-e88ce69a79a5", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3c1f9c8c6ddaba5ab461dbce7af883c50eb63c812630a783d5a889c139acde15", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "|\n\n# Hematology\n\n| X |   |   | X |   | X |   | X |   |   | X |   |   |   |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# HbA1c\n\n| X | X |   | X |   | X |   | X |   | X | X | X |   | X |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Pancreatic amylase, lipase\n\n| X | X |   | X |   | X |   | X |   | X | X | X |   | X |   |   |   |   |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# Thyroid-stimulating hormone\n\nX\n\n# Immunogenicity (includes PK sample)\n\n|   | X | X | X | X |   | X |   | X | X |   | X | X |   | X | X |   | X |\n| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\n# TZP PK\n\n|   |   | X | X |   | X |   |   | X |\n| - | - | - | - | - | - | - | - | - |\n\n# Pharmacogenetic stored sample\n\nX\n\nLY3298176    20", "mimetype": "text/plain", "start_char_idx": 2653, "end_char_idx": 3516, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "80eeb05c-311e-4663-9f56-071539c09092": {"__data__": {"id_": "80eeb05c-311e-4663-9f56-071539c09092", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f876fa40-1b85-435d-a4ad-87b8ed0f7c6e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fe4e75f00950d357bb6163446d5c97edb4e0f79971ff6361986748cae2b1d2d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48663510-780a-4688-98c5-8ffc91aee337", "node_type": "1", "metadata": {}, "hash": "86da298f8b8cde9c2e719014d1e947ffb336f025745779d98b64b7754225775e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n| Visit\\*             | 1  | 2  | 3\\* | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 99\\* | ED\\*  | 801\\*    |\n| ------------------- | -- | -- | --- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ---- | ----- | -------- |\n| Week of Treatment   | -2 | -1 | 0   | 4  | 8  | 12 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 52 | 56 | 60 | 64 | 68 | 72 | 72   | 4 wks | Post TxP |\n| Allowable Deviation | \u00b13 | \u00b13 | \u00b13  | +7 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | \u00b17 | \u00b17 | \u00b13 |      |       |          |\n\n| Fasting Visit\\*                  | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |\n| -------------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| Telephone Visit                  |   |   | X | X |   | X |   | X | X |   | X | X |   |   |   |   | X |\n| Nonpharmacogenetic stored sample | X |   | X |   | X |   |   | X |   | X |   | X |   | X |   | X |   |\n\n# Mental Health Questionnaires\n\n| PHQ\u20119\\*                               | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |\n| ------------------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| C\u2011SSRS (Baseline/Screening) Version\\* | X |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |\n| C\u2011SSRS (Since Last Visit Version)\\*   | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |\n| Self\u2011Harm Supplement Form\\*", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1573, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "48663510-780a-4688-98c5-8ffc91aee337": {"__data__": {"id_": "48663510-780a-4688-98c5-8ffc91aee337", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f876fa40-1b85-435d-a4ad-87b8ed0f7c6e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fe4e75f00950d357bb6163446d5c97edb4e0f79971ff6361986748cae2b1d2d6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80eeb05c-311e-4663-9f56-071539c09092", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7df787a41e04fafd8064b031b3a5e3ea1b4584a1f5e129fb7e37d965c4d2f62d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "- | - | - | - | - | - |\n| C\u2011SSRS (Baseline/Screening) Version\\* | X |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |\n| C\u2011SSRS (Since Last Visit Version)\\*   | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |\n| Self\u2011Harm Supplement Form\\*           | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |\n| Self\u2011Harm Follow\u2011up Form\\*            | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |\n\n# Patient Reported Outcomes\n\n| PGIS                         | X |   |   |   |   |   |   |   |   | X |   |   |   |   |   |   |\n| ---------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| SF\u201136, version 2, acute form | X |   |   |   |   |   |   |   |   | X |   |   |   |   |   |   |\n| IWQOL\u2011Lite CT                | X |   |   |   |   |   |   |   |   | X |   |   |   |   |   |   |\n| EQ\u20115D\u20115L                     | X |   |   |   |   |   |   |   |   | X |   |   |   |   |   |   |\n\nLY3298176    21", "mimetype": "text/plain", "start_char_idx": 1308, "end_char_idx": 2287, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "55504db7-97ef-48ff-b335-297cf972639a": {"__data__": {"id_": "55504db7-97ef-48ff-b335-297cf972639a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "953b2c77-73ee-4ad3-bc18-c108f70e547f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b77edc0e3401a307458d5bf71520192bbf2e6b08f714146cf1ba9c2cb6799be0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5384b178-2f6f-4b8a-ad34-993406afddf0", "node_type": "1", "metadata": {}, "hash": "5815b9359988239c2a9b0dd28e1d215455e821b3fed15598ca49d91ca55b2c0e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 1.3.2. Schedule of Activities for additional 2-year treatment period for participants with prediabetes at randomization\n\n| Visit\\*                      |   | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 199\\* | ED\\*     | 802\\* |\n| ---------------------------- | - | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ----- | -------- | ----- |\n| Week of Treatment            |   | 78  | 85  | 91  | 98  | 104 | 111 | 117 | 124 | 130 | 137 | 143 | 150 | 156 | 163 | 169 | 176 | 176   | Post TxP |       |\n| Allowable Deviation (days)\\* |   | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17    | \u00b13       |       |\n\n| Fasting Visit\\*              |   | X | X | X | X | X | X | X | X | X | X | X |   |   |   |   |   |   |   |   |   |\n| ---------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| Telephone Visit              | X | X | X | X | X | X | X |   |   |   |   |   |   |   |   |   |   |   |   |   |   |\n| Register study visit in IWRS | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |   |   |\n\n# Clinical Assessments\n\n| Weight\\*                            |   | X | X | X | X | X | X | X | X | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n| ----------------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| Waist circumference                 |   | X | X | X | X | X | X | X | X | X |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1642, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5384b178-2f6f-4b8a-ad34-993406afddf0": {"__data__": {"id_": "5384b178-2f6f-4b8a-ad34-993406afddf0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "953b2c77-73ee-4ad3-bc18-c108f70e547f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b77edc0e3401a307458d5bf71520192bbf2e6b08f714146cf1ba9c2cb6799be0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55504db7-97ef-48ff-b335-297cf972639a", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "4093c7ef9fbdd056840cdd2e553756e3c8ad98cb93df166e2362b68643d32531", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "| X |   |   |   |   |   |   |   |   |   |   |   |   |\n| ----------------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| Waist circumference                 |   | X | X | X | X | X | X | X | X | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n| Electrocardiogram\\*                 |   |   |   |   |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n| Vital signs (3 sitting BP and HR)\\* |   | X | X | X | X | X | X | X |   | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n| Adverse events/Product Complaints   |   | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |   |   |   |   |   |\n| Concomitant medications             |   | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |   |   |   |   |   |   |\n\n# Participant Education and Assessment\n\n| Hand out diary, instruct in use\\*                                 | X | X | X | X | X | X |   |   |   |   |   |   |   |   |   |   |   |   |   |\n| ----------------------------------------------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| Review study participant diary, including study drug compliance\\* | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |   |   |   |   |\n| Lifestyle Program instructions\\*                                  | X | X | X | X | X | X | X |   | X |   |   |   |   |   |   |   |   |   |   |\n| Review diet and exercise goals\\*                                  | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |   |   |   |   |\n| Dispense study drug                                               | X | X | X | X | X | X | X |   |   |   |   |   |   |   |   |   |   |   |   |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1377, "end_char_idx": 3150, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d808fb79-a234-4b2a-b5b1-c6f960642db2": {"__data__": {"id_": "d808fb79-a234-4b2a-b5b1-c6f960642db2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f28a947f-7736-489e-9265-01a1bec5a3e5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3995139f6a7c214e4831ce092591acada752eafe580cb23f10dbcf0ed8897657", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adbd8b7d-06bc-4de2-a109-0d7bb26d28a9", "node_type": "1", "metadata": {}, "hash": "d4123da3b42f5fc8ca4d21059e626eb518b772dd5b82b738809eb425d64dc5cc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Visit\n\n|                                                        | 101 | 102    | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 199\\* | ED\\* | 802\\* |\n| ------------------------------------------------------ | --- | ------ | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ----- | ---- | ----- |\n| Week of                                                |     | 17 wks |     |     |     |     |     |     |     |     |     |     |     |     |     |     |       |      |       |\n| Treatment                                              | 78  | 85     | 91  | 98  | 104 | 111 | 117 | 124 | 130 | 137 | 143 | 150 | 156 | 163 | 169 | 176 | 176   | Post | TxP   |\n| Allowable Deviation                                    | \u00b17  | \u00b17     | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17    | \u00b13   |       |\n| Fasting Visit\\*                                        | X   | X      | X   | X   | X   |     | X   | X   | X   | X   | X   | X   | X   | X   | X   |     |       |      |       |\n| Telephone Visit                                        | X   | X      | X   | X   | X   |     | X   | X   |     |     |     |     |     |     |     |     |       |      |       |\n| Participant returns study drugs and injection supplies | X   | X      | X   | X   | X   |     | X   | X   | X   |     |     |     |     |     |     |     |       |      |       |\n\n# Laboratory Tests\n\n| Urine pregnancy test\\*                                                      | X | X | X | X | X |   | X | X |   |   |   |   |   |   |   |   |   |   |\n| --------------------------------------------------------------------------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n| 2 hour oral glucose tolerance test (includes glucose, insulin,", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1888, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "adbd8b7d-06bc-4de2-a109-0d7bb26d28a9": {"__data__": {"id_": "adbd8b7d-06bc-4de2-a109-0d7bb26d28a9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f28a947f-7736-489e-9265-01a1bec5a3e5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3995139f6a7c214e4831ce092591acada752eafe580cb23f10dbcf0ed8897657", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d808fb79-a234-4b2a-b5b1-c6f960642db2", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "88e8744bc10959d07bd4c62e40faef1cf018aa40414e330fce085016dcb0fc99", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "insulin, c\u2011peptide)\\* |   |   |   | X |   |   | X | X | X |   |   |   |   |   |   |   |   |   |\n| Chemistry panel (includes Cr for eGFR calculation and glucose)\\*            | X | X | X | X | X |   | X | X | X | X |   |   |   |   |   |   |   |   |\n| Lipid panel                                                                 |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |\n| Free fatty acids                                                            |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |\n| Urinary albumin/creatinine ratio                                            |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |\n| Cystatin\u2011c                                                                  |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |\n| Calcitonin                                                                  |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |\n| Hematology                                                                  |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |\n| HbA1c                                                                       | X | X | X | X | X |   | X | X | X |   |   |   |   |   |   |   |   |   |\n| Pancreatic amylase, lipase                                                  |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |\n| Immunogenicity (includes PK sample)\\*                                       | X |   | X |   | X |   | X | X |   |   |   |   |   |   |   |   |   |   |\n| Nonpharmacogenetic stored sample                                            |   |   | X |   |   | X | X |   |   |   |   |   |   |   |   |   |   |   |\n\n# Mental Health Questionnaires\n\n| PHQ\u20119\\* | X | X | X | X | X |   | X | X | X |   |   |   |   |   |   |   |   |   |\n| ------- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |\n\nLY3298176    23", "mimetype": "text/plain", "start_char_idx": 1880, "end_char_idx": 3865, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "233ece1d-5b60-473f-8e7d-e288b6fe8341": {"__data__": {"id_": "233ece1d-5b60-473f-8e7d-e288b6fe8341", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3e41726d-dea7-4a5d-ade9-04f77a3809c9", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b4b05ccb4e1a70c832d972a05666540f6579ec5c6ceaccedc128e20a2b2b362a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c600a6da-dbe8-4897-a233-e75e01731138", "node_type": "1", "metadata": {}, "hash": "518074e99a7527655bb9dc2f87da3d13ffe0dd693bb9c85d45cc742734f351f0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n| Visit\\*                             | 101 | 102 | 103    | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 199\\* | ED\\* | 802\\* |\n| ----------------------------------- | --- | --- | ------ | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ----- | ---- | ----- |\n| Week of                             |     |     | 17 wks |     |     |     |     |     |     |     |     |     |     |     |     |     |       |      |       |\n| Treatment                           | 78  | 85  | 91     | 98  | 104 | 111 | 117 | 124 | 130 | 137 | 143 | 150 | 156 | 163 | 169 | 176 | 176   | Post | TxP   |\n| Allowable Deviation                 | \u00b17  | \u00b17  | \u00b17     | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17  | \u00b17    | \u00b13   |       |\n| Fasting Visit\\*                     | X   |     | X      |     | X   |     | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   |       |      |       |\n| Telephone Visit                     | X   | X   | X      | X   | X   | X   | X   |     |     |     |     |     |     |     |     |     |       |      |       |\n| C\u2011SSRS (Since Last Visit Version)\\* | X   | X   | X      | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X     | X    |       |\n| Self\u2011Harm Supplement Form\\*         | X   | X   | X      | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   |       |      |       |\n| Self\u2011Harm Follow\u2011up Form\\*          | X   | X   | X      | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   | X   |       |      |       |\n\n# PROs\n\n&#x3C;| PGIS                   | X |   |   |   | X |   | X |\n| ---------------------- | - | - | - | - | - | - | - |\n| SF\u201136, version 2 acute | X |   |   |   | X |   | X |\n| IWQOL\u2011Lite \u2011CT         | X |   |   |   | X |   | X |\n| EQ\u20115D\u20115L               | X |   |   |   | X |   | X |\n\n*Please see table below for corresponding additional information\n\nAbbreviations: BP = blood pressure; Cr= creatinine; C\u2011SSRS = Columbia\u2011Suicide Severity Rating Scale; ED= early discontinuation of treatment;", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2159, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c600a6da-dbe8-4897-a233-e75e01731138": {"__data__": {"id_": "c600a6da-dbe8-4897-a233-e75e01731138", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3e41726d-dea7-4a5d-ade9-04f77a3809c9", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b4b05ccb4e1a70c832d972a05666540f6579ec5c6ceaccedc128e20a2b2b362a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "233ece1d-5b60-473f-8e7d-e288b6fe8341", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "61c94656d8f63b676b5a7ea96826cb294987ac3e050947cc4ab2d746ba5286f8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "version 2 acute | X |   |   |   | X |   | X |\n| IWQOL\u2011Lite \u2011CT         | X |   |   |   | X |   | X |\n| EQ\u20115D\u20115L               | X |   |   |   | X |   | X |\n\n*Please see table below for corresponding additional information\n\nAbbreviations: BP = blood pressure; Cr= creatinine; C\u2011SSRS = Columbia\u2011Suicide Severity Rating Scale; ED= early discontinuation of treatment; eGFR = estimated glomerular filtration rate; HbA1c = hemoglobin A1c; HR = heart rate; IWQOL\u2011Lite\u2011CT = Impact of Weight on Quality of Life\u2011Lite Clinical trials; IWRS = interactive web\u2011response system; PGIS = Patient Global Impression of status for physical activity; PHQ\u20119 = Patient Health Questionnaire\u20119; PK = pharmacokinetics; SF\u201136 = Short\u2011Form\u201136 Health Survey version 2, acute form; TxP = treatment period; TZP = tirzepatide\n\nLY3298176    24", "mimetype": "text/plain", "start_char_idx": 1796, "end_char_idx": 2606, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bae81b8b-cc9a-47aa-907d-669f2e45b83f": {"__data__": {"id_": "bae81b8b-cc9a-47aa-907d-669f2e45b83f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3e900d67-ee0a-4cde-b62d-01837b4879fe", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cf0561b244ea13f076493fcfa66ada81d22fb9ef256a39f0510a220d94ce4083", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Additional Information Regarding Activities Described in Schedule of Activities\n\n| Activity      | Notes                                                                                                                                                                                                                                                                                                                                                                                                                         |\n| ------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Visit         | On all office visits, study participants should be reminded to report to the site before taking study drug(s) in a fasting condition, after a period of approximately 8 hours without eating, drinking (except water), or any significant physical activity. Since some screening procedures need to be completed in the fasting state, Visit 1 may be conducted over more than 1 day to ensure necessary conditions are met. |\n| Fasting Visit |                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| Visit 3       | Baseline assessments must be completed before processing in the IWRS.                                                                                                                                                                                                                                                                                                                                                         |\n| Visit 99      | Participants wanting to discontinue the study before Week 72 will be asked to return for Visit 99 at 72 weeks \u00b1 7 days after randomization primarily for body weight measurement and assessment of adverse events. If the participant is unwilling to attend Visit 99, it should be documented in the participant medical record that the participant has refused to attend.                                                  |\n| Visit 199     | Participants wanting to discontinue the study after Week 72 but before Week 176 will be asked to return for Visit 199 primarily for the body weight measurement and assessment of adverse events. Refusal to attend should be documented.                                                                                                                                                                                     |\n\nLY3298176    25", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3179, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "014b673d-9231-4075-910c-d36c3e75ea78": {"__data__": {"id_": "014b673d-9231-4075-910c-d36c3e75ea78", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f67be25f-680f-4aee-bc4a-a4f7ed02884a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "46c7e225b8cfeeece9767bf41a0fb999e618f620b695e79064a05fb419fe2907", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\nParticipants who are unable or unwilling to continue the study treatment for any reason will perform an ED visit. If the participant is discontinuing during an unscheduled visit or a scheduled visit, that visit should be performed as the ED visit.\n\n# Safety Follow\u2011up Visits\n\n# Visit 801\n\nVisit 801 (safety follow\u2011up visit) should be performed 4 weeks after the last visit during the 72\u2011week treatment period. Participants with prediabetes continuing to Week 78 should not perform Visit 801.\n\n# Visit 802\n\nFor participants with prediabetes who complete the 176 weeks or discontinue after Week 72, Visit 802 should be performed 17 weeks after the last visit during the additional 2\u2011year treatment period for participants with prediabetes at randomization.\n\n# Allowable Deviation (days)\n\nThe visit date is determined in relation to the date of the randomization visit (\u00b1 the allowed visit window).\n\n# Medical History\n\nMedical history includes assessment of preexisting conditions (for example, history of gallbladder disease, cardiovascular disease, and medullary thyroid carcinoma) and substance usage (such as alcohol and tobacco).\n\n# Weight\n\nWeight measurements should be obtained per the instructions in Section 10.7. Body weight must be measured in fasting state. If the participant is not fasting, the participant should be called in for a new visit within the visit window to have the fasting body weight measured.\n\n# Electrocardiogram\n\nECG measurements should be obtained per the instructions in Section 10.7. ECGs will be performed in triplicate at Weeks 0 and 36. All other ECGs will be single measurements. ECGs should be collected at least 30 minutes prior to collection of blood samples for laboratory testing, including PK samples.\n\n# Vital signs (3 sitting BP and HR)\n\nVital\u2011sign measurements should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing, per the instruction in Section 10.7.\n\n# Hand out diary, instruct in use\n\nAll training should be repeated as needed to ensure participant compliance.\n\n# Review study participant diary and study\u2011drug compliance\n\nData from diary, as well as study drug compliance, should be reviewed.\n\nLY3298176    26", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2256, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b2b745dd-ae27-460a-a597-29802a049ea9": {"__data__": {"id_": "b2b745dd-ae27-460a-a597-29802a049ea9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d3ad766b-11f5-4fb3-83f0-95e555fb81ec", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "dd2caa0cc939bb770ee523f855e65b3b0e41b0be5eac0b756d25771ed82a47a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Lifestyle Program instructions\n\nCounselling on diet and exercise, to be performed by a dietician or equivalent qualified delegate, to include calculation of individualized energy requirement and methods to change dietary composition and amount of physical activity. The Lifestyle Program Instruction may be delivered on a separate day from the rest of that visit\u2019s study procedures but must occur within the visit window. Beginning at Week 8, the Lifestyle Program Instruction may be delivered by phone.\n\n# Review diet and exercise goals\n\nAll training should be repeated as needed to ensure participant compliance. Study personnel to provide reinforcement and encouragement for lifestyle modifications.\n\n# Injection training with Autoinjector demonstration device\n\nAll training should be repeated as needed to ensure participant compliance.\n\n# Dispense study drug Visit 72\n\nThis applies only to those participants going into the additional 2\u2011year treatment period for participants with prediabetes at randomization.\n\n# Observe participant administer study drug\n\nParticipants should administer their first dose of study drug at the end of the Visit 3, after other study procedures are completed.\n\n# Serum pregnancy test\n\nA serum pregnancy test will be performed at Visit 1 for women of childbearing potential only.\n\n# Urine pregnancy test\n\nA urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy tests (beyond those required per the Schedule of Activities) should be performed at any time during the trial if a menstrual period is missed, there is clinical suspicion of pregnancy, or as required by local law or regulation.\n\n# Follicle\u2011stimulating hormone test\n\nFollicle\u2011stimulating hormone test performed at Visit 1 for postmenopausal women at least 40 years of age with an intact uterus, not on hormone therapy, and who have had spontaneous amenorrhea for more than 1 year without an alternative medical cause.\n\n# 2\u2011hour oral glucose tolerance test (includes glucose, insulin, c\u2011peptide)\n\n2\u2011hour OGTT testing should be omitted at visits following a protocol\u2011defined diabetes diagnosis.\n\nLY3298176    27", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2292, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2f640404-a5b3-428f-a4eb-36d56e4aa18e": {"__data__": {"id_": "2f640404-a5b3-428f-a4eb-36d56e4aa18e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f37976c5-8a86-401f-abb4-e26489d3ab44", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a5edcaaeb96ba5330e7b98bf917b66331da02b2d0a203aa64329d6fb31d52f79", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Urinary albumin/creatinine ratio\n\nScreening visit assessment will be used to confirm eligibility. If calcitonin results are not available, a final review of eligibility will occur at Visit 3 before randomization can proceed.\n\n# Cystatin\u2011c\n\n# Calcitonin\n\n# Hematology\n\n# Thyroid\u2011stimulating hormone (TSH)\n\n# Chemistry panel (include Cr for eGFR calculation)\n\nThe CKD\u2011EPI equation will be used by the central lab to estimate and report eGFR.\n\n# Immunogenicity (includes PK sample)\n\nPK samples for immunogenicity must be taken prior to drug administration at these visits. In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and exploratory biomarker samples.\n\n# TZP PK\n\nPK samples will be collected at these visits at time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours post dose, as assigned by IWRS at randomization. Dependent on the time windows to which a participant is assigned, they may be required to come to site for PK\u2011specific visits.\n\n# PHQ\u20119\n\nThe C\u2011SSRS, Self\u2011Harm Supplement Form and PHQ\u20119 should be administered after assessment of adverse events. For this study, the C\u2011SSRS is adapted for the assessment of the ideation and behavior categories only. The Intensity of Ideation and Lethality of Behavior sections are removed.\n\n# C\u2011SSRS (Baseline/Screening Version)\n\n# C\u2011SSRS (Since last Visit Version)\n\n# Self\u2011Harm Supplement Form\n\nSelf\u2011Harm Follow\u2011up Form is only required if triggered by the Self\u2011Harm Supplement Form, per instructions in the form.\n\n# Abbreviations:\n\nADA = antidrug antibody; BP = blood pressure; CKD\u2011EPI = Chronic Kidney Disease\u2011Epidemiology; Cr = creatinine; C\u2011SSRS = Columbia\u2011Suicide Severity Rating Scale; ECG = electrocardiogram; ED = early discontinuation of treatment; eGFR = estimated glomerular filtration rate; HR = heart rate; IWRS = interactive web\u2011response system; OGTT = oral glucose tolerance test; PHQ\u20119 = Patient Health Questionnaire\u20119; PK = pharmacokinetic; TSH = thyroid\u2011stimulating hormone; TZP = tirzepatide.\n\nLY3298176    28", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2132, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4a456271-4637-427b-8264-e08713edcd4e": {"__data__": {"id_": "4a456271-4637-427b-8264-e08713edcd4e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e74e553d-7084-4ffe-b3f1-edcebe2e0242", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a7dcddea00f0c4025eccf60d6ddcddc8578f3e534a4af7528cd498363577b793", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84a4a385-7593-4491-a0eb-b615db5f8716", "node_type": "1", "metadata": {}, "hash": "b84ab8e518f57d57df035495ca53d0c6179e34045f53e569ec452de055ec7ff7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 2. Introduction\n\nObesity is a chronic disease whose increasing prevalence is a public\u2011health concern associated with rising incidence of type 2 diabetes mellitus (T2DM), increased risk for premature death and increased risk for some cancers (Allison et al. 2008; AMA 2013; Council on Science and Public Health 2013). Although loss of 5% to 10% body weight has been shown to reduce complications related to obesity and improve quality of life (Mertens and Van Gaal 2000; Knowler et al. 2002; Jensen et al. 2014; Li et al. 2014; Warkentin et al. 2014), lifestyle therapies fail to achieve sustainable weight loss in the majority of patients with obesity (Dombrowski et al. 2014).\n\n# 2.1. Study Rationale\n\nThe gut incretin hormones, glucose\u2011dependent insulinotropic polypeptide (GIP) and glucagon\u2011like peptide\u20111 (GLP\u20111), are secreted after meal ingestion and mediate the incretin effect. Both hormones have effects on endocrine cells in the pancreas, increasing insulin biosynthesis and secretion, stimulating beta\u2011cell neogenesis and proliferation, and protecting beta cells from apoptosis. They also exert actions on alpha cells, modifying glucagon secretion (Skow et al. 2016). Based on these properties, several GLP\u20111 receptor (GLP\u20111R) agonists have been approved for pharmacological treatment of T2DM (Tomlinson et al. 2016).\n\nIn addition to its pancreatic effects, GLP\u20111R activation decreases gut motility, slows gastric emptying, and promotes satiety (presumably through a combination of GLP\u20111R activation in the central and peripheral nervous system), thereby regulating food intake and body weight (Baggio and Drucker 2007). The US Food and Drug Administration and the European Medicines Agency approved the GLP\u20111R agonist liraglutide for the treatment of overweight and obesity (SAXENDA\u00ae package insert, 2014; SAXENDA\u00ae SmPc, 2015).\n\nPreclinical data indicate that GIP exerts effects on appetite regulation and food intake, on adipose tissue and on peripheral energy metabolism. Although studies evaluating effects of GIP on body weight have yielded equivocal results, GIP receptor (GIPR) activation may play a role in body weight regulation and targeting both the GLP\u20111R and the GIPR simultaneously may result in additive or synergistic effects of the 2 incretins on body weight (Coskun et al. 2018).\n\nTirzepatide is a 39\u2011amino acid synthetic peptide with agonist activity at both the GIPR and GLP\u20111R. Its structure is based on the GIP sequence and includes a C20 fatty di\u2011acid moiety (Coskun et al. 2018). It is administered once weekly (QW) by subcutaneous (SC) injection. As a dual GIP/GLP\u20111R agonist, tirzepatide could exceed the efficacy of selective GLP\u20111R agonists by recruiting metabolically active tissues not targeted by selective GLP\u20111R agonists (for example, adipose tissue as indicated by the observation of increased energy utilization) (Baggio and Drucker 2007) and has the potential to reach higher efficacy in target tissues that express both GIPR and GLP1R.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3026, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "84a4a385-7593-4491-a0eb-b615db5f8716": {"__data__": {"id_": "84a4a385-7593-4491-a0eb-b615db5f8716", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e74e553d-7084-4ffe-b3f1-edcebe2e0242", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a7dcddea00f0c4025eccf60d6ddcddc8578f3e534a4af7528cd498363577b793", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a456271-4637-427b-8264-e08713edcd4e", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b43f80ba37646e14aec30742180465e4b28b310dfa8c2ce644d7c33a8a54783f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2018). It is administered once weekly (QW) by subcutaneous (SC) injection. As a dual GIP/GLP\u20111R agonist, tirzepatide could exceed the efficacy of selective GLP\u20111R agonists by recruiting metabolically active tissues not targeted by selective GLP\u20111R agonists (for example, adipose tissue as indicated by the observation of increased energy utilization) (Baggio and Drucker 2007) and has the potential to reach higher efficacy in target tissues that express both GIPR and GLP1R.\n\nStudy I8F\u2011MC\u2011GPHK (GPHK, SURMOUNT\u20111) is a Phase 3, multicenter, randomized, placebo\u2011controlled, double\u2011blinded study, to investigate the safety and efficacy of 5\u2011mg, 10\u2011mg, and 15\u2011mg tirzepatide QW, compared with placebo, when used in conjunction with a reduced\u2011calorie diet and increased physical activity for body weight management in participants who do not have T2DM and have obesity (BMI \u226530 kg/m\u00b2) or are overweight (BMI \u226527 kg/m\u00b2) with at least one\n\nLY3298176    29", "mimetype": "text/plain", "start_char_idx": 2551, "end_char_idx": 3500, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0c5a36c8-c046-44b2-9b12-9dcc10309220": {"__data__": {"id_": "0c5a36c8-c046-44b2-9b12-9dcc10309220", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8692462e-5b2f-47a8-abf6-b054f99557fc", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "54fc2e5fb31bed17755fbbe84472a18098f2eae79b8079fdb82ed8c297e4dfbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd676445-c694-4e31-b664-3d546406d7d0", "node_type": "1", "metadata": {}, "hash": "6628c47c7222585330404c1236baf53d43ea9a08aa29a8ccf7771b61e76b61d6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nweight\u2011related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). All participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction. Participants who have prediabetes at randomization will be studied for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to assess the effects of tirzepatide on progression to T2D and on long\u2011term body weight changes.\n\n# 2.2. Background\n\nThere remains an unmet need in the pharmacologic treatment of obesity for drugs that are safe, efficacious and well tolerated. With the exception of orlistat, a drug that blocks absorption of dietary fat, many current obesity treatments work primarily by stimulating regions of the brain to promote satiety. Weight loss induced by GLP\u20111R agonists appears to be mediated through a combination of hormonal inputs to satiety centers (van Bloemendaal et al. 2014) and has not been consistently associated with changes in mental health or with potential for addiction in long\u2011term studies conducted to establish cardiovascular safety in patients with diabetes (Marso et al. 2016a, Marso et al. 2016b, Gerstein et al. 2019). Tirzepatide, which is both a GLP\u20111R and GIPR agonist, has been associated with significant dose\u2011dependent weight loss at 5\u2011, 10\u2011 and 15\u2011 mg doses in Phase 2 studies (Frias et al. 2018).\n\nDose selection for obesity treatment has been informed by 3 clinical trials: a Phase 1 study, Study I8F\u2011MC\u2011GPGA (GPGA), and two Phase 2 studies, Study I8F\u2011MC\u2011GPGB (GPGB) and I8F\u2011MC\u2011GPGF (GPGF).\n\nPhase 1 Study GPGA was a combination of single ascending dose (SAD) and multiple ascending dose (MAD) studies in healthy subjects and a multiple dose study in patients with T2DM. A total of 142 participants (89 healthy subjects and 53 patients with T2DM) received at least 1 dose of treatment. Doses of tirzepatide ranged from:\n\n- 0.25 mg to 8 mg in the SAD (with maximum tolerated dose achieved at 5 mg)\n- multiple doses from 0.5 mg to 4.5 mg QW and titrated doses up to 10 mg QW for 4 weeks in healthy subjects\n- multiple doses at 0.5 mg and 5 mg QW and titrated up to 15 mg QW for 4 weeks in patients with T2DM in the MAD\n\nThe safety and tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profiles of tirzepatide at doses and escalation regimens administered in this Phase 1 study supported further development of tirzepatide for QW dosing in patients with T2DM.\n\nPhase 2 studies GPGB and GPGF studies provided initial safety, tolerability and efficacy data in the tirzepatide 1\u2011to\u201115\u2011mg dose range when used in treatment of patients with T2DM. In the dose range of 5 to 15 mg, tirzepatide provided significantly greater reductions in hemoglobin A1c (HbA1c) and body weight compared with dulaglutide 1.5 mg QW. The most common AEs, which were also dose dependent, were mild to moderate nausea, vomiting, and diarrhea.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2948, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cd676445-c694-4e31-b664-3d546406d7d0": {"__data__": {"id_": "cd676445-c694-4e31-b664-3d546406d7d0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8692462e-5b2f-47a8-abf6-b054f99557fc", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "54fc2e5fb31bed17755fbbe84472a18098f2eae79b8079fdb82ed8c297e4dfbc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c5a36c8-c046-44b2-9b12-9dcc10309220", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "f5d93fb35c102f8880867eb9708ed35271822a0cde9cf61ee12e3b6c2a4f8062", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Phase 2 studies GPGB and GPGF studies provided initial safety, tolerability and efficacy data in the tirzepatide 1\u2011to\u201115\u2011mg dose range when used in treatment of patients with T2DM. In the dose range of 5 to 15 mg, tirzepatide provided significantly greater reductions in hemoglobin A1c (HbA1c) and body weight compared with dulaglutide 1.5 mg QW. The most common AEs, which were also dose dependent, were mild to moderate nausea, vomiting, and diarrhea. Study GPGF showed that adjustments in the tirzepatide dose\u2011escalation algorithm resulted in additional reductions in the frequency of GI AEs and reduced the frequency of treatment discontinuations due to GI AEs.\n\nLY3298176 30", "mimetype": "text/plain", "start_char_idx": 2495, "end_char_idx": 3174, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "799d3667-0533-4178-a3d4-09e27c873624": {"__data__": {"id_": "799d3667-0533-4178-a3d4-09e27c873624", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "715b650e-7245-4a0e-a13a-1912ad4f686d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "94e3737565ffb15faf3b9af6d9e76f71d2c1912bf67b91121324349f52135bd1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 2.3.  Benefit/Risk Assessment\n\nMore information about the known and expected benefits, risks, serious AEs (SAEs) and reasonably anticipated AEs of tirzepatide are to be found in the Investigator\u2019s Brochure (IB).\n\nLY3298176    31", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 272, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8f292219-0080-44e7-b639-d53c416483ba": {"__data__": {"id_": "8f292219-0080-44e7-b639-d53c416483ba", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1de2cef1-d96e-4b89-a4bd-db7b12e14d54", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6f3abc304f311fbc1d59414975afcc5ea41569d6d5167c1e99c94dea2a1ee7c0", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 3. Objectives and Endpoints\n\n| **Objectives**                                                                                                                                                                | **Endpoints**                                                                                                                                           |\n| ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| **Primary** at 72 weeks, by dose analysis To demonstrate that tirzepatide 10 mg QW is superior to placebo for:                                                                | **mean percent change in body weight from** \u2022 percent change in body weight AND \u2022 percentage of participants with \u22655% body weight reduction             |\n|                                                                                                                                                                               | \u2022 randomization percentage of study participants who achieve \u22655% body weight reduction from randomization                                               |\n| AND/OR To demonstrate that tirzepatide 15 mg QW is superior to placebo for:                                                                                                   | \u2022 percent change in body weight AND \u2022 percentage of participants with \u22655% body weight reduction                                                         |\n| **Key Secondary (controlled for Type I error)** at 20 weeks, pooled dose analysis For pooled tirzepatide 10 mg and 15 mg QW doses, to demonstrate superiority to placebo for: | \u2022 mean change in body weight (kg) from randomization \u2022 body weight                                                                                      |\n| **Key Secondary (controlled for Type I error)** at 72 weeks, by dose analysis To demonstrate that tirzepatide 5 mg QW is superior to placebo for:                             | \u2022 mean percent change in body weight from randomization \u2022 percent change in body weight AND \u2022 percentage of participants with \u22655% body weight reduction |\n|                                                                                                                                                                               | \u2022 percentage of study participants who achieve \u22655% body weight reduction from randomization                                                             |\n\nLY3298176    32", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2745, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cc6da427-fddc-4f19-ba96-cfd76fb5befb": {"__data__": {"id_": "cc6da427-fddc-4f19-ba96-cfd76fb5befb", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ebd2a808-21fb-44af-864f-e292f3c49b97", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8fefc7a8af0ede55b8bcc2f1001ab68b89a3d772ae15a8beb555c281d250d738", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Objectives\n\nFor tirzepatide 10 mg and/or 15 mg QW doses, to demonstrate superiority to placebo for:\n\n- body weight\n- waist circumference\n\n# Endpoints\n\n- percentage of participants who achieve:\n- \u226510% body weight reduction from randomization\n- \u226515% body weight reduction from randomization\n- \u226520% body weight reduction from randomization\n- mean change in waist circumference (cm) from randomization\n\n# Key Secondary (controlled for Type I error)\n\n# at 72 weeks, pooled dose analysis\n\nTo demonstrate that pooled tirzepatide 10 mg and 15 mg QW is superior to placebo for:\n\n- patient\u2011reported outcomes (SF\u201136v2 acute form Physical Functioning domain score)\n\n# Endpoints\n\n- mean change in SF\u201136v2 acute form Physical Functioning domain score from randomization\n\n# Key Secondary (controlled for Type I error)\n\n# at 72 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo for:\n\n- lipid parameters\n- SBP\n- insulin\n\n# Endpoints\n\n- mean change from randomization in\n- triglycerides (mg/dL)\n- non\u2011HDL cholesterol (mg/dL)\n- HDL cholesterol (mg/dL)\n- mean change in SBP (mmHg) from randomization\n- mean change in fasting insulin (pmol/L) from randomization\n\n# Key Secondary (controlled for Type I error)\n\n# at 176 weeks, by dose analysis\n\nFor tirzepatide 10 mg and/or 15 mg QW doses, to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- body weight\n\n# Endpoints\n\n- mean percent change in body weight from randomization\n\nLY3298176    33", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1567, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2b5acf84-c938-4712-9139-50f69eec4db6": {"__data__": {"id_": "2b5acf84-c938-4712-9139-50f69eec4db6", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9148db7b-6a59-423a-87d0-0461afbc4fc6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e8316906d619b3d137941423f12fa6e5222c0f842fa447eaae0735191a696f5b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Objectives\n\n# Endpoints\n\n# Key Secondary (controlled for Type I error)\n\nat 176 or 193 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo (for participants with prediabetes at randomization) in:\n\n- time to onset of T2DM during 176 weeks treatment period\n- delayed progression to T2DM at 176 weeks\n- delayed progression to T2DM at 193 weeks\n- time to onset of T2DM during entire study including safety follow up period\n\n# Additional secondary at 72 weeks, by dose analysis\n\n# Efficacy\n\nFor tirzepatide 5 mg QW dose, to demonstrate superiority to placebo at 72 weeks for:\n\n- body weight\n- percentage of participants who achieve\n- \u226510% body weight reduction from randomization\n- \u226515% body weight reduction from randomization\n- waist circumference\n- mean change in waist circumference (cm) from randomization\n- patient reported outcomes (SF\u201136v2 Physical Functioning)\n- mean change in SF\u201136 v2 acute form Physical Functioning domain score from randomization\n\nFor tirzepatide 5 mg, 10 mg, and/or 15 mg QW doses, to demonstrate superiority to placebo for:\n\n- body weight\n- mean change in body weight (kg) from randomization\n- mean change in BMI (kg/m\u00b2) from randomization\n- glycemic control\n- mean change in HbA1c (%, mmol/mol) from randomization\n- mean change in fasting glucose (mg/dL) from randomization\n- Patient\u2011reported outcomes\n- Mean change in IWQOL\u2011Lite\u2011CT Physical Function composite score from randomization\n\nLY3298176    34", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1529, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8f285835-3f2a-4f78-bb75-7fa0c05d8398": {"__data__": {"id_": "8f285835-3f2a-4f78-bb75-7fa0c05d8398", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b0dba5c9-90c4-43b0-8a7e-80550665096a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "316169e5bd272e47dd27da6d26e2cda1351e5d3c7354f5199470038803713f73", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Objectives\n\n# Endpoints\n\nAdditional secondary at 72 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo at 72 weeks for\n\n- DBP\n- mean change in DBP (mmHg) from randomization\n- lipid parameters\n- mean change from randomization in:\n\nAdditional secondary at 176 weeks, by dose analysis\n\nFor tirzepatide 5 mg QW dose, to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- body weight\n- mean percent change in body weight from randomization\n\nFor tirzepatide 5 mg, 10 mg, and/or 15 mg QW doses, to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- body weight\n- percentage of study participants who achieve \u22655% body weight reduction from randomization\n\nAdditional Secondary at 176 weeks, pooled dose analysis\n\nFor tirzepatide QW (all doses combined), to demonstrate superiority to placebo (for participants with prediabetes at randomization) for:\n\n- Patient\u2011reported outcomes\n- mean change in SF\u201136v2 acute form Physical Functioning domain score from randomization\n- mean change in IWQOL\u2011Lite\u2011CT Physical Function composite score from randomization\n\nLY3298176    35", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1250, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e7347695-0937-42d9-b760-e5d783976c17": {"__data__": {"id_": "e7347695-0937-42d9-b760-e5d783976c17", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "92c87418-61aa-4986-95b5-793c4cc07d98", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9ea8f649fd2976f7cdf0c977b75b43894a0bcc229c4aeb6e8ba75147db9076f8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Objectives\n\n# Endpoints\n\n# Additional Secondary\n\n# Pharmacokinetics/Pharmacodynamics\n\n\u2022 To characterize the population PK of tirzepatide and explore the relationships between the tirzepatide concentration and efficacy, safety and tolerability measures\n\n# Endpoints\n\n\u2022 population PK and PD parameters\n\n# Abbreviations:\n\nAUC = area under the curve; BMI = body mass index; DBP = diastolic blood pressure; HbA1c = hemoglobin A1c; HDL = high\u2011density lipoprotein; IWQOL\u2011Lite\u2011CT = Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version; LDL = low\u2011density lipoprotein; PD = pharmacodynamics; PK = pharmacokinetics; QW = once\u2011weekly; SAP = statistical analysis plan; SBP = systolic blood pressure; SF\u201136v2 = Short Form survey\u201136 version 2, T2DM = type 2 diabetes mellitus; VLDL = very low\u2011density lipoprotein.\n\nLY3298176    36", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 872, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fe92fffa-ba4a-4848-8725-4853cc961d7f": {"__data__": {"id_": "fe92fffa-ba4a-4848-8725-4853cc961d7f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "41cfba3e-eafd-4c6d-86b5-880aa476c9c5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cd47d35338ba84bc11c0ccbc656ed58754489d97d7fcc13d2b6e6f9df6f5da29", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 4. Study Design\n\n# 4.1. Overall Design\n\nStudy GPHK (SURMOUNT\u20111) is a Phase 3, multicenter, randomized, double\u2011blinded, placebo\u2011controlled study that will investigate the effects of treatment with tirzepatide 5 mg, 10 mg, and 15 mg QW compared with placebo on weight loss in study participants without T2DM who are either obese (BMI \u226530 kg/m\u00b2) or overweight (\u226527 kg/m\u00b2) with at least one weight\u2011related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). The coprimary endpoints will be mean percent change in weight and percentage of participants reaching \u22655% total body weight loss, measured from randomization to Week 72.\n\nStudy participants will be randomized in a 1:1:1:1 ratio (tirzepatide 5 mg QW, tirzepatide 10 mg QW, tirzepatide 15 mg QW, and placebo). An upper limit of 70% enrollment of women will be used to ensure a sufficiently large sample of men.\n\nAll participants will undergo a 2\u2011week screening period and a 72\u2011week treatment period including a 20\u2011week dose escalation. Participants who have prediabetes will be studied for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to detect potential differences in progression to T2DM.\n\nThe safety follow\u2011up period will be 4 weeks (for participants completing or discontinuing study drug during the first 72 weeks) or 17 weeks (for participants completing or discontinuing study drug between Weeks 72 through 176).\n\n# 4.1.1. Overview of Study Periods\n\n# 4.1.1.1. Visit Structure for all Office Visits\n\nOn all designated fasting office visits, study participants are required to report to the site in a fasting condition, after approximately 8 hours without eating, drinking (except water), or performing any significant physical activity. If a participant is adversely affected by the fasting condition, they are allowed to eat; however, specific study procedures need to be completed while fasting. See Section 10.8 for a suggested order of activities that occurs at office visits.\n\n# 4.1.1.2. Main Study Period\n\n# 4.1.1.2.1. Screening Period\n\nVisit 1\n\nThe purpose of screening procedures at Visit 1 is to establish initial eligibility and to obtain blood samples for laboratory assessments needed to confirm eligibility and classify glycemic status (Section 4.1.2.1). The participant must sign the informed consent form (ICF) before the study procedures are performed, as outlined in the Schedule of Activities, Section 1.3. Since some screening procedures need to be completed in the fasting state (approximately 8 hours without eating, drinking [except water], or any significant physical activity), Visit 1 may be conducted over more than 1 day to ensure necessary conditions are met. Participants who have no glycemic assessments suggestive of T2DM (Section 4.1.2.1) and meet all other applicable", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2863, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5b777f47-9430-422a-a18e-ed6856e31e2a": {"__data__": {"id_": "5b777f47-9430-422a-a18e-ed6856e31e2a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "29ed5b1b-e2e4-46b2-8abf-ef2646e29758", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "85f9d98b7a3c34f5715c5076bcadc84b147973e0bb7090d724db4092b8bf18c8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 4.1.1.2.1. Visit 2\n\nParticipants should arrive to the clinic in the fasting state (approximately 8 hours without eating, drinking [except water], or any significant physical activity). At Visit 2, the screening laboratory results will be reviewed. For those participants without glycemic evidence of T2DM (Section 4.1.2.1), and meeting all other eligibility requirements, a 2\u2011hour oral glucose tolerance test (OGTT) will be performed. The 2\u2011hour OGTT consists of assessment of glucose, insulin, and c\u2011peptide at time 0, 30, 60, 90, and 120 minutes (Sections 4.1.2.2 and 10.7). If calcitonin results are not available, Visit 2 can proceed. A final review of eligibility will occur at Visit 3 before randomization can proceed.\n\nThe mental health questionnaires (Columbia\u2011Suicide Severity Rating Scale [C\u2011SSRS] and Self\u2011Harm Form) should be completed after the assessment for AEs.\n\n# 4.1.1.2.2. Treatment Period\n\n# Randomization (Visit 3)\n\nAt Visit 3, eligible participants will perform all required baseline study procedures (including the collection of all baseline laboratory measures and questionnaires) prior to randomization and prior to taking the first dose of study drug. Participants should arrive to the clinic in the fasting state (after a period of approximately 8 hours without eating, drinking [except water], or any significant physical activity). Patient\u2011reported outcomes (PROs) questionnaires should be administered as early as possible, as per Suggested Visit Structure (Section 10.8). Preferred administration order is: Patient Global Impression of status for physical activity (PGIS), Short Form survey\u201136 version 2 (SF\u201136v2) acute form, Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version (IWQOL\u2011Lite\u2011CT), and EQ\u20115D\u20115L. The mental health questionnaires (Patient Health Questionnaire\u20119 [PHQ\u20119], C\u2011SSRS, and Self\u2011Harm Form) should be completed after the assessment for AEs.\n\nParticipants will receive an initial consultation with a qualified dietician, according to local standards, to set lifestyle goals for caloric intake and physical activity (Sections 5.3.1 and 5.3.2). Following randomization, study site personnel will demonstrate use of the autoinjector (also referred to as single\u2011dose pen) using the provided demonstration device and observe the study participant inject the first dose of tirzepatide or placebo. The date, time, and location of the first dose of study drug will be recorded on the electronic case report form (eCRF). Beginning at randomization, all participants will receive study drug according to the randomized treatment arm for the duration of the 72\u2011week treatment period including a 20\u2011week dose escalation. Participants will be provided diaries and be trained to record key study information, as appropriate.\n\n# Treatment Period (End of Visit 3 to Visit 21)\n\nDuring the treatment period, office visits will occur monthly through 24 weeks and then every 12 weeks thereafter, to 72 weeks. The participant should be fasting for all office visits. Telephone visits will occur at 4\u2011week intervals between the office visits starting at Week 28.\n\nLY3298176 38", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3160, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "850ec10a-0b9b-4ecb-8852-e1d0dc3ff5ee": {"__data__": {"id_": "850ec10a-0b9b-4ecb-8852-e1d0dc3ff5ee", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "05e2b3a8-8a71-4b6d-9fa7-ebe3cca57788", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "10a6e76efbca75202edc8cdefd7d2644344c383eda49b5afe9984adc1fcd4d8e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nOffice visit procedures should be conducted according to the Schedule of Activities (Section 1.3), and will include:\n\n- weight, waist circumference, and vital signs measurements\n- review of participant diary information (to include reinforcement and compliance assessments for study drug administration and lifestyle goals)\n- administration of questionnaires\n- laboratory testing\n- drug dispensing\n- collect AEs, product complaints and concomitant medications\n\nMental Health Questionnaires should be completed after the assessment of AEs.\n\nDietician consultations continue at Weeks 4, 8, 12, and then every 12 weeks thereafter, to Week 72. Study drug and injection supplies will be returned per the Schedule of Activities (Section 1.3) and according to local requirements. New supplies will be dispensed as needed.\n\nStudy drug dose escalation is double\u2011blinded and will be managed via the interactive web\u2011response system (IWRS). The starting dose is 2.5 mg QW (or matching placebo) for 4 weeks, then the dose is increased by 2.5 mg (or matching placebo) every 4 weeks: 2.5 to 5 mg for those randomized to 5 mg, 2.5 to 5 to 7.5 to 10 mg for those randomized to 10 mg, and continuing to 12.5 to 15 mg for those randomized to 15 mg. The dose is then maintained up to 72 weeks.\n\nAt each of the 8 scheduled telephone visits, procedures will include:\n\n- reinforcement and compliance assessments for study drug administration and lifestyle goals,\n- listing of concomitant medications\n- AE and Product Complaints (PCs) assessment (see Schedule of Activities Section 1.3.1)\n- administration of questionnaires\n\nParticipants should be instructed to contact the investigative site for assistance as soon as possible if they experience any difficulties administering their study medication. Participants should also be advised about the appropriate course of action in the event that study drug is not taken at the required time (late/missing doses).\n\nStudy participants will be permitted to use concomitant medications that they require during the study, except certain excluded medications (see Section 5.2) that may interfere with the assessment of efficacy and safety characteristics of the study treatments.\n\nFor those participants without glycemic evidence of T2DM (Section 4.1.2.1), a 2\u2011hour oral OGTT will be performed at Visit 21.\n\n# Visit 99\n\nVisit 99 is only applicable to participants who discontinue the study treatment prematurely (before Week 72). Participants will be asked to return for Visit 99 at 72 weeks \u00b1 7 days after\n\nLY3298176 39", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2581, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6692f1e9-bdb6-45bc-8207-c5c2f1830834": {"__data__": {"id_": "6692f1e9-bdb6-45bc-8207-c5c2f1830834", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "23f8e959-43bb-4f24-a05d-d168c96fdc02", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9a6d6a122da2432e09a0b5416f8cc5ae684477a8823885daf6069177fd5fae98", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nrandomization. This visit is critical to ensure complete data collection for the primary weight\u2011loss endpoint.\n\nParticipants should attend this visit in the fasting state. Procedures to be completed are:\n\n- measurement of weight\n- listing of concomitant medications\n- assessment of AEs\n- completion of the mental health questionnaires (after the AE assessment)\n\nFor participants unwilling to attend this visit, their refusal to attend should be documented in the participant medical record.\n\n# 4.1.1.2.3. Additional 2-Year Treatment Period for Participants with Prediabetes at Randomization (Visits 101 through 116)\n\nParticipants classified as having prediabetes at randomization and who remain on study drug through Week 72, will continue follow\u2011up for an additional 104 weeks (total study duration 176 weeks). Subsequent visits will occur approximately every 1.5 months, alternating between telephone and office visits.\n\nOffice visit procedures should be conducted according to the Schedule of Activities (Section 1.3), and will include:\n\n- weight, waist circumference, and vital signs measurements\n- review of participant diary information (to include reinforcement and compliance assessments for drug administration and lifestyle goals)\n- administration of questionnaires\n- laboratory testing\n- drug dispensing\n- collection of AEs, product complaints, and concomitant medications\n\nPatient\u2011reported outcomes questionnaires should be administered as early as possible, as per Suggested Visit Structure (Section 10.8). Mental Health Questionnaires should be completed after the assessment of AEs.\n\nDietician consultations continue approximately every 3 months after Visit 21 to Visit 116. At Visits 108 and 116, participants will undergo 2 hour OGTTs, unless diabetes had been diagnosed prior to the visits (Sections 4.1.2.2 and 10.7). Study drug and injection supplies will be returned per the Schedule of Activities (Section 1.3) and according to local requirements. New supplies will be dispensed as needed.\n\nAt each of the 8 scheduled telephone visits, procedures will include:\n\n- reinforcement and compliance assessments for study drug administration and lifestyle goals\n- listing of concomitant medications\n\nLY3298176 40", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2268, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "29b8543b-76fc-4221-923c-bbee9f3086bb": {"__data__": {"id_": "29b8543b-76fc-4221-923c-bbee9f3086bb", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6d6edacb-876a-4313-975e-7e621302ed0c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "706a88257f8fc1238d5c03ee75e22b2660986d61d92e49a6342fb2724724f834", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK(b)\n\n\u2022          AE and PC assessment (see Schedule of Activities [Section 1.3])\n\n\u2022          administration of questionnaires\n\nParticipants should be instructed to contact the investigative site for assistance as soon as possible if they experience any difficulties administering their study medication. Participants should also be advised about the appropriate course of action in the event that study drug is not taken at the required time (late/missing doses).\n\n# Visit 199\n\nVisit 199 is only applicable to participants who discontinue the study treatment prematurely (between Week 72 and Week 176). Participants will be asked to return for Visit 199 at 176 weeks \u00b1 7 days after randomization. This visit is critical to ensure complete data collection for the weight\u2011loss and progression\u2011to\u2011diabetes endpoints.\n\nParticipants should attend this visit in the fasting state. Procedures to be completed are:\n\n- measurement of weight\n- measurement of waist circumference\n- listing of concomitant medications\n- assessment of AEs\n- completion of the mental health questionnaires (after the AE assessment)\n- 2\u2011hour OGTT\n\nFor participants unwilling to attend this visit, their refusal to attend should be documented in the participant medical record.\n\n# 4.1.1.2.4.  Early Discontinuation of Treatment Visit\n\nParticipants unable or unwilling to continue the study treatment for any reason will perform an early discontinuation of treatment (ED) visit. If the participant is discontinuing during an unscheduled visit, that visit should be performed as the ED visit. If the participant is discontinuing during a scheduled visit, that visit should be performed as an ED visit. Procedures should be completed according to the Schedule of Activities (Section 1.3). Patient\u2011reported outcomes questionnaires should be administered as early as possible, as per Suggested Visit Structure (Section 10.8). Administration of mental health questionnaires should follow assessment for AEs (see Section 7.2).\n\n# 4.1.1.2.5. Safety Follow-up Period\n\n# Visit 801 or Visit 802\n\nAll participants are required to complete a safety follow\u2011up visit (Visit 801 or Visit 802), according to the Schedule of Activities (Section 1.3). Participants discontinuing the study early and performing an ED visit will also be asked to perform the safety follow\u2011up visit. During the safety follow\u2011up period, participants will not receive study drug. Participants are also required to return any remaining study diaries to the study site at the end of this period.\n\nLY3298176    41", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2623, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0e77ba2e-481c-4540-85f5-ec675ba6c005": {"__data__": {"id_": "0e77ba2e-481c-4540-85f5-ec675ba6c005", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "994fb151-cf88-4e42-b7b4-38a2c1d1a993", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "34dded261aaf6826ba5ddf2dd0996d860e55f2e2094eddf0689af7e6ff4cff22", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nFor participants who discontinue or complete the study within the first 72 weeks, Visit 801 (safety follow\u2011up visit) should be performed 4 weeks after the last treatment visit (Visit 21 or 99) or 4 weeks after the ED visit for those who decline to return for Visit 99. Participants with prediabetes continuing to Week 78 should not perform Visit 801.\n\nFor those participants without glycemic evidence of T2DM (Section 4.1.2.1), a 2\u2011hour oral OGTT will be performed at Visit 802.\n\n# 4.1.2. Study Procedures\n\nParticipants will perform study procedures listed in the Schedule of Activities (Section 1.3). Participants will be permitted to use concomitant medications that they require during the study, except certain medications that may interfere with the assessment of efficacy and safety characteristics of the study treatments (Section 5.2). Study governance considerations are described in detail in Section 10.1 (Appendix 1).\n\n# 4.1.2.1. Definition of Prediabetes\n\nThe duration of treatment in Study GPHK (SURMOUNT\u20111) is determined by glycemic status at randomization, categorized into those with prediabetes or normoglycemia (participants with T2DM are excluded), as defined by the 2019 American Diabetes Association Standards of Medical Care in Diabetes (American Diabetes Association 2019b). The following populations are defined:\n\n|                 | **Normoglycemia**        | **Prediabetes**                 | **Diabetes**              |\n| --------------- | ------------------------ | ------------------------------- | ------------------------- |\n| Fasting glucose | <100 mg/dL (<5.6 mmol/L) | 100\u2011125 mg/dL (5.6\u20116.9 mmol/L)  | \u2265126 mg/dL (\u22657.0 mmol/L)  |\n| 2H glucose      | <140 mg/dL (<7.8 mmol/L) | 140\u2011199 mg/dL (7.8\u201111.0 mmol/L) | \u2265200 mg/dL (\u226511.1 mmol/L) |\n| HbA1c           | <5.7% (<39 mmol/mol)     | 5.7%\u20116.4% (39\u201147 mmol/mol)      | \u22656.5% (\u226548 mmol/mol)      |\n\nAbbreviations: H = hour; HbA1c = hemoglobin A1c; OGTT = 2\u2011hour oral glucose tolerance test.\n\nScreening to determine randomization glycemic status will occur in 2 visits:\n\n# Screening Visit 1\n\nParticipants will have a fasting glucose (FG) and HbA1c test. Results of these tests determine eligibility to proceed to Screening Visit 2.\n\n- FG \u2265126 mg/dL (7.0 mmol/L) OR HbA1c \u22656.5% (48 mmol/mol) suggests DM. These participants are excluded from the study and should be referred to their primary care physician for further work\u2011up to confirm the diagnosis.\n\nLY3298176\n\n42", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2492, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ae99e7e6-21bc-47bb-a4f9-e247d4cbde7a": {"__data__": {"id_": "ae99e7e6-21bc-47bb-a4f9-e247d4cbde7a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "777f4562-88a6-4a03-99f0-4537778d2a84", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e989c8f565c22866f1f7ef12d1397555e601396ee7cabfaa0d10e8198167ee2a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                 Protocol I8F\u2011MC\u2011GPHK(b)\n\n\u2022 All participants otherwise eligible and without FG or HbA1c values suggestive of diabetes will proceed to Screening Visit 2\n\n# Screening Visit 2\n\nAll participants attending Screening Visit 2 will undergo a 2\u2011hour OGTT test. These results, in combination with those obtained from Screening Visit 1, will be used to determine study eligibility and randomization glycemic status.\n\n\u2022 2\u2011hour OGTT results: FG \u2265126 mg/dL (\u22657.0 mmol/L) OR 2\u2011hour OGTT \u2265200 mg/dL (\u226511.1 mmol/L) suggests diabetes mellitus. These participants are excluded from the study and should be referred to their primary care physician for further work\u2011up to confirm the diagnosis.\n\n# Glycemic Classification\n\nAll participants without laboratory tests suggestive of diabetes will be classified as having either normoglycemia or prediabetes. In keeping with American Diabetes Association guidelines (American Diabetes Association 2019b), at least 2 abnormal tests are required to diagnose prediabetes. For example:\n\n- Both 0 AND 2\u2011hour values during the 2\u2011hour OGTT values are in the prediabetes range.\n- FG at Screening Visit 1 AND Visit 2 are in the prediabetes range.\n- FG at Screening Visit 1 AND 2\u2011hour values during 2\u2011hour OGTT are in the prediabetes range.\n- HbA1c AND 1 of either the FG or 2\u2011hour OGTT values are in the prediabetes range.\n\n# 4.1.2.2. Oral Glucose Tolerance Test\n\nParticipants should attend visits requiring a 2\u2011hour OGTT in the fasting state. Samples will be collected at 0, 30, 60, 90, and 120 minutes during the 2\u2011hour OGTT, unless the OGTT is repeated to confirm the diagnosis of diabetes. For glycemic classification, the values at time = 0 min (FG) and 120 minutes (2\u2011hour OGTT) will be used. If a 2\u2011hour OGTT is repeated to confirm the diagnosis of diabetes (see Section 4.1.2.3), only samples at 0 and 120 minutes for glucose measurement will be collected.\n\nTwo\u2011hour OGTTs should be performed per the Schedule of Activities (Section 1.3) and as described in Section 10.7, until such time as a protocol\u2011defined diagnosis of diabetes is confirmed (see Section 4.1.2.3). Two\u2011hour OGTT testing should be omitted at visits following a protocol\u2011defined diabetes diagnosis.\n\n# 4.1.2.3. Definition and Management of Incident Diabetes\n\n# Definition of incident diabetes\n\nIncident diabetes is defined when any 1 of the following occur after randomization (American Diabetes Association 2019b):\n\n- unequivocal hyperglycemia (random glucose \u2265200 mg/dL) with signs or symptoms of hyperglycemia\n\nLY3298176    43", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2581, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0612e6f9-36b4-4070-a628-602df130cfca": {"__data__": {"id_": "0612e6f9-36b4-4070-a628-602df130cfca", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d9bec198-6f9b-423d-8c39-33ea89f68d87", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b9a81e3a2c5c31687a1d3523be287f47e73659287f0228507e14d5e3f76ccd31", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Criteria for Diagnosis of Diabetes\n\n\u2022 any 2 of the following criteria are observed at the same visit, or 1 abnormal value is observed and subsequently confirmed:\n\n- HbA1c \u22656.5% (48 mmol/mol)\n- FG or 0\u2011hour serum glucose from 2\u2011hour OGTT \u2265126 mg/dL (7.0 mmol/L)\n- 2\u2011hour glucose \u2265200 mg/dL (11.1 mmol/L) by a 2\u2011hour OGTT\n\n\u2022 initiation of any medication for the treatment of diabetes\n\n# Confirmation of Diabetes Diagnosis\n\nIn the event 1 abnormal value is observed (HbA1c \u22656.5% [48 mmol/mol]) OR fasting glucose (or 0\u2011hour serum glucose from 2\u2011hour OGTT) \u2265126 mg/dL (7.0 mmol/L) OR 2\u2011hour glucose from 2\u2011hour OGTT \u2265200 mg/dL (11.1 mmol/L)* after randomization, the abnormal test should be repeated within 4 weeks to confirm diagnosis of diabetes and to ensure that diabetes management is initiated without delay.\n\n*If the abnormal value observed is 2\u2011hour glucose from the OGTT \u2265200 mg/dL (11.1 mmol/L), the 2\u2011hour OGTT should be repeated within 4 weeks (only samples at 0 and 120 minutes for glucose measurement will be collected).\n\nThe diagnosis of diabetes is confirmed if any of the following occur:\n\n- HbA1c \u22656.5% (48 mmol/mol) is observed at 2 measurements any time during the study.\n- 2\u2011hour glucose \u2265200 mg/dL (11.1 mmol/L) during an OGTT is observed at 2 measurements any time during the study.\n- FG value \u2265126 mg/dL (7.0 mmol/L) is observed at a consecutive FG measurement (either at a scheduled or an unscheduled visit) following an isolated FG (or 0\u2011hour serum glucose from 2\u2011hour OGTT) value \u2265126 mg/dL (7.0 mmol/L).\n\n\u2022 If diabetes diagnosis has not been confirmed at the consecutive FG measurement, another FG (or 0\u2011hour serum glucose result from 2\u2011hour OGTT) result \u2265126 mg/dL (7.0 mmol/L) observed during the study will be considered as a new finding requiring confirmation.\n\nNote: Once diabetes has been confirmed, repeating any future abnormal test within 4 weeks is no longer required.\n\n# Recording of Incident Diabetes Events\n\n- Diabetes diagnosis and the onset date as assessed by investigator will be recorded in the AE eCRF and the dedicated endpoint eCRF.\n- If the diagnosis of diabetes is based on laboratory results, the date of the first abnormal HbA1c or glucose value within the diabetes range should be indicated as the date of diagnosis, unless, in the investigator\u2019s opinion, a different date is more appropriate. If the diagnosis is based on initiation of any medication for the treatment of diabetes, the investigator should indicate the most probable date of diagnosis in the eCRFs.\n\nLY3298176 44", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2572, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e3b8a491-dac3-436b-bd31-2d701daa0566": {"__data__": {"id_": "e3b8a491-dac3-436b-bd31-2d701daa0566", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4246746e-22e3-44e7-9661-3446c77b5297", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "52f802b77d798e863b1144928f3d3a140b26916562b0c10c50718d0623e65b1b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n\u2022 All reported or suspected cases of incident diabetes will be adjudicated by an independent clinical endpoint committee (adjudication committee).\n\n\u2022 Decisions of the adjudication committee regarding diabetes diagnosis and the onset date will be recorded in the dedicated adjudication eCRF.\n\n# Management of incident diabetes\n\nParticipants who develop diabetes during the study will be\n\n- provided and trained to use a glucometer\n- educated on the signs and symptoms of hypoglycemia and its treatment, and\n- provided a diary to record hypoglycemic episodes per Section 10.3.1.1.\n\nParticipants will be referred to their usual care provider and provided with a letter showing the study results indicative of diabetes. The decision to further evaluate, to initiate antihyperglycemic therapy, and the choice of antihyperglycemic medication will be at the discretion of the participant\u2019s usual care provider, with the exception of use of dipeptidyl\u2011peptidase\u20114 (DPP\u20114) inhibitors and open\u2011label GLP\u20111R agonists, which are prohibited in the study. Monitoring for hypoglycemia includes capture of events as defined in Section 10.3 (Appendix 3).\n\n# 4.2. Scientific Rationale for Study Design\n\nTirzepatide is a 39\u2011amino acid synthetic peptide with agonist activity at both the GIPR and GLP\u20111R. Its structure is based on the GIP sequence and includes a C20 fatty di\u2011acid moiety (Coskun et al. 2018). It is administered QW by SC injection.\n\nAs a dual GIP/GLP\u20111R agonist, tirzepatide could exceed the efficacy of selective GLP\u20111R agonists by recruiting metabolically active tissues not targeted by selective GLP\u20111R agonists (for example, adipose tissue as indicated by the observation of increased energy utilization) (Baggio and Drucker 2007) and has the potential to reach higher efficacy in target tissues, such as insulin\u2011producing pancreatic beta cells that express both GIPR and GLP\u20111R, before reaching its therapeutic limitation. Results from a Phase 2 study (GPGB) demonstrated that tirzepatide use in participants with T2DM was associated with a substantial, dose\u2011dependent weight loss, greater than the weight change observed with dulaglutide, a specific GLP\u20111R agonist. General safety characteristics of all studied doses of tirzepatide were similar to that of the GLP\u20111R agonist class, consisting mainly of nausea, vomiting, and diarrhea. In general, these events were transient and mild or moderate in severity, with few severe episodes. Although GI AEs were more common at the 15\u2011mg arm of tirzepatide, this dose demonstrated the highest efficacy in terms of weight loss. This suggests that tirzepatide has the potential to become a medication for chronic weight management. An optimized dose escalation regimen, proposed in the Study GPHK (SURMOUNT\u20111) to improve tolerability (and supported by a dose\u2011escalation algorithm from study GPGF), should enable a use of higher doses to maximize effects on body weight. Study GPHK (SURMOUNT\u20111) is designed to determine the comparative benefits and risks of\n\nLY3298176 45", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3056, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "77eb6720-36c5-4c4d-a9ce-ddff1c1f6b29": {"__data__": {"id_": "77eb6720-36c5-4c4d-a9ce-ddff1c1f6b29", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b9ad44e7-e6c5-4a1f-a619-cb07fb64cde2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9549a817445352666a322ca753ea1e90ada1db96f43f0b7faf8f2e44d8a34543", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\ntirzepatide 5 mg, 10 mg or 15 mg QW versus placebo in participants who have obesity or are overweight. A double\u2011blind design was selected to minimize participant and investigator bias in assessments for efficacy, safety, and study drug tolerability.\n\nA placebo comparator was selected for this trial in accordance with regulatory guidance (FDA 2007; EMA 2016). In addition, all participants, regardless of treatment assignment, will receive lifestyle modification counselling consistent with current guidelines for weight management (Jensen et al. 2013). Specifically, participants will consult with a dietician, or equivalent qualified delegate, throughout the study to achieve at least a 500 kcal/day energy deficit through a combination of caloric restriction and increased physical activity (Section 5.3.1). The planned duration of treatment for the primary endpoint at 72 weeks allows for at least a 52\u2011week treatment period at the dose achieved following dose escalation to either 5, 10, or 15 mg. This duration is considered appropriate to assess the full effects and benefit/risk of each maintenance dose of tirzepatide compared with placebo on body weight and is consistent with regulatory guidelines (FDA 2007; EMA 2016).\n\nThe effects of drug cessation will be assessed in the 4\u2011week and in the 12\u2011week safety follow\u2011up/observational periods.\n\nAnother objective of the study is to evaluate the effect of tirzepatide on the risk of new\u2011onset diabetes. Obesity is associated with an increased risk of developing T2DM and diabetes prevention is of great importance in obese subjects to protect them from complications of the disease. Several studies have shown that interventions leading to weight loss may help prevent diabetes (Adams et al. 2017, le Roux et al. 2017).\n\nTo obtain additional information regarding the rate of conversion to diabetes on tirzepatide, participants with prediabetes diagnosed at the beginning of the study (being at increased risk of diabetes), will be treated and observed for an additional 2 years. Based on available literature, the 3 years of treatment with tirzepatide should be sufficient to demonstrate the risk reduction of developing T2DM compared to placebo. This additional treatment period would also permit collecting data on the durability of weight changes with long\u2011term therapy and safety of long\u2011term tirzepatide treatment.\n\nTo minimize the potential confounding effect of changes to concomitant medications, participants will be permitted to use concomitant medications that do not interfere with the assessment of efficacy or safety characteristics of the study treatments.\n\n# 4.3. Justification for Dose\n\nTirzepatide doses of 5 mg, 10 mg, and 15 mg QW will be evaluated in this study. These doses and associated escalation schemes were selected based on assessment of safety, efficacy (weight loss), and GI tolerability data, followed by exposure\u2011response modeling of data in patients in Phase 1 and 2 studies that predicted weight loss in obese and overweight patients without T2DM. Dosing algorithms starting at a low dose of 2.5 mg accompanied by dose escalation of 2.5\u2011mg increments every 4 weeks should permit time for development of tolerance to GI events and are predicted to minimize GI tolerability concerns. The maximum proposed dose of 15 mg maintains an exposure multiple of 1.6 to 2.4 to the no\u2011observed adverse\u2011effect level doses in 6\u2011month monkey and rat toxicology studies.\n\nLY3298176 46", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3502, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4a9863e9-1495-48f1-a6d8-6873615ec3eb": {"__data__": {"id_": "4a9863e9-1495-48f1-a6d8-6873615ec3eb", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c4189724-3c6f-4ae3-8eb4-f7f4d06aff6e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "52d0066f317593c938779edd8a5fb05a9a06699a900f4e10b56bafeefde6b168", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 4.4. End of Study Definition\n\nSection 7.2 describes the criteria used to determine if a participant has completed the study. The end of the study is defined as the date of the last visit of the last participant in the study or the last scheduled procedure shown in the Schedule of Activities (Section 1.3.1 or 1.3.2 based on randomization glycemic status), for the last participant in the trial globally.\n\nLY3298176    47", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 465, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fbfe5ad0-46fa-4b1b-90b8-31943bb36701": {"__data__": {"id_": "fbfe5ad0-46fa-4b1b-90b8-31943bb36701", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "07bb7cfc-3693-4c9a-b022-bb8b4dd96b4b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "546dee57c0a9cd46d6401eeb1e31b5e00b798079b50fa58084740f4f213033eb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 5. Study Population\n\nProspective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, is not permitted.\n\n# 5.1. Inclusion Criteria\n\nParticipants are eligible to be included in the study only if all of the following criteria apply:\n\n# Type of Participant and Disease Characteristics\n\n1. Have a BMI\n- \u226530 kg/m\u00b2 or\n- \u226527 kg/m\u00b2 and previously diagnosed with at least one of the following weight related comorbidities:\n1. hypertension: treated or with systolic blood pressure (SBP) \u2265130 mmHg or diastolic blood pressure \u226580 mmHg\n2. dyslipidemia: treated or with low\u2011density lipoprotein (LDL) \u2265160 mg/dL (4.1 mmol/L) or triglycerides \u2265150 mg/dL (1.7 mmol/L), or high\u2011density lipoprotein (HDL) &#x3C;40 mg/dL (1.0 mmol/L) for men or HDL&#x3C;50 mg/dL (1.3 mmol/L) for women\n3. obstructive sleep apnea\n4. cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I\u2011III heart failure)\n2. Have a history of at least one self\u2011reported unsuccessful dietary effort to lose body weight\n3. In the investigator\u2019s opinion, are well\u2011motivated, capable, and willing to\n- learn how to self\u2011inject study drug, as required for this protocol (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject study drug; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject study drug)\n- inject study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)\n- follow study procedures for the duration of the study, including, but not limited to: follow lifestyle advice (for example, dietary restrictions and exercise plan), maintain a study diary, and complete required questionnaires\n\nLY3298176    48", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1955, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0186137b-29ea-4e0e-a4b5-f45f69b2c951": {"__data__": {"id_": "0186137b-29ea-4e0e-a4b5-f45f69b2c951", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "45809fcb-6c1c-4861-b3f3-14430fea4a79", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b292a3aeab4c59eaec87313297b860059ecd42ec7b9a8881e75e9d04240cf27c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Participant Characteristics\n\n4. Are 18 years or older\n\n- a. male participants:\n- Male participants with partners of childbearing potential should be willing to use reliable contraceptive methods throughout the study and for 5 half-lives of study drug plus 90 days, corresponding to 4 months after the last injection.\n- b. female participants:\n- Female participants not of childbearing potential may participate and include those who are:\n- infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy or tubal ligation), congenital anomaly such as Mullerian agenesis\n- postmenopausal, defined as either\n- a woman at least 40 years of age with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, AND a follicle-stimulating hormone \u226540 mIU/mL; women in this category must test negative in pregnancy test prior to study entry\n- or a woman 55 or older not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea\n- or a woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy\n- Female participants of child-bearing potential (not surgically sterilized and between menarche and 1-year postmenopausal) must:\n- test negative for pregnancy at Visit 1 based on a serum pregnancy test\n- and if sexually active, agree to use 2 forms of effective contraception, where at least 1 form is highly effective, for the duration of the trial and for 30 days thereafter\n- not be breastfeeding\n\n# Informed Consent\n\n5. Have given written informed consent to participate in this study in accordance with local regulations and the ethical review board (ERB) governing the study site\n\n# 5.2. Exclusion Criteria\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nLY3298176\n\n49", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1889, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3ef56466-81ca-4160-b583-0079e360f5ae": {"__data__": {"id_": "3ef56466-81ca-4160-b583-0079e360f5ae", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "64f19f01-feaf-47c9-a8ef-de66a2e7831e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "13b34a643835d692a497914ef1a14bf52467dc961d1b2e9ac61fcec36e8e890b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Medical Conditions\n\n# Diabetes-related\n\n1. Have type 1 diabetes mellitus (T1DM) or T2DM, history of ketoacidosis, or hyperosmolar state/coma\n2. Have laboratory evidence diagnostic of diabetes mellitus during screening, including 1 or more of: HbA1c \u22656.5% (\u226548 mmol/mol), FG \u2265126 mg/dL (\u22657.0 mmol/L), random glucose or 2\u2011hour glucose measurement from a 2\u2011hour OGTT \u2265200 mg/dL (\u226511.1 mmol/L)\n\n# Obesity-related\n\nHave a self\u2011reported change in body weight >5 kg within 3 months prior to screening\nHave a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed >1 year prior to screening)\nHave or plan to have endoscopic and/or device\u2011based therapy for obesity or have had device removal within the last 6 months (for example, mucosal ablation, gastric artery embolization, intragastric balloon and duodenal\u2011jejunal bypass sleeve)\n\n# Other medical\n\nHave renal impairment measured as estimated glomerular filtration rate (eGFR) &#x3C;30 mL/min/1.73 m\u00b2, calculated by Chronic Kidney Disease\u2011Epidemiology as determined by central laboratory during screening\nHave a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility\nHave had a history of chronic or acute pancreatitis\nHave thyroid\u2011stimulating hormone (TSH) outside of the range of 0.4 to 6.0 mIU/L at screening visit\n- Note: Patients receiving treatment for hypothyroidism may be included, provided their thyroid hormone replacement dose has been stable for at least 3 months.\n- Note: TSH values above the normal range can, in some patients, suggest subclinical hypothyroidism. If, in the investigator\u2019s opinion, the participant has subclinical hypothyroidism and may require initiation of thyroid hormone replacement during the course of the study, the patient should be excluded from the study.\n\nHave obesity induced by other endocrinologic disorders (for example, Cushing Syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome)\nHave a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years\n\nLY3298176\n\n50", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2434, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e1cb826e-28ef-44fa-8203-60cb32ac568c": {"__data__": {"id_": "e1cb826e-28ef-44fa-8203-60cb32ac568c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "489a460f-0d59-4296-921d-5d3a67e85f95", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "72792c0804032615ab52bff9805cc5292a88109f146980dcb9370894fbcfe29d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nNote: Patients with MDD or generalized anxiety disorder whose disease state is considered stable and expected to remain stable throughout the course of the study, in the opinion of the investigator, may be considered for inclusion if they are not on excluded medications.\n\n1. Have any lifetime history of a suicide attempt\n2. Have a Patient Health Questionnaire\u20119 (PHQ\u20119) score of 15 or more at Visit 1 or 3, prior to randomization\n3. On the C\u2011SSRS at Visits 1, 2, or 3, prior to randomization:\n- a \u201cyes\u201d answer to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or\n- a \u201cyes\u201d answer to Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the \"Suicidal Ideation\" portion of the C\u2011SSRS or\n- a \u201cyes\u201d answer to any of the suicide\u2011related behaviors (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Act or Behavior) on the \"Suicidal Behavior\" portion of the C\u2011SSRS and\n- the ideation or behavior occurred within the past month\n4. Have uncontrolled hypertension (SBP above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)\n5. Have any of the following cardiovascular conditions within 3 months prior to randomization: acute myocardial infarction (MI), cerebrovascular accident (stroke), unstable angina, or hospitalization due to congestive heart failure (CHF)\n6. Have NYHA Functional Classification IV CHF\n7. Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease, or any of the following, as determined by the central laboratory during screening:\n- alanine aminotransferase (ALT) level >3.0X the upper limit of normal (ULN) for the reference range or\n- alkaline phosphatase (ALP) level >1.5X the ULN for the reference range or\n- total bilirubin (TBL) level >1.2X the ULN for the reference range (except for cases of known Gilbert\u2019s Syndrome)\n\nNote: Participants with nonalcoholic fatty liver disease are eligible to participate in this trial if their ALT level is \u22643.0X the ULN for the reference range.\n8. Have a calcitonin level (at Visit 1) of:\n\nLY3298176 51", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2176, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c5246e1f-94eb-43ab-966b-3f53f4868ff0": {"__data__": {"id_": "c5246e1f-94eb-43ab-966b-3f53f4868ff0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "064d57ce-11e3-41ac-9389-c95647d73d24", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "46d9b2f17e29cbccd84c59bb9f0a48d605033b2774c1cbf122d23d3f46c1efe4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n- \u226520 ng/L at Visit 1, if eGFR \u226560 mL/min/1.73 m\u00b2\n- \u226535 ng/L at Visit 1, if eGFR &#x3C;60 mL/min/1.73 m\u00b2\n\n1. Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2\n2. Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal\u2011 or squamous\u2011cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years\n3. Have any other condition not listed in this section (for example, hypersensitivity or intolerance) that is a contraindication to GLP\u20111R agonists\n4. Have a history of any other condition (such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder) that, in the opinion of the investigator, may preclude the participant from following and completing the protocol\n5. Have history of use of marijuana within 3 months of enrollment and unwillingness to abstain from marijuana use during the trial. Participants should also refrain from use of cannabidiol oil for the duration of the study\n6. Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or awaiting an organ transplant\n7. Have any hematological condition that may interfere with HbA1c measurement (for example, hemolytic anemias, sickle cell disease)\n\n# Prior/Concomitant Therapy\n\nAre receiving or have received within 3 months prior to screening chronic (>2 weeks or 14 days) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra\u2011articular, or inhaled preparations) or have evidence of a significant, active autoimmune abnormality (for example, lupus or rheumatoid arthritis) that has required (within the last 3 months) or is likely to require, in the opinion of the investigator, concurrent treatment with systemic glucocorticoids (excluding topical, intraocular, intranasal, intra\u2011articular or inhaled preparations) in the next 12 months\nHave current or history of (within 3 months prior to randomization) treatment with medications that may cause significant weight gain, including but not limited to: tricyclic antidepressants, atypical antipsychotic and mood stabilizers for example:\n- imipramine\n- amitriptyline\n- mirtazapine\n- paroxetine\n- phenelzine\n- chlorpromazine\n- thioridazine\n\nLY3298176 52", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2371, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1c0c58a4-0242-459e-bf26-c69f5832f262": {"__data__": {"id_": "1c0c58a4-0242-459e-bf26-c69f5832f262", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "63d736b4-37f1-4b24-91d4-bda2321b2eb9", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d36a01f338f485fed0cdf74886b760ff56ca2bfdc511b2ac3e46aa73c2f58a1b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n- clozapine\n- olanzapine\n- valproic acid and its derivatives\n- lithium\n\nNote: Selective serotonin reuptake inhibitors other than paroxetine are permitted.\n\n34. Have taken within 3 months prior to randomization, medications (prescribed or over\u2011the\u2011counter) or alternative remedies intended to promote weight loss. Examples include, but are not limited to:\n\n- Saxenda\u00ae (liraglutide 3.0 mg)\n- Xenical\u00ae/Alli\u00ae (orlistat)\n- Meridia\u00ae (sibutramine)\n- Acutrim\u00ae (phenylpropanolamine)\n- Sanorex\u00ae (mazindol)\n- Adipex\u00ae (phentermine)\n- BELVIQ\u00ae (lorcaserin)\n- Qsymia\u00ae (phentermine/topiramate combination)\n- Contrave\u00ae (naltrexone/bupropion)\n\nNote: Use of metformin or any other glucose\u2011lowering medication, whether prescribed for polycystic ovary syndrome or diabetes prevention is not permitted.\n\n35. Have started implantable or injectable contraceptives (such as Depo\u2011Provera\u00ae) within 18 months prior to screening.\n\n# Prior/Concurrent Clinical Study Experience\n\n36. Are currently enrolled in any other clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study.\n\n37. Within the last 30 days, have participated in a clinical study and received treatment, whether active or placebo. If the study involved an IP, 5 half\u2011lives or 30 days, whichever is longer, should have passed.\n\n# Other Exclusions\n\n38. Are investigator site personnel directly affiliated with this study and/or their immediate family. Immediate family is defined as a spouse, legal partner, parent, child, or sibling, whether biological or legally adopted.\n\n39. Are Eli Lilly and Company (Lilly) employees.\n\n# 5.3. Lifestyle Considerations\n\nPer the Schedule of Activities (Section 1.3), participants will consult with a dietician, or equivalent qualified delegate, according to local standards, to receive lifestyle management counseling at Weeks 0, 4, 8 and 12 during dose escalation and then at Week 24 and every 12.\n\nLY3298176 53", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2032, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ef852b94-00bc-4ded-982c-2a23b446762e": {"__data__": {"id_": "ef852b94-00bc-4ded-982c-2a23b446762e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "53b930ad-d34e-4edd-9f51-7aae00760f1e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2696fd6af9826c2488e3d1adf6121a0e4fde26c4c0f97415bb8fc94f3148883a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK(b)\n\nweeks thereafter through 72 weeks. Participants in the additional 2\u2011year treatment period for participants with prediabetes at randomization will continue to receive lifestyle management counseling at 3\u2011month intervals as defined in the Schedule of Activities (Section 1.3). Diet and exercise goals established during the lifestyle consultation and the importance of adherence to the lifestyle component of the trial will be reinforced at each trial contact by study staff.\n\n# 5.3.1. Meals and Dietary Restrictions\n\nAt Visit 3 and subsequent visits, study participants will receive diet counselling by a dietician/nutritionist, or equivalent qualified delegate, according to local standard. Dietary counseling will consist of advice on healthy food choices and focus on calorie restriction using a hypocaloric diet with macronutrient composition of:\n\n- maximum 30% of energy from fat\n- approximately 20% of energy from protein\n- approximately 50% of energy from carbohydrates\n- an energy deficit of approximately 500 kcal/day compared to the participant\u2019s estimated total energy expenditure (TEE)\n\nTo encourage adherence, it is recommended that a 3\u2011day diet and exercise diary be completed prior to each counseling visit. During each visit, the participant\u2019s diet is reviewed and advice to maximize adherence is provided if needed.\n\nThe hypocaloric diet is continued after randomization and throughout the treatment period. If a BMI \u226422 kg/m2 is reached, the recommended energy intake should be recalculated with no kcal deficit for the remainder of the trial.\n\nTotal energy expenditure (TEE) is calculated by multiplying the estimated Basal Metabolic Rate (BMR) (see table below) with a Physical Activity Level value of 1.3 (FAO/WHO/UNU 2004), which reflects an inactive lifestyle. This calculation provides a conservative estimate of caloric requirements:\n\nTEE (kcal/day) = BMR X 1.3\n\n# Equations for estimating BMR in kcal/day*\n\n| Sex   | Age         | BMR (kcal/day)                       |\n| ----- | ----------- | ------------------------------------ |\n| Men   | 18\u201130 years | 15.057 X actual weight in kg + 692.2 |\n| Men   | 31\u201160 years | 11.472 X actual weight in kg + 873.1 |\n| Men   | >60 years   | 11.711 X actual weight in kg + 587.7 |\n| Women | 18\u201130 years | 14.818 X actual weight in kg + 486.6 |\n| Women | 31\u201160 years | 8.126 X actual weight in kg + 845.6  |\n\nLY3298176 54", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2425, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "be84f6d7-a4f0-45f4-a851-a766e20043cf": {"__data__": {"id_": "be84f6d7-a4f0-45f4-a851-a766e20043cf", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6ea854ad-6ce4-454d-b9b6-378b717f0820", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6d5903547adacc4490a137ace09c7e2456d48fef0a25ea046867931b802ab342", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n>60 years 9.082 X actual weight in kg + 658.5\n\nAbbreviations: BMR = basal metabolic rate; WHO = World Health Organization.\n\n*Revised WHO equations (adapted from: FAO/WHO/UNU 2004).\n\n# 5.3.2. Physical Activity\n\nAt Visit 3 and all subsequent visits, participants will be advised to increase their physical activity to at least 150 minutes per week.\n\n# 5.4. Screen Failures\n\nScreen failures are defined as participants who consent to participate in the clinical study but are not subsequently randomly assigned to the study intervention. A minimal set of screen\u2011failure information should be collected to ensure transparent reporting of screen\u2011failure participants to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any SAE.\n\nIndividuals who do not meet the criteria for participation in this study (screen failure) may not be rescreened.\n\nLY3298176    55", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1078, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "aa7f9aed-a75e-46d0-a67d-784cc6cd9efb": {"__data__": {"id_": "aa7f9aed-a75e-46d0-a67d-784cc6cd9efb", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2d491b58-f088-47fe-b5b5-7153eaca73d5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "bf2b72e5a4c02b03498e4512758a9ac9c0cac3f4d4b5bc8b7a6f103e85ed62ac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 6. Study Intervention\n\nStudy intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study protocol.\n\n# 6.1. Study Interventions Administered\n\n| ARM Name                | Tirzepatide 5 mg                                                                                                                                                                                     | Tirzepatide 10 mg | Tirzepatide 15 mg | Placebo |\n| ----------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------- | ----------------- | ------- |\n| Dose                    | 5 mg QW                                                                                                                                                                                              | 10 mg QW          | 15 mg QW          | N/A     |\n| Route of Administration | SC                                                                                                                                                                                                   | SC                | SC                | SC      |\n| Sourcing                | Provided centrally by the Sponsor and dispensed via IWRS                                                                                                                                             |                   |                   |         |\n| Packaging and Labeling  | Study Intervention will be provided in autoinjectors (single\u2011dose pens), packaged in cartons to be dispensed. Clinical study materials will be labeled according to country regulatory requirements. |                   |                   |         |\n\nAbbreviations: IWRS = interactive web response service; N/A = not available; QW = once\u2011weekly; SC = subcutaneous.\n\nThere are no restrictions on the time of day each weekly dose of study drug is given, but it is advisable to administer the SC injections on the same day and same time each week. The actual date, time and injection site location of all dose administrations will be recorded in the diary by the participant. If a dose of study drug is missed, the participant should take it as soon as possible unless it is within 72 hours of the next dose, in which case that dose should be skipped, and the next dose should be taken at the appropriate time. The day of weekly administration can be changed if necessary, as long as the last dose was administered 72 or more hours before. All participants will inject study drug subcutaneously in the abdomen or thigh using the injection supplies provided; a caregiver may administer the injection in the participant\u2019s upper arm. The injection site location of all dose administrations will be recorded by the participant. A new autoinjector will be used for each injection. If study drug is to always be injected in the same body region, participants should be advised to rotate injection sites each week.\n\n# 6.1.1. Medical Devices\n\nThe combination products provided for use in the study are tirzepatide investigational autoinjector (or matching placebo). Any medical\u2011device incidents, including those resulting from malfunctions of the device, must be detected, documented, and reported by the investigator throughout the study (see Section 10.6).\n\nLY3298176    56", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3590, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c58dae28-4861-4ac0-9e73-833bfa951707": {"__data__": {"id_": "c58dae28-4861-4ac0-9e73-833bfa951707", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6efad591-ba4f-42f6-868a-5568347d9fab", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9c3b07aeb73ccd44986846eeaeecd0ebfe46a77e24c8120eccbdf73c9ca5f8f2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 6.2.  Preparation/Handling/Storage/Accountability\n\n- The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study intervention received and any discrepancies are reported and resolved before use of the study intervention.\n- Only participants enrolled in the study may receive study intervention and only authorized site staff may supply study intervention.\n- All study intervention must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.\n- The investigator, institution, or the head of the medical institution (where applicable) is responsible for study intervention (includes study drug and autoinjector or single\u2011dose pen) accountability, reconciliation, and record maintenance (for example, receipt, reconciliation, and final disposition of records).\n- Study site staff must regularly assess whether the participant is correctly administering the assigned study drug and storing study drug according to the provided instructions.\n\n# 6.3.  Measures to Minimize Bias: Randomization and Blinding\n\nThis is a double\u2011blind study. Participants who meet all criteria for enrollment will be randomized to one of the study treatment groups at Visit 3. Assignment to treatment groups will be determined by a computer\u2011generated, random sequence using an IWRS. Participants will be randomized in a 1:1:1:1 ratio to receive tirzepatide 5 mg, tirzepatide 10 mg, tirzepatide 15 mg, or placebo.\n\nThe randomization will be stratified by prediabetes status, country, and sex (female, male). Investigators, site staff, clinical monitors and participants will remain blinded to the treatment assignments until the study is complete. To preserve the blinding of the study, a limited number of individuals from the Sponsor will be unblinded to treatment assignments as needed for the interim analysis and for the primary endpoint (Week 72) database lock (see Section 9.5).\n\nEmergency unblinding may be performed through the IWRS. This option may be used ONLY if the participant\u2019s wellbeing requires knowledge of the participant\u2019s treatment assignment. All emergency unblinding events are recorded and reported by the IWRS.\n\nIf an investigator, site personnel performing assessments, or participant is unblinded, the participant must be discontinued from the study. In cases where there are ethical reasons to have the participant remain in the study, the investigator must obtain specific approval from a Lilly clinical research physician (CRP) for the participant to continue in the study.\n\nIn case of an emergency, the investigator has the sole responsibility for determining if unblinding of a participant\u2019s treatment assignment is warranted for medical management of the event. The participant safety must always be the first consideration in making such a determination. If a participant\u2019s treatment assignment is unblinded, Lilly must be notified immediately. If the investigator decides that unblinding is warranted, it is the responsibility of the investigator to promptly document the decision and rationale and notify Lilly as soon as possible.\n\nLY3298176    57", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3370, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "68da7bd6-1723-47da-beec-61e962085acd": {"__data__": {"id_": "68da7bd6-1723-47da-beec-61e962085acd", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e50651fc-b850-4645-9f54-4204000f9d3a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d032c6aedb26cbadb5ad508c6f0516270cd77339d7572fc050ddaa5c88d62c17", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                              Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 6.4. Study Intervention Compliance\n\nParticipant compliance with study intervention will be assessed at each visit. Compliance will be assessed by direct questioning and counting of unused study drug and/or empty cartons returned. Study drug compliance will be determined by the following:\n\n- Study drug administration data will be recorded by the participant and reviewed by the investigator at each study visit.\n- The participants will be instructed to return any unused study drug and/or empty cartons at the next visit to the study site for the purpose of performing drug accountability.\n\nTreatment compliance for each visit interval is defined as taking at least 75% of the required doses of study drug. Similarly, a participant will be considered significantly noncompliant if he or she is judged by the investigator to have intentionally or repeatedly taken more than the prescribed amount of medication (more than 125%).\n\nIn addition to the assessment of a participant\u2019s compliance with study drug administration, other aspects of compliance with the study treatments will be assessed at each visit based on the participant\u2019s adherence to the visit schedule, completion of study diaries, and any other parameters the investigator considers necessary.\n\nParticipants considered to be poorly compliant with their medication and/or the study procedures will receive additional training and instruction, as required, and will be reminded of the importance of complying with the protocol.\n\n# 6.5. Concomitant Therapy\n\nParticipants will be permitted to use concomitant medications that they require during the study, except certain medications (for example; other medications for weight management) that may interfere with the assessment of efficacy and safety characteristics of the study treatments. Participants who develop diabetes during the study may initiate medication for glucose control, with the exception of DPP\u20114 inhibitors or GLP\u20111R agonists (Section 4.1.2.3). Initiation of metformin for the treatment of diabetes is permitted, but metformin should not be initiated during the study for the treatment of other metabolic conditions (for example, polycystic ovary syndrome, diabetes prevention).\n\nInvestigative\u2011site staff will inform participants that they must consult with the investigator or a designated site staff member upon being prescribed any new medications during the study. This may not be possible when initiated for treatment of medical emergencies, in which case, the participant will inform the investigator or a designated site staff member as soon as possible.\n\nNonstudy medications taken by participants who are screened but not randomized will not be reported to Lilly unless an SAE or AE occurs that the investigator believes may have been caused by a study procedure.\n\nLY3298176    58", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2905, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9a3612c5-96ff-4e25-a2d9-4648eba181f1": {"__data__": {"id_": "9a3612c5-96ff-4e25-a2d9-4648eba181f1", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cea97c02-6934-45f7-b113-abbda869e7f0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ac8428087398e01f9285b1703de34bb6e856726decc1a52dd8947af286fb932a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 6.6. Dose Modification\n\n# 6.6.1. Tirzepatide\n\nTirzepatide is given once weekly by SC injection. There are no restrictions on the time of day each weekly dose of tirzepatide is given, but it is advisable to administer the SC injections on the same day of the week and similar time each week. If a dose of tirzepatide is missed, the participant should take it as soon as possible unless it is within 72 hours of the next dose, in which case, that dose should be skipped, and the next dose should be taken at the appropriate time.\n\nStudy drug dose modification is not permitted, except for:\n\n- management of intolerable GI symptoms during the entire course of the study (see Section 6.6.2) and,\n- management of participants with perceived excessive weight loss during the additional 2\u2011year treatment period for participants with prediabetes at randomization only (see Section 6.6.3).\n\nOnly 1 dose reduction per participant will be permitted during the entire course of the study. All dose adjustments will be managed through IWRS.\n\n# 6.6.2. Management of Participants with Gastrointestinal Symptoms\n\nParticipants who experience intolerable GI symptoms (for example, nausea, vomiting, or diarrhea) at any time during the study, should first be counselled on dietary behaviors that may help mitigate nausea and vomiting, (for example, eating smaller meals, splitting 3 daily meals into 4 or more smaller ones, and stopping eating when they feel full). If symptoms persist, the participant should be prescribed, at the investigator\u2019s discretion, symptomatic medication (for example, antiemetic or antidiarrheal medication). A temporary interruption of study drug for 1 dose is permitted, provided the participant has taken the last 3 weekly doses. Study treatment should be resumed at the assigned dose immediately, either alone or in combination with symptomatic medication, which can also be utilized to manage symptoms (Section 10.9).\n\nManagement of study drug after interruptions >1 dose is discussed in Section 7.1.1.\n\nIf intolerable GI symptoms (for example, nausea, vomiting, or diarrhea) persist despite the above measures, the investigator should contact Lilly to consider reinitiating study drug at the next\u2011lowest maintenance dose in a blinded fashion (for example, 15 mg reduced to 10 mg, 10 mg reduced to 5 mg, or 5 mg reduced to placebo) (Section 10.9).\n\nIf intolerable GI symptoms persist despite symptomatic treatment, temporary drug interruption, and resumption at a lower dose of study drug, the participant should be discontinued from study drug. All participants who discontinue study drug should continue to attend scheduled study visits.\n\nLY3298176 59", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2708, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4980f448-9bd1-4fc0-aea9-84b4a17c9049": {"__data__": {"id_": "4980f448-9bd1-4fc0-aea9-84b4a17c9049", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "15157e48-3d18-4b8d-86f5-1f7ed3860e2d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "87dccb3099d7bf745540f4e83c4de1e1c52676e3bf457a6e9afb88d83d65a8bc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL            Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 6.6.3. Management of Participants with Perceived Excessive Weight Loss During the Additional 2-year Treatment Period for Participants with Prediabetes at Randomization\n\nAs indicated in Section 5.3.1, if BMI \u226422 kg/m\u00b2 is reached any time during the study, the recommended energy intake should be recalculated. From Visit 101 onwards, in the participants who have reached BMI \u226422 kg/m\u00b2, if weight loss continues despite above measures and/or there are concerns related to degree of weight loss that may lead to discontinuation from study drug, the investigator should contact the Sponsor CRP to consider a study drug dose reduction in a blinded fashion (see Section 6.6.2 for details regarding study drug dose reduction).\n\n# 6.7. Intervention after the End of the Study\n\n# 6.7.1. Treatment after Study Completion\n\nTirzepatide will not be made available to participants after conclusion of the study.\n\nLY3298176    60", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 966, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cc2f3579-5afb-4ed3-8945-a8f8b4648da3": {"__data__": {"id_": "cc2f3579-5afb-4ed3-8945-a8f8b4648da3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4738a933-9e3d-4b0c-a047-8e5b85c0208c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "998a737ab6032a3c90562e20a76b9d59a04933f83a11a1c8b5d8dab59298ae13", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 7. Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal\n\n# 7.1. Discontinuation of Study Intervention\n\nPossible reasons leading to permanent discontinuation of IP:\n\n- participant decision\n- the participant requests to discontinue IP.\n- clinical considerations\n- initiation of open\u2011label GLP\u20111R agonist or DPP\u20114 inhibitor, if participants will not or cannot discontinue them\n- intolerable GI symptoms despite management as described in Section 6.6.2\n- BMI \u226418.5 kg/m2 is reached at any time during the treatment period\nNote: The investigator should contact the Sponsor CRP to discuss whether it is medically appropriate for the participant to continue study treatment.\n- diagnosis of T1DM\n- diagnosis of MTC after randomization\n- significant elevation of calcitonin (Section 10.3.1.4)\n- diagnosis of acute or chronic pancreatitis\n- diagnosis of an active or untreated malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) after randomization\n- development of any significant study drug\u2011related hypersensitivity reaction\n- onset of pregnancy in a female participant\n- occurrence of any other treatment\u2011emergent AE (TEAE), SAE, or clinically significant finding for which the investigator believes that permanent study drug discontinuation is the appropriate measure to be taken\n- inadvertent enrollment if continued treatment with study drug would not be medically appropriate (Section 7.2.3)\n- PHQ\u20119 score \u226515\n\nLY3298176    61", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1564, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "21ddf95a-fb2a-4f6f-8cf3-c7dabc0bb84e": {"__data__": {"id_": "21ddf95a-fb2a-4f6f-8cf3-c7dabc0bb84e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fabd0299-93dc-4a9b-a63a-24c619e5819c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2084632556e358403cca1bcb835efa73b8e6e59cd24302fbcdb30ba883999445", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nParticipants should be referred to a Mental Health Professional (MHP) to assist in deciding whether the subject should be discontinued from study drug. If a participant\u2019s psychiatric disorder can be adequately treated with psycho\u2011 and/or pharmacotherapy, then the subject, at the discretion of the Investigator (in agreement with the MHP), may be continued in the trial on randomized therapy.\n\n- In addition, study drug may be discontinued if participants:\n\nNote: A psychiatrist or appropriately trained professional may assist in the decision to discontinue the participant.\n\n- Discontinuation due to a hepatic event or liver test abnormality\n\nLY3298176 62", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 698, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7f908bfa-48a6-4105-859d-a090fe592818": {"__data__": {"id_": "7f908bfa-48a6-4105-859d-a090fe592818", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "454128c7-fd52-4d5b-9e26-9d4a5eaa4f03", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e32350560d0ae547335afd6cc20c8b7f72f4efacf1d524b5ece604e82100f277", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                             Protocol I8F\u2011MC\u2011GPHK(b)\n\n\u25aa ALP >2.5X ULN with the appearance of fatigue, nausea, vomiting, right\u2011quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)\n\nParticipants who stop study drug permanently should continue to attend all scheduled study visits to collect all planned efficacy and safety measurements. Participants who are unwilling to attend all scheduled visits and stop the study prior to 72 weeks, should return for a final weight measurement (Visit 99). If participants are unwilling to attend Visit 99, their refusal to attend should be documented in the patient medical record. Participants with prediabetes who stop study drug after 72 weeks should return for a final assessment of weight and glycemic status (Visit 199). Refusal to attend should be documented in the patient medical record.\n\nParticipants discontinuing from the IP prematurely for any reason should complete AE and other follow\u2011up procedures per Section 1.3 (Schedule of Activities), Section 8.3 (Adverse Events and Serious Adverse Events), and Section 8.2 (Safety Assessments) of the protocol.\n\n# 7.1.1. Temporary Study Drug Discontinuation\n\nIn certain situations, after randomization, the investigator may need to temporarily interrupt study drug. Every effort should be made by the investigator to maintain participants on study drug and to restart study drug after any temporary interruption, as soon as it is safe to do so. Distribution of study medication at the correct dose will be per IWRS instructions.\n\n| If study drug interruption is\u2026      | then\u2026                                                                                                   |\n| ----------------------------------- | ------------------------------------------------------------------------------------------------------- |\n| 2 consecutive doses or less         | participant restarts study drug at last administered dose, as per escalation schedule.                  |\n| 3 consecutive doses or more         | participant restarts study drug (at 5 mg, managed by IWRS) and repeats dose escalation scheme.          |\n| due to an AE                        | the event is to be documented and followed according to the procedures in Section 8.3 of this protocol. |\n| due to intolerable persistent GI AE | participants should be treated as suggested in Section 6.6.2.                                           |\n\nAbbreviations: AE = adverse event; GI = gastrointestinal; IWRS = interactive web response service. Investigators should inform Lilly that study drug has been temporarily interrupted. The data related to temporary interruption of study treatment will be documented in source documents and entered on the eCRF.\n\nLY3298176    63", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2768, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bf521a23-cc7d-4157-8bdd-2c1657e3d434": {"__data__": {"id_": "bf521a23-cc7d-4157-8bdd-2c1657e3d434", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "45a301a9-4f00-4820-a448-bbfc58e8cd6b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "bc96cc713a8e85817fa442eff771d63845b682712004d35cbdfbb962c970c9a9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                   Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 7.2 Participant Discontinuation/Withdrawal from the Study\n\nTo minimize the amount of missing data and to enable assessment of study objectives as planned in the study protocol, every attempt will be made to keep participants in the study irrespective of the following:\n\n- adherence to or discontinuation from study drug\n- adherence to visit schedule\n- missing assessments\n- study drug discontinuation due to AE\n- development of comorbidities\n- development of clinical outcomes\n\nThe circumstances listed above are not valid reasons for discontinuation from the study. Participants will be withdrawn from the study in the following circumstances:\n\n- enrollment in any other clinical study involving an IP or enrollment in any other type of medical research judged not to be scientifically or medically compatible with this study\n- participation in the study needs to be stopped for medical, safety, regulatory, or other reasons consistent with applicable laws, regulations, and good clinical practice (GCP)\n- participant requests to be withdrawn from the study and clearly indicates that there will be no further contact of any kind with the site\n- Female participants will be withdrawn from the study if the participant becomes pregnant.\n\nParticipants who agree to provide information relevant to any trial endpoint at the end of the study are not considered to have discontinued from the study. Participants discontinuing from the study prematurely for any reason should complete AE and other safety follow\u2011up per Section 1.3 (Schedule of Activities), Section 8.3 (Adverse Events and Serious Adverse Events), and Section 8.2 (Safety Assessments) of this protocol.\n\nLY3298176    64", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1771, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "43277fd5-d3ff-46a9-87fa-504c58e37ad9": {"__data__": {"id_": "43277fd5-d3ff-46a9-87fa-504c58e37ad9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "afc963e2-5fa0-4998-a7e0-64fcf93da6ab", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "185b823d8ae7caa30072b1c7013c28607172a879c4144f558591b60df1da49cc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 7.2.1.  Participant Disposition and Timing of Safety Follow-up for the Primary Endpoint (72 Weeks)\n\nAbbreviations: ED = early discontinuation of treatment; Pt = participant; wks = weeks.\n\nLY3298176    65", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 247, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "607f4f6b-b250-49d8-82fd-d890df8c263f": {"__data__": {"id_": "607f4f6b-b250-49d8-82fd-d890df8c263f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a8c5ca9f-0c9e-4615-b517-c07e84825a76", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d8f0efc131d2990bffb0c884a307c0c17e62ae141f638e1590526f60407b41a1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 7.2.2. Participant Disposition and Timing of Safety Follow-up for those with Prediabetes at Randomization\n\n# Continuing in Additional 2-year Treatment Period\n\nAbbreviations: ED = early discontinuation of treatment; wks = weeks.\n\nNote: Participants with prediabetes at randomization who discontinue study drug on or before Week 72 are not eligible to continue in additional 2\u2011year treatment period after Visit 21 (Week 72) and should proceed to V801.\n\nLY3298176    66", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 510, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1408b092-6278-4068-96cd-56ec682754d1": {"__data__": {"id_": "1408b092-6278-4068-96cd-56ec682754d1", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0c67c9dc-369b-43e8-acc7-2b5b5661f438", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c20e6d3aa818599f2bbc62119802afae8deb6ec0a5c3644976f9b1a69cce04fc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                      Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 7.2.3. Discontinuation of Inadvertently Enrolled Participants\n\nIf the Sponsor or investigator identify a participant who did not meet enrollment criteria and was inadvertently enrolled, the investigator and the Sponsor CRP must agree whether continuing the study treatment is medically appropriate. Continuation of inadvertently enrolled participants in the study, with or without study drug treatment, requires documented approval from the Sponsor CRP. Safety follow up is as outlined in Section 1.3 (Schedule of Activities), Section 8.3 (Adverse Events and Serious Adverse Events), and Section 8.2 (Safety Assessments) of the protocol.\n\n# 7.3. Lost to Follow-up\n\nA participant will be considered lost to follow\u2011up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site. Site personnel are expected to make diligent attempts to contact participants who fail to return for a scheduled visit or were otherwise unable to be followed up by the site.\n\nSite personnel, or an independent third party, will attempt to collect the vital status of the participant within legal and ethical boundaries for all participants randomized, including those who did not get IP. Public sources may be searched for vital status information. If vital status is determined, this will be documented, and the participant will not be considered lost to follow\u2011up. Eli Lilly and Company personnel will not be involved in any attempts to collect vital status information.\n\nDiscontinuation of specific sites or of the study as a whole are handled as part of Section 10.1.9.\n\nLY3298176    67", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1710, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "60bf4709-29e8-4b8f-a1d2-f814499c80b4": {"__data__": {"id_": "60bf4709-29e8-4b8f-a1d2-f814499c80b4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d48d161c-6144-4a3f-a229-dc3afcc4a658", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1ac6a2930cd7a7a4e1a64bb80d3d6849c87bca89cf91efde7beebfb702ebf206", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 8. Study Assessments and Procedures</h8>\n- Section 10.2 (Appendix 2) lists the laboratory tests that will be performed for this study. Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the samples.\n- Unless otherwise stated in the subsections below, all samples collected for specified laboratory tests will be destroyed within 60 days of receipt of confirmed test results. Certain samples may be retained for a longer period, if necessary, to comply with applicable laws, regulations, or laboratory certification standards.\n\n# Efficacy Assessments</h8>\n\n# Primary Efficacy Assessments</h8>\nThe primary efficacy assessment in this study is the body weight. Body weight measurements will be collected at specific clinic visits as summarized in the Schedule of Activities (Section 1.3). Methods for measuring body weight are described in Section 10.7 (Appendix 7).\n\n# Secondary Efficacy Assessments</h8>\nThe following secondary efficacy assessments will also be collected according to the Schedule of Activities:\n\n- waist circumference (measuring method is described in Section 10.7 [Appendix 7]).\n- fasting insulin (measured through central lab)\n- onset of T2DM (definition is described Section 4.1.2.3)\n- HbA1c (%, mmol/mol) (measured through central lab)\n- fasting glucose (measured through central lab)\n- BMI (derived using body weight in kilograms divided by the square of height in meters)\n- blood pressure\n- lipids\n\n# Patient-Reported Outcomes Assessments</h8>\nThe self\u2011reported questionnaires will be translated into the native language of the region, linguistically validated and administered according to the Schedule of Activities (Section 1.3). At these visits, the questionnaires should be completed before the participant has discussed their medical condition or progress in the study with the investigator and/or site staff, if the participant is not adversely affected by their fasting condition.\n\nLY3298176    68", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2012, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ff2d6748-40a8-49db-8f83-1144106e4a2e": {"__data__": {"id_": "ff2d6748-40a8-49db-8f83-1144106e4a2e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "164cb639-4aaf-4f1e-ace4-87caed5f234d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a7887327de6579a96735e1405cd2b70a54e365547b3c8046849d72b11c5fdedf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                      Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 8.1.4. Short Form 36 version 2, acute, 1 week recall version\n\nThe SF\u201136v2 acute, 1\u2011week recall version is a 36\u2011item, generic, patient\u2011administered measure designed to assess the following 8 domains:\n\n- Physical Functioning\n- Role\u2011Physical\n- Bodily Pain\n- General Health\n- Vitality\n- Social Functioning\n- Role\u2011Emotional\n- Mental Health\n\nThe Physical\u2011Functioning domain assesses limitations due to health \u201cnow\u201d while the remaining domains assess functioning \u201cin the past week.\u201d Each domain is scored individually and information from these 8 domains are further aggregated into 2 health\u2011component summary scores: Physical\u2011Component Summary and Mental\u2011Component Summary. Items are answered on Likert scales of varying lengths (3\u2011, 5\u2011, or 6\u2011 point scales). Scoring of each domain and both summary scores are norm\u2011based and presented in the form of T\u2011scores, with a mean of 50 and standard deviation (SD) of 10; higher scores indicate better levels of function and/or better health (Maruish 2011).\n\n# 8.1.5. Impact of Weight on Quality of Life-Lite Clinical Trials Version\n\nThe IWQOL\u2011Lite\u2011CT is a 20\u2011item, obesity\u2011specific PRO instrument developed for use in obesity clinical trials. It assesses 2 primary domains of obesity\u2011related health\u2011related quality of life (HRQoL): physical (7 items), and psychosocial (13 items). A 5\u2011item subset of the physical domain, the physical\u2011function composite is also supported. Items in the physical\u2011function composite describe physical impacts related to general and specific physical activities. All items are rated on either a 5\u2011point frequency (\u201cnever\u201d to \u201calways\u201d) scale or a 5\u2011point truth (\u201cnot at all true\u201d to \u201ccompletely true\u201d) scale (Kolotkin et al. 2017, 2018).\n\n# 8.1.6. EQ-5D-5L\n\nGeneric health\u2011related quality of life will be assessed using the EQ\u20115D\u20115L (EQ\u20115D; EuroQoL Group 2015). The EQ\u20115D\u20115L is a standardized 5\u2011item instrument for use as a measure of health outcome. It provides a simple descriptive profile and a single index value for health status that can be used in the clinical and economic evaluation of health care as well as population health surveys. The EQ\u20115D\u20115L comprises 5 dimensions of health (mobility, self\u2011care, usual activities, pain/discomfort, and anxiety/depression). The 5L version, introduced in 2005, scores each dimension at 5 levels (no problems, slight problems, moderate problems, severe problems, unable to perform/extreme problems), for a total of 3125 possible health states. In addition to the health profile, a single health\u2011state index value can be derived based on a formula that attaches weights to each of the levels in each dimension. This index value ranges between \u02c20 (where 0 is\n\nLY3298176    69", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2778, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1a1ad8d8-52c6-4c13-b89a-c7d4a6c1f1e3": {"__data__": {"id_": "1a1ad8d8-52c6-4c13-b89a-c7d4a6c1f1e3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c6009284-b37a-4d94-bd3c-fdb883fcae19", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b165e151972f9ea107f87161d9b7f3a05e9bea6bac0591d5f26ff49537da27d9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK(b)\n\na health\u2011state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health) (Dolan 1997). In addition, the EQ Visual Analog Scale records the respondent\u2019s self\u2011rated health status on a vertical graduated (0 to 100) scale. In conjunction with the health\u2011state data, it provides a composite picture of the respondent\u2019s health status.\n\nThe EQ\u20115D\u20115L is used worldwide and is available in more than 170 different languages. Details on the instrument, and scoring, organizing, and presenting the data collected can be found in the EQ\u20115D\u20115L User Guide (EuroQoL Group 2015).\n\n# 8.1.7. Patient Global Impression of Status for Physical Activity\n\nStudy participants will be asked to complete a PGIS item specifically developed for this study. This is a patient\u2011rated assessment of current health limitation and is rated on a 5\u2011point scale ranging from \u201c1\u2011 not at all limited\u201d to \u201c5\u2011 extremely limited.\u201d\n\n# 8.2. Safety Assessments\n\nPlanned time points for all safety assessments are provided in the Schedule of Activities (Section 1.3).\n\n# 8.2.1. Physical Examinations\n\n- A complete physical examination will include, at a minimum, assessments of the cardiovascular, respiratory, GI and neurological systems, as well as a thyroid exam. Height, weight, and waist circumference will also be measured and recorded, per Section 10.7.\n- Investigators should pay special attention to clinical signs related to previous serious illnesses.\n\n# 8.2.2. Vital Signs\n\nFor each participant, vital signs should be measured according to the Schedule of Activities (Section 1.3) and Section 10.7. Any clinically significant findings from vital\u2011signs measurement that result in a diagnosis and that occur after the participant receives the first dose of study treatment should be reported to Lilly or its designee as an AE via the eCRF.\n\n# 8.2.3. Electrocardiograms\n\nFor each participant, 12\u2011Lead electrocardiograms (ECGs) should be collected according to the Schedule of Activities (Section 1.3) and Section 10.7. Electrocardiograms will initially be interpreted by a qualified physician (the investigator or qualified designee) at the site as soon after the time of ECG collection as possible, and ideally while the participant is still present, for immediate subject management, should any clinically relevant findings be identified. Any clinically significant findings from ECGs that result in a diagnosis and that occur after the participant receives the first dose of the investigational treatment should be reported to Lilly or its designee as an AE via the eCRF.\n\nLY3298176    70", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2679, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5b56de18-ab46-4c12-b313-336ab970b3ef": {"__data__": {"id_": "5b56de18-ab46-4c12-b313-336ab970b3ef", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "88d3ccc3-78e6-4a3a-b212-0588eb650bd0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "497ccce8f0ee28bb5bb999f231187fe947452d9b6ae104614d208dc50cc5fa37", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                         Protocol I8F\u2011MC\u2011GPHK(b)\n\nAll digital ECGs will be obtained using centrally provided ECG machines and will be electronically transmitted to a designated central ECG laboratory. ECGs will be performed in triplicate at Weeks 0 and 36. The central ECG laboratory will perform a basic quality control check (for example, demographics and study details) and then store the ECGs in a database. At a future time, the stored ECG data may be overread by a cardiologist at the central ECG laboratory for further evaluation of machine\u2011read measurements or to meet regulatory requirements. The machine\u2011read ECG intervals and heart rate (HR) may be used for data analysis and report\u2011writing purposes, unless a cardiologist overreading of the ECGs is conducted prior to completion of the final study report (in which case, the overread data would be used).\n\n# 8.2.4. Clinical Safety Laboratory Assessments\n\n- For each participant, laboratory tests detailed in (Section 10.2) should be conducted according to the Schedule of Activities (Section 1.3).\n- With the exception of laboratory test results that may unblind the study, Lilly or its designee will provide the investigator with the results of laboratory tests analyzed by a central vendor, if a central vendor is used for the clinical trial.\n- Any clinically significant findings from laboratory tests that result in a diagnosis and that occur after the participant receives the first dose of IP should be reported to Lilly or its designee as an AE via eCRF.\n\n# 8.2.4.1. Immunogenicity Assessment\n\nWhere local regulations and ERBs allow, blood samples for immunogenicity testing will be collected to determine antibody production against tirzepatide as specified in the Schedule of Activities (Section 1.3). At the visits and times specified in the Schedule of Activities (Section 1.3), venous blood samples will be collected to determine antibody production against tirzepatide. To interpret the results of immunogenicity, a PK sample will be collected at the same time points as the immunogenicity sample. All samples for immunogenicity should be taken predose when applicable and possible. In the event of systemic drug\u2011hypersensitivity reactions (immediate or nonimmediate), additional samples will be collected (including antidrug antibodies [ADAs], PK, and exploratory biomarker samples) as close to the onset of the event as possible, at the resolution of the event, and 30 days following the event. Instructions for the collection and handling of blood samples will be provided by the Sponsor. The actual date and time (24\u2011hour clock time) of each sampling will be recorded. Immunogenicity will be assessed by a validated assay designed to detect ADAs in the presence of tirzepatide at a laboratory approved by the Sponsor. Antibodies may be further characterized and/or evaluated for their ability to neutralize the activity of tirzepatide. Sample collected at Visit 801 or Visit 802 will assess immunogenicity at washout of tirzepatide (5 half\u2011lives post end of treatment).\n\nSamples with tirzepatide ADA detected will be titered and evaluated for their ability to neutralize the activity of assigned treatment (tirzepatide\u2011neutralizing antibodies). Samples with tirzepatide ADA detected will also be tested for cross\u2011reactive binding to native GIP and GLP\u20111, and if such is detected, then for neutralizing antibodies against native GIP and GLP\u20111, respectively. Treatment\u2011emergent ADAs are defined in Section 9.4.6.\n\nLY3298176    71", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3551, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "47c25196-679b-4129-8afc-8e0ec11afd83": {"__data__": {"id_": "47c25196-679b-4129-8afc-8e0ec11afd83", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a3a3ccd1-8130-4ab1-a112-16f3ecc4e382", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c73977333b7f381e7fed792053044f44b8496d1223d91354f744456fdaed12e9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nSamples will be retained for a maximum of 15 years after the last participant visit, or for a shorter period if local regulations and ERBs allow, at a facility selected by the Sponsor. The duration allows the Sponsor to respond to future regulatory requests related to tirzepatide. Any samples remaining after 15 years will be destroyed.\n\n# 8.2.5. Safety Monitoring\n\nLilly will periodically review evolving aggregate safety data within the study by appropriate methods. The study team will review safety reports in a blinded fashion according to the schedule provided in the Trial\u2011Level Safety Review plan. Lilly will also review SAEs within time frames mandated by company procedures. The Lilly CRP will, as appropriate, consult with the functionally independent Global Patient Safety therapeutic area physician or clinical scientist.\n\n# 8.2.5.1. Hepatic Safety Monitoring\n\nIf a study participant experiences elevated ALT \u22653X ULN, ALP \u22652X ULN, or elevated TBL \u22652X ULN, liver testing (Section 10.5) should be repeated within 3 to 5 days including ALT, AST, ALP, TBL, direct bilirubin, gamma\u2011glutamyl transferase, and creatine kinase to confirm the abnormality and to determine if it is increasing or decreasing. If the abnormality persists or worsens, clinical and laboratory monitoring should be initiated by the investigator and in consultation with the study medical monitor. Monitoring of ALT, AST, TBL, and ALP should continue until levels normalize or return to approximate baseline levels.\n\nAdditional safety data should be collected via the eCRF if 1 or more of the following conditions occur:\n\n- elevation of serum ALT to \u22655X ULN on 2 or more consecutive blood tests\n- elevated serum TBL to \u22652X ULN (except for cases of known Gilbert\u2019s syndrome)\n- elevation of serum ALP to \u22652X ULN on 2 or more consecutive blood tests\n- participant discontinued from treatment due to a hepatic event or abnormality of liver tests\n- hepatic event considered to be an SAE\n\n# 8.2.6. Depression, Suicidal Ideation, and Behavior Risk Monitoring\n\nOverweight and obese patients are at increased risk for depression (Luppino et al. 2010). Depression can increase the risk for suicidal ideation and behavior. Therefore, study participants will be screened at trial entry and monitored during the study for depression, and suicidal ideation and behavior.\n\nParticipants should be monitored appropriately and observed closely for suicidal ideation and behavior or any other unusual changes in behavior, especially at the beginning and end of the course of treatment, or at the time of dose changes, either increases or decreases. Consideration should be given to discontinuing study medication in subjects who experience signs of suicidal ideation or behavior, following a risk assessment (Section 7.1).\n\nBaseline and treatment emergent assessment of depression, suicidal ideation and behavior will be monitored during the study using the C\u2011SSRS and PHQ\u20119 (Section 8.3.1.1).\n\nLY3298176 72", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3010, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a41a630c-4eae-4df1-aaa4-f2c451396a18": {"__data__": {"id_": "a41a630c-4eae-4df1-aaa4-f2c451396a18", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cf2127f9-c0fb-4e8f-97a0-8a14ae67e305", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b706493b558e9c858b76af19b83aacbae30c5c33c1949301aae78edfddca001f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 8.3. Adverse Events and Serious Adverse Events\n\nPlease refer to Section 10.3 Appendix 3 Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow\u2011up, and Reporting.\n\nInvestigators are responsible for monitoring the safety of participants who have entered this study and for alerting Lilly or its designee to any event that seems unusual, even if this event may be considered an unanticipated benefit to the participant.\n\nThe investigator is responsible for the appropriate medical care of participants during the study. Investigators must document their review of each laboratory safety report.\n\nThe investigator remains responsible for following, through an appropriate health care option, AEs that are serious or otherwise medically important, considered related to the IP or the study, or that caused the participant to discontinue the IP before completing the study. The participant should be followed until the event resolves, stabilizes with appropriate diagnostic evaluation, or is reasonably explained. The frequency of follow\u2011up evaluations of the AE is left to the discretion of the investigator.\n\nLack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to establish treatment effect.\n\nAfter the ICF is signed, study site personnel will record via eCRF the occurrence and nature of each participant\u2019s preexisting conditions, including clinically significant signs and symptoms of the disease under treatment in the study. In addition, site personnel will record any change in the condition(s) and any new conditions as AEs. Investigators should record their assessment of the potential relatedness of each AE to protocol procedure and IP via eCRF.\n\nThe investigator will interpret and document whether or not an AE has a reasonable possibility of being related to study treatment, study device, or a study procedure, taking into account the disease, concomitant treatment, or pathologies.\n\nA \u201creasonable possibility\u201d means that there is a cause and effect relationship between the IP, study device, and/or study procedure and the AE.\n\nThe investigator answers yes/no when making this assessment.\n\nPlanned surgeries and nonsurgical interventions should not be reported as AEs unless the underlying medical condition has worsened during the course of the study.\n\nIf a participant\u2019s IP is discontinued as a result of an AE, study\u2011site personnel must report this to Lilly or its designee via eCRF, clarifying if possible, the circumstances leading to any dosage modifications or discontinuations of treatment.\n\n# Serious Adverse Events\n\nAll AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious criteria. An SAE is any AE from this study that results in one of the following outcomes:\n\n- death\n- initial or prolonged inpatient hospitalization\n- a life\u2011threatening experience (that is, immediate risk of dying)\n\nLY3298176\n\n73", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2967, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "93a33755-22eb-4192-8242-516f523b5beb": {"__data__": {"id_": "93a33755-22eb-4192-8242-516f523b5beb", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "07cf93b7-7a75-4eba-b310-98aa31de4dc2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2e4118b543bee5ff232e6ef9a60f71fc45b01f24ba557af76199c550284641d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n- persistent or significant disability/incapacity\n- congenital anomaly/birth defect\n- important medical events that may not be immediately life\u2011threatening or result in death or hospitalization but may jeopardize the participant or may require intervention to prevent 1 of the other outcomes listed in the definition above. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.\n- when a condition related to the drug delivery system necessitates medical or surgical intervention to preclude either permanent impairment of a body function or permanent damage to a body structure, the serious outcome of \u201crequired intervention\u201d will be assigned.\n\nAll AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious criteria. The SAE reporting to the Sponsor begins after the participant has signed the ICF and has received IP. However, if an SAE occurs after signing the ICF, but prior to receiving IP, the SAE should be reported to the Sponsor per SAE\u2011reporting requirements and timelines (see Section 8.3.1) if it is considered reasonably possibly related to study procedure.\n\nStudy\u2011site personnel must alert Lilly or its designee of any SAE within 24 hours of investigator awareness of the event via a sponsor\u2011approved method. If alerts are issued via telephone, they are to be immediately followed with official notification on study\u2011specific SAE forms. This 24\u2011hour notification requirement refers to the initial SAE information and all follow\u2011up SAE information. Participants with a serious hepatic AE should have additional data collected using the eCRF.\n\nPregnancy (during maternal or paternal exposure to IP) does not meet the definition of an AE. However, to fulfill regulatory requirements any pregnancy should be reported following the SAE process to collect data on the outcome for both mother and fetus.\n\nInvestigators are not obligated to actively seek AEs or SAEs in subjects once they have discontinued and/or completed the study (the participant disposition case report form [CRF] has been completed). However, if the investigator learns of any SAE, including a death, at any time after a subject has been discharged from the study, and he or she considers the event reasonably possibly related to the study treatment or study participation, the investigator must promptly notify Lilly.\n\n# Suspected Unexpected Serious Adverse Reactions\n\nSuspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed in the IB and that the investigator identifies as related to IP or procedure. United States 21 CFR 312.32, European Union Clinical Trial Directive 2001/20/EC, and the associated detailed guidance or national regulatory requirements in participating countries require the reporting of SUSARs. Lilly has procedures that will be followed for the identification, recording, and expedited reporting of SUSARs that are consistent with global regulations and the associated detailed guidance.\n\nLY3298176    74", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3219, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9a3fcad9-6f27-4673-9d1e-ea331b4cfe5e": {"__data__": {"id_": "9a3fcad9-6f27-4673-9d1e-ea331b4cfe5e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bc0dcb51-73de-4a08-a309-c44ecd5ad4f2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ed44759fcbd977525b8badd26948ea881405b94215407e504b90accdf679f501", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 8.3.1. Time Period and Frequency for Collecting AE and SAE Information\n\nAll AE data will be collected from the signing of the ICF until the time points specified in the Schedule of Activities (Section 1.3). Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open\u2011ended and nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrences.\n\n# 8.3.1.1. Adverse Event Monitoring with a Systematic Questionnaire\n\nBefore administering the C\u2011SSRS or the PHQ\u20119, study site personnel will question the participant about any change in the preexisting condition(s) and the occurrence and nature of any AEs. Nonserious AEs obtained through the questionnaire are recorded and analyzed separately. Only serious AEs elicited through the C\u2011SSRS or PHQ\u20119 are to be recorded as AEs via the eCRF and reported to Lilly or its designee within 24 hours as SAEs. For this study, the C\u2011SSRS is adapted for the assessment of the ideation and behavior categories only. The Intensity of Ideation and Lethality of Behavior sections are removed.\n\nThe C\u2011SSRS is a scale that captures the occurrence, severity, and frequency of suicidal ideation and/or behavior during the assessment period. The scale includes suggested questions to solicit the type of information needed to determine if suicidal ideation and/or behavior occurred. The tool was developed by the National Institute of Mental Health trial group for the purpose of being a counterpart to the Columbia Classification Algorithm of Suicide Assessment categorization of suicidal events.\n\nThe PHQ\u20119 is a validated self\u2011report screening tool that assesses the presence and intensity of depressive symptoms. The PHQ\u20119, which incorporates the 9 Diagnostic and Statistical Manual\u2011IV depression criteria as \u201c0\u201d (not at all) to \u201c3\u201d (nearly every day), was developed for use in primary care settings (Kroenke et al. 2001).\n\n# 8.3.2. Follow-up of AEs and SAEs\n\nAfter the initial AE or SAE report, the investigator is required to proactively follow each participant at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow\u2011up (as defined in Section 1.3).\n\n# 8.3.3. Regulatory Reporting Requirements for SAEs\n\n- Prompt notification by the investigator to the Sponsor of a SAE is essential so that legal obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.\n- The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The Sponsor will comply with country\u2011specific regulatory requirements relating to safety reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees (IEC), and investigators.\n\nLY3298176 75", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3004, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eaf85fa1-18af-40f9-83a2-9f9d842b7810": {"__data__": {"id_": "eaf85fa1-18af-40f9-83a2-9f9d842b7810", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "673364d1-dae8-4197-8a80-1421b12b0bee", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7a6826d456cc5499084c5ce13094d8d012c77449459ee90e1506496a2244388b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 8.3.4. Pregnancy\n\n- Details of all pregnancies in female participants and female partners of male participants will be collected after the start of study intervention and the participant will be followed to determine the outcome of the pregnancy for mother and neonate.\n- If a pregnancy is reported, the investigator should inform the Sponsor within 24 hours of learning of the pregnancy and should follow the procedures outlined in Section 10.4 (Appendix 4).\n- Abnormal pregnancy outcomes (for example, spontaneous abortion, fetal death, stillbirth, congenital anomalies, and ectopic pregnancy) are considered SAEs.\n\n# 8.3.5. Medical Device Incidents (Including Malfunctions)\n\nMedical devices are being used in this study for the purposes of administering tirzepatide. In order to fulfill regulatory reporting obligations worldwide, the investigator is responsible for the detection and documentation of events meeting the definitions of incident or malfunction that occur during the study with such devices. The definition of a medical device incident can be found in Section 10.6 (Appendix 6).\n\nNote: Incidents fulfilling the definition of an AE/SAE will also follow the processes outlined in Section 8.3.2.\n\n# 8.3.5.1. Time Period for Detecting Medical Device Incidents\n\n- Medical device incidents, or malfunctions of the device that result in an incident, will be detected, documented, and reported to the Sponsor during all periods of the study in which the medical device is used.\n- If the investigator learns of any incident at any time after a participant has been discharged from the study, and such incident is considered reasonably related to a medical device used during the study, the investigator will promptly notify the Sponsor through the complaints process.\n\nThe method of documenting medical device incidents is provided in Section 10.6 (Appendix 6).\n\n# 8.3.5.2. Follow-up of Medical Device Incidents\n\n- All medical device incidents involving an AE will be followed and reported in the same manner as other AEs (see Section 8.3.2). This applies to all participants, including those who discontinue study intervention.\n\nLY3298176 76", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2194, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "67d9ad05-f86f-43ab-a861-3aa2b31d2181": {"__data__": {"id_": "67d9ad05-f86f-43ab-a861-3aa2b31d2181", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5044a01e-72a1-4546-81f1-3399eea41f10", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ed56b083f60e6c31fac0e1f86ca7b27552ba3301d25a0db42ee802459edbd1e3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 8.3.5.3. Prompt Reporting of Medical Device Incidents and Malfunctions to Sponsor\n\n- Medical device incidents or malfunctions will be reported to the Sponsor within a business day or as determined for the study, after the investigator determines that the event or issue meets the protocol definition of a medical device incident or malfunction.\n- Medical device incidents or malfunctions that result in an SAE will be reported to the Sponsor within 24 hours, in the same manner as other (S)AEs.\n- Malfunctions will be reported via the Product Complaint Form and sent to the Sponsor per training and per instructions provided on the Product Complaint Form.\n- The same individual at the site will be the contact for the receipt of medical device reports and SAE.\n\n# 8.3.5.4. Regulatory Reporting Requirements for Medical Device Incidents\n\n- The investigator will promptly report to the Sponsor all incidents occurring with any medical device provided for use in the study in order for the Sponsor to fulfill the legal responsibility to notify appropriate regulatory authorities and other entities about certain safety information relating to medical devices being used in clinical studies.\n- The investigator, or responsible person according to local requirements (for example; the head of the medical institution), will comply with the applicable local regulatory requirements relating to the reporting of incidents to the IRB/IEC.\n\n# 8.3.6. Complaint Handling\n\nLilly collects product complaints on all IPs (drugs/medical devices, inclusive of packaging, labeling, instructions for use, or other component) used in clinical studies, inclusive of comparators, in order to ensure the safety of study participants, monitor product quality, and facilitate process and product improvements.\n\nParticipants will be instructed to contact the investigator as soon as possible if he or she has a complaint or problem with the investigational drug or medical device, so that the situation can be assessed.\n\nInvestigators will provide complete and timely reports to the Sponsor as instructed for the study, and per the Product Complaint Form.\n\n# 8.4. Treatment of Overdose\n\nStudy drug overdose (more than the specified number of injections) will be reported as an AE. In the event of overdose, refer to the IB for tirzepatide.\n\nLY3298176 77", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2370, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2dded28f-04f2-434b-a0ba-4534cf625b51": {"__data__": {"id_": "2dded28f-04f2-434b-a0ba-4534cf625b51", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39552474-c669-4f23-9aa1-894b50bcfad1", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c0f1d3a89c5be194630fe426a1a4114e76f35304bb590a67a7a1bc4a6a44acd4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 8.5. Pharmacokinetics\n\nPharmacokinetic samples will be collected from all randomized participants. Plasma tirzepatide concentrations will only be determined from blood samples obtained from participants receiving tirzepatide treatment. Blood samples for PK assessment will be collected at Weeks 8, 16, and 36 following tirzepatide treatment per the Schedule of Activities or at ED (Section 1.3). At each visit prior to a PK assessment, each participant will be assigned via IWRS to one of the sampling PK time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose. In addition, plasma tirzepatide concentration will be determined on immunogenicity visits up to and including Week 176.\n\nThe date and time of the most recent tirzepatide SC injection administered prior to collecting the PK sample must be recorded on the eCRF from the study diaries. The date and time at which each sample was drawn must be recorded on the laboratory accession page. Concentrations of tirzepatide will be assayed using a validated liquid chromatography mass spectrometry method. Bioanalytical samples collected to measure tirzepatide concentration will be retained for a maximum of 1 year following last participant visit for the study. During this time, samples remaining after the bioanalyses may be used for exploratory analyses such as metabolism work, protein binding, and/or bioanalytical method cross\u2011validation.\n\n# 8.6. Pharmacodynamics\n\nSamples to assess the PD properties of tirzepatide are included in the efficacy measures and not applicable in this section.\n\n# 8.7. Genetics\n\n# 8.7.1. Whole Blood Sample(s) for Pharmacogenetic Research\n\nA whole blood sample will be collected for pharmacogenetic analysis as specified in the Schedule of Activities (Section 1.3) where local regulations allow. Samples will not be used to conduct unspecified disease or population genetic research either now or in the future. Samples will be used to investigate variable response to tirzepatide and to investigate genetic variants thought to play a role in obesity. Assessment of variable response may include evaluation of AEs or differences in efficacy.\n\nAll samples will be coded with the participant number. These samples and any data generated can be linked back to the patient only by the investigator site personnel. Samples will be retained at a facility selected by Lilly or its designee for a maximum of 15 years after the last participant visit for the study, or for a shorter period if local regulations and/or ERBs/ IRBs impose shorter time limits. This retention period enables use of new technologies, response to regulatory questions, and investigation of variable response that may not be observed until later in the development of tirzepatide or after tirzepatide become(s) commercially available.\n\nLY3298176                                                                                           78", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3008, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1a3cd8ef-0dfb-4620-a34f-abd8f3bc46f3": {"__data__": {"id_": "1a3cd8ef-0dfb-4620-a34f-abd8f3bc46f3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e371823b-dfd2-4370-ae31-050894bf10ed", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "38cfc5d67d763124f6aa9560777440e62c6be6c56fb90d65b3dc9f68638cf488", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                       Protocol I8F\u2011MC\u2011GPHK(b)\n\nMolecular technologies are expected to improve during the 15\u2011year storage period and therefore cannot be specifically named. However, existing approaches include whole genome or exome sequencing, genome wide association studies, and candidate gene studies. Regardless of technology utilized, genotyping data generated will be used only for the specific research scope described in this section.\n\n# 8.8. Biomarkers\n\nBiomarker research is performed to address questions of relevance to drug disposition, target engagement, PD, mechanism of action, variability of participant response (including safety), and clinical outcome. Sample collection is incorporated into clinical studies to enable examination of these questions through measurement of biomolecules including deoxyribonucleic acid (DNA), proteins, lipids, and other cellular elements.\n\nSerum, and plasma samples for biomarker research will be collected at the times specified in the Schedule of Activities (Section 1.3) where local regulations allow.\n\nSamples will be used for research on the drug target, disease process, variable response to tirzepatide, pathways associated with obesity, mechanism of action of tirzepatide, and/or research method or in validating diagnostic tools or assay(s) related to obesity.\n\nAll samples will be coded with the participant number. These samples and any data generated can be linked back to the participant only by the investigator site personnel.\n\nSamples will be retained at a facility selected by Lilly or its designee for a maximum 15 years after the last participant visit for the study, or for a shorter period if local regulations and ERBs/IRBs impose shorter time limits. This retention period enables use of new technologies, response to regulatory questions, and investigation of variable response that may not be observed until later in the development of tirzepatide or after tirzepatide become(s) commercially available.\n\n# 8.9. Health Economics\n\nHealth Economics and Medical Resource Utilization Parameters are not evaluated in this study.\n\nLY3298176    79", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2161, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "80004ae2-0808-4554-92ac-a8cc723763a1": {"__data__": {"id_": "80004ae2-0808-4554-92ac-a8cc723763a1", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bffa6e6b-338d-4a9f-a296-44cf332e21b4", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "12bdb4c4cf8b3ab7b229797f6f2fae42acf74de78dadffecaec71c7008eed7f5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 9. Statistical Considerations</h9>\n\n# 9.1. Statistical Hypotheses</h9>\nThe alternative hypotheses for the primary objective are the following:\n\n- H10,1: QW tirzepatide 10 mg is superior to placebo for percent change in body weight from randomization AND percentage of participants who achieve \u22655% body weight reduction at 72 weeks.\n- H15,1: QW tirzepatide 15 mg is superior to placebo for percent change in body weight from randomization AND percentage of participants who achieve \u22655% body weight reduction at 72 weeks.\n\nThe above two hypotheses will be tested in parallel, each at a 2\u2011sided significance level of 0.025.\n\nThe alternative hypotheses for the key secondary objective controlling for type 1 error rate are the following:\n\n- H15,2 and H10,2: superiority of tirzepatide 10 mg and/or 15 mg versus placebo for percentage of participants who achieve \u226510% body weight reduction from randomization at 72 weeks.\n- H15,3 and H10,3: superiority of tirzepatide 10 mg and/or 15 mg versus placebo for percentage of participants who achieve \u226515% body weight reduction from randomization at 72 weeks.\n- H15,4 and H10,4: superiority of tirzepatide 10 mg and/or 15 mg versus placebo for percentage of participants who achieve \u226520% body weight reduction from randomization at 72 weeks.\n- H15,5 and H10,5: superiority of tirzepatide 10 mg and/or 15 mg versus placebo for change from randomization in waist circumference (cm) at 72 weeks.\n- H1015,6: superiority of pooled tirzepatide 10 mg and 15 mg versus placebo for change in body weight (kg) from randomization at 20 weeks.\n- H5,1: superiority of tirzepatide 5 mg versus placebo for percent change in body weight from randomization and percentage of participants who achieve \u22655% body weight reduction at 72 weeks.\n- Hp,7: superiority of tirzepatide (all doses combined) versus placebo for change in systolic blood pressure (SBP) (mmHg) from randomization at 72 weeks.\n- Hp,8: superiority of tirzepatide (all doses combined) versus placebo for change in triglycerides (mg/dL) from randomization at 72 weeks.\n- Hp,9: superiority of tirzepatide (all doses combined) versus placebo for change in non\u2011high\u2011density lipoprotein cholesterol (non\u2011HDL\u2011cholesterol) (mg/dL) from randomization at 72 weeks.\n\nLY3298176    80", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2302, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2b8114a1-d710-4a41-948d-e536e30617a0": {"__data__": {"id_": "2b8114a1-d710-4a41-948d-e536e30617a0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1ea880ea-49bd-4900-b1b9-49270b79604e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "bbbde6c76fc31a34511d7349ac878a5b8c754d11c78e72da0ae4e02588373491", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                            Protocol I8F\u2011MC\u2011GPHK(b)\n\n\u2022  Hp,10: superiority of tirzepatide (all doses combined) versus placebo for change in high\u2011density lipoprotein cholesterol (HDL\u2011cholesterol) (mg/dL) from randomization at 72 weeks\n\n\u2022  Hp,11: superiority of tirzepatide (all doses combined) versus placebo for change in fasting insulin (pmol/L) from randomization at 72 weeks\n\n\u2022  H1015,12: superiority of pooled tirzepatide 10 mg and 15 mg versus placebo for change in SF\u201136v2 acute form Physical Functioning domain score from randomization at 72 weeks.\n\n\u2022  H15,13 and H10,13: superiority of tirzepatide 10 mg and/or 15 mg versus placebo for change in percent body weight from randomization at 176 weeks (for participants with prediabetes at randomization).\n\n\u2022  Hp,14 and Hp,15: superiority of tirzepatide (all doses combined) versus placebo for delaying the onset of type 2 diabetes mellitus (T2DM) during 176 weeks or 193 weeks (for participants with prediabetes at randomization).\n\nThe details of family\u2011wise type I error rate control strategy and methods for the aforementioned hypotheses will be provided in the statistical analysis plan (SAP).\n\n# 9.2. Sample Size Determination\n\nApproximately 3429 participants will be screened to achieve 2400 randomly assigned to study intervention (600 participants per intervention group).\n\nThe sample size determination assumes that evaluation of superiority of 10\u2011mg tirzepatide and tirzepatide 15 mg to placebo will be conducted in parallel, each at a 2\u2011sided significance level of 0.025 using a 2\u2011sample t\u2011test.  Additionally, a difference of at least 11% mean body weight percentage reduction from randomization at 72 weeks for 10\u2011mg tirzepatide and/or tirzepatide 15 mg compared with placebo, a common SD of 10%, and a dropout rate of 25% are assumed for statistical power calculations. Under the assumptions above, randomizing 2400 participants in a 1:1:1:1 ratio to tirzepatide 5 mg (600), tirzepatide 10 mg (600), tirzepatide 15 mg (600), and placebo (600) provides more than 90% power to demonstrate superiority of tirzepatide 10 mg and/or 15 mg to placebo.\n\nThe chosen sample size and randomization ratio also provides >90% power to establish superiority of 10\u2011mg tirzepatide and 15\u2011mg tirzepatide doses to placebo in term of percentage of participants achieving at least 5% body weight reduction at 72 weeks, conducted in parallel using a Fisher\u2019s exact test, each at a 2\u2011sided significance level of 0.025, assuming 25% placebo\u2011treated participants and 90% tirzepatide\u2011treated participants achieving the goal and a dropout rate of 25%.\n\nIn addition, assuming that approximately 60% of the randomized population will have prediabetes, the study sample size will also provide more than 90% power to demonstrate superiority of tirzepatide (all doses combined) over placebo in terms of delaying the onset of diabetes for participants with prediabetes at study entry. It is based on the following assumptions: 1.6% (corresponding to annual hazard rate of 0.54%) of participants randomized to tirzepatide and 6% of participants randomized to placebo (corresponding to annual hazard rate of\n\nLY3298176                                                                                      81", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3268, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b335cdfd-c386-48b0-a9f3-4a224d5a4f53": {"__data__": {"id_": "b335cdfd-c386-48b0-a9f3-4a224d5a4f53", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a71e27ee-9963-44f0-8c82-f806f976f893", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "4592d07d54f5102c80658f8f77d92215a70b0652a163fce435d3d26332016477", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n2.1%) will progress to diabetes during the 3\u2011year period; 49% of participants will drop out (corresponding to annual drop\u2011out rate of 22%) during the same period; and the test will be conducted at a 2\u2011sided significance level of 0.05.\n\nLY3298176    82", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 292, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "63e1c935-2ddc-4ac6-a5ec-2265170b048c": {"__data__": {"id_": "63e1c935-2ddc-4ac6-a5ec-2265170b048c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e8b65a57-b562-44e9-856a-abe3939013e5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cf9f3585e99c9f77630c40e76501a852b9024df07d43b741aa87e8b40c5f4692", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# 9.3. Populations for Analyses\n\nFor purposes of analysis, the following analysis sets are defined:\n\n| Analysis Set                    | Description                                                                                                                                                       |\n| ------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Entered Participants            | all participants who sign informed consent                                                                                                                        |\n| Randomized Participants         | all participants who are randomly assigned a study treatment                                                                                                      |\n| Modified Intent\u2011to\u2011Treat (mITT) | all randomly assigned participants who are exposed to at least 1 dose of study drug; participants will be included in the treatment group they were randomized to |\n| Efficacy Analysis Set (EAS)     | data obtained during treatment period from mITT, excluding data after discontinuation of study drug (last dose date + 7 days)                                     |\n| Full analysis set (FAS)         | data obtained during treatment period from mITT, regardless of adherence to study drug.                                                                           |\n| Safety Analysis Set (SS)        | data obtained during the treatment period plus safety follow\u2011up period from mITT, regardless of adherence to study drug                                           |\n\n# 9.4. Statistical Analyses\n\n# 9.4.1. General Statistical Considerations\n\nStatistical analysis of this study will be the responsibility of Lilly or its designee. Any change to the data analysis methods described in the protocol will require an amendment ONLY if it changes a principal feature of the protocol. Any other change to the data analysis methods described in the protocol, and the justification for making the change, will be described in the SAP or the Clinical Study Report (CSR). Additional exploratory data analyses may be conducted as deemed appropriate.\n\nUnless otherwise noted, all tests of treatment effects will be conducted at a 2\u2011sided alpha level of 0.05, and the confidence interval will be calculated at 95%, 2\u2011sided. In statistical summaries and analyses, data will be analyzed as randomized.\n\nUnless specified otherwise, efficacy and safety will be assessed using the modified intention\u2011to\u2011treat (mITT) population. Baseline will be defined as the last available non\u2011missing measurement during Visit 1 to Visit 3. Unless specified otherwise, safety assessments will be guided by an estimand comparing safety of tirzepatide doses with placebo irrespective of adherence to study drug. Thus, safety analysis will be conducted using safety analysis set (SS).\n\nSummary statistics for continuous measures will include sample size, mean, SD, median, minimum, and maximum. The analysis model to make comparisons among treatment groups relative to continuous measurements assessed over time will include a mixed model for repeated measures (MMRM), with terms of treatment, visit, and treatment\u2011by\u2011visit interaction, stratification factors, and baseline measurement as a covariate.\n\nKaplan\u2011Meier method will be used for estimation of cumulative event\u2011free survival rates over time, and Cox proportional hazards regression analysis will be used to compare hazard rates among treatments.\n\nSummary statistics for categorical measures (including categorized continuous measures) will include sample size, frequency, and percentages. Logistic regression will be used to examine the treatment difference in binary efficacy outcomes if there is a need to adjust for covariates.\n\nLY3298176 83", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3915, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a5523900-e787-4cb8-a14f-0eb36fd465af": {"__data__": {"id_": "a5523900-e787-4cb8-a14f-0eb36fd465af", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f4adfd8a-a0b0-427f-9292-21410c18f960", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "589c918ade9899ff94f43d4e973a4abf0049fd41c1a143756adffdc0200ce385", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nOtherwise, Fisher\u2019s exact test will be used to examine the treatment difference in categorical outcomes. Summary statistics for discrete count measures will include sample size, mean, SD, median, minimum, and maximum. The negative binomial regression model will be used for the treatment comparison of discrete count measures. Other statistical methods may be used, as appropriate, and details will be described in the SAP.\n\n# 9.4.2. Treatment Group Comparability\n\n# 9.4.2.1. Participant Disposition\n\nA detailed description of participant disposition will be provided at the end of the study. Frequency counts and percentages of all participants screened, randomized, and receiving at least 1 dose of study drug will be presented by treatment groups. Of the participants in the mITT population, frequency counts and percentages of participants who completed the study, prematurely discontinued the study (and/or study drug), including reason for premature discontinuation, will be presented by treatment groups. A Kaplan\u2011Meier analysis of time from randomization to premature discontinuation from study by treatment group will be provided.\n\n# 9.4.2.2. Participant Characteristics\n\nDemographics and other baseline characteristics (including years of education) will be summarized by treatment group for all randomized participants.\n\n# 9.4.2.3. Concomitant Therapy\n\nConcomitant medications, including previous therapy, will be summarized by treatment arm for SS.\n\n# 9.4.2.4. Treatment Compliance\n\nFrequency counts and percentages of participants compliant to study drug will be summarized by treatment groups and visits for full analysis set (FAS).\n\n# 9.4.3. Efficacy Analyses\n\n# 9.4.3.1. Primary Analyses\n\nThere will be 2 estimands of interest in comparing efficacy of tirzepatide doses with placebo.\n\n- For objectives controlled for Type 1 error at 72 weeks:\n1. The \u201cefficacy\u201d estimand, defined as the average treatment effect of tirzepatide relative to placebo at 72 weeks, as an adjunct to a reduced\u2011calorie diet and increased physical activity, in the randomized participants had they remained on their randomized treatment for the entire planned 72 weeks treatment duration.\n2. The \u201chybrid\u201d estimand, defined as the average treatment effect of tirzepatide relative to placebo at 72 weeks, as an adjunct to a reduced\u2011calorie diet and increased physical activity, for the randomized participants regardless of the adherence to study drug.\n\nLY3298176 84", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2495, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "42007811-066c-4622-b636-bbdb7b1f938e": {"__data__": {"id_": "42007811-066c-4622-b636-bbdb7b1f938e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3c2cfe92-b8d3-490e-b763-9b71064c8ab0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "be8bb3343de9ffbfcf540a8d854a0c777d7d42e86cb19fac36f542edbd2f01d1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n\u2022  For objectives controlled for Type 1 error assessed after 72 weeks:\n\n1. The \u201cefficacy\u201d estimand, defined as the treatment effect of tirzepatide relative to placebo at 176/193 weeks, as an adjunct to a reduced\u2011calorie diet and increased physical activity, in the randomized participants with prediabetes at randomization had they remained on their randomized treatment for the entire planned 176 weeks treatment duration.\n2. The \u201chybrid\u201d estimand, defined as the average treatment effect of tirzepatide relative to placebo at 176/193 weeks, as an adjunct to a reduced\u2011calorie diet and increased physical activity, for the randomized participants with prediabetes at randomization regardless of the adherence to study drug.\n\nFor the Food and Drug Administration, the primary efficacy analysis will be guided by the hybrid estimand and conducted using the FAS. This assessment will analyze percent change in body weight obtained at the 72\u2011week visit using an analysis of covariance (ANCOVA) and the percentage of participants achieving at least 5% body weight reduction obtained at the 72\u2011week visit using a logistic regression model. Both models will include terms of treatment, stratification factors, and baseline body weight as a covariate. Missing data at the 72\u2011week visit will be imputed and analysis will be conducted with multiple imputations (see details in the SAP). Since the mean percent change in body weight and percentage of participants with \u22655% body weight reduction objectives need to be achieved at the same time, no multiplicity adjustment is planned for these 2 tests.\n\nFor all other purposes, the primary efficacy analysis will be guided by the \u201cefficacy\u201d estimand and conducted using the efficacy analysis set (EAS). The primary analysis model will be an MMRM for body weight percent change over time and logistic regression for percentage of participants achieving at least 5% body weight reduction over time. Details of the statistical modeling will be provided in the SAP.\n\n# 9.4.3.2. Key Secondary Analyses\n\n- superiority of pooled tirzepatide 10 mg and 15 mg to placebo for change in body weight (kg) from randomization at 20 weeks visit\n- superiority of QW tirzepatide 5 mg to placebo for percent change in body weight from randomization AND percentage of participants who achieve \u22655% body weight reduction at 72 weeks visit\n- superiority of each tirzepatide dose (10 mg and 15 mg) to placebo for the percentage of study participants who achieve \u226510% body weight reduction at 72 weeks visit\n- superiority of each tirzepatide dose (10 mg and 15 mg) to placebo for the percentage of study participants who achieve \u226515% body weight reduction at 72 weeks visit\n- superiority of each tirzepatide dose (10 mg and 15 mg) to placebo for the percentage of study participants who achieve \u226520% body weight reduction at 72 weeks visit\n- superiority of each tirzepatide dose (10 mg and 15 mg) to placebo for change from randomization in waist circumference (cm) at 72 weeks visit\n\nLY3298176    85", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3054, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fd13af9b-107c-4cbe-9759-bd3c8b944b08": {"__data__": {"id_": "fd13af9b-107c-4cbe-9759-bd3c8b944b08", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cbbd9861-4751-4ed1-82c6-cac1ec6a487c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "19628266a91e37598e824d210059a4a478c9e69ee5211aaf6eebd1c5c13aa72b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 9.4.3. Superiority Analyses\n\n- superiority of pooled tirzepatide 10 mg and 15 mg to placebo for change from randomization in SF\u201136v2 acute form physical functioning domain score at 72 weeks visit\n- superiority of tirzepatide (all doses combined) to placebo for change from randomization in triglycerides (mg/dL) at 72 weeks visit\n- superiority of tirzepatide (all doses combined) to placebo for change from randomization in non\u2011HDL\u2011cholesterol (mg/dL) at 72 weeks visit\n- superiority of tirzepatide (all doses combined) to placebo for change from randomization in HDL\u2011cholesterol (mg/dL) at 72 weeks visit\n- superiority of tirzepatide (all doses combined) to placebo for change from randomization in SBP (mmHg) at 72 weeks visit\n- superiority of tirzepatide (all doses combined) to placebo for change from randomization in fasting insulin (pmol/L) at 72 weeks visit\n- superiority of each tirzepatide dose (10 mg and 15 mg) to placebo for change from randomization in percent change of body weight at 176 weeks visit (for participants with prediabetes at randomization)\n- superiority of tirzepatide (all doses combined) to placebo in delaying the onset of diabetes during 176 weeks treatment period (for participants with prediabetes at randomization)\n- superiority of tirzepatide (all doses combined) to placebo in delaying the onset of diabetes during 193 weeks study period (for participants with prediabetes at randomization)\n\nAdditional details, including analysis methods for key secondary endpoints and the strategy for controlling overall type 1 error rate at a 2\u2011sided alpha of 0.05 of primary and key secondary endpoint evaluation, will be provided in the SAP.\n\n# 9.4.4. Safety Analyses\n\nUnless specified otherwise, safety assessments will be guided by an estimand comparing safety of tirzepatide doses with placebo irrespective of adherence to study drug. Thus, safety analysis will be conducted using SS.\n\n# 9.4.4.1. Study Drug Exposure\n\nExposure to each study treatment will be calculated for each participant and summarized by treatment group.\n\n# 9.4.4.2. Adverse Events\n\nAdverse events will be coded from the actual term using the Medical Dictionary for Regulatory Activities (MedDRA) and reported with preferred terms and system organ class. Counts and percentages of participants experiencing events will be reported for each treatment group, and Fisher\u2019s exact test will be used to compare the treatment groups.\n\nLY3298176 86", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2485, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6c48f058-0a1e-44bd-b38d-ef478a601c98": {"__data__": {"id_": "6c48f058-0a1e-44bd-b38d-ef478a601c98", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6aeb67bb-8858-45fe-abaf-bf53ab18a19d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "bd8b6cf0ef550c062dbdef16e2721b16b0060b9f4f4ac8f1a6113ea8a0777442", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nThe percentage of participants experiencing TEAE, SAE, discontinuation due to AE will be summarized by treatment group.\n\n# 9.4.4.3. Adverse Event of Special Interest\n\nThis section includes areas of interest whether due to observed safety findings, potential findings based on drug class, and agreed upon consultation with regulatory agencies for the reasons previously mentioned.\n\nThe following AEs are AEs of special interest (AESI) for this study:\n\n- severe hypoglycemia\n- major adverse cardiovascular events (adjudicated); includes, but not limited to cardiovascular death, nonfatal MI, nonfatal stroke, and hospitalization for heart failure\n- treatment\u2011emergent supraventricular arrhythmias and cardiac conduction disorders\n- hepatobiliary disorders; includes biliary colic, cholecystitis, and other gallbladder disease\n- severe GI events\n- acute renal events\n- MDD/suicidal behavior and ideation\n- pancreatitis (adjudicated)\n- c\u2011cell hyperplasia and thyroid malignancies\n- allergic/hypersensitivity reactions; includes injection site reactions and ADA formation.\n\nSummaries and analyses for incidence of AESIs will be provided by treatment. The details of analysis of AESI will be provided in the SAP.\n\n# 9.4.4.4. Other Adverse Event Assessments\n\n# 9.4.4.4.1. Gastrointestinal Events\n\nSummaries and analyses for incidence and severity of nausea, vomiting, and diarrhea will be provided by each treatment.\n\n# 9.4.4.4.2. Events Related to Potential Abuse Liability\n\nTo identify AE terms suggestive of potential abuse liability, narrow terms from SMQ of Drug abuse and dependence (20000101) will be used.\n\nSummaries and analyses for incidence of potential abuse liability terms will be provided by treatment. The details will be provided in the SAP.\n\nLY3298176 87", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1806, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7f821f97-a1b4-4b70-9385-34ce9b5e15b4": {"__data__": {"id_": "7f821f97-a1b4-4b70-9385-34ce9b5e15b4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "318f2c95-d5d8-465b-a5d2-c4c61e4fe109", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8d1acb97ea35d17d590cb320fdfa86eab92383269e905907cd8b94b6b46a646d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# 9.4.4.4.3. Depression, Suicidal Ideation, and Behavior\n\nIn addition to the summary of TEAEs, suicidal ideation and behavior will be assessed by C\u2011SSRS, and depression\u2011related symptoms will be assessed using PHQ\u20119. The analysis details will be provided in the SAP.\n\n# 9.4.4.4.4. Central Laboratory Measures, Vital Signs, and Electrocardiograms\n\nActual values and change from randomization to postrandomization values of central laboratory measures, vital signs, and selected ECG parameters will be summarized at each scheduled visit. Change from randomization to postrandomization value will be summarized for participants who have both a randomization and at least 1 postrandomization result. The percentages of participants with treatment\u2011emergent (TE) abnormal, high, or low measures (including laboratory, vital, and ECG parameters) will be summarized and compared between treatment groups using Fisher\u2019s exact test. The analysis details will be provided in the SAP.\n\n# 9.4.5. Pharmacokinetic/Pharmacodynamic Analyses\n\nTirzepatide concentration data will be analyzed using a population PK approach using nonlinear mixed\u2011effects modeling techniques implemented on the NONMEM\u00ae software. The relationships between tirzepatide dose and/or concentration and selected efficacy, tolerability, and safety endpoints will be characterized. Additionally, the impact of intrinsic and extrinsic participant factors such as age, weight, gender, and renal function on tirzepatide PK and/or PD parameters may be examined. If ADA titers are detected from immunogenicity testing, then the impact of immunogenicity titers on tirzepatide PK or any relevant PD parameters may also be examined.\n\n# 9.4.6. Evaluation of Immunogenicity\n\nThe frequency and percentage of participants with preexisting ADA and with TE ADA+ to tirzepatide will be tabulated. Treatment\u2011emergent ADAs are defined as those with a titer 2\u2011fold (1 dilution) greater than the minimum required dilution (1:10) of the ADA assay if no ADAs were detected at baseline (treatment\u2011induced ADA) or those with a 4\u2011fold (2 dilutions) increase in titer compared with baseline if ADAs were detected at baseline (treatment\u2011boosted ADA). Details of the analyses will be provided in the SAP.\n\n# 9.4.7. Other Analyses\n\n# 9.4.7.1. Subgroup Analyses for Primary Outcome\n\nDetails of the subgroup analyses will be shown in the SAP. The following subgroup variables will be considered (but not limited to):\n\n- age (&#x3C;65 years and \u226565 years)\n- sex (female and male)\n- baseline BMI (&#x3C;30, \u226530 and &#x3C;35, \u226535 and &#x3C;40, \u226540 kg/m\u00b2)\n\nLY3298176 88", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2602, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f47e5d59-9fd7-433e-9cdc-624cbc203499": {"__data__": {"id_": "f47e5d59-9fd7-433e-9cdc-624cbc203499", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c0349648-42ee-430c-8882-95e1240da141", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7fbf60af864eb8f54e4f648e6570ca20c609cf24bd1585e2461e90a7fdc4c012", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 9.5. Interim Analyses\n\nBased on the projected enrollment, 3 interim analyses are planned. Changes in the number of interim analyses and the timing of conducting the interim analyses due to the change of enrollment rate will not require an amendment.\n\nThe first unblinded safety interim analysis will occur approximately 6 months after approximately 400 participants are randomized in the study to monitor the safety of the participants in the study.\n\nThe second interim analysis is the 36\u2011week interim analysis to monitor the safety of the participants in the study with a special focus to assess the effect of 5\u2011, 10\u2011, and 15\u2011mg doses of tirzepatide compared to placebo on HR. The timing of the 36\u2011week interim analysis will be triggered by the completion of a 24\u2011hour ambulatory monitoring sub\u2011study; specifically, after approximately 576 randomized participants in GPHK who agree to perform ambulatory monitoring have either completed 36 weeks of treatment or discontinued earlier. An independent data monitoring committee (DMC) will have the responsibility to review unblinded interim analysis results. A statistical analysis center independent from the Sponsor will perform the data analysis for the DMC.\n\nThe third unblinded safety interim analysis will occur approximately 6 months after the 36\u2011week interim analysis to monitor the safety of the participants in the study.\n\nFollowing the third interim analysis specified above, the primary database lock will occur after all randomized participants complete the 72\u2011week treatment period or discontinue the study early. The primary objective of the study will be assessed following the primary database lock.\n\nThe final database lock will occur after participants classified with prediabetes have completed a 176\u2011week treatment period and the safety follow\u2011up visit or discontinued the study early.\n\nA limited number of individuals will have access to the unblinded data from the interim and/or primary database lock prior to the final database lock (after all randomized participants complete the entire study). Information that may unblind the study after the interim or primary database lock will not be communicated to study sites or blinded study team prior to final database lock, unless it is deemed necessary for participant safety. Details will be specified in the blinding/unblinding plan and in the DMC charter.\n\nLY3298176    89", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2438, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "950061fa-fca2-4fa8-8f8c-44eb624f5645": {"__data__": {"id_": "950061fa-fca2-4fa8-8f8c-44eb624f5645", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a64ab452-e6f6-4e8c-8ff4-7db12c8eafc6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e4488617462105545e6fd9511599e8d99263434eaf1f59f09be84d4b1ffaf916", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10. Supporting Documentation and Operational Considerations\n\n# 10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations\n\n# 10.1.1. Regulatory and Ethical Considerations\n\n- This study will be conducted in accordance with the protocol and with the following:\n- Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines\n- Applicable The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) Guidelines\n- Applicable laws and regulations\n- The protocol, protocol amendments, ICF, investigator\u2019s brochure, and other relevant documents (for example, advertisements) must be submitted to an IRB/IEC by the investigator and reviewed and approved by the IRB/IEC before the study is initiated.\n- Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.\n- The investigator will be responsible for the following:\n- Providing written summaries of the status of the study to the ERB annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC\n- Notifying the IRB/IEC of SAEs or other significant safety findings as required by ERB procedures\n- Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations\n\n# 10.1.2. Informed Consent Process\n\n- The investigator or his or her representative will explain the nature of the study, including risks and benefits, to the study participant or his/her legally authorized representative and answer all questions regarding the study.\n\nLY3298176    90", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2053, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7b423dce-121d-4448-b542-3a8b9a389864": {"__data__": {"id_": "7b423dce-121d-4448-b542-3a8b9a389864", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d716d36f-b51a-4e51-a9f3-1d40dcfad028", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "bb8384396c1348ba16ab07edd2abd1e019bb30e33e0ccd411c8283619d09319e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK(b)\n\n\u2022 Study participants must be informed that their participation is voluntary. Study participants or their legally authorized representative will be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, and the IRB/IEC or study center.\n\n\u2022 The medical record must include a statement that written informed consent was obtained before the study participant was entered into the trial and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF.\n\n\u2022 Study participants must be reconsented to the most current version of the ICF(s) during their participation in the trial.\n\n\u2022 A copy of the ICF(s) must be provided to the study participant or the study participant\u2019s legally authorized representative.\n\n# 10.1.3. Data Protection\n\n\u2022 Study participants will be assigned a unique identifier by the investigator. Any study participant records, datasets, or tissue samples that are transferred to the Sponsor will contain the identifier only; study participant names or any information which would make the study participant identifiable will not be transferred.\n\n\u2022 The study participant must be informed that his/her personal trial\u2011related data will be used by the Sponsor in accordance with local data protection law. The level of disclosure must also be explained to the study participant.\n\n\u2022 The study participant must be informed that his/her medical records may be examined by Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.\n\n# 10.1.4. Committees Structure\n\nProspective adjudication of incident diabetes events as well as major adverse cardiovascular events and pancreatic AEs will be performed by the independent adjudication committees for this study.\n\nMore details on adjudication of incident diabetes events can be found in Section 4.1.2.3.\n\nSection 10.3 Appendix 3 outlines additional information on pancreatic and cardiovascular adjudication committees.\n\nAn independent DMC for the interim analysis (Section 9.5) will include members with no conflict of financial interest.\n\n# 10.1.5. Dissemination of Clinical Study Data\n\nRequired clinical trial registries (for example, ClinicalTrials.gov) will be updated with the results from registered clinical trials regardless of the research outcome in accordance with local laws and regulations.\n\nLY3298176 91", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2640, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d6784c45-defb-4d35-a812-c2df9e6d0fe3": {"__data__": {"id_": "d6784c45-defb-4d35-a812-c2df9e6d0fe3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ff37c69d-66d3-467b-8aaf-7b5252751b93", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6fe7a03baeb7ad92f711f111e54c810766e6223d38874aab40862aa23813ab59", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK(b)\n\nAll CSRs, amendments, and addenda will be submitted to external regulatory authorities, external partners (as applicable), and sites. The publication policy for Study I8F\u2011MC\u2011GPHK (SURMOUNT\u20111) is outlined in Section 10.1.10 and further described in the Clinical Trial Agreement.\n\n# 10.1.6. Data Quality Assurance\n\nTo ensure accurate, complete, and reliable data, Lilly or its representatives will:\n\n- provide instructional material to the study sites, as appropriate\n- provide sponsor start\u2011up training to instruct the investigators and study coordinators. This training will provide instruction on the protocol, the completion of the eCRFs, and study procedures\n- make periodic visits to the study site\n- be available for consultation and stay in contact with the study site personnel by mail, telephone, and/or fax\n- review and verify data reported to detect potential errors.\n\nIn addition, Lilly or its representatives will periodically check a sample of the participant data recorded against source documents at the study site. The study may be audited by Lilly or its representatives and/or regulatory agencies at any time. Investigators will be given notice before an audit occurs.\n\nThe investigator will keep records of all original source data. This might include laboratory tests, medical records, and clinical notes. If requested, the investigator will provide the Sponsor, applicable regulatory agencies, and applicable ERBs with direct access to original source documents.\n\n# 10.1.7. Data Capture System\n\nThe investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported to the Sponsor. An electronic data capture (EDC) system will be used in this study for the collection of CRF data. The investigator maintains a separate source for the data entered by the investigator or designee into the sponsor\u2011provided EDC system. The investigator is responsible for the identification of any data to be considered source and for the confirmation that data reported are accurate and complete by signing the eCRF.\n\nAdditionally, clinical outcome assessment data (scales, self\u2011reported diary data) will be collected by the subject/investigator site personnel via a paper source document and will be transcribed by the investigator site personnel into the EDC system.\n\nData collected via the sponsor\u2011provided data capture systems will be stored at third parties. The investigator will have continuous access to the data during the study and until decommissioning of the data capture systems. Prior to decommissioning, the investigator will receive an archival copy of pertinent data for retention.\n\nLY3298176 92", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2704, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "56cc54c1-34e7-480f-9984-4236c2369312": {"__data__": {"id_": "56cc54c1-34e7-480f-9984-4236c2369312", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9926536b-7a39-4ac2-abc5-9a3392a7a534", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "40e7d9f99981b7b6b7be819da7d3cb01f08dbc31dfeebff7d8c98fcfb73a4a13", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nData managed by a central vendor, such as laboratory test data, will be stored electronically in the central vendor\u2019s database system and electronic transfers will be provided to the investigator for review and retention. Data will subsequently be transferred from the central vendor to the Lilly data warehouse.\n\nData from complaint forms submitted to Lilly will be encoded and stored in the global product complaint management system.\n\n# 10.1.8. Source Documents\n\n- Source documents provide evidence for the existence of the study participant and substantiate the integrity of the data collected. Source documents are filed at the investigator\u2019s site.\n- Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The investigator may need to request previous medical records or transfer records, depending on the trial. Also, current medical records must be available.\n\n# 10.1.9. Study and Site Closure\n\n# 10.1.9.1. Discontinuation of Study\n\nThe study will be discontinued if Lilly or its designee judges it necessary for medical, safety, regulatory, or other reasons consistent with applicable laws, regulations, and GCP.\n\n# 10.1.9.2. Discontinuation of Study Sites\n\nStudy site participation may be discontinued if Lilly or its designee, the investigator, or the ERB of the study site judges it necessary for medical, safety, regulatory, or other reasons consistent with applicable laws, regulations, and GCP.\n\n# 10.1.10. Publication Policy\n\n- The Sponsor will comply with the requirements for publication of study results.\n- Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.\n- The publication policy for Study I8F\u2011MC\u2011GPHK (SURMOUNT\u20111) is described in the Clinical Trial Agreement.\n\nLY3298176 93", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1949, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b86ebc7f-15eb-4cc9-ba95-76b05f307044": {"__data__": {"id_": "b86ebc7f-15eb-4cc9-ba95-76b05f307044", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9b8252ce-12d3-4f4a-90bc-f7be90418548", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cb40f276abca48ea0ab57a564981669f8a743ef59e71c398e3680c1bf851e08d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.2. Appendix 2: Clinical Laboratory Tests\n\n- The tests detailed below will be performed by the central laboratory unless otherwise stated.\n- Local laboratory results are only required in the event that the central laboratory results are not available in time for response evaluation. If a local sample is required, it is important that the sample for central analysis is obtained at the same time. Additionally, if the local laboratory results are used to make either a study intervention decision or response evaluation, the results must be entered into the eCRF.\n- Protocol\u2011specific requirements for inclusion or exclusion of participants are detailed in Section 5 of the protocol.\n- Additional tests may be performed at any time during the study as determined necessary by the investigator or required by local regulations.\n- Refer to Section 5.1 (Inclusion Criteria) for screening pregnancy criteria.\n\nInvestigators must document their review of each laboratory safety report. Laboratory/analyte results that could unblind the study will not be reported to investigative sites or other blinded personnel until the study has been unblinded.\n\nLY3298176 94", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1202, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6b2c98b3-4949-420a-9b65-97ea56422940": {"__data__": {"id_": "6b2c98b3-4949-420a-9b65-97ea56422940", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3703b5f4-67b1-4eaa-ae86-9d6bc002d241", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8d05ad9cce497e182a0669e3c886a43c73baa939d116ca80e4c1d03f79fdd477", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Clinical Laboratory Tests\n\n# Hematology\u1d43\n\n- Hemoglobin\n- Hematocrit\n- Erythrocyte count (RBC)\n- Mean cell volume\n- Mean cell hemoglobin concentration\n- Leukocytes (WBC)\n- Neutrophils, segmented\n- Lymphocytes\n- Monocytes\n- Eosinophils\n- Basophils\n- Platelets\n\n# Urine Chemistries\u1d43\n\n- Albumin\n- Creatinine\n\n# Clinical Chemistry\u1d43\n\n- Sodium\n- Potassium\n- Bicarbonate\n- Total bilirubin\n- Direct bilirubin\n- Alkaline phosphatase\n- Alanine aminotransferase (ALT)\n- Aspartate aminotransferase (AST)\n- Blood urea nitrogen (BUN)\n- Creatinine\n- Uric acid\n- Calcium\n- Glucose, fasting\n- Albumin\n- Total Cholesterol\n- Triglycerides\n- Creatine kinase (CK)\n\n# Nonpharmacogenetic Stored Samples\n\n- Serum\n- EDTA plasma\n- P800 plasma\n\n# Hormones (females)\n\n- Pregnancy Test a, serum and/or urine\u1d47\n- Follicle\u2011stimulating hormone (FSH)\u1d48\n\n# Calculations\n\n- eGFR (calculated by CKD\u2011EPI equation)a,c\n- UACR (urine albumin mg/dL/creatinine g/dL=UACR mg/g)\n\n# Pharmacokinetics samplesa,e,f,g\n\n# Pharmacogenetics Sample\n\n- Whole blood (EDTA)\n\n# Pancreas (exocrine) a\n\n- Pancreatic amylase\n- Lipase\n\n# Oral Glucose Tolerance Test\n\n- glucose, insulin\u1d49\n- c\u2011peptide\u1d49\n\n# Cystatin-C\u1d43\n\n# HbA1c\u1d43\n\n# Immunogenicitya,e,g\n\n- Anti\u2011tirzepatide antibodies\n- Anti\u2011tirzepatide antibody neutralization\n\n# Endocrine\u1d43\n\n- Calcitonin\n- Thyroid\u2011stimulating hormone (TSH)\n- Insulin\u1d49\n- C-peptide\u1d49\n\n# Lipid Panel\u1d43\n\n- LDL\u2011C\n- HDL\u2011C\n- VLDL\u2011C\n\n# Free Fatty Acids\u1d49\n\n# LY3298176\n\n95", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1467, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b1e05b68-57e8-4cae-bef2-2cda85a98541": {"__data__": {"id_": "b1e05b68-57e8-4cae-bef2-2cda85a98541", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "95797838-538b-48c4-9324-5e0bb3dacea8", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "dc7079dc88398417900f99976631993f98bb3c5aeb7e6c2abce817dac2974098", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\nAbbreviations: ADA = antidrug antibody; ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; CK = creatinine kinase, CKD\u2011EPI = Chronic Kidney Disease\u2011Epidemiology; eGFR = estimated glomerular filtration rate; EDTA = ethylenediaminetetraacetic acid; FSH = follicle\u2011stimulating hormone; HbA1c = hemoglobin A1c; HDL = high\u2011density lipoprotein; IWRS = interactive web\u2011response system; LDL = low\u2011density lipoprotein; PK = pharmacokinetics; RBC = red blood cells; TSH = thyroid\u2011stimulating hormone; UACR = urine albumin/creatinine ratio; VLDL = very low\u2011density lipoprotein; WBC = white blood cells.\n\na All tests will be performed by a Lilly\u2011designated central laboratory, unless otherwise noted.\n\nb A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only.\n\nA urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy tests (beyond those required per the Schedule of Activities [Section 1.3]) should be performed at any time during the trial if a menstrual period is missed, there is clinical suspicion of pregnancy, or as required by local law or regulation.\n\nc Estimated glomerular filtration rate will be calculated by the central laboratory at all visits and included in lab result reports.\n\nd Follicle\u2011stimulating hormone test performed at Visit 1 for postmenopausal women at least 40 years of age with an intact uterus, not on hormone therapy, and who have had spontaneous amenorrhea for more than 1 year without an alternative medical cause.\n\ne Results will not be provided to the investigative sites.\n\nf PK samples will be collected at these visits at time windows of 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose, as assigned by IWRS. Dependent on the time\u2011windows to which a participant gets assigned, they may be required to come to site for PK\u2011specific visits.\n\ng In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and exploratory biomarker samples. PK samples for immunogenicity must be taken prior to drug administration.\n\nLY3298176    96", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2345, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ddbbc828-9dac-481c-8943-50cf0910f274": {"__data__": {"id_": "ddbbc828-9dac-481c-8943-50cf0910f274", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ccdb31ca-832f-4bde-b973-073a70d97fbb", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "69a7d61d53c979856f893b6cd90729d2b52459e3b6665c55deb31975ecc996e3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\nSelected tests may be obtained in the event of anaphylaxis or systemic allergic/hypersensitivity reactions.\n\n# Hypersensitivity Tests\u1d43\n\nAnti\u2011LY antibodies (immunogenicity)\nLY concentration (PK)\nTryptase\u1d47\nN\u2011methylhistamine\u1d47\nDrug Specific IgE\u1d47\nBasophil Activation Test\u1d47\nComplements\nCytokine Panel\n\nAbbreviations: LY = LY3298176; IgE = immunoglobulin E; PK = pharmacokinetics.\n\na  Assayed by Lilly\u2011designated laboratory.\n\nb  Will be performed if a validated assay is available.\n\nLY3298176    97", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 533, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "33cc0f41-75e9-45ad-8c2f-7a63382d551e": {"__data__": {"id_": "33cc0f41-75e9-45ad-8c2f-7a63382d551e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "797ba812-d289-4fe5-a5e5-1291c9e653ba", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "85f1186bf96b16ee6699f5daf62d4b71c93d2b648b36bc2342a43b109d332373", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                            Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-Up, and Reporting\n\nPlease refer to Section 8.3 Adverse Events and Serious Adverse Events.\n\n# 10.3.1. Special Safety Topics\n\n# 10.3.1.1. Hypoglycemia\n\nUpon ICF signing, all participants will be educated about signs and symptoms of hypoglycemia, how to treat hypoglycemia, and how to collect appropriate information for each episode of hypoglycemia.\n\nHypoglycemia may be identified by spontaneous reporting of symptoms from participants (whether confirmed or unconfirmed by simultaneous glucose values) or by blood glucose (BG) samples collected during study visits.\n\nAll participants who develop diabetes during the study will be provided with glucometers. Participants without diabetes may, at the investigator\u2019s discretion, be given glucometers to assist in the evaluation of reported symptoms consistent with hypoglycemia. Participants receiving glucometers will be provided a diary to record relevant information (for example, glucose values, symptoms).\n\nHypoglycemic episodes will be recorded on a specific eCRF and should not be recorded as AEs unless the event meets serious criteria. If a hypoglycemic event meets severe criteria (see definition below), it should be recorded as serious on the AE and SAE eCRFs, and reported to Lilly as an SAE.\n\nInvestigators should use the following definitions and criteria when diagnosing and categorizing an episode considered to be related to hypoglycemia (the plasma Glucose values in this section refer to values determined by a laboratory or International Federation of Clinical Chemistry and Laboratory Medicine blood\u2011equivalent glucose meters and strips) in accordance with the 2019 American Diabetes Association position statement on glycemic targets (American Diabetes Association 2019a):\n\n# Glucose Alert Value (Level 1):\n\n- Documented symptomatic hypoglycemia is defined as any time a patient feels that he or she is experiencing symptoms and/or signs associated with hypoglycemia and has a BG level of &#x3C;70 mg/dL (\u22643.9 mmol/L).\n- Documented asymptomatic hypoglycemia is defined as any event not accompanied by typical symptoms of hypoglycemia, but with a measured BG &#x3C;70 mg/dL (\u22643.9 mmol/L).\n- Documented unspecified hypoglycemia is defined as any event with no information about symptoms of hypoglycemia available, but with a measured BG &#x3C;70 mg/dL (\u22643.9 mmol/L).\n\nLY3298176    98", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2529, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "91412d37-c240-4dff-bd16-0503f8e9a73f": {"__data__": {"id_": "91412d37-c240-4dff-bd16-0503f8e9a73f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5d778d96-ec95-4e96-aa35-d637ac9ab7d0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "16a0f7a226cfe6ceae30c633adda0c2c2f0ccb8881f7a69447ba4e4d9d7f4ec9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Clinically Significant Hypoglycemia (Level 2):\n\n- Documented symptomatic hypoglycemia is defined as any time a participant feels that he or she is experiencing symptoms and/or signs associated with hypoglycemia and has a BG level of &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n- Documented asymptomatic hypoglycemia is defined as any event not accompanied by typical symptoms of hypoglycemia but with a measured BG &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n- Documented unspecified hypoglycemia is defined as any event with no information about symptoms of hypoglycemia available but with a measured BG &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n\n# Severe hypoglycemia (Level 3):\n\n- Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. Blood glucose measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration.\n\nTo avoid duplicate reporting, all consecutive BG values \u226470 mg/dL (3.9 mmol/L) occurring within a 1\u2011hour period may be considered to be a single hypoglycemic event (Weinberg et al. 2010; Danne et al. 2013).\n\n# 10.3.1.2. Pancreatitis\n\nAcute pancreatitis is defined as an AE of interest in all trials with tirzepatide, including this trial. Acute pancreatitis is an acute inflammatory process of the pancreas that may also involve peripancreatic tissues and/or remote organ systems (Banks and Freeman 2006). The diagnosis of acute pancreatitis requires 2 of the following 3 features:\n\n- abdominal pain, characteristic of acute pancreatitis (generally located in the epigastrium and radiates to the back in approximately half the cases) (Banks and Freeman 2006; Koizumi et al. 2006); the pain is often associated with nausea and vomiting);\n- serum amylase (total and/or pancreatic) and/or lipase \u22653X ULN\n- characteristic findings of acute pancreatitis on computed tomography (CT) scan or magnetic resonance imaging (MRI).\n\nIf acute pancreatitis is suspected, appropriate laboratory tests (including levels of pancreatic amylase and lipase) should be obtained via the central laboratory (and locally, if needed). Imaging studies, such as abdominal CT scan with or without contrast, MRI, or gallbladder ultrasound, should be performed. Abdominal ultrasound may be used as an alternative method only if CT and MRI cannot be performed. If laboratory values and/or abdominal imaging support the diagnosis of acute pancreatitis, the participant must discontinue therapy with\n\nLY3298176 99", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2806, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6e63ea0a-7a41-479c-aaf2-2ac788e9d436": {"__data__": {"id_": "6e63ea0a-7a41-479c-aaf2-2ac788e9d436", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1e1bcf58-c00b-4d67-be6a-43dc9b9b7b1a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7bdc28e874c6248e366c02e94062b0a5d46b7a02d668448474fa8740e17bf8f3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                      Protocol I8F\u2011MC\u2011GPHK(b)\n\ntirzepatide, but will continue in the study. A review of the participant\u2019s concomitant medications should be conducted to assess any potential causal relationship with pancreatitis.\n\nEach AE of pancreatitis must be reported. If typical signs and/or symptoms of pancreatitis are present and confirmed by laboratory values (lipase or amylase [total and/or pancreatic]) and imaging studies, the event must be reported as an SAE. For a potential case that does not meet all of these criteria, it is up to the investigator to determine the seriousness of the case (AE or SAE) and the relatedness of the event to study drug(s).\n\nEach participant will have measurements of p\u2011amylase and lipase (assessed at the central laboratory) as shown on the Schedule of Activities (Section 1.3) to assess the effects of the investigational doses of tirzepatide on pancreatic enzyme levels. Serial measurements of pancreatic enzymes have limited clinical value for predicting episodes of acute pancreatitis in asymptomatic participants (Nauck et al. 2017; Steinberg et al. 2017a, 2017b). Thus, further diagnostic follow\u2011up of cases of asymptomatic pancreatic hyperenzymemia (lipase and/or pancreatic amylase \u22653X ULN) is not mandated but may be performed based on the investigator\u2019s clinical judgment and assessment of the participant\u2019s overall clinical condition. Only cases of pancreatic hyperenzymemia that undergo additional diagnostic follow\u2011up and/or are accompanied by symptoms suggestive of pancreatitis will be submitted for adjudication.\n\nAll suspected cases of acute or chronic pancreatitis will be adjudicated by an independent clinical endpoint committee. In addition, AEs of severe or serious abdominal pain of unknown etiology will also be submitted to the adjudication committee to assess for possible pancreatitis or other pancreatic disease. Relevant data from participants with acute or chronic pancreatitis and those with severe or serious abdominal pain will be entered into a specifically designed eCRF page. The adjudication committee representative will enter the results of adjudication in a corresponding eCRF page.\n\n# 10.3.1.3. Thyroid Malignancies and C-Cell Hyperplasia\n\nIndividuals with personal or family history of MTC and/or MEN\u20112 will be excluded from the study. Participants who are diagnosed with MTC and/or MEN\u20112 during the study will have study drug stopped and should continue follow\u2011up with an endocrinologist.\n\nThe assessment of thyroid safety during the trial will include reporting of any case of thyroid malignancy (including MTC and papillary carcinoma) and measurements of calcitonin. This data will be captured in specific eCRFs. The purpose of calcitonin measurements is to assess the potential of tirzepatide to affect thyroid C\u2011cell function, which may indicate development of C\u2011cell hyperplasia and neoplasms.\n\n# 10.3.1.4. Calcitonin Measurements\n\nIf an increased calcitonin value (see definitions below) is observed in a participant who has been administered a medication that is known to increase serum calcitonin, then this medication should be stopped and calcitonin levels should be measured after an appropriate washout period. For participants who require additional endocrine assessment because of increased calcitonin concentration as defined in this section, data from the follow\u2011up assessment will be collected in the specific section of the eCRF.\n\nCalcitonin Measurements in Participants with eGFR \u226560 mL/min/1.73m\u00b2\n\nLY3298176                                                                                           100", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3655, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "252d911d-b755-41b1-bbb9-0afc5be912e2": {"__data__": {"id_": "252d911d-b755-41b1-bbb9-0afc5be912e2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "423dd833-4f87-4dcd-a92b-2a77b2bc6c2b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1d5d8cebd1880360486a4b7d501d365943a291ab0786e6fdaf97a9787b547b68", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nA significant increase in calcitonin for participants with eGFR \u226560 mL/min is defined below. If a participant\u2019s laboratory results meet these criteria, these clinically significant laboratory results should be recorded as an AE.\n\n- calcitonin value \u226520 ng/L and &#x3C;35 ng/L AND \u226550% increase from the screening value. These participants will be asked to repeat the measurement within 1 month. If this repeat value is increasing (\u226510% increase), study drug should be stopped, and the participant encouraged to undergo additional endocrine assessment and longer\u2011term follow\u2011up by an endocrinologist to exclude any serious adverse effect on the thyroid.\n- calcitonin value \u226535 ng/L AND \u226550% over the screening value. In these participants, study drug should be stopped, and the participant recommended to immediately undergo additional endocrine assessments and longer\u2011term follow\u2011up by an endocrinologist.\n\n# Calcitonin Measurement in Participants with eGFR &#x3C;60 mL/min/1.73m\u00b2\n\nA significant increase in calcitonin for participants with eGFR &#x3C;60 mL/min/1.73m\u00b2 is defined as a calcitonin value \u226535 ng/L AND \u226550% over the screening value. If a participant\u2019s labs meet these criteria, these clinically significant labs should be recorded as an AE.\n\nIn these participants, study drug should be discontinued (after first confirming the value) and the participant recommended to immediately undergo additional endocrine assessments and longer\u2011term follow\u2011up by an endocrinologist to exclude any serious adverse effect on the thyroid.\n\n# 10.3.1.5. Major Adverse Cardiovascular Events\n\nDeaths and nonfatal cardiovascular AEs will be adjudicated by a committee of physicians external to Lilly with cardiology expertise. This committee will be blinded to treatment assignment. The nonfatal cardiovascular AEs to be adjudicated include:\n\n- myocardial infarction\n- hospitalization for unstable angina\n- hospitalization for heart failure\n- coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and\n- cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack.\n\n# 10.3.1.6. Supraventricular Arrhythmias and Cardiac Conduction Disorders\n\nTreatment\u2011emergent cardiac conduction disorders will be further evaluated. Participants who develop any event from these groups of disorders should undergo an ECG, which should be submitted to the central reading center. The specific diagnosis will be recorded as an AE.\n\nEvents that meet criteria for serious conditions as described in Section 8.3 must be reported as SAEs.\n\nLY3298176 101", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2648, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "682a5002-dfbc-4bba-acb0-688493306cc1": {"__data__": {"id_": "682a5002-dfbc-4bba-acb0-688493306cc1", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "43f8c93d-8ee0-4114-95cc-757bea57b286", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e62fab8acec968e148f2b8e50724dd369ec0dcc7ee6a4a62eea32c4921a0e444", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.3.1.7. Hypersensitivity Events\n\nAll allergic or hypersensitivity reactions will be reported by the investigator as either AEs, or if any serious criterion is met, as SAEs.\n\nIn the event of suspected drug hypersensitivity reactions (immediate or nonimmediate) in subjects who experience moderate\u2011to\u2011severe injection reactions as assessed by the investigator, unscheduled blood samples will be collected for PK and ADA analyses at the following time points:\n\n- as close as possible to the onset of the event\n- at the resolution of the event\n- 30 (\u00b13) days following the event.\n\nAdditionally, unscheduled serum samples for immune safety laboratory testing (including, but not limited to \u03b2 tryptase, total IgE, complement, and cytokine panel testing) should also be collected at approximately 60 to 120 minutes and 4 to 6 weeks after the onset of the event in these participants.\n\nAdditional data, such as type of reaction and treatment received, will be collected on any AEs or SAEs that the investigator deems related to study drug(s) via the eCRF created for this purpose. Study drug(s) should be temporarily interrupted in any individual suspected of having a severe or serious allergic reaction to study drug(s). Study drug(s) may be restarted when/if it is safe to do so, in the opinion of the investigator.\n\n# 10.3.1.8. Injection Site Reactions\n\nInjection site reactions will be collected on the eCRF separate from the hypersensitivity reaction eCRF. At the time of AE occurrence, samples will be collected for measurement of tirzepatide ADA and tirzepatide concentration.\n\n# 10.3.1.9. Antidrug Antibodies\n\nThe occurrence of ADA formation will be assessed as outlined in Section 8.7.\n\n# 10.3.1.10. Hepatobiliary Disorders\n\nAll events of TE biliary colic, cholecystitis, or other suspected events related to gallbladder disease should be evaluated and additional diagnostic tests performed, as needed. In cases of elevated liver markers, hepatic monitoring should be initiated as outlined in Section 7.\n\n# 10.3.1.11. Severe Gastrointestinal Adverse Events\n\nTirzepatide may cause severe GI AEs, such as nausea, vomiting, and diarrhea. Information about severe GI AEs as well as antiemetic/antidiarrheal use will be collected in the eCRF/AE form. For detailed information concerning the management of GI AEs, please refer to Section 6.6.2.\n\n# 10.3.1.12. Acute Renal Events\n\nRenal safety will be assessed based on repeated renal functional assessment as well as assessment of AEs suggestive of acute or worsening of chronic renal failure. Gastrointestinal\n\nLY3298176 102", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2613, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a1fbfc5a-a004-4cfc-8974-8250ab255c15": {"__data__": {"id_": "a1fbfc5a-a004-4cfc-8974-8250ab255c15", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0ead8a03-8eee-42bc-abee-04db89671c33", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "12ce899666ac755fc11c0e82b76cd01fc48186979bc85e1c33d8bce2013b73a4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL Protocol I8F\u2011MC\u2011GPHK(b)\n\nAEs have been reported with tirzepatide, including nausea, diarrhea, and vomiting. This is consistent with other GLP\u20111R agonists (Aroda and Ratner 2011). The events may lead to dehydration, which could cause a deterioration in renal function, including acute renal failure. Participants should be advised to notify investigators in case of severe nausea, frequent vomiting, or symptoms of dehydration.\n\n# 10.3.1.13. Depression, Suicidal Ideation, or Behavior Monitoring\n\nParticipants will be monitored for depression and suicidal ideation or behavior through AE collection and by using the C\u2011SSRS and the PHQ\u20119. Participants will be referred to an MHP if, in the opinion of the investigator, it is necessary for the safety of the participant, or if the participant had any of the following:\n\n- a PHQ\u20119 score \u226515\n- C\u2011SSRS responses of\n- A \u201cyes\u201d answer to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan)\n- or\n- A \u201cyes\u201d answer to Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the \u201cSuicidal Ideation\u201d portion of the C\u2011SSRS\n- or\n- A \u201cyes\u201d answer to any of the suicide\u2011related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act, or behavior) on the \u201cSuicidal Behavior\u201d portion of the C\u2011SSRS.\n\nLY3298176 103", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1338, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3465a8a7-08a7-48c1-9001-cd21149e8593": {"__data__": {"id_": "3465a8a7-08a7-48c1-9001-cd21149e8593", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d6f9c3da-97ca-4fe3-a576-7850451de98a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9cbacd23823347b53080dd6cda4cc036418cfad1eef672f07c32f7bc04d9275d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information\n\n# Definitions:\n\n# Woman of Childbearing Potential\n\nA woman is considered fertile following menarche and until becoming postmenopausal unless permanently sterile (see below). If fertility is unclear (for example; amenorrhea in adolescents or athletes) and a menstrual cycle cannot be confirmed before first dose of study intervention, additional evaluation should be considered.\n\nWomen in the following categories are not considered women of childbearing potential:\n\n- Article I. Premenarchal\n- Article II. Premenopausal female with 1 of the following:\n- Documented hysterectomy\n- Documented bilateral salpingectomy\n- Documented bilateral oophorectomy\n- For individuals with permanent infertility due to an alternate medical cause other than the above, (for example; Mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.\n\nNote: Documentation can come from the site personnel\u2019s review of the participant\u2019s medical records, medical examination, or medical history interview.\n\n# Article III. Postmenopausal female\n\n- A postmenopausal state is defined as either:\n- A woman at least 40 years of age with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, AND a follicle\u2011stimulating hormone (FSH) \u226540 mIU/mL; or\n- A woman 55 or older not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea; or\n- A woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy.\n- Females on HRT and whose menopausal status is in doubt will be required to use one of the nonestrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.\n\n# Contraception Guidance:\n\nContraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nLY3298176 104", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2206, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bcddad49-a66e-472f-9601-756d0370afa6": {"__data__": {"id_": "bcddad49-a66e-472f-9601-756d0370afa6", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e4800953-4c31-4030-a9a6-caad06701856", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fe22973a608db57a7c165ee6f36a5483d1ea435ee978dd103787cfca158991bd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nTwo forms of effective contraception, where at least 1 form is highly effective, will be used. Effective contraception may be used as the second therapy. Barrier protection methods without concomitant use of a spermicide are not a reliable or acceptable method. The use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these methods are combined.\n\n# Highly Effective Methods of Contraception:\n\n- Combined oral contraceptive pill and mini pill\n- NuvaRing\n- Implantable contraceptives\n- Injectable contraceptives (such as Depo\u2011Provera\u00ae)\n- Intrauterine device (such as Mirena\u00ae and ParaGard\u00ae)\n- Contraceptive patch \u2013 ONLY women &#x3C;198 pounds or 90 kg\n- Total abstinence (if this is their preferred and usual lifestyle) or in a same\u2011sex relationship with no sexual relationship with males (as part of their preferred and usual lifestyle), and agrees to maintain this status throughout trial follow\u2011up\n\nNote: periodic abstinence (for example, calendar, ovulation, symptothermal, and postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception.\n\n- Vasectomy \u2013 for men in clinical studies\n\nNote: Implantable contraceptives and injectable contraceptives (such as Depo Provera) are only permitted if started more than 18 months prior to screening. Participants should not start these methods of contraception after being enrolled in the study.\n\n# Effective Methods of Contraception (must use combination of 2 methods):\n\n- Male condom with spermicide\n- Female condom with spermicide\n- Diaphragm with spermicide\n- Cervical sponge\n- Cervical cap with spermicide\n\nMen, regardless of their fertility status, with nonpregnant women of childbearing potential partners must agree to either remain abstinent (if this is their preferred and usual lifestyle) or use condoms plus 1 additional highly effective (less than 1% failure rate) method of contraception (such as combination oral contraceptives, implanted contraceptives, or intrauterine device) or effective method of contraception (such as diaphragms with spermicide or cervical sponge) for the duration of the study and for 5 half\u2011lives of study drug plus 90 days, which is approximately 4 months after the last injection. Periodic abstinence (for example, calendar, ovulation, symptothermal, and postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception.\n\nLY3298176 105", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2589, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2198afb4-4e18-497b-b8fe-e2f3eb6c6b59": {"__data__": {"id_": "2198afb4-4e18-497b-b8fe-e2f3eb6c6b59", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a978061c-778e-4e49-98e2-ead3d2d52681", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fc161646c613c244b0c007466bc545d39a5560897bb7fcaffb9000e44044acbd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nMen with pregnant partners should use condoms during intercourse for the duration of the study and until the end of estimated relevant potential exposure in women of childbearing potential. Men who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same\u2011sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same\u2011sex relationship without sexual relationships with females (usual lifestyle). In these situations, men are not required to use contraception. Men should refrain from sperm donation for the duration of the study and for 5 half\u2011lives of study drug plus 90 days after the last dose of study drug, corresponding to 4 months after the last injection.\n\n# Collection of Pregnancy Information\n\n# Male participants with partners who become pregnant\n\n- The investigator will attempt to collect pregnancy information on any male participant\u2019s female partner who becomes pregnant while the male participant is in this study.\n- After obtaining the necessary signed informed consent from the pregnant female partner directly, the investigator will record pregnancy information on the appropriate form and submit it to the Sponsor within 24 hours of learning of the partner\u2019s pregnancy. The female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow\u2011up will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.\n\n# Female Participants who become pregnant\n\n- The investigator will collect pregnancy information on any female participant who becomes pregnant while participating in this study. Information will be recorded on the appropriate form and submitted to the Sponsor within 24 hours of learning of a participant\u2019s pregnancy.\n- The participant will be followed to determine the outcome of the pregnancy. The investigator will collect follow\u2011up information on the participant and the neonate and the information will be forwarded to the Sponsor. Generally, follow\u2011up will not be required for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.\n- While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous abortion is always considered to be an SAE and will be reported as such. Any poststudy pregnancy\u2011related SAE considered reasonably related to the study intervention by the investigator will be reported to the Sponsor as described in Section 8.3.2. While the investigator is not obligated to actively seek this information in former study participants, he or she may learn of an SAE through spontaneous reporting.\n\nLY3298176\n\n106", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3139, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "19913956-bfd8-49a2-b4c7-ff7c59325a55": {"__data__": {"id_": "19913956-bfd8-49a2-b4c7-ff7c59325a55", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6a97e2da-cc0a-4dd0-a334-b3debfbfc855", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a6ae7c69796d1ff55176e7dee4ac73749659794411f5d7d606c64cc6034f7871", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n\u2022  Any female participant who becomes pregnant while participating in the study will discontinue study intervention and be withdrawn from the study.\n\nLY3298176    107", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 208, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5359b077-9d9a-4c49-96ec-e31298b8676d": {"__data__": {"id_": "5359b077-9d9a-4c49-96ec-e31298b8676d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fabc46c3-44f5-4111-9178-6ea27d1811d0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6f82a67f7738c5c2997a04003da0d1cc212bbe8a7284955695f41c417b2383a5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.5. Appendix 5: Liver Safety: Suggested Actions and Follow-Up Assessments\n\n# Hepatic Monitoring Tests\n\n| Hepatic Hematology     | Haptoglobin |\n| ---------------------- | ----------- |\n| Hemoglobin             |             |\n| Hematocrit             |             |\n| RBC                    |             |\n| WBC                    |             |\n| Neutrophils, segmented |             |\n| Lymphocytes            |             |\n| Monocytes              |             |\n| Eosinophils            |             |\n| Basophils              |             |\n| Platelets              |             |\n\n# Hepatic Coagulation\n\n| Prothrombin Time      |   |\n| --------------------- | - |\n| Prothrombin Time, INR |   |\n\n# Hepatic Serologies\n\n| Hepatitis A antibody, total  |   |\n| ---------------------------- | - |\n| Hepatitis A antibody, IgM    |   |\n| Hepatitis B surface antigen  |   |\n| Hepatitis B surface antibody |   |\n| Hepatitis B Core antibody    |   |\n| Hepatitis C antibody         |   |\n| Hepatitis E antibody, IgG    |   |\n| Hepatitis E antibody, IgM    |   |\n\n# Hepatic Chemistry\n\n| Total bilirubin      |   |\n| -------------------- | - |\n| Direct bilirubin     |   |\n| Alkaline phosphatase |   |\n| ALT                  |   |\n| AST                  |   |\n| GGT                  |   |\n| CPK                  |   |\n\n# Abbreviations:\n\nALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatinine phosphokinase; GGT = gamma\u2011glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red blood cells; WBC = white blood cells.\n\na Assayed by Lilly\u2011designated or local laboratory.\n\nb Reflex/confirmation dependent on regulatory requirements and/or testing availability.\n\nLY3298176    108", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1781, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "44ee6bbe-f91e-496b-a7b6-9e9146a80a22": {"__data__": {"id_": "44ee6bbe-f91e-496b-a7b6-9e9146a80a22", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6953437c-594a-444b-a696-ca828b5318aa", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "bd2ef4f4d4e8e2378ed5b9b7c2fc5799339ceac9ab7a3365f078f3da3293bf29", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.6 Appendix 6: Medical Device Incidents: Definition and Procedures for Recording, Evaluating, Follow-Up, and Reporting\n\n# Definitions of a Medical Device Incident\n\nThe detection and documentation procedures described in this protocol apply to all sponsor medical devices provided for use in the study.\n\n# Medical Device Incident Definition\n\n- A medical device incident is any malfunction or deterioration in the characteristics and/or performance of a device as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to a serious injury, death of a participant/user/other person, or to a serious deterioration in his/her state of health.\n- Not all incidents lead to death or serious deterioration in health. The nonoccurrence of such a result might have been due to other fortunate circumstances or to the intervention of health care personnel.\n\nIt is sufficient that:\n\n- An incident associated with a device happened.\n- AND\n- The incident was such that, if it occurred again, might lead to death or a serious deterioration in health.\n\n# A serious deterioration in state of health can include any of the following:\n\n- Life\u2011threatening illness\n- Permanent impairment of body function or permanent damage to body structure\n- Condition necessitating medical or surgical intervention to prevent one of the above\n- Fetal distress, fetal death, or any congenital abnormality or birth defects\n\n# Examples of Incidents\n\n- A participant, user, caregiver, or health care professional is injured as a result of a medical device failure or its misuse.\n- A participant\u2019s study intervention is interrupted or compromised by a medical device failure.\n- A misdiagnosis due to a medical device failure leads to inappropriate treatment.\n- A participant\u2019s health deteriorates due to a medical device failure.\n\nLY3298176 109", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1924, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "009fe699-dc35-46f1-98d4-b079858cdeea": {"__data__": {"id_": "009fe699-dc35-46f1-98d4-b079858cdeea", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b2b8db5d-8435-4394-a011-02b228e36a42", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1c83e11daa74749b72f4711626b8636eb5856d18d83cd5561fa51ff0bb083481", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                             Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Documenting Medical Device Incidents\n\nMedical Device Incident Documenting\n\n- Any medical device incident occurring during the study will be documented in the participant\u2019s medical records, in accordance with the investigator\u2019s normal clinical practice, and on the appropriate form of the eCRF.\n- For incidents fulfilling the definition of an AE or an SAE, the appropriate AE/SAE eCRF page will be completed as described in Section 8.3.\n- A product complaint must be submitted describing the issue or deficiency that may have led to the incident or AE.\n- The eCRF will be completed as thoroughly as possible and signed by the investigator before transmittal to the Sponsor or designee.\n- It is very important that the investigator provides his/her assessment of causality (relationship to the medical device provided by the Sponsor) at the time of the initial AE or SAE report and describes any corrective or remedial actions taken to prevent recurrence of the incident.\n\nLY3298176    110", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1072, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "260f19c6-6135-4325-9cb0-4f01ac85204b": {"__data__": {"id_": "260f19c6-6135-4325-9cb0-4f01ac85204b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "50aed202-4de5-49d1-b26a-894a8a7faa0e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "954fee18c187c8c8cbd88db8dd64d57522154244491f3f9c9415ee22a4995546", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                              Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.7. Appendix 7: Protocol GPHK Standardized Protocols for the Measurement of Height, Weight, Waist Circumference, Vital Signs, Electrocardiogram, and Oral Glucose Tolerance Test\n\nThe following information has been adapted from standardized physical measurement protocols for the World Health Organization\u2019s STEPwise approach to Surveillance (STEPS) (WHO 2008) (Available at: https://www.who.int/ncds/surveillance/steps/Section%204%20Step%202%20Physical%20Measurements.pdf) Accessed January 17, 2019.\n\n# Measuring Height\n\n1. Ask the participant to remove their footwear and any headgear (light headgear worn for religious reasons can remain, but this should be worn by the participant at every clinic visit when their height is measured).\n2. Ask the participant to stand on the calibrated height measuring board (stadiometer) or against a wall with their feet together and their knees straight with their heels against the backboard, the stadiometer, or the wall.\n3. Ask the participant to look straight ahead without tilting their head up.\n4. Ask the participant to breathe in and stand tall. Measure and record the participant\u2019s height in centimeters (cm) to 1 decimal place.\n\n# Measuring Weight\n\n- Body weight measurements should be done in a consistent manner using a calibrated electronic scale capable of measuring weight in kilograms (kg) to 1 decimal place.\n- All weights for a given participant should be measured using the same scale, whenever possible, at approximately the same time in the morning after evacuation of bladder contents.\n- Body weight must be measured in fasting state. If the participant is not fasting, the participant should be called in for a new visit within the visit window to have the fasting body weight measured.\n\n1. Ask the participant to empty their pockets, remove their footwear, outerwear (coat, jacket, etc.), and any headgear (light headgear worn for religious reasons can remain, but this should be worn by the participant at every clinic visit when weight is measured).\n2. Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a sloping surface, or a rough, uneven surface).\n3. Ask the participant to step onto the scale with 1 foot on each side of the scale.\n4. Ask the participant to stand still with arms by sides and then record weight in kilograms (kg) to the nearest one\u2011tenth kg.\n\nLY3298176    111", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2461, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cd895e16-1798-4e03-8cb1-9006f9461b2f": {"__data__": {"id_": "cd895e16-1798-4e03-8cb1-9006f9461b2f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e9fbffb5-7a7f-45f5-8081-41ca96fc99a5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "75ee7924a633d249632b531c437f3b16ab74ed3738c9bbe21a2a2651824e9c37", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                              Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Measuring Waist Circumference\n\n- Waist circumference should be measured in the horizontal plane and at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest.\n- Measurements should be taken at the end of a normal expiration using a nonstretchable measuring tape. The tape should lie flat against the skin without compressing the soft tissue.\n- The waist circumference should be measured twice, rounded to the nearest 0.5 cm. The measuring tape should be removed between the 2 measurements. Both measurements will be recorded in the eCRF. If the difference between the 2 measurements exceeds 1 cm, this set of measurements should be discarded and the 2 measurements repeated.\n\n1. Ask the participant to wear light clothing (if available, patient gowns could also be used).\n2. Ask the participant to stand with their feet close together, arms at their side, body weight evenly distributed.\n3. Ask the participant to relax and measure the participant\u2019s waist circumference.\n\n# Vital Sign Measurements (blood pressure and heart rate)\n\n- Vital sign measurements (blood pressure and heart rate, measured by pulse) should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing.\n- The participant should sit quietly for 5 minutes before vital signs measurements are taken.\n- For each parameter, 3 measurements will be taken using the same arm, preferably the nondominant arm.\n- The recordings should be taken at least 1 minute apart. Each measurement of sitting pulse and BP needs to be recorded in the eCRF.\n- Blood pressure must be taken with an automated blood pressure instrument.\n- If blood pressure and pulse measurements are taken separately, pulse should be taken prior to blood pressure.\n\nNote: In the event pulse measurement cannot be taken via an automated blood pressure instrument, the preferred location for measurement of pulse is the radial artery.\n\n# Electrocardiogram\n\n- All digital ECGs will be obtained using centrally provided ECG machines and will be electronically transmitted to a designated central ECG laboratory.\n- 12\u2011lead ECGs should be obtained after the subject has rested in a supine position for at least 10 minutes.\n\nLY3298176                                                                                     112", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2412, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9cd9c9ca-a643-46f7-a4d2-19c8bd0ff423": {"__data__": {"id_": "9cd9c9ca-a643-46f7-a4d2-19c8bd0ff423", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1231cb79-529c-4a1f-a895-d4aeb82a877d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8ca1966cf6d39127c28f08c3d94dde3f1bf887b4336f75281f9a5769bd369ae2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL            Protocol I8F\u2011MC\u2011GPHK(b)\n\n\u2022  Electrocardiograms should be collected at least 30 minutes prior to collection of blood samples for laboratory testing, including PK samples.\n\n\u2022  Triplicate ECGs (obtained at Week 0 and Week 36) should be obtained approximately 1 minute apart, with all 3 tracings to be obtained within approximately 5 minutes. Measurements that deviate substantially from previous readings should be repeated immediately.\n\n# 2-Hour Oral Glucose Tolerance Test\n\n\u2022  Participants should maintain adequate carbohydrate intake for 3 days prior to the scheduled 2\u2011hour OGTT.\n\n\u2022  In the 24 hours preceding the test, patients should refrain from drinking any alcohol or performing any extreme physical activity.\n\n\u2022  Participants should fast for approximately 8 hours before the administration of the test and should not eat until the test is complete.\n\n\u2022  Placement of a venous cannula, preferably in an antecubital vein, is recommended to simplify collection of multiple blood samples for glucose, insulin, and C\u2011peptide at time 0, 30, 60, 90, and 120 minutes.\n\nNote: Placement of a venous cannula may not be required when a 2\u2011hour OGTT is repeated to confirm the diagnosis of diabetes (see Section 4.1.2.3), and only samples at 0 and 120 minutes for glucose measurement will be collected.\n\n\u2022  Immediately after collection of the time 0 sample, a 75\u2011gram glucose dose will be given orally, using a commercial product approved for this use (and in a total volume of not more than 350 mL).\n\n\u2022  The participant should consume the glucose load within 5 minutes.\n\n\u2022  The patient should remain minimally active for the duration of the test.\n\nLY3298176    113", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1682, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6eb4466a-ca9a-45ca-830e-1472d9d86e2b": {"__data__": {"id_": "6eb4466a-ca9a-45ca-830e-1472d9d86e2b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b2f13e54-41bf-4dfd-9dd5-6cb81fecdfea", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ae4f4ddd74845f7b1413f83d1726d646bff9bec6108a1ff1551af5917726fd17", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.8.  Appendix 8: Suggested Visit Structure\n\nAbbreviations: AEs = adverse events; ECG = electrocardiogram; OGTT = 2\u2011hour oral glucose tolerance test; PK = pharmacokinetics; PRO = patient\u2011reported outcomes; SOA = schedule of activities.\n\nLY3298176    114", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 298, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "26b921ea-d590-4ee0-a844-c8a044f90f2b": {"__data__": {"id_": "26b921ea-d590-4ee0-a844-c8a044f90f2b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aea7990d-ba6e-466b-ae12-d0614042f3be", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a7efb86a484cb16b32cc9d59c7a05d407cae524624c6ecb5165112cd0a6e4939", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.9. Appendix 9: Management of Gastrointestinal Symptoms\n\nAbbreviations: GI = gastrointestinal; IWRS = interactive web\u2011response system.\n\nLY3298176                                                                    115", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 262, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "19dc683a-8c74-4b48-99e7-e6741bd20863": {"__data__": {"id_": "19dc683a-8c74-4b48-99e7-e6741bd20863", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "43e3b2d8-e28e-43c9-923c-cfb24866d9e6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0ad2938b8f33d424eb953fe7535deeb8f68298b463897e4842e62a4118cb4fa8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                       Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.10. Appendix 10: Provisions for Changes in Study Conduct During Exceptional Circumstances\n\nThere may be times of exceptional circumstances, such as pandemics or natural disasters, which may cause disruptions to the conduct of the study. Possible disruptions are limitations in the ability to conduct study procedures or ability to have on\u2011site visits occur by participants.\n\nTo mitigate the risk of participants missing visits, to allow participants to safely continue in the study, and to maintain the data integrity of the study in the case of an exceptional circumstance, sites may implement changes to the conduct of the study on a case\u2011by\u2011case basis following Sponsor\u2019s written approval (if permitted by local regulations). Good clinical practice compliance and minimization of risks to study integrity are important considerations. Ensuring the safety of study participants is the prevailing consideration.\n\nAdditional written guidance will be provided by the Sponsor in the event written approval is granted for changes in study conduct.\n\nThe following changes in study conduct captured in this Appendix will not be considered protocol deviations. Missing data will be captured as protocol deviation(s).\n\n1. Remote visit (telephone/telemedicine)\nTelephone or IT\u2011assisted virtual visits (telemedicine) to complete appropriate assessments are acceptable. The study site should capture the visit location and method with a specific explanation for any data missing because of missed in\u2011person site visits in source document and eCRF. Examples of assessments to be completed in this manner include AEs and product complaints, concomitant medications, review study participant diary (including study drug compliance), review diet and exercise goals, C\u2011SSRS (Since Last Visit Version), Self\u2011Harm Supplement Form, Self\u2011Harm Follow\u2011up Form (if applicable), and PHQ\u20119.\n2. Mobile home health visit\nMobile visits may be performed at participants\u2019 homes when participants cannot travel to the site due to exceptional circumstances. These will be performed by a qualified home nursing service provider or trained site personnel, following Sponsor written approval (if permitted by local regulations). Procedures performed may include, but are not limited to, weight measurement, taking blood samples, conducting physical assessments, administering PROs, and collecting health information. Please note that requirements related to the reporting of SAEs remain unchanged. Every effort should be made for the participant to return to on\u2011site visits as soon as reasonably possible, while ensuring the safety of the participant and investigational site staff.\n\nAdditional consent from the participant will be obtained for those who participate in home health services.\n3. Investigational product and ancillary supplies (including participant diaries)\nIn cases when a participant is unable to come to site to receive trial supplies during normal on\u2011site visit, the site should work with the Sponsor to determine appropriate actions to receive trial supplies. This may include a participant coming to the site to receive trial supplies only from site staff without full completion of a visit, a participant\u2011approved\n\nLY3298176                                                                                      116", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3384, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9b6cd0f2-9bcd-40f3-8f0c-79e2bd38cd98": {"__data__": {"id_": "9b6cd0f2-9bcd-40f3-8f0c-79e2bd38cd98", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a2c8925c-8d08-4749-a7f7-5c918a0fbc74", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "43dcc9b5ae2ccdf84ab5132a4e3748776f778a44e31b3b0f311def29fc3413c7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\ndesignee coming to the site to receive trial supplies on a participant\u2019s behalf, or delivery to a participant\u2019s home.\n\nThe following requirements must be met:\n\n- Sponsor approves the alternative method of delivery, taking local regulatory requirements into consideration\n- participant consents verbally to alternate method of delivery\n- site/Sponsor confirms the participant\u2019s receipt of the trial supplies\n- site/Sponsor confirm appropriate ethics review board notification\n- alternate delivery of investigational product should be performed in a manner that does not compromise treatment blinding and ensures product integrity. The existing protocol requirements for product accountability remain unchanged\n- when delivering supplies to a participant\u2019s home:\n- participant consent must include provision of any personal information\n- investigator/Sponsor should ensure oversight of the shipping process to ensure accountability and product quality (i.e., storage conditions and intact packaging upon receipt)\n- additional instructions should be provided to the participant on how to return any unused or completed trial supplies\n\n# 4. Local laboratory option\n\nIn exceptional circumstances, to ensure participant safety and with the Sponsor's prior written approval, local laboratory testing may be conducted in lieu of central laboratory testing. The local laboratory must be qualified in accordance with local regulations. Clinically significant laboratory findings must be recorded as an adverse event in the AE eCRF.\n\n# 5. Screening period guidance\n\nTo ensure safety of study participants, laboratory values and other eligibility assessments taken at Visit 1 are valid for a maximum of 90 days. Therefore, the following rules will be applied for participants who are paused in an active, non\u2011randomized status due to exceptional circumstances:\n\n- Paused for less than 90 days from Visit 1 to Visit 3: the participant will proceed to the next study visit per the schedule of activities in the protocol and Visit 3 (randomization visit) must be conducted within 90 days from Visit 1.\n- The site should proceed with the next visit if eligibility criteria are confirmed and document the reason for delay in the eCRF.\n- Due to the pause in screening, sites should also reconfirm each participant\u2019s consent and document in the source documentation.\n- Paused for more than 90 days from Visit 1 to Visit 3: The participant must be discontinued from the study and rescreened. The screening procedures per the schedule of activities in the protocol should be followed (starting at Visit 1) to ensure participant eligibility by randomization visit (Visit 3). Before rescreening, the\n\nLY3298176    117", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2735, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "863392cd-0830-4a93-a0f0-814f601f35c6": {"__data__": {"id_": "863392cd-0830-4a93-a0f0-814f601f35c6", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "23c46d5b-c81d-4c48-a252-a4fb11894bc8", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3582c214d4eecdfbcae7deb121298f1b4bb8853083f00edbd379c28f47d18b8d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                               Protocol I8F\u2011MC\u2011GPHK(b)\n\nParticipant must sign a new ICF and receive a new identification number through IWRS.\n\n# 6. Increasing visit window(s) for primary and secondary endpoint visits\n\n- Participants should complete primary endpoint visit (Visit 21 or 99) and the final study endpoint visit (Visit 116 or 199) as per original schedule whenever possible and safe to do so, at the investigator\u2019s discretion. However, in order to maximize the ability for such on\u2011site visits, minimize missing data, and preserve the intended conduct of the study, the visit windows may be brought forward no sooner than 14 days or extended up to 28 days, upon specific guidance from the Sponsor.\n- For the following 2 secondary endpoint visits, Visit 8 (the key secondary endpoint visit) and Visit 12 (the 36\u2011week interim analysis endpoint visit), the visit windows may be brought forward no sooner than 7 days or extended up to 7 days, upon specific guidance from the Sponsor.\n- For participants requiring the visit windows to be extended, additional study drug may need to be provided to avoid study drug interruption and maintain overall integrity of the trial. Additional consent from the participant per local regulations will be obtained for those participants who will be dispensed additional study drug during the extended treatment period.\n\n# 7. Documentation\n\n# a. Changes to study conduct\n\n- Changes to study conduct will be documented as the following:\n\n# b. Missing data and other protocol deviations\n\nThe study site should capture specific explanation for any missing data and other protocol deviations in source documents and eCRF. While protocol deviations may be unavoidable in an exceptional circumstance, documentation of deviations and missing data will be important for data analysis and reporting.\n\n# 8. Informing ethical review boards (ERBs)\n\nLY3298176    118", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1924, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3ab104a5-fa0d-493d-9066-873ad5157a32": {"__data__": {"id_": "3ab104a5-fa0d-493d-9066-873ad5157a32", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "12dd2a24-0762-4adf-b421-0392af892bd2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "bdb264799fe8d1d2eb29991822c60bd2850f8d43529093cd665bc9434f0cce55", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nThe Sponsor and study investigators will notify ERBs as early as possible to communicate implementation of changes in study conduct due to exceptional circumstances. To protect the safety of study participants, urgent changes may be implemented before such communications are made, but all changes will be reported as early as possible following implementation.\n\nLY3298176    119", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 422, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9d59d589-db0c-472c-b48c-055b41a21278": {"__data__": {"id_": "9d59d589-db0c-472c-b48c-055b41a21278", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "73179ac6-433c-4f0f-bbad-ddf1632199df", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c75fb0b35f0b8b2e88a410b6cf3e8575b41bb92eb3d97dac2b51abaf8c0e87cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.11. Appendix 11: Abbreviations\n\n| Term       | Definition                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n| ---------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| ADA        | antidrug antibodies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| AE         | adverse event: Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. |\n| AESI       | adverse events (AEs) of special interest                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| ALP        | alkaline phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| ALT        | alanine aminotransferase                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| AST        | aspartate aminotransferase                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n| BG         | blood glucose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| BMI        | body mass index                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| BMR        | basal metabolic rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| BP         | blood pressure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |\n| CHF        | congestive heart failure                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| complaint  | A complaint is any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, purity, durability, reliability, safety or effectiveness, or performance of a drug or drug delivery system.                                                                                                                                                                                                                                                               |\n| compliance | Adherence to all study\u2011related, good clinical practice (GCP), and applicable regulatory requirements.                                                                                                                                                                                                                                                                                                                                                                                               |\n| CONSORT    | Consolidated Standards of Reporting Trials                                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n| CRF        | case report form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n| CRP        | clinical research physician: Individual responsible for the medical conduct of the study. Responsibilities of the CRP may be performed by a physician, clinical research scientist, global safety physician or other medical officer.                                                                                                                                                                                                                                                               |\n| CSR        | Clinical Study Report                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |\n| C-SSRS     | Columbia\u2011Suicide Severity Rating Scale                                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| CT         | computed tomography                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| LY3298176  | 120                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 11100, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fb8722f1-d714-455f-9df1-b8684477f4de": {"__data__": {"id_": "fb8722f1-d714-455f-9df1-b8684477f4de", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "268be36a-0e1c-4cf6-9d9f-22c9004a1972", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "994e5dda7d54aad471b78661116edda616b8ff6c3dbb7445d52499626f795b93", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Abbreviations\n\n| CVD               | cardiovascular disease                                                                                                                   |\n| ----------------- | ---------------------------------------------------------------------------------------------------------------------------------------- |\n| DMC               | data monitoring committee                                                                                                                |\n| DPP-4             | dipeptidyl\u2011peptidase\u20114                                                                                                                   |\n| EAS               | efficacy analysis set                                                                                                                    |\n| ECG               | electrocardiogram                                                                                                                        |\n| ED                | early discontinuation of treatment                                                                                                       |\n| EDC               | electronic data capture                                                                                                                  |\n| eCRF              | electronic case report form                                                                                                              |\n| eGFR              | estimated glomerular filtration rate                                                                                                     |\n| enroll            | The act of assigning a patient to a treatment. Patients who are enrolled in the study are those who have been assigned to a treatment.   |\n| enter             | Patients entered into a study are those who sign the informed consent form directly or through their legally acceptable representatives. |\n| ERB               | ethical review board                                                                                                                     |\n| FAS               | full analysis set                                                                                                                        |\n| FG                | fasting glucose                                                                                                                          |\n| FSH               | follicle\u2011stimulating hormone                                                                                                             |\n| GCP               | good clinical practice                                                                                                                   |\n| GI                | gastrointestinal                                                                                                                         |\n| GIP               | glucose\u2011dependent insulinotropic polypeptide                                                                                             |\n| GIPR              | glucose\u2011dependent insulinotropic polypeptide receptor                                                                                    |\n| GLP-1             | glucagon\u2011like peptide\u20111                                                                                                                  |\n| GLP-1R            | glucagon\u2011like peptide\u20111 receptor                                                                                                         |\n| GPGA              | Study I8F\u2011MC\u2011GPGA                                                                                                                        |\n| GPGB              | Study I8F\u2011MC\u2011GPGB                                                                                                                        |\n| GPGF              | Study I8F\u2011MC\u2011GPGF                                                                                                                        |\n| GPHK (SURMOUNT-1) | Study I8F\u2011MC\u2011GPHK                                                                                                                        |\n| HbA1c             | hemoglobin A1c                                                                                                                           |\n| LY3298176         | 121                                                                                                                                      |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4566, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "98a2fd26-65a1-40cc-8b8e-0ef05b4869b3": {"__data__": {"id_": "98a2fd26-65a1-40cc-8b8e-0ef05b4869b3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "31b6d4fd-ce37-43d5-8311-af0ba4be7f88", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "48bd1ae49ed6f8d19ab13af8fc9d2f3868ccfba45669176bd5b6a86258bb1520", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Abbreviations and Definitions\n\n| HDL              | high\u2011density lipoprotein                                                                                                                                                                                                                                                                                                                                                                                                                                                  |\n| ---------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| HR               | heart rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n| HRT              | hormonal replacement therapy                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| IB               | Investigator\u2019s Brochure                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| ICF              | informed consent form                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| ICH              | The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use                                                                                                                                                                                                                                                                                                                                                                   |\n| Informed consent | A process by which a patient voluntarily confirms his or her willingness to participate in a particular study, after having been informed of all aspects of the study that are relevant to the patient\u2019s decision to participate. Informed consent is documented by means of a written, signed, and dated informed consent form.                                                                                                                                          |\n| interim analysis | An interim analysis is an analysis of clinical study data, separated into treatment groups, that is conducted before the final reporting database is created/locked.                                                                                                                                                                                                                                                                                                      |\n| INR              | international normalized ratio                                                                                                                                                                                                                                                                                                                                                                                                                                            |\n| IP               | investigational product: A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including products already on the market when used or assembled (formulated or packaged) in a way different from the authorized form, or marketed products used for an unauthorized indication, or marketed products used to gain further information about the authorized form.                                               |\n| IRB/IEC          | Institutional Review Boards/Independent Ethics Committees                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| ITT              | intention to treat: The principle that asserts that the effect of a treatment policy can be best assessed by evaluating on the basis of the intention to treat a patient (that is, the planned treatment regimen) rather than the actual treatment given. It has the consequence that patients allocated to a treatment group should be followed up, assessed, and analyzed as members of that group irrespective of their compliance to the planned course of treatment. |\n| IWQOL-Lite-CT    | Impact of Weight on Quality of Life\u2011Lite\u2011Clinical trials                                                                                                                                                                                                                                                                                                                                                                                                                  |\n| IWRS             | interactive web\u2011response system                                                                                                                                                                                                                                                                                                                                                                                                                                           |\n| LDL              | low\u2011density lipoprotein                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| Lilly            | Eli Lilly and Company                                                                                                                                                                                                                                                                                                                                                                                                                                                     |\n| MAD              | multiple ascending dose                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n| MDD              | Major Depressive Disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n| MedDRA           | Medical Dictionary for Regulatory Activities                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| MEN              | multiple endocrine neoplasia                                                                                                                                                                                                                                                                                                                                                                                                                                              |\n| LY3298176        | 122                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 10656, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "03b4d968-0f14-4e03-b663-dcfe784551df": {"__data__": {"id_": "03b4d968-0f14-4e03-b663-dcfe784551df", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1d82d2d4-4854-4cd3-8283-cb44458278ee", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e51c86f218d229c8f1a0116c7937045dcaf5c918f9008a890127ff35116b71c7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Abbreviations\n\n| MHP       | mental health professional                                                                                                                                 |\n| --------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| MI        | myocardial infarction                                                                                                                                      |\n| mITT      | modified intention\u2011to\u2011treat                                                                                                                                |\n| MMRM      | mixed\u2011model for repeated measures                                                                                                                          |\n| MRI       | magnetic resonance imaging                                                                                                                                 |\n| MTC       | medullary thyroid carcinoma                                                                                                                                |\n| NYHA      | New York Heart Association                                                                                                                                 |\n| OGTT      | oral glucose tolerance test                                                                                                                                |\n| PC        | Product Complaints                                                                                                                                         |\n| PGIS      | Patient Global Impression of status for physical activity                                                                                                  |\n| PHQ-9     | Patient Health Questionnaire\u20119                                                                                                                             |\n| PK/PD     | pharmacokinetics/pharmacodynamics                                                                                                                          |\n| PROs/ePRO | patient\u2011reported outcomes                                                                                                                                  |\n| QW        | once weekly                                                                                                                                                |\n| SAD       | single ascending dose                                                                                                                                      |\n| SAE       | serious adverse event                                                                                                                                      |\n| SAP       | Statistical Analysis Plan                                                                                                                                  |\n| SBP       | systolic blood pressure                                                                                                                                    |\n| SC        | subcutaneous                                                                                                                                               |\n| screen    | The act of determining if an individual meets minimum requirements to become part of a pool of potential candidates for participation in a clinical study. |\n| SD        | standard deviation                                                                                                                                         |\n| SF-36v2   | Short\u2011Form\u201136 Health Survey (SF\u201136), version 2                                                                                                             |\n| SMQ       | standardized MedDRA queries                                                                                                                                |\n| SS        | safety analysis set                                                                                                                                        |\n| SUSARs    | suspected unexpected serious adverse reactions                                                                                                             |\n| T1DM      | type 1 diabetes mellitus                                                                                                                                   |\n| LY3298176 | 123                                                                                                                                                        |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4846, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "96a7fa02-68cf-4b55-a4ae-1a8e246489ff": {"__data__": {"id_": "96a7fa02-68cf-4b55-a4ae-1a8e246489ff", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7f04095d-dba7-4bc3-96a1-3222d45156e9", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "658da4f1bef3b09666dbe1981dcaa434fb0a9fe89b9d4db176d62fafd93127ad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\nT2DM     type 2 diabetes mellitus\n\nTBL      total bilirubin level\n\nTE       treatment emergent\n\nTEAE     treatment\u2011emergent adverse event: An untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment.\n\nTEE      total energy exposure\n\nTSH      thyroid\u2011stimulating hormone\n\nULN      upper limit of normal\n\nLY3298176    124", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 540, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "15ba7f83-1625-425d-83d3-4da4ad0ea8f6": {"__data__": {"id_": "15ba7f83-1625-425d-83d3-4da4ad0ea8f6", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8bcbe2bb-893a-4f6a-9405-cb7a818569be", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "f5e02eb5bac77831d7e5cf5bceb1c77219087e5967e4eb6ea02c9aa4608d7c73", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                                   Protocol I8F\u2011MC\u2011GPHK(b)\n\n# 10.12.  Appendix 12: Protocol Amendment History\n\nThe Protocol Amendment Summary of Changes Table for the current amendment is located directly before the Table of Contents (TOC).\n\n# Amendment a: (24-July-2020)\n\n# Overall Rationale for the Amendment\n\nThe GPHK clinical protocol has been amended to extend the safety follow\u2011up period in order to better characterize the glycemic status of study participants. The overall changes and rationale for the changes made to this protocol are described in the following table. Note that minor edits have been made throughout the protocol, which are not captured in the amendment summary table.\n\n| Section # and Name                              | Description of Change                                                                                                                       | Brief Rationale                                                                                                                                                                  |\n| ----------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| 1.2 Schema                                      | Figure updated to reflect the extended safety follow\u2011up period                                                                              | The safety follow\u2011up period has been extended to 17 weeks to address regulatory feedback from Type C advice meeting with FDA (26 June 2019).                                     |\n| 1.3.2 Schedule of Activities                    | Schedule of Activities changed Visit 802 to 17 weeks posttreatment period                                                                   |                                                                                                                                                                                  |\n| 9.5 Interim Analysis                            | Two more interim analyses were added and text revised                                                                                       | Additional interim analyses were requested by an external DMC to perform unblinded safety reviews semi\u2011annually. Details pertaining to the timing of interim analyses was added. |\n| 1.1 Synopsis                                    | A key secondary objective was added (time to onset of T2DM during the entire study) with the associated endpoint and statistical hypothesis | An additional key secondary objective was added per FDA request from Type C advice meeting with FDA (26 June 2019).                                                              |\n| 9.4.3.2 Key Secondary Analyses                  |                                                                                                                                             |                                                                                                                                                                                  |\n| 10.10 Appendix 10                               | An appendix describing mitigation for extenuating circumstances was added as Section 10.10                                                  | Language was added to address extenuating circumstances due to unforeseen widespread emergencies (such as pandemics or natural disasters).                                       |\n| The Abbreviation Appendix 10 is now Appendix 11 |                                                                                                                                             |                                                                                                                                                                                  |\n| 9.4.3.1 Primary                                 | A sentence related to selection of variance\u2011covariance structure in                                                                         | The details will be provided in                                                                                                                                                  |\n\nLY3298176                                                                                       125", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4556, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c8973ea1-23b4-4f03-833f-122c11a32854": {"__data__": {"id_": "c8973ea1-23b4-4f03-833f-122c11a32854", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "607e882b-239f-480a-a5c0-c33308a4ef83", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "f51efc2cbc73f882187776c20e07527e309431580e5d3cab96497413e8ec4710", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL    Protocol I8F\u2011MC\u2011GPHK(b)\n\n# Section # and Name\n\n# Description of Change\n\n# Brief Rationale\n\n| Analysis                                                                                 | case of nonconvergence was deleted                                                                                  | the Statistical Analysis Plan.                                                                                                                                        |\n| ---------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| 1.3 Schedule of Activities                                                               | Allowable deviation (days) for Visit 21 was changed from +7 days to \u00b17 days                                         | This change allows more flexibility for participants to schedule the primary study endpoint visit.                                                                    |\n| 1.3 Schedule of Activities                                                               | Added measurement of waist circumference to Visit 199                                                               | The measurement was added to obtain 3 year waist circumference data for participants who discontinue the study treatment early but come to the 3\u2011year endpoint visit. |\n| 4.1.1.2.3 Continued Follow\u2011up for Participants with Prediabetes (Visits 101 through 116) | Measurement of waist circumference added to list of visit procedures                                                | The text was added to align with changes in the Schedule of Activities regarding measurement of waist circumference at Visit 199.                                     |\n| 1.3 Schedule of Activities                                                               | Added an activity entitled \u201cregister study visit in IWRS\u201d                                                           | The activity was added to the SOA to ensure all visits are registered. This allows monitoring of study activities using real\u2011time IWRS reports.                       |\n| 10.4 Appendix 4 Contraceptive Guidance and Collection of Pregnancy Information           | Added text \u201cmore than 18 months\u201d                                                                                    | The sentence was revised to maintain consistency with the text from the exclusion criteria.                                                                           |\n| 10.4 Appendix 4 Contraceptive Guidance and Collection of Pregnancy Information           | Note regarding follicle stimulating hormone levels used to confirm a postmenopausal state in women has been deleted | The note could lead to misinterpretation of inclusion criterion 4.                                                                                                    |\n\nLY3298176    126", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3157, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b5cf61d2-8a09-485b-bb5e-0f94094a75bc": {"__data__": {"id_": "b5cf61d2-8a09-485b-bb5e-0f94094a75bc", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9d3ba01c-3ee6-4a5e-859b-fc4aa7bc6b29", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fe537297b74e680e12f59425dd932520140be81a12096f001027b4823afe6fdd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 11. References\n\nAdams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, Gutierrez JM, Frogley SJ, Ibele AR, Brinton EA, Hopkins PN, McKinlay RM., Simper SC, Hunt SC. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143\u20111155.\n\nAllison DB, Downey M, Atkinson RL, Billington CJ, Bray GA, Eckel RH, Finkelstein EA, Jensen MD, Tremblay A. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of The Obesity Society. Obesity (Silver Spring). 2008;16(6):1161\u20111177.\n\nAmerican Diabetes Association. In Standards of Medical Care in Diabetes\u20112019. Glycemic Targets: Standards of Medical Care in Diabetes\u20112019. Diabetes Care. 2019a;42(suppl 1):S61\u2011S70.\n\nAmerican Diabetes Association. In Standards of Medical Care in Diabetes\u20112019. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes\u20112019. Diabetes Care 2019b; 42(suppl 1): S 13\u2011S28.\n\n[AMA] American Medical Association. American Medical Association House of Delegates Resolution: 420 (A\u201113) Recognition of Obesity as a Disease, 2013 pp 1\u20117. Available at: https://www.npr.org/documents/2013/jun/ama\u2011resolution\u2011obesity.pdf Accessed August 30, 2019.\n\nAroda VR, Ratner R. The safety and tolerability of GLP\u20111 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes Metab Res Rev. 2011;27(6):528\u2011542.\n\nBaggio LL, Drucker DJ. Biology of incretins: GLP\u20111 and GIP. Gastroenterol. 2007;132(6):2131\u20112157.\n\nBanks PA, Freeman ML; Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379\u20112400.\n\nCoskun T, Sloop KW, Loghin C, Alsina\u2011Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D\u2019Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP\u20111 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201114.\n\nCouncil on Science and Public Health. Report of the Council on Science and Public Health. Is obesity a disease? (Resolution 115\u2011A\u201112). Council on Science and Public Health. Report number: 3\u2011A\u201113, 2013.\n\nDanne T, Philotheou A, Goldman D, Guo X, Ping L, Cali A, Johnston P. A randomized trial comparing the rate of hypoglycemia \u2013 assessed using continuous glucose monitoring \u2013 in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Pediatr Diabetes. 2013;14(8):593\u2011601. Erratum in: Pediatr Diabetes. 2015;16(6):462.\n\nDolan P. Modeling valuations for EuroQol Health States. Medical Care 1997; 35(11):1095\u20111108.", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 2676, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "aea465cf-5501-4415-9d1a-7a5de52e2caa": {"__data__": {"id_": "aea465cf-5501-4415-9d1a-7a5de52e2caa", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f25ac8e7-ba6d-46e4-804e-13bf8baeb649", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "67df8683f9221adc4c926adcbc3675fea2ef4e090c6c0c04b534700ee6385f50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55832738-8e9f-42cd-a7cb-9dabd8f4c54e", "node_type": "1", "metadata": {}, "hash": "52018cb3f5318b73c2223313d56f0967fa4327cd58a30606eed19ede0f26809d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nDombrowski SU, Knittle K, Avenell A, Ara\u00fajo\u2011Soares V, Sniehotta FF. Long term maintenance of weight loss with non\u2011surgical interventions in obese adults: systematic review and meta\u2011analyses of randomized controlled trials. BMJ. 2014;348:g2646.\n\n[EMA] European Medicines Agency. Guideline on clinical evaluation of medicinal products used in weight management. Committee for Medicinal Products for Human Use. June 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500209942.pdf Accessed November 19, 2018.\n\nEuroQoL Group. EQ\u20115D\u20115L User guide: basic information on how to use the EQ\u20115D\u20115L instrument. Version 2.1. Available at: https://euroqol.org/wp\u2011content/uploads/2016/09/EQ\u20115D\u20115L_UserGuide_2015.pdf. Published April 2015. Accessed January 22, 2019.\n\nFAO/WHO/UNU. Human energy requirements. Report of a joint FAO/WHO/UNU expert, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WHH, Temelkova\u2011Kurktschiev T, for the REWIMND consultation. FAO: food and nutrition technical report series 1. Rome: FAO/WHO/UNU; 2004.\n\n[FDA] Food and Drug Administration. Guidance for Industry. Developing products for weight management. February 2007. Available at: https://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf. Accessed November 19, 2018.\n\nFrias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A. Efficacy and safety of LY3298176, a novel dual GIP and GLP\u20111 receptor agonist, in patients with type 2 diabetes: a randomised, placebo\u2011controlled and active comparator\u2011controlled phase 2 trial. Lancet. 2018;392(10160):2180\u20112193.\n\nGerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Pobstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao\u2011Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez\u2011Jaramillo P, Munoz EGC, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH\u2011H, Temelkova\u2011Kurktschiev T, for the REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double\u2011blind, randomized placebo\u2011controlled trial. Lancet 2019;394(10193):121\u2011130.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2252, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "55832738-8e9f-42cd-a7cb-9dabd8f4c54e": {"__data__": {"id_": "55832738-8e9f-42cd-a7cb-9dabd8f4c54e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f25ac8e7-ba6d-46e4-804e-13bf8baeb649", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "67df8683f9221adc4c926adcbc3675fea2ef4e090c6c0c04b534700ee6385f50", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aea465cf-5501-4415-9d1a-7a5de52e2caa", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "88d92237ba6051de0a277a6c204564f1e2b03f8558d0ce5abafc1cf6db6bcadf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double\u2011blind, randomized placebo\u2011controlled trial. Lancet 2019;394(10193):121\u2011130.\n\nJensen MD, Ryan DH, Donato KA, Aprovian, CM, Arrd, JD, Comuzzie AG, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi\u2011Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Uanovski SZ. Executive summary: guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the Obesity Expert Panel, 2013. Obesity. 2014;22:(suppl 2):S5\u2011S39.\n\nKnowler WC, Barrett\u2011Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2011403.\n\nLY3298176 128", "mimetype": "text/plain", "start_char_idx": 2099, "end_char_idx": 3190, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a48ecaca-dcd0-49b7-b802-b882a7d1d2f5": {"__data__": {"id_": "a48ecaca-dcd0-49b7-b802-b882a7d1d2f5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "87ba7679-9f28-4feb-9c6e-832a400e7830", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "14bfeb779398a5b33c41e6d00e45ad43090848e7f90130cadf90023e6fd99c95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faaaf2eb-b1ed-41f3-969e-4b30b3519847", "node_type": "1", "metadata": {}, "hash": "5015c806f088597e6f04157d4c9cf950535d05eceb02b198835a9d0872e49cba", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL\n# Protocol I8F\u2011MC\u2011GPHK(b)\n\nKoizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, Kimura Y, Takeda K, Isaji S, Otsuki M, Matsuno S; JPN. JPN Guidelines for the management of acute pancreatitis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg. 2006;13(1):25\u201132.\n\nKolotkin RL, Ervin CM, Meincke HH, Hojbjerre L, Fehnel SE. Development of a clinical trials version of the Impact of Weight on Quality of Life\u2011Lite questionnaire (IWQoL\u2011Lite Clinical Trials Version): results from two qualitative studies. Clin Obes. 2017;7(5):290\u2011299.\n\nKolotkin RL, Williams V, Ervin, CM, Meincke HH, Qin S, Smith LvH, Fehnel SE. Validation of a new measure of quality of life in obesity trials: IWQOL \u2013 Lite Clinical Trials Version. Poster presented at: Obesity Week 2018; November 13, 2018; Nashville, TN.\n\nKroenke K, Spitzer RL, Williams JB. The PHQ\u20119: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u2011616.\n\nle Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjoth TV, Manning LS, Pi\u2011Sunyer X for the SCALE Obesity Prediabetes NN8022\u20111839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomized, double\u2011blind trial. Lancet. 2017;389(10077):1399\u20111409.\n\nLi G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, Yang W, Zhang B, Shuai Y, Hong J, Engelgau MM, Li H, Roglic G, Hu Y, Bennett PH. Cardiovascular mortality, all\u2011cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23\u2011year follow\u2011up study. Lancet Diabetes Endocrinol. 2014;2(6):474\u2011480.\n\nLuppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: a systematic review and meta\u2011analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220\u2011229.\n\nMarso SP, Daniels GH, Brown\u2011Frandsen K, Kirstensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Tavn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. For the LEADER Steering Committee. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016a; 375:311\u2011322.\n\nMarso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren M, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T, for the SUSTAIN\u20116 Investigators.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2485, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "faaaf2eb-b1ed-41f3-969e-4b30b3519847": {"__data__": {"id_": "faaaf2eb-b1ed-41f3-969e-4b30b3519847", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "87ba7679-9f28-4feb-9c6e-832a400e7830", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "14bfeb779398a5b33c41e6d00e45ad43090848e7f90130cadf90023e6fd99c95", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a48ecaca-dcd0-49b7-b802-b882a7d1d2f5", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "10a6752677d3d22cc729c0e33867b87d7dfe9dfc900cfc8df6731d3a8d818047", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "For the LEADER Steering Committee. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016a; 375:311\u2011322.\n\nMarso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren M, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T, for the SUSTAIN\u20116 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016b; 375:1834\u20111844.\n\nMaruish ME, ed. User\u2019s manual for the SF\u201136v2 Health Survey. 3rd ed. Lincoln, RI: Quality Metric Incorporated; 2011.\n\nMertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8(3):270\u2011278.\n\nNauck MA, Meier JJ, Schmidt WE. Incretin\u2011based glucose\u2011lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio\u2011vascular outcome trials. Diabetes Obes Metab. 2017;19(9):1327\u20111328.\n\nLY3298176 129", "mimetype": "text/plain", "start_char_idx": 2158, "end_char_idx": 3097, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4303fd47-f317-4df4-855a-63d0f685ab3f": {"__data__": {"id_": "4303fd47-f317-4df4-855a-63d0f685ab3f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dc5ae1dc-9539-44a3-87af-6857c82af2c9", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "127ae86d7c9925631bfb92a1a9ded9935733168f7cf4bcfb7eba08cd77149e03", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "CONFIDENTIAL                                          Protocol I8F\u2011MC\u2011GPHK(b)\n\nSAXENDA\u00ae [EMA summary of product characteristics (SmPC)]. Novo Nordisk, Bagsvaerd, Denmark. Available at: https://ec.europa.eu/health/documents/community\u2011register/2015/20150323131125/anx_131125_en.pdf. Accessed April 10, 2019.\n\nSAXENDA\u00ae [package insert] Novo Nordisk, Bagsvaerd, Denmark. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf. Accessed March 2, 2019.\n\nSkow MA, Bergmann, NC, Knop FK. Diabetes and obesity treatment based on dual incretin receptor activation: \u201ctwincretins\u201d. Diabetes Obes Metab. 2016;18(9):847\u2011854.\n\nSteinberg WM, Buse JB, Ghorbani MLM, \u00d8rsted DD, Nauck MA; LEADER Steering Committee; LEADER Trial Investigators. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER Randomized Trial. Diabetes Care. 2017a;40(7):966\u2011972.\n\nSteinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program. Diabetes Care. 2017b;40(7):839\u2011848.\n\nTomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. An overview of new GLP\u20111 receptor agonists for type 2 diabetes. Expert Opin Investig Drugs. 2016;25(2):145\u2011158.\n\nvan Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon\u2011like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2014;221(1):T1\u2011T16.\n\nWarkentin LM, Das D, Majumdar SR, Johnson JA, Padwal RS. The effect of weight loss on health\u2011related quality of life: systematic review and meta\u2011analysis of randomized trials. Obes Rev. 2014;15(3):169\u2011182.\n\nWeinberg ME, Bacchetti P, Rushakoff RJ. Frequently repeated glucose measurements overestimate the incidence of inpatient hypoglycemia and severe hyperglycemia. J Diabetes Sci Technol. 2010;4(3):577\u2011582.\n\nLY3298176    130", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2060, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a277901a-e013-4cf4-a939-74a6eee2628a": {"__data__": {"id_": "a277901a-e013-4cf4-a939-74a6eee2628a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8a3d0930-fdd9-43a9-8e8a-588776d25810", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ac8a45423ea834b3f34515b526167da3a69f46d79340f3c85669505b46a58e13", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Leo Document ID = 8dd79a8d-d134-4b80-afb3-6ce848a2570c\n\n# Approvals\n\n| Approver | Approval Date & Time     | Signature meaning |\n| -------- | ------------------------ | ----------------- |\n| PPD      | 01-Oct-2021 16:14:59 GMT | Approved          |\n| PPD      | 04-Oct-2021 15:48:26 GMT | Approved          |", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 310, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c0c54ec8-8284-41bd-a063-5804d4ba9780": {"__data__": {"id_": "c0c54ec8-8284-41bd-a063-5804d4ba9780", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d4d7637c-1d4c-4c68-805e-f6d676ce6264", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ac963b7e0794aa5a9b6aee8630e3005fedc435796e29d9274ba838a7210b7909", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(1) Clinical Protocol Addendum\n\n# 1. Protocol Addendum I8F-MC-GPHK(1)\n\n# The Impact of Tirzepatide Once Weekly on Body Composition\n\n# Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)\n\nConfidential Information\n\nThe information contained in this protocol addendum is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of tirzepatide (LY3298176), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. This document and its associated attachments are subject to United States Freedom of Information Act (FOIA) Exemption 4.\n\n# Tirzepatide (LY3298176)\n\nThis addendum is to be performed in addition to all procedures required by protocol I8F-MC-GPHK or any subsequent amendments to that protocol.\n\nEli Lilly and Company\n\nIndianapolis, Indiana USA 46285\n\nProtocol Addendum (1) Electronically Signed and Approved by Lilly on date provided below.\n\nApproval Date: 10-Sep-2019 GMT\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 1299, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a7d7f928-7e39-487e-868d-e9d7edca5ce5": {"__data__": {"id_": "a7d7f928-7e39-487e-868d-e9d7edca5ce5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "5604776a-29fd-457d-bfb5-7fbfbb445b3f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "229956340f07fda8c316f5e976be2dbf5ab1efd720ae4312b84626a126ffae3c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(1) Clinical Protocol Addendum\n\n# 2. Table of Contents\n\n# Protocol Addendum I8F-MC-GPHK (1)\n\nThe Impact of Tirzepatide Once Weekly on Body Composition\n\nEfficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)\n\n| Section                                                                                                                                                                                                                                                                                                                      | Page |\n| ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---- |\n| 1. Protocol Addendum I8F\u2011MC\u2011GPHK(1) The Impact of Tirzepatide Once Weekly on Body Composition Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight\u2011Related Comorbidities: A Randomized, Double\u2011Blind, Placebo\u2011Controlled Trial (SURMOUNT\u20111) | 1    |\n| 2. Table of Contents                                                                                                                                                                                                                                                                                                         | 2    |\n| 3. Rationale for Addendum                                                                                                                                                                                                                                                                                                    | 4    |\n| 4. Protocol Additions                                                                                                                                                                                                                                                                                                        | 5    |\n| 4.1. Objectives                                                                                                                                                                                                                                                                                                              | 5    |\n| 4.1.1. Primary Objective                                                                                                                                                                                                                                                                                                     | 5    |\n| 4.1.2. Secondary Objectives                                                                                                                                                                                                                                                                                                  | 5    |\n| 4.2. Inclusion and Exclusion Criteria                                                                                                                                                                                                                                                                                        | 5    |\n| 4.2.1. Inclusion Criteria                                                                                                                                                                                                                                                                                                    | 5    |\n| 4.2.2. Exclusion Criteria                                                                                                                                                                                                                                                                                                    | 5    |\n| 4.3. Addendum Procedures                                                                                                                                                                                                                                                                                                     | 6    |\n| 4.3.1. Dual\u2011Energy X\u2011ray Absorptiometry Scan                                                                                                                                                                                                                                                                                 | 6    |\n| 4.4. Sample Size and Statistical Methods                                                                                                                                                                                                                                                                                     | 6    |\n| 4.4.1. Determination of Sample Size                                                                                                                                                                                                                                                                                          | 6    |\n| 4.4.2. Statistical and Analytical Plans                                                                                                                                                                                                                                                                                      | 6    |\n| 4.4.3. Interim Analyses                                                                                                                                                                                                                                                                                                      | 7    |\n| 4.5. Data Capture System                                                                                                                                                                                                                                                                                                     | 7    |\n| 4.6. Informed Consent                                                                                                                                                                                                                                                                                                        | 7    |\n| 5. References                                                                                                                                                                                                                                                                                                                | 8    |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 7286, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f77be182-b170-4769-baed-8d42d31c86ec": {"__data__": {"id_": "f77be182-b170-4769-baed-8d42d31c86ec", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c2fbe436-9ea9-409f-8e34-1ede4b717f96", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cd8b3e946db2f14503fd7fb2d1b9149c4c39c2a0731f0740c89d976d16878f66", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(1) Clinical Protocol Addendum\n\n# List of Attachments\n\n| Attachment                                                     | Page |\n| -------------------------------------------------------------- | ---- |\n| Attachment 1. Protocol Addendum GPHK(1) Schedule of Activities | 10   |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 300, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d85c2edb-14ab-45da-bd55-3e413112429a": {"__data__": {"id_": "d85c2edb-14ab-45da-bd55-3e413112429a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3e447a83-c0b6-4d82-bc24-8d14cd894e5b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3c37ad0e9ef82ced56979e8f89c11b672cafcde2f1fad804b23c998baa9ee581", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(1) Clinical Protocol Addendum\n\n# 3. Rationale for Addendum\n\nObesity is a growing public health concern and is associated with multiple comorbidities, including cardiovascular disease, type 2 diabetes mellitus, nonalcoholic fatty liver disease, and cancer (Allison et al. 2008; AMA resources page [WWW]; Council on Science and Public Health resources page [WWW]). Epidemiological studies on body composition and mortality suggest that high fat mass is associated with increased risk of mortality, especially at the higher range of fat mass (Lee and Giovannucci 2018). More specifically, accumulation of adipose tissue in the abdominal region has been associated with the development of obesity\u2011related comorbidities and all\u2011cause mortality (Yusuf et al. 2005; Goossens 2017).\n\nAlthough 5% to 10% body\u2011weight loss has been shown to reduce complications related to obesity and improve quality of life (Knowler et al. 2002; ACC/AHA Task Force on Practice Guidelines, Obesity Expert Panel, 2014; Li et al. 2014; Warkentin et al. 2014), both fat and lean body mass are lost (Wadstr\u00f6m et al. 2000; Jendle et al. 2009; Cava et al. 2017). Weight\u2011loss\u2011associated loss of lean body mass (including muscle) could then increase the risk of sarcopenia (defined as low muscle mass and impaired muscle function), affecting individuals\u2019 mobility, increasing the risk of falls, and reducing the ability to perform daily living activities (Cava et al. 2017; Barazzoni et al. 2018). Therefore, decreasing fat body mass while preserving sufficient lean body mass is important in any population where large decreases in body weight occur in a short period of time (Kulovitz et al. 2014).\n\nThe Food and Drug Administration (FDA) Draft Guidance for Industry, Developing Products for Weight Management (2007), recommends that a representative sample of study subjects should have an assessment of body composition by dual\u2011energy x\u2011ray absorptiometry (DXA), or a suitable alternative, to ensure that weight loss, drug or biologic induced, is caused primarily by a reduction in fat content (FDA resources page [WWW]).\n\nDual energy x\u2011ray absorptiometry total body composition with regional analysis provides a measure of physiological response to obesity interventions superior to simple anthropometrics, such as body mass index (BMI). It is safe and widely available in clinical practice (Kendler et al. 2013), making it a useful method to detect changes in fat and lean body mass in weight management studies (Dordevic et al. 2018). The risk associated with DXA scan is low, with a radiation exposure (effective dose) of about 5 \u00b5Sv or 0.005 mSv (millisievert). The typical level of background radiation to which the general population is exposed, not including radiation due to medical procedures, has been estimated to be about 2.5 mSv/year (Lewiecki et al. 2016).\n\nIn this addendum, a subset of study participants from I8F\u2011MC\u2011GPHK (SURMOUNT\u20111) (planned n=240; 60 participants per treatment group) will undergo a body composition assessment via DXA scans, measured at baseline, early termination and Week 72, with the intent of evaluating changes in body composition associated with weight loss, including both fat and lean mass compartments.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 3243, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c569053c-addc-45ef-be0a-6a7983c43161": {"__data__": {"id_": "c569053c-addc-45ef-be0a-6a7983c43161", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "91c6d626-9e93-4226-896f-98ae7b6fc320", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d713bf0b976b9eb873e1711aa7f2247866a32cdbbe141a3e47ec6272fd46d37f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Clinical Protocol Addendum\n\n# 4. Protocol Additions\n\n# 4.1. Objectives\n\n# 4.1.1. Primary Objective\n\nThe primary objective is to demonstrate that tirzepatide (5 mg, 10 mg, and 15 mg combined) once weekly (QW) is superior to placebo in percent change in total body fat mass loss from baseline to 72 weeks. Percent change is calculated as:\n\n(Total body fat mass at 72 weeks \u2011 Total body fat mass at baseline) X 100\n\nTotal body fat mass at baseline\n\n# 4.1.2. Secondary Objectives\n\nThe secondary objectives are:\n\n- To demonstrate that tirzepatide (5 mg, 10 mg, and 15 mg combined) QW is superior to placebo in loss of total body fat mass in kg from randomization to 72 weeks\n- To assess, for tirzepatide (5 mg, 10 mg, and 15 mg combined) QW, the following parameters, measured at randomization and 72 weeks:\n- percent change in total body lean mass\n- change in total body lean mass in kg.\n\n# 4.2. Inclusion and Exclusion Criteria\n\n# 4.2.1. Inclusion Criteria\n\n[40] All participants fulfilling study protocol I8F\u2011MC\u2011GPHK inclusion criteria will have the option to participate in this addendum until the required number of participants is obtained, at sites that have access to either Hologic\u2122 or Lunar\u2122 whole\u2011body DXA scanners with body composition capability.\n\n# 4.2.2. Exclusion Criteria\n\n- [41] Have had a recent procedure (within 10 days) where oral contrast or radionuclides were administered (for example, computed tomography [CT] with contrast or nuclear medicine studies)\n- [42] Have a body weight, height, and/or width that prohibits the ability to obtain accurate measurements according to the DXA manufacturer\u2019s specification\n- [43] Have any implants, hardware, devices, or other foreign materials in the measurement area that may interfere with the scan, according to the DXA manufacturer\u2019s specification", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1811, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7a16cce3-79b3-4ab5-ba1f-a82204c8dbdc": {"__data__": {"id_": "7a16cce3-79b3-4ab5-ba1f-a82204c8dbdc", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "846ce408-de2b-4b75-966d-4268f3ff976f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d14d3b568dcf697e230172a796765f3de6e6c7a9317aa6b474e30d86458402aa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Clinical Protocol Addendum\n\n# 4.3. Addendum Procedures\n\n# 4.3.1. Dual-Energy X-ray Absorptiometry Scan\n\nInvestigative sites will perform the body composition DXA scans on either Hologic\u2122 or Lunar\u2122 DXA scanners with total body composition capabilities according to the imaging guidelines. The scans will be read and evaluated by a central reader.\n\nDual energy x\u2011ray absorptiometry will be performed at the following visits:\n\n- baseline\n- end of treatment Visit 21 (Week 72) or early discontinuation (ED)\n\nParticipants who give consent and meet all eligibility requirements should have a baseline DXA scan performed between Visits 2 and 3 (randomization) in the main study protocol, before receiving the first dose of study drug. Post\u2011baseline DXA scans at Visit 21 (Week 72) or ED may be performed within \u00b17 days of the date of the main protocol study visit.\n\nRecommendations for DXA body composition scans include the following:\n\n- All scans for a given participant should be performed on the same DXA scanner using the same software.\n- All scans for a given participant should be obtained under similar circumstances (similar time of day, consistent hydration status, consistent scan status).\n\nTo obtain consistent and acceptable quality data for central review, investigators participating in the addendum will be provided with detailed instructions on the DXA scan protocol to be used.\n\n# 4.4. Sample Size and Statistical Methods\n\n# 4.4.1. Determination of Sample Size\n\nA sample size of at least 240 randomized participants (at least 60 participants from each treatment arm) is planned for this addendum.\n\nThe above sample size will provide more than 90% power to assess the primary objective of the addendum based on following assumptions:\n\n- evaluation of superiority of tirzepatide QW (5 mg, 10 mg and 15 mg combined) to placebo for fat mass loss to be conducted, at a 2\u2011sided significance level of 0.05 using a 2\u2011sample t\u2011test,\n- a treatment difference (between tirzepatide and placebo) of at least 4.8% with a common standard deviation of 8% in the percent change of total body fat mass from baseline to Week 72, and\n- a dropout rate of 25% at 72 weeks.\n\n# 4.4.2. Statistical and Analytical Plans\n\nUnless otherwise noted, all tests of treatment effects will be conducted at a 2\u2011sided alpha level of 0.05, and the confidence interval (CI) will be calculated at 95%, 2\u2011sided.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 2396, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "99439e92-ce6f-4713-a935-9180b12457ab": {"__data__": {"id_": "99439e92-ce6f-4713-a935-9180b12457ab", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "50b748bc-53ef-4655-a95a-9ebb2b65684a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "acd9d4229f181d4a0950bffe0901c3c95c92d18bc51ca36150b4ad11503c6c31", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(1) Clinical Protocol Addendum\nUnless otherwise specified, all analyses for the variables measured or derived from DXA will be conducted on all participants who are enrolled in this addendum, randomized and have at least 1 dose of study drug, with both baseline and at least 1 postbaseline measurement. Baseline is defined as the last non\u2011missing data collected at randomization (prior to first dosing of study drug). Missing data at Week 72 will be imputed using the last observation carried forward method (LOCF). There will be no multiplicity adjustment for secondary objectives.\n\nSummary statistics for continuous measures will include:\n\n- sample size\n- mean\n- standard deviation\n- median\n- minimum\n- maximum\n\nThe analysis model to make comparisons among treatment arms, relative to continuous measurements, will be an analysis of covariance model (ANCOVA), with terms of treatment and baseline measurement as a covariate.\n\nSummary statistics for categorical measures (including categorized continuous measures) will include sample size, frequency, and percentages. Logistic regression will be used to examine the treatment difference in binary outcomes if there is a need to adjust for covariates. Otherwise, Fisher\u2019s exact test will be used to examine the treatment difference in categorical outcomes. Other statistical methods may be used, as appropriate, and details will be described in the Statistical Analysis Plan.\n\n# 4.4.3. Interim Analyses\n\nNo interim analyses are planned for this addendum.\n\n# 4.5. Data Capture System\n\nAny diagnostic data collected from a contracted vendor will be stored electronically in that central vendor\u2019s database system. Data will subsequently be transferred from the central vendor according to the contract.\n\n# 4.6. Informed Consent\n\nThe investigator is responsible for ensuring that appropriate written informed consent is given by each patient or legal representative prior to the performance of any protocol addendum procedures.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1997, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f2dc7c7c-2215-4e74-8375-fb1bce71bdab": {"__data__": {"id_": "f2dc7c7c-2215-4e74-8375-fb1bce71bdab", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7e7ec26b-b193-42a0-b4a8-240a10468094", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a417f44e55dc5506a9fc97a7e9d2c70c2504f81e194b0e5a22eb51d9928202a3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Clinical Protocol Addendum\n\n# 5. References\n\nAllison DB, Downey M, Atkinson RL, Billington CJ, Bray GA, Eckel RH, Finkelstein EA, Jensen MD, Tremblay A. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring). 2008;16:1161\u20111177.\n\nAMA resources page. American Medical Association web site. American Medical Association House of Delegates Resolution: 420 (A\u201113) Recognition of Obesity as a Disease, 2013. Available at: https://www.ama\u2011assn.org/sites/ama\u2011assn.org/files/corp/media\u2011browser/public/about\u2011ama/councils/Council%20Reports/council\u2011on\u2011science\u2011public\u2011health/a13csaph3.pdf http://www.npr.org/documents/2013/jun/ama\u2011resolution\u2011obesity.pdf. Accessed November 29, 2018.\n\nAmerican College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Executive summary: guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the Obesity Expert Panel, 2013. Obesity (Silver Spring). 2014;22(suppl 2):S5\u2011S39.\n\nBarazzoni R, Bischoff S, Boirie Y, Busetto L, Cederholm T, Dicker D., Toplak H, Van Gossum A, Yumuk V, Vettor R. Sarcopenic obesity: time to meet the challenge. Obes Facts. 2018;11(4):294\u2011305.\n\nCava E, Yeat, NC, Mittendorfer B. Preserving healthy muscle during weight loss. Adv Nutr. 2017;8(3):511\u2011519.\n\nCouncil on Science and Public Health resources page. American Medical Association web site. Obesity should be considered a chronic medical disease state 2013. Resolution 115\u2011A\u201112. Available at: https://www.ama\u2011assn.org/sites/ama\u2011assn.org/files/corp/media\u2011browser/public/about\u2011ama/councils/Council%20Reports/council\u2011on\u2011science\u2011public\u2011health/a13csaph3.pdf. Accessed May 7, 2019.\n\nDordevic AL, Bonham M, Ghasem\u2011Zadeh A, Evans A, Barber E, Day K, Kwok A, Truby H. Reliability of compartmental body composition measures in weight\u2011stable adults using GE iDXA: implications for research and practice. Nutrients. 2018;10(10):e1484.\n\nFDA resources page. Food and Drug Administration web site. Guidance for Industry. Developing products for weight management. February 2007. Available at: https://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf. Accessed November 19, 2018.\n\nGoossens, GH. The metabolic phonotype in obesity: fat mass, body fat distribution, and adipose tissue function. Obes Facts. 2017;10(3):207\u2011215.\n\nJendle J, Nauck MA, Matthews DR, Frid A, Hemansen K, D\u00fcring M, Zdravkovic M, Strauss BJ, Garber AJ; LEAD\u20112 and LEAD\u20113 Study Groups. Weight loss with liraglutide, a once\u2011daily human glucagon\u2011like peptide\u20111 analogue for type 2 diabetes treatment as monotherapy or", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2927, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "43217d89-3f41-43ee-8016-4cacf9f2b4dc": {"__data__": {"id_": "43217d89-3f41-43ee-8016-4cacf9f2b4dc", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f5ca0ad5-036c-40d6-adca-4174073c8da6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "eac454f506aad5b72a7d446843058e4b5b9cc26179f7c9d6e84ae2d2b181791c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(1) Clinical Protocol Addendum\nadded to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12):1163\u20111172.\n\nKendler DL, Borges JL, Fielding RA, Itabashi A, Krueger D, Mulligan K, Camargos BM, Sabowitz B, Wu CH, Yu EW, Shepherd J. The official positions of the International Society for Clinical Densitometry: indications of use and reporting of DXA for body composition. J Clin Densitom. 2013;16(4):496\u2011507.\n\nKnowler WC, Barrett\u2011Connor E, Fowler, SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2011403.\n\nKulovitz MG, Kolkmeyer D, Conn CA, Cohen DA, Ferraro RT. Medical weight loss versus bariatric surgery: does method affect body composition and weight maintenance after 15% reduction in body weight? Nutrition. 2014;30(1):49\u201154.\n\nLee DH, Giovannucci EL. Body composition and mortality in the general population: a review of epidemiologic studies. Exp Biol Med (Maywood). 2018;243(17\u201118):1275\u20111285.\n\nLewiecki EM, Binkley N, Morgan SL, Shuhart CR, Camargos BM, Carey JJ, Gordon CM, Jankowski LG, Lee JK, Leslie WD; International Society for Clinical Densitometry. Best practices for dual\u2011energy x\u2011ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance. J Clin Densitom. 2016;19(2):127\u2011140.\n\nLi G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, Yang W, Zhang B, Shuai Y, Hong J, Engelgau MM, Li H, Roglic G, Hu Y, Bennett PH. Cardiovascular mortality, all\u2011cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23\u2011year follow\u2011up study. Lancet Diabetes Endocrinol. 2014;2(6):474\u2011480.\n\nWadstr\u00f6m C, Backman L, Forsberg AM, Nilsson E, Reizenstein P, Ekman M. Body composition and muscle constituents during weight loss: studies in obese patients following gastroplasty. Obes Surg. 2000;10(3):203\u2011213.\n\nWarkentin LM, Das D, Majumdar SR, Johnson JA, Padwal RS. The effect of weight loss on health\u2011related quality of life: systematic review and meta\u2011analysis of randomized trials. Obes Rev. 2014;15(3):169\u2011182.\n\nYusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS; INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case\u2011control study. Lancet. 2005;366(9497):1640\u20111649.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2611, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a8757889-9907-40db-9227-805e1c3280c9": {"__data__": {"id_": "a8757889-9907-40db-9227-805e1c3280c9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ce12579e-a440-4f59-89b8-102b824da561", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cc0154b14633eafb7fac36c9a4c8c9bb61f183b45fb4fbcbdd9f541f46575c00", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(1) Clinical Protocol Addendum\n# Attachment 1. Protocol Addendum GPHK(1) Schedule of Activities\n\n# Study Schedule, Protocol Addendum I8F-MC-GPHK(1)\n\n| Visit\\*                       | 1        | 2  | 3 | 4 | 5 | 6  | 7  | 8  | 9  | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 99 | ED\\*  | 801 |\n| ----------------------------- | -------- | -- | - | - | - | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | ----- | --- |\n| Week of Treatment             | -2       | -1 | 0 | 4 | 8 | 12 | 16 | 20 | 24 | 28 | 32 | 36 | 40 | 44 | 48 | 52 | 56 | 60 | 64 | 68 | 72 | 72 | 4 wks |     |\n| Fasting Visit                 | X        | X  | X | X | X | X  | X  | X  |    | X  |    | X  | X  | X  | X  | X  | X  | X  |    |    |    |    |       |     |\n| Telephone Visit               |          |    |   |   |   |    | X  | X  | X  | X  | X  | X  | X  |    |    |    |    |    |    |    |    |    |       |     |\n| Informed consent for addendum | X        |    |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |       |     |\n| Clinical Assessments          | DXA scan | X  |   |   |   |    |    |    |    |    |    |    |    |    |    |    | X  | X  |    |    |    |    |       |     |\n\n*Please see the following table for corresponding additional information.\n\nAbbreviations: DXA = dual\u2011energy absorptiometry; ED = early discontinuation; Tx = treatment; wks = weeks.\n\n# Additional Information Regarding Activities Described in Schedule of Activities\n\n| Activity | Notes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |\n| -------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Visit 2  | Baseline DXA assessments must be completed after eligibility, between Visits 2 and 3, prior to first dose of study drug.                                                                                                                                                                                                                                                                                                                                                                                    |\n| ED       | Participants who are unable or unwilling to continue the study treatment for any reason will perform an ED visit. If the participant is discontinuing during an unscheduled visit or a scheduled visit, that visit should be performed as the ED visit. A DXA scan should be performed within 1 week of ED visit, at least 1 (one) month after the baseline scan. Participants who stop study treatment but agree to return for Visits 21 or 99 will not have an additional scan performed at these visits. |\n\nAbbreviations: DXA = dual\u2011energy absorptiometry; ED = early discontinuation.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3670, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "187624ea-2e92-4c70-8a86-94473c633d59": {"__data__": {"id_": "187624ea-2e92-4c70-8a86-94473c633d59", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "23343146-0b3f-4fd3-a477-8e5956f6a55d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "78c61a872ca5fbf753c3449a04b653d95d112a8bd75cddf825b435d657b8535f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Leo Document ID = ff451f95-fa7e-4c13-a1a8-37ea2f8cabd1\n\n# Approvals\n\n| Approver | Approval Date & Time     | Signature meaning |\n| -------- | ------------------------ | ----------------- |\n| PPD      | 10-Sep-2019 16:00:38 GMT | Approved          |\n| PPD      | 10-Sep-2019 18:16:40 GMT | Approved          |", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 310, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a5241ea3-fc2f-4b96-8fb4-5bf6e2e7bb38": {"__data__": {"id_": "a5241ea3-fc2f-4b96-8fb4-5bf6e2e7bb38", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ca146124-b129-4adf-80de-954e3b05de7c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "f59101dee8c0e21f4ebf7dbf40318a924b2f2f38452f3e6a971dcd2279ad84ef", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2) Clinical Protocol Addendum    Page 1\n\n# 1. Protocol Addendum I8F-MC-GPHK(2)\n\nCharacterizing the Effect of Tirzepatide on Heart Rate and Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (ABPM)\n\n# Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)\n\nConfidential Information\n\nThe information contained in this protocol addendum is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of tirzepatide (LY3298176), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. This document and its associated attachments are subject to United States Freedom of Information Act (FOIA) Exemption 4.\n\n# Tirzepatide (LY3298176)\n\nThis addendum is to be performed in addition to all procedures required by protocol I8F-MC-GPHK or any subsequent amendments to that protocol.\n\nEli Lilly and Company\n\nIndianapolis, Indiana USA 46285\n\nProtocol Addendum (2) Electronically Signed and Approved by Lilly on date provided below:\n\nApproval Date: 11-Sep-2019 GMT\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 1382, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5b57836f-7a8e-45e7-a941-3e4b14821e6f": {"__data__": {"id_": "5b57836f-7a8e-45e7-a941-3e4b14821e6f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b21a5dbd-a1ad-4f9f-9081-6d26efab3fe2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cc395986854973a3a789d462e40b4eff6fb678018c5f0b416c94be0763f1b065", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2) Clinical Protocol Addendum\n\n# 2. Table of Contents\n\n# Protocol Addendum I8F-MC-GPHK (2)\n\nCharacterizing the Effect of Tirzepatide on Heart Rate and Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (ABPM)\n\nEfficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)\n\n| Section                                                                                                                                                                  | Page |\n| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ---- |\n| 1. Protocol Addendum I8F\u2011MC\u2011GPHK(2) Characterizing the Effect of Tirzepatide on Heart Rate and Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (ABPM) | 1    |\n| 2. Table of Contents                                                                                                                                                     | 2    |\n| 3. Rationale for Addendum                                                                                                                                                | 4    |\n| 4. Protocol Additions                                                                                                                                                    | 5    |\n| 4.1. Objectives                                                                                                                                                          | 5    |\n| 4.2. Inclusion and Exclusion Criteria                                                                                                                                    | 5    |\n| 4.2.1. Inclusion Criteria                                                                                                                                                | 5    |\n| 4.2.2. Exclusion Criteria                                                                                                                                                | 5    |\n| 4.3. Addendum Procedures                                                                                                                                                 | 6    |\n| 4.3.1. Ambulatory Monitoring Device                                                                                                                                      | 6    |\n| 4.3.2. Study Procedures                                                                                                                                                  | 6    |\n| 4.3.3. Concomitant Medications                                                                                                                                           | 7    |\n| 4.3.4. Randomization                                                                                                                                                     | 7    |\n| 4.4. Sample Size and Statistical Methods                                                                                                                                 | 7    |\n| 4.4.1. Determination of Sample Size for ABPM Analysis                                                                                                                    | 7    |\n| 4.4.2. Statistical and Analytical Plans                                                                                                                                  | 8    |\n| 4.5. Data Capture System                                                                                                                                                 | 8    |\n| 4.6. Informed Consent                                                                                                                                                    | 8    |\n| 5. References                                                                                                                                                            | 9    |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 4254, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c0dc152e-a7c1-4f38-acd8-17e813b1902c": {"__data__": {"id_": "c0dc152e-a7c1-4f38-acd8-17e813b1902c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1e084a08-16b2-4c53-9b15-5b34c93611f9", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "34c592c30ed5f18b71192fefb0236092d02d43b6ef53c7f4fab60a28bfa1701f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2) Clinical Protocol Addendum\n\n# List of Attachments\n\n| Attachment 1. | Protocol Addendum GPHK(2) Schedule of Activities | 11 |\n| ------------- | ------------------------------------------------ | -- |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 226, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e9d5a0a5-d579-483c-b131-a193e90acecb": {"__data__": {"id_": "e9d5a0a5-d579-483c-b131-a193e90acecb", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "479d3835-57fb-4649-9d1c-8dd281619c71", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "21719ec0de05ef61dd5c8f0c477d1903fd625a510dc282a1d16fe4feeb9a6bc4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2) Clinical Protocol Addendum\n\n# 3. Rationale for Addendum\n\nOne known effect of glucagon\u2011like peptide\u20111 receptor (GLP\u20111R) agonists is to increase heart rate (HR), usually with either no change or a mild reduction in blood pressure (BP) (Lorenz et. al. 2017). Changes in HR attenuate over time (Sun et al. 2015; Marso et al. 2016; Holman et al. 2017; Lorenz et al. 2017), and in long\u2011term cardiovascular outcomes studies, GLP\u20111R agonists have been associated with reduced risk for major adverse cardiovascular events (Drucker et. al. 2018). The mechanisms by which GLP\u20111R agonists increase HR are not fully understood, with recent studies suggesting direct stimulation of the sinoatrial node, although activation of the sympathetic nervous system, or reduction of systemic vascular resistance have not been excluded (Bharucha et al 2008; Mendis et al. 2012; Smits et al. 2017). The long\u2011term impact of glucose\u2011dependent insulinotropic polypeptide (GIP) receptor agonists on HR and BP is unknown.\n\nTirzepatide is a 39\u2011amino acid synthetic peptide with agonist activity at both the glucose\u2011dependent insulinotropic polypeptide receptor (GIPR) and GLP\u20111R agonist. Data from Phase 1 (I8F\u2011MC\u2011GPGA) and Phase 2 (I8F\u2011MC\u2011GPGB and I8F\u2011MC\u2011GPGF) studies with tirzepatide employing a more rapid dose escalation than is proposed in the current Phase 3 study, showed dose\u2011dependent increases in HR comparable to that seen with dulaglutide and other members of the GLP\u20111R agonists class (Lorenz et al. 2017; Gerstein et al. 2019). The impact of tirzepatide on HR over a longer term and under a slower dose escalation scheme in obese patients without type 2 diabetes is unknown.\n\nThe purpose of this addendum is to gather additional information about the impact of tirzepatide on HR and BP in a subgroup of participants randomized in SURMOUNT\u20111 (I8F\u2011MC\u2011GPHK). The data will provide information to a planned interim analysis of the main protocol, whose timing is triggered by the completion of this addendum.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2014, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "126ff972-dbec-48d0-9e0d-d2c7a48fcbe5": {"__data__": {"id_": "126ff972-dbec-48d0-9e0d-d2c7a48fcbe5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c5c9801a-f2e1-48df-8e37-d0b11e88ce74", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "61a9be6fb097250bcfd9b0a829259ce94fa24038827ac7955b4e1996e874a227", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2) Clinical Protocol Addendum\n\n# 4. Protocol Additions\n\n# 4.1. Objectives\n\nTo assess the effect of 5 mg, 10 mg, and 15 mg doses of tirzepatide compared to placebo on mean change from randomization (Week 0) to Week 36 on 24\u2011hour mean HR and 24\u2011hour mean BP [systolic blood pressure (SBP)/diastolic blood pressure (DBP)], as measured during 24\u2011hour ambulatory monitoring.\n\n# 4.2. Inclusion and Exclusion Criteria\n\nAll participants fulfilling study protocol I8F\u2011MC\u2011GPHK inclusion criteria will be asked to participate in this addendum until the required number of participants is obtained. The following additional inclusion and exclusion criteria will apply:\n\n# 4.2.1. Inclusion Criteria\n\n- [44] Participant has provided informed consent for SURMOUNT\u20111.\n- [45] Participant is willing to wear an ambulatory HR and BP monitoring device for at least 24 hours (on multiple occasions).\n- [46] Participants with hypertension should have well\u2011controlled BP (&#x3C;140/90), regardless of antihypertensive treatment.\n- [47] Participants receiving treatment for hypertension should be on a stable antihypertensive regimen for at least 3 months prior to screening.\n\nNote: If the investigator anticipates a need to add antihypertensive medication during the course of the addendum, the participant should not be included in the addendum.\n\n# 4.2.2. Exclusion Criteria\n\n- [48] Participant has an ongoing or history of frequent intermittent or chronic tachyarrhythmia syndromes (such as atrial fibrillation, supraventricular tachycardia, positional orthostatic tachycardia syndrome).\n- Note: Participants with history of premature atrial contractions or premature ventricular contractions may be included.\n- [49] Participant works rotation shifts or works during the hours of 2200 to 0700.\n- [50] Participant performs strenuous manual labor that cannot be avoided during the monitoring period.\n- [51] Participant has a nondominant arm circumference of >55 cm at Visit 1.\n- [52] Participant is unable to obtain a valid baseline ambulatory blood pressure monitoring (ABPM) reading (see Section 4.3.2).", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2095, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4cc171c5-e46c-475e-b257-8e557158b355": {"__data__": {"id_": "4cc171c5-e46c-475e-b257-8e557158b355", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bfc3d096-4e75-4040-ae3b-5fe31b9ca5dd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "5660831421e121f35f838e57d72f880b16a3d439106c09ba4b1f9deb29bc324c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2) Clinical Protocol Addendum\n\n# 4.3. Addendum Procedures\n\n# 4.3.1. Ambulatory Monitoring Device\n\nAn ambulatory monitoring device that uses an inflatable cuff attached to a portable device worn around the waist will be used to collect multiple BP and HR readings over a 24\u2011hour period, during both sleep and wake cycles. Although it is called ABPM, the device collects both HR and BP readings. The multiple readings collected by the ABPM device can be averaged to obtain mean BP and HR values, to detect variations over time, and to compute other distribution patterns.\n\n# 4.3.2. Study Procedures\n\nAt Visit 2, participants will receive education about ABPM. Those who give consent and meet all eligibility requirements will be trained in its use. Ambulatory monitoring of HR and BP will be performed prior to Visit 3 (Week 0; baseline) and following Visit 12 (Week 36; final measure).\n\n# Use of the ABPM Device\n\nThe ABPM device will be attached to the nondominant arm, and participants will be instructed to wear the monitor for a 24\u2011 to 27\u2011hour period. Participants will be instructed to keep track of daily activities throughout the testing period and not to engage in strenuous activity.\n\n# Ambulatory blood pressure measurements\n\n- Should be collected on a typical work day, not on a non\u2011working day\n- Will be recorded every 30 minutes during daytime hours (0700 to 2200 hours)\n- Will be recorded every 60 minutes during nighttime hours (2200 to 0700)\n\nA 24\u2011hour session of ambulatory monitoring produces technically acceptable measurements if \u226570% of the readings are valid.\n\n# Baseline measurement (Week 0)\n\nBetween Visit 2 &#x26; Visit 3, the participant will undergo a baseline 24\u2011hour ambulatory monitoring session. Upon return of the ABPM device, the recordings must be transmitted to the Core Laboratory and analyzed before the participant leaves the site. If the session provides technically satisfactory results (\u226570% of readings are valid), this measurement will serve as the baseline value. If a technically satisfactory result is not achieved, the investigator should review the device settings and placement and the participant\u2019s activity track in an attempt to correct any user error or device malfunctions. Another 24\u2011hour ambulatory monitoring session should be conducted prior to Visit 3 and this measurement will serve as the baseline value. If the second session also provides technically unsatisfactory results, the participant should not be included in the addendum (see Exclusion criteria #52).\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2544, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2ea2c762-6d65-482e-9db9-11ee70cca0d8": {"__data__": {"id_": "2ea2c762-6d65-482e-9db9-11ee70cca0d8", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a82ea8fe-50ad-49c7-bef1-ba913efc7765", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0a5ad4563ebd4799746c8f46f45563c81d92ef61f744fbf9613174c1868f63ba", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2) Clinical Protocol Addendum\n\nFinal measurement (Week 36)\n\nFollowing Visit 12 (within 1 week), the participant will undergo one 24\u2011hour ambulatory monitoring session. Upon return of the ABPM device, the recordings must be transmitted to the Core Laboratory and analyzed before the participant leaves the site. If the session provides technically satisfactory results (\u226570% of readings are valid), this measurement will serve as the final value. If a technically satisfactory result is not achieved, the investigator should review the device settings and placement and the participant\u2019s activity track in an attempt to correct any user error or device malfunctions. Another 24\u2011hour ambulatory monitoring session should be conducted (within 7 days after Visit 12) and this measurement will serve as the final value. If the second session also provides technically unsatisfactory results, the data will be considered missing.\n\n# 4.3.3. Concomitant Medications\n\nAntihypertensive medications and doses should remain stable throughout the study addendum period (36 weeks), unless dose adjustments are required for safety, (i.e., due to uncontrolled hypertension). Chronic use of nonsteroidal anti\u2011inflammatory agents or cyclooxygenase\u20112 (COX\u20112) inhibitors, as well as other agents, prescription or over\u2011the\u2011counter, known to affect BP, are permitted; however, use of these agents on an as needed basis (PRN) during the 48\u2011hour period immediately prior to or during each 24\u2011hour ABPM recording is prohibited. Examples include, but are not limited to decongestants (pseudoephedrine, ephedrine, phenylephrine, naphazoline, oxymetazoline) and multi\u2011symptom cold remedies. Male participants must abstain from use of phosphodiesterase type 5 (PDE\u20115) inhibitors (i.e., tadalafil, vardenafil, sildenafil) or yohimbine (herbal aphrodisiac) during the 48\u2011hour period immediately prior to or during each 24\u2011hour ABPM recording, since these medications may confound the BP measurements.\n\n# 4.3.4. Randomization\n\nParticipants who meet all criteria for enrollment to this addendum will be randomized to 1 of the 4 study treatment groups at Visit 3. Assignment to treatment groups will be determined by a computer\u2011generated random sequence using an interactive web response system (IWRS). Participants will be randomized in a 1:1:1:1 ratio to receive tirzepatide 5 mg, tirzepatide 10 mg, tirzepatide 15 mg, or placebo. The randomization will be stratified by pre\u2011diabetes status, country, sex, and baseline beta\u2011blocker use status.\n\n# 4.4. Sample Size and Statistical Methods\n\n# 4.4.1. Determination of Sample Size for ABPM Analysis\n\nA sample size of approximately 576 randomized participants (approximately 144 participants from each of the 4 treatment arms) is planned for this addendum.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2793, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e2c5b170-6650-4890-a4a3-0fb15ff84e53": {"__data__": {"id_": "e2c5b170-6650-4890-a4a3-0fb15ff84e53", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "712e1ab1-ec96-4967-bdfa-caa5eed46331", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1075265952cbb6de48e1f0b54a7605b7547f5de27bf7b25aa4e63ff1a422ff62", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2) Clinical Protocol Addendum\n\nThe above sample size will provide at least 90% probability to ensure that the upper limit of 95% confidence interval (CI) of the placebo adjusted mean 24\u2011hour HR increase induced by any tirzepatide dose is \u226410 beats per minute (bpm) at 36 weeks. Epidemiologic data has shown sustained HR increases >10 bpm to be associated with increased risk for major cardiovascular events, cardiovascular and all\u2011cause mortality (Lonn et al. 2013; Zhang et al. 2016; Aune et al. 2017).\n\nThe sample size calculation assumes a mean difference of 6 bpm between each tirzepatide dose relative to placebo with a standard deviation of 9 bpm (Balfour et al. 2014; Thase et al. 2008), and a dropout rate of 25% at 36 weeks. The sample size is calculated at a nominal alpha level of 0.05 without multiplicity adjustment.\n\n# 4.4.2. Statistical and Analytical Plans\n\nUnless otherwise noted, all tests of treatment effects will be conducted at a 2\u2011sided alpha level of 0.05, and the CI will be calculated at 95%, 2\u2011sided. All analyses for the variables measured or derived from ABPM, will be conducted on all participants who are enrolled in this addendum, randomized and have at least 1 dose of study drug, with both baseline and at least 1 postbaseline measurement.\n\nFor continuous outcomes collected from the ABPM, including BP and HR, the analysis will be conducted using an analysis of covariance model (ANCOVA), with terms of treatment, baseline measurement, and beta\u2011blocker use status.\n\nFor categorical measures (including categorized continuous measures), logistic regression will be used to examine the treatment difference, if there is a need to adjust for covariates. Otherwise, Fisher\u2019s exact test will be used to examine the treatment difference.\n\nOther statistical methods may be used, as appropriate, and details will be described in the Statistical Analysis Plan.\n\n# 4.5. Data Capture System\n\nAny diagnostic data collected from a contracted vendor will be stored electronically in that central vendor\u2019s database system. Data will subsequently be transferred from the central vendor according to the contract.\n\n# 4.6. Informed Consent\n\nThe investigator is responsible for ensuring that appropriate written informed consent is given by each participant or legal representative prior to the performance of any protocol addendum procedures.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2383, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8144e843-09c7-47f4-8e49-b5bc0872f729": {"__data__": {"id_": "8144e843-09c7-47f4-8e49-b5bc0872f729", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f85d5b99-79ee-43d2-b53a-5ce2dc45058a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "885324349f63bd68d4d1702b61e798313d535c6cef17d5cd651602504f2a2bdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17e89ef4-9c6f-4c92-b6c0-986526a56416", "node_type": "1", "metadata": {}, "hash": "b852d727f54c0e315ecd7cc08127d1c0f2a86f89aad997519d133f72c024b294", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2) Clinical Protocol Addendum\n# 5. References\n\nAune D, Sen A, \u00f3\u2019Hartaigh B, Janszky I, Romundstad P, Tonstad S, Vatten LJ. Resting heart rate and the risk of cardiovascular disease, total cancer, and all\u2011cause mortality \u2013 A systematic review and dose \u2013 response meta\u2011analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2017;27(6):504\u2011517.\n\nBalfour P, Rodriguez C, Ferdinand K. Blood Pressure and Cardiovascular Effects of New and Emerging Antidiabetic Agents. Current Hypertension Rep. 2014;16(8):455.\n\nBharucha AE, Charkoudian N, Andrews C, Camilleri M, Sletten D, Zinsmeister A, Low P. Effects of glucagon\u2011like peptide\u20111, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol. 2008;295(3):R874\u2011R880.\n\nDrucker DJ. The Ascending GLP\u20111 Road From Clinical Safety to Reduction of Cardiovascular Complications. Diabetes. 2018;67(9):1710\u20131719.\n\nGerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao\u2011Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman W, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter L, Lopez\u2011Jaramillo P, Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova\u2011Kurtschiev T, REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double\u2011blind, randomised placebo\u2011controlled trial. Lancet. 2019;394(10193):121\u2011130.\n\nHolman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, \u00d6hman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once\u2011Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;28;377(13):1228\u20111239.\n\nLonn EM, Rambihar S, Gao P, Custodis FF, Sliwa K, Teo KK, Yusuf S, B\u00f6hm M. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all\u2011cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol. 2014;103(2):149\u2011159.\n\nLorenz M, Lawson F, Owens D, Raccah D, Roy\u2011Duval C, Lehmann A, Perfetti R, Blonde L. Differential effects of glucagon\u2011like peptide\u20111 receptor agonists on heart rate. Cardiovasc Diabetol.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2383, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "17e89ef4-9c6f-4c92-b6c0-986526a56416": {"__data__": {"id_": "17e89ef4-9c6f-4c92-b6c0-986526a56416", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f85d5b99-79ee-43d2-b53a-5ce2dc45058a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "885324349f63bd68d4d1702b61e798313d535c6cef17d5cd651602504f2a2bdb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8144e843-09c7-47f4-8e49-b5bc0872f729", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3b6b200699a1c403759519317fe2412726ccb14c4bb2f1a720484fbcbc7a617c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Clin Res Cardiol. 2014;103(2):149\u2011159.\n\nLorenz M, Lawson F, Owens D, Raccah D, Roy\u2011Duval C, Lehmann A, Perfetti R, Blonde L. Differential effects of glucagon\u2011like peptide\u20111 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16(1):6.\n\nMarso SP, Daniels GH, Brown\u2011Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201122. Supplement: https://www.nejm.org/doi/suppl/10.1056/NEJMoa1603827/suppl_file/nejmoa1603827_appendix.pdf.\n\nMendis B, Simpson E, Macdonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Pharm. 2012;74(3):437\u2011444.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2157, "end_char_idx": 2996, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c30edf33-ee9c-4a86-a086-c9918c348a51": {"__data__": {"id_": "c30edf33-ee9c-4a86-a086-c9918c348a51", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ab12cb30-c41d-4e73-8dd6-d9592785495b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "093e49db02d1811ed1d6f0afeec959a052cc674299bd48e6e5757aa4fc611ac7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2) Clinical Protocol Addendum\n\nSmits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, van Raalte DH. Heart rate acceleration with GLP\u20111 receptor agonists in type 2 diabetes patients: an acute and 12\u2011week randomised, double\u2011blind, placebo\u2011controlled trial. *Eu J Endocrinol.* 2017;176(1):77\u201386.\n\nSun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S. Impact of GLP\u20111 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta\u2011analysis. *Diabetes Res Clin Pract.* 2015;110(1):26\u201137.\n\nThase ME, Haight BR, Johnson MC, Hunt T, Krishen A, Fleck RJ, Modell JG. A Randomized, Double\u2011Blind, Placebo\u2011Controlled Study of the Effect of Sustained\u2011Release Bupropion on Blood Pressure in Individuals With Mild Untreated Hypertension. *J Clin Psychopharmacol.* 2008;28(3):302\u2011307.\n\nZhang D, Wang W, LI F. Association between resting heart rate and coronary artery disease, stroke, sudden death and noncardiovascular diseases: a meta\u2011analysis. *CMAJ.* 2016;188(15):E384\u2011E392.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 1094, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1d2ca955-e0fc-458c-b568-9d38486c3048": {"__data__": {"id_": "1d2ca955-e0fc-458c-b568-9d38486c3048", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d4674474-277d-4345-bdea-f1913af114dd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "25abddcf822a7c58fade9dcf7561c20f663bed7972d91970df971b39e0fe970b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2) Clinical Protocol Addendum\n\n# Attachment 1. Protocol Addendum GPHK(2) Schedule of Activities\n\n| Visit\\*                       | 1  | 2  | 3  |    | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | ED |\n| ----------------------------- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |\n| Week of Treatment             | -2 | -1 | 0  | 4  | 8  | 12 | 16 | 20 | 24 | 28 | 32 | 36 |    |    |\n| Allowable Deviation (days)\\*  | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 |    |    |    |\n| Fasting Visit                 | X  | X  | X  | X  | X  | X  | X  | X  | X  |    | X  |    | X  |    |\n| Telephone Visit               |    |    |    |    |    |    |    |    |    | X  | X  |    |    |    |\n| Informed consent for addendum | X  |    |    |    |    |    |    |    |    |    |    |    |    |    |\n| ABPM training                 |    | X  |    |    |    |    |    |    |    |    |    |    |    |    |\n| Initiate ABPM device          |    | X  |    |    |    |    |    |    |    |    |    |    | X  |    |\n| Return ABPM device\\*          |    | X  |    |    |    |    |    |    |    |    |    |    | X  |    |\n| Record ABPM measurements\\*    |    | X  |    |    |    |    |    |    |    |    |    |    | X  |    |\n\nAbbreviations: ABPM = ambulatory blood pressure monitoring; ED = early discontinuation of treatment.\n\n*Please see following table for corresponding additional information.\n\n# Additional Information Regarding Activities Described in SOA\n\n| Activity                 | Notes                                                                                                                                                                                                                                                                            |\n| ------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Return ABPM device       | Participants should return the ABPM device at the conclusion of the 24\u2011 to 27\u2011hour monitoring period.                                                                                                                                                                            |\n| Record ABPM measurements | At the time participant visit data is uploaded by the site, the ABPM Data Validity Report will be generated and should be reviewed to ensure \u226570% of results are valid. If <70% of results are valid, the 24\u2011hour monitoring session should be repeated within the visit window. |\n\nAbbreviations: ABPM = ambulatory blood pressure monitoring; SOA = schedule of activities.\n\nLY3289176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 2810, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "428c9a34-c059-495f-92bb-730ddaebb762": {"__data__": {"id_": "428c9a34-c059-495f-92bb-730ddaebb762", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b236d035-357c-4162-b064-a5ce10cf0ed3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "87c5ea42d1cd48f3386643eed6870c73ed0bfca7b1e50e5022a6090021e727cc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Leo Document ID = 79729a5c-6b4b-446c-8be7-30151256e229\n\n# Approvals\n\n| Approver | Approval Date & Time     | Signature meaning |\n| -------- | ------------------------ | ----------------- |\n| PPD      | 10-Sep-2019 20:58:43 GMT | Approved          |\n| PPD      | 11-Sep-2019 07:43:54 GMT | Approved          |", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 310, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b314a09d-7914-40e3-9a20-6192f713b920": {"__data__": {"id_": "b314a09d-7914-40e3-9a20-6192f713b920", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "29eaa3bc-be4b-458c-9eed-7d4c124a04a4", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0f4cd93efded161d92656ca8f0420e6efe4f933785ef7fcfa81ad779598e6855", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum    Page 1\n\n# 1. Protocol Addendum I8F-MC-GPHK(2.1)\n\n# Characterizing the Effect of Tirzepatide on Heart Rate and Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (ABPM)\n\n# Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)\n\nConfidential Information\n\nThe information contained in this protocol addendum is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of tirzepatide (LY3298176), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. This document and its associated attachments are subject to United States Freedom of Information Act (FOIA) Exemption 4.\n\n# Tirzepatide (LY3298176)\n\nThis addendum is to be performed in addition to all procedures required by protocol I8F-MC-GPHK or any subsequent amendments to that protocol.\n\nEli Lilly and Company\n\nIndianapolis, Indiana USA 46285\n\nProtocol Addendum (2.1) Electronically Signed and Approved by Lilly on date provided below:\n\nApproval Date: 24-Jan-2020 GMT\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 1390, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6059ff27-8333-46aa-9476-fd45c2a0a61c": {"__data__": {"id_": "6059ff27-8333-46aa-9476-fd45c2a0a61c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d694d9f1-3939-4a26-862a-4c86afc0cffe", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cefe02bd7439d623e5db3fdaa5b5ac739b2648da891e68864c646c0cd7f770ac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum\n\n# 2. Table of Contents\n\n# Protocol Addendum I8F-MC-GPHK (2.1)\n\nCharacterizing the Effect of Tirzepatide on Heart Rate and Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (ABPM)\n\nEfficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)\n\n| Section                                                                                                                                                                    | Page |\n| -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---- |\n| 1. Protocol Addendum I8F\u2011MC\u2011GPHK(2.1) Characterizing the Effect of Tirzepatide on Heart Rate and Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (ABPM) | 1    |\n| 2. Table of Contents                                                                                                                                                       | 2    |\n| 3. Rationale for Addendum                                                                                                                                                  | 4    |\n| 4. Protocol Additions                                                                                                                                                      | 5    |\n| 4.1. Objectives                                                                                                                                                            | 5    |\n| 4.2. Inclusion and Exclusion Criteria                                                                                                                                      | 5    |\n| 4.2.1. Inclusion Criteria                                                                                                                                                  | 5    |\n| 4.2.2. Exclusion Criteria                                                                                                                                                  | 5    |\n| 4.3. Addendum Procedures                                                                                                                                                   | 6    |\n| 4.3.1. Ambulatory Monitoring Device                                                                                                                                        | 6    |\n| 4.3.2. Study Procedures                                                                                                                                                    | 6    |\n| 4.3.3. Concomitant Medications                                                                                                                                             | 7    |\n| 4.3.4. Randomization                                                                                                                                                       | 7    |\n| 4.4. Sample Size and Statistical Methods                                                                                                                                   | 8    |\n| 4.4.1. Determination of Sample Size for ABPM Analysis                                                                                                                      | 8    |\n| 4.4.2. Statistical and Analytical Plans                                                                                                                                    | 8    |\n| 4.5. Data Capture System                                                                                                                                                   | 8    |\n| 4.6. Informed Consent                                                                                                                                                      | 8    |\n| 5. References                                                                                                                                                              | 9    |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4299, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "dde21d52-9097-4735-a9e7-3ff0d99e12c6": {"__data__": {"id_": "dde21d52-9097-4735-a9e7-3ff0d99e12c6", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f17e3d30-471b-4a48-9d18-c0be124343f6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3dc81a2cb844e8dc96a22a0b2d7b0d3fc98eb88359e7a8b456d0fd06aa4cf887", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum\n\n# List of Attachments\n\n| Attachment                                                       | Page |\n| ---------------------------------------------------------------- | ---- |\n| Attachment 1. Protocol Addendum GPHK(2.1) Schedule of Activities | 11   |\n| Attachment 2. Protocol Addendum Revisions                        | 12   |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 384, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e3c840f0-c948-4084-ba80-56fc585bde32": {"__data__": {"id_": "e3c840f0-c948-4084-ba80-56fc585bde32", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7c73e8d7-d075-4b3d-aeef-845eac96e088", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0c5dc604bdfa172b22a285515a06b9d3c3e0ada8426462af944c5f4cb5fc27be", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum\n\n# 3. Rationale for Addendum\n\nOne known effect of glucagon\u2011like peptide\u20111 receptor (GLP\u20111R) agonists is to increase heart rate (HR), usually with either no change or a mild reduction in blood pressure (BP) (Lorenz et al. 2017). Changes in HR attenuate over time (Sun et al. 2015; Marso et al. 2016; Holman et al. 2017; Lorenz et al. 2017), and in long\u2011term cardiovascular outcomes studies, GLP\u20111R agonists have been associated with reduced risk for major adverse cardiovascular events (Drucker et al. 2018). The mechanisms by which GLP\u20111R agonists increase HR are not fully understood, with recent studies suggesting direct stimulation of the sinoatrial node, although activation of the sympathetic nervous system, or reduction of systemic vascular resistance have not been excluded (Bharucha et al 2008; Mendis et al. 2012; Smits et al. 2017). The long\u2011term impact of glucose\u2011dependent insulinotropic polypeptide (GIP) receptor agonists on HR and BP is unknown.\n\nTirzepatide is a 39\u2011amino acid synthetic peptide with agonist activity at both the glucose\u2011dependent insulinotropic polypeptide receptor (GIPR) and GLP\u20111R. Data from Phase 1 (I8F\u2011MC\u2011GPGA) and Phase 2 (I8F\u2011MC\u2011GPGB and I8F\u2011MC\u2011GPGF) studies with tirzepatide employing a more rapid dose escalation than is proposed in the current Phase 3 study, showed dose\u2011dependent increases in HR comparable to that seen with dulaglutide and other members of the GLP\u20111R agonist class (Lorenz et al. 2017; Gerstein et al. 2019). The impact of tirzepatide on HR over a longer term and under a slower dose escalation scheme in obese patients without type 2 diabetes is unknown.\n\nThe purpose of this addendum is to gather additional information about the impact of tirzepatide on HR and BP in a subgroup of participants randomized in SURMOUNT\u20111 (I8F\u2011MC\u2011GPHK). The data will provide information to a planned interim analysis of the main protocol, whose timing is triggered by the completion of this addendum.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2005, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3b28c363-c445-4c77-b993-b2bbc32cb091": {"__data__": {"id_": "3b28c363-c445-4c77-b993-b2bbc32cb091", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6be67a9c-c963-4283-987d-48549eefbbef", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "224d6559670d6f31d34e75e81dc260a12d6423b674f7cd67d30de2557285be45", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum\n# 4. Protocol Additions\n\n# 4.1. Objectives\n\nTo assess the effect of 5 mg, 10 mg, and 15 mg doses of tirzepatide compared to placebo on mean change from randomization (Week 0) to Week 36 on 24\u2011hour mean HR and 24\u2011hour mean BP (systolic blood pressure [SBP]/diastolic blood pressure [DBP]), as measured during 24\u2011hour ambulatory monitoring.\n\n# 4.2. Inclusion and Exclusion Criteria\n\nAll participants fulfilling study protocol I8F\u2011MC\u2011GPHK inclusion criteria will be asked to participate in this addendum until the required number of participants is obtained. The following additional inclusion and exclusion criteria will apply:\n\n# 4.2.1. Inclusion Criteria\n\n- [44] Participant has provided informed consent for SURMOUNT\u20111.\n- [45] Participant is willing to wear an ambulatory HR and BP monitoring device for at least 24 hours (on multiple occasions).\n- [46] Participants with hypertension should have well\u2011controlled BP (&#x3C;140/90), regardless of antihypertensive treatment.\n- [47] Participants receiving treatment for hypertension should be on a stable antihypertensive regimen for at least 3 months prior to screening.\n\nNote: If the investigator anticipates a need to add antihypertensive medication during the course of the addendum, the participant should not be included in the addendum.\n\n# 4.2.2. Exclusion Criteria\n\n- [48] Participant has an ongoing or history of frequent intermittent or chronic tachyarrhythmia syndromes (such as atrial fibrillation, supraventricular tachycardia, positional orthostatic tachycardia syndrome).\n- Note: Participants with history of premature atrial contractions or premature ventricular contractions may be included.\n- [49] Participant works rotation shifts or works during the hours of 2200 to 0700.\n- [50] Participant performs strenuous manual labor that cannot be avoided during the monitoring period.\n- [51] Participant has a nondominant arm circumference of >55 cm at Visit 1.\n- [52] Participant is unable to obtain a valid baseline ambulatory blood pressure monitoring (ABPM) reading (see Section 4.3.2).", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2096, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bda8f636-6e56-48bb-a548-90bd1755a80e": {"__data__": {"id_": "bda8f636-6e56-48bb-a548-90bd1755a80e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d9cdcca0-72de-4ddb-a068-c479c7047b0e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d89d93ae6142d8c716e1f3f52ddd9d8772961489eff191609773df74932ae86e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum\n\n# 4.3. Addendum Procedures\n\n# 4.3.1. Ambulatory Monitoring Device\n\nAn ambulatory monitoring device that uses an inflatable cuff attached to a portable device worn around the waist will be used to collect multiple BP and HR readings over a 24\u2011hour period, during both sleep and wake cycles. Although it is called ABPM, the device collects both HR and BP readings. The multiple readings collected by the ABPM device can be averaged to obtain mean BP and HR values, to detect variations over time, and to compute other distribution patterns.\n\n# 4.3.2. Study Procedures\n\nParticipants who give consent and meet all eligibility requirements will receive education about ABPM and will be trained in its use at Visit 2. Ambulatory monitoring of HR and BP will be performed prior to Visit 3 (Week 0; baseline) and following Visit 12 (Week 36; final measure).\n\n# Use of the ABPM Device\n\nThe ABPM device will be attached to the nondominant arm, and participants will be instructed to wear the monitor for a 24\u2011 to 27\u2011hour period. Participants will be instructed to keep track of daily activities throughout the testing period and not to engage in strenuous activity.\n\n# Ambulatory blood pressure measurements:\n\n- Should be collected on a typical work day, not on a non\u2011working day\n- Will be recorded every 30 minutes during daytime hours (0700 to 2200 hours)\n- Will be recorded every 60 minutes during nighttime hours (2200 to 0700)\n\nA 24\u2011hour session of ambulatory monitoring produces technically acceptable measurements if \u226570% of the readings are valid.\n\n# Baseline measurement (Week 0)\n\nBetween Visit 2 and Visit 3, the participant will undergo a baseline 24\u2011hour ambulatory monitoring session. Upon return of the ABPM device, the recordings must be transmitted to the Core Laboratory and analyzed before the participant leaves the site. If the session provides technically satisfactory results (\u226570% of readings are valid), this measurement will serve as the baseline value. If a technically satisfactory result is not achieved, the investigator should review the device settings and placement and the participant\u2019s activity track in an attempt to correct any user error or device malfunctions. Another 24\u2011hour ambulatory monitoring session should be conducted prior to Visit 3 and this measurement will serve as the baseline value. If the second session also provides technically unsatisfactory results, the participant should not be included in the addendum (see Exclusion criteria #52).\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2540, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6b5f5eac-a719-4354-abae-2a8a2ae47064": {"__data__": {"id_": "6b5f5eac-a719-4354-abae-2a8a2ae47064", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ba798995-6a97-4f3f-9327-3bccaa880282", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "473d696fde7be3c6f1424a387cd3492d67db35c34c50e0babfd0a25eaad76c9e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum\nPage 7\n\n# Final measurement (Week 36)\n\nFollowing Visit 12 (within 1 week), the participant will undergo one 24\u2011hour ambulatory monitoring session. Upon return of the ABPM device, the recordings must be transmitted to the Core Laboratory and analyzed before the participant leaves the site. If the session provides technically satisfactory results (\u226570% of readings are valid), this measurement will serve as the final value. If a technically satisfactory result is not achieved, the investigator should review the device settings and placement and the participant\u2019s activity track in an attempt to correct any user error or device malfunctions. Another 24\u2011hour ambulatory monitoring session should be conducted (within 7 days after Visit 12) and this measurement will serve as the final value. If the second session also provides technically unsatisfactory results, the data will be considered missing.\n\n# 4.3.3. Concomitant Medications\n\nAntihypertensive medications and doses should remain stable throughout the study addendum period (36 weeks), unless dose adjustments are required for safety, (i.e., due to uncontrolled hypertension).\n\nChronic use of nonsteroidal anti\u2011inflammatory agents or cyclooxygenase\u20112 (COX\u20112) inhibitors, as well as other agents, prescription or over\u2011the\u2011counter, known to affect BP, are permitted; however, use of these agents on an as needed basis (PRN) during the 48\u2011hour period immediately prior to or during each 24\u2011hour ABPM recording is prohibited. Examples include, but are not limited to decongestants (pseudoephedrine, ephedrine, phenylephrine, naphazoline, oxymetazoline) and multi\u2011symptom cold remedies.\n\nMale participants must abstain from use of phosphodiesterase type 5 (PDE\u20115) inhibitors (i.e., tadalafil, vardenafil, sildenafil) or yohimbine (herbal aphrodisiac) during the 48\u2011hour period immediately prior to or during each 24\u2011hour ABPM recording, since these medications may confound the BP measurements.\n\n# 4.3.4. Randomization\n\nParticipants who meet all criteria for enrollment to this addendum will be randomized to 1 of the 4 study treatment groups at Visit 3. Assignment to treatment groups will be determined by a computer\u2011generated random sequence using an interactive web response system (IWRS). Participants will be randomized in a 1:1:1:1 ratio to receive tirzepatide 5 mg, tirzepatide 10 mg, tirzepatide 15 mg, or placebo.\n\nThe randomization will be stratified by pre\u2011diabetes status, country, sex, and by baseline use status of heart rate controlling medicines, including beta\u2011blockers, calcium channel blockers (diltiazem or verapamil), potassium channel blockers (like amiodarone), and cardiac glycosides (like digoxin).\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2736, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "300107a2-dbaa-4dc6-8e88-52b65feff583": {"__data__": {"id_": "300107a2-dbaa-4dc6-8e88-52b65feff583", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6188e219-02f4-4f5d-8fd5-5e337f4fd80e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "700923784bd316ed80d75939aa1b5778deaf537b9b133bae1e44506abac4caed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum\n# 4.4. Sample Size and Statistical Methods\n\n# 4.4.1. Determination of Sample Size for ABPM Analysis\n\nA sample size of approximately 576 randomized participants (approximately 144 participants from each of the 4 treatment arms) is planned for this addendum. The above sample size will provide at least 90% probability to ensure that the upper limit of 95% confidence interval (CI) of the placebo adjusted mean 24\u2011hour HR increase induced by any tirzepatide dose is \u226410 beats per minute (bpm) at 36 weeks. Epidemiologic data has shown sustained HR increases >10 bpm to be associated with increased risk for major cardiovascular events, and cardiovascular and all\u2011cause mortality (Lonn et al. 2014; Zhang et al. 2016; Aune et al. 2017).\n\nThe sample size calculation assumes a mean difference of 6 bpm between each tirzepatide dose relative to placebo with a standard deviation of 9 bpm (Balfour et al. 2014; Thase et al. 2008), and a dropout rate of 25% at 36 weeks. The sample size is calculated at a nominal alpha level of 0.05 without multiplicity adjustment.\n\n# 4.4.2. Statistical and Analytical Plans\n\nUnless otherwise noted, all tests of treatment effects will be conducted at a 2\u2011sided alpha level of 0.05, and the CI will be calculated at 95%, 2\u2011sided. All analyses for the variables measured or derived from ABPM, will be conducted on all participants who are enrolled in this addendum, randomized and have at least 1 dose of study drug, with both baseline and at least 1 postbaseline measurement.\n\nFor continuous outcomes collected from the ABPM, including BP and HR, the analysis will be conducted using an analysis of covariance model (ANCOVA), with terms of treatment, baseline measurement, and baseline use status of heart rate controlling medicines.\n\nFor categorical measures (including categorized continuous measures), logistic regression will be used to examine the treatment difference, if there is a need to adjust for covariates. Otherwise, Fisher\u2019s exact test will be used to examine the treatment difference.\n\nOther statistical methods may be used, as appropriate, and details will be described in the Statistical Analysis Plan.\n\n# 4.5. Data Capture System\n\nAny diagnostic data collected from a contracted vendor will be stored electronically in that central vendor\u2019s database system. Data will subsequently be transferred from the central vendor according to the contract.\n\n# 4.6. Informed Consent\n\nThe investigator is responsible for ensuring that appropriate written informed consent is given by each participant or legal representative prior to the performance of any protocol addendum procedures.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2677, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1f37b4cf-a04e-4f9c-b2c7-8daf5f8e4df4": {"__data__": {"id_": "1f37b4cf-a04e-4f9c-b2c7-8daf5f8e4df4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "77ea3781-8665-4edb-a7ad-2ed535323528", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "71127c375281cc8dc7629d3e8fed4aaa61da5df69023ff34f4aca1b675bb1479", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9796a46a-5a48-4e96-9bf6-c3b2cead242d", "node_type": "1", "metadata": {}, "hash": "739163b8b4d38b9d8cd4deaeb61dfcda28ba29a1153402fb66f31495c112de3f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum\n# 5. References\n\nAune D, Sen A, \u00f3\u2019Hartaigh B, Janszky I, Romundstad PR, Tonstad S, Vatten LJ. Resting heart rate and the risk of cardiovascular disease, total cancer, and all\u2011cause mortality \u2013 a systematic review and dose\u2011response meta\u2011analysis of prospective studies. Nutr Metab Cardiovasc Dis. 2017;27(6):504\u2011517.\n\nBalfour PC Jr, Rodriguez CJ, Ferdinand KC. Blood pressure and cardiovascular effects of new and emerging antidiabetic agents. Curr Hypertens Rep. 2014;16(8):455.\n\nBharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, Zinsmeister AR, Low PA. Effects of glucagon\u2011like peptide\u20111, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol. 2008;295(3):R874\u2011R880.\n\nDrucker DJ. The ascending GLP\u20111 road from clinical safety to reduction of cardiovascular complications. Diabetes. 2018;67(9):1710\u20131719.\n\nGerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryd\u00e9n L, Xavier D, Atisso CM, Dyal L, Hall S, Rao\u2011Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez\u2011Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova\u2011Kurktschiev T, REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double\u2011blind, randomised placebo\u2011controlled trial. Lancet. 2019;394(10193):121\u2011130.\n\nHolman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, \u00d6hman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group. Effects of once\u2011weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u20111239.\n\nLonn EM, Rambihar S, Gao P, Custodis FF, Sliwa K, Teo KK, Yusuf S, B\u00f6hm M. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all\u2011cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol. 2014;103(2):149\u2011159.\n\nLorenz M, Lawson F, Owens D, Raccah D, Roy\u2011Duval C, Lehmann A, Perfetti R, Blonde L. Differential effects of glucagon\u2011like peptide\u20111 receptor agonists on heart rate. Cardiovasc Diabetol.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2395, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9796a46a-5a48-4e96-9bf6-c3b2cead242d": {"__data__": {"id_": "9796a46a-5a48-4e96-9bf6-c3b2cead242d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "77ea3781-8665-4edb-a7ad-2ed535323528", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "71127c375281cc8dc7629d3e8fed4aaa61da5df69023ff34f4aca1b675bb1479", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f37b4cf-a04e-4f9c-b2c7-8daf5f8e4df4", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6c702116454688b179b37ec573de6e1318e66df6e55a0a1e75ac65504075f611", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Clin Res Cardiol. 2014;103(2):149\u2011159.\n\nLorenz M, Lawson F, Owens D, Raccah D, Roy\u2011Duval C, Lehmann A, Perfetti R, Blonde L. Differential effects of glucagon\u2011like peptide\u20111 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16(1):6.\n\nMarso SP, Daniels GH, Brown\u2011Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u2011322.\n\nMendis B, Simpson E, MacDonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol. 2012;74(3):437\u2011444.\n\nSmits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, van Raalte DH. Heart rate acceleration with GLP\u20111 receptor agonists in type 2 diabetes patients: an acute and", "mimetype": "text/plain", "start_char_idx": 2169, "end_char_idx": 3083, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2c070022-d334-4756-9d28-ff0be1c32c5c": {"__data__": {"id_": "2c070022-d334-4756-9d28-ff0be1c32c5c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "af44db82-3e51-4411-bdba-e4ea99fa7f7e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "37b222fb8209c1963668c2b6860b6485422a80cb9873a0a17da57795d56f3784", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum\n12\u2011 week randomised, double\u2011blind, placebo\u2011controlled trial. Eur J Endocrinol. 2017;176(1):77\u201386.\n\nSun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S. Impact of GLP\u20111 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta\u2011analysis. Diabetes Res Clin Pract. 2015;110(1):26\u201137.\n\nThase ME, Haight BR, Johnson MC, Hunt T, Krishen A, Fleck RJ, Modell JG. A randomized, double\u2011blind, placebo\u2011controlled study of the effect of sustained\u2011release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol. 2008;28(3):302\u2011307.\n\nZhang D, Wang W, Li F. Association between resting heart rate and coronary artery disease, stroke, sudden death and noncardiovascular diseases: a meta\u2011analysis. CMAJ. 2016;188(15):E384\u2011E392.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 909, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d4e84d2c-07ca-475d-ac3b-61f061eaf0bb": {"__data__": {"id_": "d4e84d2c-07ca-475d-ac3b-61f061eaf0bb", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ded9dd90-e489-4c86-bcdb-03f2c3473267", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ec8d0ead2316006f9d1a44e9132f38bef80e0a17f2c011e2b16f4ad00c032299", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum\n# Attachment 1. Protocol Addendum GPHK(2.1) Schedule of Activities\n\n| Visit\\*                         | 1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  | 10 | 11 | 12 | ED |\n| ------------------------------- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |\n| Week of Treatment               | -2 | -1 | 0  | 4  | 8  | 12 | 16 | 20 | 24 | 28 | 32 | 36 |    |\n| Allowable Deviation (days)\\*    |    | \u00b13 | \u00b13 | \u00b13 | +7 | \u00b13 | +7 | \u00b13 | \u00b13 | \u00b13 | \u00b13 | +7 |    |\n| Fasting Visit                   | X  | X  | X  | X  | X  | X  | X  | X  |    | X  |    |    | X  |\n| Telephone Visit                 |    |    |    |    |    |    |    |    |    | X  | X  |    |    |\n| Informed consent for addendum\\* | X  |    |    |    |    |    |    |    |    |    |    |    |    |\n| ABPM training                   |    | X  |    |    |    |    |    |    |    |    |    |    |    |\n| Initiate ABPM device            |    | X  |    |    |    |    |    |    |    |    |    |    | X  |\n| Return ABPM device\\*            |    | X  |    |    |    |    |    |    |    |    |    |    | X  |\n| Record ABPM measurements\\*      | X  |    |    |    |    |    |    |    |    |    |    | X  |    |\n\nAbbreviations: ABPM = ambulatory blood pressure monitoring; ED = early discontinuation of treatment.\n\n*Please see following table for corresponding additional information.\n\n# Additional Information Regarding Activities Described in SOA\n\n| Activity                      | Notes                                                                                                                                                                                                                                                                            |\n| ----------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Informed consent for addendum | The informed consent for this addendum should be obtained at Visit 1. However, under special circumstances, informed consent could be obtained at Visit 2, prior to the performance of any protocol addendum procedures.                                                         |\n| Return ABPM device            | Participants should return the ABPM device at the conclusion of the 24\u2011 to 27\u2011hour monitoring period.                                                                                                                                                                            |\n| Record ABPM measurements      | At the time participant visit data is uploaded by the site, the ABPM Data Validity Report will be generated and should be reviewed to ensure \u226570% of results are valid. If <70% of results are valid, the 24\u2011hour monitoring session should be repeated within the visit window. |\n\nAbbreviations: ABPM = ambulatory blood pressure monitoring; SOA = schedule of activities.\n\nLY3289176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3108, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f7045a10-75be-4c68-abd2-7e410458d9c9": {"__data__": {"id_": "f7045a10-75be-4c68-abd2-7e410458d9c9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c0a0778d-57ab-421a-b4f7-043f1dcbbe02", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "f732d6369ed0133bda51129f02e341b27e6797b68b952d56d2466305491eb7e3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK(2.1) Clinical Protocol Addendum\n# Attachment 2. Protocol Addendum Revisions\n\n# Overview\n\nProtocol Addendum 18F\u2011MC\u2011GPHK(2.1) Characterizing the Effect of Tirzepatide on Heart Rate and Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (ABPM) Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight\u2011Related Comorbidities: A Randomized, Double\u2011Blind, Placebo\u2011Controlled Trial (SURMOUNT\u20111) has been amended. The amended protocol addendum is indicated by revision (2.1) and will be used in place of any preceding version of this protocol addendum.\n\nThe overall changes made to this protocol addendum are as described below. Note that minor edits have been made throughout the addendum, which are not captured in the summary below.\n\n- To align with regulatory guidance from the US Food and Drug Administration (FDA), Sections 4.3.4. and 4.4.2. were updated to include additional concomitant medications for use during stratification at randomization.\n- In order to allow for more flexibility for participants and investigators, the addendum schedule of activities (Attachment 1) has been modified to allow participants to sign the informed consent at Visit 2 under special circumstances. In addition, Section 4.3.2 was reworded in order to provide clarity.\n\nLY3289176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1368, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ba43da52-0b82-40be-b761-89c40a7dec92": {"__data__": {"id_": "ba43da52-0b82-40be-b761-89c40a7dec92", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ce88e2ff-70f3-4699-ac54-68cfc3f023a5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b1066a6d96fd538db4b2ac992409972f091ef1633f521e751918b9e00b2b09db", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Leo Document ID = 376ec46e-73f4-48db-baf3-b73227304a01\n\n# Approvals\n\n| Approver | Approval Date & Time     | Signature meaning |\n| -------- | ------------------------ | ----------------- |\n| PPD      | 24-Jan-2020 13:03:47 GMT | Approved          |\n| PPD      | 24-Jan-2020 13:09:47 GMT | Approved          |", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 310, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9c4bea5e-b085-4ef5-8e50-8f24dff696f0": {"__data__": {"id_": "9c4bea5e-b085-4ef5-8e50-8f24dff696f0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ac68297a-1ade-4097-9e06-87fa33753b01", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d328681bcc4c9dd4c4bd40fdfa51a835040cde2939eefa09672c23d7924a0029", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# I8F-MC-GPHK Statistical Analysis Plan Version 1\n\nPage 1\n\n# 1. Statistical Analysis Plan I8F-MC-GPHK:\n\nEfficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)\n\nConfidential Information\n\nThe information contained in this document is confidential and the information contained within it may not be reproduced or otherwise disseminated without the approval of Eli Lilly and Company or its subsidiaries.\n\nNote to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.\n\n# LY3298176 for Chronic Weight Management\n\nPhase-3 randomized, double-blind, placebo-controlled trial comparing 3-doses of LY3298176 to Placebo in participants without Type 2 Diabetes Who have obesity or are overweight with weight-related comorbidities.\n\nEli Lilly and Company\n\nIndianapolis, Indiana USA 46285\n\nProtocol I8F-MC-GPHK\n\nPhase 3\n\nStatistical Analysis Plan electronically signed and approved by Lilly on date provided below.\n\nApproval Date: 05-Sep-2020 GMT\n\n# LY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 1534, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9a4d17ce-1018-4911-aa83-be620c79e33b": {"__data__": {"id_": "9a4d17ce-1018-4911-aa83-be620c79e33b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f6e84b8e-bc38-4d80-af84-cefa918ceffc", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "4f2d77d696b20b9ca23778f72b7155a6a082f0ba3c44f002bc24e179d6d764ee", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# 2. Table of Contents\n\n| Section                                                                                                                                                                                                                                                                  | Page |\n| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ---- |\n| 1. Statistical Analysis Plan I8F\u2011MC\u2011GPHK: Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight\u2011Related Comorbidities: A Randomized, Double\u2011Blind, Placebo\u2011Controlled Trial (SURMOUNT\u20111) | 1    |\n| 2. Table of Contents                                                                                                                                                                                                                                                     | 2    |\n| 3. Revision History                                                                                                                                                                                                                                                      | 9    |\n| 4. Study Objectives                                                                                                                                                                                                                                                      | 10   |\n| 4.1. Primary Objective                                                                                                                                                                                                                                                   | 10   |\n| 4.2. Key Secondary Objectives                                                                                                                                                                                                                                            | 10   |\n| 4.3. Other Secondary Objectives                                                                                                                                                                                                                                          | 11   |\n| 5. Study Design                                                                                                                                                                                                                                                          | 13   |\n| 5.1. Summary of Study Design                                                                                                                                                                                                                                             | 13   |\n| 6. A Priori Statistical Methods                                                                                                                                                                                                                                          | 15   |\n| 6.1. Populations for Analyses                                                                                                                                                                                                                                            | 15   |\n| 6.2. General Considerations                                                                                                                                                                                                                                              | 15   |\n| 6.3. Adjustments for Covariates                                                                                                                                                                                                                                          | 17   |\n| 6.4. Handling of Dropouts or Missing Data                                                                                                                                                                                                                                | 17   |\n| 6.5. Multicenter Studies                                                                                                                                                                                                                                                 | 17   |\n| 6.6. Multiple Comparisons/Multiplicity                                                                                                                                                                                                                                   | 17   |\n| 6.7. Patient Disposition                                                                                                                                                                                                                                                 | 18   |\n| 6.8. Historical Illnesses and Preexisting Conditions                                                                                                                                                                                                                     | 18   |\n| 6.9. Patient Characteristics                                                                                                                                                                                                                                             | 18   |\n| 6.10. Concomitant Therapy                                                                                                                                                                                                                                                | 19   |\n| 6.11. Treatment Exposure and Compliance                                                                                                                                                                                                                                  | 20   |\n| 6.11.1. Study and Study Treatment Exposure                                                                                                                                                                                                                               | 20   |\n| 6.11.2. Compliance to Study Treatment                                                                                                                                                                                                                                    | 21   |\n| 6.12. Important Protocol Deviations                                                                                                                                                                                                                                      | 22   |\n| 6.13. Efficacy Analyses                                                                                                                                                                                                                                                  | 22   |\n| 6.13.1. Primary Efficacy Analysis                                                                                                                                                                                                                                        | 22   |\n| 6.13.1.1. Analysis Related to the Efficacy Estimand                                                                                                                                                                                                                      | 22   |\n| 6.13.1.2. Analysis Related to the Hybrid Estimand                                                                                                                                                                                                                        | 23   |\n| 6.13.1.3. Methods for Multiple Imputations                                                                                                                                                                                                                               | 24   |\n| 6.13.1.4. Sensitivity Analysis Related to the Treatment Regimen Estimand                                                                                                                                                                                                 | 24   |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 8905, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f4ddd6dd-e9f4-4aa0-b1c7-a5ad4b615bac": {"__data__": {"id_": "f4ddd6dd-e9f4-4aa0-b1c7-a5ad4b615bac", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d250e079-ddb8-41c9-b8a9-bfa9a5407e6e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a885af926209a561bf612dd379c5bebc5fe566736a4c444dbb6fc0d494930d8a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.13.2. Secondary Efficacy Analyses Subject to Type 1 Error Rate\n\nControl\n\n25\n\n# 6.13.3. Type 1 Error Rate Control Strategy for Primary and Key Secondary Efficacy Analyses\n\n26\n\n# 6.13.4. Other Secondary and Exploratory Efficacy Analyses\n\n26\n\n# 6.13.4.1. Other Secondary Efficacy Analyses\n\n27\n\n# 6.13.4.2. Exploratory Efficacy Analyses\n\n28\n\n# 6.14. Safety Analyses\n\n29\n\n# 6.14.1. Analysis of Adverse Events\n\n30\n\n# 6.14.1.1. Treatment Emergent Adverse Events\n\n30\n\n# 6.14.1.2. Common Adverse Events\n\n31\n\n# 6.14.1.3. Deaths\n\n31\n\n# 6.14.1.4. Other Serious Adverse Events\n\n31\n\n# 6.14.1.5. Other Significant Adverse Events\n\n31\n\n# 6.14.2. Patient Narratives\n\n32\n\n# 6.14.3. Special Safety Topics\n\n32\n\n# 6.14.3.1. Acute Gallbladder Disease\n\n32\n\n# 6.14.3.2. Amputation/Peripheral Revascularization\n\n32\n\n# 6.14.3.3. Exocrine Pancreas Safety\n\n32\n\n# 6.14.3.3.1. Pancreatic Enzyme\n\n32\n\n# 6.14.3.3.2. Pancreatitis Events\n\n32\n\n# 6.14.3.4. Gastrointestinal Safety\n\n33\n\n# 6.14.3.4.1. Nausea, Vomiting, and Diarrhea\n\n33\n\n# 6.14.3.4.2. Severe Gastrointestinal Events\n\n33\n\n# 6.14.3.5. Hepatic Safety\n\n33\n\n# 6.14.3.5.1. Hepatobiliary Disorders\n\n33\n\n# 6.14.3.5.2. Liver Enzymes\n\n33\n\n# 6.14.3.6. Hypoglycemia\n\n34\n\n# 6.14.3.7. Immunogenicity\n\n35\n\n# 6.14.3.7.1. Definitions of Sample ADA Status\n\n35\n\n# 6.14.3.7.2. Definitions of Immunogenicity Assessment Periods\n\n39\n\n# 6.14.3.7.3. Definitions of Participant ADA Status\n\n39\n\n# 6.14.3.7.4. Analyses to be Performed\n\n40\n\n# 6.14.3.8. Hypersensitivity Reactions\n\n41\n\n# 6.14.3.8.1. Serious Hypersensitivity Reactions\n\n42\n\n# 6.14.3.9. Injection Site Reaction\n\n42\n\n# 6.14.3.9.1. Severe/Serious Injection Site Reactions\n\n42\n\n# 6.14.3.10. Major Adverse Cardiovascular Events\n\n42\n\n# 6.14.3.11. Major Depressive Disorder/Suicidal Ideation\n\n43\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1816, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "25cd7f3b-688a-4af2-bed3-e24f60e90d43": {"__data__": {"id_": "25cd7f3b-688a-4af2-bed3-e24f60e90d43", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "88041be1-d7e9-4f57-9380-7a44b9c6f5c5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "68671da8557d268c31349e47283b718a5e4af96b5d21f8381f63b920e1848038", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.14.3.11.1. Patient Health Questionnaire\n\n43\n\n# 6.14.3.11.2. Suicidal Ideation and Behavior Solicited Through C\u2011SSRS\n\n44\n\n# 6.14.3.12. Malignancy\n\n45\n\n# 6.14.3.13. Metabolic Acidosis\n\n45\n\n# 6.14.3.14. Renal Safety\n\n45\n\n# 6.14.3.14.1. Acute Renal Events\n\n46\n\n# 6.14.3.14.2. Dehydration\n\n46\n\n# 6.14.3.15. Thyroid Safety Monitoring\n\n46\n\n# 6.14.3.15.1. Calcitonin\n\n46\n\n# 6.14.3.15.2. C\u2011Cell Hyperplasia and Thyroid Malignancies\n\n46\n\n# 6.14.3.16. Treatment\u2011Emergent Supraventricular Arrhythmias and Cardiac Conduction Disorders\n\n46\n\n# 6.14.3.17. Treatment of Overdose\n\n47\n\n# 6.14.3.18. Abuse Potential\n\n47\n\n# 6.14.4. Vital Signs\n\n47\n\n# 6.14.5. Electrocardiograms\n\n48\n\n# 6.14.6. Clinical Laboratory Evaluation\n\n49\n\n# 6.14.6.1. Two\u2011hour Oral Glucose Tolerance Test (OGTT)\n\n50\n\n# 6.15. Health Outcomes\n\n52\n\n# 6.15.1. Patient Global Impression of Status for Physical Activity\n\n52\n\n# 6.15.2. Short\u2011Form\u201136 Health Survey Version 2, Acute Form\n\n52\n\n# 6.15.3. Impact of Weight on Quality of Life\u2011Lite Clinical Trials\n\n53\n\n# 6.15.4. EQ\u20115D\u20115L\n\n54\n\n# 6.16. Subgroup Analyses\n\n54\n\n# 6.16.1. Subgroup Analysis of Body Weight Change\n\n54\n\n# 6.17. Interim Analyses and Data Monitoring Committee\n\n55\n\n# 7. Unblinding Plan\n\n56\n\n# 8. Novel Coronavirus (COVID\u201119) Impact\n\n57\n\n# 8.1. General Consideration\n\n57\n\n# 8.2. Exposure\n\n57\n\n# 8.3. Protocol Deviation\n\n57\n\n# 8.4. Patient Disposition\n\n57\n\n# 8.5. Adverse Events\n\n57\n\n# 8.6. Major Depressive Disorder/Suicidal Ideation\n\n57\n\n# 8.7. Local Lab\n\n58\n\n# 8.8. Missing Data Due to COVID\u201119\n\n58\n\n# 9. References\n\n59\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1597, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "08a61b6c-ed7e-4dcb-a837-cb35abcbbd0e": {"__data__": {"id_": "08a61b6c-ed7e-4dcb-a837-cb35abcbbd0e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8c51711c-379d-4028-bbca-8baf3dcc8aca", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "019ac3eb2aba451194945542a42fc1c66e7980b1d21c7cebe346c59266da78e1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# 10. Appendices\n\nPage 5\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 88, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f6d5b80e-285f-4ab9-a07e-eb85eb3ceedb": {"__data__": {"id_": "f6d5b80e-285f-4ab9-a07e-eb85eb3ceedb", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aa611b4d-839b-424b-9002-4056b4a3de67", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "321239c04674657dbcad5b08f8ccf0b71892aee785242e112ac855886549f299", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# Table of Contents\n\n| Table                                                                                                       | Page |\n| ----------------------------------------------------------------------------------------------------------- | ---- |\n| Table GPHK.6.1. Description of Analysis Datasets                                                            | 15   |\n| Table GPHK.6.2. Baseline and Postbaseline Definitions for Safety Groups                                     | 16   |\n| Table GPHK.6.3. Classification of Glycemic Status                                                           | 19   |\n| Table GPHK.6.4. Secondary Measures Controlled for Type 1 Error                                              | 25   |\n| Table GPHK.6.5. Secondary Measures Not Controlled for Type 1 Error                                          | 27   |\n| Table GPHK.6.6. Exploratory Efficacy Analysis                                                               | 28   |\n| Table GPHK.6.7. Sample Anti\u2011Drug Antibodies (ADA) Assay Results                                             | 37   |\n| Table GPHK.6.8. Sample Clinical Anti\u2011Drug Antibodies (ADA) Interpretation Results                           | 37   |\n| Table GPHK.6.9. In Silico Classification for Cross\u2011Reactive NAb                                             | 38   |\n| Table GPHK.6.10. Adverse Events for Analysis with Immunogenicity Results                                    | 40   |\n| Table GPHK.6.11. Categorical Criteria for Abnormal Treatment\u2011Emergent Blood Pressure and Pulse Measurements | 48   |\n| Table GPHK.6.12. Selected Categorical Limits for ECG Data                                                   | 49   |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1746, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "78c33e3d-ef08-4c08-b937-94a1fe60ee4d": {"__data__": {"id_": "78c33e3d-ef08-4c08-b937-94a1fe60ee4d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d8d87eac-4dc3-4dc0-81d7-a97468fd6537", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d4d69ef1fbfecd084d1822e784dec1d001bd3b4e34e8d9dfe9ecdc8cfb98e274", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# Table of Contents\n\n| Figure                                                                           | Page |\n| -------------------------------------------------------------------------------- | ---- |\n| Figure GPHK.5.1. Illustration of study design for Clinical Protocol I8F\u2011MC\u2011GPHK. | 13   |\n| Figure GPHK.6.1. Flowchart of immunogenicity multitiered testing approach.       | 36   |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 438, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "72e8cd01-55c8-4fdb-936f-8e31ac31b188": {"__data__": {"id_": "72e8cd01-55c8-4fdb-936f-8e31ac31b188", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9dec536e-02d8-4fbb-bfe9-f392a1780eac", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e278a8c5f350cb34a371078ba043533930a6aeb82fe8a5699cd12ba40c3527cc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# Table of Contents\n\n| Appendix                                                                            | Page |\n| ----------------------------------------------------------------------------------- | ---- |\n| Appendix 1. Body Composition Assessments via Dual\u2011Energy X\u2011ray Absorptiometry (DXA) | 61   |\n| Appendix 2. Ambulatory Blood Pressure Monitoring (ABPM)                             | 63   |\n| Appendix 3. Searching Criteria For Special Safety Topics                            | 66   |\n\nPage 8", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 554, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "45c79a6a-521e-44bc-abef-993c8966c293": {"__data__": {"id_": "45c79a6a-521e-44bc-abef-993c8966c293", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4fbf9320-532b-46de-8aed-e760b8511d1a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "f8f061b534f4e0744a55c8fa9187729b86695a348c7fd80d36b7301a20162c9d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# 3. Revision History\n\nThis is the first version of the statistical analysis plan (SAP) for Study I8F\u2011MC\u2011GPHK.\n\nLY3298176\n\nPage 9", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 179, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f76b8cb7-dc6f-4421-acb1-078ce9c73bc3": {"__data__": {"id_": "f76b8cb7-dc6f-4421-acb1-078ce9c73bc3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a66ec8e3-e13f-471d-8611-9d28a6b36708", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "5169ed0de545cb648306d953422e58f1228a15971863207e726042e8c3babdbf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# 4. Study Objectives\n\n# 4.1. Primary Objective\n\nThe primary objective of the study is to demonstrate that tirzepatide 10 mg and/or 15 mg once\u2011weekly (QW) are superior to placebo for percent change in body weight from randomization and percentage of participants who achieve \u22655% body weight reduction at 72 weeks.\n\n# 4.2. Key Secondary Objectives\n\nTogether with the primary objective, the following secondary objectives are subjected to strong control of the type 1 error rate (see Section 6.13.3).\n\n- To demonstrate that tirzepatide 5 mg, 10 mg, and/or 15 mg QW are superior to placebo for change in body weight (kg) from randomization at 20 weeks.\n- To demonstrate that tirzepatide 5 mg QW is superior to placebo for percent change in body weight from randomization and percentage of participants who achieve \u22655% body weight reduction at 72 weeks.\n- To demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for percentage of participants who achieve \u226510% body weight reduction from randomization at 72 weeks.\n- To demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for percentage of participants who achieve \u226515% body weight reduction from randomization at 72 weeks.\n- To demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for change from randomization in waist circumference (cm) at 72 weeks.\n- To demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for change in Short Form \u201136 version 2 Health Survey (SF\u201136v2) acute form Physical Functioning domain score from randomization at 72 weeks.\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in triglycerides (mg/dL) from randomization at 72 weeks.\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in low\u2011density lipoprotein (LDL) (mg/dL) from randomization at 72 weeks.\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in total cholesterol (mg/dL) from randomization at 72 weeks.\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in systolic blood pressure (SBP) (mmHg) from randomization at 72 weeks.\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in fasting insulin (pmol/L) from randomization at 72 weeks.\n- To demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for change in percent body weight from randomization at 176 weeks (for participants with prediabetes at randomization).", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2617, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b67b29cb-c68f-4b83-8898-99eb048f7fc8": {"__data__": {"id_": "b67b29cb-c68f-4b83-8898-99eb048f7fc8", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "80b496b8-4e7d-47ec-b9e7-5da6ac93832a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "be75dc4d37287ce1efc5177b8966cce3dad200ab6ce552b0182ceeff3fc2c06e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nPage 11\n\n# 4.3. Other Secondary Objectives\n\nThe following secondary objectives are not subjected to strong control of the type 1 error rate:\n\n- to demonstrate that tirzepatide 5 mg QW is superior to placebo at 72 weeks for\n- percentage of participants who achieve \u226510% body weight reduction from randomization\n- percentage of participants who achieve \u226515% body weight reduction from randomization\n- mean change in waist circumference (cm) from randomization, and\n- mean change in SF\u201136v2 acute form Physical Functioning domain score from randomization.\n- to demonstrate that tirzepatide 5 mg, 10 mg, and/or 15 mg QW are superior to placebo at 72 weeks for\n- mean change in absolute body weight (kg) from randomization\n- mean change in body mass index (BMI) (kg/m2) from randomization\n- mean change in hemoglobin A1c (HbA1c) (%, mmol/mol) from randomization\n- mean change in fasting glucose (mg/dL) from randomization\n- mean change in Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version (IWQOL\u2011Lite\u2011CT) Physical Function composite score from randomization\n- to demonstrate that tirzepatide QW (all doses combined) is superior to placebo at 72 weeks for\n- mean change in diastolic blood pressure (DBP) (mmHg) from randomization\n- mean change from randomization in the following lipid parameters:\n- high\u2011density lipoprotein (HDL)\u2011cholesterol (mg/dL)\n- very low density lipoprotein (VLDL)\u2011cholesterol (mg/dL)\n- free fatty acids (mg/dL)\n- to demonstrate that tirzepatide 5 mg QW is superior to placebo for percent change in body weight (kg) from randomization at 176 weeks (for participants with prediabetes at randomization)\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1693, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "435a00c5-e076-4e7b-8477-611f9721f6d5": {"__data__": {"id_": "435a00c5-e076-4e7b-8477-611f9721f6d5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "440176be-bcc4-472c-a420-cf5c560891c5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3f311042c9ffa84a65e1805ed71f0ea14f463a77e86cc2660888e6f260541992", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 12\n\n- to demonstrate that tirzepatide 5 mg, 10 mg, and/or 15 mg QW are superior to placebo for percentage of study participants who achieve \u22655% body weight reduction from randomization at 176 weeks (for participants with prediabetes at randomization), and\n- to demonstrate that tirzepatide QW (all doses combined) is superior to placebo (for participants with prediabetes at randomization) at 176 weeks for:\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 469, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a69712d1-109f-472d-b224-c3884d7e98c8": {"__data__": {"id_": "a69712d1-109f-472d-b224-c3884d7e98c8", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3296af08-1598-41ce-9a18-f5fbdc5bed59", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "968c71f72f8efc419feddff16c87f3c92b14a6dd4d97a8a03cbc232829b45f47", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# 5. Study Design\n\n# 5.1. Summary of Study Design\n\nStudy I8F\u2011MC\u2011GPHK (GPHK; SURMOUNT\u20111) is a Phase 3, multicenter, randomized, placebo\u2011controlled, double\u2011blinded study of the safety and efficacy of 5 mg, 10 mg, and 15 mg tirzepatide QW, compared with placebo, when used in conjunction with a reduced\u2011calorie diet and increased physical activity for weight management, in participants who do not have T2DM, and have obesity (BMI \u226530 kg/m2) or are overweight (BMI \u226527 kg/m2) with at least 1 weight\u2011related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). All participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction. Participants who have prediabetes will be studied for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to detect potential differences in progression to T2DM.\n\nAbbreviations: QW = once weekly; T = telephone visit; T2DM = type 2 diabetes mellitus.\n\nNote: All participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction. Participants who have prediabetes will be studied for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to detect potential differences in progression to T2DM. The safety follow\u2011up visit will occur after 4 weeks in participants discontinuing (or completing) the study within the first 72 weeks. Those discontinuing (or completing) the study after 72 weeks will undergo safety follow\u2011up after 17 weeks.\n\nFigure GPHK.5.1. Illustration of study design for Clinical Protocol I8F-MC-GPHK. The details about the overview of study periods and study visits can be found in Study GPHK protocol Section 4. The detail of the unique visits not displayed in Figure GPHK.5.1 is provided below.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1864, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3c2fbe3d-e435-48ca-997e-dae5f44f321a": {"__data__": {"id_": "3c2fbe3d-e435-48ca-997e-dae5f44f321a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0b5e5c3c-5e57-4e9d-8385-8fd6f4d013f6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "410a0f72b180f52beaf0f2d8f3dfd634eb78efe81026e0ea659bbe386dc8ecd6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# Visit 99\n\nVisit 99 is only applicable to participants who discontinue the study treatment prematurely prior to Visit 21 (Week 72). Participants will be asked to return for Visit 99 at 72 weeks \u00b1 7 days after randomization. This visit is critical to ensure complete data collection for the primary weight\u2011loss endpoint.\n\nParticipants should attend this visit in the fasting state. Procedures to be completed include:\n\n- measurement of weight and waist circumference\n- concomitant medications\n- assessment of adverse events (AEs), and\n- completion of the mental health questionnaires (after the AE assessment).\n\n# Visit 199\n\nVisit 199 is only applicable to participants who discontinue the study treatment prematurely after Visit 21 (Week 72) and prior to Visit 116 (Week 176). Participants will be asked to return for Visit 199 at 176 weeks \u00b1 7 days after randomization. This visit is critical to ensure complete data collection for the weight\u2011loss and progression\u2011to\u2011diabetes endpoints.\n\nParticipants should attend this visit in the fasting state. Procedures to be completed include:\n\n- measurement of weight and waist circumference\n- concomitant medications\n- assessment of AEs\n- completion of the mental health questionnaires (after the AE assessment), and\n- 2\u2011hour oral glucose tolerance test (OGTT).\n\n# Early Discontinuation of Treatment Visit\n\nParticipants unable or unwilling to continue the study treatment for any reason will perform an early discontinuation of treatment (ED) visit at the visit when the participant informs the site about the study treatment discontinuation.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1646, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "56625ac9-558b-4206-bf57-53494d2fdd68": {"__data__": {"id_": "56625ac9-558b-4206-bf57-53494d2fdd68", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e17cfc69-74c7-4653-b900-1eedd06cca1f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fb03a297fb1b6ace1d249383fbb5abd5f93bc1272ddf66ced176fe479a8d1960", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6. A Priori Statistical Methods\n\n# 6.1. Populations for Analyses\n\nFor purposes of analyses, Table GPHK.6.1 defines the analysis sets.\n\n| Analysis Set                    | Description                                                                                                                                                        |\n| ------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------ |\n| Entered Participants            | All participants who sign informed consent                                                                                                                         |\n| Randomized Participants         | All participants who are randomly assigned a study treatment                                                                                                       |\n| Modified Intent\u2011to\u2011Treat (mITT) | All randomly assigned participants who are exposed to at least 1 dose of study drug. Participants will be included in the treatment group they were randomized to. |\n| Efficacy Analysis Set (EAS)     | Data obtained during treatment period from mITT, excluding data after discontinuation of study drug (last dose date + 7 days).                                     |\n| Full Analysis Set (FAS)         | Data obtained during treatment period from mITT, regardless of adherence to study drug.                                                                            |\n| Safety Analysis Set (SS)        | Data obtained during the treatment period plus safety follow\u2011up period from mITT, regardless of adherence to study drug.                                           |\n\n# 6.2. General Considerations\n\nStatistical analysis of this study will be the responsibility of Eli Lilly and Company (Lilly) or its designee. Some analyses and summaries described in this analysis plan may not be conducted if not warranted by data (eg, few events to justify conducting an analysis). Additional analyses of the data may be conducted as deemed appropriate.\n\nUnless otherwise noted, tests of treatment effects will be conducted at a 2\u2011sided alpha level of 0.05, and the confidence interval (CI) will be calculated at 95% 2\u2011sided.\n\nUnless specified otherwise, efficacy and safety will be assessed using the modified intention\u2011to\u2011treat (mITT) population, and data will be analyzed based on the randomized treatment (ie, not the actual treatment received by the participant). For submission of Study GPHK to the US Food and Drug Administration (FDA) to support the registration of tirzepatide for chronic weight management, the primary efficacy analysis will be conducted using Full Analysis Set (FAS). For other purposes, the efficacy analysis will be conducted using Efficacy Analysis Set (EAS). Safety analysis will be conducted using Safety Analysis Set (SS).\n\nSummary descriptive statistics for continuous measures will include sample size, mean, standard deviation (SD), median, minimum, and maximum. The analysis model to make comparisons among treatment groups relative to continuous measurements assessed over time will be either analysis of covariance (ANCOVA) or a mixed model for repeated measures (MMRM).\n\nKaplan\u2011Meier method will be used for estimation of cumulative event\u2011free survival rates over time, and Cox proportional hazards regression analysis will be used to compare hazards rates among treatments.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3529, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "90e6a5b8-445a-474f-be08-6490b55566b1": {"__data__": {"id_": "90e6a5b8-445a-474f-be08-6490b55566b1", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "911c1d1c-82dc-4e5c-bf18-d873eb296b56", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3e51707cef302e57d089ecaea6c35363b977e22530c994dd8c628d85a20c326b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 16\n\nSummary statistics for categorical measures (including categorized continuous measures) will include sample size, frequency, and percentages. Logistic regression will be used to examine the treatment difference in binary efficacy outcomes if there is a need to adjust for covariate. Otherwise, Fisher\u2019s exact test will be used to examine the treatment difference.\n\nSummary statistics for discrete count measures will include sample size, mean, SD, median, minimum, and maximum.\n\nUnless specified otherwise, baseline will be defined as the last available non\u2011missing measurement during Visit 1 to Visit 3. For the safety related parameters, the definition of baseline and postbaseline are specified in Table GPHK.6.2.\n\n| Analysis Set                                                                                        | Analysis Type                                                                                                       | Baseline                                                                                                                                                    | Postbaseline                                                                                                                 |\n| --------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------- |\n| SS                                                                                                  | 1.1) Treatment\u2011Emergent Adverse Events                                                                              | The baseline period is defined as the start of screening and ends prior to the first dose of study treatment (typically at Week 0).                         | Starts after the first dose of study treatment and ends at the end of the study period (including off\u2011drug follow up visit). |\n| 1.2) Treatment\u2011Emergent Abnormal Labsa, Vital Signs, and ECGs.                                      | Baseline will include all scheduled and unscheduled measurements during the baseline period as defined above (1.1). | Postbaseline will be defined as above (1.1). All scheduled and unscheduled measurements will be included.                                                   |                                                                                                                              |\n| 1.3) Change from Last Baseline to Week xx and to Last Postbaseline for Labsa,Vital Signs, and ECGs. | The last scheduled and unscheduled non\u2011missing assessment recorded during the baseline period defined above (1.1).  | Postbaseline will be defined as above (1.1). Only scheduled visits will be included. The early discontinuation (ED) visits are considered scheduled visits. |                                                                                                                              |\n\nAbbreviations: ECGs = electrocardiogram; SS = Safety Analysis Set.\n\na Immunogenicity related analysis is specified in Section 6.14.3.7.\n\nThere will be 2 estimands of interest in evaluating primary and key secondary efficacy objectives. The first estimand, the \u201cefficacy\u201d estimand, represents efficacy prior to discontinuation of study drug. Analysis relative to the \u201cefficacy\u201d estimand will be conducted using EAS. The second estimand, the \u201chybrid estimand\u201d, is the treatment difference between tirzepatide and placebo relative to efficacy measures at the endpoint visit in modified intent\u2011to\u2011treat population if participants could adhere to their assigned treatment.\n\nEnd of study participation for a participant will be the earliest of date of death, date of withdrawal from further participation in the study, or date of safety follow\u2011up visit (Visit 801 or Visit 802). For participants considered to be lost\u2011to\u2011follow\u2011up, end of study participation will be the date of lost\u2011to\u2011follow\u2011up reported by the investigator. Participant data included in the database after the last date of study participation (including safety follow\u2011up period) will be excluded from statistical analysis.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4505, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "59a70918-ef24-4f84-a25a-ec1c12867c54": {"__data__": {"id_": "59a70918-ef24-4f84-a25a-ec1c12867c54", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1eed5c54-a3c0-4d16-bb58-2c532bc9e63a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c21d5e2c4ca9b05f7473e886ed7000f448b22c2aee0909ceeb9c71a70783113f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nStatistical treatment comparisons will only be performed between tirzepatide and placebo. Since the trial is not adequately powered to detect difference among tirzepatide doses, comparisons among tirzepatide doses will not be performed unless otherwise specified.\n\nStatistical summaries and results of statistical analyses will be displayed in the following order: Placebo, tirzepatide 5 mg, tirzepatide 10 mg, tirzepatide 15 mg, and pooled tirzepatide (all doses combined, if necessary).\n\nNot all analyses described in this SAP will necessarily be included in the Clinical Study Reports (CSRs). Any analysis described in this SAP and not provided in the CSR would be available upon request. Not all displays will necessarily be created as a \u201cstatic\u201d display. Some may be incorporated into interactive display tools instead of or in addition to a static display.\n\n# 6.3. Adjustments for Covariates\n\nThe study is stratified by prediabetes status at randomization, country, and sex (female, male). Where necessary to be included as a stratification factor, countries with fewer than 10 randomized participants will be pooled into 1 category (pooled country).\n\nUnless otherwise specified, for efficacy related analyses at 72 weeks, country/pooled country, sex, prediabetes status at randomization and corresponding baseline value will be used as a covariate. For efficacy analyses at 176 weeks (or 193 weeks), country/pooled country, sex and corresponding baseline value will be used as a covariate.\n\n# 6.4. Handling of Dropouts or Missing Data\n\nFor the primary and key secondary efficacy endpoint analyses subject to type 1 error rate control, data for participants with missing values at the 72\u2011week visit (or weight related measurements at 176\u2011week visit for participants with prediabetes at randomization) will be imputed based on the method described in Section 6.13.1.3. Otherwise, missing values will not be explicitly imputed except for the parameters with only 1 postbaseline measure during the analysis period per schedule of activity, where last observation carried forward (LOCF) approach will be applied to impute the endpoint when ED measure is available.\n\n# 6.5. Multicenter Studies\n\nThe randomization will be stratified by country, and the country/pooled country will be used as a covariate.\n\n# 6.6. Multiple Comparisons/Multiplicity\n\nThe type 1 error rate control strategy for primary and key secondary efficacy objectives is illustrated in Section 6.13.3. Both \u201cefficacy\u201d estimand and \u201chybrid\u201d estimand will be used to assess those objectives. As they are intended for different purposes, no multiplicity adjustments will be made for conducting separate analyses relative to the \u201cefficacy\u201d and \u201chybrid\u201d estimands. In addition, no multiplicity adjustments will be made for evaluating other secondary and exploratory objectives, and safety assessments.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2925, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fa4f0f0e-fb62-44e2-a460-84c4b24c95a3": {"__data__": {"id_": "fa4f0f0e-fb62-44e2-a460-84c4b24c95a3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "03835053-efc3-4ed1-9212-ce8c2945d488", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6d0911609c11152148e81f736673b7035baddf08fbb29db524267c175c256a89", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.7. Patient Disposition\n\nA listing of study disposition for all randomized participants will be provided at the primary database lock and final database lock, respectively. Summaries of study disposition and study drug disposition for all randomized participants will be provided by planned study treatment at the primary database lock (after 72\u2011week treatment). In addition, similar summaries might be provided for participants without prediabetes at randomization at the primary database lock. Same summaries will be provided for randomized participants with prediabetes at randomization at final lock (after 176\u2011week treatment).\n\nThe study completion status is defined as\n\n- at the end of 72\u2011week treatment period (when the primary endpoint is ascertained and primary database is locked). For participants without prediabetes at randomization, participants with a nonmissing body weight measurement at 72\u2011week (Visit 21 or Visit 99) and nonmissing safety follow\u2011up visit (Visit 801) will be considered as completers; for participants with prediabetes at randomization, participants with a nonmissing body weight measurement at 72\u2011week (Visit 21 or Visit 99) will be considered as completers; otherwise, will be considered as non\u2011completers.\n- at the end of 176\u2011week treatment period for participants with prediabetes at randomization, participants with a non\u2011missing body weight measurement at 176\u2011week (Visit 116 or Visit 199) and nonmissing safety follow\u2011up visit (Visit 802) will be considered as completers; otherwise, will be considered as non\u2011completers.\n\n# 6.8. Historical Illnesses and Preexisting Conditions\n\nThe count and percentages of participants with historical illnesses and preexisting conditions will be summarized by treatment group using the Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term (PTs) nested within System Organ Class (SOC). The SOC will be in alphabetical order. Conditions (ie, PTs) will be ordered by decreasing frequency within SOC. This will be summarized for all randomized participants.\n\n# 6.9. Patient Characteristics\n\nA listing of participant demographics for all randomized participants will be provided. All demographic and baseline clinical characteristics will be summarized by study treatment for all randomized participants. Baseline demographic and clinical characteristics of special interest include but are not limited to: age (years), sex (female, male), race, ethnicity, height (cm), weight (kg), BMI (kg/m\u00b2), waist circumference (cm), age group (&#x3C;65 years, \u226565 years), BMI group (&#x3C;30, \u226530 and &#x3C;35, \u226535 and &#x3C;40, \u226540 kg/m\u00b2), country, weight\u2011related comorbidities. In addition, similar demographics and baseline characteristics might be provided by study treatment by glycemic status (prediabetes and normoglycemia) at randomization.\n\nAll participants without laboratory tests suggestive of diabetes will be classified as having either normoglycemia or prediabetes. Populations are defined in Table GPHK.6.3.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3064, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "52c48bbb-aef7-499d-84ad-9d9199305f3e": {"__data__": {"id_": "52c48bbb-aef7-499d-84ad-9d9199305f3e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "13eaa2aa-3e37-41c2-a904-141605e09909", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "af94b5f3952bbedc90f97add7426ac3bbee75384eb7def43105fd83d03dd75bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# Table GPHK.6.3. Classification of Glycemic Status\n\n|                                              | Normoglycemia            | Prediabetes                     | Diabetes                  |\n| -------------------------------------------- | ------------------------ | ------------------------------- | ------------------------- |\n| Fasting glucose                              | <100 mg/dL (<5.6 mmol/L) | 100\u2011125 mg/dL (5.6\u20116.9 mmol/L)  | \u2265126 mg/dL (\u22657.0 mmol/L)  |\n| Obtained alone or at time = 0 during an OGTT |                          |                                 |                           |\n| 2H glucose                                   | <140 mg/dL (<7.8 mmol/L) | 140\u2011199 mg/dL (7.8\u201111.0 mmol/L) | \u2265200 mg/dL (\u226511.1 mmol/L) |\n| Obtained at time = 120 min during an OGTT    |                          |                                 |                           |\n| HbA1c                                        | <5.7% (<39 mmol/mol)     | 5.7%\u20116.4% (39\u201147 mmol/mol)      | \u22656.5% (\u226548 mmol/mol)      |\n\nAbbreviations: HbA1c = hemoglobin A1c; min = minute; OGTT = 2\u2011hour oral glucose tolerance test.\n\nIn keeping with American Diabetes Association guidelines (ADA 2019a), at least 2 abnormal tests are required to diagnose prediabetes. Specifically, participants meeting 1 of the following criteria will be categorized as prediabetes:\n\n- Both fasting glucose (FG; 0 hour of OGTT) and 2\u2011hour values during the 2\u2011hour OGTT values are in the prediabetes range, which is 100 to 125 mg/dL (5.6 to 6.9 mmol/L) and 140 mg to 199 mg/dL (7.8 to 11.0 mmol/L) for FG and 2\u2011hour OGTT, respectively.\n- FG at Screening Visit 1 and Visit 2 (0 hour of OGTT) are in the prediabetes range.\n- FG at Screening Visit 1 and 2\u2011hour values during 2\u2011hour OGTT are in the prediabetes range.\n- HbA1c AND 1 of either the FG (Visit 1 or Visit 2) or 2\u2011hour OGTT values are in the prediabetes range. For HbA1c, the prediabetes range is 5.7% to 6.4% (39 to 47 mmol/mol).\n- Any 2 of HbA1c values between Visit 1 and Visit 3 including unscheduled visits are in the prediabetes range.\n\n# 6.10. Concomitant Therapy\n\nConcomitant medication will be summarized by PTs by treatment group by decreasing frequency for SS group. The following 2 postbaseline periods will be considered, respectively:\n\n- up to 72 weeks plus safety follow\u2011up (Visit 801) for all randomized participants, and\n- up to 176 weeks plus safety follow\u2011up (Visit 801 or Visit 802) for participants with prediabetes at randomization.\n\nAdditionally, medications of interest (as defined below) will be summarized by treatment for SS. Concomitant medications of interest include the following:\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2695, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ebe56182-5f1b-4ab5-9b2a-7f58728c899e": {"__data__": {"id_": "ebe56182-5f1b-4ab5-9b2a-7f58728c899e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7cbda0ab-1a95-41f6-bd72-e02f66302aa0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cea0db8b208f1082850b14b80ad250cc33fa30b3852fc2cd51fb12431ede8c3d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.11. Treatment Exposure and Compliance\n\n# 6.11.1. Study and Study Treatment Exposure\n\nSummary of duration of follow\u2011up (defined as time in days from date of randomization to the date of the last study visit) and/or duration on study treatment (defined as time in days from date of first dose of study treatment to date of last dose of study treatment plus 7 days) will be provided by treatment group using data from SS, in the following 2 periods:\n\n- 72 weeks plus safety follow\u2011up (Visit 801) for all randomized participants.\n- 176 weeks plus the safety follow\u2011up periods (Visit 801 or Visit 802) for participants with prediabetes at randomization.\n\nFor the summary of duration on study treatment, the frequency and percentage of participants falling into the following range will be summarized by planned treatment group as well:\n\n- >0\n- \u22654 weeks\n- \u22658 weeks\n- \u226512 weeks\n- \u226516 weeks\n- \u226520 weeks\n- \u226524 weeks\n- \u226536 weeks\n- \u226548 weeks\n- \u226552 weeks\n- \u226572 weeks\n- \u226598 weeks\n- \u2265124 weeks\n- \u2265150 weeks, and", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1050, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f64f2099-50c5-4618-a81e-addcf249f0f6": {"__data__": {"id_": "f64f2099-50c5-4618-a81e-addcf249f0f6", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c9826e26-5728-4ba4-bb52-0a248552d1da", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cd039dda6dc073bbc7f27d3f184f79b9948562940dde178d058c13522e4f14e5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nPage 21\n\n\u2022  \u2265176 weeks.\n\nIn addition, the frequency and percentages of participants falling into the following study treatment exposure ranges may be summarized by planned treatment group:\n\n- 0 weeks\n- >0 to &#x3C;4 weeks\n- >=4 to &#x3C;8 weeks\n- >=8 to &#x3C;16 weeks\n- >=16 to &#x3C;24 weeks\n- >=24 to &#x3C;36 weeks\n- >=36 to &#x3C;48 weeks\n- >=48 to &#x3C;52 weeks\n- >=52 to &#x3C;72 weeks\n- >=72 to &#x3C;98 weeks (for participants with prediabetes at randomization)\n- >=98 to &#x3C;124 weeks (for participants with prediabetes at randomization)\n- >=124 to &#x3C;150 weeks (for participants with prediabetes at randomization)\n- >=150 to &#x3C;176 weeks (for participants with prediabetes at randomization), and\n- >=176 (for participants with prediabetes at randomization).\n\nNo p\u2011values will be reported in these summaries as they are intended to describe the study populations rather than test hypotheses about them.\n\n# 6.11.2. Compliance to Study Treatment\n\nSummary of prematurely discontinuing study treatment (including discontinuation reason) will be provided by study treatment. A time\u2011to\u2011event analysis of premature study treatment discontinuation will also be conducted.\n\nThe analyses related to compliance will be conducted for the following 2 periods separately:\n\n- during the 72\u2011week treatment period for all randomized participants, and\n- during the 176\u2011week treatment period for participants with prediabetes at randomization.\n\nIf data warrants, the counts and percentages of participants who follow the planned escalation scheme, have dose interruption, or have dose de\u2011escalation will be summarized for each treatment group. In addition, the proportion of participants receiving 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg may be presented by randomized treatment and visit during the dose escalation period.\n\nTreatment compliance will be defined as taking at least 75% of the scheduled tirzepatide doses. Compliance at each treatment visit and over the corresponding study period will be calculated using the number of doses administered (regardless of the actual dose in mg administered) divided by the total number of doses expected to be administered \u00d7100 at the specific visit or over the corresponding study period, respectively. Treatment compliance will be summarized descriptively at each treatment visit and over the corresponding study period by treatment using the mITT population.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2475, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "595c37d1-ddf5-4a1d-af28-571741604d8f": {"__data__": {"id_": "595c37d1-ddf5-4a1d-af28-571741604d8f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "678b4bba-729b-419d-88f8-23c62b64ae9d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "047bfc01a04971721692963dfb0b6fb756c0ce6cca1f3c005d99a2fbd4be8d26", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# 6.12. Important Protocol Deviations\n\nImportant protocol deviations are identified in the Trial Issues Management Plan (TIMP). A listing and a summary of important protocol deviations by treatment will be provided at the end of 72 weeks treatment (for all randomized participants) and at the end of the study (for participants with prediabetes at randomization).\n\n# 6.13. Efficacy Analyses\n\nFor submission of Study GPHK to the US FDA to support the registration of tirzepatide for chronic weight management, all primary and key secondary efficacy assessments will be guided by the \u201chybrid\u201d estimand conducted using the FAS. Assessment of the primary and key secondary objectives (except for endpoint \u201cdelaying the onset of diabetes during 176 weeks or 193 weeks [for participants with prediabetes at randomization]\u201d) will be conducted with multiple imputation of missing data (see Section 6.13.1.3).\n\nFor other regulatory agencies, publications and other purposes, the assessment of efficacy objectives will be guided by the \u201cefficacy\u201d estimand using the EAS.\n\n# 6.13.1. Primary Efficacy Analysis\n\nThe primary efficacy measure will be percent change in body weight from randomization and percentage of participants who achieve \u22655% body weight reduction at 72 weeks. The percent change in body weight at each nominal visit is defined as:\n\n(postbaseline body weight [kg] \u2013 baseline body weight [kg]) / baseline body weight [kg] * 100%.\n\nBoth percent change in body weight and percentage of participants who achieve \u22655% body weight reduction will be summarized by treatment and nominal visit (week) from randomization to 72 weeks.\n\n# 6.13.1.1. Analysis Related to the Efficacy Estimand\n\nThe analysis related to efficacy estimand will be conducted utilizing data in the EAS. For the mean percent body weight change from randomization, a MMRM will be conducted. Restricted maximum likelihood (REML) will be used to obtain model parameter estimates and the Kenward\u2011Roger option will be used to estimate the denominator degrees of freedom. The response variable of MMRM will be the percent change in body weight from baseline values obtained at each scheduled post baseline visit.\n\nFor the percentage of participants achieving at least 5% body weight reduction from randomization over time, a longitudinal logistic regression model will be used with the response variable of the percentage of participants achieving at least 5% body weight reduction at each scheduled postbaseline visit.\n\nFor both models (MMRM and longitudinal logistic regression model), the independent variables of analysis model is treatment group, visit, treatment\u2011by\u2011visit interaction, stratification factors (prediabetes status at randomization, sex and country/pooled country) as fixed effects, and baseline body weight as a covariate. An unstructured covariance structure will model.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2903, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "aa10f33f-8b2a-4498-9e78-402d5806be1a": {"__data__": {"id_": "aa10f33f-8b2a-4498-9e78-402d5806be1a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e6086451-a606-4296-981e-a3f5865ccb76", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "127d04b7f9afeff49888bd6188a626778bba74cc0a4efa2a137b9be673f4410e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nrelationship of within\u2011patient errors. If this model fails to converge, the following variance covariance structures will be tested in order until convergence is achieved:\n\n- heterogeneous Toeplitz\n- heterogeneous first order autoregressive\n- heterogeneous compound symmetry\n- Toeplitz\n- first order autoregressive, and\n- compound symmetry.\n\nThe first covariance structure that converges will be used.\n\nWith the aid of the MMRM analysis, 2\u2011sided 95% CIs for mean percent change in body weight from randomization to the 72\u2011week visit for tirzepatide 10 mg and 15 mg compared to placebo will be derived and summarized. The resulting least squares mean (LSM) estimates of mean percent change in body weight from baseline will be plotted by visit and by study treatment.\n\nWith the aid of the longitudinal logistic regression model, 2\u2011sided 95% CI and odds ratio relative to placebo for percentage of participants achieving at least 5% body weight reduction from randomization to the 72\u2011week visit for tirzepatide 10 mg and 15 mg compared to placebo will be summarized. The estimated proportion of participants with at least 5% body weight reduction will be plotted by visit and by study treatment.\n\n# 6.13.1.2. Analysis Related to the Hybrid Estimand\n\nThe analysis related to \u201chybrid\u201d estimand will be conducted using data in the FAS. The analysis for the mean percent change in body weight will be conducted utilizing ANCOVA. The response variable for the ANCOVA model will be percent change in body weight from randomization at 72 weeks. A logistic regression model will be used for the analysis of the percentage of participants achieving at least 5% body weight reduction obtained at the 72\u2011week visit. Both models will include terms of treatment group, country/pooled country, sex, and prediabetes status at randomization as fixed effects and baseline body weight as a covariate. The ANCOVA analysis will be conducted with multiple imputation of missing body weight at 72 weeks (see Section 6.13.1.3 for details) and statistical inference over multiple imputation of missing data guided by Rubin (1987). As for the logistic regression, missing body weight data at 72 weeks will be imputed first based on Section 6.13.1.3, then the continuous measurements will be categorized into status of achieving at least 5% body weight reduction (Yes or No).\n\nWith the aid of the ANCOVA model, 2\u2011sided 95% CI for mean change in percent body weight from baseline to the 72\u2011week visit between tirzepatide 10 mg and placebo, as well as tirzepatide 15 mg and placebo will be derived.\n\nWith the aid of the logistic regression model, 2\u2011sided 95% CI and odds ratio for percentage of participants achieving at least 5% body weight reduction from baseline to the 72\u2011week visit between tirzepatide 10 mg and placebo, as well as tirzepatide 15 mg and placebo will be derived.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2902, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9cf21bbb-0ed2-4a9c-a750-9dd42334fa17": {"__data__": {"id_": "9cf21bbb-0ed2-4a9c-a750-9dd42334fa17", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "745e20b2-a3b7-48d0-b9ca-4b1fc6b3261a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a2efa43dd34363aead6351903aabb902eb7668a339778d3e986074e6ae15fdd2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.13.1.3. Methods for Multiple Imputations\n\nFor efficacy analyses relative to \u201chybrid\u201d estimand, the intercurrent events (ICEs) and the resulting missing values will be handled as follows:\n\n- Category 1: for ICEs of treatment discontinuation due to AE or death, considers that these participants could not adhere to their assigned treatment and may not benefit from the assigned treatment.\n- If the primary outcome measure is collected, assumes the treatment effect is generally washed out (between the treatment discontinuation to the primary outcome measurement), and the measurement after ICE reflects \u201cno treatment benefit.\u201d Therefore, the primary outcome measure collected after ICE will be used in the primary analysis.\n- If the primary outcome measure is not collected, will use data from participants who discontinue due to AE, but with non\u2011missing primary outcome measures from the same treatment arm to impute the missing value (retrieved dropout imputation). In cases where there are not enough retrieved dropouts to provide a reliable imputation model, will impute the missing data with reference to the placebo arm.\n- Category 2: for missing data specified in the situations listed in bullets below, considers the missing data as missing at random. The missing data will be imputed using all nonmissing data (excluding data collected after ICEs) of the primary outcome measurement from the same treatment arm.\n- Primary endpoint measurement is not collected for participants without ICEs.\n- Primary endpoint measurement is not collected for participants with ICEs due to reasons other than AE or death.\n- For ICEs of treatment discontinuation due to reasons other than AEs or death, Lilly is interested in any treatment benefits if the participants could adhere to the treatment. Thus, the primary endpoint measurement collected after these ICEs will be set to missing.\n\n# 6.13.1.4. Sensitivity Analysis Related to the Treatment Regimen Estimand\n\nFor submission of Study GPHK to the US FDA to support the registration of tirzepatide for chronic weight management, additional sensitivity analyses of the primary efficacy outcomes will be conducted using the FAS and guided by the \u201ctreatment\u2011regimen\u201d estimand, which represents the efficacy irrespective of adherence to study drug. This assessment will analyze percent change in body weight obtained at the 72\u2011week visit using an ANCOVA and the percentage of participants achieving at least 5% body weight reduction obtained at the 72\u2011week visit using a logistic regression model. The terms for both models will be the same as specified in Section 6.13.1.2 for \u201chybrid\u201d estimand.\n\nMissing values of change in body weight at the 72\u2011week visit will be imputed based on observed body weight change from baseline values at the visit from participants in the same treatment group who had their efficacy assessed after early discontinuation of study drug. In cases where there are not enough retrieved dropouts to provide a reliable imputation model (for example, the", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3073, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "661c1bd0-f5d5-4eb8-a712-558c54eb69d4": {"__data__": {"id_": "661c1bd0-f5d5-4eb8-a712-558c54eb69d4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "982c64d8-51b7-4fc6-bd33-a6738b73b6f5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d8ab26e97273c5ffd59a5693adcfada57e99870c3604a4b5d32519444eb3512b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\nmodel implemented by the SAS program does not converge), an alternative multiple imputation method with reference to the placebo group (placebo multiple imputation) will be used. Analysis will be conducted with multiple imputations.\n\n# 6.13.2. Secondary Efficacy Analyses Subject to Type 1 Error Rate Control\n\n| Objectives                                                       | Relative to the efficacy measure:                                                                                                            | Analysis conducted in a manner similar to                                                                                                                                | Additional Information                                                                                                                                     |\n| ---------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Tirzepatide 5 mg, 10 mg, and/or 15 mg QW is superior to placebo: | Mean change in body weight (kg) from randomization at 20 weeks                                                                               | MMRM model in Section 6.13.1.1 for efficacy estimand and ANCOVA model in Section 6.13.1.2 for hybrid estimand                                                            |                                                                                                                                                            |\n| Tirzepatide 5 mg is superior to placebo:                         | Mean percent change in body weight from randomization and percentage of participants achieving at least 5% body weight reduction at 72 weeks | Section 6.13.1.1 for efficacy estimand and Section 6.13.1.2 for hybrid estimand                                                                                          |                                                                                                                                                            |\n| Tirzepatide 10 mg and/or 15 mg is superior to placebo:           | Percentage of participants achieving body weight reduction \u226510% (and \u226515%) at 72 weeks                                                       | longitudinal logistic model in Section 6.13.1.1 for efficacy estimand and logistic model in Section 6.13.1.2 for hybrid estimand                                         |                                                                                                                                                            |\n|                                                                  | Mean change in waist circumference (cm) from randomization at 72 weeks                                                                       | MMRM model in Section 6.13.1.1 for efficacy estimand and ANCOVA model in Section 6.13.1.2 for hybrid estimand                                                            | LSM estimates will be plotted by treatment through 72\u2011weeks.                                                                                               |\n|                                                                  | Mean change in SF\u201136 acute form Physical Functioning domain score from randomization at 72 weeks                                             | ANCOVA model with the terms of treatment group, stratification factors as fixed effects, and baseline SF\u201136 acute form Physical Functioning domain score as a covariate. | For efficacy estimand, missing data will be imputed based on LOCF method. For hybrid estimand, missing data for will be imputed based on Section 6.13.1.3. |\n| Tirzepatide (all doses combined) is superior to placebo:         | Mean change in triglycerides, LDL\u2011C, total cholesterol, SBP and fasting insulin from randomization at 72 weeks                               | MMRM model in Section 6.13.1.1 for efficacy estimand and ANCOVA model in Section 6.13.1.2 for hybrid estimand                                                            | For hybrid estimand, missing data will be imputed first for each treatment based on Section 6.13.1.3, then combine all tirzepatide doses.                  |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4690, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "814152fb-00e5-4fc2-8cdd-7af6f5904a82": {"__data__": {"id_": "814152fb-00e5-4fc2-8cdd-7af6f5904a82", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "156468a8-a720-40de-b2d2-e6367caf47dc", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1193cf7d16be81666363d5a806e2bdf88a616ce0d630fb24eb018345daff494f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# Page 26\n\n# Secondary Measures Controlled for Type 1 Error\n\n| Objectives                                               | Relative to the efficacy measure:                                                                                       | Analysis conducted in a manner similar to                                                                                                                                                                        | Additional Information                                                                                                                           |\n| -------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------ |\n| Tirzepatide 10 mg, and/or 15 mg is superior to placebo:  | Mean percent change in body weight from randomization at 176 weeks (for participants with prediabetes at randomization) | MMRM model in Section 6.13.1.1 for efficacy estimand and ANCOVA model in Section 6.13.1.2 for hybrid estimand. Include country, sex as stratification factors in each model.                                     | Only for participants with prediabetes at baseline. For the hybrid estimand, missing data at 176 week will be imputed based on Section 6.13.1.3. |\n| Tirzepatide (all doses combined) is superior to placebo: | Time to onset of T2DM during 176 weeks (or during 193 weeks) for participants with prediabetes at randomization         | Cox\u2011proportional hazards model will be used with the terms of treatment group (all tirzepatide doses combined and placebo), country and sex as fixed effects, and baseline fasting glucose value as a covariate. | Only for participants with prediabetes at baseline.                                                                                              |\n\nAbbreviations: ANCOVA = analysis of covariance; LDL\u2011C = low\u2011density lipoprotein cholesterol; LOCF = last observation carried forward; LSM = least squares mean; MMRM = mixed model for repeated measures; QW = once\u2011weekly; SBP = systolic blood pressure; SF\u201136 = Short Form \u201136 version 2 Health Survey; T2DM = type 2 diabetes mellitus.\n\nDecision will be guided by the 2\u2011sided p\u2011values in each objective, and details will be included in Section 6.13.3.\n\n# 6.13.3. Type 1 Error Rate Control Strategy for Primary and Key Secondary Efficacy Analyses\n\nSince they are intended for different purposes, no type 1 error rate adjustments will be made for conducting analyses relative to \u201cefficacy\u201d estimand and \u201chybrid\u201d estimand. The details of type I error control strategy will be provided before primary database lock (in a later version of the SAP).\n\n# 6.13.4. Other Secondary and Exploratory Efficacy Analyses\n\nUnless otherwise specified, other secondary and exploratory efficacy analyses will be conducted for EAS. Missing data will be imputed using LOCF or handled through MMRM without utilizing multiple imputation technique.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3405, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6e5176bb-1a87-42e4-87d8-36baa97f2449": {"__data__": {"id_": "6e5176bb-1a87-42e4-87d8-36baa97f2449", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ad5a96e3-03fe-441b-9c9c-8a93bf854db0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b26cda5448aa6e7ae050d532035e837ddbdea257cf8b63cb1b254aec0604e154", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.13.4.1. Other Secondary Efficacy Analyses\n\n| Objective                                                                   | Relative to the efficacy measure:                                                                     | Analysis conducted in a manner similar to:      | Additional Information                                                                                                                               |\n| --------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------- | ----------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------- |\n| tirzepatide 5 mg QW is superior to placebo at 72 weeks:                     | Percentage of participants achieving \u226510% (and \u226515%) body weight reduction from randomization         | longitudinal logistic model in Section 6.13.1.1 | None                                                                                                                                                 |\n|                                                                             | Change in waist circumference (cm) from randomization                                                 | MMRM model in Section 6.13.1.1                  | Use baseline waist circumference as a covariate.                                                                                                     |\n|                                                                             | Change in SF\u201136 v2 acute form Physical Functioning domain (PF) score from randomization               | ANCOVA model                                    | with terms of treatment, stratification factors, and baseline SF\u201136v2 PF score as a covariate. Missing data will be imputed using LOCF.              |\n| tirzepatide 5 mg, 10 mg and/or 15 mg QW is superior to placebo at 72 weeks: | Mean change in body weight (kg) from randomization                                                    | MMRM model in Section 6.13.1.1                  | LSM estimates through 72 weeks will be plotted by study treatment.                                                                                   |\n|                                                                             | Mean change in BMI (kg/m\u00b2) from randomization                                                         | MMRM model in Section 6.13.1.1                  | Use baseline BMI (kg/m\u00b2) as a covariate. LSM estimates through 72 weeks will be plotted by study treatment.                                          |\n|                                                                             | Mean change in HbA1c (%, mmol/mol) from randomization                                                 | MMRM model in Section 6.13.1.1                  | Use baseline HbA1c (%, mmol/mol) as a covariate. LSM estimates through 72 weeks will be plotted by study treatment.                                  |\n|                                                                             | Mean change in fasting glucose (mg/dL) from randomization                                             | MMRM model in Section 6.13.1.1                  | Use baseline fasting glucose as a covariate. LSM estimates through 72 weeks will be plotted by study treatment.                                      |\n|                                                                             | Mean change in IWQOL\u2011Lite\u2011CT Physical Function composite (PF) score from randomization                | ANCOVA model                                    | with terms of treatment, stratification factors, and baseline IWQOL\u2011Lite CT PF score as a covariate. Missing data will be imputed using LOCF method. |\n| Tirzepatide QW (all doses combined) is superior to placebo at 72 weeks      | Mean change in DBP (mmHg), HDL\u2011C (mg/dL), VLDL\u2011C (mg/dL), free fatty acids (mg/dL) from randomization | MMRM model in Section 6.13.1.1                  | All tirzepatide doses will be pooled together. LSM estimates through 72 weeks will be plotted by study treatment.                                    |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4341, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "587ed59d-a511-4073-a76d-9644dddb7bac": {"__data__": {"id_": "587ed59d-a511-4073-a76d-9644dddb7bac", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4f131185-fe75-4d19-b1ff-6284067ec09e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d30a07db31d29dd2568dcf764d2ac1f6885c38ababcd9c316f11c45d0f19bd0d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# Secondary Measures Not Controlled for Type 1 Error\n\n| Objective                                                                                                                         | Relative to the efficacy measure:                                                           | Analysis conducted in a manner similar to:      | Additional Information                                                                                                                                                                                                                          |\n| --------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------- | ----------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| Tirzepatide 5 mg QW (for participants with prediabetes at randomization) is superior to placebo at 176 weeks                      | Mean percent change in body weight from randomization                                       | MMRM model in Section 6.13.1.1                  | Only for participants with prediabetes at randomization in the EAS. Model terms will include treatment group, visit, and treatment\u2011by\u2011visit interaction, country/pooled country, sex as fixed effects, and baseline body weight as a covariate. |\n| Tirzepatide 5 mg, 10 mg, and/or 15 mg QW is superior to placebo (for participants with prediabetes at randomization) at 176 weeks | Percentage of participants achieving \u22655% body weight reduction from randomization           | longitudinal logistic model in Section 6.13.1.1 | same as above                                                                                                                                                                                                                                   |\n| tirzepatide (all doses combined) is superior to placebo (for participants with prediabetes at randomization) at 176 weeks:        | Mean change in SF\u201136v2 acute form physical functioning domain (PF) score from randomization | MMRM model in Section 6.13.1.1                  | same as above but using baseline SF\u201136 v2 acute PF score as a covariate.                                                                                                                                                                        |\n|                                                                                                                                   | Mean change in IWQOL\u2011Lite\u2011CT Physical function composite (PF) score from randomization      | MMRM model in Section 6.13.1.1                  | Similar to above but using baseline IWQOL\u2011Lite\u2011CT PF score as a covariate.                                                                                                                                                                      |\n\nAbbreviations: BMI = body mass index; DBP = diastolic blood pressure; HbA1c = hemoglobin A1c; HDL\u2011C = high\u2011density lipoprotein cholesterol; IWQOL\u2011Lite\u2011CT = Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version; LDL = low\u2011density lipoprotein; LOCF = last observation carried forward; LSM = least squares mean; MMRM = mixed model for repeated measures; QW = once\u2011weekly; SF\u201136v2 = Short Form 36 version 2 Health Survey; VLDL\u2011C = very low\u2011density lipoprotein cholesterol.\n\n# 6.13.4.2. Exploratory Efficacy Analyses\n\n| Objective                                                              | Relative to the efficacy measure:                                                                                                                                                                                 | Analysis Conducted                                       |\n| ---------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------- |\n| compare tirzepatide 5 mg, 10 mg, and/or 15 mg with placebo at 72 weeks | Percentage of participants achieving \u226520% and 25% body weight reduction from randomization                                                                                                                        | Longitudinal logistic model in Section 6.13.1.1          |\n| Compare tirzepatide 5 mg, 10 mg, and/or 15 mg with placebo at 72 weeks | Percentage of participants whose BMI shifts between clinically relevant categories, ie, from baseline (<25, 25 to <30, 30 to < 35, 35 to < 40, \u226540) to postbaseline (<25, 25 to <30, 30 to < 35, 35 to < 40, \u226540) | Shift analysis will be conducted based on data from EAS. |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 5142, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f393c084-ea00-4e75-9cf3-14cfdae2677c": {"__data__": {"id_": "f393c084-ea00-4e75-9cf3-14cfdae2677c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fc27cb4a-d82b-442d-94af-57c6746d7313", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "267c6f72e563cf1b9868e19b86e5aef0321ea6cea17caacfb6a6f0468febe436", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 29. Exploratory Efficacy Analysis\n\n| Objective                                                                                                                                       | Relative to the efficacy measure:                                                                                                                                                                                                                                                                        | Analysis Conducted                                                                                                    |\n| ----------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------- |\n| compare tirzepatide 5 mg, 10 mg and/or 15 mg with placebo at 176 weeks                                                                          | Same as above                                                                                                                                                                                                                                                                                            | Shift analysis will be conducted for the participants with prediabetes at randomization from EAS.                     |\n| visualize tirzepatide 5 mg, 10 mg and/or 15 mg with placebo percent weight loss change from randomization up to safety follow-up after 72 weeks | Percent body weight loss measured at postbaseline from randomization to 72 weeks plus 4 weeks safety follow-up                                                                                                                                                                                           | Only the participants who complete the 72 weeks treatment and have the safety follow-up (Visit 801) will be included. |\n| compare tirzepatide QW (all dose combined) with placebo at 72 weeks                                                                             | Percentage of participants change in glycemic category, ie, from baseline (normoglycemia, prediabetes, T2DM) to postbaseline (normoglycemia, prediabetes, T2DM)                                                                                                                                          | Shift analysis will be conducted based on data from EAS.                                                              |\n| compare tirzepatide QW (all dose combined) with placebo at 176 weeks                                                                            | Same as above                                                                                                                                                                                                                                                                                            | Shift analysis will be conducted for the participants with prediabetes at randomization from EAS.                     |\n| compare tirzepatide QW (all doses combined) to placebo (for participants with prediabetes at randomization) at 176 weeks:                       | * SF\u201136acute form Role\u2011Emotional domain (RE)\n* SF\u201136acute form Mental Health domain (MH)\n* IWQOL\u2011Lite\u2011CT total score\n* IWQOL\u2011Lite\u2011CT Physical composite score\n* IWQOL\u2011Lite\u2011CT Pain/Discomfort composite score\n* IWQOL\u2011Lite\u2011CT Psychosocial composite score\n* EQ\u20115D\u20115L utility score\n* EQ\u20115D\u20115L VAS score |                                                                                                                       |\n\nAbbreviations: BMI = body mass index; EAS = Efficacy Analysis Set; IWQOL\u2011Lite\u2011CT = Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version; MMRM = mixed model for repeated measures; QW = once weekly; T2DM = type 2 diabetes mellitus; VAS = Visual Analog Scale.\n\n# 6.14. Safety Analyses\n\nUnless specified otherwise, safety assessments will be based on the SS (Table GPHK.6.1). All events that occur between the first dose date of study drug and the end date of study participation will be included, regardless of the adherence to study drug.\n\nThe statistical assessment of homogeneity of the distribution of categorical safety responses between tirzepatide doses and placebo will be conducted using Fisher\u2019s exact test, unless specified otherwise.\n\nThe mean change from baseline differences among treatments at all scheduled visits will be assessed via an MMRM using REML. Unless specified otherwise, if the safety parameter is assessed at the 72 weeks, then the model will include country/pooled country, sex, prediabetes.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 5097, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "37da712f-104d-4bca-b23b-3dd0fbdba72f": {"__data__": {"id_": "37da712f-104d-4bca-b23b-3dd0fbdba72f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "de97da0f-d5f7-4be7-9409-8ff225902ab3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7c1f2fcfb0148353a5036760fa90ed691c6df7df2602b8fc5417fbd2bc02731e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nstatus at randomization, treatment group, visit and treatment\u2011by\u2011visit interaction as fixed effects, and baseline value of the safety parameter as a covariate. If the safety parameter is assessed at the 176 weeks (or 193 weeks), only participants with prediabetes at randomization in the SS will be included, and the model will contain the terms of country/pooled country, sex, treatment group, visit and treatment\u2011by\u2011visit interaction as fixed effects, and baseline value of the safety parameter as a covariate. To model the covariance structure within participants, the unstructured covariance matrix will be used. If this model fails to converge, the covariance structures specified in Section 6.13.1.1 will be tested in order until met convergence. If the data does not warrant the MMRM model, then ANCOVA model will be conducted.\n\nFor selected safety parameters, time\u2011to\u2011first\u2011event analysis via the Cox\u2011proportional hazards model may be conducted. Participants without the event will be censored at the end of study participation. For participants experiencing the event, the \u201ctime\u2011to\u2011first\u2011event\u201d will be the time (in days) from first dose to first occurrence of the event.\n\nWhere necessary, the rate of events will be analyzed using a generalized linear mixed\u2011effects model assuming the number of events follow a negative binomial distribution and with treatment as a fixed effect. The logarithm of days during the active treatment period will be adjusted as an offset to account for possible unequal treatment duration of follow\u2011up between participants.\n\nUnless otherwise specified, all the analyses listed in this section will be conducted using SS in the following 2 postbaseline periods, respectively:\n\n- p to 72 weeks treatment period plus the safety follow\u2011up (Visit 801) for all randomized participants, and\n- up to 176 weeks treatment period plus the safety follow\u2011up (Visit 801 or Visit 802) for participants with prediabetes at randomization.\n\n# 6.14.1. Analysis of Adverse Events\n\n# 6.14.1.1. Treatment Emergent Adverse Events\n\nA treatment\u2011emergent adverse event (TEAE) is defined as an event that first occurred or worsened in severity after baseline. The MedDRA Lowest Level Term (LLT) will be used in the treatment\u2011emergent derivation. The maximum severity for each LLT during the baseline period including ongoing medical history will be used as baseline severity. For events with a missing severity during the baseline period, it will be treated as \u201cmild\u201d in severity for determining treatment\u2011emergence. Events with a missing severity during the postbaseline period will be treated as \u201csevere\u201d and treatment\u2011emergence will be determined by comparing to baseline severity.\n\nFor events occurring on the day of first taking study medication, the case report form (CRF)\u2011collected information (eg, treatment emergent flag, start time of study treatment and event) will be used to determine whether the event was pre\u2011 versus post\u2011treatment if available. If the relevant information is not available, then the events will be counted as post\u2011treatment.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3129, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d30cb208-7147-481f-ae87-b328a09f7f80": {"__data__": {"id_": "d30cb208-7147-481f-ae87-b328a09f7f80", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cba30e59-e502-4833-a031-bc2d17d68b53", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "aba61032caf35acb0a4cee125d1d8f9b79ed2eafada18da83644c87084fc5f26", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\nThe counts and percentages of participants with TEAEs will be summarized by treatment using MedDRA Preferred Term (PT) nested within System Organ Class (SOC). Statistical comparisons will be applied at both the SOC and PT levels. Events will be ordered by decreasing frequency within SOC. The SOC will be in alphabetical order. For events that are sex\u2011specific, the denominator and computation of the percentage will include only participants from the given sex.\n\nAn overview of the number and percentage of participants who experienced a TEAE, serious adverse event (SAE), death, discontinued from study treatment or study due to an AE, relationship to study drug will be summarized by treatment.\n\nThe counts and percentages of patients with TEAEs by maximum severity will be summarized by treatment using MedDRA PT. For each participant and TEAE, the maximum severity for the MedDRA PT is the maximum postbaseline severity observed from all associated LLTs mapping to the MedDRA PT. The maximum severity will be determined based on the nonmissing severities. If all severities are missing for the defined postbaseline period of interest, it will show as missing in the table.\n\n# 6.14.1.2. Common Adverse Events\n\nThe counts and percentages of participants with TEAEs, overall and common (common TEAEs occurred in \u22655% of participants before rounding), will be summarized by treatment using MedDRA PT. Events will be ordered by decreasing frequency.\n\n# 6.14.1.3. Deaths\n\nA listing of all deaths during the study will be provided. The listing will include participant identification including the treatment, site number, date of death, age at the time of enrollment, sex, associated AE group identification, time from last dose of study drug to death (if participant had discontinued study drug), and primary cause of death.\n\n# 6.14.1.4. Other Serious Adverse Events\n\nThe counts and percentages of participants who experienced an SAE (including deaths and SAEs temporally associated or preceding deaths) during the postbaseline period will be summarized by treatment using MedDRA PT nested within SOC. Events will be ordered by decreasing frequency within SOC. The SOC will be in alphabetical order.\n\nA listing of all SAEs will be provided. The listing will include treatment, participant identification including the site number, date of event, age at the time of enrollment, sex, AE group identification, MedDRA SOC and PT, severity, outcome, relationship to study drug, time from first dose of study drug to the event, and time from most recent dose to event (if participant discontinued study drug prior to the event).\n\n# 6.14.1.5. Other Significant Adverse Events\n\nThe counts and percentages of participants who discontinued from study treatment or study due to an AE during the postbaseline period may be summarized by treatment group using MedDRA PT nested within SOC. Events will be ordered by decreasing frequency within SOC.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2993, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7cb33f51-b158-4fa3-9a16-a33ae1c731d9": {"__data__": {"id_": "7cb33f51-b158-4fa3-9a16-a33ae1c731d9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "91014d5a-ca19-4e0a-ac4f-5759ffae1de3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "48e9932c967f27af11ed05fcf5e61ac0421998831054d9e84516866a0b0df63e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.14.2. Patient Narratives\n\nPatient narratives will be provided for all participants who experience any of the following \u201cnotable\u201d events:\n\n- death\n- serious adverse event, or\n- permanent discontinuation of study treatment due to AEs.\n\nPatient narratives (patient level data and summary paragraph) will be provided for participants in the randomized population with at least 1 notable event.\n\n# 6.14.3. Special Safety Topics\n\n# 6.14.3.1. Acute Gallbladder Disease\n\nAll events of TEAE biliary colic, cholecystitis, or other suspected events related to gallbladder disease will be summarized by treatment groups by PT with decreasing frequency. Detailed searching criteria can be found in Appendix 3.\n\n# 6.14.3.2. Amputation/Peripheral Revascularization\n\nThis section is applicable for participants developing T2DM during the study treatment (up to primary database lock [72 weeks] and final database lock [176 weeks]). The counts and percentages of participants with amputations/peripheral revascularization may be summarized by treatment based on searching criteria in Appendix 3.\n\n# 6.14.3.3. Exocrine Pancreas Safety\n\n# 6.14.3.3.1. Pancreatic Enzyme\n\nObserved pancreatic enzyme data (p\u2011amylase and lipase) will be summarized by treatment and nominal visit. The counts and percentages of participants with maximum postbaseline pancreatic enzyme value exceeding the following thresholds will be provided by baseline pancreatic enzyme value (\u2264 upper limit of normal [ULN], > ULN), and treatment: \u22641x ULN, (>1 to \u22643) x ULN, (>3 to \u22645) x ULN, (>5 to \u226410) x ULN, >10x ULN. An MMRM analysis will be used to analyze each pancreatic enzyme with a log transformed (postbaseline measure/baseline measure) response variable and treatment, nominal visit, treatment\u2011by\u2011nominal visit interaction as fixed effects.\n\n# 6.14.3.3.2. Pancreatitis Events\n\nSummaries of adjudicated and investigator\u2011reported pancreatic events will be provided by treatment. Detailed searching criteria can be found in Appendix 3.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2054, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a5209975-58ea-4737-ac7f-f859a3a15246": {"__data__": {"id_": "a5209975-58ea-4737-ac7f-f859a3a15246", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "477898d4-ba08-4d4c-8390-2b71504d5310", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0c62cbc1bbbc3430dd6323d720005dc4f35a1a3ac6ee9eede6e80865034d2791", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.14.3.4. Gastrointestinal Safety\n\n# 6.14.3.4.1. Nausea, Vomiting, and Diarrhea\n\nSummaries and analyses for incidence and severity of nausea, vomiting, diarrhea, and 3 events combined, will be provided by each treatment group. Summary of the prevalence over time for nausea, vomiting, and diarrhea will also be presented. Time to the onset of nausea, vomiting, and diarrhea will be plotted.\n\n# 6.14.3.4.2. Severe Gastrointestinal Events\n\nSevere gastrointestinal (GI) adverse events (GI SOC) will be captured with AE\u2011CRF form and serious cases will be captured with the SAE form. The PTs in the GI SOC MedDRA V21.1 will be used to identify GI AEs, and only the PTs with serious/severe cases will be considered as AESIs. The counts and percentages of participants with severe GI events will be summarized by treatment.\n\n# 6.14.3.5. Hepatic Safety\n\n# 6.14.3.5.1. Hepatobiliary Disorders\n\nHepatobiliary disorders will be considered as AESI. The counts and percentages of participants with treatment\u2011emergent potentially drug\u2011related hepatic disorders will be summarized by treatment using the MedDRA PTs. Detailed searching criteria can be found in Appendix 3. A listing of participants with treatment emergent hepatobiliary disorders may be provided if deemed necessary.\n\n# 6.14.3.5.2. Liver Enzymes\n\nAnalyses for laboratory analyte measurements are described in Section 6.14.6. This section describes additional analyses of liver enzymes. The counts and percentages of participants with the following elevations in hepatic laboratory tests at any time during the treatment period and during the entire study including follow up period will be summarized between treatment groups:\n\n- The counts and percentages of participants with an alanine aminotransferase (ALT) measurement \u22653 times (3x), 5 times (5x), and 10 times (10x) the Covance ULN will be summarized for all participants with a postbaseline value and for subsets based on various levels of baseline value.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2014, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7e309790-7784-4744-9eb5-1ca38f782c0c": {"__data__": {"id_": "7e309790-7784-4744-9eb5-1ca38f782c0c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "79b8664e-f89e-476b-816d-5ca495703ddf", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8746fd2025067ccf978c750a1ab7be5beef064b606e86e1f3c5fa97d4297b364", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nPage 34\n\n\u2022 The counts and percentages of participants with an aspartate aminotransferase (AST) measurement \u22653x, 5x, and 10x the Covance ULN during the treatment period will be summarized for all patients with a postbaseline value and for subsets based on various levels of baseline, as described above for ALT.\n\n\u2022 The counts and percentages of participants with a total bilirubin (TBL) measurement \u22652x the Covance ULN during the treatment period will be summarized for all participants with a postbaseline value, and subset into 4 subsets:\n\n- participants whose nonmissing maximum baseline value is \u22641 x ULN\n- participants whose maximum baseline is >1 x ULN, but &#x3C;2 x ULN\n- participants whose maximum baseline value is \u22652 x ULN, and\n- participants whose baseline values are missing.\n\n\u2022 The counts and percentages of participants with a serum alkaline phosphatase (ALP) measurement \u22652x the Covance ULN during the treatment period will be summarized for all participants with a postbaseline value and for the subsets described above to TBL. Maximum baseline will be the maximum non\u2011missing observation in the baseline period. The maximum value will be the maximum non\u2011missing value from the postbaseline period. Planned and unplanned measurements will be included.\n\n# 6.14.3.6. Hypoglycemia\n\nThe following categories in accordance with the 2019 American Diabetes Association position statement on glycemic targets (ADA 2019b) will be defined in the database.\n\n# Glucose alert value (Level 1):\n\n- Documented symptomatic hypoglycemia is defined as any time a patient feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a blood glucose (BG) level of &#x3C;70 mg/dL (&#x3C;3.9 mmol/L).\n- Documented asymptomatic hypoglycemia is defined as any event not accompanied by typical symptoms of hypoglycemia, but with a measured BG &#x3C;70 mg/dL (&#x3C;3.9 mmol/L).\n- Documented unspecified hypoglycemia is defined as any event with no information about symptoms of hypoglycemia available, but with a measured BG &#x3C;70 mg/dL (&#x3C;3.9 mmol/L).\n\n# Documented Clinically Significant Hypoglycemia (Level 2):\n\n- Documented symptomatic hypoglycemia is defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a BG level of &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n- Documented asymptomatic hypoglycemia is defined as any event not accompanied by typical symptoms of hypoglycemia but with a measured BG &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2594, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "58e96070-8c92-4e82-89ec-dae0df84aa9e": {"__data__": {"id_": "58e96070-8c92-4e82-89ec-dae0df84aa9e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fb83bbc4-669d-422e-adb8-71dabe065e2d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3f792a14c87ed3abc38a2fbbab56dc65ffe5b3359980f17d4621ecb5243413fe", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.14.3.6. Hypoglycemia\n\n\u2022 Documented unspecified hypoglycemia is defined as any event with no information about symptoms of hypoglycemia available but with a measured BG &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n\n# Severe Hypoglycemia (Level 3):\n\n\u2022 Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. Plasma glucose measurements may not be available during such an event, but neurological recovery attributable to the restoration of PG to normal is considered sufficient evidence that the event was induced by a low PG concentration.\n\n# Other hypoglycemia categories:\n\n\u2022 Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking.\n\nIf a hypoglycemic event meets the criteria of severe, the event would specifically be collected as an SAE. Serious hypoglycemia are defined by pharmacovigilance criteria and will also be captured with an SAE form.\n\nTo avoid duplicate reporting, all consecutive hypoglycemic events occurring within a 1\u2011hour period will be considered to be a single hypoglycemic event.\n\nHypoglycemia data will be censored at the time of receipt of new antihyperglycemic medication. This censoring will occur regardless of whether the reason for the alternative medication is rescue from severe, persistent hyperglycemia (with or without continuation of assigned study medication) or maintenance of glucose control in the event of cessation of assigned study medication.\n\nBoth the incidence (percent of patients experiencing \u22651 episode) and the rate (episodes/patient/year) of level 2 or level 3 hypoglycemia, and level 3 hypoglycemia will be reported by treatment group.\n\nSevere hypoglycemia will be considered as AESIs. The summaries of severe/serious hypoglycemia will be provided by treatment group. A listing of all events of severe hypoglycemia may be provided, if deemed necessary. This listing will provide treatment allocation, clinical characteristics of the hypoglycemic event, and concomitant antihyperglycemic medications.\n\n# 6.14.3.7. Immunogenicity\n\n# 6.14.3.7.1. Definitions of Sample ADA Status\n\nAt a high level, an individual sample is potentially examined multiple times, in a hierarchical procedure, to produce a sample anti\u2011drug antibodies (ADA) assay result and potentially multiple cross\u2011reactive antibodies assay results and multiple neutralizing antibodies (NAb) assay results.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2639, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "15c44524-3849-4c80-92f4-61c13b9b9d9f": {"__data__": {"id_": "15c44524-3849-4c80-92f4-61c13b9b9d9f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "07a90ac3-ff97-465e-b15e-a5e732580a5f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7eb72b7ff982b0b28512d90853cf810ebf65338132d21bfb7d05651daa84d096", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 36\n\nThe cut points used, the drug tolerance of each assay, and the possible values of titers are operating characteristics of the assay.\n\nFigure GPHK.6.1 details a flow chart that reflects the multitiered testing approach.\n\nAbbreviations: ADA = anti\u2011drug antibody; CP = cut point; GIP = glucose\u2011dependent insulinotropic polypeptide; GIPR = glucose\u2011dependent insulinotropic polypeptide receptor; GLP\u20111 = glucagon\u2011like peptide\u20111; GLP\u20111R = glucagon\u2011like peptide\u20111 receptor; LY = LY3298176; NAb = neutralizing antibodies.\n\n# Figure GPHK.6.1. Flowchart of immunogenicity multitiered testing approach.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 657, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3b1a3ce1-4097-4dcb-a6c5-8229d93a9906": {"__data__": {"id_": "3b1a3ce1-4097-4dcb-a6c5-8229d93a9906", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "edb08ae8-f974-4bf0-9bac-4b13635d192d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "35cc157ec9a9830cff36743a4c7750dd43ea02b1e88d8b8c05d346aa83d6a140", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\nPage 37\n\nTable GPHK.6.7 outlines results as reported from Tier 2a of the multitiered testing approach. Tier 4 results are reported similarly.\n\n| Sample            | Laboratory Result                                                                                                                                              | Explanation |\n| ----------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------- |\n| Detected          | ADA are detected and confirmed.                                                                                                                                |             |\n| Not Detected      | The raw result as reported from the laboratory indicates not detected. The clinical interpretation of such results depends other factors (see Table GPHK.6.8). |             |\n| NO TEST, QNS, etc | Sample exists but was unevaluable by the assay.                                                                                                                |             |\n\nAbbreviations: ADA = anti\u2011drug antibodies; QNS = quantity not sufficient.\n\nIt can be the case that the presence of high concentrations of tirzepatide will affect immunoassays, and conversely high levels of antibodies may affect the measurement of tirzepatide concentration. Thus, a tirzepatide drug concentration, assessed from a sample drawn at the same time as the ADA sample, plays a key role in clinical interpretation of a sample when the laboratory results is Not Detected (see Table GPHK.6.8).\n\n| Sample           | Clinical Interpretation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Explanation |\n| ---------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------- |\n| ADA Present      | ADA assay result is Detected                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |             |\n| ADA Not Present  | ADA assay result is Not Detected and simultaneous drug concentration is at a level that has been demonstrated to not interfere in the ADA detection method (ie, drug concentration is below the assay\u2019s drug tolerance level). For participants receiving placebo, drug concentration is not assessed and is assumed to be below the assay\u2019s drug tolerance level. If drug concentration was planned but is not available for a treatment\u2011period sample, a Not Detected sample will be declared ADA Not present. |             |\n| ADA Inconclusive | ADA assay result is Not Detected but drug concentration in the sample is at a level that can cause interference in the ADA detection method.                                                                                                                                                                                                                                                                                                                                                                     |             |\n| ADA Missing      | ADA sample not drawn, QNS, not tested, etc., causing there to be no laboratory result reported or the result is reported as \u201cno test.\u201d                                                                                                                                                                                                                                                                                                                                                                           |             |\n\nAbbreviations: ADA = anti\u2011drug antibodies; QNS = quantity not sufficient.\n\nAll ADA present samples will be evaluated for cross\u2011reactive glucose\u2011dependent insulinotropic polypeptide (GIP), cross\u2011reactive glucagon\u2011like peptide\u20111 (GLP\u20111), Nab LY3298176 (LY) on glucose\u2011dependent insulinotropic popypeptide receptor (GIP\u2011R), and NAb LY on glucagon\u2011like peptide\u20111 receptor (GLP\u20111R). If cross\u2011reactive GIP is detected, NAb GIP on GIP\u2011R is evaluated. If cross\u2011reactive GLP\u20111 is detected, NAb GLP on GLP\u20111R is evaluated (Figure GPHK.6.1).\n\nSimilar terminology to Table GPHK.6.8 applies for each type of cross\u2011reactive and NAb assay. Importantly, each of these are distinct assays and, in general, have different assay operating characteristics.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 5633, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0e665d51-e018-47ce-bcf8-96a7252e8ef0": {"__data__": {"id_": "0e665d51-e018-47ce-bcf8-96a7252e8ef0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "768faeeb-51f6-4fa8-8845-126c689f4bdd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "beca22c8cc8156d334315d5f2ac14d598261186e6a85b414b50d8a94da58d40a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0346cd8-b164-49a8-9de9-69ebf09cca55", "node_type": "1", "metadata": {}, "hash": "52fff1cc10b2793d4fd3f6e3b5fdf03ca1eebf36154d6270df8121cd833331c4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 38\n\nThe following are considered inconclusive for the NAb result:\n\n- NAb LY on GIP\u2011R: if NAb result is not detected, and pharmacokinetic (PK) concentration is \u2265159 ng/mL\n- NAb LY on GLP\u20111R: if NAb result is not detected, and PK concentration is \u2265530 ng/mL\n- NAb GIP on GIP\u2011R: if NAb result is not detected, and PK concentration is \u22650.479 ng/mL, and\n- NAb GLP on GLP\u20111R: if NAb result is not detected, and PK concentration is \u22656.77 ng/mL.\n\nDue to the low concentration level, many samples would be classified as inconclusive for the cross\u2011reactive neutralizing against nGIP or nGIP\u20111. An in silico method utilizing results from Tiers 2b and 2c, Tiers 4a and 4b, and tirzepatide concentrations is introduced. The in silico method is outlined in Table GPHK.6.9.\n\n# Table GPHK.6.9.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 828, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d0346cd8-b164-49a8-9de9-69ebf09cca55": {"__data__": {"id_": "d0346cd8-b164-49a8-9de9-69ebf09cca55", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "768faeeb-51f6-4fa8-8845-126c689f4bdd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "beca22c8cc8156d334315d5f2ac14d598261186e6a85b414b50d8a94da58d40a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e665d51-e018-47ce-bcf8-96a7252e8ef0", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "adaf49452b35ca982e4feb1678eb6605eb0da2742b37724a72ccda9683f2fd30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10eef76f-d87b-4747-9e3b-9712f194653a", "node_type": "1", "metadata": {}, "hash": "eabd234fd0b67ade46f8756534a9539988a6f3fd44ce803cb6053a0e8a34c71b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Due to the low concentration level, many samples would be classified as inconclusive for the cross\u2011reactive neutralizing against nGIP or nGIP\u20111. An in silico method utilizing results from Tiers 2b and 2c, Tiers 4a and 4b, and tirzepatide concentrations is introduced. The in silico method is outlined in Table GPHK.6.9.\n\n# Table GPHK.6.9. In Silico Classification for Cross-Reactive NAb\n\n| In Silico Classification              | Cross-Reactive ADA Result | NAb Result              |      | In Silico Cross-Reactive NAb Interpretation |   |\n| ------------------------------------- | ------------------------- | ----------------------- | ---- | ------------------------------------------- | - |\n| Circulating Tirzepatide Level (ng/mL) |                           | NAb Result              |      |                                             |   |\n| Cross\u2011Reactive NAb to nGIP            | Tier 2b: \u201cNot Detected\u201d   | N/A                     | N/A  | N/A                                         |   |\n| Cross\u2011Reactive NAb to nGIP            | Tier 2b: \u201cDetected\u201d       | Tier 4a: \u201cNot Detected\u201d | <159 | Not Detected                                |   |\n| Cross\u2011Reactive NAb to nGIP            | Tier 2b: \u201cDetected\u201d       | Tier 4a: \u201cNot Detected\u201d | \u2265159 | Inconclusive                                |   |\n| Cross\u2011Reactive NAb to nGIP            | Tier 2b: \u201cDetected\u201d       | Tier 4a: \u201cDetected\u201d     | <159 | Detected                                    |   |\n| Cross\u2011Reactive NAb to nGIP            | Tier 2b: \u201cDetected\u201d       | Tier 4a: \u201cDetected\u201d     | \u2265159 | Detected                                    |   |\n| Cross\u2011Reactive NAb to nGLP\u20111          | Tier 2c: \u201cNot Detected\u201d   | N/A                     | N/A  | N/A                                         |   |\n| Cross\u2011Reactive NAb to nGLP\u20111          | Tier 2c: \u201cDetected\u201d       | Tier 4b: \u201cNot Detected\u201d | <530 | Not Detected                                |   |\n| Cross\u2011Reactive NAb to nGLP\u20111          | Tier 2c: \u201cDetected\u201d       | Tier 4b: \u201cNot Detected\u201d | \u2265530 | Inconclusive                                |   |\n| Cross\u2011Reactive NAb to nGLP\u20111          | Tier 2c: \u201cDetected\u201d       | Tier 4b: \u201cDetected\u201d     | <530 | Detected                                    |   |\n| Cross\u2011Reactive NAb to nGLP\u20111          | Tier 2c: \u201cDetected\u201d       | Tier 4b: \u201cDetected\u201d     | \u2265530 | Detected                                    |   |\n\nAbbreviations: ADA = anti\u2011drug antibodies; GIPR = glucose\u2011dependent insulinotropic polypeptide receptor; GLP\u20111R = glucagon\u2011like peptide\u20111 receptor; N/A = not applicable; NAb = neutralizing antibodies; nGIP = native glucose\u2011dependent insulinotropic polypeptide; nGLP\u20111 = native glucagon\u2011like peptide\u20111; Tier 2b = cross\u2011reactive ADA to nGIP; Tier 2c = cross\u2011reactive ADA to nGLP\u20111; Tier 4a = NAb LY (tirzepatide) on GIPR; Tier 4b = NAb LY (tirzepatide) on GLP\u20111R.", "mimetype": "text/plain", "start_char_idx": 490, "end_char_idx": 3329, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "10eef76f-d87b-4747-9e3b-9712f194653a": {"__data__": {"id_": "10eef76f-d87b-4747-9e3b-9712f194653a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "768faeeb-51f6-4fa8-8845-126c689f4bdd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "beca22c8cc8156d334315d5f2ac14d598261186e6a85b414b50d8a94da58d40a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0346cd8-b164-49a8-9de9-69ebf09cca55", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fa66350d28e2a9322752e1f4678c79c22c3a80320a4763d0f8518a994c98ab57", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Note that in the case of an ADA Inconclusive sample, each of the NAb and Cross\u2011Reactive NAb assay results is taken to be Inconclusive.\n\nNote also that any reference to an assay cut point and/or drug tolerance is population specific, and is subject to modification to study\u2011specific parameters per regulatory guidance.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 3331, "end_char_idx": 3659, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eb01fe87-2186-4deb-8444-816f0f6f9ab0": {"__data__": {"id_": "eb01fe87-2186-4deb-8444-816f0f6f9ab0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4793ee5e-507e-4c61-b30f-6bc1f7757101", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fe159eccf473441c9767dfd4690a6f907cfa9e8bad37d32bc5e61377ccbbe63d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.14.3.7.2. Definitions of Immunogenicity Assessment Periods\n\nImmunogenicity Baseline Observations: Baseline period for immunogenicity assessment for each participant includes all observations on or prior to baseline visit. In instances where multiple baseline observations are collected, to determine participant ADA status the last nonmissing immunogenicity assessment prior to first administration of study is used to determine treatment\u2011emergent status (see below).\n\nImmunogenicity Postbaseline Period Observations: Postbaseline period observations for each participant includes all observations after the first administration of study drug.\n\n# 6.14.3.7.3. Definitions of Participant ADA Status\n\nParticipant evaluable for treatment\u2011emergent ADA (TE ADA): A participant is evaluable for TE ADA if the participant has a non\u2011missing baseline ADA result, and at least 1 non\u2011missing postbaseline ADA result.\n\nTreatment\u2011emergent ADA positive (TE ADA+) participant: A participant who is evaluable for TE ADA is TE ADA+ if either of the following holds:\n\n- The participant has baseline status of ADA Not Present and at least 1 postbaseline status of ADA Present with titer \u22652*MRD, where the MRD is the minimum required dilution of the ADA assay.\n- The participant has baseline and postbaseline status of ADA Present, with the postbaseline titer being 2 dilutions (4\u2011fold) greater than the baseline titer. That is, the participant has baseline status of ADA Present, with titer 1:B, and at least 1 postbaseline status of ADA Present, with titer 1:P, with P/B \u2265 4.\n\nAs shown in Figure GPHK.6.1, a titer is expected when ADA assay result is Detected. On occasion, the corresponding assay cannot be performed, in which case a titer value will be imputed for the purpose of TE ADA determination. A baseline sample with detected ADA and no titer is imputed to be the minimum required dilution (MRD) (1:10) and a post\u2011baseline sample with ADA detected and no titer is imputed to be one dilution above the MRD (1:20).\n\nTreatment\u2011emergent ADA Inconclusive participant: A participant who is evaluable for TE ADA is TE ADA Inconclusive if \u226520% of the participant\u2019s postbaseline samples, drawn predose, are ADA Inconclusive and all remaining postbaseline samples are ADA Not Present.\n\nTreatment\u2011emergent ADA negative (TE ADA\u2011) participant: A participant who is evaluable for TE ADA is TE ADA\u2011 when the participant is not TE ADA+ and the participant is not TE ADA Inconclusive.\n\nFor each NAb assay, the following are defined:\n\nNAb positive (NAb+) participant: A participant who is TE ADA+ and has a NAb positive sample in the postbaseline period.\n\nNAb Inconclusive participant: A participant who is TE ADA+, is not NAb+, and all samples that have TE ADA+ titer have a NAb Inconclusive sample result.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2844, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fa760af7-33b8-442c-89b1-7603b16b7fff": {"__data__": {"id_": "fa760af7-33b8-442c-89b1-7603b16b7fff", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c0c15dd3-3f26-4693-9fe7-969d902c6eff", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c449d11ec1a96caadd667fd98d081d59dd59185a6a21cfabf39c30b77ffbd5c2", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\nNAb negative (NAb\u2011) participant: A participant is NAb\u2011 when the participant is neither NAb+ nor NAb Inconclusive.\n\n# 6.14.3.7.4. Analyses to be Performed\n\nThe count and proportion of participants who are TE ADA+ will be tabulated by treatment group, where proportion are relative to the number of participants who are TE ADA evaluable, as defined above. The tabulation will include the number and proportion of participants with ADA Present at baseline and the number and proportion of TE ADA+ participant exhibiting each type of cross\u2011reactive antibodies and NAb.\n\nThis analysis will be performed for:\n\n- the planned treatment period\n- the entire postbaseline period including follow\u2011up, and\n- both the cross\u2011reactive NAb based on Tier 4c and 4d results, and the in silico classification for cross\u2011reactive NAb will be summarized.\n\nA listing will be provided of all immunogenicity assessments for those participants who at any time had ADA Present. This includes the tirzepatide concentration from a simultaneous PK sample, and the clinical interpretation result (ADA Present, ADA Not Present, ADA Inconclusive, Missing). In the case of ADA Present, a titer will be included, and TE ADA+ observations will be flagged. Also included, for each cross\u2011reactive antibodies and Nab assay that was performed, will be the clinical interpretation result.\n\nA summary will be provided of the count and percentage of tirzepatide\u2011treated participants experiencing specific TEAE (see Table GPHK.6.10) by participant TE ADA status (TE ADA+, TE ADA\u2011, TE ADA Inconclusive). The PT will be ordered by decreasing incidence in TE ADA+ status group.\n\n# Table GPHK.6.10. Adverse Events for Analysis with Immunogenicity Results\n\nEvents satisfying Anaphylaxis SMQ (narrow)\nEvents satisfying Hypersensitivity SMQ (narrow)\nEvents satisfying Angioedema SMQ (narrow)\nEvents mapping to High Level Term (HLT) of Injection site reaction\nEvents mapping to HLT of Infusion site reaction\n\nAbbreviations MedDRA = Medical Dictionary for Regulatory Activity; SMQ = Standardised MedDRA Query.\n\nA listing will be provided of all TEAEs alongside ADA data, for any participant who had ADA Present at any time (including baseline) or had any specific TEAE (see Table GPHK.6.10). This listing includes a time course of ADA (clinical interpretation result plus flags for samples meeting TE ADA+ criteria and for samples with cross\u2011reactive antibodies and NAb present) along with the TEAE.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2506, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6e90fbda-0081-4203-8dc1-8f3594b9df42": {"__data__": {"id_": "6e90fbda-0081-4203-8dc1-8f3594b9df42", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3d4558b4-ceb5-4e3e-b65a-e4546e18bb7d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "f553eb58d1b9833d6f1a6ae471dbde67e28134aee7d2c33b86434d409f932aac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nAdditional immunogenicity analyses as determined later may be presented. The relationship between antibody titers, the PK parameters, and pharmacodynamics (PD) response to tirzepatide may also be assessed. Cases of treatment\u2011emergent ADA that are associated with AEs of either hypersensitivity or injection site reaction will be classified as AESI.\n\n# 6.14.3.8. Hypersensitivity Reactions\n\nTwo main analyses are performed in support of assessment of potential immediate hypersensitivity, including anaphylaxis as well as potential nonimmediate hypersensitivity. Time Period A, of potential immediate hypersensitivity includes all TEAEs occurring from start of study drug administration up to 24 hours after end of study drug administration. Time Period B, of potential non\u2011immediate hypersensitivity, includes all TEAEs occurring more than 24 hours after the end of study drug administration, but prior to subsequent drug administration.\n\nThe counts and percentages of participants who experienced a TEAE will be summarized by PT with decreasing frequency by treatment. Analyses for both time periods are based on the following:\n\n- Narrow and algorithm terms in Anaphylactic reaction Standardised MedDRA Query (SMQ; 20000021)\n- Narrow terms in Angioedema SMQ (20000024)\n- Narrow terms in Severe cutaneous adverse reactions SMQ (20000020), and\n- Narrow terms in Hypersensitivity SMQ (20000214).\n\nFor the Anaphylactic reaction SMQ, each term is classified by scope (Narrow, Broad) and by category (A, B, C, D). All Narrow terms are category A, and all Broad terms are category B, C, or D. In addition to the usual Narrow and Broad searches, the SMQ defines an algorithm to further refine the cases of interest. For Time Period A analysis, the Anaphylactic reaction SMQ algorithm will be included. The algorithm is based upon events that occur within Time Period A.\n\nThe counts and percentages of participants who experienced a TEAE for the following will be analyzed for each of the 2 time periods:\n\n- any narrow term from any one of the 4 SMQs indicated above (ie, combined search across narrow of all 4 SMQs) and\n- any narrow scope term within each SMQ, separately (ie, narrow SMQ search). For Time Period A analysis, any term from Anaphylactic reaction SMQ algorithm.\n\nWithin query, individual PTs that satisfied the queries will be summarized. For Time Period A analysis, the Anaphylactic reaction SMQ algorithm will be summarized. Also, a single event may satisfy multiple SMQs, in which case the event contributes to every applicable SMQ.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2602, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "599b4230-e07d-4f94-83d2-231cf2ddf5a8": {"__data__": {"id_": "599b4230-e07d-4f94-83d2-231cf2ddf5a8", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4b688342-6c7d-4f4d-b77c-616256675e92", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9746a5f1556bd6f6b2feba6bce4c60b56526573a6fcc9b37487f19de8a8c8306", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.14.3.8.1. Serious Hypersensitivity Reactions\n\nThe serious/severe cases of hypersensitivity will be considered as AESI. All serious hypersensitivity events will be collected with the SAE form. A listing of participants with serious hypersensitivity reactions may be provided if deemed necessary.\n\n# 6.14.3.9. Injection Site Reaction\n\nInjection site reactions, incidence and rates, and related information reported via the \u201cInjection Site Reactions\u201d eCRF will be summarized by treatment. Information to be summarized includes the location of the reaction, timing of the reaction relative to study drug administration, and characteristics of the injection site reaction: erythema, induration, pain, pruritis, and edema. Patient\u2011based analysis and event\u2011based analysis may be provided if necessary. The patient\u2011based analysis summarizes all injection\u2011site reaction (ISR) questionnaire forms for an individual patient with a single statistic, typically an extreme value. This analysis allows each patient to contribute only once for each parameter, at the expense of a focus on the most extreme events. By contrast, the event\u2011based analysis summarizes all ISR questionnaire forms received, without regard to individual patients. This provides characteristics of ISR events as a proportion of all events for which questionnaire responses were provided, at the expense of some potential bias due to differential contribution of individual patients to the analysis.\n\nThe counts and percentages of participants with treatment emergent injection site reaction will be summarized by treatment using the MedDRA PTs. Detailed searching criteria can be found in Appendix 3. The PT will be listed for summary in decreasing order of incidence for tirzepatide\u2011treated participants.\n\n# 6.14.3.9.1. Severe/Serious Injection Site Reactions\n\nThe severe/serious injection site reactions (eg, abscess, cellulitis, erythema, hematomas/hemorrhage, exfoliation/necrosis, pain, subcutaneous nodules, swelling, induration, inflammation) will be considered as AESI. The counts and percentage of participants with severe/serious ISRs will be summarized by treatment. A listing of participants with treatment\u2011emergent severe/serious ISRs may be provided, if deemed necessary.\n\n# 6.14.3.10. Major Adverse Cardiovascular Events\n\nMajor adverse cardiovascular events (MACE) reported by investigators are adjudicated by an independent clinical endpoint committee (CEC) in a blinded fashion. The cardiovascular AEs to be adjudicated include: deaths due to CV cause, myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft [CABG] or percutaneous coronary intervention [PCI]); and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack (TIA).", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2899, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "db84cd80-7117-458e-b125-08cb2ad60bc7": {"__data__": {"id_": "db84cd80-7117-458e-b125-08cb2ad60bc7", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cd154823-2478-4ca3-9c43-819089866e6c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "966f21247a8a96bad1ead4916e432bc845f54cdb910575f61cc5950170b140b7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nOnly adjudicated MACE will be considered as AESI. The counts and percentages of participants with adjudicated MACE may be summarized by treatment. In addition, MACE reported by investigator may also be summarized although a major adverse cardiovascular event reported by investigator is not considered as AESI. A listing of participants reporting MACE events, either reported by investigator or identified by the CEC, will be provided. The listing will include treatment, participants identification including the site number, date of event, type of event as reported by the investigator, type of event as adjudicated by the CEC, time from first dose of study drug to the event, and time from last dose to the event (if participant has discontinued study drug prior to the event).\n\n# 6.14.3.11. Major Depressive Disorder/Suicidal Ideation\n\nThe major depressive disorder/suicidal ideation or behavior will be captured as AESI. Adverse events will be searched using MedDRA PT terms. Detailed searching criteria can be found in Appendix 3. The counts and percentages of participants with TEAEs will be summarized by treatment group using MedDRA PT nested within SMQ. Events will be ordered by decreasing frequency in the total tirzepatide group nested within SMQ. A listing of participants with major depressive disorder/suicidal ideation or behavior may be provided if deemed necessary. Additionally, suicidal ideation and behavior, and depression will be assessed by the investigator via spontaneously reported AEs and through the use of the Columbia\u2011Suicide Severity Rating Scale (C\u2011SSRS) and the Patient Health Questionnaire (PHQ\u20119).\n\n# 6.14.3.11.1. Patient Health Questionnaire\n\nTotal scores for the PHQ\u20119 range from 0 to 27 with total scores categorized as:\n\n- none (not depressed): 0 through 4\n- mild: 5 through 9\n- moderate: 10 through 14\n- moderately severe: 15 through 19, and\n- severe: 20 through 27.\n\nShift tables will be provided showing the counts and percentages of participants within each baseline category (maximum value) versus each postbaseline category (maximum value) by treatment. Additionally, the following 3 outcomes of interest will be compared between treatments (based on the maximum value during baseline and postbaseline):\n\n- any increase in depression category (ie, worsening of depression): includes participants in the none, mild, moderate, or moderately severe category during baseline and with at least 1 postbaseline measurement", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2511, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b45a730b-9ce4-4ace-be8e-d3a39cf86ef1": {"__data__": {"id_": "b45a730b-9ce4-4ace-be8e-d3a39cf86ef1", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c3a3ac1e-bd91-4518-8875-6d5a5b90fede", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "da7c6cb1e3c2f6e08597ceece96b29523490d826400522e2f21f815d46ec2774", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nPage 44\n\n# 6.14.3.11.2. Suicidal Ideation and Behavior Solicited Through C-SSRS\n\nSuicide\u2011related thoughts and behaviors occurring during the entire study period, based on the C\u2011SSRS, will be summarized by treatment group. In particular, for each of the following suicide\u2011related events, the counts and percentages of participants with the event will be summarized by treatment group:\n\n- died by suicide\n- nonfatal suicide attempt\n- interrupted attempt\n- aborted attempt\n- preparatory acts or behavior\n- active suicidal ideation with specific plan and intent\n- active suicidal ideation with some intent to act without specific plan\n- active suicidal ideation with any methods (no plan) without intent to act\n- nonspecific active suicidal thoughts\n- wish to be dead, and\n- non\u2011suicidal, self\u2011injurious behavior.\n\nIn addition, the counts and percentages of participants who experienced at least 1 of the composite measures will be presented. The participants with at least 1 post\u2011baseline C\u2011SSRS assessment are included. The composite measure is determined at each assessment by the \u201cyes\u201d or \u201cno\u201d responses in C\u2011SSRS categories by the study participant:\n\n- Category 1 \u2013 Wish to be Dead\n- Category 2 \u2013 Non\u2011specific Active Suicidal Thoughts\n- Category 3 \u2013 Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act\n- Category 4 \u2013 Active Suicidal Ideation with Some Intent to Act, without Specific Plan\n- Category 5 \u2013 Active Suicidal Ideation with Specific Plan and Intent\n- Category 6 \u2013 Preparatory Acts or Behavior\n- Category 7 \u2013 Aborted Attempt\n- Category 8 \u2013 Interrupted Attempt\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1652, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b52dfd36-b346-4d4d-8c38-f63b306532b1": {"__data__": {"id_": "b52dfd36-b346-4d4d-8c38-f63b306532b1", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "90ffe0c1-f750-450f-9ae1-69dcfa857132", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "54bf98f276b955b7f2f54807a519fd8bf87dd1e0d29310901bed8196aa4ec3d5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\u2022  Category 9 \u2013 Actual Attempt (non\u2011fatal), and\n\n\u2022  Category 10 \u2013 Completed Suicide.\n\nComposite endpoints of suicidal ideation and suicidal behavior based on the above categories are defined below:\n\n- Suicidal ideation: A \u201cyes\u201d answer at any time during study to any 1 of the 5 suicidal ideation questions (Categories 1 through 5) on the C\u2011SSRS.\n- Suicidal behavior: A \u201cyes\u201d answer at any time during study to any 1 of the 5 suicidal behavior questions (Categories 6 through 10) on the C\u2011SSRS.\n- Suicidal ideation or behavior: A \u201cyes\u201d answer at any time during study to any 1 of the 10 suicidal ideation and behavior questions (Categories 1 through 10) on the C\u2011SSRS.\n\nA listing contains data for each participant with suicidal ideation, suicidal behavior, or non\u2011suicidal self\u2011injurious behavior during the study by treatment and visit. Data from all visits are displayed, regardless of a \u201cyes\u201d or \u201cno\u201d answer, for patients with any \u201cyes\u201d answer for suicidal ideation, suicidal behavior, or self\u2011injurious behavior without suicidal intent.\n\n# 6.14.3.12. Malignancy\n\nThe counts and percentages of participants with treatment emergent malignancy will be summarized by treatment and PT with decreasing order. Detailed searching criteria can be found in Appendix 3.\n\n# 6.14.3.13. Metabolic Acidosis\n\nThis section is applicable for participants developing T2DM during the study treatment (up to primary database lock [72 weeks] and final database lock [176 weeks]).\n\nThe counts and percentages of participants with metabolic acidosis, including diabetic ketoacidosis may be summarized by treatment based on searching criteria in Appendix 3.\n\n# 6.14.3.14. Renal Safety\n\nLaboratory measures related to renal safety will be analyzed as specified for laboratory measurements in Section 6.14.6.\n\nTwo shift tables examining renal function will be created. A min\u2011to\u2011min shift table of estimated glomerular filtration rate (eGFR) estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD\u2011EPI) equation with units ml/min/1.73m2, using categories (&#x3C;30, \u226530 to &#x3C;45, \u226545 to &#x3C;60, \u226560 to &#x3C;90, and \u226590 mL/min/1.73m2). A max\u2011to\u2011max shift table of urine albumin\u2011to\u2011creatinine ratio (UACR), using the categories UACR &#x3C;30 mg/g, 30 mg/g \u2264 UACR \u2264300 mg/g, UACR >300 mg/g (respectively, these represent normal, microalbuminuria, and macroalbuminuria).\n\nMixed model repeated measure analyses for eGFR and UACR will be provided. Log transformation will be performed for UACR.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2546, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cdd60fd5-c9b7-467e-80ad-c6efb4edb69f": {"__data__": {"id_": "cdd60fd5-c9b7-467e-80ad-c6efb4edb69f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "69ee12e2-80f3-44f5-8e1e-c97eda47ad65", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "00976c6cf623d2ca26894e90c4abc5fe85de09d19e142aadc9756ea57474da46", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.14.3.14.1. Acute Renal Events\n\nBecause severe GI events may lead to dehydration, which could cause a deterioration in renal function including acute renal failure, dehydration events will be analyzed. Acute renal events associated with chronic renal failure exacerbation will also be captured. Acute renal events will be considered as AESI.\n\nThe counts and percentages of participants with acute renal events will be summarized by treatment by using the MedDRA PTs contained in any of the following SMQs:\n\n- Acute renal failure: Narrow terms in Acute renal failure SMQ (20000003)\n- Chronic kidney disease: Narrow terms in Chronic kidney disease SMQ (20000213).\n\nIn addition, a listing of participants with treatment\u2011emergent acute renal events may be provided, if deemed necessary.\n\n# 6.14.3.14.2. Dehydration\n\nDehydration events will be captured in the Narrow terms in Dehydration SMQ (20000232). A listing of participants with treatment\u2011emergent dehydration events will be provided.\n\n# 6.14.3.15. Thyroid Safety Monitoring\n\n# 6.14.3.15.1. Calcitonin\n\nObserved calcitonin data (a thyroid\u2011specific laboratory assessment) will be summarized by treatment and nominal visit. The counts and percentages of participants with a maximum postbaseline calcitonin value in the following thresholds will be provided by treatment and baseline calcitonin value (\u226420 ng/L, >20 ng/L to \u226435 ng/L, >35 ng/L). Postbaseline: \u226420 ng/L, >20 ng/L to \u226435 ng/L, >35 ng/L to \u226450 ng/L, >50 ng/L to \u2264100 ng/L, and >100 ng/L.\n\n# 6.14.3.15.2. C-Cell Hyperplasia and Thyroid Malignancies\n\nThyroid malignancies and C\u2011Cell hyperplasia will be considered as AESI. Treatment\u2011emergent thyroid malignancies and C\u2011Cell hyperplasia will be identified using MedDRA High Level Term (HLT) for Thyroid neoplasms and PT for Thyroid C\u2011cell hyperplasia. The counts and percentages of participants with treatment\u2011emergent thyroid C\u2011cell hyperplasia and malignancies will be summarized by treatment and PT ordered with decreasing frequency. In addition, a listing of participants with treatment\u2011emergent thyroid C\u2011cell hyperplasia and neoplasms may be provided if deemed necessary.\n\n# 6.14.3.16. Treatment-Emergent Supraventricular Arrhythmias and Cardiac Conduction Disorders\n\nTreatment\u2011emergent supraventricular arrhythmias and cardiac conduction disorders will be considered as AESI. The cardiovascular events will include clinically relevant rhythm and conduction disorders.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2495, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "05c51672-c1a7-4165-9bec-b1f9a9e2b4d4": {"__data__": {"id_": "05c51672-c1a7-4165-9bec-b1f9a9e2b4d4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9a0e2b60-7f40-4de3-8a17-29056de0eeb0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a0ed3fa68614493220367ef29d5179e581d507e4eac23fc640988cefecb3c5ca", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nPage 47\n\nThe treatment\u2011emergent supraventricular arrhythmias and cardiac conduction disorders events will be included using the MedDRA PTs. Detailed searching criteria can be found in Appendix 3.\n\nThe counts and percentages of participants with treatment emergent supraventricular arrhythmias and cardiac conduction disorders will be summarized by treatment and PT nested within SMQ. The PT will be ordered with decreasing frequency within SMQ. A listing of participants with treatment\u2011emergent supraventricular arrhythmias and cardiac conduction disorders may be provided if deemed necessary.\n\n# 6.14.3.17. Treatment of Overdose\n\nA listing of patients reporting AEs related to over dosing of tirzepatide will be provided.\n\n# 6.14.3.18. Abuse Potential\n\nTo identify AE terms suggestive of abuse liability potential, 2 clusters of PTs will be analyzed. The first cluster includes SMQ of Drug abuse and dependence (20000101). The second cluster is a Lilly Search Cluster \u201cadditional abuse potential\u201d terms, which are additional terms suggestive of abuse liability that are not included in the SMQ Drug abuse and dependence (20000101). The full standardized list of PTs of these 2 clusters is located in CLUWE (/lillyce/prd/dictionaries/current/daldac/abuse_terms.sas7bdat and /lillyce/prd/dictionaries/current/daldac/abuse_smq.sas7bdat where SMQ CODE = 20000101). The counts and percentages of participants will be summarized by treatment group with decreasing frequency.\n\n# 6.14.4. Vital Signs\n\nIn the case that multiple records of an individual vital sign are collected at the same visit, they will be averaged prior to being used for data summaries and analyses. Descriptive summaries by treatment and by nominal visit will be provided for baseline and postbaseline values as well as change from baseline values. An MMRM and/or an ANCOVA model as in Section 6.14 might be conducted if necessary.\n\nCounts and percentages of participants with treatment\u2011emergent abnormal sitting SBP, sitting DBP, and pulse will be presented by treatment for participants who have both baseline and at least 1 postbaseline result. A treatment\u2011emergent high result is defined as a change from a value less than or equal to the high limit at baseline to a value greater than the high limit at any time that meets the specified change criteria during the postbaseline period. A treatment\u2011emergent low result is defined as a change from a value greater than or equal to the low limit at baseline to a value less than the low limit at any time that meets the specified change criteria during the postbaseline period. To assess decreases, change from the minimum value during the baseline period to the minimum value during the postbaseline period will be used. To assess increases, changes from the maximum value during the baseline period to the maximum value during the postbaseline period will be used. Both planned and unplanned measurements will be included in\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3002, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1a6a4990-58a5-4d82-8e91-dab9c8455625": {"__data__": {"id_": "1a6a4990-58a5-4d82-8e91-dab9c8455625", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "15197f76-c69d-425e-86e9-1fcf9772d6fd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3388e255d09ff9c42629d60d9b9baf6ac621c4996233af98e4c04da122ca8fa8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nthe analysis. The criteria for identifying patients with treatment\u2011emergent vital sign abnormalities are stated in Table GPHK.6.11.\n\n# Table GPHK.6.11. Categorical Criteria for Abnormal Treatment-Emergent Blood Pressure and Pulse Measurements\n\n| Parameter                                                         | Low                                | High                                |\n| ----------------------------------------------------------------- | ---------------------------------- | ----------------------------------- |\n| Systolic BP (mm Hg) (Supine or sitting \u2013 forearm at heart level)  | \u226490 and decrease from baseline \u226520 | \u2265140 and increase from baseline \u226520 |\n| Diastolic BP (mm Hg) (Supine or sitting \u2013 forearm at heart level) | \u226450 and decrease from baseline \u226510 | \u226590 and increase from baseline \u226510  |\n| Pulse (bpm) (Supine or sitting)                                   | <50 and decrease from baseline \u226515 | >100 and increase from baseline \u226515 |\n\nAbbreviations: BP = blood pressure; bpm = beats per minute\n\nIn addition, following analyses will be conducted by treatment:\n\n- counts and percentages of participants who had resting heart rate changes from baseline at 2 consecutive visits of more than 10 bpm and/or 20 bpm\n- counts and percentages of participants who had at least 1 resting heart rate exceeding 100 bpm, and\n- counts and percentages of participants who had at least 1 resting heart rate exceeding 100 bpm occurring at 2 consecutive study visits.\n\n# 6.14.5. Electrocardiograms\n\nFor electrocardiogram (ECG) parameters that collect in triplicates (ie, Visit 3 and Visit 12), the average from the 3 measurements for the same parameter at the same visit will be calculated and used for all the subsequent summaries and analyses.\n\nSummary statistics by treatment and by nominal visit will be provided for ECG parameters (heart rate, PR, QRS, QT, and QT corrected using Fredericia\u2019s correction factor [QTcF = QT / RR0.333]). When the QRS is prolonged (eg, a complete bundle branch block), QT and QTc should be used to assess ventricular repolarization. Thus, for a particular ECG, the following will be set to missing (for analysis purposes) when QRS is \u2265120 msec: QT and QTcF.\n\nChange from baseline to postbaseline values for ECG parameters will be summarized for patients who have both a baseline and at least 1 postbaseline result. Only planned measurements will be included in the mean change analyses.\n\nThe criteria for identifying participants with treatment\u2011emergent quantitative ECG abnormalities is based on Table GPHK.6.12.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2623, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "98268bda-4022-4da5-8e76-3b2b0bfe5bcc": {"__data__": {"id_": "98268bda-4022-4da5-8e76-3b2b0bfe5bcc", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cc5ae223-c842-498d-a196-1d2b7c5e4c28", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9a175f59bbba52acbe8a204bc1d3aee6c355b3e63622804fc42fa32279f674c7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nPage 49\n\nThe counts and percentages of participants who meet the following criteria at any time during the entire study period (including the off-drug follow up time period) will be summarized by treatment group:\n\n- treatment-emergent ECG abnormalities as listed in Table GPHK.6.12\n- QT greater than 500 msec\n- QTcF greater than 500 msec, and\n- treatment-emergent increase from the maximum baseline in QTcF interval of greater than 30 msec, 60 msec, or 75 msec. Maximum baseline will be the maximum nonmissing observation in the baseline period. The maximum value during the treatment period will be analyzed. Scheduled and unscheduled measurements will be included.\n\nTreatment-emergent qualitative ECG abnormalities are defined as qualitative abnormalities that first occurred after baseline. A listing of abnormal qualitative ECGs will be created.\n\n# Table GPHK.6.12. Selected Categorical Limits for ECG Data\n\n| Parameter           | Low   |                       | High    |                       |\n| ------------------- | ----- | --------------------- | ------- | --------------------- |\n| Heart Rate (bpm)    | Males | <50 and decrease \u226515  | Females | <50 and decrease \u226515  |\n|                     | Males | >100 and increase \u226515 | Females | >100 and increase \u226515 |\n| PR Interval (msec)  | Males | <120                  | Females | <120                  |\n|                     | Males | \u2265220                  | Females | \u2265220                  |\n| QRS Interval (msec) | Males | <60                   | Females | <60                   |\n|                     | Males | \u2265120                  | Females | \u2265120                  |\n| QTcF (msec)         | Males | <330                  | Females | <340                  |\n|                     | Males | >450                  | Females | >470                  |\n\nAbbreviations: bpm = beats per minute; ECG = electrocardiogram; QTcF = Fredericia\u2019s corrected QT interval.\n\n# 6.14.6. Clinical Laboratory Evaluation\n\nAll laboratory data will be reported in the International System of Units. Selected laboratory measures will also be reported using conventional units. Limits from the performing lab will be used to define low (L) and high (H). Descriptive summaries by treatment and by nominal visit will be provided for the baseline and postbaseline values as well as the change from baseline values.\n\nObserved and change from baseline values for each visit may be displayed in plots for participants who have both a baseline and at least 1 postbaseline planned measurement. Baseline will be the last nonmissing observation prior to taking the first study drug. Unplanned measurements will be excluded from plots.\n\nA shift table will be provided including unplanned measurements. The shift table will include the number and percentage of participants within each baseline category (low, normal, high, or missing) versus each postbaseline category (low, normal, high, or missing) by treatment. The proportion of participants shifted will be compared between treatments using Fisher\u2019s exact test.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3102, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "818ce439-7251-4c5e-b4ce-cab1587be841": {"__data__": {"id_": "818ce439-7251-4c5e-b4ce-cab1587be841", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6ce04762-f890-47bd-bf5d-d429a56a4baa", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0c032aedf2755de2cc50296ea6909f76ecfeecfb47245f5f1afd5b9ad6d9ebb3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# 6.14.6.1. Two-hour Oral Glucose Tolerance Test (OGTT)\n\nThe following parameters will be collected during 2\u2011hour OGTT for each scheduled OGTT visit:\n\n- glucose\n- insulin, and\n- C\u2011peptide.\n\nFor each above parameter, the mean concentration over 120 minutes plots will be created by glycemia status at randomization and by treatment group and by OGTT visit (ie, at baseline and at Week 72). After 72 week, these plots will be created for participants with prediabetes at randomization.\n\nFor each above parameter, the area under the curve from time zero to 2 hours (AUC)(0\u20112h) during OGTT will be calculated using the trapezoidal rule. The respective AUC(0\u20112h) will be summarized by treatment group and by OGTT visit.\n\nIn addition, the following OGTT derived parameters (Armato et al. 2018) will be calculated at each OGTT visit for each participants with OGTT:\n\n# Glycemic response categories:\n\n- Normal: normal glucose tolerance (ADA) and a 1\u2011hour PG concentration &#x3C;8.6 mmol/L (154.8 mg/dL), where normal glucose tolerance is defined by the 2019 American Diabetes Association Standards of Medical Care in Diabetes (ADA 2019a) as follows:\n- Fasting glucose: obtained alone or at time = 0 during an OGTT is &#x3C;100 mg/dL (5.6 mmol/L) and\n- 2\u2011hour glucose: obtained at time = 120 minutes during an OGTT is &#x3C;140 mg/dL (7.8 mmol/L)\n- Moderate impairment:\n- Normal glucose tolerance and 1\u2011hour plasma glucose \u22658.6 mmol/L, or\n- Impaired fasting glucose or impaired glucose tolerance, or both, and 1\u2011hour PG concentration &#x3C;8.6 mmol/L (154.8 mg/dL), where impaired fasting glucose is defined as fasting plasma glucose (FPG) levels between", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1695, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eab4db7a-b6b9-49fd-b55b-5f68dbb0a950": {"__data__": {"id_": "eab4db7a-b6b9-49fd-b55b-5f68dbb0a950", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0694beca-8c13-4a9c-9ee8-69fdb9c0b75c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "45f794ea4fd5452ce22f21d89dd8af84cc2c0ff99fa7e3a191d73cc990312771", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 51\n\n100 and 125 mg/dL (between 5.6 and 6.9 mmol/L), and impaired glucose tolerance is defined as 2\u2011hour PG during 75 g OGTT levels between 140 and 199 mg/dL (between 7.8 and 11.0 mmol/L) (ADA 2019a)\n\n- Severe abnormality: impaired fasting glucose or impaired glucose tolerance, or both, and 1\u2011hour PG concentration \u22658.6 mmol/L\n\nMatsuda Index = 10000 , where FPG is the fasting glucose, FPI is the fasting insulin, denotes the mean glucose during OGTT, and denotes the mean insulin during OGTT\n\n- Normal insulin sensitivity: Matsuda index >25th percentile of Matsuda index values from participants with normal glucose tolerance at baseline\n- Moderate insulin resistance: Matsuda index in the 5th to 25th percentile (inclusive) of Matsuda index values from participants with normal glucose tolerance at baseline\n- Severe insulin resistance: Matsuda index &#x3C; the lowest fifth percentile of the range of Matsuda index values from participants with normal glucose tolerance at baseline\n\nInsulin secretion = ( LlCpep) 0 , where \u0394C\u209a\u2091\u209a denotes the incremental area under the plasma C\u2011peptide curve during the 2\u2011hour OGTT, and \u0394 denotes the incremental area under the plasma glucose concentration curve during 2\u2011hour OGTT\n\nInsulin secretion index = ( LlCpep)0 , where normal level of insulin secretion is the median value for insulin secretion, ie, ( LlCpep) 0, in participants with normal glucose tolerance at baseline\n\n- Normal insulin secretion: insulin secretion index >70%\n- Moderate impairment of insulin secretion: 50% to 70% (inclusive) of the insulin secretion index\n- Severe impairment of insulin secretion: &#x3C;50% of the insulin secretion index\n\n\u2013cell function = Insulin secretion * Matsuda index = ( LlCpep) * ( 10000 LlG 0-120 \u00d7 )\u00d7( \u00d7 )\n\nThe descriptive summaries for the above continuous derived OGTT parameters (eg, sample size, mean, median, SD, minimum, maximum) will be calculated at each scheduled OGTT visit by treatment group and by glycemia status (ie, normalglycemia and prediabetes at randomization) if applicable. For the categorical derived OGTT parameters, descriptive summaries (ie, sample size, frequency, percentage) will be calculated at each scheduled OGTT visit by treatment group and by glycemia status (ie, normalglycemia and prediabetes at randomization) if applicable.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2365, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8bfb2761-0860-4813-b609-75163039e02b": {"__data__": {"id_": "8bfb2761-0860-4813-b609-75163039e02b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9f164476-ad69-4c91-8bad-b3ac4cb5d330", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1dfde27bd8edff66be2ad33913086d90db5d4bcce3c07f9925f16e96f622fdf3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nUnless other specified, the ANOVA model will be applied to the following parameters with terms of treatment groups (tirzepatide 5 mg, 10 mg, 15 mg, and placebo) and baseline value of the corresponding parameter at 72 weeks. For the measurements assessed at 176 weeks, MMRM model might apply for participants with prediabetes at baseline.\n\n# 6.15. Health Outcomes\n\nThe patient\u2011reported outcome questionnaires will be analyzed using the mITT population on the EAS, unless specified otherwise. Item\u2011level missingness is dealt with as per the instrument developers\u2019 instruction. Additional psychometric analyses will be performed by Global Patient Outcomes Real World Evidence at Lilly and documented in a separate analysis plan.\n\n# 6.15.1. Patient Global Impression of Status for Physical Activity\n\nThe counts and percents of participants for Patient Global Impression of Status for Physical Activity (PGIS) response categories at each time point will be summarized by nominal visit and by treatment. For time points >72 weeks, only the participants with prediabetes at randomization will be included so that the denominator for percents will be participants with prediabetes at randomization only. A shift table from baseline to postbaseline of 5 PGIS response categories will be created at each postbaseline visit.\n\n# 6.15.2. Short-Form-36 Health Survey Version 2, Acute Form\n\nPer copyright owner, the QualityMetric Health Outcomes\u2122 Scoring Software 4.5 will be used to derive the following domain and component scores:\n\n- Mental Component Score (MCS)\n- Physical Component Score (PCS)\n- Physical Functioning domain (PF)\n- Role\u2011Physical domain (RP)\n- Bodily Pain domain (BP)\n- General Health domain (GH)\n- Vitality domain (VT)\n- Social Functioning domain (SF)\n- Role\u2011Emotional domain (RE)\n- Mental Health domain (MH)\n\nFor each above parameter, the raw scores will be transformed into the domain scores (t\u2011scores) and the following analyses for the actual value and change from baseline value will be conducted:\n\n- descriptive summaries by treatment group, and", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2106, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "583e0d2b-1446-4682-864b-3deb156561c1": {"__data__": {"id_": "583e0d2b-1446-4682-864b-3deb156561c1", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8a8cdb8a-81c5-4f30-b917-4a4d0b375d81", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e8f0c9cd1d2d1c81dc0708a15720246fe19c8e4fc5c392acc2f724a1a275f18d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nPage 53\n\n\u2022  analysis described in Table GPHK.6.4, Table GPHK.6.5, and Table GPHK.6.6.\n\n# 6.15.3. Impact of Weight on Quality of Life-Lite Clinical Trials\n\nThe following parameters will be included from IWQOL\u2011Lite\u2011CT:\n\n- IWQOL Lite CT total score (all items: items 1 through 20)\n- Physical Function composite score (5 items: items 1 through 3, 16, 17)\n- Pain/Discomfort composite score (2 items: items 4 and 5)\n- Physical composite score (7 items: item 1 through 5, 16, 17), and\n- Psychosocial composite score (13 items: item 6 through 15, 18, 19, 20).\n\nIWQOL\u2011Lite\u2011CT total and composite scores range from 0 to 100, with higher scores reflecting better levels of functioning.\n\nIWQOL\u2011Lite\u2011CT scores are computed according to the IWQOL\u2011Lite scoring rules (Kolotkin et al. 2002) as following:\n\n- Each composite raw score will be calculated if a minimum of 50% of the items for that composite has a nonmissing value; the total score will be calculated if a minimum of 75% of all 20 items has a nonmissing value.\n- If the minimum required number of items are answered then:\n\nFor total and each composite score, the actual value and change from baseline value following analyses will be conducted:\n\n- descriptive summaries by treatment group and\n- ANCOVA analysis described in Table GPHK.6.5 and Table GPHK.6.6.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1364, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9296035b-6d98-4413-8508-91e28dfacbf6": {"__data__": {"id_": "9296035b-6d98-4413-8508-91e28dfacbf6", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7172c760-78df-4348-b7ec-369432b311f4", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2ae4eafaddf29966375d26ad21cf4a3c82e3a32c0e9a8056ae84d714782b7c85", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 6.15.4. EQ-5D-5L\n\nFor the utility score and the Visual Analog Scale (VAS) scores, following analyses of the actual value and change from baseline value will conducted:\n\n- descriptive summaries by treatment group and\n- analysis of covariance described in Table GPHK.6.6.\n\n# 6.16. Subgroup Analyses\n\nEfficacy subgroup analyses will be guided by the efficacy estimand in EAS. Subgroup analyses may be done by country to support local regulatory registrations.\n\n# 6.16.1. Subgroup Analysis of Body Weight Change\n\nSubgroup analyses by the following baseline characteristics will be provided:\n\n- age group (&#x3C;65, \u226565 years)\n- race\n- sex\n- ethnicity\n- region of enrollment (US, outside of US [OUS])\n- body mass index group (&#x3C;30, \u226530 and &#x3C;35, \u226535 and &#x3C;40, \u226540 kg/m2), and\n- glycemic status at randomization (normoglycemia vs prediabetes).\n\nThe outcome measures for the subgroup analyses will include:\n\n- percent change in body weight from randomization at 72 weeks and\n- percentage of participants achieving at least 5% body weight reduction at 72 weeks.\n\nFor the percentage change in body weight from randomization at 72 weeks, for each subgroup analyses aforementioned, the following 2 models will be conducted:\n\n- Conduct MMRM model on the subgroup only with terms of treatment group, visit, treatment\u2011by\u2011visit\u2011interaction, country/pooled country, sex, and prediabetes status at randomization as fixed effects, and baseline body weight as a covariate. Variance\u2011covariance structure for within\u2011patient errors will be same as Section 6.13.1.1.\n- Full MMRM model: treatment group, visit, subgroup, treatment\u2011by\u2011visit\u2011interaction, treatment\u2011by\u2011subgroup\u2011interaction, subgroup\u2011by\u2011visit\u2011interaction, treatment\u2011visit\u2011subgroup\u2011interaction, country/pooled country, sex, and prediabetes status at randomization as fixed effects, and baseline body weight as a covariate. Variance\u2011covariance structure for within\u2011patient errors will be same as Section 6.13.1.1.\n\nFor the percentage of participants achieving at least 5% body weight reduction at 72 weeks, for each subgroup analyses aforementioned, the following 2 models will be conducted:\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2202, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3f221c45-2a61-42ae-87af-1fc12757b181": {"__data__": {"id_": "3f221c45-2a61-42ae-87af-1fc12757b181", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d8e6ef44-3ebf-4aaf-96af-b61ed094a0d8", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d2a6ba9f9b0345ad39aaa10c9e9f6d15b3426fe39b930256497f045dc003aecd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\nPage 55\n\n- Conduct longitudinal logistic regression model on the subgroup only with terms of treatment group, visit, treatment\u2011by\u2011visit\u2011interaction, country/pooled country, sex, and prediabetes status at randomization as fixed effects, and baseline body weight as a covariate. Variance\u2011covariance structure for within\u2011patient errors will be same as Section 6.13.1.1.\n- Full longitudinal logistic regression model: treatment group, visit, subgroup, treatment\u2011by\u2011visit\u2011interaction, treatment\u2011by\u2011subgroup\u2011interaction, subgroup\u2011by\u2011visit\u2011interaction, treatment\u2011visit\u2011subgroup\u2011interaction, country/pooled country, sex, and prediabetes status at randomization as fixed effects, and baseline body weight as a covariate. Variance\u2011covariance structure for within\u2011patient errors will be same as Section 6.13.1.1.\n\n# 6.17. Interim Analyses and Data Monitoring Committee\n\nThe details for the interim analyses and DMC will be provided in the Data Monitoring Committee (DMC) Charter.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1028, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7b4bfffc-242b-4b69-a355-262db1fabf7e": {"__data__": {"id_": "7b4bfffc-242b-4b69-a355-262db1fabf7e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "750d73e1-5de5-4f6b-a7f9-766b7354983a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0bd92c25d606cdf628750e45855dadabbd6b520d4b50ea1bd327f9f65dfe4ad6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# 7. Unblinding Plan\n\nDetails of the blinding and unblinding will be provided in Blinding and Unblinding Plan document for Study GPHK.\n\nLY3298176\n\nPage 56", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 205, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bacb60c3-5d2e-4581-b201-4417bc1e3e62": {"__data__": {"id_": "bacb60c3-5d2e-4581-b201-4417bc1e3e62", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e3af7681-ae9b-4af1-99f9-42f0dc14388c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1e55901c28b7db36562746b39c5af2032070cec9e2bd841dfca9e98f08bd3744", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 8. Novel Coronavirus (COVID-19) Impact</h8>\nThis section lists additional statistical analyses that may be performed at the primary database lock and final database lock to assess the impact of COVID\u201119 pandemic if the data warrants.\n\n# 8.1. General Consideration</h8>\nPercentage and count of randomized participants who followed the COVID\u201119 mitigation plan may be summarized by treatment group. This includes, but not limited to, participants rescreened, procedures conducted via remote visit or mobile home health visit, visits occurred using the extended visit windows, alternative way of investigator product shipment/dispensing, use of a local lab, etc.\n\nPercentage and count of randomized participants who completely missed at least 1 study visit due to COVID\u201119 pandemic may also be summarized.\n\n# 8.2. Exposure</h8>\nA listing of randomized participants who had study drug temporary interruption due to COVID\u201119 pandemic may be provided.\n\n# 8.3. Protocol Deviation</h8>\nPercentage and count of randomized participants having important protocol deviation related to COVID\u201119 pandemic will be summarized by treatment.\n\nPercentage and count of randomized participants with protocol deviation related to COVID\u201119 pandemic may also be summarized by treatment.\n\nA listing of all randomized participants who had important protocol deviation due to COVID\u201119 pandemic may be provided.\n\n# 8.4. Patient Disposition</h8>\nA summary table for all randomized participants that discontinue study or study treatment due to COVID\u201119 pandemic will be provided by treatment.\n\nA listing of randomized participants who discontinued the study or study treatment due to COVID\u201119 infection will be provided.\n\n# 8.5. Adverse Events</h8>\nA listing of randomized participants who had COVID\u201119 infection, including death due to COVID\u201119, during the post\u2011randomization period will be provided.\n\n# 8.6. Major Depressive Disorder/Suicidal Ideation</h8>\nThe counts and percentages of participants with TEAEs for major depression may be summarized by treatment group using MedDRA PT nested within SMQ by COVID\u201119 subgroup (ie, participants without impact versus with impact) for SS group.\n\nLY3298176\n\nPage 57", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2233, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "66491d2e-215e-4968-9de2-57f2fce30145": {"__data__": {"id_": "66491d2e-215e-4968-9de2-57f2fce30145", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c270651a-0705-48df-a8a6-524f5d9fc383", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9285445c870bc50e2596c2813c4c1441a73a2ab13da9b7242126bb87178a770d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# 8.6. Impact of COVID-19 on Participants\n\nA participant is defined as impacted by COVID\u201119 if either one of the following is satisfied:\n\n- no COVID\u201119 illness, but impacted by quarantine and travel restrictions, clinics closing, visits being canceled, delay or nondelivery of the investigational product, virtual visits, etc.\n- with COVID\u201119 illness.\n\nThe suicidal ideation and behavior solicited through C\u2011SSRS may be summarized by treatment group by COVID\u201119 subgroup (ie, participants without impact vs with impact) for SS group.\n\n# 8.7. Local Lab\n\nIf local lab data was brought into the Lilly database, additional details around how to combine with central lab data and analyze it will be provided before primary database lock.\n\n# 8.8. Missing Data Due to COVID-19\n\nFor the primary endpoints and key secondary endpoints, missing data due to COVID\u201119 will be handled as described in Section 6.13.1.3.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 964, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "daac12a1-9017-49f2-ac69-0aea288b1e7c": {"__data__": {"id_": "daac12a1-9017-49f2-ac69-0aea288b1e7c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8ff3b18f-aae9-478f-8bcf-3efd8b2cf1b9", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "dba66e4120fe810272d693aee6b0bae1dae2e925764a92f38d02876a3fa70826", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# 9. References\n\n[ADA] American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20112019. Diabetes Care. 2019a; 42(suppl 1):S 13\u2011S28. https://doi.org/10.2337/dc19\u2011S002\n\n[ADA] American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes\u20112019. Diabetes Care. 2019b;42(suppl 1):S61\u2011S70. https://doi.org/10.2337/dc19\u2011S006\n\nAnwar YA, White WB. Ambulatory monitoring of the blood pressure devices, analysis, and clinical utility. In: William White, editor. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. Humana Press, Inc; 2001:p 64.\n\nArmato JP, DeFronzo RA, Abdul\u2011Ghani M, Ruby RJ. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). Lancet Diabetes Endocrinol. 2018;6(10):781\u2011789. https://doi.org/10.1016/S2213\u20118587(18)30234\u20111\n\nErnst ME, Bergus GR. Noninvasive 24\u2011hour ambulatory blood pressure monitoring: overview of technology and clinical applications. Pharmacotherapy. 2002;22(5):597\u2011612. https://doi.org/10.1592/phco.22.8.597.33212\n\nPickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142\u2011161. https://doi.org/10.1161/01.HYP.0000150859.47929.8e\n\nKolotkin RL, Crosby RD, Rhys Williams G. Health\u2010related quality of life varies among obese subgroups. Obes Res. 2002;10(8):748\u2011756. https://doi.org/10.1038/oby.2002.102\n\nRubin DB. Multiple imputation for nonresponse in surveys. John Wiley &#x26; Sons Inc.; 1987.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 1837, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5783214f-df83-430c-98b2-cf56cca6e8b2": {"__data__": {"id_": "5783214f-df83-430c-98b2-cf56cca6e8b2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "77d39405-1bdf-4c29-9c54-09acbce134f0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "10cb2b27a19570d0bae08852443425e0408ab1311e0028971d0cd6618334301d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 10. Appendices\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 28, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "159bd6e2-9e1b-4dff-b953-e9303f696045": {"__data__": {"id_": "159bd6e2-9e1b-4dff-b953-e9303f696045", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2f3c13cf-933a-4203-a879-a0ddef1d85fb", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fccba86cf04314316c1dddf50a4f23329c5200e4468861273d6146b1d2c37d8e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# Appendix 1. Body Composition Assessments via Dual-Energy X-ray Absorptiometry (DXA)\n\nThis section is applicable to the participants who are enrolled in the Dual Energy X\u2011ray Absorptiometry (DXA) addendum.\n\nThe primary objective of DXA addendum is to demonstrate that tirzepatide (5 mg, 10 mg, and 15 mg combined) once weekly (QW) is superior to placebo in percent change in total body fat mass loss from baseline to 72 weeks.\n\nPercent change of total body fat mass will be calculated as:\n\n[(Total body fat mass at 72 weeks - Total body fat mass at baseline) / Total body fat mass at baseline] *100\n\nThe secondary objectives include:\n\n- To demonstrate that tirzepatide (5 mg, 10 mg, and 15 mg combined) QW is superior to placebo in loss of total body fat mass in kg from randomization to 72 weeks, and\n- To assess, for tirzepatide (5 mg, 10 mg, and 15 mg combined) QW, the following parameters, measured at randomization and 72 weeks:\n- Percent change in total body lean mass, and\n- Change in total body lean mass in kg.\n\nPercent change of total body lean mass will be calculated as:\n\n[(Total body lean mass at 72 weeks - Total body lean mass at baseline) / Total body lean mass at baseline] *100\n\nDXA will be performed at the baseline and at the end of 72\u2011week treatment (Visit 21) or early discontinuation visit (ED).\n\nIn addition to the primary and secondary outcomes listed above, the following parameters will also be analyzed:\n\n- Total body mass (kg)\n- Total body fat mass (kg)\n- Total body lean mass (kg)\n- Percent body fat mass = total body fat mass / total body mass * 100\n- Percent body lean mass = total body lean mass / total body mass * 100\n- Fat lean mass ratio = total body fat mass / total body lean mass\n- Fat lean mass loss ratio = total body fat mass change / total body lean mass change\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1867, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "01a7eb97-ad86-463a-97f2-6267c01c0f49": {"__data__": {"id_": "01a7eb97-ad86-463a-97f2-6267c01c0f49", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "acfd69af-093a-4130-a795-7f7905b20c5d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "68e39f3dfcff78b560183f9db2628d87bdbb813343061731ce3f74c49ff72592", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# Page 62\n\n\u2022 fat lean mass percent loss ratio = percent change of total body fat mass / percent change of total body lean mass.\n\nUnless otherwise specified, all analyses for the variables measured or derived from DXA will be conducted on all participants who are enrolled in this addendum, randomized, and have at least 1 dose of study drug, with both baseline and at least 1 postbaseline measurement. Baseline is defined as the last non\u2011missing data collected at randomization (prior to first dosing of study drug). Missing data at Week 72 will be imputed using the last observation carried forward method.\n\nDescriptive summary statistics (eg, sample size, mean, standard deviation, min, max, and median) of all parameters above (but not limited to) will be provided by treatment group (placebo, tirzepatide 5 mg, tirzepatide 10 mg, tirzepatide 15 mg, and all tirzepatide doses combined) at baseline and postbaseline visits (for both actual value and change from baseline value).\n\nIn addition, summary of demographics and baseline characteristics for participants in the DXA addendum will be provided.\n\nUnless otherwise noted, all tests of treatment effects will be conducted at a 2\u2011sided alpha level of 0.05, and the confidence interval will be calculated at 95%, 2\u2011sided. There will be no multiplicity adjustment.\n\nThe analysis of covariance (ANCOVA) model will be used to analyze the continuous outcomes. Each model will include the treatment group (all tirzepatide doses combined and placebo) and corresponding baseline value for the dependent value.\n\nSummary statistics for categorical measures (including categorized continuous measures) will include sample size, frequency, and percentages, if necessary. Logistic regression will be used to examine the treatment difference in binary outcomes if there is a need to adjust for covariates. Otherwise, Fisher\u2019s exact test will be used to examine the treatment difference in categorical outcomes.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2010, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1b3768e4-6009-41e0-9592-0d27d433300c": {"__data__": {"id_": "1b3768e4-6009-41e0-9592-0d27d433300c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0d438650-5a0f-4ed0-8c3b-2f413414cbb3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6d533b5dd4592a3513faa1f4099e915e0fe309e4528c7aaa9edcb63b21a62174", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# Appendix 2. Ambulatory Blood Pressure Monitoring (ABPM)\n\nThis section is applicable to the participants who are enrolled in the Ambulatory Blood Pressure Monitoring (ABPM) addendum.\n\nThe main objective of ABPM addendum is to assess the effect of 5 mg, 10 mg, and 15 mg doses of tirzepatide compared to placebo on mean change from randomization (Week 0) to Week 36 on 24\u2011hour mean heart rate (HR) and 24\u2011hour mean blood pressure (BP) (systolic blood pressure [SBP]/diastolic blood pressure [DBP]), as measured during 24\u2011hour ABPM.\n\nAmbulatory monitoring of HR and BP will be performed prior to Visit 3 (Week 0; baseline) and again at Visit 12 (Week 36; final measure).\n\nOnly the valid readings will be used in the summary and analyses of the ABPM measurements. The ABPM measurements are downloaded to the ABPM vendor by the study site at the time of the participant visit. If the ABPM recording does not have \u226570% valid readings (assessed by the vendor), the entire 24\u2011hour ABPM recordings are considered not valid and the participant is asked to wear the ABPM device for another 24\u2011hour period.\n\nFor an ABPM recording session that is valid, all of the individual ABPM measurements that are flagged as valid and were recorded during the first 24 hours of recordings will be used in the analyses. No further editing of the values will be performed beyond the values flagged as invalid by the ABPM machine.\n\nThe following ABPM derived measurements will be evaluated:\n\n- Mean 24\u2011hour SBP, DBP, and HR\n- Mean daytime SBP, DBP, and HR. For analysis of daytime recordings, only session with >14 valid measurements during daytime (0700 to 2200 hours) will be included.\n- Mean nighttime SBP, DBP, and HR. For analysis of nighttime recordings, only session with >7 valid measurements during nighttime (2200 to 0700 hours, inclusive) will be included.\n- Dipper and nondipper response. Blood pressure normally has a circadian pattern in which BP drops at night and is higher during the awake hours. This is referred to as dipping. The following equation (White 2001) will be used to assess dipping status:\n\n(mean daytime SBP \u2013 mean nighttime SBP) / (mean daytime SBP) * 100%\n\nParticipants will be classified into the following categories based on their dipping status:\n\n- dipper: \u226510%\n- nondipper: 0% to 10%\n- riser (reverse dipper): &#x3C;0%", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2382, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5940d23b-8bb8-4643-8149-8ce16141ae76": {"__data__": {"id_": "5940d23b-8bb8-4643-8149-8ce16141ae76", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "81311d6b-9222-4ab4-b9f7-34d95cb1d1d8", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "9fb9e8be1bba4746f4a277e3af0e89fcd12cbe88df3e9cedba839d7a61792f90", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# Page 64\n\n- Mean 24\u2011hour, daytime, and nighttime BP load. Blood pressure load will be defined as follows (Ernst and Bergus 2002):\n- daytime: percent of SBP readings >140 mmHg and percent of DBP readings >90 mmHg (reported separately)\n- nighttime: percent of SBP readings >120 mmHg and percent of DBP readings >80 mmHg (reported separately)\n- mean 24 hour: percent above systolic limits (daytime and nighttime combined) and percent above diastolic limits (daytime and nighttime combined)\n- Mean 24\u2011hour, daytime, and nighttime pulse pressure (PP)\n- PP = SBP \u2013 DBP\n- Mean 24\u2011hour, daytime, and nighttime mean arterial pressure (MAP)\n- MAP = (2 * diastolic + systolic) / 3\n- Treatment\u2011emergent abnormally high HR (based on mean 24\u2011hour values) as defined in Table GPHK.6.11.\n- Treatment\u2011emergent abnormally high SBP and DBP defined as following (adapted from Pickering et al. 2005):\n- Mean Daytime SBP/DBP: >140/90 mmHg\n- Mean Nighttime SBP/DBP: >125/75 mmHg\n- Mean 24\u2011hour SBP/DBP: >135/85 mmHg\n\nThe daytime (0700 to 2200 hours) and nighttime (2200 to 0700 hours, inclusive) definitions will be used to provide accurate estimates of the BPs and heart rates during the awake and sleeping periods.\n\nMean plots for each derived continuous measurement above by treatment group by visit may be created.\n\nSummary statistics for actual and change from baseline for each derived measurements above will be performed by treatment group and by visit.\n\nBlood pressure load is an indicator of hypertensive burden and has been shown to correlate with markers of cardiovascular morbidity in participants with hypertension and has been used as a method of assessing antihypertensive drug efficacy. Summary statistics of 24\u2011hour BP load for all participants and those with or without hypertension at baseline will be calculated at baseline and at 36 weeks.\n\nIn addition to these derived measurements, the following summary measurements that provide information on the individual ABPM recordings sessions will be assessed:\n\n- total duration of recording session\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2103, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "67af3805-1da9-44d7-a08e-d6d0e0fd352e": {"__data__": {"id_": "67af3805-1da9-44d7-a08e-d6d0e0fd352e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "36851490-a1a4-45e9-a718-ba8e0c7cb2c7", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "83d85379271d984a80a37dba2a04b9fcda4e87283753c00c2d9d59e63ae567a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n\n# 65\n\n\u2022 total duration of recording session in the first 24 hours\n\n\u2022 total number of measurements in the first 24 hours\n\n\u2022 Number of valid measurements in the first 24 hours, and\n\n\u2022 Percent of valid measurements in the first 24 hours.\n\nIn addition to the above analyses of outcomes specifically collected through ABPM reading, following analyses may be performed for participants in the ABPM addendum if deemed necessary:\n\n\u2022 summary of demographics and baseline characteristics\n\n\u2022 summary of concomitant medication at baseline, and\n\n\u2022 summary of change in concomitant medication of interest (eg, antihypertensive)\n\nUnless otherwise noted, all tests of treatment effects will be conducted at a 2\u2011sided alpha level of 0.05, and the CI will be calculated at 95%, 2\u2011sided. There will be no multiplicity adjustment.\n\nAll analyses for the variables measured or derived from ABPM, will be conducted on all participants who are enrolled in ABPM addendum, randomized and have at least 1 dose of study drug, with both baseline and at least 1 postbaseline measurement.\n\nFor continuous outcomes collected from the ABPM, including BP and HR, the analysis will be conducted using an analysis of covariance model, with terms of treatment group (tirzepatide 5 mg, 10 mg, 15 mg, and placebo), baseline measurement, and HR controlling medicine use status at baseline.\n\nFor categorical measures (including categorized continuous measures), logistic regression will be used to examine the treatment difference, if there is a need to adjust for covariates. Otherwise, Fisher\u2019s exact test will be used to examine the treatment difference.\n\n# References\n\nAnwar YA, White WB. Ambulatory monitoring of the blood pressure devices, analysis, and clinical utility. In: William White, editor. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. Humana Press, Inc; 2001:p 64.\n\nErnst ME, Bergus GR. Noninvasive 24\u2011hour ambulatory blood pressure monitoring: overview of technology and clinical applications. Pharmacotherapy. 2002;22(5):597\u2011612. https://doi.org/10.1592/phco.22.8.597.33212\n\nPickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142\u2011161. https://doi.org/10.1161/01.HYP.0000150859.47929.8e\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2555, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eaf507ee-355c-4831-87a4-ac65a38ee87b": {"__data__": {"id_": "eaf507ee-355c-4831-87a4-ac65a38ee87b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "8425062e-980f-4c7d-bc7f-f1a34e3d6509", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "54deb2e146d8285bafaae93afedebdba4933e63c92a5282c751358f576a9c1cd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# Appendix 3. Searching Criteria For Special Safety Topics\n\n# Pancreatitis Events\n\nDetermination of investigator\u2011reported events will be through the \u201cAcute pancreatitis\u201d Standardized Medical Dictionary for Regulatory Activities (MedDRA) Query (SMQ) (20000022, narrow scope) and a \u201cChronic pancreatitis\u201d Preferred Term (PT) search of the adverse event (AE) database, while adjudication\u2011confirmed pancreatitis are found from adjudication forms.\n\n# Malignancies\n\nThe malignancy events will be included using the MedDRA PT contained in Malignant tumours SMQ (20000194) narrow scope or Tumours of unspecified malignancy SMQ (20000195) narrow scope.\n\n# Supraventricular Arrhythmias and Cardiac Conduction Disorders\n\nTreatment\u2011emergent supraventricular arrhythmias, arrhythmias and cardiac conduction disorders will be considered as an adverse event of special interest (AESI). The cardiovascular events will include clinically relevant rhythm and conduction disorders. The treatment\u2011emergent supraventricular arrhythmias and cardiac conduction disorders events will be included using the MedDRA PT contained in any of the following SMQs:\n\n1. Supraventricular Arrhythmias:\n- For symptoms: Arrhythmia related investigations, signs and symptoms SMQ (20000051), narrow and broad terms\n- For supraventricular arrhythmias: In Cardiac arrhythmia SMQ, under tachyarrhythmia sub SMQ\n- Supraventricular tachyarrhythmia SMQ (20000057), broad and narrow terms\n- Tachyarrhythmia terms, nonspecific SMQ (20000164), narrow terms only;\n- Ventricular tachyarrhythmia SMQ (20000058), narrow terms only.\n2. Cardiac Conduction Disorders\n- Conduction defects SMQ (20000056), narrow terms only;\n- Cardiac conduction disorders High Level Term (HLT; 10000032), all PTs.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1799, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6231447c-3760-4e44-8628-91f398f87a4b": {"__data__": {"id_": "6231447c-3760-4e44-8628-91f398f87a4b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fbc12338-3929-4053-8b50-8ceeab215833", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8c609da1c4585c53fd81bb84fb7bb6a075baf9277bf949e4382ab18cd1101912", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# Page 67\n\n# Injection Site Reactions\n\nTreatment emergent injection site reaction will be summarized by treatment using the MedDRA PT in any of the following:\n\n- MedDRA HLT of Injection site reaction\n- HLT of Administration site reaction\n- HLT of Infusion Site Reactions\n\n# Acute Gallbladder Disease\n\nAll events of TEAE biliary colic, cholecystitis, or other suspected events related to gallbladder disease will be summarized by treatment groups by PT with decreasing frequency under following SMQs:\n\n- Narrow PTs in Gallbladder related disorders SMQ (20000124)\n- Narrow PTs in Biliary tract disorders SMQ (20000125)\n- Narrow PTs in Gallstone related disorders SMQ (20000127)\n\n# Hepatic Treatment-Emergent Adverse Events\n\nTreatment\u2011emergent potentially drug\u2011related hepatic disorders will be summarized by treatment using the MedDRA PTs contained in any of the following SMQs:\n\n- Broad and narrow terms in the Liver related investigations, signs and symptoms SMQ (20000008)\n- Broad and narrow terms in the Cholestasis and jaundice of hepatic origin SMQ (20000009)\n- Broad and narrow terms in the Hepatitis non\u2011infections SMQ (20000010)\n- Broad and narrow terms in the Hepatic failure, fibrosis and cirrhosis and other liver damage SMQ (20000013)\n- Narrow terms in the Liver\u2011related coagulation and bleeding disturbances SMQ (20000015)\n- Narrow PTs in Gallbladder related disorders SMQ (20000124)\n- Narrow PTs in Biliary tract disorders SMQ (20000125)\n- Narrow PTs in Gallstone related disorders SMQ (20000127)\n\n# Major Depressive Disorder/Suicidal Ideation\n\nThe major depressive disorder/suicidal ideation or behavior will be captured as AESI. Adverse events will be searched using MedDRA PT terms. The PTs from the Depression and suicide/self\u2011injury SMQ as defined in MedDRA (SMQs: 20000037 [Suicide/self\u2011injury] and 20000167 [Depression (excl suicide and self injury)]) will be summarized.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1951, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "678d53af-0e94-4115-ae34-a10415da6781": {"__data__": {"id_": "678d53af-0e94-4115-ae34-a10415da6781", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7c49a808-cbd3-439e-8511-979a53e74141", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "dfd24093e3c4d236b1ee2a48d3e24f0c9ba4474a7eb1c7a99abb509d4f73a969", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 1\n# Amputation/Peripheral Revascularization\n\nAmputation/Peripheral revascularization will be considered as AESIs. Patients with amputations/peripheral revascularization will be searched using the following MedDRA PTs:\n\n- Amputation\n- Peripheral revascularization.\n\n# Metabolic Acidosis, Including Diabetic Ketoacidosis\n\nMetabolic acidosis including diabetic ketoacidosis will be searched using the following MedDRA v21.1 PTs:\n\n- Diabetic ketoacidosis\n- Ketoacidosis\n- Euglycaemic diabetic ketoacidosis\n- Ketonuria\n- Diabetic ketosis\n- Diabetic ketoacidotic hyperglycaemic coma\n- Ketosis\n- Lactic acidosis\n- Urine ketone body present\n- Blood ketone body\n- Blood ketone body increased\n- Urine ketone body\n- Blood ketone body present.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 789, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e416dc65-8a49-4e5c-bbab-5beb0d05bb9b": {"__data__": {"id_": "e416dc65-8a49-4e5c-bbab-5beb0d05bb9b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "92504585-1f56-480d-9e2c-2227203564ea", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3dc397de95e7b0b3bb2bd9a9f885160774595e48453c782be9bc661b21d6950e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Leo Document ID = a0458e47-712b-4e2c-b1ea-83118610bbf1\n\nApprover: PPD\n\nApproval Date &#x26; Time: 05-Sep-2020 13:28:11 GMT\n\nSignature meaning: Approved", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 155, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "030f56e0-5f0f-4f19-becd-1747066aa47b": {"__data__": {"id_": "030f56e0-5f0f-4f19-becd-1747066aa47b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a1259d4b-bcf3-4edf-9735-fd462f450f9f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "c19fd28c1e0e26405cb9abacb6ddae31a1c26b9a562e1849415f285419a56f19", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# Page 1\n\n# 1. Statistical Analysis Plan I8F-MC-GPHK:\n\n# Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight-Related Comorbidities:\n\n# A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)\n\nConfidential Information\n\nThe information contained in this document is confidential and the information contained within it may not be reproduced or otherwise disseminated without the approval of Eli Lilly and Company or its subsidiaries.\n\nNote to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.\n\n# LY3298176 for Chronic Weight Management\n\nPhase-3 randomized, double-blind, placebo-controlled trial comparing 3-doses of LY3298176 to Placebo in participants without Type 2 Diabetes Who have obesity or are overweight with weight-related comorbidities.\n\nEli Lilly and Company\n\nIndianapolis, Indiana USA 46285\n\nProtocol I8F-MC-GPHK\n\nPhase 3\n\nStatistical Analysis Plan electronically signed and approved by Lilly on date provided below.\n\nApproval Date: 28-Sep-2021 GMT\n\n# LY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 1541, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c8f6dc8d-9808-4d57-b586-17dae0411e28": {"__data__": {"id_": "c8f6dc8d-9808-4d57-b586-17dae0411e28", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aa9fbcaf-0487-41a6-9653-c6b2607a0b5b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2ec2d6cab72719336654c1268fad1ead2c0d2870c5f089c6ffcff74a182b1388", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# 2. Table of Contents\n\n| Section                                                                                                                                                                                                                                                                  | Page |\n| ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ---- |\n| 1. Statistical Analysis Plan I8F\u2011MC\u2011GPHK: Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type 2 Diabetes Who Have Obesity or are Overweight with Weight\u2011Related Comorbidities: A Randomized, Double\u2011Blind, Placebo\u2011Controlled Trial (SURMOUNT\u20111) | 1    |\n| 2. Table of Contents                                                                                                                                                                                                                                                     | 2    |\n| 3. Revision History                                                                                                                                                                                                                                                      | 9    |\n| 4. Study Objectives                                                                                                                                                                                                                                                      | 12   |\n| 4.1. Primary Objective                                                                                                                                                                                                                                                   | 12   |\n| 4.2. Key Secondary Objectives                                                                                                                                                                                                                                            | 12   |\n| 4.3. Other Secondary Objectives                                                                                                                                                                                                                                          | 13   |\n| 5. Study Design                                                                                                                                                                                                                                                          | 15   |\n| 5.1. Summary of Study Design                                                                                                                                                                                                                                             | 15   |\n| 6. A Priori Statistical Methods                                                                                                                                                                                                                                          | 18   |\n| 6.1. Populations for Analyses                                                                                                                                                                                                                                            | 18   |\n| 6.2. General Considerations                                                                                                                                                                                                                                              | 18   |\n| 6.3. Adjustments for Covariates                                                                                                                                                                                                                                          | 20   |\n| 6.4. Handling of Dropouts or Missing Data                                                                                                                                                                                                                                | 20   |\n| 6.5. Multicenter Studies                                                                                                                                                                                                                                                 | 21   |\n| 6.6. Multiple Comparisons/Multiplicity                                                                                                                                                                                                                                   | 21   |\n| 6.7. Patient Disposition                                                                                                                                                                                                                                                 | 21   |\n| 6.8. Historical Illnesses and Preexisting Conditions                                                                                                                                                                                                                     | 22   |\n| 6.9. Patient Characteristics                                                                                                                                                                                                                                             | 22   |\n| 6.10. Concomitant Therapy                                                                                                                                                                                                                                                | 23   |\n| 6.11. Treatment Exposure and Compliance                                                                                                                                                                                                                                  | 23   |\n| 6.11.1. Study and Study Treatment Exposure                                                                                                                                                                                                                               | 23   |\n| 6.11.2. Compliance to Study Treatment                                                                                                                                                                                                                                    | 25   |\n| 6.12. Important Protocol Deviations                                                                                                                                                                                                                                      | 25   |\n| 6.13. Efficacy Analyses                                                                                                                                                                                                                                                  | 25   |\n| 6.13.1. Primary Efficacy Analysis                                                                                                                                                                                                                                        | 25   |\n| 6.13.1.1. Analysis Related to the Efficacy Estimand                                                                                                                                                                                                                      | 26   |\n| 6.13.1.2. Analysis Related to the Hybrid Estimand                                                                                                                                                                                                                        | 27   |\n| 6.13.1.3. Methods for Imputations                                                                                                                                                                                                                                        | 27   |\n| 6.13.1.4. Sensitivity Analysis Related to the Hybrid Estimand                                                                                                                                                                                                            | 28   |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 8905, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b6337df0-0578-4f20-b652-2c760069fcfd": {"__data__": {"id_": "b6337df0-0578-4f20-b652-2c760069fcfd", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "56d4e786-1d98-404d-9356-a97d6ba9629a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8894ed96b48afeded208be37cbf84a0ad5bf93dd32581e64820e2ed244533d00", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# 6.13.2. Secondary Efficacy Analyses Subject to Type 1 Error Rate\n\nControl 28\n\n# 6.13.3. Type 1 Error Rate Control Strategy for Primary and Key Secondary Efficacy Analyses\n\n29\n\n# 6.13.3.1. Other Secondary and Exploratory Efficacy Analyses\n\n32\n\n# 6.13.3.2. Other Secondary Efficacy Analyses\n\n32\n\n# 6.13.3.3. Exploratory Efficacy Analyses\n\n33\n\n# 6.14. Safety Analyses\n\n35\n\n# 6.14.1. Analysis of Adverse Events\n\n35\n\n# 6.14.1.1. Treatment Emergent Adverse Events\n\n35\n\n# 6.14.1.2. Common Adverse Events\n\n36\n\n# 6.14.1.3. Deaths\n\n36\n\n# 6.14.1.4. Other Serious Adverse Events\n\n36\n\n# 6.14.1.5. Other Significant Adverse Events\n\n37\n\n# 6.14.2. Patient Narratives\n\n37\n\n# 6.14.3. Special Safety Topics\n\n37\n\n# 6.14.3.1. Acute Gallbladder Disease\n\n37\n\n# 6.14.3.2. Amputation/Peripheral Revascularization\n\n37\n\n# 6.14.3.3. Exocrine Pancreas Safety\n\n38\n\n# 6.14.3.3.1. Pancreatic Enzyme\n\n38\n\n# 6.14.3.3.2. Pancreatitis Events\n\n38\n\n# 6.14.3.4. Gastrointestinal Safety\n\n38\n\n# 6.14.3.4.1. Nausea, Vomiting, and Diarrhea\n\n38\n\n# 6.14.3.4.2. Severe Gastrointestinal Events\n\n38\n\n# 6.14.3.5. Hepatic Safety\n\n38\n\n# 6.14.3.5.1. Hepatobiliary Disorders\n\n38\n\n# 6.14.3.5.2. Liver Enzymes\n\n39\n\n# 6.14.3.6. Hypoglycemia\n\n40\n\n# 6.14.3.7. Immunogenicity\n\n41\n\n# 6.14.3.7.1. Definitions of Sample ADA Status\n\n41\n\n# 6.14.3.7.2. Definitions of Immunogenicity Assessment Periods\n\n45\n\n# 6.14.3.7.3. Definitions of Participant ADA Status\n\n45\n\n# 6.14.3.7.4. Analyses to be Performed\n\n46\n\n# 6.14.3.8. Hypersensitivity Reactions\n\n47\n\n# 6.14.3.8.1. Severe/Serious Hypersensitivity Reactions\n\n48\n\n# 6.14.3.9. Injection Site Reaction\n\n48\n\n# 6.14.3.9.1. Severe/Serious Injection Site Reactions\n\n48\n\n# 6.14.3.10. Major Adverse Cardiovascular Events\n\n48\n\n# 6.14.3.11. Major Depressive Disorder/Suicidal Ideation or Behavior\n\n49\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1837, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ae6ab64a-ad08-44db-aa15-b14fca731fb0": {"__data__": {"id_": "ae6ab64a-ad08-44db-aa15-b14fca731fb0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9282ab04-e15f-4a72-9c37-fbee73cc3e4f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6aca6c474a2320d20f61d8cac03f52e71182381848572166d2ca92de4e093203", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.14.3.11.1. Patient Health Questionnaire\n\n49\n\n# 6.14.3.11.2. Suicidal Ideation and Behavior Solicited Through C\u2011SSRS\n\n50\n\n# 6.14.3.12. Malignancy\n\n51\n\n# 6.14.3.13. Metabolic Acidosis\n\n51\n\n# 6.14.3.14. Renal Safety\n\n51\n\n# 6.14.3.14.1. Acute Renal Events\n\n52\n\n# 6.14.3.14.2. Dehydration\n\n52\n\n# 6.14.3.15. Thyroid Safety Monitoring\n\n52\n\n# 6.14.3.15.1. Calcitonin\n\n52\n\n# 6.14.3.15.2. C\u2011Cell Hyperplasia and Thyroid Malignancies\n\n52\n\n# 6.14.3.16. Treatment\u2011Emergent Supraventricular Arrhythmias and Cardiac Conduction Disorders\n\n53\n\n# 6.14.3.17. Overdose\n\n53\n\n# 6.14.3.18. Abuse Liability\n\n53\n\n# 6.14.4. Vital Signs\n\n53\n\n# 6.14.5. Electrocardiograms\n\n54\n\n# 6.14.6. Clinical Laboratory Evaluation\n\n55\n\n# 6.14.6.1. Two\u2011hour Oral Glucose Tolerance Test (OGTT)\n\n56\n\n# 6.15. Health Outcomes\n\n58\n\n# 6.15.1. Patient Global Impression of Status for Physical Activity\n\n58\n\n# 6.15.2. Short\u2011Form\u201136 Health Survey Version 2, Acute Form\n\n58\n\n# 6.15.3. Impact of Weight on Quality of Life\u2011Lite Clinical Trials\n\n59\n\n# 6.15.4. EQ\u20115D\u20115L\n\n60\n\n# 6.16. Subgroup Analyses\n\n60\n\n# 6.16.1. Subgroup Analysis of Body Weight Change\n\n60\n\n# 6.17. Interim Analyses and Data Monitoring Committee\n\n61\n\n# 7. Unblinding Plan\n\n62\n\n# 8. COVID\u201119 Pandemic Impact\n\n63\n\n# 8.1. General Consideration\n\n63\n\n# 8.2. Exposure\n\n63\n\n# 8.3. Protocol Deviation\n\n63\n\n# 8.4. Patient Disposition\n\n63\n\n# 8.5. Adverse Events\n\n63\n\n# 8.6. Major Depressive Disorder/Suicidal Ideation\n\n64\n\n# 8.7. Local Lab\n\n64\n\n# 8.8. Missing Data Due to COVID\u201119\n\n64\n\n# 9. References\n\n65\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1573, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "149641f1-4736-426e-9231-5ace0c4a7a2c": {"__data__": {"id_": "149641f1-4736-426e-9231-5ace0c4a7a2c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "740ea1e7-c6e3-4dc3-b0a8-74acb449fcb6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7b99a68f8d90842ebe0c89e9b5f225736d4c2cf771d9894ec47384e855f6853f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# 10. Appendices\n\nPage 5\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 88, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d559304c-0b7d-45ef-81de-95212f0badb7": {"__data__": {"id_": "d559304c-0b7d-45ef-81de-95212f0badb7", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "06947c9e-2cae-4f6d-aefc-1ef66d3a0eb7", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d1cabf9ab321a23ae45e656c1730ad60773cbf541cc1bc6f0d2643f64a819288", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Table of Contents\n\n| Table                                                                                                       | Page |\n| ----------------------------------------------------------------------------------------------------------- | ---- |\n| Table GPHK.6.1. Description of Analysis Datasets                                                            | 18   |\n| Table GPHK.6.2. Baseline and Postbaseline Definitions for Safety Groups                                     | 19   |\n| Table GPHK.6.3. Classification of Glycemic Status                                                           | 22   |\n| Table GPHK.6.4. Secondary Measures Controlled for Type 1 Error                                              | 28   |\n| Table GPHK.6.5. Secondary Measures Not Controlled for Type 1 Error                                          | 32   |\n| Table GPHK.6.6. Exploratory Efficacy Analysis                                                               | 33   |\n| Table GPHK.6.7. Sample Anti\u2011Drug Antibodies (ADA) Assay Results                                             | 43   |\n| Table GPHK.6.8. Sample Clinical Anti\u2011Drug Antibodies (ADA) Interpretation Results                           | 43   |\n| Table GPHK.6.9. In Silico Classification for Cross\u2011Reactive NAb                                             | 44   |\n| Table GPHK.6.10. Adverse Events for Analysis with Immunogenicity Results                                    | 47   |\n| Table GPHK.6.11. Categorical Criteria for Abnormal Treatment\u2011Emergent Blood Pressure and Pulse Measurements | 54   |\n| Table GPHK.6.12. Selected Categorical Limits for ECG Data                                                   | 55   |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1735, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "46d31f3c-72de-4089-9b7c-688d73538298": {"__data__": {"id_": "46d31f3c-72de-4089-9b7c-688d73538298", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "92cb6b14-d919-4cf8-96f7-f5acad5259a6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "52b61579ad44e6c68b7ffc40ad6d40b26d67b7d04c4dbe511e4e196ed8d01df7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# Table of Contents\n\n| Figure                                                                                           | Page |\n| ------------------------------------------------------------------------------------------------ | ---- |\n| Figure GPHK.5.1. Illustration of study design for Clinical Protocol I8F\u2011MC\u2011GPHK.                 | 16   |\n| Figure GPHK.6.1. Type 1 error control strategy for primary and key secondary efficacy endpoints. | 31   |\n| Figure GPHK.6.2. Flowchart of immunogenicity multitiered testing approach.                       | 42   |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 622, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6d51a858-c4fb-4648-b901-a12b09065353": {"__data__": {"id_": "6d51a858-c4fb-4648-b901-a12b09065353", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b0d49d83-b62b-4eb9-8426-4b6a52e20ed5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "02c957c5e87ab8055ab4a0b72149d7f506a2496e9d7176d4656cec1c728b8441", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# Table of Contents\n\n| Appendix                                                                            | Page |\n| ----------------------------------------------------------------------------------- | ---- |\n| Appendix 1. Body Composition Assessments via Dual\u2011Energy X\u2011ray Absorptiometry (DXA) | 67   |\n| Appendix 2. Ambulatory Blood Pressure Monitoring (ABPM)                             | 69   |\n| Appendix 3. Searching Criteria for Special Safety Topics                            | 72   |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 545, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "10803f36-f244-42f2-b5d8-2c590b423d92": {"__data__": {"id_": "10803f36-f244-42f2-b5d8-2c590b423d92", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "279ad5f6-65c2-46cf-9e10-c5993fb029ee", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "733ac53dadd6939b786221cb58252343575960ed3a90cba8e63514461e8b19d7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 3. Revision History\n\nThis is the second version of the statistical analysis plan (SAP) for Study I8F\u2011MC\u2011GPHK. The SAP Version 1 was approved on 05\u2011Sep\u20112020. The key changes of the SAP Version 2 are summarized below:\n\n1. Added the details on type 1 error rate control strategy (see Section 6.13.3).\n2. Updated the method for multiple imputation for \u201chybrid\u201d estimand per the US Food and Drug Administration (FDA) comments issued 21\u2011Sep\u20112020 (see Section 6.13.1.3).\n3. Updated the key secondary objectives (see Section 4.2):\n1. Added the objective: \u2018Demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for the percentage of participants who achieve \u2265 20% body weight reduction from randomization at 72 weeks\u2019 as key secondary objective. Adding this objective as another key secondary objective should provide data on efficacy of the investigational product that would be valuable to better inform clinical decisions in management of people living with obesity. Lilly considers the characterization of tirzepatide efficacy in terms of this weight loss target as an important metric to characterize in labelling and thus has determined that it warrants inclusion in secondary endpoints controlled for Type 1 error.\n2. Revised the key secondary objective from \u2018Demonstrate that tirzepatide 5 mg, 10 mg, and/or 15 mg QW are superior to placebo for change in body weight (kg) from randomization at 20 weeks\u2019 to \u2018Demonstrate that pooled tirzepatide 10 mg and 15 mg QW is superior to placebo for change in body weight (kg) from randomization at 20 weeks\u2019. Analysis of pooled data from participants on different tirzepatide doses (10 mg and 15 mg QW) is more appropriate as participants randomized to the 15\u2011mg dose of tirzepatide will not be exposed to that dose until Week 20. In addition, the purpose of this endpoint at 20 weeks is to demonstrate a relatively early weight loss during or shortly after dose escalation in order to address the potential clinical concern that the long dose escalation schedules of the 10\u2011mg and 15\u2011mg doses may pose a challenge to adherence. Since the 5\u2011mg dose has a much shorter dose escalation, early weight loss has less clinical value for that dose and therefore the 5\u2011mg dose is not being included in the revised 20\u2011week endpoint.\n3. Revised the key secondary objective from \u2018Demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for change in Short Form\u201136 version 2 Health Survey (SF\u201136v2) acute form Physical Functioning domain score from randomization at 72 week\u2019 to \u2018Demonstrate that pooled tirzepatide 10 mg and 15 mg QW is superior to placebo for change in Short Form\u201136 version 2 Health Survey (SF\u201136v2) acute form Physical Functioning domain score from\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2798, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d52ae396-fbba-4561-b987-c342c75203ea": {"__data__": {"id_": "d52ae396-fbba-4561-b987-c342c75203ea", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d221d6eb-35bb-4caa-aa55-698fb545035a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "412149352a90052cef747fb591491e3f2f40e1940c060dbf77cf8ef9dcd93a2e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 10\n\nrandomization at 72 weeks\u2019. This was to reduce the number of key secondary objective.\n\n1. Replaced the key secondary objective of \u2018Demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in LDL\u2011cholesterol from randomization at 72 weeks\u2019 with \u2018Demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in non\u2011high\u2011density lipoprotein (HDL)\u2011cholesterol from randomization at 72 weeks\u2019. Non\u2011HDL\u2011cholesterol is a strong independent cardiovascular disease (CVD) risk factor. It represents an estimation of the total amount of atherogenic lipoproteins in plasma (very low\u2011density lipoprotein [VLDL] cholesterol, VLDL remnants, intermediate\u2011density lipoprotein [IDL] cholesterol, low\u2011density lipoprotein [LDL] cholesterol, Lp[a]) (Catapano et.al. 2016). In addition, there is a growing body of evidence suggesting that non\u2011HDL\u2011cholesterol may provide a more accurate measure of CVD risk in comparison to LDL\u2011cholesterol (Kilgore et al. 2014; Paredes et al. 2019).\n2. Replaced the key secondary objective of \u2018Demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in total cholesterol from randomization at 72 weeks\u2019 with \u2018Demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in HDL\u2011cholesterol from randomization at 72 weeks\u2019. HDL\u2011cholesterol is also a strong independent risk factor of CVD and it is recommended to be used in CVD risk estimation (Catapano et.al. 2016). Furthermore, total cholesterol is composed of non\u2011HDL\u2011cholesterol and HDL\u2011cholesterol. Studying the HDL and non\u2011HDL separately provides more information.\n3. Revised the language regarding the \u2018hybrid\u2019 estimand and \u2018efficacy\u2019 estimand based on new estimand language template (see Section 6.2)\n4. Added sensitivity analyses to evaluate the difference in proportions for binary endpoints per the FDA comments on 21\u2011Sep\u20112020 (see Section 6.13.3.3)\n5. Deleted the censoring analysis for post\u2011baseline hypoglycemia events per response to the FDA comments of IND 139721 on 20\u2011Feb\u20112020 (see Section 6.14.3.6)\n6. Changed the longitudinal logistic regression to logistic regression with imputation for binary outcomes dichotomized from an underlying continuous variables per recent research work (Ma et.al. 2021) for efficacy estimand (see Section 6.13.1.1)\n7. Changed the search criteria for identifying adverse event preferred terms suggestive of potential abuse liability (see Appendix 3). Based on mechanism of action of tirzepatide, anticipated gastrointestinal adverse events, and low likelihood for abuse potential/psychoactive effects, it would be reasonable to narrow the list of abuse terms to use.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2755, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "36110606-e3e8-417d-8b77-524aa8106672": {"__data__": {"id_": "36110606-e3e8-417d-8b77-524aa8106672", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e4505c9e-afff-4481-8873-8f116b778807", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "877101cd9de1f7d5f065dac82695817995cfb16a48becb9be25c1f8c94468cfb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# 9.\n\nAdded more analyses for SF\u201136v2 physical function domain score and IWQOL physical function composite score per FDA comments of IND 139721 on 27\u2011Aug\u20112021 (see Section 6.15.2 and Section 6.15.3)\n\n# 10.\n\nUpdated language related to special safety topics to align with program safety analysis plan (PSAP) version 3:\n\n- a) changes in adverse events of special interest (AESI) definition\n- b) other additional changes for clarification purposes.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 507, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4c66a980-ed51-4237-aa08-94c041bb6997": {"__data__": {"id_": "4c66a980-ed51-4237-aa08-94c041bb6997", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "298c7cea-d0d0-4511-bac3-5badcd7a0a24", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "365baac3157d56b0faa744da9cad0415a0b59c1510a44d8bc101e84239bee9df", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 4. Study Objectives\n\n# 4.1. Primary Objective\n\nThe primary objective of the study is to demonstrate that tirzepatide 10 mg and/or 15 mg once\u2011weekly (QW) are superior to placebo for percent change in body weight from randomization and percentage of participants who achieve \u22655% body weight reduction at 72 weeks.\n\n# 4.2. Key Secondary Objectives\n\nTogether with the primary objective, the following secondary objectives are subjected to strong control of the type 1 error rate (see Section 6.13.3).\n\n- To demonstrate that pooled tirzepatide 10 mg and 15 mg QW is superior to placebo for change in body weight (kg) from randomization at 20 weeks.\n- To demonstrate that tirzepatide 5 mg QW is superior to placebo for percent change in body weight from randomization and percentage of participants who achieve \u22655% body weight reduction at 72 weeks.\n- To demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for percentage of participants who achieve \u226510% body weight reduction from randomization at 72 weeks.\n- To demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for percentage of participants who achieve \u226515% body weight reduction from randomization at 72 weeks.\n- To demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for the percentage of participants who achieve \u226520% body weight reduction from randomization at 72 weeks.\n- To demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for change from randomization in waist circumference (cm) at 72 weeks.\n- To demonstrate that pooled tirzepatide 10 mg and 15 mg QW is superior to placebo for change in Short Form \u201136 version 2 Health Survey (SF\u201136v2) acute form Physical Functioning domain score from randomization at 72 weeks.\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in triglycerides (mg/dL) from randomization at 72 weeks.\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in non\u2011high\u2011density lipoprotein cholesterol (non\u2011HDL\u2011cholesterol) (mg/dL) from randomization at 72 weeks.\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in \u2011 high\u2011density lipoprotein cholesterol (HDL\u2011cholesterol) (mg/dL) from randomization at 72 weeks.\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in systolic blood pressure (SBP) (mmHg) from randomization at 72 weeks.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2521, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8dc80343-3cf9-4984-8c0b-2575cffcbcae": {"__data__": {"id_": "8dc80343-3cf9-4984-8c0b-2575cffcbcae", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ce8c739d-be87-469f-b042-9a27b78245d5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "76909d764c13dfa452fa63a304ad1827333daffdd01e298e69c273c3c1dbe442", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\nPage 13\n\n# 4.2. Primary Objectives\n\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for change in fasting insulin (pmol/L) from randomization at 72 weeks.\n- To demonstrate that tirzepatide 10 mg and/or 15 mg QW are superior to placebo for percent change in body weight from randomization at 176 weeks (for participants with prediabetes at randomization).\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for delaying the onset of type 2 diabetes mellitus (T2DM) during 176 weeks (for participants with prediabetes at randomization).\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo for delaying the onset of T2DM during 193 weeks (for participants with prediabetes at randomization).\n\n# 4.3. Other Secondary Objectives\n\nThe following secondary objectives are not subjected to strong control of the type 1 error rate:\n\n- To demonstrate that tirzepatide 5 mg QW is superior to placebo at 72 weeks for\n- percentage of participants who achieve \u226510% body weight reduction from randomization\n- percentage of participants who achieve \u226515% body weight reduction from randomization\n- mean change in waist circumference (cm) from randomization\n- mean change in SF\u201136v2 acute form Physical Functioning domain score from randomization.\n- To demonstrate that tirzepatide 5 mg, 10 mg, and/or 15 mg QW are superior to placebo at 72 weeks for\n- mean change in body weight (kg) from randomization\n- mean change in body mass index (BMI) (kg/m2) from randomization\n- mean change in hemoglobin A1c (HbA1c) (%, mmol/mol) from randomization\n- mean change in fasting glucose (mg/dL) from randomization\n- mean change in Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version (IWQOL\u2011Lite\u2011CT) Physical Function composite score from randomization\n- To demonstrate that tirzepatide QW (all doses combined) is superior to placebo at 72 weeks for\n- mean change in diastolic blood pressure (DBP) (mmHg) from randomization\n- mean change from randomization in the following lipid parameters:\n- low\u2011density lipoprotein cholesterol (LDL\u2011cholesterol)(mg/dL)\n- total cholesterol (mg/dL)", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2205, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "359526ea-fc4b-4716-b7ec-3b6641eacbac": {"__data__": {"id_": "359526ea-fc4b-4716-b7ec-3b6641eacbac", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d2748500-3ce0-4676-98c1-f45f4a9c6bfc", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "05f9a98d21eeed341766fef1ab58b17be645221de20f43afeca81461602ababf", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 14\n\n- very low\u2011density lipoprotein cholesterol (VLDL\u2011cholesterol)(mg/dL)\n- free fatty acids (mg/dL)\n\nto demonstrate that tirzepatide 5 mg QW is superior to placebo for percent change in body weight (kg) from randomization at 176 weeks (for participants with prediabetes at randomization)\n\nto demonstrate that tirzepatide 5 mg, 10 mg, and/or 15 mg QW are superior to placebo for percentage of study participants who achieve \u22655% body weight reduction from randomization at 176 weeks (for participants with prediabetes at randomization), and\n\nto demonstrate that tirzepatide QW (all doses combined) is superior to placebo (for participants with prediabetes at randomization) at 176 weeks for:\n\n- change in SF\u201136v2 acute form Physical Functioning domain score from randomization and\n- change in IWQOL\u2011Lite\u2011CT Physical Function composite score from randomization.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 920, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "440a8149-6a2f-4d40-8581-9095d19126d8": {"__data__": {"id_": "440a8149-6a2f-4d40-8581-9095d19126d8", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7ea9b745-1be3-4603-b9d4-0eb8fba961e7", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e41d5cb706b889e059cd73907e8146e3b3de84b34aad878ab06359396cc0735e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 5. Study Design\n\n# 5.1. Summary of Study Design\n\nStudy I8F\u2011MC\u2011GPHK (GPHK; SURMOUNT\u20111) is a Phase 3, multicenter, randomized, placebo\u2011controlled, double\u2011blinded study of the safety and efficacy of 5 mg, 10 mg, and 15 mg tirzepatide QW, compared with placebo, when used in conjunction with a reduced\u2011calorie diet and increased physical activity for weight management, in participants who do not have T2DM, and have obesity (BMI \u226530 kg/m2) or are overweight (BMI \u226527 kg/m2) with at least 1 weight\u2011related comorbid condition (for example, hypertension, dyslipidemia, or cardiovascular disease). All participants will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction. Participants who have prediabetes will be studied for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to detect potential differences in progression to T2DM.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 939, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "845f22ce-5c5c-4322-9384-b95e41e706bc": {"__data__": {"id_": "845f22ce-5c5c-4322-9384-b95e41e706bc", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "77a47a5d-ab45-44c0-aa14-ace7a2a19f61", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "dffb769a4ba5f978decb0a2c2fdeb4758d1cacf35b103b2bcc7e2b9f4e1c7074", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Page 16\n\nAbbreviations: QW = once weekly; T = telephone visit; T2DM = type 2 diabetes mellitus.\n\nNote: All participants (regardless of prediabetes status [Y/N] at screening) will be randomized to at least 72 weeks of treatment to study the effects on body weight reduction. Participants who have prediabetes will continue for a total of 176 weeks of treatment to provide sufficient follow\u2011up time to detect potential differences in progression to T2DM. The safety follow\u2011up visit will occur after 4 weeks in participants discontinuing (or completing) the study within the first 72 weeks. Those discontinuing (or completing) the study after 72 weeks will undergo safety follow\u2011up after 17 weeks.\n\n# Figure GPHK.5.1.\n\nIllustration of study design for Clinical Protocol I8F-MC-GPHK. The details about the overview of study periods and study visits can be found in Study GPHK protocol Section 4. The detail of the unique visits not displayed in Figure GPHK.5.1. is provided below.\n\n# Visit 99\n\nVisit 99 is only applicable to participants who discontinue the study treatment prematurely prior to Visit 21 (Week 72). Participants will be asked to return for Visit 99 at 72 weeks \u00b1 7 days after randomization. This visit is critical to ensure complete data collection for the primary weight\u2011loss endpoint.\n\nParticipants should attend this visit in the fasting state. Procedures to be completed include:\n\n- measurement of weight and waist circumference\n- concomitant medications\n- assessment of adverse events (AEs), and\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1574, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9b6b4be3-55ee-4928-8a88-a69e07131764": {"__data__": {"id_": "9b6b4be3-55ee-4928-8a88-a69e07131764", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6e4c6930-f6fe-4949-9049-4b495f602afd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1e03faecfa4f87e782f4cef8fb33ddabe123a53d4f9e64f32512e72a5063e7ce", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Page 17\n\n\u2022  completion of the mental health questionnaires (after the AE assessment).\n\n# Visit 199\n\nVisit 199 is only applicable to participants who discontinue the study treatment prematurely after Visit 21 (Week 72) and prior to Visit 116 (Week 176). Participants will be asked to return for Visit 199 at 176 weeks \u00b1 7 days after randomization. This visit is critical to ensure complete data collection for the weight\u2011loss and progression\u2011to\u2011diabetes endpoints.\n\nParticipants should attend this visit in the fasting state. Procedures to be completed include:\n\n- measurement of weight and waist circumference\n- concomitant medications\n- assessment of AEs\n- completion of the mental health questionnaires (after the AE assessment)\n- 2\u2011hour oral glucose tolerance test (OGTT)\n\n# Early Discontinuation of Treatment Visit\n\nParticipants unable or unwilling to continue the study treatment for any reason will perform early discontinuation of treatment (ED) visit at the visit when the participant informs the site about the study treatment discontinuation.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1114, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "64ec86eb-bfa7-4ccf-8024-416c911342ac": {"__data__": {"id_": "64ec86eb-bfa7-4ccf-8024-416c911342ac", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6aa998ac-fef7-4557-b4ee-04e0308daef2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "48e18adef4b98fd4e775c72d7a00ad2090621a86234d939ca2ce30089bbcfd5c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6. A Priori Statistical Methods\n\n# 6.1. Populations for Analyses\n\nFor purposes of analyses, Table GPHK.6.1 defines the analysis sets.\n\n| Analysis Set                    | Description                                                                                                                                                        |\n| ------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------ |\n| Entered Participants            | All participants who sign informed consent                                                                                                                         |\n| Randomized Participants         | All participants who are randomly assigned a study treatment                                                                                                       |\n| Modified Intent\u2011to\u2011Treat (mITT) | All randomly assigned participants who are exposed to at least 1 dose of study drug. Participants will be included in the treatment group they were randomized to. |\n| Efficacy Analysis Set (EAS)     | Data obtained during treatment period from mITT, excluding data after discontinuation of study drug (last dose date + 7 days).                                     |\n| Full Analysis Set (FAS)         | Data obtained during treatment period from mITT, regardless of adherence to study drug.                                                                            |\n| Safety Analysis Set (SS)        | Data obtained during the treatment period plus safety follow\u2011up period from mITT, regardless of adherence to study drug.                                           |\n\n# 6.2. General Considerations\n\nStatistical analysis of this study will be the responsibility of Eli Lilly and Company (Lilly) or its designee. Some analyses and summaries described in this analysis plan may not be conducted if not warranted by data (for example, few events to justify conducting an analysis). Additional analyses of the data may be conducted as deemed appropriate.\n\nUnless otherwise noted, tests of treatment effects will be conducted at a 2\u2011sided alpha level of 0.05, and the confidence interval (CI) will be calculated at 95% 2\u2011sided.\n\nUnless specified otherwise, efficacy and safety will be assessed using the modified intention\u2011to\u2011treat (mITT) population, and data will be analyzed based on the randomized treatment (that is, not the actual treatment received by the participant). For submission of Study GPHK to the US Food and Drug Administration (FDA) to support the registration of tirzepatide for chronic weight management, the primary efficacy analysis will be conducted using Full Analysis Set (FAS). For other purposes, the efficacy analysis will be conducted using Efficacy Analysis Set (EAS). Safety analysis will be conducted using Safety Analysis Set (SS).\n\nSummary descriptive statistics for continuous measures will include sample size, mean, standard deviation (SD), median, minimum, and maximum. The analysis model to make comparisons among treatment groups relative to continuous measurements assessed over time will be either analysis of covariance (ANCOVA) or a mixed model for repeated measures (MMRM).\n\nKaplan\u2011Meier method will be used for estimation of cumulative event\u2011free survival rates over time, and Cox proportional hazards regression analysis will be used to compare hazards rates among treatments.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3554, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "745dfb66-19ad-47a5-9ebf-0cfe4646c443": {"__data__": {"id_": "745dfb66-19ad-47a5-9ebf-0cfe4646c443", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "96db3495-0a4c-402a-8bb1-3a9db7de0477", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "5ae516333f52364730c9050c66cabd58accd26021f79446a7eaa73fbfbf1824f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 19\n\nSummary statistics for categorical measures (including categorized continuous measures) will include sample size, frequency, and percentages. Logistic regression will be used to examine the treatment difference in binary efficacy outcomes if there is a need to adjust for covariate. Otherwise, Fisher\u2019s exact test will be used to examine the treatment difference.\n\nSummary statistics for discrete count measures will include sample size, mean, SD, median, minimum, and maximum.\n\nUnless specified otherwise, baseline will be defined as the last available non\u2011missing measurement during Visit 1 to Visit 3. For the safety related parameters, the definition of baseline and postbaseline are specified in Table GPHK.6.2.\n\n| Analysis Set | Analysis Type                                                                                        | Baseline                                                                                                                            | Postbaseline                                                                                                                                                |\n| ------------ | ---------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| SS           | 1.1) Treatment\u2011Emergent Adverse Events                                                               | The baseline period is defined as the start of screening and ends prior to the first dose of study treatment (typically at Week 0). | Starts after the first dose of study treatment and ends at the end of the study period (including off\u2011drug follow up visit).                                |\n| SS           | 1.2) Treatment\u2011Emergent Abnormal Labsa, Vital Signs, and ECGs.                                       | Baseline will include all scheduled and unscheduled measurements during the baseline period (Visit 1 to Visit 3).                   | Postbaseline will be defined as measurements after Visit 3. All scheduled and unscheduled measurements will be included.                                    |\n| SS           | 1.3) Change from Last Baseline to Week xx and to Last Postbaseline for Labsa, Vital Signs, and ECGs. | The last scheduled and unscheduled non\u2011missing assessment recorded during the baseline period defined above (1.2).                  | Postbaseline will be defined as above (1.2). Only scheduled visits will be included. The early discontinuation (ED) visits are considered scheduled visits. |\n\nAbbreviations: ECGs = electrocardiogram; SS = Safety Analysis Set.\n\na Immunogenicity related analysis is specified in Section 6.14.3.7.\n\nThere will be 2 estimands of interest in evaluating primary and key secondary efficacy objectives:\n\n- For objectives controlled for Type 1 error at 72 weeks:\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3139, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8ccbccb8-8b69-4c72-b680-8ecfcc971d82": {"__data__": {"id_": "8ccbccb8-8b69-4c72-b680-8ecfcc971d82", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ab33b7e3-1997-4b18-a024-d119d89e2537", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a3c98016446b5ab5f53984c3ef7fa7b40872b26dcb80e78c5fae06d6f923a154", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\nPage 20\n\n\u2022 For objectives controlled for Type 1 error assessed after 72 weeks:\n\n- the \u201cefficacy\u201d estimand, defined as the treatment effect of tirzepatide relative to placebo at 176/193 weeks, as an adjunct to a reduced\u2011calorie diet and increased physical activity, in the randomized participants with prediabetes at randomization had they remained on their randomized treatment for the entire planned 176 weeks treatment duration.\n- the \u201chybrid\u201d estimand, is the average treatment effect of tirzepatide relative to placebo at 176/193 weeks, as an adjunct to a reduced\u2011calorie diet and increased physical activity, for the randomized participants with prediabetes at randomization regardless of the adherence to treatment.\n\nEnd of study participation for a participant will be the earliest of date of death, date of withdrawal from further participation in the study, or date of safety follow\u2011up visit (Visit 801 or Visit 802). For participants considered to be lost\u2011to\u2011follow\u2011up, end of study participation will be the date of lost\u2011to\u2011follow\u2011up reported by the investigator. Participant data included in the database after the last date of study participation (including safety follow\u2011up period) will be excluded from statistical analysis.\n\nStatistical treatment comparisons will only be performed between tirzepatide and placebo. Since the trial is not adequately powered to detect difference among tirzepatide doses, comparisons among tirzepatide doses will not be performed unless otherwise specified.\n\nStatistical summaries and results of statistical analyses will be displayed in the following order: Placebo, tirzepatide 5 mg, tirzepatide 10 mg, tirzepatide 15 mg, and pooled tirzepatide (10 mg and 15 mg, or all doses combined, if necessary).\n\nNot all analyses described in this SAP will necessarily be included in the Clinical Study Reports (CSRs). Any analysis described in this SAP and not provided in the CSR would be available upon request. Not all displays will necessarily be created as a \u201cstatic\u201d display. Some may be incorporated into interactive display tools instead of or in addition to a static display.\n\n# 6.3. Adjustments for Covariates\n\nThe study is stratified by prediabetes status at randomization, country, and sex (female, male). Where necessary to be included as a stratification factor, countries with fewer than 10 randomized participants will be pooled into 1 category (pooled country).\n\nUnless otherwise specified, for efficacy related analyses at 72 weeks, country/pooled country, sex, prediabetes status at randomization and corresponding baseline value will be used as a covariate. For efficacy analyses at 176 weeks (or 193 weeks), country/pooled country, sex and corresponding baseline value will be used as a covariate.\n\n# 6.4. Handling of Dropouts or Missing Data\n\nFor the primary and key secondary efficacy endpoint analyses subject to type 1 error rate control, data for participants with missing values at the 72\u2011week visit (or weight related measurements at", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3049, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0f93b9f4-374d-450f-b40e-eefde8f23ff2": {"__data__": {"id_": "0f93b9f4-374d-450f-b40e-eefde8f23ff2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d829383f-25a7-461e-b803-078ee64d7668", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d28a9ddbded476b615c0e447f2e458204cee6a86e1265c9ea4796df5eab96355", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n176-week visit for participants with prediabetes at randomization) will be imputed based on the method described in Section 6.13.1.3. However, for the parameters with only 1 postbaseline measure during the analysis period per schedule of activity, the last observation carried forward (LOCF) approach will be applied to impute the endpoint when ED measure is available.\n\n# 6.5. Multicenter Studies\n\nThe randomization will be stratified by country, and the country/pooled country will be used as a covariate.\n\n# 6.6. Multiple Comparisons/Multiplicity\n\nThe type 1 error rate control strategy for primary and key secondary efficacy objectives is illustrated in Section 6.13.3. These objectives will be assessed separately for the \u201cefficacy\u201d estimand and \u201chybrid\u201d estimand. As they are intended for different purposes, no multiplicity adjustments will be made for conducting separate analyses relative to the \u201cefficacy\u201d and \u201chybrid\u201d estimands. In addition, no multiplicity adjustments will be made for evaluating other secondary and exploratory objectives, and safety assessments.\n\n# 6.7. Patient Disposition\n\nA listing of study disposition for all randomized participants will be provided at the primary database lock and final database lock, respectively. Summaries of study disposition and study drug disposition for all randomized participants will be provided by planned study treatment at the primary database lock (after 72-week treatment). In addition, similar summaries might be provided for participants without prediabetes at randomization at the primary database lock. Same summaries will be provided for randomized participants with prediabetes at randomization at final lock (after 176-week treatment).\n\nThe study completion status is defined as follows:\n\n- at the end of 72-week treatment period (when the primary endpoint is ascertained, and primary database is locked):\n- for participants without prediabetes at randomization: participants with a non-missing body weight measurement at 72-week (Visit 21 or Visit 99) and non-missing safety follow-up visit (Visit 801) will be considered as completers.\n- for participants with prediabetes at randomization: participants with a non-missing body weight measurement at 72-week (Visit 21 or Visit 99) will be considered as completers.\n- otherwise, they will be considered as non-completers.\n- at the end of 176-week treatment period for participants with prediabetes at randomization:\n- participants with a non-missing body weight measurement at 176-week (Visit 116 or Visit 199) and non-missing safety follow-up visit (Visit 802) will be considered as completers; otherwise, will be considered as non-completers.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2731, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f1301a21-0d44-40ea-a7ac-7e50ca174ec3": {"__data__": {"id_": "f1301a21-0d44-40ea-a7ac-7e50ca174ec3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6320a82a-dd51-4d58-a25c-fa00227eec08", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e18d979434fd74b692ac0875b231e565bd0cbf7c7c5e7a0b52efec4528dde2bc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# 6.8. Historical Illnesses and Preexisting Conditions\n\nThe count and percentages of participants with historical illnesses and preexisting conditions will be summarized by treatment group using the Medical Dictionary for Regulatory Activities (MedDRA) Preferred Terms (PTs) nested within System Organ Class (SOC). The SOC will be in alphabetical order. Conditions (that is, PTs) will be ordered by decreasing frequency within SOC. This will be summarized for all randomized participants.\n\n# 6.9. Patient Characteristics\n\nA listing of participant demographics for all randomized participants will be provided. All demographic and baseline clinical characteristics will be summarized by study treatment for all randomized participants. Baseline demographic and clinical characteristics of special interest include but are not limited to: age (years), sex (female, male), race, ethnicity, height (cm), weight (kg), BMI (kg/m\u00b2), waist circumference (cm), age group (&#x3C;65 years, \u226565 years), BMI group (&#x3C;30, \u226530 and &#x3C;35, \u226535 and &#x3C;40, \u226540 kg/m\u00b2), country, weight\u2011related comorbidities. In addition, similar demographics and baseline characteristics might be provided by study treatment by glycemic status (prediabetes and normoglycemia) at randomization.\n\nAll participants without laboratory tests suggestive of diabetes will be classified as having either normoglycemia or prediabetes. Populations are defined in Table GPHK.6.3.\n\n# Table GPHK.6.3. Classification of Glycemic Status\n\n|                                              | Normoglycemia            | Prediabetes                     | Diabetes                  |\n| -------------------------------------------- | ------------------------ | ------------------------------- | ------------------------- |\n| Fasting glucose                              | <100 mg/dL (<5.6 mmol/L) | 100\u2011125 mg/dL (5.6\u20116.9 mmol/L)  | \u2265126 mg/dL (\u22657.0 mmol/L)  |\n| Obtained alone or at time = 0 during an OGTT |                          |                                 |                           |\n| 2H glucose                                   | <140 mg/dL (<7.8 mmol/L) | 140\u2011199 mg/dL (7.8\u201111.0 mmol/L) | \u2265200 mg/dL (\u226511.1 mmol/L) |\n| Obtained at time = 120 min during an OGTT    |                          |                                 |                           |\n| HbA1c                                        | <5.7% (<39 mmol/mol)     | 5.7%\u20116.4% (39\u201147 mmol/mol)      | \u22656.5% (\u226548 mmol/mol)      |\n\nAbbreviations: HbA1c = hemoglobin A1c; min = minute; OGTT = 2\u2011hour oral glucose tolerance test.\n\nIn keeping with American Diabetes Association guidelines (ADA 2019a), at least 2 abnormal tests are required to diagnose prediabetes. Specifically, participants meeting 1 of the following criteria will be categorized as prediabetes:\n\n- Both fasting glucose (FG; 0 hour of OGTT) and 2\u2011hour values during the 2\u2011hour OGTT values are in the prediabetes range, which is 100 to 125 mg/dL (5.6 to 6.9 mmol/L) and 140 mg to 199 mg/dL (7.8 to 11.0 mmol/L) for FG and 2\u2011hour OGTT, respectively.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3095, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "35fcc5b4-d6bb-4aa8-9384-dc6485835c8d": {"__data__": {"id_": "35fcc5b4-d6bb-4aa8-9384-dc6485835c8d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c0eb76d5-0a3c-444f-8000-a743edc835b6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b124fbced33266d0a39f2e94248bdd7f5a16d4319ed771b21bcd15536347215e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n\u2022  FG at Screening Visit 1 and Visit 2 (0 hour of OGTT) are in the prediabetes range.\n\n\u2022  FG at Screening Visit 1 and 2\u2011hour values during 2\u2011hour OGTT are in the prediabetes range.\n\n\u2022  HbA1c AND 1 of either the FG (Visit 1 or Visit 2) or 2\u2011hour OGTT values are in the prediabetes range. For HbA1c, the prediabetes range is 5.7% to 6.4% (39 to 47 mmol/mol).\n\n\u2022  Any 2 of HbA1c values between Visit 1 and Visit 3 including unscheduled visits are in the prediabetes range.\n\n# 6.10. Concomitant Therapy\n\nConcomitant medication will be summarized by PTs by treatment group by decreasing frequency for SS group. The following 2 postbaseline periods will be considered, respectively:\n\n- up to 72 weeks plus safety follow\u2011up (Visit 801) for all randomized participants, and\n- up to 176 weeks plus safety follow\u2011up (Visit 801 or Visit 802) for participants with prediabetes at randomization.\n\nAdditionally, medications of interest (as defined below) will be summarized by treatment for SS. Concomitant medications of interest include the following:\n\n- baseline antihypertensive therapy\n- baseline lipid lowering therapy\n- changes to baseline medication in post\u2011randomization (in term of type/class and dose):\n- - antihypertensive therapy, and\n- lipid lowering therapy.\n\nutilization after randomization of:\n\n# 6.11. Treatment Exposure and Compliance\n\n# 6.11.1. Study and Study Treatment Exposure\n\nSummary of duration of follow\u2011up (defined as time in days from date of randomization to the date of the last study visit) and/or duration on study treatment (defined as time in days from date of first dose of study treatment to date of last dose of study treatment plus 7 days) will be provided by treatment group using data from SS, in the following 2 periods:\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1809, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ca113084-8c42-4a50-a940-fe5c3195dd27": {"__data__": {"id_": "ca113084-8c42-4a50-a940-fe5c3195dd27", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "25b628c3-67ee-42f9-9530-be6dd0d5cd72", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "889f248991e45981cc759e93260f5261eb159159908fe016bde0f9f8f6ef1d63", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Page 24\n\n\u2022  72 weeks plus safety follow\u2011up (Visit 801) for all randomized participants. and\n\n\u2022  176 weeks plus the safety follow\u2011up periods (Visit 801 or Visit 802) for participants with prediabetes at randomization.\n\nFor the summary of duration on study treatment, the frequency and percentage of participants falling into the following range will be summarized by planned treatment group as well:\n\n- >0\n- \u22654 weeks\n- \u22658 weeks\n- \u226512 weeks\n- \u226516 weeks\n- \u226520 weeks\n- \u226524 weeks\n- \u226536 weeks\n- \u226548 weeks\n- \u226552 weeks\n- \u226572 weeks\n- \u226598 weeks\n- \u2265124 weeks\n- \u2265150 weeks, and\n- \u2265176 weeks.\n\nIn addition, the frequency and percentages of participants falling into the following study treatment exposure ranges may be summarized by planned treatment group:\n\n- 0 weeks\n- >0 to &#x3C;4 weeks\n- \u22654 to &#x3C;8 weeks\n- \u22658 to &#x3C;16 weeks\n- \u226516 to &#x3C;24 weeks\n- \u226524 to &#x3C;36 weeks\n- \u226536 to &#x3C;48 weeks\n- \u226548 to &#x3C;52 weeks\n- \u226552 to &#x3C;72 weeks\n- \u226572 to &#x3C;98 weeks (for participants with prediabetes at randomization)\n- \u226598 to &#x3C;124 weeks (for participants with prediabetes at randomization)\n- \u2265124 to &#x3C;150 weeks (for participants with prediabetes at randomization)\n- \u2265150 to &#x3C;176 weeks (for participants with prediabetes at randomization), and\n- \u2265176 (for participants with prediabetes at randomization).\n\nNo p\u2011values will be reported in these summaries as they are intended to describe the study populations rather than test hypotheses about them.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1527, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e00b3890-8bab-482a-aef8-bd4c2fe093f5": {"__data__": {"id_": "e00b3890-8bab-482a-aef8-bd4c2fe093f5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c3df6ef-4c7d-43e8-9f4e-198a7cf16927", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "58206abbd1d0d1d51fefe91a091ace2253fbe1e4b53adbdb87da81814129fb5f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.11.2. Compliance to Study Treatment\n\nSummary of prematurely discontinuing study treatment (including discontinuation reason) will be provided by study treatment. A time\u2011to\u2011event analysis of premature study treatment discontinuation will also be conducted.\n\nThe analyses related to compliance will be conducted for the following 2 periods separately:\n\n- during the 72\u2011week treatment period for all randomized participants, and\n- during the 176\u2011week treatment period for participants with prediabetes at randomization.\n\nIf data warrants, the counts and percentages of participants who follow the planned escalation scheme, have dose interruption, or have dose de\u2011escalation may be summarized for tirzepatide treatment group. In addition, the proportion of participants receiving 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg may be presented by randomized tirzepatide treatment and visit during the dose escalation period.\n\nTreatment compliance will be defined as taking at least 75% of the scheduled tirzepatide doses. Compliance over the study period will be calculated using the number of doses administered (regardless of the actual dose in mg administered) divided by the total number of doses expected to be administered \u00d7100 over the study period. Treatment compliance will be summarized descriptively in the study period by treatment using the mITT population.\n\n# 6.12. Important Protocol Deviations\n\nImportant protocol deviations are identified in the Trial Issues Management Plan (TIMP). A listing and a summary of important protocol deviations by treatment will be provided at the end of 72 weeks treatment (for all randomized participants) and at the end of the study (for participants with prediabetes at randomization).\n\n# 6.13. Efficacy Analyses\n\nFor submission of Study GPHK to the US FDA to support the registration of tirzepatide for chronic weight management, all primary and key secondary efficacy assessments will be guided by the \u201chybrid\u201d estimand conducted using the FAS. Assessment of the primary and key secondary objectives (except for endpoint \u201cdelaying the onset of diabetes during 176 weeks or 193 weeks [for participants with prediabetes at randomization]\u201d) will be conducted with multiple imputation of missing data (see Section 6.13.1.3).\n\nFor other regulatory agencies, publications and other purposes, the assessment of efficacy objectives will be guided by the \u201cefficacy\u201d estimand using the EAS.\n\n# 6.13.1. Primary Efficacy Analysis\n\nThe primary efficacy measure will be percent change in body weight from randomization and percentage of participants who achieve \u22655% body weight reduction at 72 weeks. The percent change in body weight at each nominal visit is defined as:\n\n(postbaseline body weight [kg] \u2013 baseline body weight [kg]) / baseline body weight [kg] * 100%.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2856, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2b9c01b2-bb80-4eab-9a14-0436f08dc7bd": {"__data__": {"id_": "2b9c01b2-bb80-4eab-9a14-0436f08dc7bd", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f44eb63f-a431-4353-92f3-bff387dc257f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1af12f09912f3cd494a2a4c75e7f1ccb7ab7929104785ff811f1d4e79cc00185", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\nBoth percent change in body weight and percentage of participants who achieve \u22655% body weight reduction will be summarized by treatment and nominal visit (week) from randomization to 72 weeks.\n\n# 6.13.1.1. Analysis Related to the Efficacy Estimand\n\nThe analysis related to efficacy estimand will be conducted utilizing data in the EAS. For the mean percent body weight change from randomization, a MMRM will be conducted. Restricted maximum likelihood (REML) will be used to obtain model parameter estimates and the Kenward\u2011Roger option will be used to estimate the denominator degrees of freedom. The response variable of MMRM will be the percent change in body weight from baseline values obtained at each scheduled post baseline visit.\n\nFor the percentage of participants achieving at least 5% body weight reduction from randomization over time, a logistic regression model will be used with the response variable of the percentage of participants achieving at least 5% body weight reduction at each scheduled postbaseline visit.\n\nFor MMRM the independent variables of analysis model is treatment group, visit, treatment\u2011by\u2011visit interaction, stratification factors (prediabetes status at randomization, sex and country/pooled country) as fixed effects, and baseline body weight as a covariate. An unstructured covariance structure will model relationship of within\u2011patient errors. If this model fails to converge, the following variance covariance structures will be tested in order until convergence is achieved:\n\n- heterogeneous Toeplitz\n- heterogeneous first order autoregressive\n- heterogeneous compound symmetry\n- Toeplitz\n- first order autoregressive\n- compound symmetry.\n\nThe first covariance structure that converges will be used.\n\nWith the aid of the MMRM analysis, 2\u2011sided 95% CIs for mean percent change in body weight from randomization to the 72\u2011week visit for tirzepatide 10 mg and 15 mg compared to placebo will be derived and summarized. The resulting least squares mean (LSM) estimates of mean percent change in body weight from baseline will be plotted by visit and by study treatment.\n\nA logistic regression model with terms of treatment group, country/pooled country, sex, and prediabetes status at randomization as fixed effects, and baseline body weight as a covariate, will be conducted for percentage of participants achieving at least 5% body weight reduction from randomization at the 72 week visit. Missing body weight measurement at 72 week will be imputed by the predicted value from MMRM model aforementioned, then the continuous measurements will be dichotomized into status of achieving at least 5% body weight reduction.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2717, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bb4f85f3-088c-4c39-8d03-7c8f0869f202": {"__data__": {"id_": "bb4f85f3-088c-4c39-8d03-7c8f0869f202", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "766e8ebd-c590-4fe1-8e5d-5648b25dc01a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "cb5bf9453d481d92054811561bd9e564a862f1947d0793d7413464350c9cc866", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.13.1.2. Analysis Related to the Hybrid Estimand\n\nThe analysis related to \u201chybrid\u201d estimand will be conducted using data in the FAS. The analysis for the mean percent change in body weight will be conducted utilizing ANCOVA. The response variable for the ANCOVA model will be percent change in body weight from randomization at 72 weeks. A logistic regression model will be used for the analysis of the percentage of participants achieving at least 5% body weight reduction obtained at the 72\u2011week visit. Both models will include terms of treatment group, country/pooled country, sex, and prediabetes status at randomization as fixed effects and baseline body weight as a covariate. The ANCOVA analysis will be conducted with multiple imputation of missing body weight at 72 weeks (see Section 6.13.1.3 for details) and statistical inference over multiple imputation of missing data guided by Rubin (1987). As for the logistic regression, missing body weight data at 72 weeks will be imputed first based on Section 6.13.1.3, then the continuous measurements will be categorized into status of achieving at least 5% body weight reduction (Yes or No).\n\nWith the aid of the ANCOVA model, 2\u2011sided 95% CI for mean change in percent body weight from baseline to the 72\u2011week visit between tirzepatide 10 mg and placebo, as well as tirzepatide 15 mg and placebo will be derived. With the aid of the logistic regression model, 2\u2011sided 95% CI and odds ratio for percentage of participants achieving at least 5% body weight reduction from baseline to the 72\u2011week visit between tirzepatide 10 mg and placebo, as well as tirzepatide 15 mg and placebo will be derived.\n\n# 6.13.1.3. Methods for Imputations\n\nFor efficacy analyses relative to \u201chybrid\u201d estimand, the intercurrent events (ICEs) and the resulting missing values will be handled as follows:\n\n- Category 1: for missing data solely due to exceptional circumstances, such as pandemic or natural disasters (after other reasons for missing data are ruled out), the analysis will consider the missing data as missing at random. The missing data will be imputed using all non\u2011missing data of the primary outcome measurement from the same treatment arm.\n- Category 2: for missing data due to all other ICEs: missing data will be imputed based on retrieved dropouts in the same treatment arm, defined as observed primary outcome measurements, from participants in the same treatment group, who had their efficacy assessed after early discontinuation of the study drug. In case where there are not enough retrieved dropouts to provide a reliable imputation model (for example, the model implemented by the SAS program does not converge), an alternative multiple imputation method with reference to the placebo group (that is, placebo multiple imputation) will be used.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2868, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fd9a5733-f7a2-4059-94d5-500c6c5819d2": {"__data__": {"id_": "fd9a5733-f7a2-4059-94d5-500c6c5819d2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7fbe58f6-8d17-40e9-8a41-01d4323a803a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "697176eba54f396857c2032f8913068c72fa90a4adb4b0b1897b5274f77643b9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.13.1.4. Sensitivity Analysis Related to the Hybrid Estimand\n\nFor submission of Study GPHK to the US FDA to support the registration of tirzepatide for chronic weight management, additional sensitivity analyses of the primary efficacy outcomes will be conducted using the FAS and guided by the \u201ctreatment\u2011regimen estimand, which represents the efficacy irrespective of adherence to study drug. This assessment will analyze percent change in body weight obtained at the 72\u2011week visit using an ANCOVA and the percentage of participants achieving at least 5% body weight reduction obtained at the 72\u2011week visit using a logistic regression model. The terms for both models will be the same as specified in Section 6.13.1.2 for \u201chybrid\u201d estimand.\n\nMissing values of change in body weight at the 72\u2011week visit will be imputed based on observed body weight change from baseline values at the visit from participants in the same treatment group who had their efficacy assessed after early discontinuation of study drug. In cases where there are not enough retrieved dropouts to provide a reliable imputation model (for example, the model implemented by the SAS program does not converge), an alternative multiple imputation method with reference to the placebo group (placebo multiple imputation) will be used. Analysis will be conducted with multiple imputations.\n\n# 6.13.2. Secondary Efficacy Analyses Subject to Type 1 Error Rate Control\n\n| Objectives                                                   | Relative to the efficacy measure:                                                                                                            | Analysis conducted in a manner similar to                                                                           | Additional Information                                       |\n| ------------------------------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------ |\n| Tirzepatide 10 mg and 15 mg combined is superior to placebo: | Mean change in body weight (kg) from randomization at 20 weeks                                                                               | MMRM model in Section 6.13.1.1 for efficacy estimand and ANCOVA model in Section 6.13.1.2 for hybrid estimand       |                                                              |\n| Tirzepatide 5 mg is superior to placebo:                     | Mean percent change in body weight from randomization and percentage of participants achieving at least 5% body weight reduction at 72 weeks | Section 6.13.1.1 for efficacy estimand and Section 6.13.1.2 for hybrid estimand                                     |                                                              |\n| Tirzepatide 10 mg and/or 15 mg is superior to placebo:       | Percentage of participants achieving body weight reduction \u226510%, \u226515% and \u226520% at 72 weeks                                                   | logistic model in Section 6.13.1.1 for efficacy estimand and logistic model in Section 6.13.1.2 for hybrid estimand |                                                              |\n|                                                              | Mean change in waist circumference (cm) from randomization at 72 weeks                                                                       | MMRM model in Section 6.13.1.1 for efficacy estimand and ANCOVA model in Section 6.13.1.2 for hybrid estimand       | LSM estimates will be plotted by treatment through 72\u2011weeks. |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3830, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e20215cf-e2a3-470a-880e-1737ecbf75bc": {"__data__": {"id_": "e20215cf-e2a3-470a-880e-1737ecbf75bc", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a53700ce-a744-4d38-9abf-75d0a69e3bbd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a3b585c92fe02fc255a541c716b092fd7d110938ce49fead2d300c6d1672c039", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00735c34-2c69-4140-a2d6-07248c35a094", "node_type": "1", "metadata": {}, "hash": "57b3ddc1fd4eabb223a202862e6d328d83440d1bc45687ec489c9bc82ece3f20", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 29\n\n# Secondary Measures Controlled for Type 1 Error\n\n| Objectives                                                  | Relative to the efficacy measure:                                                                                       | Analysis conducted in a manner similar to                                                                                                                                                                        | Additional Information                                                                                                                                 |\n| ----------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------ |\n| Tirzepatide 10 mg and 15 mg combined is superior to placebo | Mean change in SF\u201136 v2 acute form Physical Functioning domain score from randomization at 72 weeks                     | ANCOVA model with the terms of treatment group, stratification factors as fixed effects, and baseline SF\u201136 v2 acute form Physical Functioning domain score as a covariate.                                      | For efficacy estimand, missing data will be imputed based on LOCF method. For hybrid estimand, missing data will be imputed based on Section 6.13.1.3. |\n| Tirzepatide (all doses combined) is superior to placebo:    | Mean change in triglycerides, HDL\u2011C, non\u2011HDL\u2011C, SBP and fasting insulin from randomization at 72 weeks                  | MMRM model in Section 6.13.1.1 for efficacy estimand and ANCOVA model in Section 6.13.1.2 for hybrid estimand                                                                                                    | For hybrid estimand, missing data will be imputed first for each treatment based on Section 6.13.1.3, then combine all tirzepatide doses.              |\n| Tirzepatide 10 mg, and/or 15 mg is superior to placebo:     | Mean percent change in body weight from randomization at 176 weeks (for participants with prediabetes at randomization) | MMRM model in Section 6.13.1.1 for efficacy estimand and ANCOVA model in Section 6.13.1.2 for hybrid estimand. Include country, sex as stratification factors in each model.                                     | Only for participants with prediabetes at baseline. For the hybrid estimand, missing data at 176 week will be imputed based on Section 6.13.1.3.       |\n| Tirzepatide (all doses combined) is superior to placebo:    | Time to onset of T2DM during 176 weeks (or during 193 weeks) for participants with prediabetes at randomization         | Cox\u2011proportional hazards model will be used with the terms of treatment group (all tirzepatide doses combined and placebo), country and sex as fixed effects, and baseline fasting glucose value as a covariate. | Only for participants with prediabetes at baseline.                                                                                                    |\n\nAbbreviations: ANCOVA = analysis of covariance; HDL\u2011C = high\u2011density lipoprotein cholesterol; LOCF = last observation carried forward; LSM = least squares mean; MMRM = mixed model for repeated measures; SBP = systolic blood pressure; SF\u201136 = Short Form \u201136 version 2 Health Survey; T2DM = type 2 diabetes mellitus.\n\nDecision will be guided by the 2\u2011sided p\u2011values in each objective, and details will be included in Section 6.13.3.\n\n# 6.13.3. Type 1 Error Rate Control Strategy for Primary and Key Secondary Efficacy Analyses\n\nNo type 1 error rate adjustments will be made for conducting analyses relative to \u201cefficacy\u201d estimand and \u201chybrid\u201d estimand, as these two estimands are intended for different purposes. For analysis within each estimand, type 1 error rate control strategy for evaluation of primary and key secondary objectives is illustrated in Figure GPHK.6.1.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4276, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "00735c34-2c69-4140-a2d6-07248c35a094": {"__data__": {"id_": "00735c34-2c69-4140-a2d6-07248c35a094", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a53700ce-a744-4d38-9abf-75d0a69e3bbd", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a3b585c92fe02fc255a541c716b092fd7d110938ce49fead2d300c6d1672c039", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e20215cf-e2a3-470a-880e-1737ecbf75bc", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7840dfc8a12812e7cd3e45c3c2671b7c09c13f4ea04ab5b8c9af94ac0f82a0a8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 6.13.3. Type 1 Error Rate Control Strategy for Primary and Key Secondary Efficacy Analyses\n\nNo type 1 error rate adjustments will be made for conducting analyses relative to \u201cefficacy\u201d estimand and \u201chybrid\u201d estimand, as these two estimands are intended for different purposes. For analysis within each estimand, type 1 error rate control strategy for evaluation of primary and key secondary objectives is illustrated in Figure GPHK.6.1. The hypotheses for the primary and key secondary objectives are as follows:\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 3838, "end_char_idx": 4363, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f9379dbd-ec25-40f9-b247-039e2dcefa3d": {"__data__": {"id_": "f9379dbd-ec25-40f9-b247-039e2dcefa3d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dcf35350-86dd-4402-993e-d6354cbb0e3b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "df171d8a4c5357b362e0908c2f13b3489ddf6b9a2d1d8d43213de61ec9b5ee88", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 30\n\n- H15,1 and H10,1: superiority of tirzepatide 10 mg and/or 15 mg versus placebo for percent change in body weight from randomization and percentage of participants who achieve \u22655% body weight reduction at 72 weeks\n- H15,2 and H10,2: superiority of tirzepatide 10 mg and/or 15 mg versus placebo for percentage of participants who achieve \u226510% body weight reduction from randomization at 72 weeks\n- H15,3 and H10,3: superiority of tirzepatide 10 mg and/or 15 mg versus placebo for percentage of participants who achieve \u226515% body weight reduction from randomization at 72 weeks\n- H15,4 and H10,4: superiority of tirzepatide 10 mg and/or 15 mg versus placebo for percentage of participants who achieve \u226520% body weight reduction from randomization at 72 weeks\n- H15,5 and H10,5: superiority of tirzepatide 10 mg and/or 15 mg versus placebo for change from randomization in waist circumference (cm) at 72 weeks\n- H1015,6: superiority of pooled tirzepatide 10 mg and 15 mg versus placebo for change in body weight (kg) from randomization at 20 weeks\n- H5,1: superiority of tirzepatide 5 mg versus placebo for percent change in body weight from randomization and percentage of participants who achieve \u22655% body weight reduction at 72 weeks\n- Hp,7: superiority of tirzepatide (all doses combined) versus placebo for change in systolic blood pressure (SBP) (mmHg) from randomization at 72 weeks\n- Hp,8: superiority of tirzepatide (all doses combined) versus placebo for change in triglycerides (mg/dL) from randomization at 72 weeks\n- Hp,9: superiority of tirzepatide (all doses combined) versus placebo for change in non-high-density lipoprotein cholesterol (non-HDL-cholesterol) (mg/dL) from randomization at 72 weeks\n- Hp,10: superiority of tirzepatide (all doses combined) versus placebo for change in high-density lipoprotein cholesterol (HDL-cholesterol) (mg/dL) from randomization at 72 weeks\n- Hp,11: superiority of tirzepatide (all doses combined) versus placebo for change in fasting insulin (pmol/L) from randomization at 72 weeks\n- H1015,12: superiority of pooled tirzepatide 10 mg and 15 mg versus placebo for change in SF-36v2 acute form Physical Functioning domain score from randomization at 72 weeks.\n- H15,13 and H10,13: superiority of tirzepatide 10 mg and/or 15 mg versus placebo for change in percent body weight from randomization at 176 weeks (for participants with prediabetes at randomization).\n- Hp,14 and Hp,15: superiority of tirzepatide (all doses combined) versus placebo for delaying the onset of type 2 diabetes mellitus (T2DM) during 176 weeks or 193 weeks (for participants with prediabetes at randomization).\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2701, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c3c6b60d-bfa8-48ee-a30e-492e10958ea3": {"__data__": {"id_": "c3c6b60d-bfa8-48ee-a30e-492e10958ea3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "98114f8d-a514-4ea3-a0b6-4065dccd1f47", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d891812efda0e176bff7dcb3e1a65333af164ee0bc91490d227b86807e1655ad", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# Figure GPHK.6.1.\n\nType 1 error control strategy for primary and key secondary efficacy endpoints.\n\nAbbreviations:\n\n- HDL\u2011C = high\u2011density lipoprotein cholesterol\n- SBP = systolic blood pressure\n- SF\u201136v2 PF = Short Form survey\u201136 version 2 physical functioning\n- T2DM = type 2 diabetes mellitus\n- p = tirzepatide all doses combined\n- PWL = percent weight loss\n- WC = waist circumference\n- wk = week\n- WT = weight loss in kg\n\nLY3298176\n\nPage 31", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 496, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1be9a6d2-6dbf-4f36-a71b-687fc80fd101": {"__data__": {"id_": "1be9a6d2-6dbf-4f36-a71b-687fc80fd101", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c47a3081-3a7b-47db-ad02-d7f0d49c673e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3fbf8f815f8472fed9f56a7c7bec91b07c2848f2657a73111ada0d4adc198cc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1509df48-ab6d-4182-b7b8-b4fbabe4b810", "node_type": "1", "metadata": {}, "hash": "edfa4ecd08041deff48fa95464caaf8300cb514dea993fa57cf31650c89794f8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# 6.13.3.1. Other Secondary and Exploratory Efficacy Analyses\n\nUnless otherwise specified, other secondary and exploratory efficacy analyses will be conducted using EAS. Missing data will be imputed using LOCF or handled through MMRM without utilizing multiple imputation technique.\n\n# 6.13.3.2. Other Secondary Efficacy Analyses\n\n| Table GPHK.6.5. Secondary Measures Not Controlled for Type 1 Error                      |                                                                                                                          |                                            |                                                                                                                                                      |   |\n| --------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------ | ------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------- | - |\n| Objective                                                                               | Relative to the efficacy measure:                                                                                        | Analysis conducted in a manner similar to: | Additional Information                                                                                                                               |   |\n| tirzepatide 5 mg QW is superior to placebo at 72 weeks:                                 | Percentage of participants achieving \u226510% (and \u226515%) body weight reduction from randomization                            | logistic model in Section 6.13.1.1         | None                                                                                                                                                 |   |\n| Change in waist circumference (cm) from randomization                                   |                                                                                                                          | MMRM model in Section 6.13.1.1             | Use baseline waist circumference as a covariate.                                                                                                     |   |\n| Change in SF\u201136 v2 acute form Physical Functioning domain (PF) score from randomization |                                                                                                                          | ANCOVA model                               | with terms of treatment, stratification factors, and baseline SF\u201136v2 PF score as a covariate. Missing data will be imputed using LOCF.              |   |\n| tirzepatide 5 mg, 10 mg and/or 15 mg QW is superior to placebo at 72 weeks:             | Mean change in body weight (kg) from randomization                                                                       | MMRM model in Section 6.13.1.1             | LSM estimates through 72 weeks will be plotted by study treatment.                                                                                   |   |\n| Mean change in BMI (kg/m\u00b2) from randomization                                           |                                                                                                                          | MMRM model in Section 6.13.1.1             | Use baseline BMI (kg/m\u00b2) as a covariate. LSM estimates through 72 weeks will be plotted by study treatment.                                          |   |\n| Mean change in HbA1c (%, mmol/mol) from randomization                                   |                                                                                                                          | MMRM model in Section 6.13.1.1             | Use baseline HbA1c (%, mmol/mol) as a covariate. LSM estimates through 72 weeks will be plotted by study treatment.                                  |   |\n| Mean change in fasting glucose (mg/dL) from randomization                               |                                                                                                                          | MMRM model in Section 6.13.1.1             | Use baseline fasting glucose as a covariate. LSM estimates through 72 weeks will be plotted by study treatment.                                      |   |\n| Mean change in IWQOL\u2011Lite\u2011CT Physical Function composite (PF) score from randomization  |                                                                                                                          | ANCOVA model                               | with terms of treatment, stratification factors, and baseline IWQOL\u2011Lite CT PF score as a covariate. Missing data will be imputed using LOCF method.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4939, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1509df48-ab6d-4182-b7b8-b4fbabe4b810": {"__data__": {"id_": "1509df48-ab6d-4182-b7b8-b4fbabe4b810", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c47a3081-3a7b-47db-ad02-d7f0d49c673e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "3fbf8f815f8472fed9f56a7c7bec91b07c2848f2657a73111ada0d4adc198cc9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1be9a6d2-6dbf-4f36-a71b-687fc80fd101", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "18a4666a182c0c2f773d095290ced4a7d55768f14544ae9e63011c3506322696", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "LSM estimates through 72 weeks will be plotted by study treatment.                                      |   |\n| Mean change in IWQOL\u2011Lite\u2011CT Physical Function composite (PF) score from randomization  |                                                                                                                          | ANCOVA model                               | with terms of treatment, stratification factors, and baseline IWQOL\u2011Lite CT PF score as a covariate. Missing data will be imputed using LOCF method. |   |\n| tirzepatide QW (all doses combined) is superior to placebo at 72 weeks                  | Mean change in DBP (mmHg), LDL\u2011C (mg/dL), VLDL\u2011C (mg/dL), total\u2011cholesterol, free fatty acids (mg/dL) from randomization | MMRM model in Section 6.13.1.1             | All tirzepatide doses will be pooled together. LSM estimates through 72 weeks will be plotted by study treatment.                                    |   |", "mimetype": "text/plain", "start_char_idx": 4421, "end_char_idx": 5360, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d81dc526-60e8-4a93-9cc4-9024efc09160": {"__data__": {"id_": "d81dc526-60e8-4a93-9cc4-9024efc09160", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "40c3afdd-ca38-4b69-b4f1-73886501d142", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "09a4fa0cc8f5cccc1007d1b3c6bcde35177e46b5f2f7fe42718f2f88290e183f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Secondary Measures Not Controlled for Type 1 Error\n\n| Objective                                                                                                                         | Relative to the efficacy measure:                                                           | Analysis conducted in a manner similar to: | Additional Information                                                                                                                                                                                                                          |\n| --------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------- | ------------------------------------------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| tirzepatide 5 mg QW (for participants with prediabetes at randomization) is superior to placebo at 176 weeks                      | Mean percent change in body weight from randomization                                       | MMRM model in Section 6.13.1.1             | Only for participants with prediabetes at randomization in the EAS. Model terms will include treatment group, visit, and treatment\u2011by\u2011visit interaction, country/pooled country, sex as fixed effects, and baseline body weight as a covariate. |\n| tirzepatide 5 mg, 10 mg, and/or 15 mg QW is superior to placebo (for participants with prediabetes at randomization) at 176 weeks | Percentage of participants achieving \u22655% body weight reduction from randomization           | logistic model in Section 6.13.1.1         | same as above                                                                                                                                                                                                                                   |\n| tirzepatide (all doses combined) is superior to placebo (for participants with prediabetes at randomization) at 176 weeks         | Mean change in SF\u201136v2 acute form physical functioning domain (PF) score from randomization | MMRM model in Section 6.13.1.1             | same as above but using baseline SF\u201136 v2 acute PF score as a covariate.                                                                                                                                                                        |\n|                                                                                                                                   | Mean change in IWQOL\u2011Lite\u2011CT Physical function composite (PF) score from randomization      | MMRM model in Section 6.13.1.1             | Similar to above but using baseline IWQOL\u2011Lite\u2011CT PF score as a covariate.                                                                                                                                                                      |\n\nAbbreviations: ANCOVA = analysis of covariance; BMI = body mass index; DBP = diastolic blood pressure; HbA1c = hemoglobin A1c; IWQOL\u2011Lite\u2011CT = Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version; LDL\u2011C = low\u2011density lipoprotein cholesterol; LOCF = last observation carried forward; LSM = least squares mean; MMRM = mixed model for repeated measures; QW = once\u2011weekly; SF\u201136v2 = Short Form 36 version 2 Health Survey; VLDL\u2011C = very low\u2011density lipoprotein cholesterol.\n\n# 6.13.3.3. Exploratory Efficacy Analyses\n\n| Objective                                                              | Relative to the efficacy measure:                                                                                                                                                                                   | Analysis Conducted                                       |\n| ---------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------- |\n| compare tirzepatide 5 mg, 10 mg, and/or 15 mg with placebo at 72 weeks | Percentage of participants achieving >25% body weight reduction from randomization                                                                                                                                  | logistic model in Section 6.13.1.1                       |\n| compare tirzepatide 5 mg, 10 mg, and/or 15 mg with placebo at 72 weeks | Percentage of participants whose BMI shifts between clinically relevant categories, i.e., from baseline (<25, 25 to <30, 30 to < 35, 35 to < 40, \u226540) to postbaseline (<25, 25 to <30, 30 to < 35, 35 to < 40, \u226540) | Shift analysis will be conducted based on data from EAS. |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 5121, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f1775753-d014-4eb9-9674-c312075d6c8f": {"__data__": {"id_": "f1775753-d014-4eb9-9674-c312075d6c8f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "01c08c97-1709-459f-a91e-9aa533a40b4e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2b97e83c753c568c4df4fbe432d1a9fa353b4b10e811ff3935238112fdc1556d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Exploratory Efficacy Analysis\n\n| Objective                                                                                                                                       | Relative to the efficacy measure:                                                                                                                                                                                                                              | Analysis Conducted                                                                                                                                                                                                                                                                |\n| ----------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n| compare tirzepatide 5 mg, 10 mg and/or 15 mg with placebo at 176 weeks                                                                          | Same as above                                                                                                                                                                                                                                                  | Shift analysis will be conducted for the participants with prediabetes at randomization from EAS.                                                                                                                                                                                 |\n| visualize tirzepatide 5 mg, 10 mg and/or 15 mg with placebo percent weight loss change from randomization up to safety follow-up after 72 weeks | Percent body weight loss measured at postbaseline from randomization to 72 weeks plus 4 weeks safety follow-up                                                                                                                                                 | Only the participants who complete the 72 weeks treatment and have the safety follow-up (Visit 801) will be included.                                                                                                                                                             |\n| compare tirzepatide QW (all dose combined) with placebo at 72 weeks                                                                             | Percentage of participants change in glycemic category, that is, from baseline (normoglycemia, prediabetes, T2DM) to postbaseline (normoglycemia, prediabetes, T2DM)                                                                                           | Shift analysis will be conducted based on data from EAS.                                                                                                                                                                                                                          |\n| compare tirzepatide QW (all dose combined) with placebo at 176 weeks                                                                            | Same as above                                                                                                                                                                                                                                                  | Shift analysis will be conducted for the participants with prediabetes at randomization from EAS.                                                                                                                                                                                 |\n| compare tirzepatide QW (all doses combined) to placebo (for participants with prediabetes at randomization) at 176 weeks:                       | * SF\u201136v2 acute form Role\u2011Emotional domain (RE)\n* SF\u201136v2 acute form Mental Health domain (MH)\n* IWQOL\u2011Lite\u2011CT total score\n* IWQOL\u2011Lite\u2011CT Physical composite score\n* IWQOL\u2011Lite\u2011CT Psychosocial composite score\n* EQ\u20115D\u20115L utility score\n* EQ\u20115D\u20115L VAS score | Only data from participants with prediabetes at randomization from EAS will be included. MMRM model with terms of treatment (tirzepatide combined, placebo), visit, treatment\u2011by\u2011visit interaction, country/pooled country, sex, and corresponding baseline score as a covariate. |\n\nAbbreviations: BMI = body mass index; EAS = Efficacy Analysis Set; IWQOL\u2011Lite\u2011CT = Impact of Weight on Quality of Life\u2011Lite\u2011Clinical Trials Version; MMRM = mixed model for repeated measures; QW = once weekly; T2DM = type 2 diabetes mellitus; VAS = Visual Analog Scale.\n\nIn addition, the following endpoints, risk difference in proportions for an unconditional treatment effect (Ge et al.2011) among each tirzepatide dose and placebo arm may be conducted:\n\n- percentage of participants achieving at least 5% body weight reduction at 72 weeks\n- percentage of participants achieving at least 10% body weight reduction at 72 weeks\n- percentage of participants achieving at least 15% body weight reduction at 72 weeks\n- percentage of participants achieving at least 20% body weight reduction at 72 weeks.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 5660, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0bf4c050-954a-40ea-af2b-a4e4b5b62e65": {"__data__": {"id_": "0bf4c050-954a-40ea-af2b-a4e4b5b62e65", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f2b2c351-6e8a-456d-b4a9-4c0eec4ab980", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "0f93f62ac2516065ae3f15992b7dca810634f5470e3af693bd038ae9c8de2012", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.14. Safety Analyses\n\nUnless specified otherwise, safety assessments will be based on the SS (Table GPHK.6.1). All events that occur between the first dose date of study drug and the end date of study participation will be included, regardless of the adherence to study drug.\n\nThe statistical assessment of homogeneity of the distribution of categorical safety responses between tirzepatide doses and placebo will be conducted using Fisher\u2019s exact test, unless specified otherwise.\n\nFor selected continuous safety parameters, the mean change from baseline differences vs. placebo will be assessed via a MMRM using REML. Data from scheduled visits will be utilized for this analysis. Unless specified otherwise, the model for the analysis during 72 weeks treatment period will include country/pooled country, sex, prediabetes status at randomization, treatment group, visit and treatment\u2011by\u2011visit interaction as fixed effects, and baseline value of the safety parameter as a covariate. For the analysis during the 176 weeks treatment period (or 193 weeks), only participants with prediabetes at randomization in the SS will be included, and the model will contain the terms of country/pooled country, sex, treatment group, visit and treatment\u2011by\u2011visit interaction as fixed effects, and baseline value of the safety parameter as a covariate. To model the covariance structure within participants, the unstructured covariance matrix will be used. If this model fails to converge, the covariance structures specified in Section 6.13.1.1 will be tested in order until met convergence. If the data does not warrant the MMRM model, then ANCOVA model will be conducted.\n\nFor selected safety parameters, time\u2011to\u2011first\u2011event analysis via the Cox\u2011proportional hazards model may be conducted. Participants without the event will be censored at the end of study participation. For participants experiencing the event, the \u201ctime\u2011to\u2011first\u2011event\u201d will be the time (in days) from first dose to first occurrence of the event.\n\nWhere necessary, the rate of events will be analyzed using a generalized linear mixed\u2011effects model assuming the number of events follow a negative binomial distribution and with treatment as a fixed effect. The logarithm of days during the active treatment period will be adjusted as an offset to account for possible unequal treatment duration of follow\u2011up between participants.\n\nUnless otherwise specified, all the analyses listed in this section will be conducted using SS in the following 2 postbaseline periods, respectively:\n\n- up to 72 weeks treatment period plus the safety follow\u2011up (Visit 801, if applicable) for all randomized participants, and\n- up to 176 weeks treatment period plus the safety follow\u2011up (Visit 801 or Visit 802) for participants with prediabetes at randomization.\n\n# 6.14.1. Analysis of Adverse Events\n\n# 6.14.1.1. Treatment Emergent Adverse Events\n\nA treatment\u2011emergent adverse event (TEAE) is defined as an event that first occurred or worsened in severity after baseline. The MedDRA Lowest Level Term (LLT) will be used in the\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3132, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6c10267b-fa06-4c55-bbeb-702180432cad": {"__data__": {"id_": "6c10267b-fa06-4c55-bbeb-702180432cad", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7b177ef4-3739-439f-b812-4b6c813e628e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "831b870ee4441b935fd3a24cee7fab93c1fd8adb21173ccf9d3ca7c59e5056c4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\ntreatment\u2011emergent derivation. The maximum severity for each LLT during the baseline period including ongoing medical history will be used as baseline severity. For events with a missing severity during the baseline period, it will be treated as \u201cmild\u201d in severity for determining treatment\u2011emergence. Events with a missing severity during the postbaseline period will be treated as \u201csevere\u201d and treatment\u2011emergence will be determined by comparing to baseline severity.\n\nFor events occurring on the day of first taking study medication, the case report form (CRF)\u2011collected information (for example, treatment emergent flag, start time of study treatment and event) will be used to determine whether the event was pre\u2011 versus post\u2011treatment if available. If the relevant information is not available, then the events will be counted as post\u2011treatment.\n\nThe counts and percentages of participants with TEAEs will be summarized by treatment using MedDRA PT nested within SOC. Statistical comparisons will be applied at both the SOC and PT levels. Events will be ordered by decreasing frequency within SOC. The SOC will be in alphabetical order. For events that are sex\u2011specific, the denominator and computation of the percentage will include only participants from the given sex.\n\nAn overview of the number and percentage of participants who experienced a TEAE, serious adverse event (SAE), death, discontinued from study treatment or study due to an AE, relationship to study drug will be summarized by treatment.\n\nThe counts and percentages of participants with TEAEs by maximum severity will be summarized by treatment using MedDRA PT. For each participant and TEAE, the maximum severity for the MedDRA PT is the maximum postbaseline severity observed from all associated LLTs mapping to the MedDRA PT. The maximum severity will be determined based on the nonmissing severities. If all severities are missing for the defined postbaseline period of interest, it will show as missing in the table.\n\n# 6.14.1.2. Common Adverse Events\n\nThe counts and percentages of participants with TEAEs, overall and common (common TEAEs occurred in \u22655% of participants before rounding), will be summarized by treatment using MedDRA PT. Events will be ordered by decreasing frequency.\n\n# 6.14.1.3. Deaths\n\nA listing of all deaths during the study will be provided. The listing will include participant identification including the treatment, site number, date of death, age at the time of enrollment, sex, cause of death as reported by investigator, cause of death as adjudicated by CEC., etc.\n\n# 6.14.1.4. Other Serious Adverse Events\n\nThe counts and percentages of participants who experienced a SAE (including deaths and SAEs temporally associated or preceding deaths) during the postbaseline period will be summarized by treatment using MedDRA PT nested within SOC. Events will be ordered by decreasing frequency within SOC. The SOC will be in alphabetical order.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3010, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "51a78a97-47b6-46c2-bbf5-34dbf621746b": {"__data__": {"id_": "51a78a97-47b6-46c2-bbf5-34dbf621746b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "dc2c524e-45c8-4523-bb87-bb6754e5563b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1dd01c46213beddd7a24a006df172c32da322a9fd05c66614bd6f7ddfc97ce9c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.14. Adverse Events\n\nA listing of all SAEs will be provided. The listing will include treatment, participant identification including the site number, date of event, age at the time of enrollment, sex, MedDRA SOC and PT, Reported term, severity, outcome, relationship to study drug, time from first dose of study drug to the event, AE start date, AE end date, seriousness, and action taken related to study treatment.\n\n# 6.14.1.5. Other Significant Adverse Events\n\nThe counts and percentages of participants who discontinued from study treatment or study due to an AE during the postbaseline period may be summarized by treatment group using MedDRA PT nested within SOC. Events will be ordered by decreasing frequency within SOC.\n\n# 6.14.2. Patient Narratives\n\nPatient narratives will be provided for all participants who experience any of the following \u201cnotable\u201d events:\n\n- death\n- serious adverse event, or\n- permanent discontinuation of study treatment due to AEs.\n\nPatient narratives (patient level data and summary paragraph) will be provided for participants in the randomized population with at least 1 notable event.\n\n# 6.14.3. Special Safety Topics\n\nFor adverse events of special interest (AESI) or special safety topics, the counts and percentages of participants will be summarized by treatment and PT with decreasing frequency. Individual participant level data may be presented. Displays with individual participant level data may be created using various formats, such as a customized listing and/or a customized graphical participant profile. Adverse events of special interest are defined in each section of special safety topics, where applicable.\n\n# 6.14.3.1. Acute Gallbladder Disease\n\nAll events of TEAE biliary colic, cholecystitis, or other suspected events related to gallbladder disease will be summarized by treatment groups by PT with decreasing frequency. Detailed searching criteria can be found in Appendix 3.\n\n# 6.14.3.2. Amputation/Peripheral Revascularization\n\nThis section is applicable for participants developing T2DM during the study treatment (up to primary database lock [72 weeks] and final database lock [176 weeks]). Treatment\u2011emergent amputation/peripheral revascularization will be considered as AESIs. The counts and percentages of participants with amputations/peripheral revascularization may be summarized by treatment.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2429, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "18abd514-ab82-4277-8246-8eeb7f7ccd15": {"__data__": {"id_": "18abd514-ab82-4277-8246-8eeb7f7ccd15", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "9d8dcd36-9690-4abc-b014-4c84059a3fb1", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1443c0886ce32de9344925181d6b8dcdbf5ba2f919a5c8995067afba97d33fb5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# 6.14.3.3. Exocrine Pancreas Safety\n\n# 6.14.3.3.1. Pancreatic Enzyme\n\nObserved pancreatic enzyme data (p\u2011amylase and lipase) will be summarized by treatment and nominal visit. The counts and percentages of participants with maximum postbaseline pancreatic enzyme value exceeding the following thresholds will be provided by baseline pancreatic enzyme value (\u2264 upper limit of normal [ULN], > ULN), and postbaseline: \u22641x ULN, (>1 to \u22643) x ULN, (>3 to \u22645) x ULN, (>5 to \u226410) x ULN, >10x ULN. An MMRM analysis will be used to analyze each pancreatic enzyme with a log transformed (postbaseline measure/baseline measure) response variable and treatment, nominal visit, treatment\u2011by\u2011nominal visit interaction as fixed effects.\n\n# 6.14.3.3.2. Pancreatitis Events\n\nSummaries of adjudicated and investigator\u2011reported pancreatic events will be provided by treatment. Detailed searching criteria can be found in Appendix 3. Treatment emergent adjudicated\u2011confirmed pancreatitis will be considered as an AESI. Listing of participants with adjudicated pancreatitis may be provided if deemed necessary.\n\n# 6.14.3.4. Gastrointestinal Safety\n\n# 6.14.3.4.1. Nausea, Vomiting, and Diarrhea\n\nSummaries and analyses for incidence and severity of nausea, vomiting (including \u201cvomiting\u201d and \u201cvomiting projectile\u201d), diarrhea (including \u201cdiarrhea\u201d and \u201cdiarrhoea\u201d), and 3 events combined, will be provided by each treatment group. Summary of the prevalence over time for nausea, vomiting, and diarrhea will also be presented. Time to the onset of nausea, vomiting, and diarrhea will be plotted.\n\n# 6.14.3.4.2. Severe Gastrointestinal Events\n\nSevere gastrointestinal (GI) adverse events will be captured with the AE\u2011CRF form and serious cases will be captured with the SAE form. The PTs in the GI SOC MedDRA version at the time of database locks will be used to identify GI AEs, and only the PTs with serious/severe treatment\u2011emergent cases will be considered as AESIs. The counts and percentages of participants with severe/serious treatment\u2011emergent GI events will be summarized by treatment.\n\n# 6.14.3.5. Hepatic Safety\n\n# 6.14.3.5.1. Hepatobiliary Disorders\n\nSevere/serious treatment\u2011emergent hepatobiliary disorders will be considered as AESI. The counts and percentages of participants with treatment\u2011emergent potentially drug\u2011related hepatic", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2374, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3da4be38-a3cc-4674-992f-c8c0c01cedf4": {"__data__": {"id_": "3da4be38-a3cc-4674-992f-c8c0c01cedf4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "48c8d820-b4be-4d3d-a72a-7b04834b25ca", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e6fe221f91212647bad764f667253cbca7617614f2d7cbeefcbd1a8ca8f9fd3c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\ndisorders will be summarized by treatment using the MedDRA PTs. Detailed searching criteria can be found in Appendix 3. A listing of participants with treatment emergent hepatobiliary disorders may be provided if deemed necessary.\n\n# 6.14.3.5.2. Liver Enzymes\n\nAnalyses for laboratory analyte measurements are described in Section 6.14.6. This section describes additional analyses of liver enzymes. The counts and percentages of participants with the following elevations in hepatic laboratory tests at any time during the treatment period and during the entire study including follow up period will be summarized between treatment groups:\n\n- The counts and percentages of participants with an alanine aminotransferase (ALT) measurement \u22653 times (3x), 5 times (5x), and 10 times (10x) the Covance ULN will be summarized for all participants with a postbaseline value and for subsets based on various levels of baseline value.\n- participants whose nonmissing maximum baseline value is \u22641x ULN\n- participants whose maximum baseline is >1x ULN, and\n- participants whose baseline values are missing.\n- The counts and percentages of participants with an aspartate aminotransferase (AST) measurement \u22653x, 5x, and 10x the Covance ULN during the treatment period will be summarized for all participants with a postbaseline value and for subsets based on various levels of baseline, as described above for ALT.\n- The counts and percentages of participants with a total bilirubin (TBL) measurement \u22652x the Covance ULN during the treatment period will be summarized for all participants with a postbaseline value, and subset into 4 subsets:\n- participants whose nonmissing maximum baseline value is \u22641 x ULN\n- participants whose maximum baseline is >1 x ULN, but &#x3C;2 x ULN\n- participants whose maximum baseline value is \u22652 x ULN, and\n- participants whose baseline values are missing.\n- The counts and percentages of participants with a serum alkaline phosphatase (ALP) measurement \u22652x the Covance ULN during the treatment period will be summarized for all participants with a postbaseline value and for the subsets described above to TBL.\n\nMaximum baseline will be the maximum non\u2011missing observation in the baseline period. The maximum value will be the maximum non\u2011missing value from the postbaseline period. Planned and unplanned measurements will be included.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2417, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8adf1712-db17-44b3-b07c-b25888ef5954": {"__data__": {"id_": "8adf1712-db17-44b3-b07c-b25888ef5954", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2e7d6875-6726-49d6-8733-a8ca6a06898c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a10c049c11d108789ceb5cf6c06e42d6dec38fdb7ca4f2ab9a6945ec559cb0b1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.14.3.6. Hypoglycemia\n\nThe following categories in accordance with the 2019 American Diabetes Association position statement on glycemic targets (ADA 2019b) will be defined in the database.\n\n# Glucose alert value (Level 1):\n\n- Documented symptomatic hypoglycemia is defined as any time a patient feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a blood glucose (BG) level of &#x3C;70 mg/dL (&#x3C;3.9 mmol/L).\n- Documented asymptomatic hypoglycemia is defined as any event not accompanied by typical symptoms of hypoglycemia, but with a measured BG &#x3C;70 mg/dL (&#x3C;3.9 mmol/L).\n- Documented unspecified hypoglycemia is defined as any event with no information about symptoms of hypoglycemia available, but with a measured BG &#x3C;70 mg/dL (&#x3C;3.9 mmol/L).\n\n# Documented Clinically Significant Hypoglycemia (Level 2):\n\n- Documented symptomatic hypoglycemia is defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a BG level of &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n- Documented asymptomatic hypoglycemia is defined as any event not accompanied by typical symptoms of hypoglycemia but with a measured BG &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n- Documented unspecified hypoglycemia is defined as any event with no information about symptoms of hypoglycemia available but with a measured BG &#x3C;54 mg/dL (&#x3C;3.0 mmol/L).\n\n# Severe Hypoglycemia (Level 3):\n\n- Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. Plasma glucose (PG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of PG to normal is considered sufficient evidence that the event was induced by a low PG concentration.\n\n# Other hypoglycemia categories:\n\n- Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking.\n\nIf a hypoglycemic event meets the criteria of severe, the event would specifically be collected as a SAE. Serious hypoglycemia are defined by pharmacovigilance criteria and will also be captured with a SAE form.\n\nTo avoid duplicate reporting, all consecutive hypoglycemic events occurring within a 1\u2011hour period will be considered to be a single hypoglycemic event.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2577, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b4754450-ea23-41c3-ac50-72df885b422d": {"__data__": {"id_": "b4754450-ea23-41c3-ac50-72df885b422d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "39859c0f-4ffd-4908-9276-365eafd7cde2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "822e41193831b3b176aa7b1fd27ac37c09bf6451638b650b9fae1643b0dcbeb3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\nPage 41\n\nBoth the incidence (percent of participants experiencing \u22651 episode) and the rate (episodes/participant/year) of level 2 or level 3 hypoglycemia, and level 3 hypoglycemia will be reported by treatment group.\n\nSevere/serious hypoglycemia will be considered as AESIs. The summaries of severe/serious hypoglycemia will be provided by treatment group. A listing of all events of severe hypoglycemia may be provided, if deemed necessary. This listing will provide treatment allocation, clinical characteristics of the hypoglycemic event, and concomitant antihyperglycemic medications.\n\n# 6.14.3.7. Immunogenicity\n\n# 6.14.3.7.1. Definitions of Sample ADA Status\n\nAt a high level, an individual sample is potentially examined multiple times, in a hierarchical procedure, to produce a sample anti\u2011drug antibodies (ADA) assay result and potentially multiple cross\u2011reactive antibodies assay results and multiple neutralizing antibodies (NAb) assay results. The cut points used, the drug tolerance of each assay, and the possible values of titers are operating characteristics of the assay.\n\nFigure GPHK.6.2 details a flow chart that reflects the multitiered testing approach.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1234, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "33d6f08f-790d-4c3d-b9ff-61e02c2f49c6": {"__data__": {"id_": "33d6f08f-790d-4c3d-b9ff-61e02c2f49c6", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "79ce62ef-3b80-4a4f-89b1-c4e68d9b865b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "fa6088545d261130002cd149f3e6128358a1fdc85ba34ef6915113c1d57d3765", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# Abbreviations\n\nADA = anti\u2011drug antibodies; CP = cut point; GIP = glucose\u2011dependent insulinotropic polypeptide; GIPR = glucose\u2011dependent insulinotropic polypeptide receptor; GLP\u20111 = glucagon\u2011like peptide\u20111; GLP\u20111R = glucagon\u2011like peptide\u20111 receptor; LY = LY3298176; NAb = neutralizing antibodies.\n\n# Figure GPHK.6.2\n\nFlowchart of immunogenicity multitiered testing approach.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 437, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2189e3e2-082b-4a7f-9af7-3c39c5c4eff5": {"__data__": {"id_": "2189e3e2-082b-4a7f-9af7-3c39c5c4eff5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f9c91904-8056-432e-aa0b-78afd13e5666", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "4fbd93767420ffbb6aeb1f3645aebd9bbea9c90329389f88f82fd21aeaf85613", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# Table GPHK.6.7. Sample Anti-Drug Antibodies (ADA) Assay Results\n\n| Sample             | Laboratory Result                                                                                                                                              | Explanation |\n| ------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------- |\n| Detected           | ADA are detected and confirmed.                                                                                                                                |             |\n| Not Detected       | The raw result as reported from the laboratory indicates not detected. The clinical interpretation of such results depends other factors (see Table GPHK.6.8). |             |\n| NO TEST, QNS, etc. | Sample exists but was unevaluable by the assay.                                                                                                                |             |\n\nAbbreviations: ADA = anti\u2011drug antibodies; QNS = quantity not sufficient.\n\nIt can be the case that the presence of high concentrations of tirzepatide will affect immunoassays, and conversely high levels of antibodies may affect the measurement of tirzepatide concentration. Thus, a tirzepatide drug concentration, assessed from a sample drawn at the same time as the ADA sample, plays a key role in clinical interpretation of a sample when the laboratory results is Not Detected (see Table GPHK.6.8).\n\n# Table GPHK.6.8. Sample Clinical Anti-Drug Antibodies (ADA) Interpretation Results\n\n| Sample           | Clinical Interpretation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Explanation |\n| ---------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------- |\n| ADA Present      | ADA assay result is Detected                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |\n| ADA Not Present  | ADA assay result is Not Detected and drug concentration is at a level that has been demonstrated to not interfere in the ADA detection method (that is, drug concentration is below the assay\u2019s drug tolerance level). For participants receiving placebo, drug concentration is not assessed and is assumed to be below the assay\u2019s drug tolerance level. If drug concentration was planned but is not available for a treatment\u2011period sample, a Not Detected sample will be declared ADA Not present. |             |\n| ADA Inconclusive | ADA assay result is Not Detected but drug concentration in the sample is at a level that can cause interference in the ADA detection method.                                                                                                                                                                                                                                                                                                                                                             |             |\n| ADA Missing      | ADA sample not drawn, QNS, not tested, etc., causing there to be no laboratory result reported or the result is reported as \u201cno test.\u201d                                                                                                                                                                                                                                                                                                                                                                   |             |\n\nAbbreviations: ADA = anti\u2011drug antibodies; QNS = quantity not sufficient.\n\nAll ADA present samples will be evaluated for cross\u2011reactive glucose\u2011dependent insulinotropic polypeptide (GIP), cross\u2011reactive glucagon\u2011like peptide\u20111 (GLP\u20111), Nab LY3298176 (LY) on glucose\u2011dependent insulinotropic polypeptide receptor (GIP\u2011R), and NAb LY on glucagon\u2011like peptide\u20111 receptor (GLP\u20111R). If cross\u2011reactive GIP is detected, NAb GIP on GIP\u2011R is evaluated. If cross\u2011reactive GLP\u20111 is detected, NAb GLP on GLP\u20111R is evaluated (Figure GPHK.6.2).\n\nSimilar terminology to Table GPHK.6.8 applies for each type of cross\u2011reactive and NAb assay. Importantly, each of these are distinct assays and, in general, have different assay operating characteristics.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 5599, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "52887db8-9151-4633-b416-9fd5069e66d4": {"__data__": {"id_": "52887db8-9151-4633-b416-9fd5069e66d4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "3ca65200-48e4-48c9-b523-f6f57e6ca9a0", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ffd5171cbf0fedaaef51073e02e6761ce057bd1afbccb4c7db9c8269d2a78655", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 44\n\nThe following are considered inconclusive for the NAb result:\n\n- NAb LY on GIP\u2011R: if NAb result is not detected, and pharmacokinetic (PK) concentration is \u2265 drug tolerance limit of the NAb LY on GIP\u2011R assay\n- NAb LY on GLP\u20111R: if NAb result is not detected, and PK concentration is \u2265 drug tolerance limit of the NAb LY on GLP\u20111R assay\n- NAb GIP on GIP\u2011R: if NAb result is not detected, and PK concentration is \u2265 drug tolerance limit of the NAb GIP on GIP\u2011R assay\n- NAb GLP\u20111 on GLP\u20111R: if NAb result is not detected, and PK concentration is \u2265 drug tolerance limit of the NAb GLP\u20111 on GLP\u20111R assay\n\nTo mitigate inconclusive cross\u2011reactive NAb interpretations against nGIP and nGLP\u20111 due to potential tirzepatide concentrations greater than or equal to the drug tolerance limit of the cross\u2011reactive NAb assays (Tier 4c and 4d, respectively), an in silico method utilizing results from Tiers 2b and 2c, Tiers 4a and 4b, and tirzepatide concentrations is introduced. The in silico method is outlined in Table GPHK.6.9.\n\n# Table GPHK.6.9. In Silico Classification for Cross-Reactive NAb\n\n| In Silico Classification     | Cross-reactive Binding ADA Result | NAb Result                            | Circulating Tirzepatide Level (ng/mL)  | In Silico Cross-reactive NAb Interpretation |\n| ---------------------------- | --------------------------------- | ------------------------------------- | -------------------------------------- | ------------------------------------------- |\n| Cross\u2011reactive NAb to nGIP   | Tier 2b: \u201cNot Detected\u201d           | Tier 4a: \u201cNot Detected\u201d               | Any Value or Missing                   | Not Present                                 |\n|                              |                                   | Tier 4a: \u201cDetected\u201d or N/A or Missing |                                        |                                             |\n|                              | Tier 2b: \u201cDetected\u201d               | Tier 4a: \u201cNot Detected\u201d               |                                        | Not Present                                 |\n|                              |                                   | Tier 4a: \u201cNot Detected\u201d               |                                        |                                             |\n|                              | Tier 2b: \u201cDetected\u201d               | Tier 4a: \u201cDetected\u201d                   |                                        | Present                                     |\n|                              |                                   | Tier 4a: \u201cDetected\u201d                   |                                        |                                             |\n|                              | Tier 2b: \u201cDetected\u201d               | Tier 4a: \u201cDetected\u201d                   | \u2265drug tolerance limit of Tier 4a assay | Present                                     |\n|                              |                                   | Tier 4a: \u201cDetected\u201d                   |                                        |                                             |\n| Cross\u2011reactive NAb to nGLP\u20111 | Tier 2c: \u201cNot Detected\u201d           | Tier 4b: \u201cNot Detected\u201d               | Any Value or Missing                   | Not Present                                 |\n|                              |                                   | Tier 4b: \u201cDetected\u201d or NA or Missing  |                                        |                                             |\n|                              | Tier 2c: \u201cDetected\u201d               | Tier 4b: \u201cNot Detected\u201d               |                                        | Not Present                                 |\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3697, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ecdd2daa-3958-4353-8de8-893bac524431": {"__data__": {"id_": "ecdd2daa-3958-4353-8de8-893bac524431", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "fe9765f8-aa63-4457-b2ab-a7620c5657d6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6e7718851643b58edaf33faa0639e2be43ab57aade6999f84894690b31fc09af", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# In Silico Classification for Cross-Reactive NAb\n\n| In Silico Classification     | Cross-reactive Binding ADA Result | NAb Result              | Circulating Tirzepatide Level (ng/mL)  | In Silico Cross-reactive NAb Interpretation |\n| ---------------------------- | --------------------------------- | ----------------------- | -------------------------------------- | ------------------------------------------- |\n| Cross\u2011reactive NAb to nGLP\u20111 | Tier 2c: \u201cDetected\u201d               | Tier 4b: \u201cNot Detected\u201d | \u2265drug tolerance limit of Tier 4b assay | Inconclusive                                |\n|                              | Tier 2c: \u201cDetected\u201d               | Tier 4b: \u201cDetected\u201d     |                                        | Present                                     |\n|                              | Tier 2c: \u201cDetected\u201d               | Tier 4b: \u201cDetected\u201d     | \u2265drug tolerance limit of Tier 4b assay | Present                                     |\n\nAbbreviations: ADA = antidrug antibodies; GIP = glucose\u2011dependent insulinotropic polypeptide; GLP\u20111 = glucagon\u2011like peptide\u20111; NAb = neutralizing antibodies; nGIP = native glucose\u2011dependent insulinotropic polypeptide; nGLP\u20111 = native glucagon\u2011like peptide\u20111; Tier 2b = cross\u2011reactive ADA to nGIP; Tier 4a = NAb LY (tirzepatide) on GIP receptor; Tier 4b = NAb LY (tirzepatide) on GLP\u20111 receptor.\n\nNote: Only the drug tolerance limits of the Tier 4a and 4b assays are used for in silico classifications as they are lower than the drug tolerance limits of the Tier 2b and 2c assays, respectively.\n\n# 6.14.3.7.2. Definitions of Immunogenicity Assessment Periods\n\nImmunogenicity Baseline Observations: Baseline period for immunogenicity assessment for each participant includes all observations up to baseline visit. In instances where multiple baseline observations are collected, to determine participant ADA status the last non\u2011missing immunogenicity assessment up to first administration of study is used to determine treatment\u2011emergent status (see below).\n\nImmunogenicity Postbaseline Period Observations: Postbaseline period observations for each participant include all observations after the first administration of study drug. There are two different periods listed below:\n\n- The planned treatment period is defined as from the first dose of treatment to end of the treatment period.\n- The entire postbaseline period is defined as from the first dose of treatment to the end of safety follow\u2011up visit or date of study withdrawal.\n\n# 6.14.3.7.3. Definitions of Participant ADA Status\n\nTreatment\u2011emergent (TE) ADA\u2011evaluable participants: a participant with a non\u2011missing baseline ADA result and at least 1 non\u2011missing postbaseline ADA result.\n\nTE ADA\u2011unevaluable participant: any participant who does not meet the evaluable criteria.\n\nBaseline ADA Present (preexisting antibody): ADA detected in a sample collected up to the first dose date and time.\n\nBaseline ADA Not Present: ADA is not detected, and the corresponding PK concentration is missing or below the drug tolerance limit in a sample collected up to the first dose date and time.\n\nTreatment\u2011emergent ADA positive (TE ADA+) participant: an evaluable participant who had a:\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3256, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6d59bfac-1414-4117-9e8b-e46a259cc22c": {"__data__": {"id_": "6d59bfac-1414-4117-9e8b-e46a259cc22c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "22261e96-ee27-495f-8185-2ff5179c50c5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2c83ce255b86a3f78f7ce62090705388cf42852867a5d96da2156980894c68ac", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\u2022  baseline status of ADA Not Present and at least 1 post\u2011baseline status of ADA Present with titer \u22652 x minimum required dilution (MRD), where the MRD is the minimum required dilution of the ADA assay or\n\n\u2022  baseline and postbaseline status of ADA Present, with the postbaseline titer being 2 dilutions (4\u2011fold) greater than the baseline titer. That is, the participant has baseline status of ADA Present, with titer 1:B, and at least 1 postbaseline status of ADA Present, with titer 1:P, with P/B \u2265 4.\n\nAs shown in Figure GPHK.6.2, a titer is expected when ADA assay result is Detected. On occasion, the corresponding assay cannot be performed, in which case a titer value will be imputed for the purpose of TE ADA determination. A baseline sample with detected ADA and no titer is imputed to be the MRD (1:10) and a post\u2011baseline sample with ADA detected and no titer is imputed to be one dilution above the MRD (1:20).\n\nTE ADA\u2011Inconclusive participant: a TE ADA\u2011evaluable participant is TE ADA Inconclusive if \u226520% of the participant\u2019s postbaseline samples are ADA Inconclusive and all remaining postbaseline samples are ADA Not Present.\n\nTE ADA\u2011negative (TE ADA\u2011) participant: a TE ADA\u2011evaluable participant is TE ADA\u2011 when the participant is not TE ADA+ and not TE ADA Inconclusive.\n\nNAb\u2011positive (NAb+) participant: a participant who is TE ADA+ and has a NAb positive sample in the postbaseline period.\n\nNAb\u2011Inconclusive participant: a participant who is TE ADA+, is not NAb+, and all samples that have TE ADA+ titer have a NAb\u2011Inconclusive sample result.\n\nNAb\u2011negative (NAb\u2011) participant: a participant is not either NAb+ or NAb inconclusive.\n\nUnless specified otherwise, the above\u2011mentioned definitions of NAb are applicable to all NAb analyses, including cross\u2011reactive NAb analyses, and cross\u2011reactive antibodies.\n\n# 6.14.3.7.4. Analyses to be Performed\n\nThe count and proportion of participants who are TE ADA+ will be tabulated by treatment group, where proportion are relative to the number of TE ADA\u2011evaluable participants, as defined above. The tabulation will include the count and proportion of participants with ADA Present at baseline and the count and proportion of TE ADA+ participants exhibiting each type of cross\u2011reactive antibodies and NAb.\n\nThis analysis will be performed for\n\n- the planned treatment period\n- the entire postbaseline period including safety follow\u2011up.\n\nThe cross\u2011reactive NAb will exclude Tier 4c and 4d results but include in silico classification as cross\u2011reactive NAb for summary.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2588, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "eeb0fcff-d7cf-4291-906a-98d23d99e013": {"__data__": {"id_": "eeb0fcff-d7cf-4291-906a-98d23d99e013", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1f012e1d-e5fa-48fe-a396-0a8575b93763", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "18168b93e03f637bf112f3cfae67b7ae58a1ae0466844165d5171cde8c7dcb19", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\nA summary will be provided of the count and percentage of tirzepatide\u2011treated participants experiencing specific TEAE (see Table GPHK.6.10) by TE ADA status (TE ADA+, TE ADA\u2011, TE ADA Inconclusive) during the planned treatment period. The PT will be ordered by decreasing incidence in TE ADA+ status group.\n\n| TEAE category              | Criteria                                                                                                                                   |\n| -------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------ |\n| Hypersensitivity reactions | Anaphylaxis SMQ (narrow or algorithm) Hypersensitivity SMQ (narrow) Angioedema SMQ (narrow) Severe Cutaneous Adverse Reaction SMQ (narrow) |\n| Injection site reactions   | Injection site reaction HLT Infusion site reaction HLT Administration site reaction HLT                                                    |\n\nAbbreviations: HLT = high level term; MedDRA = Medical Dictionary for Regulatory Activity; SMQ = Standardised MedDRA Query; TEAE = treatment\u2011emergent adverse event.\n\nAdditional immunogenicity analyses as determined later may be presented. The relationship between antibody titers, the PK parameters, and pharmacodynamics (PD) response to tirzepatide may also be assessed.\n\nCases of TE ADA that are associated with TEAEs of either severe/serious hypersensitivity or injection site reactions will be classified as AESIs.\n\n# 6.14.3.8. Hypersensitivity Reactions\n\nTwo main analyses are performed in support of assessment of potential immediate hypersensitivity, including anaphylaxis as well as potential nonimmediate hypersensitivity.\n\nTime Period A, of potential immediate hypersensitivity includes all TEAEs occurring from start of study drug administration up to 24 hours after end of study drug administration. For events without the hypersensitivity electronic case report form (eCRF), only date (no time) information are collected, the event occurred on the same date as the study drug injection date will be included in Time Period A.\n\nTime Period B, of potential non\u2011immediate hypersensitivity, includes all TEAEs occurring more than 24 hours after the end of study drug administration, but prior to subsequent drug administration.\n\nThe counts and percentages of participants who experienced a TEAE will be summarized by PT with decreasing frequency by treatment.\n\nDetailed searching criteria can be found in Appendix 3. Within query, individual PTs that satisfied the queries will be summarized. For Time Period A analysis, the Anaphylactic reaction SMQ algorithm will be summarized. Also, a single event may satisfy multiple SMQs, in which case the event contributes to every applicable SMQ.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2855, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "19dd0a7a-5b45-47a0-9e3d-d369b9a6c24d": {"__data__": {"id_": "19dd0a7a-5b45-47a0-9e3d-d369b9a6c24d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "157c292c-1125-493e-899b-3db2e3cb0598", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "6845642a1ca9a085eb466c0502cecff5127cb46029bade09aff8d3c28dc437a7", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.14.3.8.1. Severe/Serious Hypersensitivity Reactions\n\nThe serious/severe cases of treatment\u2011emergent hypersensitivity will be considered as AESIs. All serious hypersensitivity events will be collected with the SAE form. A listing of participants with serious hypersensitivity reactions may be provided if deemed necessary.\n\n# 6.14.3.9. Injection Site Reaction\n\nInjection site reactions, incidence and rates, and related information reported via the \u201cInjection Site Reactions\u201d eCRF will be summarized by treatment. Information to be summarized includes the location of the reaction, timing of the reaction relative to study drug administration, and characteristics of the injection site reaction: erythema, induration, pain, pruritis, and edema. Patient\u2011based analysis and event\u2011based analysis may be provided if necessary. The patient\u2011based analysis summarizes all injection\u2011site reaction (ISR) questionnaire forms for an individual patient with a single statistic, typically an extreme value. This analysis allows each patient to contribute only once for each parameter, at the expense of a focus on the most extreme events. By contrast, the event\u2011based analysis summarizes all ISR questionnaire forms received, without regard to individual patients. This provides characteristics of ISR events as a proportion of all events for which questionnaire responses were provided, at the expense of some potential bias due to differential contribution of individual patients to the analysis.\n\nThe counts and percentages of participants with treatment emergent injection site reaction will be summarized by treatment using the MedDRA PTs. Detailed searching criteria can be found in Appendix 3. The PT will be listed for summary in decreasing order of incidence for tirzepatide\u2011treated participants.\n\n# 6.14.3.9.1. Severe/Serious Injection Site Reactions\n\nThe severe/serious treatment\u2011emergent injection site reactions (for example, abscess, cellulitis, erythema, hematomas/hemorrhage, exfoliation/necrosis, pain, subcutaneous nodules, swelling, induration, inflammation) will be considered as AESIs. The counts and percentage of participants with severe/serious treatment\u2011emergent ISRs will be summarized by treatment. A listing of participants with treatment\u2011emergent severe/serious ISRs may be provided, if deemed necessary.\n\n# 6.14.3.10. Major Adverse Cardiovascular Events\n\nThe following positively adjudicated major adverse cardiovascular events (MACE) will be considered as AESIs:\n\n- death due to cardiovascular AEs\n- myocardial infarction (MI)\n- hospitalization for unstable angina\n- hospitalization for heart failure\n- coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention)\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2783, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "aec53e9f-a6b7-48e8-bdba-9e42189580cd": {"__data__": {"id_": "aec53e9f-a6b7-48e8-bdba-9e42189580cd", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b38f553d-7cbd-48f5-83d1-9eea563a41af", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "691cfa8c547f79d6b8c4945b0fff54ffdbff3ed7e3c942661da4bf842b18b13b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\nPage 49\n\n\u2022 cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack.\n\nThe counts and percentages of participants with positively adjudicated MACE may be summarized by treatment.\n\nIn addition, MACE reported by investigator may also be summarized although a major adverse cardiovascular event reported by investigator is not considered as AESI.\n\nA listing of participants reporting MACE events, either reported by investigator or identified by the clinical endpoint committee (CEC), may be provided.\n\n# 6.14.3.11. Major Depressive Disorder/Suicidal Ideation or Behavior\n\nThe severe/serious treatment\u2011emergent major depressive disorder/suicidal ideation or behavior will be captured as AESI. Adverse events will be searched using MedDRA PT terms. Detailed searching criteria can be found in Appendix 3.\n\nThe counts and percentages of participants with TEAEs will be summarized by treatment group using MedDRA PT nested within SMQ. Events will be ordered by decreasing frequency in the total tirzepatide group nested within SMQ. A listing of participants with major depressive disorder/suicidal ideation or behavior may be provided if deemed necessary.\n\nAdditionally, suicidal ideation and behavior, and depression will be assessed by the investigator via spontaneously reported AEs and through the use of the Columbia\u2011Suicide Severity Rating Scale (C\u2011SSRS) and the Patient Health Questionnaire (PHQ\u20119).\n\n# 6.14.3.11.1. Patient Health Questionnaire\n\nTotal scores for the PHQ\u20119 range from 0 to 27 with total scores categorized as\n\n- none (not depressed): 0 through 4\n- mild: 5 through 9\n- moderate: 10 through 14\n- moderately severe: 15 through 19, and\n- severe: 20 through 27.\n\nShift tables will be provided showing the counts and percentages of participants within each baseline category (maximum value) versus each postbaseline category (maximum value) by treatment.\n\nAdditionally, the following 3 outcomes of interest will be compared between treatments (based on the maximum value during baseline and postbaseline):\n\n- any increase in depression category (that is, worsening of depression): includes participants in the none, mild, moderate, or moderately severe category during baseline and with at least 1 postbaseline measurement", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2322, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2fcf14dd-a2e6-4455-a4d0-1208444a8ec2": {"__data__": {"id_": "2fcf14dd-a2e6-4455-a4d0-1208444a8ec2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "61c3e6fa-bdc9-4dc5-8186-43c785244db2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "1962572115826de48dccf241917e4bacd6fc47f63ebfc134a98b2cd8575396ba", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\nPage 50\n\n# 6.14.3.11.2. Suicidal Ideation and Behavior Solicited Through C-SSRS\n\nSuicide\u2011related thoughts and behaviors occurring during the entire study period, based on the C\u2011SSRS, will be summarized by treatment group. In particular, for each of the following suicide\u2011related events, the counts and percentages of participants with the event will be summarized by treatment group:\n\n- died by suicide\n- nonfatal suicide attempt\n- interrupted attempt\n- aborted attempt\n- preparatory acts or behavior\n- active suicidal ideation with specific plan and intent\n- active suicidal ideation with some intent to act without specific plan\n- active suicidal ideation with any methods (no plan) without intent to act\n- nonspecific active suicidal thoughts\n- wish to be dead, and\n- non\u2011suicidal, self\u2011injurious behavior.\n\nIn addition, the counts and percentages of participants who experienced at least 1 of the composite measures will be presented. The participants with at least 1 post\u2011baseline C\u2011SSRS assessment are included. The composite measure is determined at each assessment by the \u201cyes\u201d or \u201cno\u201d responses in C\u2011SSRS categories by the study participant:\n\n- Category 1 \u2013 Wish to be Dead\n- Category 2 \u2013 Non\u2011specific Active Suicidal Thoughts\n- Category 3 \u2013 Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act\n- Category 4 \u2013 Active Suicidal Ideation with Some Intent to Act, without Specific Plan\n- Category 5 \u2013 Active Suicidal Ideation with Specific Plan and Intent\n- Category 6 \u2013 Preparatory Acts or Behavior\n- Category 7 \u2013 Aborted Attempt\n- Category 8 \u2013 Interrupted Attempt\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1652, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d85e4ebc-90f9-4d37-b7a8-37b864e302f9": {"__data__": {"id_": "d85e4ebc-90f9-4d37-b7a8-37b864e302f9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6129b1ed-7eb1-4923-9e5d-b4ca6d2efffa", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "5e886bcd8368a3d65c8a769ea2c5b7f099b81ee95be9336314cbbbf0f3cfff12", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.14.3.12. Malignancy\n\nTreatment\u2011emergent malignancy will be considered an AESI. The counts and percentages of participants with treatment emergent malignancy will be summarized by treatment and PT with decreasing order. Detailed searching criteria can be found in Appendix 3.\n\n# 6.14.3.13. Metabolic Acidosis\n\nThis section is applicable for participants developing T2DM during the study treatment (up to primary database lock [72 weeks] and final database lock [176 weeks]). Severe/serious treatment\u2011emergent metabolic acidosis, including diabetic ketoacidosis will be captured as an AESI. The counts and percentages of participants with metabolic acidosis, including diabetic ketoacidosis may be summarized by treatment based on searching criteria in Appendix 3.\n\n# 6.14.3.14. Renal Safety\n\nLaboratory measures related to renal safety will be analyzed as specified for laboratory measurements in Section 6.14.6. Two shift tables examining renal function will be created. A min\u2011to\u2011min shift table of estimated glomerular filtration rate (eGFR) estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD\u2011EPI) equation with units ml/min/1.73m2, using categories (&#x3C;30, \u226530 to &#x3C;45, \u226545 to &#x3C;60, \u226560 to &#x3C;90, and \u226590 mL/min/1.73m2). A max\u2011to\u2011max shift table of urine albumin\u2011to\u2011creatinine ratio (UACR), using the categories UACR &#x3C;30 mg/g, 30 mg/g \u2264 UACR \u2264300 mg/g, UACR >300 mg/g (respectively, these represent normal, microalbuminuria, and macroalbuminuria).", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1542, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f42268e7-f1f8-4aa8-8bb0-cadde78000f3": {"__data__": {"id_": "f42268e7-f1f8-4aa8-8bb0-cadde78000f3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7a77c3c8-2aef-44a8-9c8a-17a5163781c7", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "76f54e8e7d9e26f36ba0b161552a498229d6456502311a283b00e9f4c2fc088d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\nPage 52\n\n# 6.14.3.14.1. Acute Renal Events\n\nBecause severe GI events may lead to dehydration, which could cause a deterioration in renal function including acute renal failure, dehydration events will be analyzed. Acute renal events associated with chronic renal failure exacerbation will also be captured. Severe/serious renal events from the following SMQ search will be considered AESIs. The counts and percentages of participants with acute renal events will be summarized by treatment by using the MedDRA PTs contained in any of the following SMQs:\n\n- Acute renal failure: Narrow terms in Acute renal failure SMQ (20000003)\n- Chronic kidney disease: Narrow terms in Chronic kidney disease SMQ (20000213).\n\nIn addition, a listing of participants with treatment\u2011emergent acute renal events may be provided, if deemed necessary.\n\n# 6.14.3.14.2. Dehydration\n\nDehydration events will be captured in the Narrow terms in Dehydration SMQ (20000232). Severe/serious dehydration events will be considered AESIs. A listing of participants with treatment\u2011emergent dehydration events will be provided.\n\n# 6.14.3.15. Thyroid Safety Monitoring\n\n# 6.14.3.15.1. Calcitonin\n\nObserved calcitonin data (a thyroid\u2011specific laboratory assessment) will be summarized by treatment and nominal visit. The counts and percentages of participants with a maximum postbaseline calcitonin value in the following thresholds will be provided by treatment and baseline calcitonin value (\u226420 ng/L, >20 ng/L to \u226435 ng/L, >35 ng/L). Postbaseline: \u226420 ng/L, >20 ng/L to \u226435 ng/L, >35 ng/L to \u226450 ng/L, >50 ng/L to \u2264100 ng/L, and >100 ng/L.\n\n# 6.14.3.15.2. C-Cell Hyperplasia and Thyroid Malignancies\n\nTreatment\u2011emergent thyroid malignancies and C\u2011Cell hyperplasia will be considered AESIs. Detailed searching criteria can be found in Appendix 3. The counts and percentages of participants with treatment\u2011emergent thyroid C\u2011cell hyperplasia and malignancies will be summarized by treatment and PT ordered with decreasing frequency. In addition, a listing of participants with treatment\u2011emergent thyroid C\u2011cell hyperplasia and neoplasms may be provided if deemed necessary.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2198, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4cc55906-aabd-4413-b8e1-694f0c822236": {"__data__": {"id_": "4cc55906-aabd-4413-b8e1-694f0c822236", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0b182325-1de6-4f0d-a3eb-b1b6fcfc14de", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "89a2abbfd770143c83d0f4f9a94006e1e459f92934a1c48d9ae9dfe6d88c27fc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# 6.14.3.16. Treatment-Emergent Supraventricular Arrhythmias and Cardiac Conduction Disorders\n\nSevere/serious treatment\u2011emergent supraventricular arrhythmias and cardiac conduction disorders will be considered AESIs.\n\nThe treatment\u2011emergent supraventricular arrhythmias and cardiac conduction disorders events will be identified using the MedDRA PTs. Detailed searching criteria can be found in Appendix 3.\n\nThe counts and percentages of participants with treatment emergent supraventricular arrhythmias and cardiac conduction disorders will be summarized by treatment and PT nested within SMQ. The PT will be ordered with decreasing frequency within SMQ. A listing of participants with treatment\u2011emergent supraventricular arrhythmias and cardiac conduction disorders may be provided if deemed necessary.\n\n# 6.14.3.17. Overdose\n\nA listing of participants reporting AEs related to overdosing of tirzepatide will be provided.\n\n# 6.14.3.18. Abuse Liability\n\nThe counts and percentages of participants with treatment emergent potential abuse liability events will be summarized by treatment group with decreasing frequency. Detailed searching criteria can be found in Appendix 3.\n\n# 6.14.4. Vital Signs\n\nIn the case that multiple records of an individual vital sign are collected at the same visit, they will be averaged prior to being used for data summaries and analyses.\n\nDescriptive summaries by treatment and by nominal visit will be provided for baseline and postbaseline values as well as change from baseline values.\n\nAn MMRM and/or an ANCOVA model as in Section 6.14 might be conducted if necessary.\n\nCounts and percentages of participants with treatment\u2011emergent abnormal sitting SBP, sitting DBP, and pulse at any time during the entire study (including the off\u2011drug follow up time period) will be presented by treatment for participants who have both baseline and at least 1 postbaseline result. A treatment\u2011emergent high result is defined as a change from a value less than or equal to the high limit at baseline to a value greater than the high limit at any time that meets the specified change criteria during the postbaseline period. A treatment\u2011emergent low result is defined as a change from a value greater than or equal to the low limit at baseline to a value less than the low limit at any time that meets the specified change criteria during the postbaseline period. To assess decreases, change from the minimum value during the baseline period to the minimum value during the postbaseline period will be used. To assess increases, changes from the maximum value during the baseline period to the maximum value during the postbaseline period will be used. Both planned and unplanned measurements will be included in the analysis.\n\nThe criteria for identifying participants with treatment\u2011emergent vital sign abnormalities are stated in Table GPHK.6.11.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2931, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "70173a99-205a-4db2-9494-f54061892aef": {"__data__": {"id_": "70173a99-205a-4db2-9494-f54061892aef", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "008cddd8-aff9-414e-9be2-b23751bcba6b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7924516f1bb12473a6fbb1121c59c19a88af320c16807155ba18b7fd0a7fbf37", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\nPage 54\n\n# Table GPHK.6.11. Categorical Criteria for Abnormal Treatment-Emergent Blood Pressure and Pulse Measurements\n\n| Parameter                                                         | Low                                | High                                |\n| ----------------------------------------------------------------- | ---------------------------------- | ----------------------------------- |\n| Systolic BP (mm Hg) (Supine or sitting \u2013 forearm at heart level)  | \u226490 and decrease from baseline \u226520 | \u2265140 and increase from baseline \u226520 |\n| Diastolic BP (mm Hg) (Supine or sitting \u2013 forearm at heart level) | \u226450 and decrease from baseline \u226510 | \u226590 and increase from baseline \u226510  |\n| Pulse (bpm) (Supine or sitting)                                   | <50 and decrease from baseline \u226515 | >100 and increase from baseline \u226515 |\n\nAbbreviations: BP = blood pressure; bpm = beats per minute\n\nIn addition, following analyses will be conducted by treatment:\n\n- counts and percentages of participants who had resting heart rate changes from baseline at 2 consecutive visits of more than 10 bpm and/or 20 bpm\n- counts and percentages of participants who had resting heart rate maximum changes from baseline at visit &#x3C;20 bpm or \u226520 bpm\n- counts and percentages of participants who had at least 1 resting heart rate exceeding 100 bpm, and\n- counts and percentages of participants who had at least 1 resting heart rate exceeding 100 bpm occurring at 2 consecutive study visits.\n\n# 6.14.5. Electrocardiograms\n\nFor electrocardiogram (ECG) parameters that collect in triplicates (that is, Visit 3 and Visit 12), the average from the 3 measurements for the same parameter at the same visit will be calculated and used for all the subsequent summaries and analyses.\n\nSummary statistics by treatment and by nominal visit will be provided for ECG parameters (heart rate, PR, QRS, QT, and QT corrected using Fredericia\u2019s correction factor [QTcF = QT / RR0.333]). When the QRS is prolonged (for example, a complete bundle branch block), QT and QTc should be used to assess ventricular repolarization. Thus, for a particular ECG, the following will be set to missing (for analysis purposes) when QRS is \u2265120 msec: QT and QTcF.\n\nChange from baseline to postbaseline values for ECG parameters (heart rate [HR] and PR) will be summarized for participants who have both a baseline and at least 1 postbaseline result. Only planned measurements will be included in the mean change analyses.\n\nThe criteria for identifying participants with treatment\u2011emergent quantitative ECG abnormalities is based on Table GPHK.6.12.\n\nThe counts and percentages of participants who meet following criteria at any time during the entire study period (including the off\u2011drug follow up time period) will be summarized by treatment group:\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2874, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "731d6df7-71bc-4ca5-a62a-6d85a41d48fc": {"__data__": {"id_": "731d6df7-71bc-4ca5-a62a-6d85a41d48fc", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2cac1317-9e55-462a-95b8-0599ef76007e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "81ae882d99e2b0a274482fc4ee4ac85a360f3af749c7f3694df026cc52830a31", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\nPage 55\n\n- treatment\u2011emergent ECG abnormalities as listed in Table GPHK.6.12\n- QT greater than 500 msec\n- QTcF greater than 500 msec, and\n- treatment\u2011emergent increase from the maximum baseline in QTcF interval of greater than 30 msec, 60 msec, or 75 msec. Maximum baseline will be the maximum non\u2011missing observation in the baseline period. The maximum value during the treatment period will be analyzed. Scheduled and unscheduled measurements will be included.\n\n# Table GPHK.6.12. Selected Categorical Limits for ECG Data\n\n| Parameter           | Males                |                      | Females               |                       |\n| ------------------- | -------------------- | -------------------- | --------------------- | --------------------- |\n| Heart Rate (bpm)    | <50 and decrease \u226515 | <50 and decrease \u226515 | >100 and increase \u226515 | >100 and increase \u226515 |\n| PR Interval (msec)  | <120                 | <120                 | \u2265220                  | \u2265220                  |\n| QRS Interval (msec) | <60                  | <60                  | \u2265120                  | \u2265120                  |\n| QTcF (msec)         | <330                 | <340                 | >450                  | >470                  |\n\nAbbreviations: bpm = beats per minute; ECG = electrocardiogram; QTcF = Fredericia\u2019s corrected QT interval.\n\n# 6.14.6. Clinical Laboratory Evaluation\n\nLimits from the performing lab will be used to define low (L) and high (H). Descriptive summaries by treatment and by nominal visit will be provided for the baseline and postbaseline values as well as the change from baseline values. The associated descriptive will be presented in System International (SI) units and in conventional (CN) units.\n\nObserved and change from baseline values for each visit may be displayed in plots for participants who have both a baseline and at least 1 postbaseline planned measurement. Baseline will be the last non missing observation prior to taking first study drug. Unplanned measurements will be excluded from plots.\n\nA shift table will be provided including unplanned measurements. The shift table will include the number and percentage of participants within each baseline category (low, normal, high, or missing) versus each postbaseline category (low, normal, high, or missing) by treatment. The proportion of participants shifted will be compared between treatments using Fisher\u2019s exact test.\n\nFor qualitative laboratory analytes, the number and percentage of participants with normal and abnormal values will be summarized by treatment.\n\nA listing of abnormal findings will be created for laboratory analyte measurements, including qualitative measures. The listing will include participant identification, treatment group, laboratory collection date, study day, analyte name, and analyte finding.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2886, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2370d84c-304a-4901-8a94-220dd32ad52e": {"__data__": {"id_": "2370d84c-304a-4901-8a94-220dd32ad52e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d3381f7e-7fc4-4e0c-acf4-0f52db886b2e", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2a5d0effb3aa8e7af59ed063e310a3dfacb698d773b17d8e29323b1369544d1b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\nPage 56\n\nThe MMRM model or ANCOVA (if MMRM model is not applicable) will be used for the analysis during the treatment period for the continuous measurements for selected lab tests.\n\n# 6.14.6.1. Two-hour Oral Glucose Tolerance Test (OGTT)\n\nThe following parameters will be collected during 2\u2011hour OGTT for each scheduled OGTT visit:\n\n- glucose\n- insulin, and\n- C\u2011peptide.\n\nFor each above parameter, the mean concentration over 120 minutes plots will be created by glycemia status at randomization and by treatment group and by OGTT visit (that is, at baseline and at Week 72). After 72 weeks, these plots will be created for participants with prediabetes at randomization.\n\nFor each above parameter, the area under the curve from time zero to 2 hours (AUC)(0\u20112h) during OGTT will be calculated using the trapezoidal rule. The respective AUC(0\u20112h) will be summarized by treatment group and by OGTT visit.\n\nIn addition, the following OGTT derived parameters (Armato et al. 2018) will be calculated at each OGTT visit for each participant with OGTT:\n\n- Glycemic response categories:\n- Normal: normal glucose tolerance and a 1\u2011hour PG concentration &#x3C;8.6 mmol/L (154.8 mg/dL), where normal glucose tolerance is defined by the 2019 American Diabetes Association Standards of Medical Care in Diabetes (ADA 2019a) as follows:\n- Fasting glucose: obtained alone or at time = 0 during an OGTT is &#x3C;100 mg/dL (5.6 mmol/L) and\n- 2\u2011hour glucose: obtained at time = 120 minutes during an OGTT is &#x3C;140 mg/dL (7.8 mmol/L)\n- Moderate impairment:\n- Normal glucose tolerance and 1\u2011hour plasma glucose \u22658.6 mmol/L, or\n- Impaired fasting glucose or impaired glucose tolerance, or both, and 1\u2011hour PG concentration &#x3C;8.6 mmol/L (154.8 mg/dL), where impaired fasting glucose is defined as fasting plasma glucose (FPG) levels between 100 and 125 mg/dL (between 5.6 and 6.9 mmol/L), and impaired glucose tolerance is defined as 2\u2011hour PG during 75 g OGTT levels between 140 and 199 mg/dL (between 7.8 and 11.0 mmol/L) (ADA 2019a)\n- Severe abnormality: impaired fasting glucose or impaired glucose tolerance, or both, and 1\u2011hour PG concentration \u22658.6 mmol/L\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2208, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2c061279-5d38-4011-bbd2-40d5691be6b2": {"__data__": {"id_": "2c061279-5d38-4011-bbd2-40d5691be6b2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a45fa8ef-aea5-4767-b137-6761b78a2701", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "f55d5281180b268781db9e19ddf54420f99580686b1427ec85af1d5357665d73", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Page 57\n\n\u2022  Matsuda Index = 10000, where FPG is the fasting glucose, FPI is the fasting insulin, denotes the mean glucose during OGTT, and denotes the mean insulin during OGTT\n\n- Normal insulin sensitivity: Matsuda index >25th percentile of Matsuda index values from participants with normal glucose tolerance at baseline\n- Moderate insulin resistance: Matsuda index in the 5th to 25th percentile (inclusive) of Matsuda index values from participants with normal glucose tolerance at baseline\n- Severe insulin resistance: Matsuda index &#x3C; the lowest fifth percentile of the range of Matsuda index values from participants with normal glucose tolerance at baseline\n\n\u2022  Insulin secretion = ( \u0394C\u209a\u2091\u209a)\u2080, where \u0394C\u209a\u2091\u209a denotes the incremental area under the plasma C\u2011peptide curve during the 2\u2011hour OGTT, and \u0394LlG denotes the incremental area under the plasma glucose concentration curve during 2\u2011hour OGTT\n\nInsulin secretion index = ( \u0394C\u209a\u2091\u209a)\u2080, where normal level of insulin secretion is the median value for insulin secretion, ie, ( \u0394C\u209a\u2091\u209a)\u2080, in participants with normal glucose tolerance at baseline\n\n- Normal insulin secretion: insulin secretion index >70%\n- Moderate impairment of insulin secretion: 50% to 70% (inclusive) of the insulin secretion index\n- Severe impairment of insulin secretion: &#x3C;50% of the insulin secretion index\n\n\u2022 \u03b2-cell function = Insulin secretion * Matsuda index = ( \u0394C\u209a\u2091\u209a)\u2080 * 10000\n\nThe descriptive summaries for the above continuous derived OGTT parameters (for example, sample size, mean, median, SD, minimum, maximum) will be calculated at each scheduled OGTT visit by treatment group and by glycemia status (that is, normoglycemia and prediabetes at randomization) if applicable. For the categorical derived OGTT parameters, descriptive summaries (that is, sample size, frequency, percentage) will be calculated at each scheduled OGTT visit by treatment group and by glycemia status (that is, normoglycemia and prediabetes at randomization) if applicable.\n\nUnless otherwise specified, the ANOVA model will be applied to the following parameters with terms of treatment groups (tirzepatide 5 mg, 10 mg, 15 mg, and placebo) and baseline value of the corresponding parameter at 72 weeks. For the measurements assessed at 176 weeks, MMRM model might apply for participants with prediabetes at baseline.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2393, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0adb595c-88ff-4486-acb6-1e343c5ea243": {"__data__": {"id_": "0adb595c-88ff-4486-acb6-1e343c5ea243", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "cacd7cdf-c893-4812-a438-00507ee55a89", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "7ef7f523e8f4330309ff26f49c058fda0bfdfe5d386ac84cf7784d26bbd3873c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.15. Health Outcomes\n\nThe patient\u2011reported outcome questionnaires will be analyzed using the mITT population on the EAS, unless specified otherwise. Item\u2011level missingness is dealt with as per the instrument developers\u2019 instruction. Additional psychometric analyses will be performed by Global Patient Outcomes Real World Evidence at Lilly and documented in a separate analysis plan.\n\n# 6.15.1. Patient Global Impression of Status for Physical Activity\n\nThe counts and percents of participants for Patient Global Impression of Status for Physical Activity (PGIS) response categories at each time point will be summarized by nominal visit and by treatment. For time points >72 weeks, only the participants with prediabetes at randomization will be included so that the denominator for percents will be participants with prediabetes at randomization only. A shift table from baseline to postbaseline of 5 PGIS response categories will be created at each postbaseline visit.\n\n# 6.15.2. Short-Form-36 Health Survey Version 2, Acute Form\n\nPer copyright owner, the QualityMetric Health Outcomes\u2122 Scoring (PRO_CoRe V2.0) Software will be used to derive the following domain and component scores:\n\n- Mental Component Score (MCS)\n- Physical Component Score (PCS)\n- Physical Functioning domain (PF)\n- Role\u2011Physical domain (RP)\n- Bodily Pain domain (BP)\n- General Health domain (GH)\n- Vitality domain (VT)\n- Social Functioning domain (SF)\n- Role\u2011Emotional domain (RE), and\n- Mental Health domain (MH).\n\nThe following analyses for the actual value and change from baseline value for each domain and component score will be conducted:\n\n- descriptive summaries by treatment group, and\n- analysis described in Table GPHK.6.4, Table GPHK.6.5, and Table GPHK.6.6.\n\nIf data allowed, analysis for SF\u201136 physical function domain score analysis described in Table GPHK.6.4, Table GPHK.6.5, and Table GPHK.6.4 will be conducted to evaluate the treatment effect in participants who have impaired physical function at baseline, which is defined as PGI\u2011S response at baseline of \u201cmoderately limited,\u201d \u201cvery much limited,\u201d or \u201cextremely limited\u201d.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2172, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a4d106d1-aad2-4aa2-8d2e-99a175ef1728": {"__data__": {"id_": "a4d106d1-aad2-4aa2-8d2e-99a175ef1728", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c2c764e2-57db-4e01-b96c-928aaf1a5192", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "950b403f75b7b88ca0fef4a5a39f8dcf1facc1e70862755a185b6fa58150f712", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.15.3. Impact of Weight on Quality of Life-Lite Clinical Trials\n\nThe following parameters will be included from IWQOL\u2011Lite\u2011CT:\n\n- IWQOL Lite CT total score (all items: items 1 through 20)\n- Physical Function composite score (5 items: items 1 through 3, 16, 17)\n- Physical composite score (7 items: item 1 through 5, 16, 17), and\n- Psychosocial composite score (13 items: item 6 through 15, 18, 19, 20).\n\nIWQOL\u2011Lite\u2011CT total and composite scores range from 0 to 100, with higher scores reflecting better levels of functioning.\n\nIWQOL\u2011Lite\u2011CT scores are computed according to the IWQOL\u2011Lite scoring rules (Kolotkin et al. 2002) as following:\n\n- Each composite raw score will be calculated if a minimum of 50% of the items for that composite has a non\u2011missing value; the total score will be calculated if a minimum of 75% of all 20 items has a non\u2011missing value.\n- - physical composite score: 4 of 7 items\n- physical function composite score: 3 of 5 items\n- psychosocial composite score: 7 of 13 items\n- IWQOL Lite CT total score: 15 of 20 items\n\nIf the minimum required number of items are answered for a composite then:", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1170, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6ee6b166-38af-405a-a9a9-bf8eb77102a0": {"__data__": {"id_": "6ee6b166-38af-405a-a9a9-bf8eb77102a0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d5850104-d5a1-41e0-b990-9ab47a319a35", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "395464ab65003ae166d0baf05ade47a683b77fa9057791063917ca457931036f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\nPage 60\n\nFor total and each composite score, the actual value and change from baseline value following analyses will be conducted:\n\n- descriptive summaries by treatment group and\n- ANCOVA analysis described in Table GPHK.6.5 and Table GPHK.6.6.\n\nIf data allowed, analysis for IWQOL physical function composite score analysis described in Table GPHK.6.5 and Table GPHK.6.6 will be conducted to evaluate the treatment effect in participants who have impaired physical function at baseline (as defined in Section 6.15.2).\n\n# 6.15.4. EQ-5D-5L\n\nFor the utility score and the Visual Analog Scale (VAS) scores, following analyses of the actual value and change from baseline value will conducted:\n\n- descriptive summaries by treatment group and\n- analysis of covariance described in Table GPHK.6.6.\n\n# 6.16. Subgroup Analyses\n\nEfficacy subgroup analyses will be guided by the efficacy estimand in EAS. Subgroup analyses may be done by country to support local regulatory registrations.\n\n# 6.16.1. Subgroup Analysis of Body Weight Change\n\nSubgroup analyses by the following baseline characteristics will be provided:\n\n- age group (&#x3C;65, \u226565 years)\n- race\n- sex\n- ethnicity\n- region of enrollment (US, outside of US [OUS])\n- body mass index group (&#x3C;30, \u226530 and &#x3C;35, \u226535 and &#x3C;40, \u226540 kg/m2), and\n- glycemic status at randomization (normoglycemia vs prediabetes).\n\nThe outcome measures for the subgroup analyses will include:\n\n- percent change in body weight from randomization at 72 weeks and\n- percentage of participants achieving at least 5% body weight reduction at 72 weeks.\n\nFor the percentage change in body weight from randomization at 72 weeks, for each subgroup analyses aforementioned, the following 2 models will be conducted:\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1806, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "91e32d0f-4927-4140-aa03-56f248417b95": {"__data__": {"id_": "91e32d0f-4927-4140-aa03-56f248417b95", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "aa7c31ae-e1b1-41f2-aad1-ed3e9bfe672d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "65918bb137ec37580209edef69b436a2fabda003153ef3de638ba7c90f4a9655", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 6.16. Statistical Analyses\n\n\u2022 Conduct MMRM model on the subgroup only with terms of treatment group, visit, treatment\u2011by\u2011visit\u2011interaction, country/pooled country, sex, and prediabetes status at randomization as fixed effects, and baseline body weight as a covariate. Variance\u2011covariance structure for within\u2011patient errors will be same as Section 6.13.1.1.\n\n\u2022 Full MMRM model: treatment group, visit, subgroup, treatment\u2011by\u2011visit\u2011interaction, treatment\u2011by\u2011subgroup\u2011interaction, subgroup\u2011by\u2011visit\u2011interaction, treatment\u2011visit\u2011subgroup\u2011interaction, country/pooled country, sex, and prediabetes status at randomization as fixed effects, and baseline body weight as a covariate. Variance\u2011covariance structure for within\u2011patient errors will be same as Section 6.13.1.1.\n\nFor the percentage of participants achieving at least 5% body weight reduction at 72 weeks, for each subgroup analyses aforementioned, the following 2 models will be conducted:\n\n\u2022 Conduct logistic regression model on the subgroup with terms of treatment group, country/pooled country, sex and prediabetes status at randomization as fixed effects, and baseline body weight as covariate. Missing body weight measurement at 72 weeks will be imputed by the predicted value from MMRM model on the subgroup aforementioned, then the continuous measurements will be dichotomized into status of achieving at least 5% body weight reduction (Yes or No).\n\n\u2022 Conduct logistic regression model with terms of treatment group, subgroup, treatment\u2011by\u2011subgroup\u2011interaction, country/pooled country, sex, and prediabetes status at randomization as fixed effects, and baseline body weight as a covariate. Missing body weight measurement at 72 weeks will be imputed by the predicted value from full MMRM model aforementioned, then the continuous measurements will be dichotomized into status of achieving at least 5% body weight reduction (Yes or No).\n\n# 6.17. Interim Analyses and Data Monitoring Committee\n\nThe details for the interim analyses and Data Monitoring Committee (DMC) will be provided in the DMC Charter.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2125, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6be66739-4dda-4c06-bb88-831f2ed6cf95": {"__data__": {"id_": "6be66739-4dda-4c06-bb88-831f2ed6cf95", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f2fa8fd5-6fce-46cd-bab7-6cf854651965", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2575d601aa9922c8bbbee635c5149a6a1257c33f3da02f4a88398502050cb58a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# 7. Unblinding Plan\n\nDetails of the blinding and unblinding will be provided in Blinding and Unblinding Plan document for Study GPHK.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 196, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "23a5e0d2-53cb-4ff5-9fc9-7fae636bba0e": {"__data__": {"id_": "23a5e0d2-53cb-4ff5-9fc9-7fae636bba0e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "955739d3-0f70-48c7-8383-40f01e5d4a5b", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "63d3d605afb76ec37f7e2d1072c5c6d8f314f0ddec34be2d183220059d0e102d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 8. COVID-19 Pandemic Impact</h8>\nThis section lists additional statistical analyses that may be performed at the primary database lock and final database lock to assess the impact of COVID\u201119 pandemic if the data warrants.\n\n# General Consideration</h8>\nPercentage and count of randomized participants who followed the COVID\u201119 mitigation plan may be summarized by treatment group. This includes, but not limited to, participants rescreened, procedures conducted via remote visit or mobile home health visit, visits occurred using the extended visit windows, alternative way of investigator product shipment/dispensing, use of a local lab, etc. A listing of randomized participants who followed the COVID\u201119 mitigation plan may be provided. Similar analyses may be provided by country and by treatment group.\n\nPercentage and count of randomized participants whose study visits were impacted by COVID\u201119 pandemic may also be summarized. A listing may be provided.\n\n# Exposure</h8>\nA listing of randomized participants who had study drug temporary interruption due to COVID\u201119 pandemic may be provided.\n\n# Protocol Deviation</h8>\nPercentage and count of randomized participants having important protocol deviation related to COVID\u201119 pandemic will be summarized by treatment.\n\nPercentage and count of randomized participants with protocol deviation related to COVID\u201119 pandemic may also be summarized by treatment.\n\nA listing of all randomized participants who had important protocol deviation due to COVID\u201119 pandemic may be provided.\n\n# Patient Disposition</h8>\nA summary table for all randomized participants that discontinue study or study treatment due to COVID\u201119 pandemic will be provided by treatment.\n\nA listing of randomized participants who discontinued the study or study treatment due to COVID\u201119 pandemic will be provided.\n\n# Adverse Events</h8>\nA listing of randomized participants who had COVID\u201119 infection, including death due to COVID\u201119, during the post\u2011randomization period will be provided. A summary table may be provided if deemed necessary.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2124, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2c06e8bf-0f13-487e-a7fd-92c4caa1cc14": {"__data__": {"id_": "2c06e8bf-0f13-487e-a7fd-92c4caa1cc14", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "17f5606d-1e38-47c5-8b04-b2710958115c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "e365a0fb1cba69e4be7f2a8816e760b0911b6001b08710156651efdffb0d59e5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 8.6. Major Depressive Disorder/Suicidal Ideation\n\nThe counts and percentages of participants with TEAEs for major depression may be summarized by treatment group using MedDRA PT nested within SMQ by COVID\u201119 subgroup (that is, participants without impact versus with impact) for SS group.\n\nA participant is defined as impacted by COVID\u201119 if either one of the following is satisfied:\n\n- no COVID\u201119 illness, but impacted by quarantine and travel restrictions, clinics closing, visits being canceled, delay or nondelivery of the investigational product, virtual visits, etc.\n- with COVID\u201119 illness.\n\nThe suicidal ideation and behavior solicited through C\u2011SSRS may be summarized by treatment group by COVID\u201119 subgroup (that is, participants without impact vs with impact) for SS group.\n\n# 8.7. Local Lab\n\nLocal lab due to exceptional circumstances will not be brought into the Lilly database at the time of primary database lock and final database lock per data collection system in Study GPHK, even though local laboratory is one of the options in exceptional circumstances. Therefore, this section is not applicable for analysis purpose.\n\n# 8.8. Missing Data Due to COVID-19\n\nFor the primary endpoints and key secondary endpoints, missing data due to COVID\u201119 will be handled as described in Section 6.13.1.3. In addition, a summary table for participants whose primary or key secondary measurements were impacted by COVID\u201119 (including missing, collected using alternative options) may be provided. A listing of participants whose primary or key secondary measurements were impacted by COVID\u201119 (including missing, collected using alternative options) may be provided if deemed necessary.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1753, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e8147c24-c399-4b79-b799-bc291b2a6e3d": {"__data__": {"id_": "e8147c24-c399-4b79-b799-bc291b2a6e3d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bcc91102-bcf6-416e-bd1a-2dc544d23d26", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d1dbfafc4738af71dc2eee1aa437172df751c280d3b8342372ca982f8bc6baa8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e495cf1-8f1f-4208-b17b-ab3fcc80c379", "node_type": "1", "metadata": {}, "hash": "b9456e408082ee51ea0e99363a4271de75ca85281c02a335433044813b5ecb9a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# 9. References\n\n[ADA] American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20112019. Diabetes Care. 2019a; 42(suppl 1):S 13\u2011S28. https://doi.org/10.2337/dc19\u2011S002\n\n[ADA] American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes\u20112019. Diabetes Care. 2019b;42(suppl 1):S61\u2011S70. https://doi.org/10.2337/dc19\u2011S006\n\nAnwar YA, White WB. Ambulatory monitoring of the blood pressure devices, analysis, and clinical utility. In: William White, editor. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. Humana Press, Inc; 2001:p 64.\n\nArmato JP, DeFronzo RA, Abdul\u2011Ghani M, Ruby RJ. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). Lancet Diabetes Endocrinol. 2018;6(10):781\u2011789. https://doi.org/10.1016/S2213\u20118587(18)30234\u20111\n\nCatapano AL, Graham I, De Backer G, Wiklund O, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37(39):2999\u20133058. https://doi.org/10.1093/eurheartj/ehw272\n\nErnst ME, Bergus GR. Noninvasive 24\u2011hour ambulatory blood pressure monitoring: overview of technology and clinical applications. Pharmacotherapy. 2002;22(5):597\u2011612. https://doi.org/10.1592/phco.22.8.597.33212\n\nGe M, Durham LK, and DR Meyer. Covariate\u2011Adjusted Difference in Proportions from Clinical Trials Using Logistic Regression and Weighted Risk Differences. Drug Information Journal. 2011;45(4):481\u2011493. https://doi.org/10.1177/009286151104500409\n\nKilgore M, Muntner P, Woolley JM, Sharma P, Bittner V, Rosenson RS. Discordance between high non\u2011HDL cholesterol and high LDL\u2011cholesterol among US adults. Journal of Clinical Lipidology. 2014 Jan\u2011Feb;8(1):86\u201193. https://doi.org/10.1016/j.jacl.2013.11.001\n\nMa C, Shen X, Qu YM, Du Y. Analysis of an Incomplete Binary Outcome Dichotomized From an Underlying Continuous Variable in Clinical Trials.\n\nParedes, S., Fonseca, L., Ribeiro, L. et al. Novel and traditional lipid profiles in Metabolic Syndrome reveal a high atherogenicity. Scientific Reports. 2019;9:11792. https://doi.org/10.1038/s41598\u2011019\u201148120\u20115\n\nPickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142\u2011161.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2567, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6e495cf1-8f1f-4208-b17b-ab3fcc80c379": {"__data__": {"id_": "6e495cf1-8f1f-4208-b17b-ab3fcc80c379", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "bcc91102-bcf6-416e-bd1a-2dc544d23d26", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d1dbfafc4738af71dc2eee1aa437172df751c280d3b8342372ca982f8bc6baa8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8147c24-c399-4b79-b799-bc291b2a6e3d", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a6b8ce182a97fd4936e4f2f0eb78907b0905b0a416db01318929a01402e7c533", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Scientific Reports. 2019;9:11792. https://doi.org/10.1038/s41598\u2011019\u201148120\u20115\n\nPickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142\u2011161. https://doi.org/10.1161/01.HYP.0000150859.47929.8e\n\nKolotkin RL, Crosby RD, Rhys Williams G. Health\u2010related quality of life varies among obese subgroups. Obes Res. 2002;10(8):748\u2011756. https://doi.org/10.1038/oby.2002.102\n\nRubin DB. Multiple imputation for nonresponse in surveys. John Wiley &#x26; Sons Inc.; 1987.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 2123, "end_char_idx": 2893, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bbd74dcc-a594-48a6-bd61-fc5d301c9083": {"__data__": {"id_": "bbd74dcc-a594-48a6-bd61-fc5d301c9083", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "11151cf0-395d-46fb-9f20-490eba8b9b0f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "10cb2b27a19570d0bae08852443425e0408ab1311e0028971d0cd6618334301d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 10. Appendices\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 28, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3ddc2503-02cf-4c0c-b02d-6f7e77d7fac2": {"__data__": {"id_": "3ddc2503-02cf-4c0c-b02d-6f7e77d7fac2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ea8e34fb-1616-4ecf-9f91-c3f80fe06867", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "2d2d8bde6f4477ad3163eeb3f7d9abd22398658906c8fedc9bd5e691308ff585", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Appendix 1. Body Composition Assessments via Dual-Energy X-ray Absorptiometry (DXA)\n\nThis section is applicable to the participants who are enrolled in the Dual Energy X\u2011ray Absorptiometry (DXA) addendum.\n\nThe primary objective of DXA addendum is to demonstrate that tirzepatide (5 mg, 10 mg, and 15 mg combined) QW is superior to placebo in percent change in total body fat mass from baseline to 72 weeks.\n\nPercent change of total body fat mass will be calculated as:\n\n[(Total body fat mass at 72 weeks - Total body fat mass at baseline) / Total body fat mass at baseline] *100\n\n# The secondary objectives include\n\n- To demonstrate that tirzepatide (5 mg, 10 mg, and 15 mg combined) QW is superior to placebo in loss of total body fat mass in kg from randomization to 72 weeks, and\n- To assess, for tirzepatide (5 mg, 10 mg, and 15 mg combined) QW, the following parameters, measured at randomization and 72 weeks:\n- Percent change in total body lean mass, and\n- Change in total body lean mass in kg.\n\nPercent change of total body lean mass will be calculated as:\n\n[(Total body lean mass at 72 weeks - Total body lean mass at baseline) / Total body lean mass at baseline] *100\n\nDXA will be performed at the baseline and at the end of 72\u2011week treatment (Visit 21) or ED.\n\nIn addition to the primary and secondary outcomes listed above, the following parameters will also be analyzed:\n\n- Total body mass (kg)\n- Total body fat mass (kg)\n- Total body lean mass (kg)\n- Percent body fat mass = total body fat mass / total body mass * 100\n- Percent body lean mass = total body lean mass / total body mass * 100\n- Fat lean mass ratio = total body fat mass / total body lean mass\n- Fat lean mass loss ratio = total body fat mass change / total body lean mass change, and\n- Fat lean mass percent loss ratio = percent change of total body fat mass / percent change of total body lean mass.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1941, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f616cf1f-90dd-4315-9bec-47a11fb6c572": {"__data__": {"id_": "f616cf1f-90dd-4315-9bec-47a11fb6c572", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "76f93ae6-8028-4cee-9b6f-ff20fcf49d00", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "a5f4f8cbe257c6c9d896f9e2b206a6f7d4f7f2262d5346d770b463d0f2bca671", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Page 68\n\nUnless otherwise specified, all analyses for the variables measured or derived from DXA will be conducted on all participants who are enrolled in this addendum, randomized, and have at least 1 dose of study drug, with both baseline and at least 1 postbaseline measurement. Baseline is defined as the last non\u2011missing data collected at randomization (prior to first dosing of study drug). Missing data at Week 72 will be imputed using the last observation carried forward method.\n\nDescriptive summary statistics (for example, sample size, mean, standard deviation, min, max, and median) of all parameters above (but not limited to) will be provided by treatment group (placebo, tirzepatide 5 mg, tirzepatide 10 mg, tirzepatide 15 mg, and all tirzepatide doses combined) at baseline and postbaseline visits (for both actual value and change from baseline value).\n\nIn addition, summary of demographics and baseline characteristics for participants in the DXA addendum will be provided.\n\nUnless otherwise noted, all tests of treatment effects will be conducted at a 2\u2011sided alpha level of 0.05, and the CI will be calculated at 95%, 2\u2011sided. There will be no multiplicity adjustment.\n\nThe ANCOVA model will be used to analyze the continuous outcomes. Each model will include the treatment group (all tirzepatide doses combined and placebo) and corresponding baseline value for the dependent value.\n\nSummary statistics for categorical measures (including categorized continuous measures) will include sample size, frequency, and percentages, if necessary. Logistic regression will be used to examine the treatment difference in binary outcomes if there is a need to adjust for covariates. Otherwise, Fisher\u2019s exact test will be used to examine the treatment difference in categorical outcomes.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1859, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "457592c3-10c1-41e9-96ad-8662f6b3333b": {"__data__": {"id_": "457592c3-10c1-41e9-96ad-8662f6b3333b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d90af1c0-4e00-4557-b77a-4c516756f757", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "8035527fe07d5326f2e25065d72e0ce19aad8203c97ae040cbbdfa93e272f3a4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Appendix 2. Ambulatory Blood Pressure Monitoring (ABPM)\n\nThis section is applicable to the participants who are enrolled in the Ambulatory Blood Pressure Monitoring (ABPM) addendum.\n\nThe main objective of ABPM addendum is to assess the effect of 5 mg, 10 mg, and 15 mg doses of tirzepatide compared to placebo on mean change from randomization (Week 0) to Week 36 on 24\u2011hour mean HR and 24\u2011hour mean blood pressure (BP) (SBP/ DBP), as measured during 24\u2011hour ABPM.\n\nAmbulatory monitoring of HR and BP will be performed prior to Visit 3 (Week 0; baseline) and again at Visit 12 (Week 36; final measure).\n\nOnly the valid readings will be used in the summary and analyses of the ABPM measurements. The ABPM measurements are downloaded to the ABPM vendor by the study site at the time of the participant visit. The validity of each ABPM recording will be provided by ABPM vendor.\n\nFor an ABPM recording session that is valid, all of the individual ABPM measurements that are flagged as valid and were recorded during the first 24 hours of recordings will be used in the analyses. No further editing of the values will be performed beyond the values flagged as invalid by the ABPM machine.\n\nThe following ABPM derived measurements will be evaluated:\n\n- Mean 24\u2011hour SBP, DBP, and HR\n- Mean daytime SBP, DBP, and HR.\n- Mean nighttime SBP, DBP, and HR.\n- Dipper and nondipper response. Blood pressure normally has a circadian pattern in which BP drops at night and is higher during the awake hours. This is referred to as dipping. The following equation (Anwar and White 2001) will be used to assess dipping status:\n\n(mean daytime SBP \u2013 mean nighttime SBP) / (mean daytime SBP) * 100%\n\nParticipants will be classified into the following categories based on their dipping status:\n\n- dipper: \u226510%\n- nondipper: 0% to 10%, and\n- riser (reverse dipper): &#x3C;0%\n\nMean 24\u2011hour, daytime, and nighttime BP load. Blood pressure load will be defined as follows (Ernst and Bergus 2002):\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2031, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "d3555915-5c9e-4ec5-8933-ddd80dc88a9e": {"__data__": {"id_": "d3555915-5c9e-4ec5-8933-ddd80dc88a9e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d7b16935-8249-4168-9e87-3817dcc67a69", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "b77c3e484e3530b08d0b5a34c2340b867a20535c0f8f9a6877966d258975b473", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Page 70\n\n- daytime: percent of SBP readings >140 mmHg and percent of DBP readings >90 mmHg (reported separately)\n- nighttime: percent of SBP readings >120 mmHg and percent of DBP readings >80 mmHg (reported separately)\n- mean 24 hour: percent above systolic limits (daytime and nighttime combined) and percent above diastolic limits (daytime and nighttime combined)\n\n\u2022 Mean 24\u2011hour, daytime, and nighttime pulse pressure (PP)\n\n- PP = SBP \u2013 DBP\n\n\u2022 Mean 24\u2011hour, daytime, and nighttime mean arterial pressure (MAP)\n\n- MAP = (2 * diastolic + systolic) / 3\n\n\u2022 Treatment\u2011emergent abnormally high HR (based on mean 24\u2011hour values) as defined in Table GPHK.6.11.\n\n\u2022 Treatment\u2011emergent abnormally high SBP and DBP defined as following (adapted from Pickering et al. 2005):\n\n- Mean Daytime SBP/DBP: >140/90 mmHg\n- Mean Nighttime SBP/DBP: >125/75 mmHg\n- Mean 24\u2011hour SBP/DBP: >135/85 mmHg\n\nThe daytime (0700 to 2200 hours) and nighttime (2200 to 0700 hours, inclusive) definitions will be used to provide accurate estimates of the BPs and heart rates during the awake and sleeping periods.\n\nMean plots for each derived continuous measurement above by treatment group by visit may be created.\n\nSummary statistics for actual and change from baseline for each derived measurements above will be performed by treatment group and by visit.\n\nBlood pressure load is an indicator of hypertensive burden and has been shown to correlate with markers of cardiovascular morbidity in participants with hypertension and has been used as a method of assessing antihypertensive drug efficacy. Summary statistics of 24\u2011hour BP load for all participants and those with or without hypertension at baseline will be calculated at baseline and at 36 weeks.\n\nIn addition to these derived measurements, the following summary measurements that provide information on the individual ABPM recordings sessions will be assessed:\n\n- total duration of recording session\n- total duration of recording session in the first 24 hours\n- total number of measurements in the first 24 hours\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2103, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4ac501ad-12c7-4f04-a9a7-13f23867a8d4": {"__data__": {"id_": "4ac501ad-12c7-4f04-a9a7-13f23867a8d4", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1df9a4ef-ff0c-420a-be8f-a0fab197ca27", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "22085bd5b5276e3957b0bd8c4149e7e1596bba976d6548f4f75a05ef03f934ec", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Page 71\n\n\u2022 Number of valid measurements in the first 24 hours, and\n\n\u2022 Percent of valid measurements in the first 24 hours.\n\nIn addition to the above analyses of outcomes specifically collected through ABPM reading, following analyses may be performed for participants in the ABPM addendum if deemed necessary:\n\n- summary of demographics and baseline characteristics\n- summary of concomitant medication at baseline, and\n- summary of change in concomitant medication of interest (for example, antihypertensive)\n\nUnless otherwise noted, all tests of treatment effects will be conducted at a 2\u2011sided alpha level of 0.05, and the CI will be calculated at 95%, 2\u2011sided. There will be no multiplicity adjustment.\n\nAll analyses for the variables measured or derived from ABPM, will be conducted on all participants who are enrolled in ABPM addendum, randomized and have at least 1 dose of study drug, with both baseline and at least 1 postbaseline measurement.\n\nFor continuous outcomes collected from the ABPM, including BP and HR, the analysis will be conducted using an analysis of covariance model, with terms of treatment group (tirzepatide 5 mg, 10 mg, 15 mg, and placebo), baseline measurement, and HR controlling medicine use status at baseline.\n\nFor categorical measures (including categorized continuous measures), logistic regression will be used to examine the treatment difference, if there is a need to adjust for covariates. Otherwise, Fisher\u2019s exact test will be used to examine the treatment difference.\n\n# References\n\n- Anwar YA, White WB. Ambulatory monitoring of the blood pressure devices, analysis, and clinical utility. In: William White, editor. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. Humana Press, Inc; 2001:p 64.\n- Ernst ME, Bergus GR. Noninvasive 24\u2011hour ambulatory blood pressure monitoring: overview of technology and clinical applications. Pharmacotherapy. 2002;22(5):597\u2011612. https://doi.org/10.1592/phco.22.8.597.33212\n- Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142\u2011161. https://doi.org/10.1161/01.HYP.0000150859.47929.8e\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2455, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "04ceb7ba-a8f4-40a2-884c-470b40acdab9": {"__data__": {"id_": "04ceb7ba-a8f4-40a2-884c-470b40acdab9", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "74f3e3a6-05b7-4584-8a58-deedb43a5be2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "d05689b697ecda9c9d9677edcc92b76eafd8cc38b6de87193e8e605de3eb4cf1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Appendix 3. Searching Criteria for Special Safety Topics\n\n# Abuse Liability\n\nTo identify AE terms suggestive of potential abuse liability, narrow terms from SMQ of Drug abuse and dependence (20000101) will be used.\n\n# Acute Gallbladder Disease\n\nAll biliary colic, cholecystitis, or other suspected events related to gallbladder disease will be identified using the MedDRA PTs in any of the following:\n\n- Narrow PTs in Gallbladder related disorders SMQ (20000124)\n- Narrow PTs in Biliary tract disorders SMQ (20000125)\n- Narrow PTs in Gallstone related disorders SMQ (20000127)\n\n# Amputation/Peripheral Revascularization\n\nAmputations/peripheral revascularization events will be identified using the following MedDRA PTs:\n\n- Amputation\n- Peripheral revascularization\n\n# C-cell Hyperplasia and Thyroid Malignancies\n\nThyroid malignancies and C\u2011Cell hyperplasia will be identified using MedDRA HLT for Thyroid neoplasms and PT for thyroid C\u2011cell hyperplasia.\n\n# Hepatic Treatment-Emergent Adverse Events\n\nTreatment\u2011emergent potentially drug\u2011related hepatic disorders will be identified using the MedDRA PTs contained in any of the following:\n\n- Broad and narrow terms in the Liver related investigations, signs and symptoms SMQ (20000008)\n- Broad and narrow terms in the Cholestasis and jaundice of hepatic origin SMQ (20000009)\n- Broad and narrow terms in the Hepatitis non\u2011infections SMQ (20000010)\n- Broad and narrow terms in the Hepatic failure, fibrosis and cirrhosis and other liver damage SMQ (20000013)\n- Narrow terms in the Liver\u2011related coagulation and bleeding disturbances SMQ (20000015)\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1656, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "65d50cd9-1a6a-45e8-817c-489a811b5c90": {"__data__": {"id_": "65d50cd9-1a6a-45e8-817c-489a811b5c90", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "e7bbfc7a-b432-40d7-b91e-cbcd2f90febb", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "12faded1e76b95ca1a8d6af60aee23a50374dea616a6624055385dc3a32d2809", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Page 73\n\n# Hypersensitivity Reactions\n\nAnalyses are based on the following:\n\n- Narrow and algorithm terms in Anaphylactic reaction SMQ (20000021)\n- Narrow terms in Angioedema SMQ (20000024)\n- Narrow terms in Severe cutaneous adverse reactions SMQ (20000020)\n- Narrow terms in Hypersensitivity SMQ (20000214).\n\nFor the Anaphylactic reaction SMQ, each term is classified by scope (Narrow, Broad) and by category (A, B, C, D). All Narrow terms are category A, and all Broad terms are category B, C, or D. In addition to the usual Narrow and Broad searches, the SMQ defines an algorithm to further refine the cases of interest. For Time Period A analysis, the Anaphylactic reaction SMQ algorithm will be included. The algorithm is based upon events that occur within Time Period A.\n\nThe counts and percentages of participants who experienced a TEAE for the following will be analyzed for each of the 2 time periods:\n\n- any narrow term from any one of the 4 SMQs indicated above (that is, combined search across narrow of all 4 SMQs)\n- any narrow scope term within each SMQ, separately (that is, narrow SMQ search). For Time Period A analysis, any term from Anaphylactic reaction SMQ algorithm.\n\n# Injection Site Reactions\n\nThe ISR AE will be identified using the MedDRA PT in any of the following:\n\n- HLT of Injection site reaction\n- HLT of Administration site reaction\n- HLT of Infusion Site Reactions\n\n# Pancreatitis Events\n\nDetermination of investigator\u2011reported events will be through the \u201cAcute pancreatitis\u201d MedDRA SMQ (20000022, narrow scope) and a \u201cChronic pancreatitis\u201d PT search of the AE database, while adjudication\u2011confirmed pancreatitis are found from adjudication forms.\n\n# Malignancy\n\nThe malignancy events will be identified using the MedDRA PT contained in Malignant tumours SMQ (20000194) narrow scope or Tumours of unspecified malignancy SMQ (20000195) narrow scope.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1944, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9c2e8bb0-0dd0-4ad0-99b7-97405050a56f": {"__data__": {"id_": "9c2e8bb0-0dd0-4ad0-99b7-97405050a56f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "41fe348a-fda1-4e46-af47-74ae1a64244c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "4e59b27a0ecc706306dac03cfce7a9331ee584bd4c3767a27af9765fa6407023", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n# Major Depressive Disorder/Suicidal Ideation\n\nAEs will be searched using MedDRA PTs from SMQs narrow scope: 20000037 [Suicide/self\u2011injury] and 20000167 [Depression (excl suicide and self injury)].\n\n# Metabolic Acidosis, Including Diabetic Ketoacidosis\n\nMetabolic acidosis including diabetic ketoacidosis will be identified using the following MedDRA PTs:\n\n- Diabetic ketoacidosis\n- Ketoacidosis\n- Euglycaemic diabetic ketoacidosis\n- Ketonuria\n- Diabetic ketosis\n- Diabetic ketoacidotic hyperglycaemic coma\n- Ketosis\n- Lactic acidosis\n- Urine ketone body present\n- Blood ketone body\n- Blood ketone body increased\n- Urine ketone body\n- Blood ketone body present.\n\n# Supraventricular Arrhythmias and Cardiac Conduction Disorders\n\nThe supraventricular arrhythmias and cardiac conduction disorders events will be identified using the MedDRA PT contained in any of the following SMQs:\n\n1. Supraventricular Arrhythmias:\n- For symptoms: Arrhythmia related investigations, signs and symptoms SMQ (20000051), narrow and broad terms\n- For supraventricular arrhythmias: In Cardiac arrhythmia SMQ, under tachyarrhythmia sub SMQ\n- Supraventricular tachyarrhythmia SMQ (20000057), broad and narrow terms\n- Tachyarrhythmia terms, nonspecific SMQ (20000164), narrow terms only;\n- Ventricular tachyarrhythmia SMQ (20000058), narrow terms only.\n\nLY3298176", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1386, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1dec04f3-76a5-4857-99f6-fd81205ccd6f": {"__data__": {"id_": "1dec04f3-76a5-4857-99f6-fd81205ccd6f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "85914d69-b362-42d3-b6a8-06ddd1453850", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "ca77072beb9683497cdad1337ae04a1a39b4756312cf70aef993790a57d014aa", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "I8F-MC-GPHK Statistical Analysis Plan Version 2\n\n# 2) Cardiac Conduction Disorders\n\n- Conduction defects SMQ (20000056), narrow terms only; and\n- Cardiac conduction disorders High Level Term (HLT; 10000032), all PTs.\n\nPage 75", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 226, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a1a29f5a-8dca-47f3-b009-ca42b7424b0a": {"__data__": {"id_": "a1a29f5a-8dca-47f3-b009-ca42b7424b0a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "ae541519-9682-4506-9959-f77e5c01436a", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nejmoa2206038_protocol.pdf", "file_name": "nejmoa2206038_protocol.pdf", "file_type": "application/haansoftpdf", "file_size": 5707820, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nejmoa2206038_protocol.pdf", "source_type": "medical_document"}, "hash": "82b398e0d6a8ac1e2666a910be1efbd6e6aa67a94ec3616ee1058e5cd0daa83f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Leo Document ID = 4179a915-5987-41e3-8d60-7981e462f8bc\n\nApprover: PPD\n\nApproval Date &#x26; Time: 28-Sep-2021 17:47:59 GMT\n\nSignature meaning: Approved", "mimetype": "text/plain", "start_char_idx": 3, "end_char_idx": 154, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "da5d37e0-1128-4a75-aadb-f571de105424": {"__data__": {"id_": "da5d37e0-1128-4a75-aadb-f571de105424", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "45991a6d-db10-4bdc-b928-92b4c1b387b1", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "51671e1e82887f1783f53d62f5d9d46f9a95573875bf544cfbf173274157b0db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20fb55bb-489f-4b0b-8acf-a11379975154", "node_type": "1", "metadata": {}, "hash": "aab89b45e5aa72b47851efd72a946de330f21581dc7937078a48dccf5075f4a3", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Nutrients\n\n# Systematic Review\n\n# Are Dietary Proteins the Key to Successful Body Weight Management? A Systematic Review and Meta-Analysis of Studies Assessing Body Weight Outcomes after Interventions with Increased Dietary Protein\n\nThea Toft Hansen *, Arne Astrup and Anders Sj\u00f6din\n\nDepartment of Nutrition, Exercise and Sports, Section for Obesity Research, Faculty of Science, University of Copenhagen, 1958 Frederiksberg C, Denmark; ast@nexs.ku.dk (A.A.); amsj@nexs.ku.dk (A.S.)\n\n* Correspondence: tha@nexs.ku.dk\n\nAbstract: The primary aim was to systematically review the current evidence investigating if dietary interventions rich in protein lead to improved body weight management in adults with excessive body weight. The secondary aim was to investigate potential modifying effects of phenotyping. A systematic literature search in PubMed, Web of Science, and Cochrane Library identified 375 randomized controlled trials with 43 unique trials meeting the inclusion criteria. The Cochrane collaboration tool was used for a thorough risk of bias assessment. Based on 37 studies evaluating effects of dietary protein on body weight, the participants with increased protein intake (ranging from 18\u201359 energy percentage [E%]) were found to reduce body weight by 1.6 (1.2; 2.0) kg (mean [95% confidence interval]) compared to controls (isocaloric interventions with energy reduction introduced in certain studies). Individuals with prediabetes were found to benefit more from a diet high in protein compared to individuals with normoglycemia, as did individuals without the obesity risk allele (AA genotype) compared to individuals with the obesity risk alleles (AG and GG genotypes). Thus, diets rich in protein would seem to have a moderate beneficial effect on body weight management.\n\nCitation: Hansen, T.T.; Astrup, A.; Sj\u00f6din, A. Are Dietary Proteins the Key to Successful Body Weight Management? A Systematic Review and Meta-Analysis of Studies Assessing Body Weight Outcomes after Interventions with Increased Dietary Protein. Nutrients 2021, 13, 3193. https://doi.org/10.3390/nu13093193\n\nKeywords: appetite; obesity; overweight; satiety; weight loss\n\nAcademic Editor: Maret G. Traber\n\n# 1. Introduction\n\nMany different diets are proposed for prevention and treatment of overweight and obesity. In several popular diets, the overall strategy is to manipulate macronutrient composition within the whole diet and to focus on limiting or increasing one macronutrient [1\u20133]. Classic theories posit that macronutrient composition of a diet or a meal affects appetite via homeostatic mechanisms, triggering or inhibiting energy intake to ensure that the intake of energy or nutrients matches bodily needs [4]. Accordingly, the amino static theory suggests that there is a nutrient-specific hierarchy of satiating power, with protein having a more satiating power than carbohydrate, which is in turn more satiating than fat [5]. Several mechanisms have been suggested to contribute to the satiating value of dietary protein, including that the presence of amino acids or peptides in the gastrointestinal (GI) tract contributes as ligands for receptors in the small intestine, triggering release of anorexigenic signaling molecules, and is thereby involved in the gut-brain axis [6\u201311]. As appetite is one of the numerous influences that determine energy intake, it has been argued that increased intake of dietary protein is beneficial for body weight management. Furthermore, there is a fairly consistent body of evidence suggesting that diets higher in protein increase energy expenditure due to an increased thermic effect [12].", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3639, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "20fb55bb-489f-4b0b-8acf-a11379975154": {"__data__": {"id_": "20fb55bb-489f-4b0b-8acf-a11379975154", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "45991a6d-db10-4bdc-b928-92b4c1b387b1", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "51671e1e82887f1783f53d62f5d9d46f9a95573875bf544cfbf173274157b0db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da5d37e0-1128-4a75-aadb-f571de105424", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "b3774b295ff36f1cb8fa7805e61042b6f7e92531220439b9cc82ae890ab67f17", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "As appetite is one of the numerous influences that determine energy intake, it has been argued that increased intake of dietary protein is beneficial for body weight management. Furthermore, there is a fairly consistent body of evidence suggesting that diets higher in protein increase energy expenditure due to an increased thermic effect [12]. This may, at least in part, be explained by the fact that the body has a limited capacity for storing amino acids or protein, and thus needs to metabolize dietary protein immediately, which includes processes requiring energy [13,14].\n\nCopyright: \u00a9 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).\n\ncC Nutrients 2021, 13, 3193. https://doi.org/10.3390/nu13093193 https://www.mdpi.com/journal/nutrients", "mimetype": "text/plain", "start_char_idx": 3294, "end_char_idx": 4230, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "168b9fc0-0c35-467e-81f7-61132150dba2": {"__data__": {"id_": "168b9fc0-0c35-467e-81f7-61132150dba2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1cbc38f2-56ea-4916-945b-5171710b2022", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "c5eda12bd7d7f221ad77e9011271d309d932d5223c3fe32110a2b81848e88d27", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\nThe positive effects of dietary protein on body weight management have been observed in large long-term randomized controlled trials [15]. However, a previous meta-analysis assessed low-carbohydrate/high-protein diets effects on body composition during energy restriction, and the amount of dietary protein was not found to be linked to the degree of changes in body weight. However, there was a tendency for reported protein intake to predict changes in body fat [16]. Several studies investigating the effects of dietary protein on appetite have failed to control for energy density, which renders results showing a more satiating power of protein per se. Therefore, it remains unclear whether dietary protein is beneficial for body weight management in the context of overweight. Furthermore, recent findings suggest that successful body weight management with specific diets varying in macronutrient content may be highly dependent on specific phenotypes including degree of glucose tolerance, appetite and eating behavior characteristics as well as different genotypes [17\u201320].\n\nOn this basis, the primary aim of this systematic review and meta-analysis was to summarize the current literature, to investigate if dietary interventions rich in protein lead to improved body weight management in adults with overweight or obesity. The secondary aim was to investigate potential modifying effects of physiological or behavioral phenotypes.\n\n# 2. Materials and Methods\n\nA comprehensive review protocol was prepared in collaboration between the authors in advance of the systematic literature search. The review protocol followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [21] and was used to identify objectives of the review including population, intervention, comparison, outcome, and setting (PICOS), as well as methods for literature search and data extraction. No major deviations to the original protocol occurred and minor updates were recorded with protocol version number and date. The review protocol was not pre-registered.\n\n# 2.1. Data Sources and Search Strategy\n\nThe systematic literature searches were conducted in PubMed, Web of Science, and the Cochrane Library. Studies potentially eligible for inclusion and available as of 1 September 2021 were identified. The search strategy was built in PubMed based on screening of medical subject heading (MeSH) term index list, as well as testing numerous combinations of search terms, to obtain the most hits. Similar searches were subsequently conducted in Web of Science and Cochrane Library. The final primary search syntaxes employed for each of the databases are described in Table 1. To identify more recently completed trials, unpublished research, and research reported in grey literature, unsystematic searches were conducted in Google Scholar and ClinicalTrials.gov, and experts within the field were consulted. Finally, reference lists of the included papers were screened. Secondary unsystematic literature searches were also conducted in PubMed and Google Scholar in order to identify more studies, additional to what was identified from the primary searches, investigating potential different effects of specific proteins, peptides, and/or amino acids, as well as physiological or behavioral characteristics (phenotypes) that may cause differentiated effects.\n\nAll authors contributed to the search strategies, and ultimately the first author conducted the searches. The first and last authors independently assessed eligibility of the studies based on screening of titles, abstracts, and full texts. All authors contributed to discussions of eligibility.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3706, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9481ac0b-bcc1-469a-a913-effce15d8a31": {"__data__": {"id_": "9481ac0b-bcc1-469a-a913-effce15d8a31", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1e645bb1-4057-4de7-8dc9-6c04f579e578", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "26221968c50ad71848183fb3f3a37973b0fdbbc45ce4e8d9c0b00738d52f4dfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdf38bf1-621a-44ed-8122-6566af13619d", "node_type": "1", "metadata": {}, "hash": "e0ac4ece8f72a241f22d13ca430944932d69e6f377aa6ebf3d91077132fdb3f5", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\n# Table 1. Strategy for the primary literature search conducted to investigate the evidence for the effect of dietary protein on body weight management.\n\n|                       | PubMed                                                                                                                                                                                                                                                 | Web of Science                                                                                                                                                                                                                                          | Cochrane Library                                                                                                                                                                                                                                                   |\n| --------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |\n| Search                | \u201cdietary protein\\*\u201d AND \u201cbody weight change\\*\u201d OR \u201cbody weight management\\*\u201d OR \u201cbody weight control\\*\u201d OR \u201c\\*weight loss\\*\u201d OR \u201cweight loss maintenance\u201d OR \u201c\\*weight regain\\*\u201d NOT exercise\\* OR \u201cphysical activity\\*\u201d OR \\*training\\* OR \\*pharma\\* | \u201cdietary protein\\*\u201d AND \u201cbody weight change\\*\u201d OR \u201cbody weight management\\*\u201d OR \u201cbody weight control\\*\u201d OR \u201c\\*weight loss\\*\u201d OR \u201cweight loss maintenance\u201d OR \u201c\\*weight regain\\*\u201d NOT OR \u201cphysical activity\\*\u201d OR \\*training\\* OR \\*pharma\\* AND human\\* | \u201cdietary protein\\*\u201d AND \u201cbody weight change\\*\u201d OR \u201cbody weight management\\*\u201d OR \u201cbody weight control\\*\u201d OR \u201c\\*weight loss\\*\u201d OR \u201cweight loss maintenance\u201d OR \u201c\\*weight regain\\*\u201d NOT exercise\\* OR \u201cphysical activity\\*\u201d OR \\*training\\* OR \\*pharma\\* AND human\\* |\n| Filters               | Humans; Clinical trial; Clinical study; Adult: 19\u201344 years; Middle Aged: 45\u201364 years                                                                                                                                                                   | Article                                                                                                                                                                                                                                                 | Trials                                                                                                                                                                                                                                                             |\n| Language restrictions | None                                                                                                                                                                                                                                                   | None                                                                                                                                                                                                                                                    | None                                                                                                                                                                                                                                                               |\n| Search field          | All fields                                                                                                                                                                                                                                             | Topic                                                                                                                                                                                                                                                   | Title abstract keyword                                                                                                                                                                                                                                             |\n| Sort by               | Most recent                                                                                                                                                                                                                                            | Date (high to low)                                                                                                                                                                                                                                      | Year first published\u2014new to old                                                                                                                                                                                                                                    |\n\nThe systematic literature searches were conducted in PubMed, Web of Science, and Cochrane Library. Studies potentially eligible for inclusion and available as of 1 September 2021 were identified. *, Included to identify all derived word forms (e.g., dietary proteins); \u201cx x\u201d, Identifies only studies with the words combined (e.g. do not include studies only identified based on \u201cdietary\u201d, rather \u201cdietary protein\u201d.\n\n# 2.2. Inclusion and Exclusion Criteria\n\nOnly studies with adult (\u226518 years) human populations with overweight or obesity with or without comorbidities were included in the review. Papers were excluded if the study population consisted of athletes, underweight participants, or participants with anorectic diseases. The interventions and comparisons eligible for inclusion included dietary protein compared to other macronutrients (substituting carbohydrate or fat with protein), or only adding more protein to the diet without manipulating carbohydrate or fat. No specific criteria for \u201chigh dietary protein\u201d were set, but the studies were required to justify a relative difference. Interventions investigating potential effects of different proteins, peptides, and/or amino acids compared to each other were also included and assessed in a separate meta-analysis. Papers reporting effects of protein recommendations based on phenotyping were also included in the review, but these were not included in the meta-analysis. Certain peptides have been identified as effective in reducing appetite and potentially beneficial for body weight management and are increasingly being used as pharmaceuticals for obesity treatment [22\u201326]. However, interventions that included pharmaceuticals were excluded, as the focus of this review was on dietary protein.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 7450, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fdf38bf1-621a-44ed-8122-6566af13619d": {"__data__": {"id_": "fdf38bf1-621a-44ed-8122-6566af13619d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "1e645bb1-4057-4de7-8dc9-6c04f579e578", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "26221968c50ad71848183fb3f3a37973b0fdbbc45ce4e8d9c0b00738d52f4dfd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9481ac0b-bcc1-469a-a913-effce15d8a31", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "c8cccb4d70c48809e3d50e271a1349bc3b4ed2121fdad9d4e1b358a99aa152fd", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Interventions investigating potential effects of different proteins, peptides, and/or amino acids compared to each other were also included and assessed in a separate meta-analysis. Papers reporting effects of protein recommendations based on phenotyping were also included in the review, but these were not included in the meta-analysis. Certain peptides have been identified as effective in reducing appetite and potentially beneficial for body weight management and are increasingly being used as pharmaceuticals for obesity treatment [22\u201326]. However, interventions that included pharmaceuticals were excluded, as the focus of this review was on dietary protein. Interventions including changes in exercise were excluded since this may mask potential dietary effects on body weight management. Effects of interventions on body weight changes (weight loss, weight loss maintenance or weight maintenance) were assessed. Thus, interventions could include energy restriction or not, but similar recommended energy restriction was required for the intervention and the controls groups within each study. No acute studies could be included in this review since the outcome was changes in weight, but there were no specific restrictions on intervention duration. All outcomes were required to be assessed under laboratory settings, and only studies including randomized controlled trials were included.\n\n# 2.3. Outcomes and Data Extraction\n\nThe primary outcome was body weight change (kg), which was included in the meta-analyses. If available, data from intention-to-treat (ITT) analyses were included in", "mimetype": "text/plain", "start_char_idx": 6784, "end_char_idx": 8386, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7003c701-7b41-4d3a-8aa8-f210a52abeec": {"__data__": {"id_": "7003c701-7b41-4d3a-8aa8-f210a52abeec", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "288cc7cd-18e8-41e1-9164-40b17a495ba2", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "e535c9163ad28ebd943d078bed574b0f7be06434133b484564fe4c2c5e93c472", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\nthe meta-analyses. Details of the study protocols and methodologies as well as mean \u00b1 standard deviation (SD) demographic characteristics (n [male/female], age, and body mass index (BMI)) of the study populations within each of the studies were extracted. These details are summarized, describing the key characteristics, in Table 2. Detailed descriptions of each of the studies are presented in Table S1 of the supplementary material. The intervention and relative daily prescription of macronutrient distribution was calculated based on the quantity of protein per kg of mean baseline body weight if energy percentage (E%) was not reported. High/rich protein diet was defined relative to the control diet in each study. Thus, for certain studies, high/rich protein diet constitutes diets of normal protein content (15\u201320 E%), but the control diet constitutes diets of low protein content (&#x3C;15 E%). Diets are referred to as \u201chigh protein\u201d vs. \u201cstandard protein\u201d throughout the paper. Thus, overlap in E% protein between high protein (HP) and standard protein (SP) exists between papers. Diet characteristics are summarized in Table 2 and detailed descriptions for each of the studies are presented in Table 1.\n\n# Table 2. Key study features and participant characteristics of studies included in this systematic review.\n\n| Study Characteristic                    | Mean (Range)\u2014Unless Indicated Otherwise |\n| --------------------------------------- | --------------------------------------- |\n| Protein vs. digestible CHO              |                                         |\n| Number of studies                       | 35                                      |\n| Number of participants                  | 113 (12\u2013773)                            |\n| Male/Female                             | 30 (0\u2013168)/63 (0\u2013300)                   |\n| Age                                     | 46 (22\u201362) \\*                           |\n| BMI                                     | 33.9 (29.9\u201345.6) \\*                     |\n| Diet characteristics                    |                                         |\n| Protein                                 |                                         |\n| HP                                      | 30 (20\u201359) E%                           |\n| SP                                      | 15 (2\u201320) E%                            |\n| Fat                                     |                                         |\n| HP                                      | 28 (5\u201330) E%                            |\n| SP                                      | 28 (3\u201330) E%                            |\n| CHO                                     |                                         |\n| HP                                      | 41 (25\u201348) E%                           |\n| SP                                      | 57 (50\u201395) E%                           |\n| Number of studies evaluating effects on |                                         |\n| Weight loss                             | 18                                      |\n| Weight loss maintenance                 | 11                                      |\n| Weight maintenance                      | 6                                       |\n| Protein vs. fiber                       |                                         |\n| Number of studies                       | 2                                       |\n| Number of participants                  | 104 (83\u2013125)                            |\n| Male/Female                             | 30 (0\u201359)/75 (66\u201383)                    |\n| Age                                     | 41 (40\u201342) \\*                           |\n| BMI                                     | 32.3 (31.5\u201334.0) \\*                     |\n| Diet characteristics                    | See Supplementary Material Table S1     |\n| Number of studies evaluating effects on |                                         |\n| Weight loss                             | 0                                       |\n| Weight loss maintenance                 | 1                                       |\n| Weight maintenance                      | 1                                       |", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4191, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "66357342-b047-4083-b831-94c9e245896e": {"__data__": {"id_": "66357342-b047-4083-b831-94c9e245896e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d515bd6d-13cb-404a-b996-6012bb17f06d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "dc9b379759dd7d0ebf18af384518e65298728911e8e9ebaf502d00814ca5069a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "918f18d4-2f38-4876-8178-f5f56c228b44", "node_type": "1", "metadata": {}, "hash": "744768d4e6a4588129e251c0e2a274fe1ddb1133eba78230da80c83994ccd1d6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\n# Table 2. Cont.\n\n| Study Characteristic                                               | Mean (Range)\u2014Unless Indicated Otherwise       |\n| ------------------------------------------------------------------ | --------------------------------------------- |\n| Protein vs. fat                                                    |                                               |\n| Number of studies                                                  | 2                                             |\n| Number of participants                                             | 75 (57\u201393)                                    |\n| Male/Female                                                        | 13 (0\u201325)/63 (32\u201393)                          |\n| Age                                                                | 50 (mean only reported in one of the studies) |\n| BMI                                                                | 34.9 (34.0\u201335.7) \\*                           |\n| Diet characteristics                                               |                                               |\n| Protein                                                            |                                               |\n| HP                                                                 | 35 (30\u201340) E%                                 |\n| HF                                                                 | 20 (20) E%                                    |\n| Fat                                                                |                                               |\n| HP                                                                 | 30 (30) E%                                    |\n| HF                                                                 | 45 (40\u201350) E%                                 |\n| CHO                                                                |                                               |\n| HP                                                                 | 35 (30\u201340) E%                                 |\n| HF                                                                 | 35 (30\u201340) E%                                 |\n| Number of studies evaluating effects on                            |                                               |\n| Weight loss                                                        | 1                                             |\n| Weight loss maintenance                                            | 1                                             |\n| Weight maintenance                                                 | 0                                             |\n| Protein supplementation vs. no supplementation (no placebo used)   |                                               |\n| Number of studies                                                  | 2                                             |\n| Number of participants                                             | 134 (120\u2013148)                                 |\n| Male/Female                                                        | NR                                            |\n| Age                                                                | 44 (mean only reported in one of the studies) |\n| BMI                                                                | 29.5 (29.4\u201329.5) \\*                           |\n| Diet characteristics                                               |                                               |\n| Amount of protein supplementation                                  | 39.1 (30.0\u201348.2) g/d                          |\n| Protein intake                                                     |                                               |\n| I                                                                  | 18 (18) E%                                    |\n| C                                                                  | 15 (15) E%                                    |\n| Number of studies evaluating effects on                            |                                               |\n| Weight loss                                                        | 0                                             |\n| Weight loss maintenance                                            | 2                                             |\n| Weight maintenance                                                 | 0                                             |\n| Different proteins\u2014studies only included in separate meta-analysis |                                               |\n| Number of studies                                                  | 6                                             |\n| Number of participants                                             | 76 (18\u2013131)                                   |\n| Male/Female                                                        | 26 (0\u201368)/50 (15\u201395)                          |\n| Age                                                                | 45 (26\u201351) \\*                                 |\n| BMI                                                                | 31.4 (28.3\u201334.4) \\*                           |\n| Diet characteristics                                               | Number of studies                             |\n| Whey protein                                                       | 3                                             |\n| Lupin                                                              | 1                                             |\n| Animal vs. vegetable protein                                       | 1                                             |\n| Specific peptide                                                   | 1                                             |\n| Number of studies evaluating effects on                            |                                               |\n| Weight loss                                                        | 2                                             |\n| Weight loss maintenance                                            | 2                                             |\n| Weight maintenance                                                 | 2                                             |\n\n*, Range is based on means from the studies; BMI, body mass index; C, control group; CHO, carbohydrate, d, day; E%, energy percentage; HF, high fat (range: 40\u201350 E%); HP, high protein (range: 20\u201359 E%); I, intervention group; SP, standard protein (range: 2\u201320 E%).\n\nThe first author extracted the data, which was randomly checked by the last author. The investigators of the original studies were contacted if information was lacking.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 6668, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "918f18d4-2f38-4876-8178-f5f56c228b44": {"__data__": {"id_": "918f18d4-2f38-4876-8178-f5f56c228b44", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d515bd6d-13cb-404a-b996-6012bb17f06d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "dc9b379759dd7d0ebf18af384518e65298728911e8e9ebaf502d00814ca5069a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66357342-b047-4083-b831-94c9e245896e", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "69c08be6eb5b643af559b4f9efc8408f3021885ab7fc8fffb0d7f6c71c931e1d", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The first author extracted the data, which was randomly checked by the last author. The investigators of the original studies were contacted if information was lacking. For studies with multiple treatment arms, where certain arms did not meet the inclusion criteria for this review, only data from the arms meeting our inclusion criteria were included.", "mimetype": "text/plain", "start_char_idx": 6500, "end_char_idx": 6852, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e3049080-968d-4df7-81bf-64b5a4396197": {"__data__": {"id_": "e3049080-968d-4df7-81bf-64b5a4396197", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6aa55cba-379c-41d6-90b0-01439bee8468", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "d4163b039daa7514d22783c28b8db081ba9ade071a7423b6004c03cbec2b12c6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\n# 2.4. Risk of Bias Assessment\n\nCriteria for risk of bias were set based on the Cochrane collaboration tool for assessing risk of bias [27]:\n\n1. Random sequence generation (selection bias).\n2. Allocation concealment (selection bias).\n3. Blinding of participants and personnel (performance bias).\n4. Blinding of outcome assessment (detection bias).\n5. Incomplete outcome (body weight) data (attrition bias) (including whether or not data from ITT analyses are available).\n6. Selective reporting (reporting bias) (reporting differences in body weight outcome between groups or not).\n7. Power calculation.\n8. Drop out.\n9. Compliance.\n\nRisk of bias was rated as \u201clow\u201d or \u201chigh\u201d according to predefined specifications (see Supplementary Material Table S2 (legend)), or \u201cunclear\u201d if no information on a potential bias was reported.\n\n# 2.5. Meta-Analyses\n\nRandom effects meta-analyses were performed to allow for differences in the study populations, treatments etc. The primary analysis included differences in body weight change (kg) between exposures to various interventions with increased protein intake compared to controls (digestible carbohydrate, fiber, fat, no supplementation (no placebo used)). Additionally, analysis of differences in body weight changes (kg) between exposures to specific proteins was conducted to investigate if certain dietary proteins seem more effective for body weight management than others.\n\nIf mean and 95% confidence interval (CI) difference in body weight change were not directly reported in the papers, the effect sizes were calculated based on reported changes within each group. If no SD, standard error of mean (SEM), or 95% CI for the differences in body weight change between groups were reported, the 95% CI was imputed based on the mean difference calculated from the changes within each diet group and the average SEM from the other studies [28]. We report the cases where this imputation resulted in a non-significance/significance between groups contrary to the findings in the original paper.\n\nThe presence of inter-study heterogeneity was quantified using the I2 statistic evaluating >50% as substantial [28]. Potential sources of clinical and methodological heterogeneity were investigated by sensitivity and subgroup analyses. Sensitivity analyses were performed removing all studies weighing >3.0% in the random effects analysis, as well as based on the risk of bias assessment removing all studies evaluated to have >3 criteria with high risk of bias, or >5 criteria with high risk of bias or unclear. In addition, a priori post hoc subgroup analyses removing studies based on subgroups of risk of bias were conducted, including removal of studies evaluated with high risk of bias due to high drop-out rate or due to low compliance. Additionally, if several comparisons were reported in a study, each comparison was included in the meta-analysis. Thereby, the same study population of the control groups could be represented several times, which may introduce a risk of bias. A sensitivity analysis excluding the studies represented several times was conducted to exclude that these cases affect the overall result of the primary meta-analysis.\n\nPublication bias was assessed by visual inspection of funnel plot and by Egger test to assess asymmetry, as well as by Begg test to assess small study effects [29\u201331]. The meta-analyses were conducted using StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. Texas, USA.\n\n# 3. Results\n\n# 3.1. Studies Included\n\nThe searches identified a total of 375 publications for screening, of which 291 were excluded based on titles and abstracts. An additional 44 were excluded based on full-text assessments. Three additional papers were included after screening of reference lists of the included papers, resulting in inclusion of 43 papers in total (Figure 1).", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3918, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "372046f5-48f3-4d15-accc-415d26092e35": {"__data__": {"id_": "372046f5-48f3-4d15-accc-415d26092e35", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4e63e548-649c-4c05-acd4-2e61ea7f049c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "723cd2eae72b4eff975d6f2ba408697ae84491a66db770d74a7059200ce1c2da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a4f1ae8-80f3-4cde-9256-218a559e6d21", "node_type": "1", "metadata": {}, "hash": "1a5814f6d5e694995672c2c0f6ce6417c485f61189886303c2222af2bde96838", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\n# 3. Results\n\n# 3.1. Studies Included\n\nThe searches identified a total of 375 publications for screening, of which 291 were excluded based on titles and abstracts. An additional 44 were excluded based on full-text assessments. Three additional papers were included after screening of reference lists of the included papers, resulting in inclusion of 43 papers in total (Figure 1).\n\n| Papers identified through                                                                                   | PubMed (n = 52), Web of Science (n = 52), Cochrane Library (n = 270)       | (n = 374)                                                                                                   |\n| ----------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------- |\n| Additional papers included through other sources                                                            | (n = 1)                                                                    |                                                                                                             |\n| Papers excluded based on title                                                                              | (n = 226)                                                                  | Papers screened based on title (n = 375)                                                                    |\n| Duplicate                                                                                                   | (n = 51)                                                                   | Review                                                                                                      |\n| Not including adult humans                                                                                  | (n = 20)                                                                   | Not reporting body weight outcomes \u2014 reporting effects of increased dietary protein on specific diseases    |\n| (n = 54)                                                                                                    | Not reporting body weight outcomes \u2014 reporting other physiological effects | (n = 77)                                                                                                    |\n| Papers screened based on abstract                                                                           | (n = 149)                                                                  | Examining protein quality or other things \u2013 not reporting effects of different proteins/peptides or amounts |\n| (n = 76)                                                                                                    | Pharmaceutical intervention                                                | (n = 4)                                                                                                     |\n| Full-text papers excluded                                                                                   |                                                                            | (n = 291)                                                                                                   |\n| Duplicate                                                                                                   | (n = 2)                                                                    | Not including adult humans                                                                                  |\n| (n = 1)                                                                                                     | Not reporting body weight outcomes \u2014 reporting other physiological effects | (n = 23)                                                                                                    |\n| Examining protein quality or other things \u2013 not reporting effects of different proteins/peptides or amounts | (n = 4)                                                                    | Reporting results for each subject \u2013 not comparing groups                                                   |\n| (n = 6)                                                                                                     | Increase physical activity included along with dietary intervention        | (n = 2)                                                                                                     |\n| Only conference abstract available                                                                          | (n = 3)                                                                    | Observational study                                                                                         |\n| (n = 3)                                                                                                     |                                                                            |                                                                                                             |\n\nFigure 1. PRISMA flow chart explaining the literature selection process after systematic literature searches in PubMed, Web of Science and Cochrane Library, identifying studies potentially eligible for inclusion and available as of 1 September 2021.\n\n# 3.2. Study Characteristics\n\nAll studies employed a parallel design of which the majority used a non-blinded approach. The diets were included during a mean of 32 weeks interventions, ranging from 8 to 104 weeks. Interventions primarily included comparisons of dietary protein and digestible carbohydrate totaled 35 unique papers [32\u201366], of which one also assessed comparison of dietary protein with fat [47], three also assessed different effects from specific proteins (whey protein) [33,36,51], and three investigated effects of personalized protein recommendations based on phenotyping [37,41,59]. Several studies investigated comparisons of dietary protein with fiber (two papers) [67,68], with fat (one paper) [69], or with no supplementation (no placebo used) (two papers) [70,71]. Several studies only compared effects of specific proteins (lupin, animal vs. vegetable protein and glycomacropeptide) and were included only in the secondary meta-analysis (three papers) [72\u201374]. See Table 2 and Supplementary Material Table S1 for information on study features and participant characteristics.", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 6548, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4a4f1ae8-80f3-4cde-9256-218a559e6d21": {"__data__": {"id_": "4a4f1ae8-80f3-4cde-9256-218a559e6d21", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4e63e548-649c-4c05-acd4-2e61ea7f049c", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "723cd2eae72b4eff975d6f2ba408697ae84491a66db770d74a7059200ce1c2da", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "372046f5-48f3-4d15-accc-415d26092e35", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "9f5d9da4f1c5d55c2458d2742f7d631ae2f811bee49fe185ae727dace8a43098", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Several studies investigated comparisons of dietary protein with fiber (two papers) [67,68], with fat (one paper) [69], or with no supplementation (no placebo used) (two papers) [70,71]. Several studies only compared effects of specific proteins (lupin, animal vs. vegetable protein and glycomacropeptide) and were included only in the secondary meta-analysis (three papers) [72\u201374]. See Table 2 and Supplementary Material Table S1 for information on study features and participant characteristics.\n\n# 3.3. Effects of Dietary Protein on Body Weight Management\n\nMeta-analysis of the 37 studies [32\u201336,38\u201340,42\u201358,60\u201371] evaluating effects of dietary protein on body weight changes found that participants exposed to various interventions increasing dietary protein (ranging from 18\u201359 energy percentage (E%)) reduced their body weight by 1.6 (1.2; 2.0) kg (mean (95% CI)) compared to controls (digestible carbohydrate, fiber, fat or no supplementation (no placebo used); Figure 2). Studies were closely weighed in the random effects meta-analysis, but there was a moderate uncertainty around the estimate (I2 = 56%). A sensitivity analysis was performed removing all studies weighing > 3.0% in the random effects analysis (6 assessments [34,50,62,64,68,69]), resulting in a slight decrease in the heterogeneity and increased estimated effect size (mean (95% CI) body weight reduction compared to controls: 1.7 (1.2; 2.1) kg; I2 = 51%).\n\n7 of 17", "mimetype": "text/plain", "start_char_idx": 6050, "end_char_idx": 7493, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8496d85d-c61f-48ee-a22c-9ddd5a38d0cf": {"__data__": {"id_": "8496d85d-c61f-48ee-a22c-9ddd5a38d0cf", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d0d0ac07-6895-49ff-b546-3fa568811ddc", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "9c7fee898a714c448455f8f935bd5bc05537d647def15567d7ecadefa5432541", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fc6d2a1-e321-4e3a-9d48-56cd8f77945d", "node_type": "1", "metadata": {}, "hash": "d22092e92e5b6369cf3198f59e07444ee9e3df472f987b38d078af080abd6281", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "studies weighing > 3.0% in the random effects analysis (6 assessments [34,50,62,64,68,69]), resulting in a slight decrease in the heterogeneity and increased estimated effect size (mean (95% CI) body weight reduction compared to controls: 1.7 (1.2; 2.1) kg; I2 = 51%). The funnel plot showed no sign of asymmetry (Supplementary Material Figure S1).\n\nNutrients 2021, 13, 3193 Slight tendencies for asymmetry (mean bias (95% CI): \u22121.4 (\u22122.8; 0.1), p = 0.06) and small-study effects (Kendall\u2019s tau: 1.8, p = 0.07) were indicated by the Eggers and Begg tests, respectively.\n\n# Risk of bias\n\n| Intervention category                                           | Reference                          | Effect size (95% CI) | Weight (%)      | Notes       |\n| --------------------------------------------------------------- | ---------------------------------- | -------------------- | --------------- | ----------- |\n| Protein vs digestible CHO                                       | Abete et al (2009)                 | -2.90 (-4.73, -1.07) | 2.38            |             |\n| Aldrich et al. (2011 (HP vs SP))                                | -1.50 (-3.33, 0.33)                | 2.38                 | \\*\u2260 ( = 0.08)   |             |\n| Aldrich et al. (2011 (HP with high whey protein vs SP)          | -3.60 (-5.43, -1.77)               | 2.38                 |                 |             |\n| Aller et al. (2014)                                             | -2.80 (-4.10, -1.40)               | 3.07                 |                 |             |\n| Baba et al. (1999)                                              | -2.30 (-4.13, -0.47)               | 2.38                 |                 |             |\n| Baer et al. (2011 (Whey protein vs CHO))                        | -1.80 (-3.63, 0.03)                | 2.38                 | \u2217 \u2020 (p < 0.006) |             |\n| Baer et al. (2011 (Soy protein vs CHO)                          | 0.90 (-0.93, 2.73)                 | 2.38                 |                 |             |\n| Brinkworth et al. (2004a)                                       | -0.50 (-2.33, 1.33)                | 2.38                 |                 |             |\n| Brinkworth et al. (2004b)                                       | -1.50 (-4.20, 0.80)                | 1.66                 |                 |             |\n| Campos-Nonato et al. (2017)                                     | -2.00 (-2.98, -1.02)               | 3.68                 |                 |             |\n| Claessens et al. (2009)                                         | -2.28 (-4.11, -0.45)               | 2.38                 |                 |             |\n| Clifton et al. (2008)                                           | -0.20 (-2.03, 1.63)                | 2.38                 |                 |             |\n| Dalle Grave et al. (2013)                                       | -0.50 (-2.33, 1.33)                | 2.38                 |                 |             |\n| Delbridge et al.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3006, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7fc6d2a1-e321-4e3a-9d48-56cd8f77945d": {"__data__": {"id_": "7fc6d2a1-e321-4e3a-9d48-56cd8f77945d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d0d0ac07-6895-49ff-b546-3fa568811ddc", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "9c7fee898a714c448455f8f935bd5bc05537d647def15567d7ecadefa5432541", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8496d85d-c61f-48ee-a22c-9ddd5a38d0cf", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "4facba1af84484190c9e0f20aad0de980041307152aff31e26d2c79fba0005b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9bd3c95-f216-480b-b114-d43e343f33f2", "node_type": "1", "metadata": {}, "hash": "36f35298adab508938bbf15574308e4765ab2e5935565d9edfb9ca873547e796", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(2009)                                         | -2.28 (-4.11, -0.45)               | 2.38                 |                 |             |\n| Clifton et al. (2008)                                           | -0.20 (-2.03, 1.63)                | 2.38                 |                 |             |\n| Dalle Grave et al. (2013)                                       | -0.50 (-2.33, 1.33)                | 2.38                 |                 |             |\n| Delbridge et al. (2009)                                         | -0.50 (-2.33, 1.33)                | 2.38                 |                 |             |\n| Due et al. (2004)                                               | -3.50 (-6.20, -0.80)               | 1.50                 |                 |             |\n| Farnworth et al. (2003)                                         | 0.10 (-1.73, 1.93)                 | 2.38                 |                 |             |\n| Flechtner-Mors et al. (2010)                                    | -2.60 (-4.43, -0.77)               | 2.38                 |                 |             |\n| Griffin et al. (2013)                                           | -3.40 (-5.23, -1.57)               | 2.38                 | \u2217; \u00b1 (p = NR)   |             |\n| Jesudason et al. (2013)                                         | -3.10 (-4.93, -1.27)               | 2.38                 |                 |             |\n| Kasim-Karakas et al. (2009)                                     | -2.30 (-4.13, -0.47)               | 2.38                 |                 |             |\n| Krebs et al. (2012)                                             | 0.00 (-1.20, 1.21)                 | 3.30                 |                 |             |\n| Labayen et al. (2003)                                           | -4.40 (-6.23, -2.57)               | 2.38                 |                 |             |\n| Larsen et al. (2010)                                            | -0.93 (-1.55, -0.31)               | 4.24                 |                 |             |\n| Layman et al. (2003)                                            | -0.57 (-2.40, 1.26)                | 2.38                 | \u2217; \u00b1 (p = NR)   |             |\n| Layman et al. (2009)                                            | -1.90 (-3.73,-0.07)                | 2.38                 |                 |             |\n| Mahon et al. (2007 (Chicken vs SP)                              | -2.50 (-4.33, -0.67)               | 2.38                 |                 |             |\n| Mahon et al. (2007 (Beef vs SP)                                 | -1.00 (-2.83, 0.83)                | 2.38                 |                 |             |\n| McAuley et al. (2006)                                           | -2.20 (-4.03, -0.37)               | 2.38                 | \\* (p = 0.041)  |             |\n| Noakes et al. (2005)                                            | -1.20 (-3.03, 0.63)                | 2.38                 |                 |             |\n| Parker et al.", "mimetype": "text/plain", "start_char_idx": 2527, "end_char_idx": 5563, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a9bd3c95-f216-480b-b114-d43e343f33f2": {"__data__": {"id_": "a9bd3c95-f216-480b-b114-d43e343f33f2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d0d0ac07-6895-49ff-b546-3fa568811ddc", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "9c7fee898a714c448455f8f935bd5bc05537d647def15567d7ecadefa5432541", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fc6d2a1-e321-4e3a-9d48-56cd8f77945d", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "db3e6f6a5b8a73c52c798acde9c7eb3286f2ef165af6d652ab948979e104a040", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bab7ecc8-5078-4cf4-b92e-4aa2298c0436", "node_type": "1", "metadata": {}, "hash": "89c8aa036c2b5aa66d213a40d7c2ee330ab666bc01139109026c57df89299b44", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(2006)                                           | -2.20 (-4.03, -0.37)               | 2.38                 | \\* (p = 0.041)  |             |\n| Noakes et al. (2005)                                            | -1.20 (-3.03, 0.63)                | 2.38                 |                 |             |\n| Parker et al. (2002)                                            | -0.70 (-2.53, 1.13)                | 2.38                 | \u2217 \u00b1 (p = 0.32)  |             |\n| Pedersen et al. (2014)                                          | -3.10 (-4.93, -1.27)               | 2.38                 |                 |             |\n| Sargrad et al. (2005)                                           | -0.30 (-2.13, 1.53)                | 2.38                 |                 |             |\n| Skov et al. (1999)                                              | -3.70 (-6.20, -1.30)               | 1.70                 |                 |             |\n| Subtotal (1-squared = 58.8%, p = 0.000)                         | -1.66 (-2.11, -1.21)               | 84.14                |                 |             |\n| Protein vs fibre                                                | Reimer et al. (2017)               | -0.90 (-2.73, 0.93)  | 3.31            |             |\n|                                                                 | Te Morenga et al. (2011)           | -1.30 (-2.50, -0.10) | 5.69            |             |\n| Subtotal (-squared = 0.0%, p = 0.720)                           |                                    | -1.18 (-2.18, -0.18) |                 |             |\n| Protein vs fat                                                  | McAuley et al. (2006)              |                      | 2.38            |             |\n|                                                                 | Moran et al. (2005)                | 0.40 (-0.97, 1.77)   | 3.03            |             |\n| Subtotal (-squared = 46.9%, p = 0.170)                          |                                    | -0.28 (-1.83, 1.27)  | 5.41            |             |\n| Protein supplementation vs no supplementation (no placebo used) | Lejeune et al. (2005)              | -2.50 (-4.33, -0.67) | 2.38            | \u2260 (p <0.05) |\n|                                                                 | Westerterp-Plantenga et al. (2004) | -1.30 (-3.13, 0.53)  | 2.38            |             |\n| Subtotal (-squared = 0.0%, p = 0.363)                           |                                    | -1.90 (-3.19, -0.61) | 4.76            |             |\n| Overall (1-squared = 56.3%, p = 0.000)                          |                                    | -1.56 (-1.96, -1.16) | 100.00          |             |\n\nThe following criteria for risk of bias were assessed: 1. Random sequence generation (selection bias). 2. Allocation concealment (selection bias). 3. Blinding of participants and personnel (performance bias). 4. Blinding of outcome assessment (detection bias). 5.", "mimetype": "text/plain", "start_char_idx": 5245, "end_char_idx": 8212, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bab7ecc8-5078-4cf4-b92e-4aa2298c0436": {"__data__": {"id_": "bab7ecc8-5078-4cf4-b92e-4aa2298c0436", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "d0d0ac07-6895-49ff-b546-3fa568811ddc", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "9c7fee898a714c448455f8f935bd5bc05537d647def15567d7ecadefa5432541", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9bd3c95-f216-480b-b114-d43e343f33f2", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "2e946acd9df06190727a53c3380bbe40c178f40cb101d20ddcb4b15482743fc8", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Random sequence generation (selection bias). 2. Allocation concealment (selection bias). 3. Blinding of participants and personnel (performance bias). 4. Blinding of outcome assessment (detection bias). 5. Incomplete outcome (body weight) data (attrition bias) (including if data from ITT analyses are available or not). 6. Selective reporting (reporting bias) (reporting differences in body weight outcome between groups or not). 7. Power calculation. 8. Drop out. 9. Compliance. Risk of bias was rated as \u201cLow\u201d\u2014indicated as green or \u201cHigh\u201d\u2014indicated.", "mimetype": "text/plain", "start_char_idx": 8007, "end_char_idx": 8559, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "26a462a8-52d7-4a3b-9f86-f5054d737f7d": {"__data__": {"id_": "26a462a8-52d7-4a3b-9f86-f5054d737f7d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "78872d06-71da-4d71-8de7-35e2578ec81f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "42cad7c199db31a8f25e809b29a2d18cda57d2e9db2362172b54de5d579a5add", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0af3d8a1-8b69-4d47-8017-50e6e49f9179", "node_type": "1", "metadata": {}, "hash": "f888dc95b1848d457a267c9b5552b302a5b78a535256c4dff940cacbe1bf6138", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\n# 3.4. Evaluation of Risk of Bias\n\nThe risk of bias assessments is summarized along with the meta-analysis in Figure 2 and reported in detail in Supplementary Material Table S2. For most of the studies, allocation was described as randomized, but many of the studies lacked detailed description of allocation concealment procedure. Most of the studies were evaluated to give a high risk of biasing the outcome of this review as they were non-blinded, because of obvious differences between intervention and control diets. Additionally, most studies failed to report whether data firstly were assessed blinded by a person not directly involved in the study. Most of the studies reported results from complete case analyses, introducing a risk of bias if the discontinued participants were the ones experiencing no benefit from the interventions. Most of the studies reported comparisons between the groups including significance levels for the differences, but most of the studies failed to report the estimated difference including the variance. For most of the studies 95% CI was therefore imputed based on the mean difference calculated from the changes within each diet group and the average SEM from the other studies. Many of the studies failed to report whether a power calculation was conducted; thus, we could not evaluate whether the preferred sample size was achieved. Nevertheless, many of the studies achieved acceptable completion rates (\u226425% drop-out was evaluated as expectable, as most of the studies include long-term interventions) and reported high compliance in both intervention and control groups.\n\nSensitivity analysis removing all studies evaluated to have >3 criteria with high risk of bias, or >5 criteria with high risk of bias or unclear (i.e., 11 studies [38,43,44,48,52,56,60,63,66,69,71]), resulted in an outcome comparable to the main analysis with mean (95% CI) body weight reduction compared to controls of 1.8 (1.3; 2.2) kg; I2 = 53% in a random effects analysis. The first post hoc subgroup analysis where studies evaluated with high risk of bias due to high drop-out rate were removed (13 studies [40,45,48,49,52,54,57,58,60\u201362,64,69]) showed a mean (95% CI) body weight reduction compared to control of 1.6 (1.2; 2.1) kg; I2 = 52% in a random effects analysis. The second post hoc subgroup analysis where studies evaluated with high risk of bias due to low or unclear compliance were removed (13 studies [35,43,47,48,50,52,54,60\u201363,67,68]) showed a mean (95% CI) body weight reduction compared to controls of 1.6 (1.1; 2.1) kg; I2 = 60% in a random effects analysis. Sensitivity analysis removing studies that reported several comparisons (this was only the case for four out of the 37 studies [33,36,46,47]) did not affect the outcome of the meta-analysis (mean (95% CI) body weight reduction compared to controls: 1.6 (1.2; 2.0) kg; I2 = 55%).\n\n# 3.5. Different Effects from Specific Proteins\n\nIn the six studies [33,36,51,72\u201374] assessing different effects from specific proteins (whey protein vs. soy or casein, lupin flour vs. wheat flour, animal vs. vegetable protein, glycomacropeptide-enriched whey protein isolate vs. skim milk powder), no specific protein seemed to be superior compared to the matching controls.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3287, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "0af3d8a1-8b69-4d47-8017-50e6e49f9179": {"__data__": {"id_": "0af3d8a1-8b69-4d47-8017-50e6e49f9179", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "78872d06-71da-4d71-8de7-35e2578ec81f", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "42cad7c199db31a8f25e809b29a2d18cda57d2e9db2362172b54de5d579a5add", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26a462a8-52d7-4a3b-9f86-f5054d737f7d", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "0dc590cd56db72065f9ea91346bfd063f8eef820c881bb74a3f09f003769671a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 3.5. Different Effects from Specific Proteins\n\nIn the six studies [33,36,51,72\u201374] assessing different effects from specific proteins (whey protein vs. soy or casein, lupin flour vs. wheat flour, animal vs. vegetable protein, glycomacropeptide-enriched whey protein isolate vs. skim milk powder), no specific protein seemed to be superior compared to the matching controls. However, only one [72] of the six studies reported the estimated difference including the variance. Thereby, the variance was imputed for the remaining five studies, introducing a significant risk of bias. Therefore, this evidence was not found sufficient to qualify for a proper meta-analysis, and the results are limited to the Supplementary Material Figure S2 and should be interpreted with caution.\n\n# 3.6. Effects on Body Weight Management of Personalized Protein Recommendations Based on Phenotyping\n\nTwo studies were identified that assessed differences between normoglycemic and pre-diabetic individuals in body weight management [37,59]. Ballesteros-Pomar et al. assessed potential differentiated effects during weight loss. After 16 weeks of energy restriction, they found non-significant mean difference of 1.9 kg in responsiveness to the high protein diet (30 E% protein) vs. the standard protein diet (15 E% protein) between participants of normo-", "mimetype": "text/plain", "start_char_idx": 2912, "end_char_idx": 4248, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8b2427b9-75f1-4a13-a3ac-f471fc75436b": {"__data__": {"id_": "8b2427b9-75f1-4a13-a3ac-f471fc75436b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f3b49f9e-2822-4406-a716-d2d1618425b1", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "99ae8d0b752baa8196f8d846b91038f0ccffd0ec0e8ae4e50815b0e14f9101c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7a0c283-7fdd-4d0b-89bd-49b1f60b0b6c", "node_type": "1", "metadata": {}, "hash": "e8db2c8dc3ebbd6392d4061f78718175faeaec9be1b3645ee5a958d02a3d2ac4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\nglycemia (n = 15) and prediabetes (n = 21) based on the homeostatic model assessment for insulin resistance (HOMA-IR). Participants with prediabetes consuming the high protein diet (n = 10) were found to lose 2.6 kg more than those consuming the standard protein diet (n = 11), whereas the participants with normoglycemia lost only 0.7 kg more on the high protein diet (n = 8) compared to the standard protein diet (n = 7) [37]. Hjorth et al. assessed potential differentiated effects during weight loss maintenance. After a mean weight loss of 10.3 kg in the DIOGENES study, they found a mean (95% CI) difference of 4.4 (1.8; 7.0, p = 0.001) kg in responsiveness to the high protein diet (21 E% protein) vs. the standard protein diet (17 E% protein) between participants of normoglycemia (n = 225) and prediabetes (n = 41) based on fasting plasma glucose. Participants with prediabetes consuming the standard protein diet (n = 7) were found to regain 5.8 (3.3; 8.2) kg more than those consuming the high protein diet (n = 23), whereas the participants with normoglycemia regained only 1.4 (0.5; 2.4) kg more on the standard protein diet (n = 88) compared to the high protein diet (n = 91) [59].\n\nOne study assessing differences in body weight management based on genotyping was identified [41]. Stocks et al. assessed potential differentiated effects during weight loss maintenance. After a mean weight loss of 11.0 kg in the DIOGENES study, they found that the rs987237 single nucleotide polymorphism (SNP) of the transcription factor AP-2 beta gene (TFAP2B) interacted with protein intake in relation to weight loss maintenance (p = 0.047). The authors found that the participants without the obesity risk allele (AA genotype) (n = 251) regained 1.5 (0.7; 2.2) kg (mean (95% CI)) on the standard protein diet (13 E% protein), whereas they lost an additional 0.9 (0.0; 1.7) kg on the high protein diet (26 E% protein). This beneficial effect of the high protein diet on body weight was not seen among carriers of the obesity risk alleles (AG (n = 110) and GG genotypes (n = 12)). Stocks et al. also found that the participants consuming the high protein diet regained 1.8 (0.0; 3.7) kg more body weight per obesity risk allele (G allele) compared to participants consuming the standard protein diet [41].\n\n# 4. Discussion\n\nDietary protein seems to have a more beneficial effect on body weight management in individuals with overweight or obesity than carbohydrate. This meta-analysis also indicates, although less strongly, that dietary protein is more beneficial for body weight management than dietary fiber, as well as when protein is additionally supplemented to the diet, whereas no effect is seen when compared with fat. However, the number of studies substituting dietary protein with alternatives other than carbohydrate is small. There does not seem to be sufficient evidence to determine whether specific proteins are linked to a greater effect than others, but this may again be due to the limited number of studies fulfilling the criteria for this review.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3096, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b7a0c283-7fdd-4d0b-89bd-49b1f60b0b6c": {"__data__": {"id_": "b7a0c283-7fdd-4d0b-89bd-49b1f60b0b6c", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f3b49f9e-2822-4406-a716-d2d1618425b1", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "99ae8d0b752baa8196f8d846b91038f0ccffd0ec0e8ae4e50815b0e14f9101c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b2427b9-75f1-4a13-a3ac-f471fc75436b", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "e10028f981a045eb2297a421bf2fa051809ad299b48d42cd0fdc4ce0caab95ca", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "This meta-analysis also indicates, although less strongly, that dietary protein is more beneficial for body weight management than dietary fiber, as well as when protein is additionally supplemented to the diet, whereas no effect is seen when compared with fat. However, the number of studies substituting dietary protein with alternatives other than carbohydrate is small. There does not seem to be sufficient evidence to determine whether specific proteins are linked to a greater effect than others, but this may again be due to the limited number of studies fulfilling the criteria for this review. The effect size of dietary protein in body weight management may also be dependent on specific phenotypes, where individuals with prediabetes may benefit more compared to individuals with normoglycemia. Furthermore, individuals without the obesity risk allele (AA genotype) may benefit more compared to individuals with the obesity risk alleles (AG and GG genotypes).\n\n# 4.1. Efficacy of Higher Dietary Protein Intake for Body Weight Management\n\nThe analyses in this review are limited to the effects of higher dietary protein on body weight changes because studies investigating potential effects on changes in body composition are scarce. Differences in efficacy may be observed dependent on whether the effects on body weight or fat mass changes are evaluated, which is indicated in the meta-analyses by Chen et al. and Abargouei et al. [75,76]. A more beneficial effect of higher intakes of dietary protein may thus be evident if changes in fat mass are taken into consideration. Compliance with the intervention and study duration can also be expected to affect the observed efficacy. An overall effect of dietary protein is demonstrated in this meta-analysis, despite including 13 studies reporting poor compliance or not reporting compliance. Additionally, many of the studies evaluate good compliance based solely on self-reporting, which is known to be", "mimetype": "text/plain", "start_char_idx": 2494, "end_char_idx": 4458, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "171f228c-c353-45aa-ab27-2bf576a49b91": {"__data__": {"id_": "171f228c-c353-45aa-ab27-2bf576a49b91", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "812560f0-129a-4f4f-a873-18407f47654d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "bd0e95d04297b3f2d3449fc92a4144c675f70ac3865b2ec35a15743304cc05f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06f082e4-c6de-4192-ba72-c211acc799c3", "node_type": "1", "metadata": {}, "hash": "5d21c06f35991cf0fedeb3a3386fd5ee1dbe381670a96cac0bdbaf9a2bbed09c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\nprone to give rise to bias due to over/underreporting [77]. Poor compliance may therefore be relevant in more of the studies, indicating that real effect size might be increased if these could be properly identified and excluded in the relevant subgroup analysis. In the primary meta-analysis, 19 of the studies show no significant difference in body weight change between the intervention and the control groups. Nevertheless, since the sensitivity analysis removing almost one third of the studies revealed comparable overall result, the potential biases of the studies is likely to have a limited effect the identified efficacy. In 11 of these studies, the mean duration of the intervention was 15 weeks, and the remaining eight studies were long-term interventions (\u226524 weeks). This implies that a time factor may affect efficacy. The ability to detect an effect on body weight changes is reduced if the intervention is too short, whereas compliance may decrease over time in long intervention studies.\n\n# 4.2. Personalized Dietary Approaches\n\nCommon to all the interventions in the studies included in this review is that, in order to increase dietary protein content, something else was decreased. In most cases, this was achieved through a relative decrease in carbohydrate. It is not possible to determine from these studies whether the effects seen can be attributed to an increased intake of protein or whether they are rather a result of a reduced intake of one of the other macronutrients. Especially, the reduction in carbohydrate intake may improve body weight management in individuals with compromised glucose control independently of the amount of protein consumed. Glucose response in the brain has been found to be diminished in individuals with obesity and poorly controlled type 2 diabetes mellitus compared to individuals of normal weight, which has been found to be related to low self-reported scores of satiety and fullness [78]. Additionally, in individuals of normal weight, an inverse association has been observed between postprandial insulin response and the subsequent ad libitum energy intake [20,79]. The effect on appetite has been suggested to be that the absorbed carbohydrate elevating the blood glucose needs to enter the brain (and possibly other tissues) before it can lead to satiety and reduce hunger. The findings suggest that post-prandial glucostatic control may be important for control of appetite, and that reduced carbohydrate intake may have a beneficial effect on body weight management in individuals with compromised glucose control [17,80]. We do not know all details about the populations in the studies included in this meta-analysis, so the effect on body weight management may be masked by the fact that certain individuals perhaps responded strongly to the interventions while others did not. This is suggested by the associations between consumption of low glycemic load diets high in protein, fiber, and whole grains a with improved body weight management observed in individuals with prediabetes, but less so in individuals with normoglycemia (retrospective analyses by Ballesteros-Pomar et al. and Hjorth et al. [19,37,59]. The non-significant difference in responsiveness observed by Ballesteros-Pomar et al. is probably due to the lower number of individuals assessed (n = 36) as compared to the analyses by Hjorth et al. (n = 266) [37,59]. Thereby, HOMA-IR and fasting plasma glucose seem to be important biomarkers for successful dietary weight loss and weight loss maintenance. In individuals with compromised glucose control, body weight may be managed better if carbohydrate content of the diet is decreased, but we do not know whether carbohydrate should be replaced with protein or fat. This highlights the general limitation of such interventions, where substitutions are necessary to keep the energy content constant in order for the diets to be comparable [81].", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3963, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "06f082e4-c6de-4192-ba72-c211acc799c3": {"__data__": {"id_": "06f082e4-c6de-4192-ba72-c211acc799c3", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "812560f0-129a-4f4f-a873-18407f47654d", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "bd0e95d04297b3f2d3449fc92a4144c675f70ac3865b2ec35a15743304cc05f5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "171f228c-c353-45aa-ab27-2bf576a49b91", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "204db87b9b114a3e4d811691b0198a4a042266bb00ca26155a8c925d8ba63217", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "(n = 266) [37,59]. Thereby, HOMA-IR and fasting plasma glucose seem to be important biomarkers for successful dietary weight loss and weight loss maintenance. In individuals with compromised glucose control, body weight may be managed better if carbohydrate content of the diet is decreased, but we do not know whether carbohydrate should be replaced with protein or fat. This highlights the general limitation of such interventions, where substitutions are necessary to keep the energy content constant in order for the diets to be comparable [81]. Nevertheless, given that fat is less satiating than protein [5], we can still assume that substitution with protein instead of fat is more beneficial for body weight management. Findings show that the effect of increased dietary protein on body weight management is mediated by a lower energy density, suggesting that substitution with fat would be less beneficial. Furthermore, if only improvements in cardio-metabolic risk factors are taken into consideration, Hyde et al. recently showed that substituting carbohydrate with fat in isoenergetic diets benefits metabolic syndrome risk factors independent of whole-body or fat mass [82].", "mimetype": "text/plain", "start_char_idx": 3414, "end_char_idx": 4601, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4be7f25d-a903-4266-bb05-6b94877242ba": {"__data__": {"id_": "4be7f25d-a903-4266-bb05-6b94877242ba", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7ae5bda9-3fc3-4f5e-9676-3e3a5b04ada3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "e18f35d0a747999faa7c0d4fd85c4f63580311edd11814963f69e959a3f653b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8b98277-fd86-4384-b942-6a453fcd0e41", "node_type": "1", "metadata": {}, "hash": "afba5265bfa4bc484c61a3d5ac9ff584b95c76c92059bdaa3f2bbc7e6c5a30e9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\n# 4.3. Validity of Results\n\nThe validity of our conclusions depends on the possible publication bias in this area. It has previously been shown that publication bias (the tendency to publish positive rather than negative findings) exists in the obesity treatment literature, and probably more so in observational studies than in randomized controlled trials [83,84]. However, we included only randomized controlled trials in the meta-analyses, and half of the studies identified did not show a significant difference in body weight change, so the effect identified from the primary meta-analysis is unlikely to be driven by publication bias. There was no indication of bias in the funnel plot, so the non-significant tendencies to asymmetry and small study effects identified by the Eggers and Begg tests, presumably caused by the similar SEM of most of the studies, can be assumed to be trustworthy [30]. Nevertheless, the results are limited by the fact that CI is imputed for most of the studies in the meta-analyses. However, it is important to note that this does not change the significance of the results for most of the studies. Furthermore, results are affected by the imputation in both directions, i.e., significant results are obtained despite non-significance being reported in the original paper and vice versa.\n\nA general weakness of the studies is that the majority have a non-blinded design, as blinding is extremely difficult in studies applying full replacements in regular diets. If all foods are provided to the participants, at least a single-blinded design with blinding of the participants may be achievable, although this would be very time consuming and costly. Even so, such a study might not reflect a true effect of the diets in everyday life, as many of the foods will be pre-packed and perhaps prepared in advance to maintain the blinding. The non-blinded procedures in which the participants buy and cook the foods themselves, better represent the true effectiveness of the diets. However, compliance is known to increase when the foods are provided [34,48,56,64,66], which highlights a risk of bias in studies where substitutes are provided to the intervention group but not to the control group [33,68,70,71]. This creates a risk of a non-relevant control, since it is unknown whether the participants find substitutes that are relevant to compare with the items provided to the intervention group, and it may introduce difference in energy intake.\n\nThe effectiveness of increased dietary protein on body weight management must be interpreted in the light of other aspects. Further studies on the health benefits of different protein sources are needed before recommending increased intake of dietary protein. Protein sources should also be considered in terms of environmental footprint and socioeconomic availability. Potential differences in health benefits from different protein sources remain mainly unresolved, and little is known about the environmental footprint of increasing the production of different protein sources [85]. The price per gram protein varies considerably, dependent on the source, a factor that needs to be considered if recommendations are to be relevant for most of the population. Thereby, a holistic view is needed, balancing the potential metabolic benefits of increased dietary protein, the environmental impact of production, as well as affordability and accessibility of the diet.\n\n# 5. Conclusions\n\nThe studies identified for this review suggest that diets rich in protein (ranging from 18\u201359 energy percentage (E%)) may have a beneficial effect on body weight management. However, there is insufficient evidence to determine the optimal level of protein based on this review. We did not find sufficient evidence to determine whether certain specific proteins have stronger effects than others. The effect sizes on group level may be limited, and the degree to which this approach is beneficial may be dependent on specific phenotypes, which indicates a need for more personalized approaches for prevention and treatment of overweight and obesity.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 4145, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b8b98277-fd86-4384-b942-6a453fcd0e41": {"__data__": {"id_": "b8b98277-fd86-4384-b942-6a453fcd0e41", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "7ae5bda9-3fc3-4f5e-9676-3e3a5b04ada3", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "e18f35d0a747999faa7c0d4fd85c4f63580311edd11814963f69e959a3f653b7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4be7f25d-a903-4266-bb05-6b94877242ba", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "8d0c9215727f0ac84eb56f1a020cd3d651e4725f7b0887ebde054bd6f448f3bb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# 5. Conclusions\n\nThe studies identified for this review suggest that diets rich in protein (ranging from 18\u201359 energy percentage (E%)) may have a beneficial effect on body weight management. However, there is insufficient evidence to determine the optimal level of protein based on this review. We did not find sufficient evidence to determine whether certain specific proteins have stronger effects than others. The effect sizes on group level may be limited, and the degree to which this approach is beneficial may be dependent on specific phenotypes, which indicates a need for more personalized approaches for prevention and treatment of overweight and obesity.\n\nSupplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/nu13093193/s1, Table S1: Study features and participant characteristics of studies included in this systematic review; Table S2: Risk of bias assessment of studies included in in this systematic review.", "mimetype": "text/plain", "start_char_idx": 3479, "end_char_idx": 4449, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "49b0ae62-4ef7-49c3-83d2-8ed6e31719e5": {"__data__": {"id_": "49b0ae62-4ef7-49c3-83d2-8ed6e31719e5", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2cacf691-112c-49b8-917c-4b95010d0871", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "4d8d05145b0a900f94a34c92e48e44dae2762f86684c3d04390f822ae21ac898", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77b2e161-194b-4975-8bb8-f55d1e71101a", "node_type": "1", "metadata": {}, "hash": "a7434fc8729ade564c9459bcfbea05eaaa5b05b33156757fc0a3f15388b156bc", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\nreview; Figure S1: Funnel plot with one-time representation of all studies included in the primary meta-analysis; Figure S2: Meta-analysis of mean difference in body weight changes with 95% CI (kg) between exposures to various interventions with specific protein sources compared to matching controls.\n\n# Author Contributions\n\nConceptualization, T.T.H., A.A., and A.S.; methodology, T.T.H. and A.S.; software, T.T.H.; validation, T.T.H., A.A. and A.S.; formal analysis, T.T.H.; investigation, T.T.H.; data curation, T.T.H.; writing\u2014original draft preparation, T.T.H.; writing\u2014review and editing, T.T.H., A.A. and A.S.; visualization, T.T.H., A.A. and A.S.; supervision, A.A. and A.S. All authors have read and agreed to the published version of the manuscript.\n\n# Funding\n\nThis review was conducted during TTH\u2019s postdoctoral research, which was funded by the StrucSat project (a research project financed by the Danish Council for Strategic Research, DuPont Nutrition Biosciences Aps and Arla Foods Ingredients Group R&#x26;D). The funders had no role in any aspects of this review.\n\n# Conflicts of Interest\n\nA.A. is currently employed as project director at the Novo Nordisk Foundation to develop a National Center for Healthy Weight and also reports personal fees from Groupe \u00c9thique et Sant\u00e9, France, personal fees from Weight Watchers, USA, and personal fees and other from Gelesis, USA, outside the submitted work. In addition, A.A. has a patent in methods of inducing weight loss, treating obesity and preventing weight gain pending, owned by University of Copenhagen &#x26; Gelesis, USA. A.A. is co-owner and member of the board of the consultancy company Dentacom Aps, Denmark, 2005Flaxslim ApS (also member of the board, 2015-); co-founder and co-owner of Personalised Weight Management Research Consortium ApS (Gluco-diet.dk, 2017-). T.T.H. and A.S. declare no conflicts of interest related to this work.\n\n# Abbreviations\n\nBMI, body mass index; CI, confidence interval; E%, energy percentage; GI, gastrointestinal; MeSH, medical subject heading; HOMA-IR, homeostatic model assessment for insulin resistance; HP, high protein; ITT, intention-to-treat; PICOS, population, intervention, comparison, outcome and setting; PRISMA, preferred reporting items for systematic reviews and meta-analyses; SD, standard deviation; SEM, standard error of mean; SNP, single nucleotide polymorphism; TFAP2B, transcription factor AP-2 beta gene; SP, standard protein.\n\n# References\n\n1. Kennedy, G.C. The Role of Depot Fat in the Hypothalamic Control of Food Intake in the Rat. Proc. R. Soc. London Ser. B Biol. Sci. 1953, 140, 578\u2013596. [CrossRef]\n2. Mayer, J. Glucostatic Mechanism of Regulation of Food Intake. N. Engl. J. Med. 1953, 249, 13\u201316. [CrossRef]\n3. Mellinkoff, S.M.; Frankland, M.; Boyle, D.; Greipel, M. Relationship between Serum Amino Acid Concentration and Fluctuations in Appetite. J. Appl. Physiol.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2935, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "77b2e161-194b-4975-8bb8-f55d1e71101a": {"__data__": {"id_": "77b2e161-194b-4975-8bb8-f55d1e71101a", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2cacf691-112c-49b8-917c-4b95010d0871", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "4d8d05145b0a900f94a34c92e48e44dae2762f86684c3d04390f822ae21ac898", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49b0ae62-4ef7-49c3-83d2-8ed6e31719e5", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "861e177920241575162cc7d902c461444f20fba15ebbd5b602d9c769a33525b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "827634ea-0225-4226-ae31-9d1a6190ef4b", "node_type": "1", "metadata": {}, "hash": "e74e675e65d45d92e46f1ac7bc8078789f31f8c5f51eb736dfdae2649bc66b6f", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "London Ser. B Biol. Sci. 1953, 140, 578\u2013596. [CrossRef]\n2. Mayer, J. Glucostatic Mechanism of Regulation of Food Intake. N. Engl. J. Med. 1953, 249, 13\u201316. [CrossRef]\n3. Mellinkoff, S.M.; Frankland, M.; Boyle, D.; Greipel, M. Relationship between Serum Amino Acid Concentration and Fluctuations in Appetite. J. Appl. Physiol. 1956, 8, 535\u2013538. [CrossRef] [PubMed]\n4. Tremblay, A.; Bellisle, F. Nutrients, Satiety, and Control of Energy Intake. Appl. Physiol. Nutr. Metab. 2015, 40, 971\u2013979. [CrossRef]\n5. Veldhorst, M.; Smeets, A.; Soenen, S.; Hochstenbach-Waelen, A.; Hursel, R.; Diepvens, K.; Lejeune, M.; Luscombe-Marsh, N.; Westerterp-Plantenga, M. Protein-Induced Satiety: Effects and Mechanisms of Different Proteins. Physiol. Behav. 2008, 94, 300\u2013307. [CrossRef] [PubMed]\n6. Tom\u00e9, D.; Schwarz, J.; Darcel, N.; Fromentin, G. Protein, Amino Acids, Vagus Nerve Signaling, and the Brain. Am. J. Clin. Nutr. 2009, 90, 838\u2013843. [CrossRef] [PubMed]\n7. Moran, T.H.; Dailey, M.J. Intestinal Feedback Signaling and Satiety. Physiol. Behav. 2011, 105, 77\u201381. [CrossRef] [PubMed]\n8. Lejeune, M.P.; Westerterp, K.R.; Adam, T.C.M.; Luscombe-Marsh, N.D.; Westerterp-Plantenga, M.S. Ghrelin and Glucagon-like Peptide 1 Concentrations, 24-h Satiety, and Energy and Substrate Metabolism during a High-Protein Diet and Measured in a Respiration Chamber. Am. J. Clin. Nutr. 2006, 83, 89\u201394. [CrossRef] [PubMed]\n9. Kondoh, T.; Mallick, H.N.; Torii, K. Activation of the Gut-Brain Axis by Dietary Glutamate and Physiologic Significance in Energy Homeostasis. Am. J. Clin. Nutr. 2009, 90, 832\u2013837. [CrossRef] [PubMed]\n10. Jenkins, T.A.; Nguyen, J.C.D.; Polglaze, K.E.; Bertrand, P.P. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients 2016, 8, 56. [CrossRef] [PubMed]\n11. Belza, A.; Ritz, C.; S\u00f8rensen, M.Q.; Holst, J.J.; Rehfeld, J.F.; Astrup, A. Contribution of Gastroenteropancreatic Appetite Hormones to Protein-Induced Satiety. Am. J. Clin.", "mimetype": "text/plain", "start_char_idx": 2610, "end_char_idx": 4602, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "827634ea-0225-4226-ae31-9d1a6190ef4b": {"__data__": {"id_": "827634ea-0225-4226-ae31-9d1a6190ef4b", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "2cacf691-112c-49b8-917c-4b95010d0871", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "4d8d05145b0a900f94a34c92e48e44dae2762f86684c3d04390f822ae21ac898", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77b2e161-194b-4975-8bb8-f55d1e71101a", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "b0f1be2d4a302a0f62f3df7e81ae4d76fcf7019c7776d6df1d2eb76bd8f4da2a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "; Bertrand, P.P. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients 2016, 8, 56. [CrossRef] [PubMed]\n11. Belza, A.; Ritz, C.; S\u00f8rensen, M.Q.; Holst, J.J.; Rehfeld, J.F.; Astrup, A. Contribution of Gastroenteropancreatic Appetite Hormones to Protein-Induced Satiety. Am. J. Clin. Nutr. 2013, 97, 980\u2013989. [CrossRef] [PubMed]\n12. Halton, T.L.; Hu, F.B. The Effects of High Protein Diets on Thermogenesis, Satiety and Weight Loss: A Critical Review. J. Am. Coll. Nutr. 2004, 23, 373\u2013385. [CrossRef]", "mimetype": "text/plain", "start_char_idx": 4261, "end_char_idx": 4819, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f38875ec-8395-4ee5-86b3-0510203e20ce": {"__data__": {"id_": "f38875ec-8395-4ee5-86b3-0510203e20ce", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f122079e-0696-43e7-954d-3c9ab0837715", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "372efd7d1b048169ea3f8b85603ac6fa660b901b9cc1b9b186a7799d6620f835", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a10c853-f117-46c1-a02c-362a5f771083", "node_type": "1", "metadata": {}, "hash": "df16f4c1e4d2a5a46fc627186910b5eb3e546240341727e4ec7e6acb0074d247", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Nutrients 2021, 13, 3193\n\n14 of 17\n\n1. Mikkelsen, P.B.; Toubro, S.; Astrup, A. Effect of Fat-Reduced Diets on 24-h Energy Expenditure: Comparisons between Animal Protein, Vegetable Protein, and Carbohydrate. Am. J. Clin. Nutr. 2000, 72, 1135\u20131141. [CrossRef]\n2. Robinson, S.M.; Jaccard, C.; Persaud, C.; Jackson, A.A.; Jequier, E.; Schutz, Y. Protein Turnover and Thermogenesis in Response to High-Protein and High-Carbohydrate Feeding in Men. Am. J. Clin. Nutr. 1990, 52, 72\u201380. [CrossRef] [PubMed]\n3. Astrup, A.; Raben, A.; Geiker, N. The Role of Higher Protein Diets in Weight Control and Obesity-Related Comorbidities. Int. J. Obes. 2015, 39, 721\u2013726. [CrossRef] [PubMed]\n4. Krieger, J.W.; Sitren, H.S.; Daniels, M.J.; Langkamp-Henken, B. Effects of Variation in Protein and Carbohydrate Intake on Body Mass and Composition during Energy Restriction: A Meta-Regression. Am. J. Clin. Nutr. 2006, 83, 260\u2013274. [CrossRef]\n5. Astrup, A.; Hjorth, M.F. Classification of Obesity Targeted Personalized Dietary Weight Loss Management based on Carbohydrate Tolerance. Eur. J. Clin. Nutr. 2018, 72, 1300\u20131304. [CrossRef]\n6. Hansen, T.T.; Hjorth, M.F.; Sandby, K.; Andersen, S.V.; Astrup, A.; Ritz, C.; Bull\u00f3, M.; Camacho-Barc\u00eda, M.L.; Garc\u00eda-Gavil\u00e1n, J.F.; Salas-Salvad\u00f3, J.; et al. Predictors of Successful Weight Loss with Relative Maintenance of Fat-Free Mass in Individuals with Overweight and Obesity on an 8 Week Low Energy Diet. Br. J. Nutr. 2019, 122, 468\u2013479. [CrossRef] [PubMed]\n7. Hjorth, M.F.; Due, A.; Larsen, T.M.; Astrup, A. Pretreatment Fasting Plasma Glucose Modifies Dietary Weight Loss Maintenance Success: Results from a Stratified RCT. Obesity 2017, 25, 2045\u20132048. [CrossRef] [PubMed]\n8. Verdich, C.; Toubro, S.; Buemann, B.; Madsen, J.L.; Holst, J.J.; Astrup, A. The Role of Postprandial Releases of Insulin and Incretin Hormones in Meal-Induced Satiety\u2014Effect of Obesity and Weight Reduction. Int. J. Obes. 2001, 25, 1206\u20131214. [CrossRef] [PubMed]\n9. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Academia and Clinic Annals of Internal Medicine Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Ann. Intern. Med.", "mimetype": "text/plain", "start_char_idx": 2, "end_char_idx": 2157, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2a10c853-f117-46c1-a02c-362a5f771083": {"__data__": {"id_": "2a10c853-f117-46c1-a02c-362a5f771083", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f122079e-0696-43e7-954d-3c9ab0837715", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "372efd7d1b048169ea3f8b85603ac6fa660b901b9cc1b9b186a7799d6620f835", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f38875ec-8395-4ee5-86b3-0510203e20ce", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "b724aeec0f2fc292a43d415333d5c611d342258b0c88a0d22037f3de6921716d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38bb7438-28de-4116-82bb-858ae992f43d", "node_type": "1", "metadata": {}, "hash": "32190a583c6ee22dc2d21b5ca3ca9c07e3035868cfe504a8241957ec5c50670b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "; Astrup, A. The Role of Postprandial Releases of Insulin and Incretin Hormones in Meal-Induced Satiety\u2014Effect of Obesity and Weight Reduction. Int. J. Obes. 2001, 25, 1206\u20131214. [CrossRef] [PubMed]\n9. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Academia and Clinic Annals of Internal Medicine Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Ann. Intern. Med. 2009, 151, 264\u2013269. [CrossRef]\n10. Aronne, L.J.; Nelinson, D.S.; Lillo, J.L. Obesity as a Disease State: A New Paradigm for Diagnosis and Treatment. Clin. Cornerstone 2009, 9, 9\u201329. [CrossRef]\n11. Astrup, A.; R\u00f6ssner, S.; Van Gaal, L.; Rissanen, A.; Niskanen, L.; Al Hakim, M.; Madsen, J.; Rasmussen, M.F.; Lean, M.E. Effects of Liraglutide in the Treatment of Obesity: A Randomised, Double-Blind, Placebo-Controlled Study. Lancet 2009, 374, 1606\u20131616. [CrossRef]\n12. Astrup, A.; Van Gaal, L.; Rissanen, A.; Niskanen, L.; Al Hakim, M.; Madsen, J.; Rasmussen, M.F.; R\u00f6ssner, S. Liraglutide, a Once-Daily Human GLP-1 Analogue, Reduces Body Weight and Improves Obesity-Related Risk Factors in Obese Non-Diabetic Subjects: A Randomised Placebo-Controlled Trial. Obesity 2008, 16, 64\u201374.\n13. Halford, J.C.G.; Boyland, E.J.; Blundell, J.E.; Kirkham, T.C.; Harrold, J.A. Pharmacological Management of Appetite Expression in Obesity. Nat. Rev. Endocrinol. 2010, 6, 255\u2013269. [CrossRef]\n14. Srivastava, G.; Apovian, C. Future Pharmacotherapy for Obesity: New Anti-Obesity Drugs on the Horizon. Curr. Obes. Rep. 2018, 7, 147\u2013161. [CrossRef]\n15. Higgins, J.P.; Savovi\u0107, J.; Page, M.J.; Elbers, R.G.; Sterne, J.A. Assessing Risk of Bias in a Randomized Trial. In Cochrane Handbook for Systematic Reviews of Interventions; Version 6.0 (Updated July 2019); Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., Welch, V.A., Eds.; Cochrane: London, UK, 2019; Available online: https://training.cochrane.org/handbook/current/chapter-08 (accessed on 29 January 2020).\n16. Deeks, J.J.; Higgins, J.P.; Altman, D.G.; Cochrane Statistical Methods Group. Analysing Data and Undertaking Meta-Analyses.", "mimetype": "text/plain", "start_char_idx": 1770, "end_char_idx": 3858, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "38bb7438-28de-4116-82bb-858ae992f43d": {"__data__": {"id_": "38bb7438-28de-4116-82bb-858ae992f43d", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f122079e-0696-43e7-954d-3c9ab0837715", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "372efd7d1b048169ea3f8b85603ac6fa660b901b9cc1b9b186a7799d6620f835", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a10c853-f117-46c1-a02c-362a5f771083", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "492f449d2ddf4bd155293535e560d63fb7d829eb8596fb5bbaf7a22df5b94e97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41b160e8-3c5d-4fd5-af1f-cedffa097bd1", "node_type": "1", "metadata": {}, "hash": "0f8444bcc9d2e1089a18360ac95e66180a3151a33b864668ff927bd003cc6fed", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "; Cochrane: London, UK, 2019; Available online: https://training.cochrane.org/handbook/current/chapter-08 (accessed on 29 January 2020).\n16. Deeks, J.J.; Higgins, J.P.; Altman, D.G.; Cochrane Statistical Methods Group. Analysing Data and Undertaking Meta-Analyses. In Cochrane Handbook for Systematic Reviews of Interventions; Version 6.0 (Updated July 2019); Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., Welch, V.A., Eds.; Cochrane: London, UK, 2019; Available online: https://training.cochrane.org/handbook/current/chapter-10 (accessed on 3 March 2020).\n17. Begg, C.B.; Mazumdar, M. Operating Characteristics of a Rank Correlation Test for Publication Bias. Biometrics 1994, 50, 1088\u20131101. [CrossRef]\n18. Sterne, J.A.C.; Sutton, A.J.; Ioannidis, J.P.A.; Terrin, N.; Jones, D.R.; Lau, J.; Carpenter, J.; R\u00fccker, G.; Harbord, R.M.; Schmid, C.H.; et al. Recommendations for Examining and Interpreting Funnel Plot Asymmetry in Meta-Analyses of Randomised Controlled Trials. BMJ 2011, 343, d4002. [CrossRef] [PubMed]\n19. Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in Meta-Analysis Detected by a Simple, Graphical Test Measures of Funnel Plot Asymmetry. BMJ 1997, 315, 629\u2013634. [CrossRef] [PubMed]\n20. Abete, I.; Parra, D.; Martinez, J.A. Legume-, Fish-, or High-Protein-Based Hypocaloric Diets: Effects on Weight Loss and Mitochondrial Oxidation in Obese Men. J. Med. Food 2009, 12, 100\u2013108. [CrossRef] [PubMed]\n21. Aldrich, N.D.; Reicks, M.M.; Sibley, S.D.; Redmon, J.B.; Thomas, W.; Raatz, S.K. Varying Protein Source and Quantity do not Significantly Improve Weight Loss, Fat Loss, or Satiety in Reduced Energy Diets among Midlife Adults. Nutr. Res. 2011, 31, 104\u2013112. [CrossRef]\n22. Aller, E.E.; Larsen, T.M.; Claus, H.; Lindroos, A.K.; Kafatos, A.; Pfeiffer, A.; Martinez, J.A.; Handjieva-Darlenska, T.; Kunesova, M.; Stender, S.; et al. Weight Loss Maintenance in Overweight Subjects on Ad Libitum Diets with High or Low Protein Content and Glycemic Index: The DIOGENES Trial 12-Month Results. Int. J. Obes. 2014, 38, 1511\u20131517. [CrossRef] [PubMed]\n23. Baba, N.H.; Sawaya, S.; Torbay, N.; Habbal, Z.; Azar, S.; Hashim, S.A.", "mimetype": "text/plain", "start_char_idx": 3594, "end_char_idx": 5764, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "41b160e8-3c5d-4fd5-af1f-cedffa097bd1": {"__data__": {"id_": "41b160e8-3c5d-4fd5-af1f-cedffa097bd1", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "f122079e-0696-43e7-954d-3c9ab0837715", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "372efd7d1b048169ea3f8b85603ac6fa660b901b9cc1b9b186a7799d6620f835", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38bb7438-28de-4116-82bb-858ae992f43d", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "9323236964db72c205acd00a8b477e6dbe7ed0e28ff7589d14d99958cd504d37", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Weight Loss Maintenance in Overweight Subjects on Ad Libitum Diets with High or Low Protein Content and Glycemic Index: The DIOGENES Trial 12-Month Results. Int. J. Obes. 2014, 38, 1511\u20131517. [CrossRef] [PubMed]\n23. Baba, N.H.; Sawaya, S.; Torbay, N.; Habbal, Z.; Azar, S.; Hashim, S.A. High Protein vs High Carbohydrate Hypoenergetic Diet for the Treatment of Obese Hyperinsulinemic Subjects. Int. J. Obes. Relat. Metab. Disord. 1999, 23, 1202\u20131206. [CrossRef]\n24. Baer, D.J.; Stote, K.S.; Paul, D.R.; Harris, G.K.; Rumpler, W.V.; Clevidence, B.A. Whey Protein but Not Soy Protein Supplementation Alters Body Weight and Composition in Free-Living Overweight and Obese Adults. J. Nutr. 2011, 141, 1489\u20131494. [CrossRef]", "mimetype": "text/plain", "start_char_idx": 5478, "end_char_idx": 6196, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "28951f6e-67ce-44c5-89d6-f5e16fdeeff2": {"__data__": {"id_": "28951f6e-67ce-44c5-89d6-f5e16fdeeff2", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0776b31-c3ac-4c62-b9e9-39ec3249ddb5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "ffd4a1f393909d38c120fb66fd22aee695d532127f6c075d321a58c3dd22fa8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31a64274-4d4e-4171-b86a-e2a192f7be00", "node_type": "1", "metadata": {}, "hash": "ea348d0f39a79f28274470729a4d0d589670455275689cddfd6b1227fb04c34b", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\n1. Ballesteros-Pomar, M.D.; Calleja-Fern\u00e1ndez, A.R.; Vidal-Casariego, A.; Urioste-Fondo, A.M.; Cano-Rodr\u00edguez, I. Effectiveness of Energy-Restricted Diets with Different Protein: Carbohydrate Ratios: The Relationship to Insulin Sensitivity. Public Health Nutr. 2009, 13, 2119\u20132126. [CrossRef] [PubMed]\n2. Sargrad, K.R.; Homko, C.; Mozzoli, M.; Boden, G. Effect of High Protein vs High Carbohydrate Intake on Insulin Sensitivity, Body Weight, Hemoglobin A1c, and Blood Pressure in Patients with Type 2 Diabetes Mellitus. J. Am. Diet. Assoc. 2005, 105, 573\u2013580. [CrossRef] [PubMed]\n3. Skov, A.R.; Toubro, S.; R\u00f8nn, B.; Holm, L.; Astrup, A. Randomized Trial on Protein vs Carbohydrate in Ad Libitum Fat Reduced Diet for the Treatment of Obesity. Int. J. Obes. Relat. Metab. Disord. 1999, 23, 528\u2013536. [CrossRef]\n4. Sorensen, L.B.; Soe, M.; Halkier, K.H.; Stigsby, B.; Astrup, A. Effects of Increased Dietary Protein-to-Carbohydrate Ratios in Women with Polycystic Ovary Syndrome. Am. J. Clin. Nutr. 2012, 95, 39\u201348. [CrossRef] [PubMed]\n5. Stocks, T.; \u00c4ngquist, L.; Hager, J.; Charon, C.; Holst, C.; Martinez, J.A.; Saris, W.H.; Astrup, A.; S\u00f8rensen, T.I.; Larsen, L.H. TFAP2B-Dietary Protein and Glycemic Index Interactions and Weight Maintenance after Weight Loss in the DiOGenes Trial. Hum. Hered. 2013, 75, 213\u2013219. [CrossRef]\n6. Tang, M.; Armstrong, C.L.; Leidy, H.J.; Campbell, W.W. Normal vs. High-Protein Weight Loss Diets in Men: Effects on Body Composition and Indices of Metabolic Syndrome. Obesity 2013, 21, 204\u2013210. [CrossRef]\n7. Noakes, M.; Keogh, J.B.; Foster, P.R.; Clifton, P.M. Effect of an Energy-Restricted, High-Protein, Low-Fat Diet Relative to a Conventional High-Carbohydrate, Low-Fat Diet on Weight Loss, Body Composition, Nutritional Status, and Markers of Cardiovascular Health in Obese Women. Am. J. Clin. Nutr. 2005, 81, 1298\u20131306. [CrossRef] [PubMed]\n8. Parker, B.; Noakes, M.; Luscombe, N.; Clifton, P. Effect of a High-Protein, High-Monounsaturated Fat Weight Loss Diet on Glycemic Control and Lipid Levels in Type 2 Diabetes. Diabetes Care 2002, 25, 425\u2013430. [CrossRef] [PubMed]\n9. Pedersen, E.; Jesudason, D.R.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2167, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "31a64274-4d4e-4171-b86a-e2a192f7be00": {"__data__": {"id_": "31a64274-4d4e-4171-b86a-e2a192f7be00", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0776b31-c3ac-4c62-b9e9-39ec3249ddb5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "ffd4a1f393909d38c120fb66fd22aee695d532127f6c075d321a58c3dd22fa8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28951f6e-67ce-44c5-89d6-f5e16fdeeff2", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "6ff6d10ca592576b3789465c49111a912da49a7a29e421f408f4e0b360e26df3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e39dcace-5031-47a8-be55-c6220ca61f55", "node_type": "1", "metadata": {}, "hash": "56b7ca337ffbeabc6707386fbba87c587178e08959e954620c95215a11dc7d35", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Am. J. Clin. Nutr. 2005, 81, 1298\u20131306. [CrossRef] [PubMed]\n8. Parker, B.; Noakes, M.; Luscombe, N.; Clifton, P. Effect of a High-Protein, High-Monounsaturated Fat Weight Loss Diet on Glycemic Control and Lipid Levels in Type 2 Diabetes. Diabetes Care 2002, 25, 425\u2013430. [CrossRef] [PubMed]\n9. Pedersen, E.; Jesudason, D.R.; Clifton, P.M. High Protein Weight Loss Diets in Obese Subjects with Type 2 Diabetes Mellitus. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 554\u2013562. [CrossRef] [PubMed]\n10. Mahon, A.K.; Flynn, M.G.; Stewart, L.K.; McFarlin, B.K.; Iglay, H.B.; Mattes, R.D.; Lyle, R.M.; Considine, R.V.; Campbell, W.W. Protein Intake during Energy Restriction: Effects on Body Composition and Markers of Metabolic and Cardiovascular Health in Postmenopausal Women. J. Am. Coll. Nutr. 2007, 26, 182\u2013189. [CrossRef]\n11. McAuley, K.A.; Smith, K.J.; Taylor, R.W.; McLay, R.T.; Williams, S.M.; Mann, J.I. Long-Term Effects of Popular Dietary Approaches on Weight Loss and Features of Insulin Resistance. Int. J. Obes. 2006, 30, 342\u2013349. [CrossRef]\n12. Brinkworth, G.D.; Noakes, M.; Keogh, J.B.; Luscombe, N.D.; Wittert, G.A.; Clifton, P.M. Long-Term Effects of a High-Protein, Low-Carbohydrate Diet on Weight Control and Cardiovascular Risk Markers in Obese Hyperinsulinemic Subjects. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 661\u2013670. [CrossRef]\n13. Brinkworth, G.D.; Noakes, M.; Parker, B.; Foster, P.; Clifton, P.M. Long-Term Effects of Advice to Consume a High-Protein, Low-Fat Diet, Rather than a Conventional Weight-Loss Diet, in Obese Adults with Type 2 Diabetes: One-Year Follow-up of a Randomised Trial. Diabetologia 2004, 47, 1677\u20131686. [CrossRef] [PubMed]\n14. Campos-Nonato, I.; Hernandez, L.; Barquera, S. Effect of a High-Protein Diet versus Standard-Protein Diet on Weight Loss and Biomarkers of Metabolic Syndrome: A Randomized Clinical Trial. Obes. Facts 2017, 10, 238\u2013251. [CrossRef] [PubMed]\n15. Claessens, M.; van Baak, M.A.; Monsheimer, S.; Saris, W.H. The Effect of a Low-Fat, High-Protein or High-Carbohydrate Ad Libitum Diet on Weight Loss Maintenance and Metabolic Risk Factors. Int. J. Obes. 2009, 33, 296\u2013304. [CrossRef]\n16. Clifton, P.M.", "mimetype": "text/plain", "start_char_idx": 1844, "end_char_idx": 4008, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e39dcace-5031-47a8-be55-c6220ca61f55": {"__data__": {"id_": "e39dcace-5031-47a8-be55-c6220ca61f55", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0776b31-c3ac-4c62-b9e9-39ec3249ddb5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "ffd4a1f393909d38c120fb66fd22aee695d532127f6c075d321a58c3dd22fa8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31a64274-4d4e-4171-b86a-e2a192f7be00", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "2dedb41e172344044b153bf94dca4d2edc03be447ae945d0e165c43d3befabc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "860f5b32-d621-4ae9-8170-87db736895d0", "node_type": "1", "metadata": {}, "hash": "3598a8d40205356c05234f3d14e75c3fabf98e7564600c2ce66b281b8a25f773", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Obes. Facts 2017, 10, 238\u2013251. [CrossRef] [PubMed]\n15. Claessens, M.; van Baak, M.A.; Monsheimer, S.; Saris, W.H. The Effect of a Low-Fat, High-Protein or High-Carbohydrate Ad Libitum Diet on Weight Loss Maintenance and Metabolic Risk Factors. Int. J. Obes. 2009, 33, 296\u2013304. [CrossRef]\n16. Clifton, P.M.; Keogh, J.B.; Noakes, M. Long-Term Effects of a High-Protein Weight-Loss Diet. Am. J. Clin. Nutr. 2008, 87, 23\u201329. [CrossRef]\n17. Dalle Grave, R.; Calugi, S.; Gavasso, I.; El Ghoch, M.; Marchesini, G. A Randomized Trial of Energy-Restricted High-Protein versus High-Carbohydrate, Low-Fat Diet in Morbid Obesity. Obesity 2013, 21, 1774\u20131781. [CrossRef]\n18. Delbridge, E.A.; Prendergast, L.A.; Pritchard, J.E.; Proietto, J. One-Year Weight Maintenance after Significant Weight Loss in Healthy Overweight and Obese Subjects: Does Diet Composition Matter? Am. J. Clin. Nutr. 2009, 90, 1203\u20131214. [CrossRef] [PubMed]\n19. Due, A.; Toubro, S.; Skov, A.R.; Astrup, A. Effect of Normal-Fat Diets, Either Medium or High in Protein, on Body Weight in Overweight Subjects: A Randomised 1-Year Trial. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 1283\u20131290. [CrossRef] [PubMed]\n20. Farnsworth, E.; Luscombe, N.D.; Noakes, M.; Wittert, G.; Argyiou, E.; Clifton, P.M. Effect of a High-Protein, Energy-Restricted Diet on Body Composition, Glycemic Control, and Lipid Concentrations in Overweight and Obese Hyperinsulinemic Men and Women. Am. J. Clin. Nutr. 2003, 78, 31\u201339. [CrossRef] [PubMed]\n21. Flechtner-Mors, M.; Boehm, B.O.; Wittmann, R.; Thoma, U.; Ditschuneit, H.H. Enhanced Weight Loss with Protein-Enriched Meal Replacements in Subjects with the Metabolic Syndrome. Diabetes/Metab. Res. Rev. 2010, 26, 393\u2013405. [CrossRef] [PubMed]\n22. Griffin, H.J.; Cheng, H.L.; O\u2019Connor, H.T.; Rooney, K.B.; Petocz, P.; Steinbeck, K.S. Higher Protein Diet for Weight Management in Young Overweight Women: A 12-Month Randomized Controlled Trial. Diabetes Obes. Metab. 2013, 15, 572\u2013575. [CrossRef]\n23. Hjorth, M.F.; Ritz, C.; Blaak, E.E.; Saris, W.H.; Langin, D.; Poulsen, S.K.; Larsen, T.M.", "mimetype": "text/plain", "start_char_idx": 3703, "end_char_idx": 5778, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "860f5b32-d621-4ae9-8170-87db736895d0": {"__data__": {"id_": "860f5b32-d621-4ae9-8170-87db736895d0", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a0776b31-c3ac-4c62-b9e9-39ec3249ddb5", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "ffd4a1f393909d38c120fb66fd22aee695d532127f6c075d321a58c3dd22fa8a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e39dcace-5031-47a8-be55-c6220ca61f55", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "c015a003271074d6406f03bfdfaf158b7668c5e9827b00d27fe591ec7574f733", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "; O\u2019Connor, H.T.; Rooney, K.B.; Petocz, P.; Steinbeck, K.S. Higher Protein Diet for Weight Management in Young Overweight Women: A 12-Month Randomized Controlled Trial. Diabetes Obes. Metab. 2013, 15, 572\u2013575. [CrossRef]\n23. Hjorth, M.F.; Ritz, C.; Blaak, E.E.; Saris, W.H.; Langin, D.; Poulsen, S.K.; Larsen, T.M.; S\u00f8rensen, T.I.; Zohar, Y.; Astrup, A. Pretreatment Fasting Plasma Glucose and Insulin Modify Dietary Weight Loss Success: Results from 3 Randomized Clinical Trials. Am. J. Clin. Nutr. 2017, 106, 499\u2013505. [CrossRef] [PubMed]\n24. Jesudason, D.R.; Pedersen, E.; Clifton, P.M. Weight-Loss Diets in People with Type 2 Diabetes and Renal Disease: A Randomized Controlled Trial of the Effect of Different Dietary Protein Amounts. Am. J. Clin. Nutr. 2013, 98, 494\u2013501. [CrossRef] [PubMed]", "mimetype": "text/plain", "start_char_idx": 5464, "end_char_idx": 6260, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "72a2e743-a08d-4029-a42d-7cbef763d51e": {"__data__": {"id_": "72a2e743-a08d-4029-a42d-7cbef763d51e", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6d1b1009-9f31-49f1-b1ee-4f26dc589405", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "4e5c0ca67a485e95d5a1b18a52e2c53ce1a372b4115f5797dfb131ebe55a514f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a787cf3-587f-43ab-a92f-04834985d2c8", "node_type": "1", "metadata": {}, "hash": "7b4800d5361969d32a15c90553510c0ace6c407f9f580f7a5f5d79c8076a96e9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\n1. Kasim-Karakas, S.E.; Almario, R.U.; Cunningham, W. Effects of Protein versus Simple Sugar Intake on Weight Loss in Polycystic Ovary Syndrome (According to the National Institutes of Health Criteria). Fertil. Steril. 2009, 92, 262\u2013270. [CrossRef]\n2. Krebs, J.D.; Elley, C.R.; Parry-Strong, A.; Lunt, H.; Drury, P.L.; Bell, D.A.; Robinson, E.; Moyes, S.A.; Mann, J.I. The Diabetes Excess Weight Loss (DEWL) Trial: A Randomised Controlled Trial of High-Protein versus High-Carbohydrate Diets over 2 Years in Type 2 Diabetes. Diabetologia 2012, 55, 905\u2013914. [CrossRef] [PubMed]\n3. Labayen, I.; D\u00edez, N.; Gonz\u00e1lez, A.; Parra, D.; Mart\u00ednez, J.A. Effects of Protein vs. Carbohydrate-Rich Diets on Fuel Utilisation in Obese Women during Weight Loss. Forum Nutr. 2003, 56, 168\u2013170.\n4. Larsen, T.M.; Dalskov, S.-M.; van Baak, M.; Jebb, S.A.; Papadaki, A.; Pfeiffer, A.F.H.; Martinez, J.A.; Handjieva-Darlenska, T.; Kune\u0161ov\u00e1, M.; Pihlsg\u00e5rd, M. Diets with High or Low Protein Content and Glycemic Index for Weight-Loss Maintenance. N. Engl. J. Med. 2010, 363, 2102\u20132113. [CrossRef]\n5. Layman, D.K.; Evans, E.M.; Erickson, D.; Seyler, J.; Weber, J.; Bagshaw, D.; Griel, A.; Psota, T.; Kris-Etherton, P. A Moderate-Protein Diet Produces Sustained Weight Loss and Long-Term Changes in Body Composition and Blood Lipids in Obese Adults. J. Nutr. 2009, 139, 514\u2013521. [CrossRef] [PubMed]\n6. Layman, D.K.; Boileau, R.A.; Erickson, D.J.; Painter, J.E.; Shiue, H.; Sather, C.; Christou, D.D. Human Nutrition and Metabolism A Reduced Ratio of Dietary Carbohydrate to Protein Improves Body Composition and Blood Lipid Profiles during Weight Loss in Adult Women 1,2. Am. Soc. Nutr. Sci. 2003, 133, 411\u2013417.\n7. Reimer, R.A.; Willis, H.J.; Tunnicliffe, J.M.; Park, H.; Madsen, K.L.; Soto-Vaca, A. Inulin-Type Fructans and Whey Protein Both Modulate Appetite but Only Fructans Alter Gut Microbiota in Adults with Overweight/Obesity: A Randomized Controlled Trial. Mol. Nutr. Food Res. 2017, 61, 1700484. [CrossRef]\n8. Te Morenga, L.A.; Levers, M.T.; Williams, S.M.; Brown, R.C.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2080, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1a787cf3-587f-43ab-a92f-04834985d2c8": {"__data__": {"id_": "1a787cf3-587f-43ab-a92f-04834985d2c8", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6d1b1009-9f31-49f1-b1ee-4f26dc589405", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "4e5c0ca67a485e95d5a1b18a52e2c53ce1a372b4115f5797dfb131ebe55a514f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72a2e743-a08d-4029-a42d-7cbef763d51e", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "ac057a75e2b40a9d9f2ba77d3a42fb208d12209cb41a0840ce73f3980211f3c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75a1ecaf-4e1e-439d-b1b8-324643db379f", "node_type": "1", "metadata": {}, "hash": "09d15e0da779124c4108d69de056e731e703a3484d7ddf4e93c3dc4169c1ed8e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "; Tunnicliffe, J.M.; Park, H.; Madsen, K.L.; Soto-Vaca, A. Inulin-Type Fructans and Whey Protein Both Modulate Appetite but Only Fructans Alter Gut Microbiota in Adults with Overweight/Obesity: A Randomized Controlled Trial. Mol. Nutr. Food Res. 2017, 61, 1700484. [CrossRef]\n8. Te Morenga, L.A.; Levers, M.T.; Williams, S.M.; Brown, R.C.; Mann, J. Comparison of High Protein and High Fiber Weight-Loss Diets in Women with Risk Factors for the Metabolic Syndrome: A Randomized Trial. Nutr. J. 2011, 10, 40. [CrossRef] [PubMed]\n9. Moran, L.J.; Luscombe-Marsh, N.D.; Noakes, M.; Wittert, G.A.; Keogh, J.B.; Clifton, P.M. The Satiating Effect of Dietary Protein Is Unrelated to Postprandial Ghrelin Secretion. J. Clin. Endocrinol. Metab. 2005, 90, 5205\u20135211. [CrossRef] [PubMed]\n10. Lejeune, M.P.; Kovacs, E.M.; Westerterp-Plantenga, M.S. Additional Protein Intake Limits Weight Regain after Weight Loss in Humans. Br. J. Nutr. 2005, 93, 281\u2013289. [CrossRef]\n11. Westerterp-Plantenga, M.S.; Lejeune, M.P.G.M.; Nijs, I.; Van Ooijen, M.; Kovacs, E.M.R. High Protein Intake Sustains Weight Maintenance after Body Weight Loss in Humans. Int. J. Obes. 2004, 28, 57\u201364. [CrossRef] [PubMed]\n12. Belski, R.; Mori, T.A.; Puddey, I.B.; Sipsas, S.; Woodman, R.J.; Ackland, T.R.; Beilin, L.J.; Dove, E.R.; Carlyon, N.B.; Jayaseena, V.; et al. Effects of Lupin-Enriched Foods on Body Composition and Cardiovascular Disease Risk Factors: A 12-Month Randomized Controlled Weight Loss Trial. Int. J. Obes. 2011, 35, 810\u2013819. [CrossRef]\n13. Karamali, M.; Kashanian, M.; Alaeinasab, S.; Asemi, Z. The Effect of Dietary Soy Intake on Weight Loss, Glycaemic Control, Lipid Profiles and Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: A Randomised Clinical Trial. J. Hum. Nutr. Diet. 2018, 31, 533\u2013543. [CrossRef]\n14. Keogh, J.B.; Clifton, P. The Effect of Meal Replacements High in Glycomacropeptide on Weight Loss and Markers of Cardiovascular Disease Risk. Am. J. Clin. Nutr. 2008, 87, 1602\u20131605. [CrossRef]\n15. Abargouei, A.S.", "mimetype": "text/plain", "start_char_idx": 1742, "end_char_idx": 3788, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "75a1ecaf-4e1e-439d-b1b8-324643db379f": {"__data__": {"id_": "75a1ecaf-4e1e-439d-b1b8-324643db379f", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6d1b1009-9f31-49f1-b1ee-4f26dc589405", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "4e5c0ca67a485e95d5a1b18a52e2c53ce1a372b4115f5797dfb131ebe55a514f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a787cf3-587f-43ab-a92f-04834985d2c8", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "20ee85c1572cd4cb11d04f20c7730440b10e0bda309b5bf11b07604249fd10d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3639e37-007e-4971-bf01-3b76407111bf", "node_type": "1", "metadata": {}, "hash": "a3c7d39ff9eef98cacfe245ca92e939b2de4f3949435a2abb72ec65b5a63ad14", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "J. Hum. Nutr. Diet. 2018, 31, 533\u2013543. [CrossRef]\n14. Keogh, J.B.; Clifton, P. The Effect of Meal Replacements High in Glycomacropeptide on Weight Loss and Markers of Cardiovascular Disease Risk. Am. J. Clin. Nutr. 2008, 87, 1602\u20131605. [CrossRef]\n15. Abargouei, A.S.; Janghorbani, M.; Salehi-Marzijarani, M.; Esmaillzadeh, A. Effect of Dairy Consumption on Weight and Body Composition in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Int. J. Obes. 2012, 36, 1485\u20131493. [CrossRef]\n16. Chen, M.; Pan, A.; Malik, V.S.; Hu, F.B. Effects of Dairy Intake on Body Weight and Fat: A Meta-Analysis of Randomized Controlled Trials. Am. J. Clin. Nutr. 2012, 96, 735\u2013747. [CrossRef] [PubMed]\n17. Black, A.E.; Cole, T.J. Biased Over- or under-Reporting is Characteristic of Individuals Whether over Time or by Different Assessment Methods. J. Am. Diet. Assoc. 2001, 101, 70\u201380. [CrossRef]\n18. Hwang, J.J.; Jiang, L.; Hamza, M.; Sanchez Rangel, E.; Dai, F.; Belfort-DeAguiar, R.; Parikh, L.; Koo, B.B.; Rothman, D.L.; Mason, G.; et al. Blunted Rise in Brain Glucose Levels during Hyperglycemia in Adults with Obesity and T2DM. JCI Insight 2017, 2, e95913. [CrossRef] [PubMed]\n19. Flint, A.; Gregersen, N.T.; Gluud, L.L.; M\u00f8ller, B.K.; Raben, A.; Tetens, I.; Verdich, C.; Astrup, A. Associations between Postprandial Insulin and Blood Glucose Responses, Appetite Sensations and Energy Intake in Normal Weight and Overweight Individuals: A Meta-Analysis of Test Meal Studies. Br. J. Nutr. 2007, 98, 17\u201325. [CrossRef] [PubMed]\n20. Chaput, J.-P.; Tremblay, A. The Glucostatic Theory of Appetite Control and the Risk of Obesity and Diabetes. Int. J. Obes. 2009, 33, 46\u201353. [CrossRef]\n21. Stubbs, J.; Ferres, S.; Horgan, G. Energy Density of Foods: Effects on Energy Intake. Crit. Rev. Food Sci. Nutr. 2000, 40, 481\u2013515. [CrossRef]\n22. Hyde, P.N.; Sapper, T.N.; Crabtree, C.D.; LaFountain, R.A.; Bowling, M.L.; Buga, A.; Fell, B.; McSwiney, F.T.; Dickerson, R.M.; Miller, V.J.; et al. Dietary Carbohydrate Restriction Improves Metabolic Syndrome Independent of Weight Loss. JCI Insight 2019, 4, e128308.", "mimetype": "text/plain", "start_char_idx": 3522, "end_char_idx": 5647, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a3639e37-007e-4971-bf01-3b76407111bf": {"__data__": {"id_": "a3639e37-007e-4971-bf01-3b76407111bf", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "6d1b1009-9f31-49f1-b1ee-4f26dc589405", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "4e5c0ca67a485e95d5a1b18a52e2c53ce1a372b4115f5797dfb131ebe55a514f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75a1ecaf-4e1e-439d-b1b8-324643db379f", "node_type": "1", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "50c947eb2b5fe982f020ba2b9b57266f3df4db58d56c65a96f99fb8e88801f17", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutr. 2000, 40, 481\u2013515. [CrossRef]\n22. Hyde, P.N.; Sapper, T.N.; Crabtree, C.D.; LaFountain, R.A.; Bowling, M.L.; Buga, A.; Fell, B.; McSwiney, F.T.; Dickerson, R.M.; Miller, V.J.; et al. Dietary Carbohydrate Restriction Improves Metabolic Syndrome Independent of Weight Loss. JCI Insight 2019, 4, e128308. [CrossRef]\n23. Easterbrook, P.J.; Gopalan, R.; Berlin, J.A.; Matthews, D.R. Publication Bias in Clinical Research. Lancet 1991, 337, 867\u2013872. [CrossRef]", "mimetype": "text/plain", "start_char_idx": 5340, "end_char_idx": 5800, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6895513c-ddd0-43ba-8ade-7aa34d346c88": {"__data__": {"id_": "6895513c-ddd0-43ba-8ade-7aa34d346c88", "embedding": null, "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "042dc8e1-50a3-48aa-8025-e59c1e3d54f6", "node_type": "4", "metadata": {"file_path": "C:\\Eo_project\\FastCampus\\test\\med-rag\\data\\pdfs\\nutrients-13-03193.pdf", "file_name": "nutrients-13-03193.pdf", "file_type": "application/haansoftpdf", "file_size": 1411876, "creation_date": "2025-12-07", "last_modified_date": "2025-12-07", "source": "nutrients-13-03193.pdf", "source_type": "medical_document"}, "hash": "140317e9252245c9a35f4335aade12d534bc783feb19dea977794e561206f523", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Nutrients 2021, 13, 3193\n\n1. Allison, D.B.; Faith, M.S.; Gorman, B.S. Publication Bias in Obesity Treatment Trials? Int. J. Obes. Relat. Metab. Disord. J. Int. Assoc. Study Obes. 1996, 20, 931\u2013937.\n2. Magkos, F.; Tetens, I.; B\u00fcgel, S.G.; Felby, C.; Schacht, S.R.; Hill, J.O.; Ravussin, E.; Astrup, A. Perspective: A Perspective on the Transition to Plant-Based Diets: A Diet Change May Attenuate Climate Change, but Can It Also Attenuate Obesity and Chronic Disease Risk? Adv. Nutr. 2019, 11, 1\u20139. [CrossRef] [PubMed]\n\n17 of 17", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 528, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"12bfbbf1-b9d5-44f1-944d-9eed91300535": {"doc_hash": "ee7755c50b423f0de69fe14b66a92443a808de5d8584343247c61077e6bfe508", "ref_doc_id": "5cc84e52-7fa7-489f-ac2a-32e2264395b6"}, "4d9a7f09-8021-4b65-81fb-f92c5eb5a98a": {"doc_hash": "8888f1a1cdecdafcf4f4de9ae7c0333935f0f33f453c849c9d7072a4062da465", "ref_doc_id": "e9e50c4d-d16f-49ae-b2b9-09ba12897637"}, "69c75384-b9ae-4a0c-baa1-487c554002cd": {"doc_hash": "26a3bd4a45491cbd29783082bcd7192ff4c1254e1b75f0c8e3f41d7f6570f026", "ref_doc_id": "74b4ccb3-3e13-406d-a0fa-4d5ccd8c88a4"}, "0a0d989d-8975-432d-9617-efabfd1f5535": {"doc_hash": "5916f0ee9b4179e9a614381434e6bbe461703fadc930bca8543effa765b8675d", "ref_doc_id": "3a6176a7-7dc4-4217-b5b6-a6bbe28072bf"}, "abf5edef-6d14-4d7d-9154-16a245b01710": {"doc_hash": "dcc1174df2859211b23cb6253a31e29720d35156f9d645f799478b3cbf12155a", "ref_doc_id": "4a27b2b2-2241-49a9-83c1-d694a3b1b6cc"}, "508afd52-7429-4cc9-ad2b-6e7f4d0547cf": {"doc_hash": "b592544cc10a66a3f8ea9aaf57734808697fd013c3d0f4c4d055fdec48bf4348", "ref_doc_id": "fa0add45-4478-4049-9f36-4bbbd72e5a51"}, "eea7cf1c-2311-4850-b75a-e4ee23010280": {"doc_hash": "c21e16431a2a29334873cf9d8fab0d80b196502c5d024eb59424cc37dc78372f", "ref_doc_id": "a28b2b7e-71ff-40d9-8f3c-b240d46cd2ed"}, "bcc1cb49-9a5c-42c1-89d0-628f3300f107": {"doc_hash": "6cb88434b646a1accefe9e9decf1295040239ce81074f8c714a860c380137a28", "ref_doc_id": "ff781cfc-3bb3-494b-bffa-85c8326f8aa3"}, "8af70d71-cf6c-4d40-8360-358b919f08e1": {"doc_hash": "b65817d8ee37ee2ed6054c8e6dda0383c99ca04bb0ded11bef8b40d8048b00c8", "ref_doc_id": "12300e16-86fc-4720-9bf8-73091ef9103c"}, "acc47be9-b5a4-4619-b1b4-f7dc543bafbe": {"doc_hash": "0da5c4f9f5a0b9c354e241ebcb020de7b10346eecfb759574a66cca172f831e1", "ref_doc_id": "04a585bb-270e-4507-9ebc-b0f80a58ceed"}, "e2572690-a2e6-4751-8833-d04843c1510d": {"doc_hash": "928a64a5d487153fc342523a542329c6476420b0b01c4d3eca8bd79a5c6a8ae5", "ref_doc_id": "ba62259a-b46f-40dd-a519-ea084e24dde2"}, "8f3ed4b4-9def-496d-8087-53ff1f75af8f": {"doc_hash": "8bab701aa4b46164ba3ba6c141ae98e0bb65a26a71a9a524934e8f7709793995", "ref_doc_id": "c04c6851-68de-43f7-afab-c2eef6af2d9a"}, "7bef0868-211d-43a5-87b3-d307952a51d5": {"doc_hash": "5e12114a26d793982233c86fdb5defc2abea6d70ffaf261bba41bf2240c6f05b", "ref_doc_id": "be5bacf9-d850-4fbc-908e-4658119e1097"}, "89403449-44ca-4fae-b241-812de9f15dec": {"doc_hash": "d77ba30a299ca7c55ae3a37dd9ce0081be3f2a29fc232660c93627107f5bfae4", "ref_doc_id": "d3bef375-4ec0-4365-b26b-69955c6cc073"}, "52c6dfe1-3eb2-43d5-bf09-217881d57809": {"doc_hash": "5aa70001558c89695d675d4816038319886f3873e62bc1de249e0ab6e757788d", "ref_doc_id": "637db76b-9865-4a56-9956-1f4a2c4e5875"}, "8cd8e432-af4c-4f3b-bd85-697502da4083": {"doc_hash": "050ccb42dd1752186bd2f7dcec188274e5505943c97e972556c84577701164de", "ref_doc_id": "66bd758f-415d-4fcb-9280-fa22df891619"}, "6d6a63bc-4d10-4e90-8723-fe7e11cbcb89": {"doc_hash": "c802f62e1d9fe467418cb1735e24834a52fd836e47c1a4c20a07c2e485b3deb8", "ref_doc_id": "cc23d20b-1441-4e08-8377-88f08689f558"}, "bf48b5e2-88e4-446b-9013-2aab4d3111f5": {"doc_hash": "ce0f3195c1c465919e64097b2aa1f8b5eab4d1d675b1867bac68a52dae0d683e", "ref_doc_id": "e6f43136-aa5d-49f5-b814-329a296da6f0"}, "976e1a38-35aa-4c2b-bef0-21bf9f3fc59e": {"doc_hash": "0db5efbc97163c1168eb91c8610e36655a394bd588f5c3bf03feb172cd77228e", "ref_doc_id": "d972c690-7fd4-4ee9-bc13-d0f769f68721"}, "f627f81b-721e-4dbe-9dcd-262751c0f88e": {"doc_hash": "96ca50e14d289f2d4208693b9b50363888ce56844074f4e48aa0a612bbe413ee", "ref_doc_id": "59e3d050-5d9f-4a77-94ed-a5f5fa109136"}, "dea046f4-632d-45b8-a4b9-61cb2b142024": {"doc_hash": "ad7ecd18034069b81a8fe64b2fe263c1d592cb09505c0374bf6119496d24f757", "ref_doc_id": "af01b4e9-edb5-472c-93d8-894d4b32dffa"}, "f68be336-28ad-4818-8848-df697737c1f2": {"doc_hash": "d3e0dad1b5bde2b217300ddb9de78ca9ef3672be71c9142091eae8786754040b", "ref_doc_id": "d2424e2f-847f-47dd-8c02-d4deb09e5710"}, "493561d0-3b31-403d-bca2-0b85c027f047": {"doc_hash": "aaea3c361037053c3f13416a25c3daec7a55f4be5bc5e75b11ab85bf460958a9", "ref_doc_id": "42911f43-0b70-4674-928c-fcccc1462c9d"}, "51d2371a-b199-45f0-bef6-8912d7fcc563": {"doc_hash": "4a62a228be321a3a410a557ac0fef6faaecc64510cb08f8550c5328fed299b17", "ref_doc_id": "4ef0ff0f-c249-4d63-8acc-5c4df7b912bf"}, "1d091764-94cd-42be-b387-a2af886f46ac": {"doc_hash": "f93669d478d412518182307f8a8997ac450bc12d9c018f242092f082c618e261", "ref_doc_id": "4c8b0266-eb33-4241-bd0a-94456fbe6034"}, "c5cacbcd-a282-43d4-a0cd-f0de9a5e7402": {"doc_hash": "6d49d8412fdd4ce9f0dfa489c02bdc073e1209a8500556b1fd29b37e490d0942", "ref_doc_id": "01c17e6c-bbbc-47de-88f1-aa8c7b93cb62"}, "ce874262-8e2e-4fbc-9f89-699bc6e8e889": {"doc_hash": "9a62422df7e8231b9f26c03b04d27961980a7b74e42b92c18ac9930955650c07", "ref_doc_id": "53ac8d95-8ed5-4398-8613-7d87e513363d"}, "ea39294d-6c99-4bb5-b4bd-3f999bfbd0d9": {"doc_hash": "9a3dcc9336ce71eefc7e01374e3d9da6e7d25f5679c33191e7b1a0c704f230a7", "ref_doc_id": "cb1de74d-585b-4c20-886e-2081c3aa2c19"}, "2857959a-a3b6-4b63-95f0-707e4a52744a": {"doc_hash": "fb6a3a8a2d7ac90ca25b0e5ba43af3dc243b15b9932384befcfcb5ab171da502", "ref_doc_id": "1def02ee-a12e-4e6d-96f4-7fcde7cbeadb"}, "06eca883-e31c-4f1c-9687-b7215ea26427": {"doc_hash": "0fe68f83d593616e8473ee68aa30cbd6ca27b9d34a4f0593bfe8e5a426650a54", "ref_doc_id": "6fa35e93-d004-4acd-98c0-ff8b44bfee13"}, "0fff3251-c4db-47a0-8088-4d24784bdb84": {"doc_hash": "517a538d31ef98c86fc083aae474cc0976b74ff98b89c281bb5096419b40585c", "ref_doc_id": "acff764f-19de-4cd5-8013-acd83cda2667"}, "aa0122f5-61e3-4b36-b156-04f126ea617c": {"doc_hash": "a1a4c768d60e01b971db505a222d9bc20a72cc965efce9f7fa45c039a103c21c", "ref_doc_id": "db8fa304-fee4-499c-ad1a-872980c85845"}, "2d927dd5-1c23-4a06-aaed-603be3a12742": {"doc_hash": "78940f586290237b5b6ee758e98661907a19881b2727b69ce7fbfa40857bf0c8", "ref_doc_id": "a593f579-2bbf-4517-a269-b80d6aa6f111"}, "bc8b3740-6791-468d-b088-cde0d5cf8e08": {"doc_hash": "b8872429f26d326d4efa9b51a3047cec3a96e22b1d47607c03ae5b43cfd1f26d", "ref_doc_id": "a593f579-2bbf-4517-a269-b80d6aa6f111"}, "7dbd2c33-0b0b-4f6f-b5d4-6d4b121bdf39": {"doc_hash": "40596239ae0cac578b6125b6f21207a3adfeb0e5a6b1c3b1450bef43f2109bbe", "ref_doc_id": "a593f579-2bbf-4517-a269-b80d6aa6f111"}, "3f0456b9-7b60-40b5-9a4a-5f82eca3fdc9": {"doc_hash": "fe539156dee26bb1f0b9dfa674f5ea69c3014d9745e95f6ed054c3e993ab2824", "ref_doc_id": "a593f579-2bbf-4517-a269-b80d6aa6f111"}, "55e4e3c6-8615-49e7-b4c9-fb0dda0a0c63": {"doc_hash": "7157cb0e01cf0e64c53f961eef2b249e248f1a8c53f426212474436de75dabb4", "ref_doc_id": "0b0a029a-56bc-43b2-88d8-88a0c75b2527"}, "63db807c-c6fd-4a7d-828a-7aafcdae4d36": {"doc_hash": "a7ff9ab375f1fce746c34a6023ff3e08ed687fe3a5007ce64326a953f5f7d883", "ref_doc_id": "0b0a029a-56bc-43b2-88d8-88a0c75b2527"}, "9f8b574d-b38d-4a56-8ec2-33adb1ce3ef5": {"doc_hash": "16cbd30247cd988678016f8fcacf959f6e9f5d29572fa5c421b4c58a7caf8191", "ref_doc_id": "43fb8e82-07ae-4173-8391-dc4b0fd48669"}, "aa6d3512-4ad8-4a0f-8027-0b4c8ae8d5f3": {"doc_hash": "52b8b0a02f90a731d3cb37efa14ec8df5f7529ea49315b18d33ccf00e2055963", "ref_doc_id": "d1be9396-079c-4b78-88bb-4fd37d811428"}, "d8929ec1-a649-46ce-8cf0-c8a5aaa6eeeb": {"doc_hash": "ff4edb63c6c3a9ea93ec991fe3a226141b6b7e5b9f309e09090f1b5ae2905754", "ref_doc_id": "512f94e0-dbed-48a1-afe7-dac48f9bfb30"}, "75d823b4-f7fa-462b-b996-866c9cae4bcd": {"doc_hash": "5fe5bce264db9db5329b1e25c42b50b0546254db48fd2ebe91ccb2ac874aa1cc", "ref_doc_id": "512f94e0-dbed-48a1-afe7-dac48f9bfb30"}, "148db91d-5de0-4e1f-846a-32c30e0498a5": {"doc_hash": "30adf915dc36ba7912ba4886fbf04cc7c5d9a36d72fb5cab9385426cfc13b319", "ref_doc_id": "512f94e0-dbed-48a1-afe7-dac48f9bfb30"}, "415d18b9-474b-4cfb-b9b0-8a2fee063e69": {"doc_hash": "61eb06aefc35b00ea0c143e3cdf6af1f0656ada59eca0b972294d00e4dcdad33", "ref_doc_id": "512f94e0-dbed-48a1-afe7-dac48f9bfb30"}, "af86ec6d-75e8-4291-b54c-35facc4607b9": {"doc_hash": "479a61aa715994812d23f49362fe60fff191709bcbb74cdb8a49c599dd758cb2", "ref_doc_id": "512f94e0-dbed-48a1-afe7-dac48f9bfb30"}, "582f0cbb-99d4-4e24-b400-98b1cf3abb66": {"doc_hash": "befa0e1f08a01fd84c8e95b84fbdd98456a1fe59febf7864f8197322e83a5834", "ref_doc_id": "00c59cb8-b14e-4521-80a9-88414b8f18a2"}, "2a761464-e219-4196-ba6e-f056757df3ce": {"doc_hash": "9a73d24368be9e04cd5d2b3d00e3173cf43779a2766edfe7d6308d2c07f46d21", "ref_doc_id": "00c59cb8-b14e-4521-80a9-88414b8f18a2"}, "930ae542-8de8-4f45-b028-1d7e9d54d38e": {"doc_hash": "1429123864096965b56fde0744e84a104f3c40e3a8d6c2f630a328f69f2ae651", "ref_doc_id": "f3e0ce61-f519-4d4c-a4dd-a165c95cc1fa"}, "4b95ad8f-545f-4986-a89e-759479fccf46": {"doc_hash": "93943af9259f8d3dab7e49368d53cea91fa25cbb43a2b5060692dfb3ec7bfc37", "ref_doc_id": "f3e0ce61-f519-4d4c-a4dd-a165c95cc1fa"}, "1726fdd5-a145-42c2-946e-eabd165612ce": {"doc_hash": "5bd22cfe599fe8b11e477549578e13d57bde0457f421946bb7d4344504b8b4b3", "ref_doc_id": "c5b6b360-beb5-4893-bec8-60f062a7cccd"}, "e60365c9-1c38-4576-a509-98d144269e58": {"doc_hash": "763722e72525af87413052a87ed4e69a1ec82d12d0f242a8efb7e4843eb90139", "ref_doc_id": "e9386ab6-405f-4079-90e3-ec21aba2fdf7"}, "b0cf5336-6072-4708-92eb-a50acf539895": {"doc_hash": "008c89d4608b08cf81b8bb9cd12d924dcae7e02cf013cf7cf0958fa6a6365126", "ref_doc_id": "c8c12c85-3c54-470d-9783-53f5cc8733a7"}, "bc342e9a-f742-4fb6-acd6-0f4eaf5e3b61": {"doc_hash": "e1e111fcc56855c90d177b16df304be1dc03e5da7c63bfc9333eb4a4a7f8cc18", "ref_doc_id": "0706e444-41ad-4d13-bb7f-c9ecdffd575b"}, "3187a720-2c40-4d53-9f21-a0c47b623058": {"doc_hash": "0bc680266062c3171ae17a6ddc9071e13a48f375269871fc74f764d692256eb2", "ref_doc_id": "50a7ec3f-9c6e-4759-b1d4-54fbf2b426e3"}, "e83811b2-7ce8-4dc9-a0cf-a74b47c01120": {"doc_hash": "47ef69d4c0cc2d9ca4d58d490d8a0d260bb9958a7eea59f2475929d0ce9f8ba3", "ref_doc_id": "50a7ec3f-9c6e-4759-b1d4-54fbf2b426e3"}, "8853035c-5944-4b75-a801-deaf4d3dffb3": {"doc_hash": "b61f98505b35e62e83c3e61ba26aeeefbe6f68c82d7b3591bbaa6fd7105660b9", "ref_doc_id": "76d4ba1f-23ce-43f2-9743-0b6e3560c1e3"}, "34d10113-81d5-4b44-882f-efeb66f169b4": {"doc_hash": "3da096610f0bcd90772ccc992f35b5415e860d2c8510e175c5aec10b863b986d", "ref_doc_id": "76d4ba1f-23ce-43f2-9743-0b6e3560c1e3"}, "79c5a763-c636-4851-9f40-08fdad8429b3": {"doc_hash": "dc1c3b39e6ece13baaab9017cebf5639e4a5815c5e47f2a6cc90869f50d17e68", "ref_doc_id": "007931ca-7497-4494-ae71-d1b69d701b45"}, "1af0d2e5-9e93-4b98-aa34-dddadd8628c9": {"doc_hash": "4d89279b02c406dd9e1428913ae2caa2943d7f2beb96a480532fe446fa21bff1", "ref_doc_id": "eeffd6c0-12f5-4a5e-a9e6-51fceeb60870"}, "5d20cd0e-395d-46ca-bd9e-9c3d990cba78": {"doc_hash": "a5b35c4204fff14d8c9e7f5f073bc38e75588a5c92f9dd4c0a7fee0ed091ba37", "ref_doc_id": "567ac3f9-8160-429a-99bc-96b08904bc83"}, "d4b0fa38-90ad-42fc-80d2-0c0223900d6c": {"doc_hash": "77be70817466b2dbb138b333224b63c3dfdc4601ac5cc9c97f459e8ef7100a68", "ref_doc_id": "403755d6-e286-4e3c-b335-abf570a2f25d"}, "88c202f8-cac4-421b-a539-55cbe190522c": {"doc_hash": "14244aaeff428ae8a415cb1715a7fb06ec5c1af848fd7aa110d35df16d407b1c", "ref_doc_id": "8674df02-31c5-48eb-bf7f-55eb9d17d8ac"}, "396cc111-a720-428b-92bf-4e96ff2a10b5": {"doc_hash": "1c69134ded8a8da29c968959ceec89b060ab96529f9b544f78c99ec6ef2d3f55", "ref_doc_id": "ddc59ad3-ef77-4c86-a2e9-513ac5d53697"}, "eba6571d-e975-457d-8190-230e4eaaed7b": {"doc_hash": "444db3c4a49bd4b01d9f6f4ebdd35094452ac867ef9a973608b26bcf92a5ee45", "ref_doc_id": "9f36b2a6-6d1f-4cc3-86eb-2a06ed41c1f2"}, "0250f366-77d4-4972-b042-35ed862fbe30": {"doc_hash": "fc35b3af284f4ac53210f59175271ed8295b88d54e01bab43a6fde8b338edc29", "ref_doc_id": "fe1fe893-f9d1-4f45-b093-1adc8c32e232"}, "bb454bdf-d7b4-4396-87cf-702f2fe28922": {"doc_hash": "da48f08326336d1239b01e66ac21a1c8b77cfde46af35a0d353b6a25265a220b", "ref_doc_id": "ade8b0cd-5fe2-4225-ace0-d88f8bd503e4"}, "d68205f4-24ed-4aaf-8154-830524857362": {"doc_hash": "8f4667adb6dd3588aafd8d62843fda6e66289520b8e4fcc1557dcfc83e65ac7e", "ref_doc_id": "85db7d61-406e-4006-b6dd-63f8c027b04c"}, "53b66f95-aa2b-43d0-be2b-02b25082d8f7": {"doc_hash": "0484c581ad7314f11b8172e42e92796ce55b7e864dfdf255acdf4296ee5c675c", "ref_doc_id": "01ea736a-9c16-4c69-9ab9-3b2b7448815e"}, "5126dcfe-4b6b-4c51-a011-36621b0f1fce": {"doc_hash": "5c85a133091100898cfb67dd906398268d01d9752a95c995e12b6eb2a417b6b5", "ref_doc_id": "a9dcdda0-ff0e-4483-bfbb-7d83651a86ad"}, "fba6cf3a-53c9-476b-86e8-c52d18972dc9": {"doc_hash": "a2909f301d4d73b7920b81a13fd93cd7c6a03cbd76ab1634d153c2fa67327c13", "ref_doc_id": "a9dcdda0-ff0e-4483-bfbb-7d83651a86ad"}, "b27c6366-6ebf-4b5a-9737-df546dedc359": {"doc_hash": "a20b2c23963ca665cc4f0f900404ddffe1c7d34211105f94abc3a150f6c4087e", "ref_doc_id": "a81321a4-9e4a-441b-848f-8fc67c7466d5"}, "32f225d5-84d6-4b06-bdf3-2cee403916a5": {"doc_hash": "8eedba7691bf76b6ba7b18b54dd77015bc3e9ce9cb8c710dad7d826add4e66b4", "ref_doc_id": "f4ea5b2a-37fc-4a62-8b0e-c1249cfd2075"}, "4836db2d-7e2e-4b1c-9c28-2122125759b3": {"doc_hash": "26dd3ee1fc659bf78dceb48c5d82411a3b0e11b139a4e28a0c8f2fd5308b2bea", "ref_doc_id": "fa86e237-7412-4906-b592-63e7774a6075"}, "f84b52d7-e639-4ac9-acee-29c42c56545a": {"doc_hash": "d1009e58e47807f6f0b68049334d956ac4bb6a3ac430e3d64665f55fb3747a7a", "ref_doc_id": "a459c278-cfb2-417d-a339-7c5ae3550b10"}, "02d05981-5f0e-4aee-a651-15a0bd6bbf6a": {"doc_hash": "366627d4ee3dc73d50b753bb7281cdacb319823be6fa37916313bfcad7db7dd5", "ref_doc_id": "a33d7137-d933-412e-b3b1-c53fc29004f9"}, "eb84caf7-445f-4eeb-a5d7-8b4b1f38fc4f": {"doc_hash": "40fed84f6030f074df640ac5bb96750aa330cc7aa9a2d810ad3d60363e1fd8e2", "ref_doc_id": "86e29a4c-8220-4a65-a6f1-222b9c54f25f"}, "68292c4a-41fb-4b9d-ba88-453a8d0dfd5c": {"doc_hash": "c54e009f2dd37d1a0fca4bf2a7236bbd8ae5d7a4fd445089d827eb18a5d53a43", "ref_doc_id": "c27d1392-fa30-4f92-be71-84a2a668245c"}, "eb0621d1-3b9f-4b0d-8276-0e153326daa3": {"doc_hash": "da277384eaa98d8765a2a73f84db0a1a5bd980ba6b2aa554864b2228deda20dc", "ref_doc_id": "62f73e79-d0fa-41c0-8a3f-eb55f0ef6fb3"}, "a902bec2-0082-44b2-a7da-7b7e5aa6206c": {"doc_hash": "84530b92ec2414b31888110bcf9954d2d3e91dac7a00d0ea80039137e8d38f12", "ref_doc_id": "15ac59e7-059b-4429-ad1c-58d1c4a4233d"}, "bf822dd0-5c24-4cbc-951e-a3d4b388cdf9": {"doc_hash": "45a969a40fa73328492bf58d66375308d933c29a58ab39d15b66403c2780d428", "ref_doc_id": "12009ceb-9cd7-452d-8dbc-e586beba08a0"}, "f9bd162e-3232-4b42-801c-016d3d4f1c6f": {"doc_hash": "359a172b8004b2e8b9da932d816248bf397e0636a6d684606c2410303d70703c", "ref_doc_id": "48dc58f0-d511-452b-9110-e27041456e3c"}, "23f18b3e-757b-4cfe-8ec5-6623dd7fd613": {"doc_hash": "1f5e1de58c5c968a71fbf3740b1f29f80524317829650f6424a983c702c51a24", "ref_doc_id": "7068ead6-bff9-4210-bca9-e8ff5ec448d5"}, "f6a91855-338c-4a29-b0ee-69c60576b6f2": {"doc_hash": "2c494c3a1013b209ab5b2ecfdb398a5d17b8312cece11a9a6b704db5c376b7ee", "ref_doc_id": "3063a9fa-607b-4d2e-bc02-cbc66075c395"}, "831b1cea-6418-42bb-adbf-c842904c9d98": {"doc_hash": "2b740428c951f86f89b2bcbd5c86e75447225a22bb6e021277f4763c9e871fb6", "ref_doc_id": "b3c225e0-4e56-44fc-9b33-4b4e5419adbb"}, "b1779acc-465d-471b-8eff-721f3b33ceee": {"doc_hash": "d50f4c0c8958fccd3ebccd538806e32d4a35f24be097f846ffb15259f7b39b33", "ref_doc_id": "5aa4cf96-662a-4d7d-940c-ea2af130484c"}, "bd39dde2-cfc8-4bd5-8617-dcdd690c52ff": {"doc_hash": "060dc945398782a329198b373228d66e90247d86788b5b1f7adb9cce5f8feaa7", "ref_doc_id": "29ce36da-cfa6-4d5d-a2c6-0afb63511d0d"}, "cbbdde6c-3d0f-40ea-9194-f72a662a069c": {"doc_hash": "652f9ab27390f31155eda1a5c2cf150718b808174976a130ca4de7e203853047", "ref_doc_id": "731d0a10-87ef-4e01-8259-076ac86ad025"}, "468d8044-ac37-433c-aa0c-f2d67750fc5d": {"doc_hash": "f6d499e8a750ad91037a088ae184112128ec9bc9457392812073a2279ae4e8ce", "ref_doc_id": "98996976-478a-457e-9906-40283f4b3b82"}, "94ecadfb-2398-4889-8be2-87430f62aa8c": {"doc_hash": "2830e7decb253ee976a7d9e879e48b3e8af0b95b465f171c66fe236fd4f7fdfc", "ref_doc_id": "b29a5b4e-30af-44c9-bf34-1c068b9009a0"}, "e73afaee-4a88-4662-86d2-d66e1033842f": {"doc_hash": "f77ebafc1f19bb57a60679c17e0b32c37e3a594808e7e3c7d21e0b21ae5dd279", "ref_doc_id": "1dfbd6c0-0b14-4489-9c38-599fa7edcf21"}, "30c54383-81ca-4567-a7de-cb201687dcda": {"doc_hash": "69fd8437399e3a4d4998d064ce128c33f8e8b30c6520cc488a465ed26b9a36ba", "ref_doc_id": "f26210d0-98de-4a96-bf3b-59ca2bb817bd"}, "e102594c-5637-462d-8905-0f970ea0e04a": {"doc_hash": "0104e9add3a806998ef23c03d3db2ac0b2d41e1e7184503f512b50cbfd6dd151", "ref_doc_id": "489cc81f-ad58-44c3-9c60-97183ff4c076"}, "8a361c8b-6598-4e6e-8429-ce1356e77a1c": {"doc_hash": "c1132a49661962049f390940e3680987e32559b33ffbcc3b701d380fb0835055", "ref_doc_id": "e9767c28-87a9-46de-b5c2-8050c7cf473f"}, "b5e196c5-c97a-4022-9658-0d3b2b5a0012": {"doc_hash": "e0af249e77f2672c9b49c0bdd77df213ce44bc9e41ed88f7e07ecedf9d558ce3", "ref_doc_id": "c09c7c3f-bdab-4052-be34-59c24509e7f2"}, "208aecd1-6596-4620-80ce-db068a4490cd": {"doc_hash": "94b22137a8b2736d588bfb85e15f213c067d8265f1cb32cdd066c4ebfa30fd89", "ref_doc_id": "1079c67f-84b7-489f-b08f-f0a27d3db911"}, "ed5aa648-d32c-4ae1-b5fb-11ab9ee7c1ab": {"doc_hash": "038f17c8b961442f58ede175ac84242baf981773b5e9e226b21796172e2babad", "ref_doc_id": "eb22fdff-fe5b-4595-9141-6d614228b3e0"}, "9dd98725-cbc3-4230-a9e4-721ae0eec176": {"doc_hash": "030a53db0978821c1c14a60855808d6a945ebe8d20e345ece3211bf0da11b953", "ref_doc_id": "72420c7d-b97f-4629-90d5-7707ebe04528"}, "9a79732b-d597-4866-9df1-ae5889296399": {"doc_hash": "d644db9b1d7801f891c0e6e9bd1361aab6e14ac99cbb80d58f1d9dea8873312c", "ref_doc_id": "fb49db7e-8189-46db-bdeb-7fe0227c91fa"}, "292ba253-c450-47bb-aa99-8f8b44bc624e": {"doc_hash": "ea9722b270ab02c89807087994e8213270909ac0a7a9a0eb8c705931b037cb66", "ref_doc_id": "11f35436-25e2-4f7d-9c43-a3dce47996be"}, "3b1fcf63-c013-4619-a89d-443aa21b3023": {"doc_hash": "272af050232a6c5557d2d9e8cb2690f411a5580a2695721e5750a6404397b9f8", "ref_doc_id": "220da70b-77eb-4401-bd40-f07c9a039d58"}, "80ba2782-dd65-4974-8182-b7ff344dbe05": {"doc_hash": "1401722d0036f89aa24d1a0397c2fe23eaf66cb5180eac69ebb5723002f75440", "ref_doc_id": "20b26d4c-6ad2-4b3f-9856-23e4656d8a23"}, "2d995442-5846-4cd2-a2d5-e73bb0e86fb4": {"doc_hash": "880324da9bc60d08d17be25a57f5e905e8b60aee016c0e7fcec3016ff55385ce", "ref_doc_id": "b29aef51-944e-4fa2-a47a-eb3a4a09beaa"}, "8303726f-187f-423b-9609-f28144218107": {"doc_hash": "4855cbf327d375286b198c7bb098da022401a395213e391c95c8dbb92144e927", "ref_doc_id": "f52c9fc1-53e6-4708-8b84-c2584dbb85a4"}, "4aaa129a-a913-42c5-b0d6-3cb0797ca623": {"doc_hash": "bd5709378536fc3f9df882810b06ea8cfc833031c04276a3e2f6675a0e06aa63", "ref_doc_id": "43ab2c44-01f9-48bd-b692-2cc20871dfd1"}, "f3d25c71-e7a5-4625-a140-1c521d5aaff6": {"doc_hash": "e70a2fc68ee695afc51cf38596fed2ec517ad3ee77397ec8e53a20d9446a096a", "ref_doc_id": "66ab9ff0-f98b-4030-b6d8-a64dbab51deb"}, "3ee2e69d-c712-4592-bf4d-b82fb5542889": {"doc_hash": "cdc5ee638f7bd105d3146098312fad7bf0e2905585005df506e6a83d0812272a", "ref_doc_id": "eb3b34c2-63f7-4d2b-8e5e-06da1bcb5b22"}, "2f1257a2-32a1-4272-8582-16cdff15ae4b": {"doc_hash": "74ab00636a6034496733ec3dc3ea0d76aec8a0300136389e548cf8034ff59bdd", "ref_doc_id": "ea94617c-964a-406e-94f1-f0fe9e985f32"}, "f0bbb000-0428-4e8b-b8cf-c94ca4fbb6fd": {"doc_hash": "0aec8fb2d2bdf4edcc0116db85ffc9e2cbb9565109eeb96b949585b69221370f", "ref_doc_id": "313a2366-cd6b-4063-901c-03a9e44ff0ef"}, "ec12dd59-5add-41d3-a44c-7ae672d20483": {"doc_hash": "4770aed8dbd726c182dda6dfb46025a3228d043e3f4a55c60c310df720445ef1", "ref_doc_id": "ae26847e-8873-4011-889a-50acd7402270"}, "2693b941-0715-4834-aa6a-2cea3c53141c": {"doc_hash": "b36b88fd498447a8491b0fb3d433bfc5d99b5c41c51defa9d7b7d47a3f61e374", "ref_doc_id": "acb1c4fb-e545-47f0-ba4b-86b81c2ae6ce"}, "5c91ff1a-7b8c-430d-95f7-e8115e04bb75": {"doc_hash": "bd2daa58170feab0a191c65ac5b92f44d36f234735f07c9390ef839d713c87f9", "ref_doc_id": "59327998-9b68-414e-b5cd-5acdf43c0ac0"}, "69e59392-38ff-4578-9548-c5976a6f38e0": {"doc_hash": "b5f0625d6b8a369c2ccee60216af0160aca6cedbb1518d9fb6dc54587dca9260", "ref_doc_id": "00e23163-96f6-4f04-873a-979543754858"}, "e277a41c-91bb-4aa0-bef1-dd5b233becd2": {"doc_hash": "3819dbd571f0362ab0ebe5738f4a5b87b152ac67516c97d71d9b5d2bc244d985", "ref_doc_id": "90636f21-8a19-4c71-8608-76da9c30d726"}, "c57eef32-13d2-4bb7-b3ad-4c03a91def6d": {"doc_hash": "1e8b9ed37002540b1e7607acbe5a37141a9499979a6b168d5d471b92ad6edde4", "ref_doc_id": "3a352d79-8f01-4f60-a2cb-ddb081454c0b"}, "1e72d523-3df1-437e-bbdc-b70e8e3d7f07": {"doc_hash": "446df69803ff03f1903d0f1720e59f15b438103108298e1b2755f34baac8976c", "ref_doc_id": "cc3ca0f3-cd8c-4f5f-ae7a-82387eb8306a"}, "2752743f-bcc2-46dc-82ce-935b23f3dca0": {"doc_hash": "387721f61a6cd082a82ac06519df231e466828213df5dd7ae22a445618f22f5f", "ref_doc_id": "ad6a8f8b-7f16-4815-8932-6d98ff9c9312"}, "a6fd29f5-aab0-4fb5-a116-8dc773a81b41": {"doc_hash": "cb1894e27be2f44d80872263a219c6b4d6d8246916a409e2f4072472b0d831e3", "ref_doc_id": "68b9230c-ee63-4cfb-9ad0-bfa985cbf8ce"}, "465cfca3-3b44-4334-9e0e-ff14e3038c96": {"doc_hash": "b40656642379de36eccb25de6055e597c3ea98c7172347e369392ba8ef362d9e", "ref_doc_id": "855dd3d7-3a78-4d55-874e-12c4c38bc7f8"}, "b3f47417-4767-47ab-82ac-ca67c5c00742": {"doc_hash": "08b192df03be4c85f91708ed1cab496bceade9e5b033c5cb9522f56b34a594a4", "ref_doc_id": "9d9538dd-9ba6-4a7b-ae44-70338d4b63ce"}, "3417d99c-4acc-4367-8a9d-8f0fcf69aaa1": {"doc_hash": "65743c5047c7779a4ea362520a2966fd9a8d41c99e43fb4a2b6159a5af6ded9c", "ref_doc_id": "7900954a-c796-4e35-9508-efd12118066b"}, "2b002f52-0b24-4a75-b997-21442d8c2bd0": {"doc_hash": "e54e5f3783a7fee3d2a49238e25c9b61d3b2a41311b0efc1f0b30534fbc1ab56", "ref_doc_id": "d24614c8-16fe-439d-8707-6409d3ad2ea2"}, "4b0e758f-b2a4-4d2d-8f71-31dd4f774663": {"doc_hash": "0ffe198a8fdfe6008dca5ecacc76d81210554c08d119d4508d9456199d607a9d", "ref_doc_id": "b32c7cf3-8bee-48a2-a66a-7c1c9d759abf"}, "85a4de42-a9ea-48b5-8ec1-36de138b5ad8": {"doc_hash": "f4932348fca4316651f1784e6514a9b13959050593b7f344c408c689217bdc1b", "ref_doc_id": "6384ebff-8022-4289-abe2-9e08ea6db172"}, "6a8801bb-dd32-46cd-8a53-669512e0734b": {"doc_hash": "e4709c96f877fcf4b5278ca7ceea795bee3cbde34a23d87c27316b8625fb79e0", "ref_doc_id": "b4f7b7c1-248e-4773-b69b-807db7d36bff"}, "3d24e3f1-75ab-43d5-b7c4-9757ec72d0d5": {"doc_hash": "aff3b9f1d7d082062bd9276bdee389ba96a2d4c9f062f0c8d38fe866f0413abb", "ref_doc_id": "c2f64ffa-deab-48ad-96a3-ba7a278e1670"}, "4479bab3-8309-4b0e-8e2a-ec5f6dd49b87": {"doc_hash": "084d1b96ac147af1d14d64d549337a0f08edf6ebf04c210ae22ba7acdf7cf76e", "ref_doc_id": "038be2f2-2613-4619-87ea-a10a0039510e"}, "49f4d782-47bd-4a62-9476-46196ec307c6": {"doc_hash": "cc8eb75cc73098f9b406ca6422c9f5731fb980abacb46e98108972a5f930574e", "ref_doc_id": "d76e6ea5-bc13-438c-9e6b-60206770cbaa"}, "e5a55b4f-8f94-46fa-9821-2a4a80ef1b88": {"doc_hash": "4eb1a30c036135bfdaef616a9b6c615a1ed67e337c4fbba0c12df9b33ee518a6", "ref_doc_id": "375d1d63-dcf4-4a27-983c-e1087a3fdf4c"}, "2312d4fa-b8df-40b3-8352-b699ba518cb3": {"doc_hash": "588b9e0f92ff90fa8c688d5fd2cde242b4c7e4fc2426fdf07950afd86029fcb6", "ref_doc_id": "1b7c47bd-533e-478b-9ad8-f00f0f20ca51"}, "9ca77fa8-aafb-4098-910e-fea3bfd01a5f": {"doc_hash": "25a06a17dac106ee60b6de7a847390dc0586408824db3daf7fac6097ab8f3330", "ref_doc_id": "d5c26cf0-1296-4c1a-8df0-0f57a81a33de"}, "a0bd5e49-5c5a-4d25-a7fa-665bcf7f270d": {"doc_hash": "37ace5bcfb0a63c0c029485bc9dfdfa9783e2c872d22c4016df8e86f25c81979", "ref_doc_id": "3f6c49da-f89a-4070-b978-f8b29501a358"}, "35f097a8-4e0a-41d0-9d8e-79b3aa3d0394": {"doc_hash": "3bf7e94c5cdf1ab3a3ef44a92dadc8fa32d38952fb83667ee4b0f31156240cb4", "ref_doc_id": "d1c4b196-8861-4274-a818-fec3b0be49a9"}, "60219114-1ee5-4c6a-8eea-a467dfa10f92": {"doc_hash": "eb6804c5b3c0cc4f077daf107a13224bb0aa991dc6d00a8c66081b8e7b3b11bb", "ref_doc_id": "6fb4aca7-f879-4edd-9dca-60c982dfb96c"}, "2bb66447-d3e1-4a02-a687-ea0b1ed26e33": {"doc_hash": "3027d0908af8fd308c5b44126d349f7a54fa3019f712018b5b1aaaa0c4116371", "ref_doc_id": "db5aac8e-d115-4e64-bf7f-4fd43fe9ca84"}, "0ec5c557-e863-44a9-92d3-d3cf0ec3bc4b": {"doc_hash": "ff6a5c9fead5bee786ef3f38a12c5bce67dfa680f3d8226a6dc13fe223b39f6f", "ref_doc_id": "992614f7-f20c-4340-b618-20868edcbc3b"}, "406f687a-16d3-4655-876a-5fc585ffa03a": {"doc_hash": "98873450c50ef25150ff29feb1051969c6a9fa4f18e8197c24663693288f07c8", "ref_doc_id": "f3f090f0-17da-41dc-902a-e19b9693d59c"}, "79de6f11-dba2-44f4-9498-7f69ad5289ec": {"doc_hash": "7260c29450a85faf07436244b1ea0383e22b48aebf2c6723550a669be1f686d5", "ref_doc_id": "7c19bf4a-c6d7-4543-a778-6113d4bbd187"}, "d6195b68-94b0-4363-b9a0-1f92b1108085": {"doc_hash": "cdb4f4221beb87085e28f745b23d4507d3ce2781f204e7ad831fe28029d727d6", "ref_doc_id": "460807a3-82eb-4b47-a45b-940c6aad46cf"}, "adbdc4e1-9064-4883-9c8a-cba21692ebfd": {"doc_hash": "c757c4ee5426bbad1df5678b1c2182483aee37fda583cf505868ecf7ec0239bd", "ref_doc_id": "6cc29c47-5332-4726-beec-96dafa0a46be"}, "3431e5eb-23cd-46b1-b13f-565a5671ef63": {"doc_hash": "c6b3e6c12e1e3a9a552b016d2d739698a71e35bb19cc1d4ee4529212576c4c9f", "ref_doc_id": "ee453ded-3922-4b8b-b082-9a164373ed61"}, "53b276da-1071-4669-94e0-20722cb94c74": {"doc_hash": "747be78b82fff784afc89d14a4fae2d312bb798013455ef69e6c132b1755e5d2", "ref_doc_id": "2613e220-cf71-42e7-bceb-47782bce63a2"}, "d8d79ac3-29c4-440c-9543-8b2a1494d6b4": {"doc_hash": "22552e6180e3d940a422c064e9fd995650204ff57413fa6356e8b14e7719200b", "ref_doc_id": "9463c141-aded-4652-ab3c-c4990daa2923"}, "210f8336-be58-4c71-b23d-281f0f821e19": {"doc_hash": "446cb1ddbd56d37c87a8ad386ca6b92ac270858383bfad5b3d39b97a89fa1d88", "ref_doc_id": "85ddc4ac-7e21-4bdd-82f1-a26b6bf446b9"}, "40b43e3c-8c3e-46ce-98a0-d8c4dfeb99e8": {"doc_hash": "05994032f5748bd3d19ccf77746f8d0b47151b1e7e53fb68d115a2faffce82fd", "ref_doc_id": "7f635757-632d-4748-86ce-ae7609268a31"}, "76059695-a6fc-4d4e-8072-277af3e8f49a": {"doc_hash": "eb3406c6ab767861d789be4129604a2273f6f5756be718ea23c4846b9bd78dfd", "ref_doc_id": "3edbb0c7-985b-41ed-869c-70d6a3ad1753"}, "8bae01e0-c5c7-4af5-8538-1efedf85fbea": {"doc_hash": "15b7619a378a2ba681ab43d396fbbec31d095a047e8bc134d68b980a7e1eebe1", "ref_doc_id": "3edbb0c7-985b-41ed-869c-70d6a3ad1753"}, "f7013c54-fa38-4b3e-a6cc-49636cf0db86": {"doc_hash": "6c3c6f6bf452df20d3c547ab09f1cd1fa64bcd857cf022bc6d5051a2fc158f74", "ref_doc_id": "b41b90f1-0078-4a2b-ae30-5306949207b3"}, "d923e09a-d584-4103-b147-fa829a5beea0": {"doc_hash": "68dbf45b5c50cc4325739604c8705acf3522ca7f16a2de1fa30fb383c4c6f93d", "ref_doc_id": "b41b90f1-0078-4a2b-ae30-5306949207b3"}, "00296e25-99e4-433f-a9aa-93b6f39c2202": {"doc_hash": "5e30f22ff8d58c2a011a01e6f5c92b8d3de272028a57a58e081b1fc66914b884", "ref_doc_id": "c3d5e15b-3a2a-46db-8d47-33cb20f2779b"}, "6611225f-f0b9-4364-bc02-73fad8398a8c": {"doc_hash": "373d148e7d2ecd70c558b8f9272a4b6ec189c465b36e36c5887bb5a9bd0b7906", "ref_doc_id": "c3d5e15b-3a2a-46db-8d47-33cb20f2779b"}, "537d976f-2b01-4126-b980-62762e2c4fd3": {"doc_hash": "5acec055cb9d97c5a153fa6bc300d02cb30de50264830f389ce6ef2ce8208b57", "ref_doc_id": "0a1e5bb8-c01b-4f34-8b5b-9227b342f2a2"}, "ce8f9408-c81e-4dfd-be19-de7c64083a02": {"doc_hash": "cef2c2be7c3140a79a58afad94d22d7e3634b8c25bc10119f8ad32fcdc83e137", "ref_doc_id": "3b38f7eb-e40d-41ed-bbaf-f5fc2929d3d5"}, "0bcd0e6b-eb31-4b7f-9b9e-e388402b6ddd": {"doc_hash": "7d3b24add2d43cc850b7aec7e619f87bba44c1a8330c8737a18bc6ff170d0646", "ref_doc_id": "2d2acc2a-0840-4616-9ecb-f2ed5605f2d7"}, "b5f2d3f7-7c51-47f1-8358-4e58bcab9d1a": {"doc_hash": "32b36b982dbd969f04218329ce4a7859652c5c6d47e207bf21f22b0ad2665995", "ref_doc_id": "d7058f0d-1005-41c1-a902-b46c2e7be85b"}, "bbd1585b-68e0-4f41-bf79-aeb7fe52505c": {"doc_hash": "a830c28656fc990798304df2bae0e5dbaf3b3c5010252beb7650e0121ab6b719", "ref_doc_id": "df452501-dee4-47cb-bf1c-85867286d2a5"}, "9a485bb7-e5e0-4ad9-9416-c42737a8dfc8": {"doc_hash": "cdf1dfc42261a8489fceab998b4c0e99cf33a70dd3b145b6fd3ac0ff047dd61b", "ref_doc_id": "1683fc9a-2286-462f-9476-593909d379d8"}, "d4a57fba-858b-4498-8d5d-4d50dff123c7": {"doc_hash": "a04feec489e7d652216cf4ac17a00e4f79ed2a03220e4cbd119784c633b57e07", "ref_doc_id": "7de4552b-db33-4db6-afaa-79864b7b2384"}, "ab8098dc-a83d-4812-be9e-7f43a6d7aec5": {"doc_hash": "ca74a7cb7cfb38ab8956c3607a4afbbc5330c8c7b7f1773435bf6180dc606e7c", "ref_doc_id": "cf8d35d4-4706-4368-9f93-6def7dab9980"}, "0113205c-6803-4fdb-9c03-8d499d191298": {"doc_hash": "0bf4e1f6a82e5e474f1563d9365bd0c56030177942d4e64d3886cfa243b24533", "ref_doc_id": "358e92cf-6cbf-46e9-94d9-1dd62d54dab1"}, "be1a0711-0880-4610-86cb-af312eeb6233": {"doc_hash": "e2cc1e8ba2138043d728414f82da6cad5c2a5ad7a72fe17369c0aa3a8522d42a", "ref_doc_id": "358e92cf-6cbf-46e9-94d9-1dd62d54dab1"}, "2c826dba-e412-4b47-b863-47a1764dd3da": {"doc_hash": "cdb533188aab85e8e99cda19db1295a4f5d364d91c5880e74d41abb5d19f43b7", "ref_doc_id": "255cff82-532f-46b0-8073-e321a2f14f82"}, "3d111f06-7bf8-4866-85a4-f23facab30e9": {"doc_hash": "5d0d9ff90eac29aa8e68c6085f7304adaaf6e184a304d35dd41f2536c4dba837", "ref_doc_id": "679dfa8c-ab07-4e9d-9c8a-5595ebe0f0e7"}, "5a17299c-de3a-452f-b353-d35ebe6eb8d2": {"doc_hash": "7d7f2213777f6a261b09c4a5866b0f7bdd78e375ab3462458e0f11a961855bc8", "ref_doc_id": "f4a80547-3a29-4741-97e7-acd81cd6079c"}, "ed1967ad-ec71-4ad9-90fc-bf7980c40f78": {"doc_hash": "e2c6d4b5fedaec1fd91b8a84d946a1903850d9c9666d809f95769d50b4fae81c", "ref_doc_id": "42444b4f-24e2-4bfe-9bc9-9ad3a7b95e48"}, "66d543d3-bcb5-4085-b49f-072bbc37a222": {"doc_hash": "ea7c99d45f60e9e45fd8dfc000fe56ef11a418ba23c8dd23693c0669dd6649d4", "ref_doc_id": "3fedaa4d-dbb0-46da-9109-cbac88a63cd6"}, "a611ea6f-5795-4343-b978-5d4d28b32e0a": {"doc_hash": "9a5418fd4fa884ef7bce106dec83aea1c96ae73d2f8309cc95c6460db157088b", "ref_doc_id": "7e679b46-87cb-4db8-ab40-6f03dd3cdf09"}, "e611ff35-a2cd-46a0-9b2b-c2f51fa6de97": {"doc_hash": "9524ddef1361165a030cd4f7b29b36d83a1ec7876b2862bba61cfe4f03d3f3a2", "ref_doc_id": "66385e9f-6c2a-4929-9638-caa5f8ef824f"}, "203d003d-e414-4c84-94ed-2f02618a9d44": {"doc_hash": "f2ecfecdd73fadbe523c4c36baf6b36e751d0f842d20c52769ad457292038f8c", "ref_doc_id": "6e8bd49f-b7d2-439f-899f-63d871204d62"}, "2328d5d0-9a9b-4273-8e3d-6bc07710b1e0": {"doc_hash": "2af591ab49a6dda7f2327982ad43ed05a29c2188bf080fb91f8410bd6c61b87a", "ref_doc_id": "e6ce08c5-59ca-49e6-a053-e81f5321e5c3"}, "8530d91c-c5f4-431b-b929-9e52657293cc": {"doc_hash": "c36f966912ff50524489d5c212f99a4c54229d19db7f43706889107c54c49f68", "ref_doc_id": "c0de51ca-cab9-4299-9997-2a49d33a85dd"}, "9c223bfa-a549-4a10-8620-e00996a9d2c9": {"doc_hash": "e6e097ec12f9284ee97ad1896387c59ef7ba53002b4329746d1e3011edebdeba", "ref_doc_id": "95f9918f-925c-4a2f-a198-b068ffe1140f"}, "7f70a74a-4ea8-4205-9262-87da14ad5f96": {"doc_hash": "ae12ed10ff8c3ec65d9ca55ecb1fe85cfee3ed427883e58e8300fe6419f4c3bd", "ref_doc_id": "95f9918f-925c-4a2f-a198-b068ffe1140f"}, "513d3268-e6c7-4b6a-adc3-b67af432ad36": {"doc_hash": "0f5e4c432c11a7f254c259fe34b5c4fc2fc5d2c60bc7ccb87cd0d695a59d4da5", "ref_doc_id": "95f9918f-925c-4a2f-a198-b068ffe1140f"}, "2524e69f-355c-4000-8517-9c8a2cfa482c": {"doc_hash": "7dab113e974058c9c3d658d2f967d36f3cd2267abf26ee2b5e082896ff446262", "ref_doc_id": "95f9918f-925c-4a2f-a198-b068ffe1140f"}, "4f2c792e-676a-484e-b56b-7344fc16d2e4": {"doc_hash": "45d79b4e4ee1d73f9f512113c12ec962ccbd5b3a545bfb90ff135895deac3067", "ref_doc_id": "95f9918f-925c-4a2f-a198-b068ffe1140f"}, "04f32862-4b40-462f-b6c5-bd0852ba7192": {"doc_hash": "a887bd53703eb2f2f18de4f478192c6d275199be049c114edd0b66b2fb3f20ff", "ref_doc_id": "95f9918f-925c-4a2f-a198-b068ffe1140f"}, "25e3d104-0da5-4de7-8340-16559c6c79d4": {"doc_hash": "b417c14b1b6e80dc229b8f9b0f20776b8c3eecdacd1a72e19f0a0c1d1cad2ab8", "ref_doc_id": "7e313f4c-4894-4228-b2ff-25d5a6cf6c04"}, "84892c70-e79e-4d64-ac4a-132d7904e776": {"doc_hash": "b83ad0612c6566e044965c869987d7eca97acd9c8328f7472537c2abaa98cb75", "ref_doc_id": "7e313f4c-4894-4228-b2ff-25d5a6cf6c04"}, "552f9b62-dad0-4fe7-9f9b-32475c5faeed": {"doc_hash": "6ea6dc1fd927be7514418734555a69e18fcc845e5d5f7ad49d11ca43906f1fd1", "ref_doc_id": "db37cc98-edf6-4f92-9751-e2a87808f93a"}, "b23510cb-ed6b-4ebf-b338-e88ce69a79a5": {"doc_hash": "3c1f9c8c6ddaba5ab461dbce7af883c50eb63c812630a783d5a889c139acde15", "ref_doc_id": "db37cc98-edf6-4f92-9751-e2a87808f93a"}, "f317cab3-8f90-4f1f-b17e-ce12bc01b097": {"doc_hash": "4fbf3b15f347860cbb239fffc3ce608d0a6565be63f65850a43d91fc7a7fc08a", "ref_doc_id": "db37cc98-edf6-4f92-9751-e2a87808f93a"}, "80eeb05c-311e-4663-9f56-071539c09092": {"doc_hash": "7df787a41e04fafd8064b031b3a5e3ea1b4584a1f5e129fb7e37d965c4d2f62d", "ref_doc_id": "f876fa40-1b85-435d-a4ad-87b8ed0f7c6e"}, "48663510-780a-4688-98c5-8ffc91aee337": {"doc_hash": "15748ef6180974eeb727f2f0c57eaa87507738465e6f0c367250a6765af764eb", "ref_doc_id": "f876fa40-1b85-435d-a4ad-87b8ed0f7c6e"}, "55504db7-97ef-48ff-b335-297cf972639a": {"doc_hash": "4093c7ef9fbdd056840cdd2e553756e3c8ad98cb93df166e2362b68643d32531", "ref_doc_id": "953b2c77-73ee-4ad3-bc18-c108f70e547f"}, "5384b178-2f6f-4b8a-ad34-993406afddf0": {"doc_hash": "9b855fc402503c11e95dc793e2694fe4475721eb8299987f3000b6504f1f3b65", "ref_doc_id": "953b2c77-73ee-4ad3-bc18-c108f70e547f"}, "d808fb79-a234-4b2a-b5b1-c6f960642db2": {"doc_hash": "88e8744bc10959d07bd4c62e40faef1cf018aa40414e330fce085016dcb0fc99", "ref_doc_id": "f28a947f-7736-489e-9265-01a1bec5a3e5"}, "adbd8b7d-06bc-4de2-a109-0d7bb26d28a9": {"doc_hash": "a152778f213ed38c8e190bf7182cb634d59a73760a0fe0fced5de53bb6c91cd8", "ref_doc_id": "f28a947f-7736-489e-9265-01a1bec5a3e5"}, "233ece1d-5b60-473f-8e7d-e288b6fe8341": {"doc_hash": "61c94656d8f63b676b5a7ea96826cb294987ac3e050947cc4ab2d746ba5286f8", "ref_doc_id": "3e41726d-dea7-4a5d-ade9-04f77a3809c9"}, "c600a6da-dbe8-4897-a233-e75e01731138": {"doc_hash": "6249205f9308ab94511f6d4247907e539cf942335fc4199e0efad09fcd66e031", "ref_doc_id": "3e41726d-dea7-4a5d-ade9-04f77a3809c9"}, "bae81b8b-cc9a-47aa-907d-669f2e45b83f": {"doc_hash": "23521a07f7b08efceb6887def2f71bbc4deec35f8470bf12452968e77586984d", "ref_doc_id": "3e900d67-ee0a-4cde-b62d-01837b4879fe"}, "014b673d-9231-4075-910c-d36c3e75ea78": {"doc_hash": "ceb21d179bae5390d7f22c63ae5f6a16235725976d2ef59b2b3807f20228af64", "ref_doc_id": "f67be25f-680f-4aee-bc4a-a4f7ed02884a"}, "b2b745dd-ae27-460a-a597-29802a049ea9": {"doc_hash": "c2175bb8b55e6a1dbc6fab4f83bed4c48d7c7b7752797055dfd54111388aa81a", "ref_doc_id": "d3ad766b-11f5-4fb3-83f0-95e555fb81ec"}, "2f640404-a5b3-428f-a4eb-36d56e4aa18e": {"doc_hash": "ba3a79dec0a335d4f133de185b5e7113684da0b5fc5f4015b36e30d99fd1949a", "ref_doc_id": "f37976c5-8a86-401f-abb4-e26489d3ab44"}, "4a456271-4637-427b-8264-e08713edcd4e": {"doc_hash": "b43f80ba37646e14aec30742180465e4b28b310dfa8c2ce644d7c33a8a54783f", "ref_doc_id": "e74e553d-7084-4ffe-b3f1-edcebe2e0242"}, "84a4a385-7593-4491-a0eb-b615db5f8716": {"doc_hash": "f92858d1412e79fb17cf46967757cadd0edad558d54d0d9dc0a87fd22d5cb055", "ref_doc_id": "e74e553d-7084-4ffe-b3f1-edcebe2e0242"}, "0c5a36c8-c046-44b2-9b12-9dcc10309220": {"doc_hash": "f5d93fb35c102f8880867eb9708ed35271822a0cde9cf61ee12e3b6c2a4f8062", "ref_doc_id": "8692462e-5b2f-47a8-abf6-b054f99557fc"}, "cd676445-c694-4e31-b664-3d546406d7d0": {"doc_hash": "926997e6d77cd63ac10a8d677f1c4e2fa28cec38af7ecde20ec986dd07d9f221", "ref_doc_id": "8692462e-5b2f-47a8-abf6-b054f99557fc"}, "799d3667-0533-4178-a3d4-09e27c873624": {"doc_hash": "57210ffc8c7fa094ef231e39d84a1b1a81aea6a08db0e237d292c4dde7e389ec", "ref_doc_id": "715b650e-7245-4a0e-a13a-1912ad4f686d"}, "8f292219-0080-44e7-b639-d53c416483ba": {"doc_hash": "f04581be3cf7fac5f3c2c4bba6931306c314bcbd75125dbebafc30cfdd59a603", "ref_doc_id": "1de2cef1-d96e-4b89-a4bd-db7b12e14d54"}, "cc6da427-fddc-4f19-ba96-cfd76fb5befb": {"doc_hash": "da5f4dcb079630de8b79eadb1d568cf5a806987e184b10d0066f98c7904bd4ba", "ref_doc_id": "ebd2a808-21fb-44af-864f-e292f3c49b97"}, "2b5acf84-c938-4712-9139-50f69eec4db6": {"doc_hash": "9a3c24e025d495e6b10c26c06e3bb8794a665dac48f2b22479c89be487925586", "ref_doc_id": "9148db7b-6a59-423a-87d0-0461afbc4fc6"}, "8f285835-3f2a-4f78-bb75-7fa0c05d8398": {"doc_hash": "bfd20c82b9829eb4268d748fc4c416d2037e6fe94ff848e5d7024e9f83686e09", "ref_doc_id": "b0dba5c9-90c4-43b0-8a7e-80550665096a"}, "e7347695-0937-42d9-b760-e5d783976c17": {"doc_hash": "1b768003babc9be520c6cd7c46f928a3086251cadbc7ab82a1812dfa1ebf8cbb", "ref_doc_id": "92c87418-61aa-4986-95b5-793c4cc07d98"}, "fe92fffa-ba4a-4848-8725-4853cc961d7f": {"doc_hash": "07ac4e588480ffcbae780435f9735ff82089bd9372b9324fba011a24274b40c4", "ref_doc_id": "41cfba3e-eafd-4c6d-86b5-880aa476c9c5"}, "5b777f47-9430-422a-a18e-ed6856e31e2a": {"doc_hash": "a13df9c2aa32d071735e388c6a6df4e02e74feaf3c87d3d8d2ea8db0fa75b9d2", "ref_doc_id": "29ed5b1b-e2e4-46b2-8abf-ef2646e29758"}, "850ec10a-0b9b-4ecb-8852-e1d0dc3ff5ee": {"doc_hash": "86741ffb02d720ca6d5da707fe61827702f6598245bed61b992ec885ca2b050d", "ref_doc_id": "05e2b3a8-8a71-4b6d-9fa7-ebe3cca57788"}, "6692f1e9-bdb6-45bc-8207-c5c2f1830834": {"doc_hash": "171e965f015843f3547ce479881fdeb9fe9a7d47ba70eac9d38f366f90dc10c6", "ref_doc_id": "23f8e959-43bb-4f24-a05d-d168c96fdc02"}, "29b8543b-76fc-4221-923c-bbee9f3086bb": {"doc_hash": "beb42f9875abc6d55ae841c16d9dafcf6c0f2bc15b366093d39a5ab36de782b6", "ref_doc_id": "6d6edacb-876a-4313-975e-7e621302ed0c"}, "0e77ba2e-481c-4540-85f5-ec675ba6c005": {"doc_hash": "745a142901ab3e17327a4efba2fafbbff1982697a5c91cbdd33e18b293690dad", "ref_doc_id": "994fb151-cf88-4e42-b7b4-38a2c1d1a993"}, "ae99e7e6-21bc-47bb-a4f9-e247d4cbde7a": {"doc_hash": "aeb89fb562723ceba42ad7eed712d14e486b7857be7fec1ab2f953730ad47931", "ref_doc_id": "777f4562-88a6-4a03-99f0-4537778d2a84"}, "0612e6f9-36b4-4070-a628-602df130cfca": {"doc_hash": "723be70bd18c11dcf88e8c0277a421e01d5fbba85a4357249d33fbed182f2bdd", "ref_doc_id": "d9bec198-6f9b-423d-8c39-33ea89f68d87"}, "e3b8a491-dac3-436b-bd31-2d701daa0566": {"doc_hash": "2df352a6e9541dd3d7656d91914d1feb1a8a7891337c0dbe4e8e99609b2e27f4", "ref_doc_id": "4246746e-22e3-44e7-9661-3446c77b5297"}, "77eb6720-36c5-4c4d-a9ce-ddff1c1f6b29": {"doc_hash": "cd94485b4094d0fcc02a9a3e0684e861c6ec09bd90bde98a09d6f1492e210508", "ref_doc_id": "b9ad44e7-e6c5-4a1f-a619-cb07fb64cde2"}, "4a9863e9-1495-48f1-a6d8-6873615ec3eb": {"doc_hash": "7adb104623a7fa243c61f1185c576c98730afd07e4cb6b05f94d7f2b78a2dcb2", "ref_doc_id": "c4189724-3c6f-4ae3-8eb4-f7f4d06aff6e"}, "fbfe5ad0-46fa-4b1b-90b8-31943bb36701": {"doc_hash": "f6f7013ee8068bd091f832aef1ce8c65cae03ea495217c7b82bdb373102989ed", "ref_doc_id": "07bb7cfc-3693-4c9a-b022-bb8b4dd96b4b"}, "0186137b-29ea-4e0e-a4b5-f45f69b2c951": {"doc_hash": "295924ff8d00d7ac91e48d3466b3d3c75db481d764d39d54a64e4811cf196789", "ref_doc_id": "45809fcb-6c1c-4861-b3f3-14430fea4a79"}, "3ef56466-81ca-4160-b583-0079e360f5ae": {"doc_hash": "e08dc29f22a7b8aeb2117865aee8a4abd00eaec575ee773c69309d763fd3f5c5", "ref_doc_id": "64f19f01-feaf-47c9-a8ef-de66a2e7831e"}, "e1cb826e-28ef-44fa-8203-60cb32ac568c": {"doc_hash": "d9d28584852266806fbdfd696af3581dba849a8152831f53bbca7aa52083ee94", "ref_doc_id": "489a460f-0d59-4296-921d-5d3a67e85f95"}, "c5246e1f-94eb-43ab-966b-3f53f4868ff0": {"doc_hash": "3de478d9b596c96790dc99d789ad5824669f0437bac9dac28c599503e033a2b2", "ref_doc_id": "064d57ce-11e3-41ac-9389-c95647d73d24"}, "1c0c58a4-0242-459e-bf26-c69f5832f262": {"doc_hash": "04d3fd8e6e3a164c5416f2179233344b9154a6b586a56f8fe9cf2599e33dc3f4", "ref_doc_id": "63d736b4-37f1-4b24-91d4-bda2321b2eb9"}, "ef852b94-00bc-4ded-982c-2a23b446762e": {"doc_hash": "c7d9bf9eb295da992df9c9ff41d44947b9e8b3926f62b5554f9cb1dfc72c0fbb", "ref_doc_id": "53b930ad-d34e-4edd-9f51-7aae00760f1e"}, "be84f6d7-a4f0-45f4-a851-a766e20043cf": {"doc_hash": "02696a214936dbc69caf6106f6d4efdc4d218b707fa6c8b21902b1fe1720f9bc", "ref_doc_id": "6ea854ad-6ce4-454d-b9b6-378b717f0820"}, "aa7f9aed-a75e-46d0-a67d-784cc6cd9efb": {"doc_hash": "672406d264d9590d3c59f67ca9af82361bceb4bc08cf88f0b0d655592486b18c", "ref_doc_id": "2d491b58-f088-47fe-b5b5-7153eaca73d5"}, "c58dae28-4861-4ac0-9e73-833bfa951707": {"doc_hash": "5f310ba3946d03f9f06cdbe57d3c3d4ce1a56aa1600e4b4d962a9d94199bf73e", "ref_doc_id": "6efad591-ba4f-42f6-868a-5568347d9fab"}, "68da7bd6-1723-47da-beec-61e962085acd": {"doc_hash": "215b88fda523c85cf2d625eec68b3af35946a02a4f5e4f4aa34e89557ed74897", "ref_doc_id": "e50651fc-b850-4645-9f54-4204000f9d3a"}, "9a3612c5-96ff-4e25-a2d9-4648eba181f1": {"doc_hash": "9138e1e09b1c40164218645ab04d2d24f8c7516e941e562aadf265de010a6c5b", "ref_doc_id": "cea97c02-6934-45f7-b113-abbda869e7f0"}, "4980f448-9bd1-4fc0-aea9-84b4a17c9049": {"doc_hash": "693429ee42af054b1100cebaf20d76db0f9a10187afe42ae340244bd652d53d8", "ref_doc_id": "15157e48-3d18-4b8d-86f5-1f7ed3860e2d"}, "cc2f3579-5afb-4ed3-8945-a8f8b4648da3": {"doc_hash": "ca832fd74df2a422ff678abea5a7adc1509f5ea265ce8e9be898528cb192206f", "ref_doc_id": "4738a933-9e3d-4b0c-a047-8e5b85c0208c"}, "21ddf95a-fb2a-4f6f-8cf3-c7dabc0bb84e": {"doc_hash": "5fe229e92f87d25a8069696e5a28f80ce0fca6f10783aa4fb5202836f8f5f906", "ref_doc_id": "fabd0299-93dc-4a9b-a63a-24c619e5819c"}, "7f908bfa-48a6-4105-859d-a090fe592818": {"doc_hash": "da7aeffe82a094978b5ec31277477cffac34eeb23ccaa83f3e67451ad307b499", "ref_doc_id": "454128c7-fd52-4d5b-9e26-9d4a5eaa4f03"}, "bf521a23-cc7d-4157-8bdd-2c1657e3d434": {"doc_hash": "e1cc5602bd7c02c9a518328f81f3b6b52002e670198e0528330fc3f47f7fc3e0", "ref_doc_id": "45a301a9-4f00-4820-a448-bbfc58e8cd6b"}, "43277fd5-d3ff-46a9-87fa-504c58e37ad9": {"doc_hash": "faa9d3909e2a363e70a81e6a743a6aa34a404408b3c21722ac6fc66e613cda2b", "ref_doc_id": "afc963e2-5fa0-4998-a7e0-64fcf93da6ab"}, "607f4f6b-b250-49d8-82fd-d890df8c263f": {"doc_hash": "6d3a9d5345f0d9dc15ef34e247e95a299bb38855b87d83059e2c213448a759a2", "ref_doc_id": "a8c5ca9f-0c9e-4615-b517-c07e84825a76"}, "1408b092-6278-4068-96cd-56ec682754d1": {"doc_hash": "c775bc12f145280e93df05339101fc52b94978d5e49b472aebfaf6c43784988b", "ref_doc_id": "0c67c9dc-369b-43e8-acc7-2b5b5661f438"}, "60bf4709-29e8-4b8f-a1d2-f814499c80b4": {"doc_hash": "de3502b6c6c8d2df23ce113c543ee332a487a545cb822dc5ee54766720abecff", "ref_doc_id": "d48d161c-6144-4a3f-a229-dc3afcc4a658"}, "ff2d6748-40a8-49db-8f83-1144106e4a2e": {"doc_hash": "848cd57203e994aae6fa82be702cfc6d778f7638947895fc3bc1128d395fa9df", "ref_doc_id": "164cb639-4aaf-4f1e-ace4-87caed5f234d"}, "1a1ad8d8-52c6-4c13-b89a-c7d4a6c1f1e3": {"doc_hash": "03c8676a9e844436a049dfe13824b85600965eafae10a7eca0cc0dae483015c1", "ref_doc_id": "c6009284-b37a-4d94-bd3c-fdb883fcae19"}, "5b56de18-ab46-4c12-b313-336ab970b3ef": {"doc_hash": "6ac9a4b38fc344b7f869745f443c8b88d4ab4cef2e171ca1497ae3450d28b111", "ref_doc_id": "88d3ccc3-78e6-4a3a-b212-0588eb650bd0"}, "47c25196-679b-4129-8afc-8e0ec11afd83": {"doc_hash": "7ca2bd94f8a493a8519f7487056f550372cafdee2e25fac92d70922211d0e731", "ref_doc_id": "a3a3ccd1-8130-4ab1-a112-16f3ecc4e382"}, "a41a630c-4eae-4df1-aaa4-f2c451396a18": {"doc_hash": "15ae77f359089b746b6826023b34e8f2e4c2cf5433d89850464718a2c101c42e", "ref_doc_id": "cf2127f9-c0fb-4e8f-97a0-8a14ae67e305"}, "93a33755-22eb-4192-8242-516f523b5beb": {"doc_hash": "f4cb120bb43f994cfbf51280cbeea9b4cd012dc534301a9cddd66cfaf8d1b8a5", "ref_doc_id": "07cf93b7-7a75-4eba-b310-98aa31de4dc2"}, "9a3fcad9-6f27-4673-9d1e-ea331b4cfe5e": {"doc_hash": "b7a03b1872d3c425e91375e2ad23fb6fd366f58db4f4850c43c04ceefc00c306", "ref_doc_id": "bc0dcb51-73de-4a08-a309-c44ecd5ad4f2"}, "eaf85fa1-18af-40f9-83a2-9f9d842b7810": {"doc_hash": "8d370849684c379301b31140d060787bd3a91fe58cdf762a38d8bad4ec78bf79", "ref_doc_id": "673364d1-dae8-4197-8a80-1421b12b0bee"}, "67d9ad05-f86f-43ab-a861-3aa2b31d2181": {"doc_hash": "a28799e69a6a575709812e76584514c27e5c5dbe3dce43f131877ffb8c051f63", "ref_doc_id": "5044a01e-72a1-4546-81f1-3399eea41f10"}, "2dded28f-04f2-434b-a0ba-4534cf625b51": {"doc_hash": "71542e5e77ab79def0db8a526557c3e8002c9547fd3de4b03dc5beb09bc9c271", "ref_doc_id": "39552474-c669-4f23-9aa1-894b50bcfad1"}, "1a3cd8ef-0dfb-4620-a34f-abd8f3bc46f3": {"doc_hash": "6b5df091c7e50201cea2807cec0ce8e56c8f94ed52c51b8754a9ee89d2d49528", "ref_doc_id": "e371823b-dfd2-4370-ae31-050894bf10ed"}, "80004ae2-0808-4554-92ac-a8cc723763a1": {"doc_hash": "5d1f33b38d4d9466742f39c21669afc2c3f786663a7a581af9686e40479b2db1", "ref_doc_id": "bffa6e6b-338d-4a9f-a296-44cf332e21b4"}, "2b8114a1-d710-4a41-948d-e536e30617a0": {"doc_hash": "0096331ea720b7e1a6ab46f71c5b4a8657ab2df634c4bb8d365495c0a0b0e02d", "ref_doc_id": "1ea880ea-49bd-4900-b1b9-49270b79604e"}, "b335cdfd-c386-48b0-a9f3-4a224d5a4f53": {"doc_hash": "fe91022a8a19f1e0df9c692625b69a9a537b9c288b812c6dd267cabc0926c660", "ref_doc_id": "a71e27ee-9963-44f0-8c82-f806f976f893"}, "63e1c935-2ddc-4ac6-a5ec-2265170b048c": {"doc_hash": "ffdeab87ea1294e3f471b6fff327a89533ff8f781e849ed4f8e8a1653caf6de8", "ref_doc_id": "e8b65a57-b562-44e9-856a-abe3939013e5"}, "a5523900-e787-4cb8-a14f-0eb36fd465af": {"doc_hash": "afea0f67ee35076140cdbb2a307157df8e632ea75ea66d790de5845d2a6f5d28", "ref_doc_id": "f4adfd8a-a0b0-427f-9292-21410c18f960"}, "42007811-066c-4622-b636-bbdb7b1f938e": {"doc_hash": "79f748ab92b3eaa9bf73fa8a298de48ab4acb2d554d86ea355997e5fac41ba6d", "ref_doc_id": "3c2cfe92-b8d3-490e-b763-9b71064c8ab0"}, "fd13af9b-107c-4cbe-9759-bd3c8b944b08": {"doc_hash": "7bf74cec4181da5cc4e54f32eee1c948d58bbda036427a4bc0758f1fb59b4ebd", "ref_doc_id": "cbbd9861-4751-4ed1-82c6-cac1ec6a487c"}, "6c48f058-0a1e-44bd-b38d-ef478a601c98": {"doc_hash": "b893606e8d0a96ec8abfe0f0b4e1ae6ff78c4f5def3ec79a5f59dbaae75a5a2d", "ref_doc_id": "6aeb67bb-8858-45fe-abaf-bf53ab18a19d"}, "7f821f97-a1b4-4b70-9385-34ce9b5e15b4": {"doc_hash": "4a2f94005aae25da9b8d2d3d2b458d59a48f84b945c293418cbf9c111b4c9e4f", "ref_doc_id": "318f2c95-d5d8-465b-a5d2-c4c61e4fe109"}, "f47e5d59-9fd7-433e-9cdc-624cbc203499": {"doc_hash": "99b5250bfe1c7c6ef1bdec5cecbc6871248dd85598165f5aca664f66b0d648a1", "ref_doc_id": "c0349648-42ee-430c-8882-95e1240da141"}, "950061fa-fca2-4fa8-8f8c-44eb624f5645": {"doc_hash": "5ac2714618f07927681d569f6871030db97b72845b8807b07377ce728759235e", "ref_doc_id": "a64ab452-e6f6-4e8c-8ff4-7db12c8eafc6"}, "7b423dce-121d-4448-b542-3a8b9a389864": {"doc_hash": "0eddd391a8b45d61d0bb4498f4b68b19b9103b8902127a46f26a281e565cd18b", "ref_doc_id": "d716d36f-b51a-4e51-a9f3-1d40dcfad028"}, "d6784c45-defb-4d35-a812-c2df9e6d0fe3": {"doc_hash": "d8dedf5fb6add4b0bd440f23187d8bc43def92cb4e64b0803231fd9411cce658", "ref_doc_id": "ff37c69d-66d3-467b-8aaf-7b5252751b93"}, "56cc54c1-34e7-480f-9984-4236c2369312": {"doc_hash": "38f72cd7b2dfbcc2b10c74f8c2c236214ac836a1fd9c5f64eef009734cea4b51", "ref_doc_id": "9926536b-7a39-4ac2-abc5-9a3392a7a534"}, "b86ebc7f-15eb-4cc9-ba95-76b05f307044": {"doc_hash": "372d8e7e198a6210877d9406f6b6c9bab5cd5822b0db9f851d92fbb3c08ee234", "ref_doc_id": "9b8252ce-12d3-4f4a-90bc-f7be90418548"}, "6b2c98b3-4949-420a-9b65-97ea56422940": {"doc_hash": "cdaf7697d263427c2f20ac3afb472b3e68858e0df780870195a2c4075759c1ce", "ref_doc_id": "3703b5f4-67b1-4eaa-ae86-9d6bc002d241"}, "b1e05b68-57e8-4cae-bef2-2cda85a98541": {"doc_hash": "3b87cc6c0036085c1601413e4d9f785e9252be029b090a81888658d6b2147258", "ref_doc_id": "95797838-538b-48c4-9324-5e0bb3dacea8"}, "ddbbc828-9dac-481c-8943-50cf0910f274": {"doc_hash": "6841bbc7a365aedacf16e2e00446ac2f7f44fe8d093d97e27ec0d973b3d25135", "ref_doc_id": "ccdb31ca-832f-4bde-b973-073a70d97fbb"}, "33cc0f41-75e9-45ad-8c2f-7a63382d551e": {"doc_hash": "d84e33be2cbc5fbd97c8039821366287814f26632f5f1be5770b782ce0a64fa4", "ref_doc_id": "797ba812-d289-4fe5-a5e5-1291c9e653ba"}, "91412d37-c240-4dff-bd16-0503f8e9a73f": {"doc_hash": "4c80b4ebfaf29ff5a06024a9e9b36a426bcd7ecc7bdc542689c0fdb3fa796777", "ref_doc_id": "5d778d96-ec95-4e96-aa35-d637ac9ab7d0"}, "6e63ea0a-7a41-479c-aaf2-2ac788e9d436": {"doc_hash": "74c87e4ee3be2502076b6f9eb146fb3cfff467082c8d697a731476aba23f71ff", "ref_doc_id": "1e1bcf58-c00b-4d67-be6a-43dc9b9b7b1a"}, "252d911d-b755-41b1-bbb9-0afc5be912e2": {"doc_hash": "e8c5b11cd535c9a91ced489d702998193f0f2cd894e6f5ea457344dd65b2c58d", "ref_doc_id": "423dd833-4f87-4dcd-a92b-2a77b2bc6c2b"}, "682a5002-dfbc-4bba-acb0-688493306cc1": {"doc_hash": "0f7299c914eb8cffdc8929dc67bb49233908692f86bd32bcaaf41699c87bac25", "ref_doc_id": "43f8c93d-8ee0-4114-95cc-757bea57b286"}, "a1fbfc5a-a004-4cfc-8974-8250ab255c15": {"doc_hash": "c7517b3661b7a8d3f7451ee31eca4ac4ad4a5a421a750c9f5be6f410228dad8b", "ref_doc_id": "0ead8a03-8eee-42bc-abee-04db89671c33"}, "3465a8a7-08a7-48c1-9001-cd21149e8593": {"doc_hash": "b1654f9bca89a4223fd02e7157b7878d0433989a1c3934cab90e0cb5ec6b6cd2", "ref_doc_id": "d6f9c3da-97ca-4fe3-a576-7850451de98a"}, "bcddad49-a66e-472f-9601-756d0370afa6": {"doc_hash": "5a06b3db90286cdd944f9d20a32288f37cd0942b75d0027fa82eb55c01fbe74e", "ref_doc_id": "e4800953-4c31-4030-a9a6-caad06701856"}, "2198afb4-4e18-497b-b8fe-e2f3eb6c6b59": {"doc_hash": "db4d0bfb58b82615ba296b098f2a6f0eeba3f90747b0a93e62f3f162e6b836b4", "ref_doc_id": "a978061c-778e-4e49-98e2-ead3d2d52681"}, "19913956-bfd8-49a2-b4c7-ff7c59325a55": {"doc_hash": "ade0041d14adbb6b9c663e4e4692c67c4d19e80abaaba8629c2266eff230d3c2", "ref_doc_id": "6a97e2da-cc0a-4dd0-a334-b3debfbfc855"}, "5359b077-9d9a-4c49-96ec-e31298b8676d": {"doc_hash": "afbb453ae1b136e7f13b4fa355a458cfd0a5e4290df59f9fe431ed613a67a227", "ref_doc_id": "fabc46c3-44f5-4111-9178-6ea27d1811d0"}, "44ee6bbe-f91e-496b-a7b6-9e9146a80a22": {"doc_hash": "d9450482169247b6fdee7ec032b81c56985f699e4d78ea262a51acb405cf717e", "ref_doc_id": "6953437c-594a-444b-a696-ca828b5318aa"}, "009fe699-dc35-46f1-98d4-b079858cdeea": {"doc_hash": "135b71693f491aa50153e5eb7a840ed325430aea8990074323f5252163f6a842", "ref_doc_id": "b2b8db5d-8435-4394-a011-02b228e36a42"}, "260f19c6-6135-4325-9cb0-4f01ac85204b": {"doc_hash": "beb71ac349b8e25d873d350f3c9d54374446254ab28cbc0f38ffb3b34ed2ed0d", "ref_doc_id": "50aed202-4de5-49d1-b26a-894a8a7faa0e"}, "cd895e16-1798-4e03-8cb1-9006f9461b2f": {"doc_hash": "7ffb883784145c652814b4e62428c22b4cf496d5bfa6a1f90861024d72d16097", "ref_doc_id": "e9fbffb5-7a7f-45f5-8081-41ca96fc99a5"}, "9cd9c9ca-a643-46f7-a4d2-19c8bd0ff423": {"doc_hash": "9efe9667b876798666b4780271b6b1497a4f7abc3325427c9976ea327497cc26", "ref_doc_id": "1231cb79-529c-4a1f-a895-d4aeb82a877d"}, "6eb4466a-ca9a-45ca-830e-1472d9d86e2b": {"doc_hash": "bfcf736eefddd2b2527c75b19253f8a07936f3109a8ea794a49c532bce00b998", "ref_doc_id": "b2f13e54-41bf-4dfd-9dd5-6cb81fecdfea"}, "26b921ea-d590-4ee0-a844-c8a044f90f2b": {"doc_hash": "cc7fd9a5de98975353dd1bb5eba0083056bce66ae24e2cae3330ccc800f2a965", "ref_doc_id": "aea7990d-ba6e-466b-ae12-d0614042f3be"}, "19dc683a-8c74-4b48-99e7-e6741bd20863": {"doc_hash": "3bcce14158f8fc2330d02af87aedcd9139cbd51ee7269029f359332d05f65141", "ref_doc_id": "43e3b2d8-e28e-43c9-923c-cfb24866d9e6"}, "9b6cd0f2-9bcd-40f3-8f0c-79e2bd38cd98": {"doc_hash": "8e7f8c9176a9d25bc5de0239b9cf32756b5aaafc053c6d87e710bfbdcc3f1795", "ref_doc_id": "a2c8925c-8d08-4749-a7f7-5c918a0fbc74"}, "863392cd-0830-4a93-a0f0-814f601f35c6": {"doc_hash": "8fa6684bea94dc000c338468ff2284b0a1fdbf38620d90405aec3a013195cb31", "ref_doc_id": "23c46d5b-c81d-4c48-a252-a4fb11894bc8"}, "3ab104a5-fa0d-493d-9066-873ad5157a32": {"doc_hash": "e5ef9c51c6ed032dd19fb034649fe950b77ecb6d535bbb46e41787b25afff1f5", "ref_doc_id": "12dd2a24-0762-4adf-b421-0392af892bd2"}, "9d59d589-db0c-472c-b48c-055b41a21278": {"doc_hash": "2b454ec8111acee92570da256c35904b70e4c8c81c306ddc637b0cbd9dee7403", "ref_doc_id": "73179ac6-433c-4f0f-bbad-ddf1632199df"}, "fb8722f1-d714-455f-9df1-b8684477f4de": {"doc_hash": "0b7aa73253ccdb6e03975f321ccaa3c006d9e384edd493d3727c2c29f440cf9a", "ref_doc_id": "268be36a-0e1c-4cf6-9d9f-22c9004a1972"}, "98a2fd26-65a1-40cc-8b8e-0ef05b4869b3": {"doc_hash": "e41fbe925221d246382aea79e909c5b92aa30f28d20241b68bf67e7050de1f12", "ref_doc_id": "31b6d4fd-ce37-43d5-8311-af0ba4be7f88"}, "03b4d968-0f14-4e03-b663-dcfe784551df": {"doc_hash": "d1079fcf65dd6ee7dec3745f06acb765fb5eb67e05a96e6463f2a2f5e8c1ae2d", "ref_doc_id": "1d82d2d4-4854-4cd3-8283-cb44458278ee"}, "96a7fa02-68cf-4b55-a4ae-1a8e246489ff": {"doc_hash": "5b495c049739449448f047e80321764050d84661996dc9d9d14f2b04bbf32240", "ref_doc_id": "7f04095d-dba7-4bc3-96a1-3222d45156e9"}, "15ba7f83-1625-425d-83d3-4da4ad0ea8f6": {"doc_hash": "4fd20de2d9c044d1ebe5b157e661759307bf9a85a2ad6c250173ea40c480f5c9", "ref_doc_id": "8bcbe2bb-893a-4f6a-9405-cb7a818569be"}, "c8973ea1-23b4-4f03-833f-122c11a32854": {"doc_hash": "44be0b130e225b7b3754e4b2c7aa6208539744b6a0070dc6048ad8b0ce458fff", "ref_doc_id": "607e882b-239f-480a-a5c0-c33308a4ef83"}, "b5cf61d2-8a09-485b-bb5e-0f94094a75bc": {"doc_hash": "2c97821850114d0e9abff8ee2eae07c551334bf95c1ebe5de8b4707508f516b5", "ref_doc_id": "9d3ba01c-3ee6-4a5e-859b-fc4aa7bc6b29"}, "aea465cf-5501-4415-9d1a-7a5de52e2caa": {"doc_hash": "88d92237ba6051de0a277a6c204564f1e2b03f8558d0ce5abafc1cf6db6bcadf", "ref_doc_id": "f25ac8e7-ba6d-46e4-804e-13bf8baeb649"}, "55832738-8e9f-42cd-a7cb-9dabd8f4c54e": {"doc_hash": "fba5b0c46c2f84ed75a50391e6ece4931bae120382a94a2cfdd1ecbdc280ca9c", "ref_doc_id": "f25ac8e7-ba6d-46e4-804e-13bf8baeb649"}, "a48ecaca-dcd0-49b7-b802-b882a7d1d2f5": {"doc_hash": "10a6752677d3d22cc729c0e33867b87d7dfe9dfc900cfc8df6731d3a8d818047", "ref_doc_id": "87ba7679-9f28-4feb-9c6e-832a400e7830"}, "faaaf2eb-b1ed-41f3-969e-4b30b3519847": {"doc_hash": "e10d2cec97a9b55fb6f153eecd1c70fb8b1c3cdc2a859edc83fdad47e137264b", "ref_doc_id": "87ba7679-9f28-4feb-9c6e-832a400e7830"}, "4303fd47-f317-4df4-855a-63d0f685ab3f": {"doc_hash": "767a84b9a29639d4c77493fdba917d32dbe96770c7ff338aa068bcdc70d3dfe3", "ref_doc_id": "dc5ae1dc-9539-44a3-87af-6857c82af2c9"}, "a277901a-e013-4cf4-a939-74a6eee2628a": {"doc_hash": "646617299dc4b65a15c8cdc757b27f4f2a92d78acd01b96b18ee105bd5ee817b", "ref_doc_id": "8a3d0930-fdd9-43a9-8e8a-588776d25810"}, "c0c54ec8-8284-41bd-a063-5804d4ba9780": {"doc_hash": "a7ba16e2a0f9282cc091b52ba3369e56aa5cc762aa098437123adccccdd10e99", "ref_doc_id": "d4d7637c-1d4c-4c68-805e-f6d676ce6264"}, "a7d7f928-7e39-487e-868d-e9d7edca5ce5": {"doc_hash": "95cc4a56b446600a2c5bbe7d5304d9643719afe3ce7b1dd10cceb45d02ab23ea", "ref_doc_id": "5604776a-29fd-457d-bfb5-7fbfbb445b3f"}, "f77be182-b170-4769-baed-8d42d31c86ec": {"doc_hash": "55a5806f13d70acdd25eeffbb7fece540eef4f14f26c4836b1a90992d3cbfd33", "ref_doc_id": "c2fbe436-9ea9-409f-8e34-1ede4b717f96"}, "d85c2edb-14ab-45da-bd55-3e413112429a": {"doc_hash": "ed986ee5dc2cea41745ed142120e7fce87ad98bbb8b57a912235c08434714d6a", "ref_doc_id": "3e447a83-c0b6-4d82-bc24-8d14cd894e5b"}, "c569053c-addc-45ef-be0a-6a7983c43161": {"doc_hash": "a089d1990ee65fd5a4db5a96fca79aa78020bcc879fc6e098364ef2075563264", "ref_doc_id": "91c6d626-9e93-4226-896f-98ae7b6fc320"}, "7a16cce3-79b3-4ab5-ba1f-a82204c8dbdc": {"doc_hash": "14a50da45158eaa6bbbe0d0636b158d6993953bf59a520b67c0bae9e4ebb15dc", "ref_doc_id": "846ce408-de2b-4b75-966d-4268f3ff976f"}, "99439e92-ce6f-4713-a935-9180b12457ab": {"doc_hash": "dbe81838498eaeab1c43f111cc4f806c0b618872c8dc2004341645dc36b6ac00", "ref_doc_id": "50b748bc-53ef-4655-a95a-9ebb2b65684a"}, "f2dc7c7c-2215-4e74-8375-fb1bce71bdab": {"doc_hash": "239d345667a18453c45b375c1730a6996c417711386ec14ec735073ccd90cb37", "ref_doc_id": "7e7ec26b-b193-42a0-b4a8-240a10468094"}, "43217d89-3f41-43ee-8016-4cacf9f2b4dc": {"doc_hash": "8bfab175c4831dda839fdf1264b453a0ef716d558d7325d931a70b9a5a1a129e", "ref_doc_id": "f5ca0ad5-036c-40d6-adca-4174073c8da6"}, "a8757889-9907-40db-9227-805e1c3280c9": {"doc_hash": "e733a37d3e3724057e133dc1bdf6f3c4de271b4a965934c360b505a7646e45cf", "ref_doc_id": "ce12579e-a440-4f59-89b8-102b824da561"}, "187624ea-2e92-4c70-8a86-94473c633d59": {"doc_hash": "962adb98a6a2dde65ce45945c8314d588d4445482ede46d1e1a6d287bcc13903", "ref_doc_id": "23343146-0b3f-4fd3-a477-8e5956f6a55d"}, "a5241ea3-fc2f-4b96-8fb4-5bf6e2e7bb38": {"doc_hash": "d14702d3618119c8149a72e18bf1e6d802e5ff72d1f42f258978f8c6f154de2c", "ref_doc_id": "ca146124-b129-4adf-80de-954e3b05de7c"}, "5b57836f-7a8e-45e7-a941-3e4b14821e6f": {"doc_hash": "c3d5c6c57015df0eed679f05dee0c3d5f6a0b5918e3ffa4aa1ce27fd87a4c990", "ref_doc_id": "b21a5dbd-a1ad-4f9f-9081-6d26efab3fe2"}, "c0dc152e-a7c1-4f38-acd8-17e813b1902c": {"doc_hash": "f23b02f0de239eb702fb10ff58ed5401c332725cf72a925b4db311708241ac21", "ref_doc_id": "1e084a08-16b2-4c53-9b15-5b34c93611f9"}, "e9d5a0a5-d579-483c-b131-a193e90acecb": {"doc_hash": "b5d4b0f45a7d974ccfae8f69c965772dffeaa64411a7afae6493423c5174df44", "ref_doc_id": "479d3835-57fb-4649-9d1c-8dd281619c71"}, "126ff972-dbec-48d0-9e0d-d2c7a48fcbe5": {"doc_hash": "e92cb017456b6c1a0d5265af3e3fac02557c4a670cf277bfe3b2aa3d03f930b0", "ref_doc_id": "c5c9801a-f2e1-48df-8e37-d0b11e88ce74"}, "4cc171c5-e46c-475e-b257-8e557158b355": {"doc_hash": "4ff8e96b1c29639802db459655e7c61fcf93cdf29478baace97842cd9c2e2c53", "ref_doc_id": "bfc3d096-4e75-4040-ae3b-5fe31b9ca5dd"}, "2ea2c762-6d65-482e-9db9-11ee70cca0d8": {"doc_hash": "309ca102941bb050c2d2a492a21f023fbf983d3fcf6209bfa0176b6d4210d405", "ref_doc_id": "a82ea8fe-50ad-49c7-bef1-ba913efc7765"}, "e2c5b170-6650-4890-a4a3-0fb15ff84e53": {"doc_hash": "d22cd569ab4fe8740d14b6e169e6e70499311efb6c1658c642cc607408116d5f", "ref_doc_id": "712e1ab1-ec96-4967-bdfa-caa5eed46331"}, "8144e843-09c7-47f4-8e49-b5bc0872f729": {"doc_hash": "3b6b200699a1c403759519317fe2412726ccb14c4bb2f1a720484fbcbc7a617c", "ref_doc_id": "f85d5b99-79ee-43d2-b53a-5ce2dc45058a"}, "17e89ef4-9c6f-4c92-b6c0-986526a56416": {"doc_hash": "c32d2a91561071cefaa351cd0177161c1acea0b7b34e74b81ac6fd8f324a45af", "ref_doc_id": "f85d5b99-79ee-43d2-b53a-5ce2dc45058a"}, "c30edf33-ee9c-4a86-a086-c9918c348a51": {"doc_hash": "58a09a8be88103ac26468a3ade8b067dd5f4a1d4771b26eb557db751984a491b", "ref_doc_id": "ab12cb30-c41d-4e73-8dd6-d9592785495b"}, "1d2ca955-e0fc-458c-b568-9d38486c3048": {"doc_hash": "24e2c650aff0f09b79c5e66afd671ab5b531689a8382e1cb1312fe4f690235ab", "ref_doc_id": "d4674474-277d-4345-bdea-f1913af114dd"}, "428c9a34-c059-495f-92bb-730ddaebb762": {"doc_hash": "85591b2f1922e7cd509706db84da08f278a3ea33bc6bc6438d596bcf27345499", "ref_doc_id": "b236d035-357c-4162-b064-a5ce10cf0ed3"}, "b314a09d-7914-40e3-9a20-6192f713b920": {"doc_hash": "2ba90749713b4a285f3fbb72a03147da36e908413624f6ce8b2d0f94ff9bbf3f", "ref_doc_id": "29eaa3bc-be4b-458c-9eed-7d4c124a04a4"}, "6059ff27-8333-46aa-9476-fd45c2a0a61c": {"doc_hash": "e9637df6b6358f265dc1c0d801fc57e9c9a26e423f5e5ae58d9b4940473ab99e", "ref_doc_id": "d694d9f1-3939-4a26-862a-4c86afc0cffe"}, "dde21d52-9097-4735-a9e7-3ff0d99e12c6": {"doc_hash": "c032a263f0ce7dfdd15c40792be7899d4c9aadb80994c366a0e508f852040f7f", "ref_doc_id": "f17e3d30-471b-4a48-9d18-c0be124343f6"}, "e3c840f0-c948-4084-ba80-56fc585bde32": {"doc_hash": "e95f9114e6d4b68edfdc51a8dda4e7496d570945ae26ac8526a80b46d177c43c", "ref_doc_id": "7c73e8d7-d075-4b3d-aeef-845eac96e088"}, "3b28c363-c445-4c77-b993-b2bbc32cb091": {"doc_hash": "c49a60571964fa03baf1b6c5fb7bd05459886f2b69e7bea1f69be4cb1b8d5c94", "ref_doc_id": "6be67a9c-c963-4283-987d-48549eefbbef"}, "bda8f636-6e56-48bb-a548-90bd1755a80e": {"doc_hash": "46e9426790c98728a4b25371a0f6a51dda7fbbec6856750124619ef91d1675bf", "ref_doc_id": "d9cdcca0-72de-4ddb-a068-c479c7047b0e"}, "6b5f5eac-a719-4354-abae-2a8a2ae47064": {"doc_hash": "e68f76424d9056e1f2bfcb5dcd40b5953c107b915763dd54c4bae3b08980ee78", "ref_doc_id": "ba798995-6a97-4f3f-9327-3bccaa880282"}, "300107a2-dbaa-4dc6-8e88-52b65feff583": {"doc_hash": "9b0d37e465b4d9a45557375bcec4d35fd9043c0adb44a41471b61c156b28136a", "ref_doc_id": "6188e219-02f4-4f5d-8fd5-5e337f4fd80e"}, "1f37b4cf-a04e-4f9c-b2c7-8daf5f8e4df4": {"doc_hash": "6c702116454688b179b37ec573de6e1318e66df6e55a0a1e75ac65504075f611", "ref_doc_id": "77ea3781-8665-4edb-a7ad-2ed535323528"}, "9796a46a-5a48-4e96-9bf6-c3b2cead242d": {"doc_hash": "11ee18d8a46d7f4b4580a60032a55d494dca2c3bd93246a8c828065b37f8b55f", "ref_doc_id": "77ea3781-8665-4edb-a7ad-2ed535323528"}, "2c070022-d334-4756-9d28-ff0be1c32c5c": {"doc_hash": "f03fb00fb97e8bdd70f795972950547defe8800798c598d8d628998f3ee054cf", "ref_doc_id": "af44db82-3e51-4411-bdba-e4ea99fa7f7e"}, "d4e84d2c-07ca-475d-ac3b-61f061eaf0bb": {"doc_hash": "6e5458f1a14f96edcc6e68d9768dc297edea43ceb59b023d4c3e722f154b47a4", "ref_doc_id": "ded9dd90-e489-4c86-bcdb-03f2c3473267"}, "f7045a10-75be-4c68-abd2-7e410458d9c9": {"doc_hash": "2f5d5f70b1aea7a68f870fe5df866f763590c271e86c6b8a182fa37163c26df3", "ref_doc_id": "c0a0778d-57ab-421a-b4f7-043f1dcbbe02"}, "ba43da52-0b82-40be-b761-89c40a7dec92": {"doc_hash": "82bc890156bb2f8a10df99a1ae03b6347bcc21ebe0da31b6a1c6f2446f716d84", "ref_doc_id": "ce88e2ff-70f3-4699-ac54-68cfc3f023a5"}, "9c4bea5e-b085-4ef5-8e50-8f24dff696f0": {"doc_hash": "bdab69c8f334e25db6fe20c4a6c2a9b2d71523e9911ddc571f88612be8ef1f32", "ref_doc_id": "ac68297a-1ade-4097-9e06-87fa33753b01"}, "9a4d17ce-1018-4911-aa83-be620c79e33b": {"doc_hash": "493a81542f16be6ae19672cfa0ec8c754e1c76feeec7473801498c6f1360c8ea", "ref_doc_id": "f6e84b8e-bc38-4d80-af84-cefa918ceffc"}, "f4ddd6dd-e9f4-4aa0-b1c7-a5ad4b615bac": {"doc_hash": "4db63a58903de1a6e63f505c5e62e4a2ad2ddd792b70d39e969f5242635fae9c", "ref_doc_id": "d250e079-ddb8-41c9-b8a9-bfa9a5407e6e"}, "25cd7f3b-688a-4af2-bed3-e24f60e90d43": {"doc_hash": "9ee1e738fcf346b24595e618ae4bac2326de21d852ffedf47a9a29a6613e7c6c", "ref_doc_id": "88041be1-d7e9-4f57-9380-7a44b9c6f5c5"}, "08a61b6c-ed7e-4dcb-a837-cb35abcbbd0e": {"doc_hash": "2b08cedc03f6d4d8f75aa9f607b40c08463619872f0956bc9d90b823cdaacf12", "ref_doc_id": "8c51711c-379d-4028-bbca-8baf3dcc8aca"}, "f6d5b80e-285f-4ab9-a07e-eb85eb3ceedb": {"doc_hash": "89d73975a47eaf50c8d2682fe51e91ac7d052ba74832834b1aac8116ae9e9b79", "ref_doc_id": "aa611b4d-839b-424b-9002-4056b4a3de67"}, "78c33e3d-ef08-4c08-b937-94a1fe60ee4d": {"doc_hash": "3f910c5ce5dcb95cf69085e416b3b75ed609de25bbaf637a030955d53a391ea2", "ref_doc_id": "d8d87eac-4dc3-4dc0-81d7-a97468fd6537"}, "72e8cd01-55c8-4fdb-936f-8e31ac31b188": {"doc_hash": "4854e55644c7f157bbee0f447c466807d8fca21896861d7d8525c35b99006614", "ref_doc_id": "9dec536e-02d8-4fbb-bfe9-f392a1780eac"}, "45c79a6a-521e-44bc-abef-993c8966c293": {"doc_hash": "fee0e8c5d8a536ef7f11bfa3c71384f3dfe289c355ced8d24f67cf6c3843105b", "ref_doc_id": "4fbf9320-532b-46de-8aed-e760b8511d1a"}, "f76b8cb7-dc6f-4421-acb1-078ce9c73bc3": {"doc_hash": "b4a4188a6fcd8807c3b6d99aa54241dab619043e30b4459cc1f20cb214a844af", "ref_doc_id": "a66ec8e3-e13f-471d-8611-9d28a6b36708"}, "b67b29cb-c68f-4b83-8898-99eb048f7fc8": {"doc_hash": "5a366d42e93a31bd87aff2b880807ed5a426ab5228dedd6105dcab0fb23152e7", "ref_doc_id": "80b496b8-4e7d-47ec-b9e7-5da6ac93832a"}, "435a00c5-e076-4e7b-8477-611f9721f6d5": {"doc_hash": "e97d54de0f814f9f3047c28237a6d7e2648d2d2057fc6a6e6fb4f9f0a4f99ee9", "ref_doc_id": "440176be-bcc4-472c-a420-cf5c560891c5"}, "a69712d1-109f-472d-b224-c3884d7e98c8": {"doc_hash": "b52087e0f49fab5f38f7b56f3152fcb39e63b82050ce7dd7aa1b0d2f44495da7", "ref_doc_id": "3296af08-1598-41ce-9a18-f5fbdc5bed59"}, "3c2fbe3d-e435-48ca-997e-dae5f44f321a": {"doc_hash": "61617ce9970aee0888276bd7247f6986ff8305eb1dabfba9d414e1c9fce523a5", "ref_doc_id": "0b5e5c3c-5e57-4e9d-8385-8fd6f4d013f6"}, "56625ac9-558b-4206-bf57-53494d2fdd68": {"doc_hash": "02c3fe9acc83595d92377f3af668883dc918e838fad00676009c684ae80a50e8", "ref_doc_id": "e17cfc69-74c7-4653-b900-1eedd06cca1f"}, "90e6a5b8-445a-474f-be08-6490b55566b1": {"doc_hash": "89a98cda611f2a700303e38385604bfacef1738a48ff7be858ec90e1723551dd", "ref_doc_id": "911c1d1c-82dc-4e5c-bf18-d873eb296b56"}, "59a70918-ef24-4f84-a25a-ec1c12867c54": {"doc_hash": "99d6304a49efefa26fe45a2b1ee8884302a2eca8c50e6d30b9f6096d5704e8f2", "ref_doc_id": "1eed5c54-a3c0-4d16-bb58-2c532bc9e63a"}, "fa4f0f0e-fb62-44e2-a460-84c4b24c95a3": {"doc_hash": "99505e0dc0ce123761b345419d07ca628b120aeb810f8ee162646228b69d100d", "ref_doc_id": "03835053-efc3-4ed1-9212-ce8c2945d488"}, "52c48bbb-aef7-499d-84ad-9d9199305f3e": {"doc_hash": "2b61fa3155de8efc6bac8fbb0ff6a1a05ca1d449e8b5b1ea19800e4aa3d0cc58", "ref_doc_id": "13eaa2aa-3e37-41c2-a904-141605e09909"}, "ebe56182-5f1b-4ab5-9b2a-7f58728c899e": {"doc_hash": "24b733455290931ad315b1832d25e6e860a710b63eabd5c7300fed3c39d634a4", "ref_doc_id": "7cbda0ab-1a95-41f6-bd72-e02f66302aa0"}, "f64f2099-50c5-4618-a81e-addcf249f0f6": {"doc_hash": "98cf80b44a5434578bcbc13071c00db30fe2aac5c9443254ecec3c34dc5c22ea", "ref_doc_id": "c9826e26-5728-4ba4-bb52-0a248552d1da"}, "595c37d1-ddf5-4a1d-af28-571741604d8f": {"doc_hash": "476783a924d36b1e24213f15dd8ed36c965981770fa5a526c9a364569ee37335", "ref_doc_id": "678b4bba-729b-419d-88f8-23c62b64ae9d"}, "aa10f33f-8b2a-4498-9e78-402d5806be1a": {"doc_hash": "ed36746e3c6fc471daca9764ae42a4596f456118486f8559df563b75e678f263", "ref_doc_id": "e6086451-a606-4296-981e-a3f5865ccb76"}, "9cf21bbb-0ed2-4a9c-a750-9dd42334fa17": {"doc_hash": "aaa483fc692cd09e84e228aed3140cba21fae5252fe9bbfe0f096890b74dfce0", "ref_doc_id": "745e20b2-a3b7-48d0-b9ca-4b1fc6b3261a"}, "661c1bd0-f5d5-4eb8-a712-558c54eb69d4": {"doc_hash": "b6e69a8d771691accefa3e18f3ded59d75752269d73f08cd40681354a476c79c", "ref_doc_id": "982c64d8-51b7-4fc6-bd33-a6738b73b6f5"}, "814152fb-00e5-4fc2-8cdd-7af6f5904a82": {"doc_hash": "1442cb5f00a6c356635ba2f029c88370bf4b2c8927932e1edc6fe729cf52f2cf", "ref_doc_id": "156468a8-a720-40de-b2d2-e6367caf47dc"}, "6e5176bb-1a87-42e4-87d8-36baa97f2449": {"doc_hash": "cb83d369021a72b16383c77ba0f624dbe36afe83cc6dd3ff99556482e5fd5abc", "ref_doc_id": "ad5a96e3-03fe-441b-9c9c-8a93bf854db0"}, "587ed59d-a511-4073-a76d-9644dddb7bac": {"doc_hash": "d4da6af3b9e6e0095dcd28c3ba442f7c31b951b39a7d29cd9b10e0459e5c2065", "ref_doc_id": "4f131185-fe75-4d19-b1ff-6284067ec09e"}, "f393c084-ea00-4e75-9cf3-14cfdae2677c": {"doc_hash": "825575435a8b6d071a3a5c593c6f970424ed965d62013318d003427a96b57b46", "ref_doc_id": "fc27cb4a-d82b-442d-94af-57c6746d7313"}, "37da712f-104d-4bca-b23b-3dd0fbdba72f": {"doc_hash": "0b47db9d7af28332450a10c91fb9528e931a2c9f3d2d7b8877f94ece7fbf9536", "ref_doc_id": "de97da0f-d5f7-4be7-9409-8ff225902ab3"}, "d30cb208-7147-481f-ae87-b328a09f7f80": {"doc_hash": "206ce34cddce502e7e38c6782cfcec124ecc0e8c3bb487ffef495925995773e8", "ref_doc_id": "cba30e59-e502-4833-a031-bc2d17d68b53"}, "7cb33f51-b158-4fa3-9a16-a33ae1c731d9": {"doc_hash": "daaed423f118bd648ba1d3de95a7bd96c547f70bdca7d2802371a877b6ed8bc8", "ref_doc_id": "91014d5a-ca19-4e0a-ac4f-5759ffae1de3"}, "a5209975-58ea-4737-ac7f-f859a3a15246": {"doc_hash": "471f8eaa94f9d11e0183dd4e2062db9ed2f86a4b5c50702c9b4d09903bc0fd03", "ref_doc_id": "477898d4-ba08-4d4c-8390-2b71504d5310"}, "7e309790-7784-4744-9eb5-1ca38f782c0c": {"doc_hash": "d569bfab08eecb2ead8cd68f9246070aa38ddd8b5822401f8def0f603e08904b", "ref_doc_id": "79b8664e-f89e-476b-816d-5ca495703ddf"}, "58e96070-8c92-4e82-89ec-dae0df84aa9e": {"doc_hash": "049d7bfd82c7db0d8077fbad3445f5bc32c6adc40e4fc4c2ea61648187252d2b", "ref_doc_id": "fb83bbc4-669d-422e-adb8-71dabe065e2d"}, "15c44524-3849-4c80-92f4-61c13b9b9d9f": {"doc_hash": "5157042257d0ad670d02ac234be95f5939e5e6d375918fec79a367629cb8f141", "ref_doc_id": "07a90ac3-ff97-465e-b15e-a5e732580a5f"}, "3b1a3ce1-4097-4dcb-a6c5-8229d93a9906": {"doc_hash": "b2fe382dc15bfdf506bfd076d86df3c7dee084ab87dc8e26ca73e04417a2d459", "ref_doc_id": "edb08ae8-f974-4bf0-9bac-4b13635d192d"}, "0e665d51-e018-47ce-bcf8-96a7252e8ef0": {"doc_hash": "adaf49452b35ca982e4feb1678eb6605eb0da2742b37724a72ccda9683f2fd30", "ref_doc_id": "768faeeb-51f6-4fa8-8845-126c689f4bdd"}, "d0346cd8-b164-49a8-9de9-69ebf09cca55": {"doc_hash": "fa66350d28e2a9322752e1f4678c79c22c3a80320a4763d0f8518a994c98ab57", "ref_doc_id": "768faeeb-51f6-4fa8-8845-126c689f4bdd"}, "10eef76f-d87b-4747-9e3b-9712f194653a": {"doc_hash": "6f765ae2d45d3701c6b324e89bcb0789fdfed77a7bcfb02bddfa4317e25d8147", "ref_doc_id": "768faeeb-51f6-4fa8-8845-126c689f4bdd"}, "eb01fe87-2186-4deb-8444-816f0f6f9ab0": {"doc_hash": "a0c8986f7f7abe477cd8b1bb1a216be2d7c6b741758b71e2928e084cc71ac13f", "ref_doc_id": "4793ee5e-507e-4c61-b30f-6bc1f7757101"}, "fa760af7-33b8-442c-89b1-7603b16b7fff": {"doc_hash": "27de09460314cec27f8b446c105c672c361a4c5878ad09d7277fffb230f9ac83", "ref_doc_id": "c0c15dd3-3f26-4693-9fe7-969d902c6eff"}, "6e90fbda-0081-4203-8dc1-8f3594b9df42": {"doc_hash": "723614655aa18b539893e55105edb14511a45087db1237de6aafce5b6f118d03", "ref_doc_id": "3d4558b4-ceb5-4e3e-b65a-e4546e18bb7d"}, "599b4230-e07d-4f94-83d2-231cf2ddf5a8": {"doc_hash": "4fc1597792397950a42726de9fbd9dd29f7d91459ab8d0d2813ffcff26af177f", "ref_doc_id": "4b688342-6c7d-4f4d-b77c-616256675e92"}, "db84cd80-7117-458e-b125-08cb2ad60bc7": {"doc_hash": "241b71df090e5a0fe15449a746ef4b7be17a6b6e73a6e1b8a90dac17ec68f062", "ref_doc_id": "cd154823-2478-4ca3-9c43-819089866e6c"}, "b45a730b-9ce4-4ace-be8e-d3a39cf86ef1": {"doc_hash": "f040d903a6f11ca31cb7d291f4db6dcbbb2c833b4abd8ea299d7b5f22a62253f", "ref_doc_id": "c3a3ac1e-bd91-4518-8875-6d5a5b90fede"}, "b52dfd36-b346-4d4d-8c38-f63b306532b1": {"doc_hash": "4ffe5943d9e3e7d0c25bc9bc5b894cc6026792c9af9016300bd8ab143debbb95", "ref_doc_id": "90ffe0c1-f750-450f-9ae1-69dcfa857132"}, "cdd60fd5-c9b7-467e-80ad-c6efb4edb69f": {"doc_hash": "22efed509a92b6665ef27e5d57a6f4b6f3c3cbdeac3621dbc494e63a34d22440", "ref_doc_id": "69ee12e2-80f3-44f5-8e1e-c97eda47ad65"}, "05c51672-c1a7-4165-9bec-b1f9a9e2b4d4": {"doc_hash": "d1e750de0ffa0814281d99b0bd8dea4d0f0b94bb724306b1d529cc6881b84957", "ref_doc_id": "9a0e2b60-7f40-4de3-8a17-29056de0eeb0"}, "1a6a4990-58a5-4d82-8e91-dab9c8455625": {"doc_hash": "16185161c381705aa53340ee731a651bcd63e6f3b34d8b8b1d0b344c8b63242d", "ref_doc_id": "15197f76-c69d-425e-86e9-1fcf9772d6fd"}, "98268bda-4022-4da5-8e76-3b2b0bfe5bcc": {"doc_hash": "772111b5074da555a05c2c4097df6efc7052f2ea72ec336fc027d89052d6963b", "ref_doc_id": "cc5ae223-c842-498d-a196-1d2b7c5e4c28"}, "818ce439-7251-4c5e-b4ce-cab1587be841": {"doc_hash": "7a0d38f25946a47a3c481b86be55216692acfe509bb3988be7ec1be2a59c9f8a", "ref_doc_id": "6ce04762-f890-47bd-bf5d-d429a56a4baa"}, "eab4db7a-b6b9-49fd-b55b-5f68dbb0a950": {"doc_hash": "a2cef3d8bf7e418ee7c5583a1e6b99d8dfa8a612f3e4c2a60b88e54797628479", "ref_doc_id": "0694beca-8c13-4a9c-9ee8-69fdb9c0b75c"}, "8bfb2761-0860-4813-b609-75163039e02b": {"doc_hash": "b96656171626fadc14524871bbf3a9f0416b1a2699ae83cf8970e68f3b19f157", "ref_doc_id": "9f164476-ad69-4c91-8bad-b3ac4cb5d330"}, "583e0d2b-1446-4682-864b-3deb156561c1": {"doc_hash": "bc3ab8c82dbfeb146a92804ecacc1fff185663f68c29454216bed5fda0a5bcf4", "ref_doc_id": "8a8cdb8a-81c5-4f30-b917-4a4d0b375d81"}, "9296035b-6d98-4413-8508-91e28dfacbf6": {"doc_hash": "ef10e072164d9967187f7cfda696fc70f14992a507b1ea2c16adef6637f35679", "ref_doc_id": "7172c760-78df-4348-b7ec-369432b311f4"}, "3f221c45-2a61-42ae-87af-1fc12757b181": {"doc_hash": "859b5bbf15c5750848350d2ce8f01716d8988a29a064bd0bc9aa2fd63d2257e3", "ref_doc_id": "d8e6ef44-3ebf-4aaf-96af-b61ed094a0d8"}, "7b4bfffc-242b-4b69-a355-262db1fabf7e": {"doc_hash": "9dff89ca18cf9788e05f217acd7a388e13c69c34996693742491611b0bcf50eb", "ref_doc_id": "750d73e1-5de5-4f6b-a7f9-766b7354983a"}, "bacb60c3-5d2e-4581-b201-4417bc1e3e62": {"doc_hash": "2d1df675b97475003ec1f9bd3b7bc5d58332a43c77ead7e0d8dc1192ca5e1c88", "ref_doc_id": "e3af7681-ae9b-4af1-99f9-42f0dc14388c"}, "66491d2e-215e-4968-9de2-57f2fce30145": {"doc_hash": "6184833818c6c3363d01b52eb19347a2ea5a31a40b7e92e4178e1f02e8f4d8b2", "ref_doc_id": "c270651a-0705-48df-a8a6-524f5d9fc383"}, "daac12a1-9017-49f2-ac69-0aea288b1e7c": {"doc_hash": "6423e2e1e28fc8906e09e435858eb20d5b9b475cdbe63218578b44c9c20d0712", "ref_doc_id": "8ff3b18f-aae9-478f-8bcf-3efd8b2cf1b9"}, "5783214f-df83-430c-98b2-cf56cca6e8b2": {"doc_hash": "f4621c75538f771450835bb90a1742a5956ffb5f31eb8776da8a99db7c54e18a", "ref_doc_id": "77d39405-1bdf-4c29-9c54-09acbce134f0"}, "159bd6e2-9e1b-4dff-b953-e9303f696045": {"doc_hash": "2f4ef11c20da2b17636d66122a123828cec703a03ae32357cdd0dbced1cb4d56", "ref_doc_id": "2f3c13cf-933a-4203-a879-a0ddef1d85fb"}, "01a7eb97-ad86-463a-97f2-6267c01c0f49": {"doc_hash": "790dd89e7540ad68382ac5d2e66c6f04aacda6e8f2a3a53c2332548eb094f7a0", "ref_doc_id": "acfd69af-093a-4130-a795-7f7905b20c5d"}, "1b3768e4-6009-41e0-9592-0d27d433300c": {"doc_hash": "3e088adbd8c01f6665dcf61855efad760ff5fb8c1068f6828028e9558b71ef0d", "ref_doc_id": "0d438650-5a0f-4ed0-8c3b-2f413414cbb3"}, "5940d23b-8bb8-4643-8149-8ce16141ae76": {"doc_hash": "294ed0fdfcf8380925b164d6fa1ac82079a8e505a8c43a8cf4f0b1978200cdf0", "ref_doc_id": "81311d6b-9222-4ab4-b9f7-34d95cb1d1d8"}, "67af3805-1da9-44d7-a08e-d6d0e0fd352e": {"doc_hash": "ced3c63cc3a7c2af2202e80af2d45eef6bf629d50278767e6e97c1ca9033320e", "ref_doc_id": "36851490-a1a4-45e9-a718-ba8e0c7cb2c7"}, "eaf507ee-355c-4831-87a4-ac65a38ee87b": {"doc_hash": "dd284bd4f0645ecd47f2aa5936ffcc7b674e9d819d0408f21de84fac7d6d8819", "ref_doc_id": "8425062e-980f-4c7d-bc7f-f1a34e3d6509"}, "6231447c-3760-4e44-8628-91f398f87a4b": {"doc_hash": "9f9593b368f20591f6fac3297d1888962dfbd67472d970cb040fc311499ffe6f", "ref_doc_id": "fbc12338-3929-4053-8b50-8ceeab215833"}, "678d53af-0e94-4115-ae34-a10415da6781": {"doc_hash": "656531797408c6569fa7e178f6144fad178ad8c938f2dcb95ef20d510d4731f1", "ref_doc_id": "7c49a808-cbd3-439e-8511-979a53e74141"}, "e416dc65-8a49-4e5c-bbab-5beb0d05bb9b": {"doc_hash": "c6c26a27b5151fc981b8a0b04e2896b0c2a0a9e763c4c610338b6eab0968f45d", "ref_doc_id": "92504585-1f56-480d-9e2c-2227203564ea"}, "030f56e0-5f0f-4f19-becd-1747066aa47b": {"doc_hash": "fe5e37932bfa3da44f1ad86d1d1f3fba1187af03af25565d39cc044480858dbb", "ref_doc_id": "a1259d4b-bcf3-4edf-9735-fd462f450f9f"}, "c8f6dc8d-9808-4d57-b586-17dae0411e28": {"doc_hash": "2c51fce6337e5eaf3249651b80bc4272fab37ea952c6bd9fd9d60250d2bc6060", "ref_doc_id": "aa9fbcaf-0487-41a6-9653-c6b2607a0b5b"}, "b6337df0-0578-4f20-b652-2c760069fcfd": {"doc_hash": "e3bd87dc68462d5e4186f68ce8d166c96adfc57a82ceb88a94adfeed5fc75033", "ref_doc_id": "56d4e786-1d98-404d-9356-a97d6ba9629a"}, "ae6ab64a-ad08-44db-aa15-b14fca731fb0": {"doc_hash": "6afe845607c0745440675daad1c3903aa78c7c87d88c651ca48b7f0714a26ff8", "ref_doc_id": "9282ab04-e15f-4a72-9c37-fbee73cc3e4f"}, "149641f1-4736-426e-9231-5ace0c4a7a2c": {"doc_hash": "760176137aa58652d30d7c994e11507286849147f146223dc2686c4697e1eb42", "ref_doc_id": "740ea1e7-c6e3-4dc3-b0a8-74acb449fcb6"}, "d559304c-0b7d-45ef-81de-95212f0badb7": {"doc_hash": "f2ec5ed3a42da8ab7d0f17f51ef2058990f9846a1e0c69dafd1c42e06fd8456e", "ref_doc_id": "06947c9e-2cae-4f6d-aefc-1ef66d3a0eb7"}, "46d31f3c-72de-4089-9b7c-688d73538298": {"doc_hash": "ba08e9005febe3f7a6d593731f266c5c0991cba5d95b1920df36138554d8b432", "ref_doc_id": "92cb6b14-d919-4cf8-96f7-f5acad5259a6"}, "6d51a858-c4fb-4648-b901-a12b09065353": {"doc_hash": "f8d3902a2b969cf8dd131fc24608952d627566bc7a8ecc4b4a25e25eeb36c934", "ref_doc_id": "b0d49d83-b62b-4eb9-8426-4b6a52e20ed5"}, "10803f36-f244-42f2-b5d8-2c590b423d92": {"doc_hash": "8f8567b7af25cd65471e360f571a05f4c7be85f7d62b47f38758fbee4862e501", "ref_doc_id": "279ad5f6-65c2-46cf-9e10-c5993fb029ee"}, "d52ae396-fbba-4561-b987-c342c75203ea": {"doc_hash": "21d0b61c83e2a233fd378cdef48ee920e4664c8ea6e2aae2ff3094cd62a2fd04", "ref_doc_id": "d221d6eb-35bb-4caa-aa55-698fb545035a"}, "36110606-e3e8-417d-8b77-524aa8106672": {"doc_hash": "0af1b321cc0d8311935f6f9e9e93cac1b97eed5ab5a37dfab412519084bb8864", "ref_doc_id": "e4505c9e-afff-4481-8873-8f116b778807"}, "4c66a980-ed51-4237-aa08-94c041bb6997": {"doc_hash": "b1da688d480ea1020cec3243a9091c3d7eed009addf63cb0d4b0478bd07e2aae", "ref_doc_id": "298c7cea-d0d0-4511-bac3-5badcd7a0a24"}, "8dc80343-3cf9-4984-8c0b-2575cffcbcae": {"doc_hash": "701d098d0418d5ab469add30e5dd7010ed9a5b4b6fc9d6c10ef4efbfcc4afa87", "ref_doc_id": "ce8c739d-be87-469f-b042-9a27b78245d5"}, "359526ea-fc4b-4716-b7ec-3b6641eacbac": {"doc_hash": "3867531107eb1a2b32e242c5336d62fafa40a4f12ccc23c3b19d4946d9ac6d46", "ref_doc_id": "d2748500-3ce0-4676-98c1-f45f4a9c6bfc"}, "440a8149-6a2f-4d40-8581-9095d19126d8": {"doc_hash": "3d8c64272539b265431dc99fdcb1e79cce01340250cc39994d472910619423a3", "ref_doc_id": "7ea9b745-1be3-4603-b9d4-0eb8fba961e7"}, "845f22ce-5c5c-4322-9384-b95e41e706bc": {"doc_hash": "439ef4a47d7b07253ce1473f4d606b59b7f242c91c8462e9b971946844c8602c", "ref_doc_id": "77a47a5d-ab45-44c0-aa14-ace7a2a19f61"}, "9b6b4be3-55ee-4928-8a88-a69e07131764": {"doc_hash": "61d9ae5b5e5feabf89035872f2ba363c91655bb11d089dc48e7be0ea16694994", "ref_doc_id": "6e4c6930-f6fe-4949-9049-4b495f602afd"}, "64ec86eb-bfa7-4ccf-8024-416c911342ac": {"doc_hash": "fe8a7f020a01c7699286ecc20b9a19e9039ff4df8936d22daca2b5fdbeefc0f9", "ref_doc_id": "6aa998ac-fef7-4557-b4ee-04e0308daef2"}, "745dfb66-19ad-47a5-9ebf-0cfe4646c443": {"doc_hash": "e9516b0692fc6b77baacfda849a79c5c1ac27a2e35285a36dad5e982c11c9e3d", "ref_doc_id": "96db3495-0a4c-402a-8bb1-3a9db7de0477"}, "8ccbccb8-8b69-4c72-b680-8ecfcc971d82": {"doc_hash": "d53ff179d51aee7c1fa36a0c5f941bc651a361f74b5b91b0431fb2391ca79e76", "ref_doc_id": "ab33b7e3-1997-4b18-a024-d119d89e2537"}, "0f93b9f4-374d-450f-b40e-eefde8f23ff2": {"doc_hash": "6668859edec45a5b9a663b510d2ade4a69b83ef6d5525e27ea30c8c4b5a65d02", "ref_doc_id": "d829383f-25a7-461e-b803-078ee64d7668"}, "f1301a21-0d44-40ea-a7ac-7e50ca174ec3": {"doc_hash": "6a5a655de11582c3a56a081b0852bf2326704d9376be634d90f6571adbdae6f3", "ref_doc_id": "6320a82a-dd51-4d58-a25c-fa00227eec08"}, "35fcc5b4-d6bb-4aa8-9384-dc6485835c8d": {"doc_hash": "259e002d3109640e63a2f30b1369ab1c899dadb6c26cabb48c31738a499f5a3d", "ref_doc_id": "c0eb76d5-0a3c-444f-8000-a743edc835b6"}, "ca113084-8c42-4a50-a940-fe5c3195dd27": {"doc_hash": "86f33510591288e911793ee7a7079dc066eae75d16f9e0d3e9c40a2b6e1fefe4", "ref_doc_id": "25b628c3-67ee-42f9-9530-be6dd0d5cd72"}, "e00b3890-8bab-482a-aef8-bd4c2fe093f5": {"doc_hash": "20a8b2a81ae1132a9780bf46c35a8f5322e177c6185ea11c370fdf7f02fe6fc1", "ref_doc_id": "4c3df6ef-4c7d-43e8-9f4e-198a7cf16927"}, "2b9c01b2-bb80-4eab-9a14-0436f08dc7bd": {"doc_hash": "dd6fcdbc047570d0867150cb66350a5944c9d8a88ec5bfe844f671569679ad46", "ref_doc_id": "f44eb63f-a431-4353-92f3-bff387dc257f"}, "bb4f85f3-088c-4c39-8d03-7c8f0869f202": {"doc_hash": "f5e8344a9d860df4173d79bcce2acdcbceef96e13a9c1f8bda6178e6563995ff", "ref_doc_id": "766e8ebd-c590-4fe1-8e5d-5648b25dc01a"}, "fd9a5733-f7a2-4059-94d5-500c6c5819d2": {"doc_hash": "e2fdfe4e3d53c1475e162ea90ea2f5ae246ed3841d4f330f988e6fa2ddedf68e", "ref_doc_id": "7fbe58f6-8d17-40e9-8a41-01d4323a803a"}, "e20215cf-e2a3-470a-880e-1737ecbf75bc": {"doc_hash": "7840dfc8a12812e7cd3e45c3c2671b7c09c13f4ea04ab5b8c9af94ac0f82a0a8", "ref_doc_id": "a53700ce-a744-4d38-9abf-75d0a69e3bbd"}, "00735c34-2c69-4140-a2d6-07248c35a094": {"doc_hash": "0ebe8dd716b83f61aacc91b7e050e9d7827f50624c6698e8316b50adb0f69308", "ref_doc_id": "a53700ce-a744-4d38-9abf-75d0a69e3bbd"}, "f9379dbd-ec25-40f9-b247-039e2dcefa3d": {"doc_hash": "27ec387ebc8db74499c2902428ea8eb964d7da9f4e5902c84be71e994280387c", "ref_doc_id": "dcf35350-86dd-4402-993e-d6354cbb0e3b"}, "c3c6b60d-bfa8-48ee-a30e-492e10958ea3": {"doc_hash": "f6b11903af9c2fd78c7554a30bc3927ed269f1341e695ceff53d43022ef62429", "ref_doc_id": "98114f8d-a514-4ea3-a0b6-4065dccd1f47"}, "1be9a6d2-6dbf-4f36-a71b-687fc80fd101": {"doc_hash": "18a4666a182c0c2f773d095290ced4a7d55768f14544ae9e63011c3506322696", "ref_doc_id": "c47a3081-3a7b-47db-ad02-d7f0d49c673e"}, "1509df48-ab6d-4182-b7b8-b4fbabe4b810": {"doc_hash": "ea4ac110b840f122e7184f2d84113911f77ba2249166729057e072775f4b2d63", "ref_doc_id": "c47a3081-3a7b-47db-ad02-d7f0d49c673e"}, "d81dc526-60e8-4a93-9cc4-9024efc09160": {"doc_hash": "1044e7b50ebbdbdceaef9a0bf8508634693f22f71a622a68d76638cfe75af5ef", "ref_doc_id": "40c3afdd-ca38-4b69-b4f1-73886501d142"}, "f1775753-d014-4eb9-9674-c312075d6c8f": {"doc_hash": "c27bc235147f879360b444b9071a0a2db832f3b32e8c33a2525216b1bf684cf7", "ref_doc_id": "01c08c97-1709-459f-a91e-9aa533a40b4e"}, "0bf4c050-954a-40ea-af2b-a4e4b5b62e65": {"doc_hash": "7e7c792e248ba93027404f6962fa94b98b43d91e801eb292d60dc81973651216", "ref_doc_id": "f2b2c351-6e8a-456d-b4a9-4c0eec4ab980"}, "6c10267b-fa06-4c55-bbeb-702180432cad": {"doc_hash": "99cd38dd7b8cbbe4c874bc21d6313fe6c16c69c710be4ffbc2ec4bae35d75ece", "ref_doc_id": "7b177ef4-3739-439f-b812-4b6c813e628e"}, "51a78a97-47b6-46c2-bbf5-34dbf621746b": {"doc_hash": "226f058599497f811ef2e5c9d344da924b7c831984238f2440dd798266b2cb53", "ref_doc_id": "dc2c524e-45c8-4523-bb87-bb6754e5563b"}, "18abd514-ab82-4277-8246-8eeb7f7ccd15": {"doc_hash": "c6b8bad83b70025925fbb00d4cd0af26f3643de84bb63211cd49c92d905e8235", "ref_doc_id": "9d8dcd36-9690-4abc-b014-4c84059a3fb1"}, "3da4be38-a3cc-4674-992f-c8c0c01cedf4": {"doc_hash": "aa92978809abd1429b7463091b09197e53d669e9ff3a67058bd62fccea194dfc", "ref_doc_id": "48c8d820-b4be-4d3d-a72a-7b04834b25ca"}, "8adf1712-db17-44b3-b07c-b25888ef5954": {"doc_hash": "e93ade538bfa94e9ee5be97e4e4105a22c9b0df143e849e5a333f66c1eb1664a", "ref_doc_id": "2e7d6875-6726-49d6-8733-a8ca6a06898c"}, "b4754450-ea23-41c3-ac50-72df885b422d": {"doc_hash": "5a986cfe071d4afe3478137367194a907dd3d88848f7d5c970c8f7805fa97355", "ref_doc_id": "39859c0f-4ffd-4908-9276-365eafd7cde2"}, "33d6f08f-790d-4c3d-b9ff-61e02c2f49c6": {"doc_hash": "135b47dcf99a186b6c474581e09e6db56f795c0cd57107eab2e6cb1c0a0218df", "ref_doc_id": "79ce62ef-3b80-4a4f-89b1-c4e68d9b865b"}, "2189e3e2-082b-4a7f-9af7-3c39c5c4eff5": {"doc_hash": "82187c65a927b914f6177e4031509cb6403b5f8a15785f4d3635336fad0fc111", "ref_doc_id": "f9c91904-8056-432e-aa0b-78afd13e5666"}, "52887db8-9151-4633-b416-9fd5069e66d4": {"doc_hash": "b6261ab7f6f6b885e404dbb5f2b33a0a13349d9c2ad45d17b1234450b3ebd627", "ref_doc_id": "3ca65200-48e4-48c9-b523-f6f57e6ca9a0"}, "ecdd2daa-3958-4353-8de8-893bac524431": {"doc_hash": "e4d65b5cf7d99ebbc4ef24829ccf350df6be92a71241731ebeb86dac3b1cce59", "ref_doc_id": "fe9765f8-aa63-4457-b2ab-a7620c5657d6"}, "6d59bfac-1414-4117-9e8b-e46a259cc22c": {"doc_hash": "f94586a1dc34353d72e367ed42133fd4d0cbdd7be500829dd1736f0f9f4e4139", "ref_doc_id": "22261e96-ee27-495f-8185-2ff5179c50c5"}, "eeb0fcff-d7cf-4291-906a-98d23d99e013": {"doc_hash": "610b2ca467d6983db3c23ba291fb352989865516037e6f48573bb4e95fef66a3", "ref_doc_id": "1f012e1d-e5fa-48fe-a396-0a8575b93763"}, "19dd0a7a-5b45-47a0-9e3d-d369b9a6c24d": {"doc_hash": "2b0a651866e3326561b6dc785ddb7968cdb86a62a611d48372f32d40a9e3fe2d", "ref_doc_id": "157c292c-1125-493e-899b-3db2e3cb0598"}, "aec53e9f-a6b7-48e8-bdba-9e42189580cd": {"doc_hash": "c85a9d1cce045e7447ab5ba5b333c67814b61bcb0e4758dd8459cda4c2415503", "ref_doc_id": "b38f553d-7cbd-48f5-83d1-9eea563a41af"}, "2fcf14dd-a2e6-4455-a4d0-1208444a8ec2": {"doc_hash": "6f7c7d599bc73e79e4ca8f9e3b9b8f64e1144cbbe9ef09f4b653bcf9aa4ccf6a", "ref_doc_id": "61c3e6fa-bdc9-4dc5-8186-43c785244db2"}, "d85e4ebc-90f9-4d37-b7a8-37b864e302f9": {"doc_hash": "85100fc82f2710ab049a465437945cb9215a6b5dd7b4f89a2e0040fe1bbdbaae", "ref_doc_id": "6129b1ed-7eb1-4923-9e5d-b4ca6d2efffa"}, "f42268e7-f1f8-4aa8-8bb0-cadde78000f3": {"doc_hash": "57206bc9ced9c95a95761b99fa2762b9deeeadc907bea25fe6741c83a462aa91", "ref_doc_id": "7a77c3c8-2aef-44a8-9c8a-17a5163781c7"}, "4cc55906-aabd-4413-b8e1-694f0c822236": {"doc_hash": "0fffdfe80756de15313ae3e9a0e53322c3aab271cdac471f6f84d1dc00c35023", "ref_doc_id": "0b182325-1de6-4f0d-a3eb-b1b6fcfc14de"}, "70173a99-205a-4db2-9494-f54061892aef": {"doc_hash": "71844946bc906782e6eb65135a6393abdc87d6a1deab45495f2b1006aadfcbde", "ref_doc_id": "008cddd8-aff9-414e-9be2-b23751bcba6b"}, "731d6df7-71bc-4ca5-a62a-6d85a41d48fc": {"doc_hash": "917847b0a03cd69e42ebbcac97fc41f071590221805bc2d25791c1e3064f2003", "ref_doc_id": "2cac1317-9e55-462a-95b8-0599ef76007e"}, "2370d84c-304a-4901-8a94-220dd32ad52e": {"doc_hash": "156311cb1b3f7042a5b16764b66a3a2525bdf0ae550f429a15e5813f7433bef1", "ref_doc_id": "d3381f7e-7fc4-4e0c-acf4-0f52db886b2e"}, "2c061279-5d38-4011-bbd2-40d5691be6b2": {"doc_hash": "fef9375fe6b14f2b187be844c05bfe49efad278c1284d9506bf9ed9507a2fdb5", "ref_doc_id": "a45fa8ef-aea5-4767-b137-6761b78a2701"}, "0adb595c-88ff-4486-acb6-1e343c5ea243": {"doc_hash": "890f4c1f73d5c1f3ff4454d1a61a1b09292d4180be86f638bc121222ca8d935e", "ref_doc_id": "cacd7cdf-c893-4812-a438-00507ee55a89"}, "a4d106d1-aad2-4aa2-8d2e-99a175ef1728": {"doc_hash": "c4cce0cd65abb4d8add57c51ff0410b6a73df4d69e92352bdbadd02fe7c75b9d", "ref_doc_id": "c2c764e2-57db-4e01-b96c-928aaf1a5192"}, "6ee6b166-38af-405a-a9a9-bf8eb77102a0": {"doc_hash": "b457d864f26a94de250a3b92fc97118ee477f3f9445af84dda0d0ddaae0df525", "ref_doc_id": "d5850104-d5a1-41e0-b990-9ab47a319a35"}, "91e32d0f-4927-4140-aa03-56f248417b95": {"doc_hash": "3d2cecfa9f667a277a42d66ccd8470a0d57cf407c1febd5887b17bfea7738116", "ref_doc_id": "aa7c31ae-e1b1-41f2-aad1-ed3e9bfe672d"}, "6be66739-4dda-4c06-bb88-831f2ed6cf95": {"doc_hash": "093a9106e20ef1ff64ecfc7736c7487813105f10b5d35d493800d8584077e9d1", "ref_doc_id": "f2fa8fd5-6fce-46cd-bab7-6cf854651965"}, "23a5e0d2-53cb-4ff5-9fc9-7fae636bba0e": {"doc_hash": "241069e721d95f57d1c958c6e02f350f5eeaf2e97c5dde7c3c85e46be5d3a691", "ref_doc_id": "955739d3-0f70-48c7-8383-40f01e5d4a5b"}, "2c06e8bf-0f13-487e-a7fd-92c4caa1cc14": {"doc_hash": "8f35b4b64466c1146ca8c83865d24f7947333889ae923500ef4208a7efb7dcad", "ref_doc_id": "17f5606d-1e38-47c5-8b04-b2710958115c"}, "e8147c24-c399-4b79-b799-bc291b2a6e3d": {"doc_hash": "a6b8ce182a97fd4936e4f2f0eb78907b0905b0a416db01318929a01402e7c533", "ref_doc_id": "bcc91102-bcf6-416e-bd1a-2dc544d23d26"}, "6e495cf1-8f1f-4208-b17b-ab3fcc80c379": {"doc_hash": "d111910f3becf1fcdc5df6585ca599a428b0c02092ad0be09c827e710723349a", "ref_doc_id": "bcc91102-bcf6-416e-bd1a-2dc544d23d26"}, "bbd74dcc-a594-48a6-bd61-fc5d301c9083": {"doc_hash": "f4621c75538f771450835bb90a1742a5956ffb5f31eb8776da8a99db7c54e18a", "ref_doc_id": "11151cf0-395d-46fb-9f20-490eba8b9b0f"}, "3ddc2503-02cf-4c0c-b02d-6f7e77d7fac2": {"doc_hash": "be5e2a811d6174f53822819a91c59107fe12bc50c135b56c127b03d6322038a5", "ref_doc_id": "ea8e34fb-1616-4ecf-9f91-c3f80fe06867"}, "f616cf1f-90dd-4315-9bec-47a11fb6c572": {"doc_hash": "51d979cf27b640b56d1a949821c30f41e39045c3f284fcf13e4b29c0473eb2fa", "ref_doc_id": "76f93ae6-8028-4cee-9b6f-ff20fcf49d00"}, "457592c3-10c1-41e9-96ad-8662f6b3333b": {"doc_hash": "76cb69770c95dc5033c7534756442aeddb666e5126aeb5e737eae72076fb450c", "ref_doc_id": "d90af1c0-4e00-4557-b77a-4c516756f757"}, "d3555915-5c9e-4ec5-8933-ddd80dc88a9e": {"doc_hash": "61b4d151764cf183471e5fcab3011b7e49e491c607f004543e664546c86c49c7", "ref_doc_id": "d7b16935-8249-4168-9e87-3817dcc67a69"}, "4ac501ad-12c7-4f04-a9a7-13f23867a8d4": {"doc_hash": "1fd3ea88b975f9a024dac043624b3ee262bcb1ce94b8c743cf43a87cc1780282", "ref_doc_id": "1df9a4ef-ff0c-420a-be8f-a0fab197ca27"}, "04ceb7ba-a8f4-40a2-884c-470b40acdab9": {"doc_hash": "7f8a4c1d39d89428b09a0a8e912296870f2b947d20cd05e0725ff5dce1a37e89", "ref_doc_id": "74f3e3a6-05b7-4584-8a58-deedb43a5be2"}, "65d50cd9-1a6a-45e8-817c-489a811b5c90": {"doc_hash": "fcd06c54cad4f3d9072b37613e10cdab152b0cc5d23c94c3dd1cdab3bd5f88a6", "ref_doc_id": "e7bbfc7a-b432-40d7-b91e-cbcd2f90febb"}, "9c2e8bb0-0dd0-4ad0-99b7-97405050a56f": {"doc_hash": "90c05bf9196511ed2d13aad1dfb88c3952e4b4099d54c9d5e34ad140fe291cd8", "ref_doc_id": "41fe348a-fda1-4e46-af47-74ae1a64244c"}, "1dec04f3-76a5-4857-99f6-fd81205ccd6f": {"doc_hash": "39af5eb8bc86fc2599e03653d885ce5892c11cbe4f4ae2b9b257e245a470bc5c", "ref_doc_id": "85914d69-b362-42d3-b6a8-06ddd1453850"}, "a1a29f5a-8dca-47f3-b009-ca42b7424b0a": {"doc_hash": "437af56da4fb65bda723869a1de8cac228403a4f0fbcdb2bfb0f52b796c0127d", "ref_doc_id": "ae541519-9682-4506-9959-f77e5c01436a"}, "da5d37e0-1128-4a75-aadb-f571de105424": {"doc_hash": "b3774b295ff36f1cb8fa7805e61042b6f7e92531220439b9cc82ae890ab67f17", "ref_doc_id": "45991a6d-db10-4bdc-b928-92b4c1b387b1"}, "20fb55bb-489f-4b0b-8acf-a11379975154": {"doc_hash": "35b027ff141b7ceeaba5839fd70bdda92d3c28758def40f3d474e771decc72de", "ref_doc_id": "45991a6d-db10-4bdc-b928-92b4c1b387b1"}, "168b9fc0-0c35-467e-81f7-61132150dba2": {"doc_hash": "cec779dfc5ed918b3393a3c945215781ff75c539c08e1c11bb7916969f60a404", "ref_doc_id": "1cbc38f2-56ea-4916-945b-5171710b2022"}, "9481ac0b-bcc1-469a-a913-effce15d8a31": {"doc_hash": "c8cccb4d70c48809e3d50e271a1349bc3b4ed2121fdad9d4e1b358a99aa152fd", "ref_doc_id": "1e645bb1-4057-4de7-8dc9-6c04f579e578"}, "fdf38bf1-621a-44ed-8122-6566af13619d": {"doc_hash": "576f924289f45469d56c5d4a865cbadca54a9d698751d45a029e6a65d202bf40", "ref_doc_id": "1e645bb1-4057-4de7-8dc9-6c04f579e578"}, "7003c701-7b41-4d3a-8aa8-f210a52abeec": {"doc_hash": "4eb45cd112131176ed468e688edc8e5f2aedb7203e67553a3e11a0e33ae1ee6e", "ref_doc_id": "288cc7cd-18e8-41e1-9164-40b17a495ba2"}, "66357342-b047-4083-b831-94c9e245896e": {"doc_hash": "69c08be6eb5b643af559b4f9efc8408f3021885ab7fc8fffb0d7f6c71c931e1d", "ref_doc_id": "d515bd6d-13cb-404a-b996-6012bb17f06d"}, "918f18d4-2f38-4876-8178-f5f56c228b44": {"doc_hash": "7e3a9fd48330ddfcc9bfe338e071ae57455a9d361ecb1c78285339cec72b02c8", "ref_doc_id": "d515bd6d-13cb-404a-b996-6012bb17f06d"}, "e3049080-968d-4df7-81bf-64b5a4396197": {"doc_hash": "b9dec05a70d39483d9113bf7f14584e00f1b8f1c77c73af0e129186207383848", "ref_doc_id": "6aa55cba-379c-41d6-90b0-01439bee8468"}, "372046f5-48f3-4d15-accc-415d26092e35": {"doc_hash": "9f5d9da4f1c5d55c2458d2742f7d631ae2f811bee49fe185ae727dace8a43098", "ref_doc_id": "4e63e548-649c-4c05-acd4-2e61ea7f049c"}, "4a4f1ae8-80f3-4cde-9256-218a559e6d21": {"doc_hash": "ea29dbf380322a651bed2795a3c06b684eaeea0295a78a853a7f79d09d5ef95d", "ref_doc_id": "4e63e548-649c-4c05-acd4-2e61ea7f049c"}, "8496d85d-c61f-48ee-a22c-9ddd5a38d0cf": {"doc_hash": "4facba1af84484190c9e0f20aad0de980041307152aff31e26d2c79fba0005b7", "ref_doc_id": "d0d0ac07-6895-49ff-b546-3fa568811ddc"}, "7fc6d2a1-e321-4e3a-9d48-56cd8f77945d": {"doc_hash": "db3e6f6a5b8a73c52c798acde9c7eb3286f2ef165af6d652ab948979e104a040", "ref_doc_id": "d0d0ac07-6895-49ff-b546-3fa568811ddc"}, "a9bd3c95-f216-480b-b114-d43e343f33f2": {"doc_hash": "2e946acd9df06190727a53c3380bbe40c178f40cb101d20ddcb4b15482743fc8", "ref_doc_id": "d0d0ac07-6895-49ff-b546-3fa568811ddc"}, "bab7ecc8-5078-4cf4-b92e-4aa2298c0436": {"doc_hash": "154013706d5724048a6d86fee7251b01ec15d82cd8586bf91b37aaf96a2d2d12", "ref_doc_id": "d0d0ac07-6895-49ff-b546-3fa568811ddc"}, "26a462a8-52d7-4a3b-9f86-f5054d737f7d": {"doc_hash": "0dc590cd56db72065f9ea91346bfd063f8eef820c881bb74a3f09f003769671a", "ref_doc_id": "78872d06-71da-4d71-8de7-35e2578ec81f"}, "0af3d8a1-8b69-4d47-8017-50e6e49f9179": {"doc_hash": "4750536ba49a1fa689f19391fda66cd0bcbd667196218b4b23aadc43f4c6e31d", "ref_doc_id": "78872d06-71da-4d71-8de7-35e2578ec81f"}, "8b2427b9-75f1-4a13-a3ac-f471fc75436b": {"doc_hash": "e10028f981a045eb2297a421bf2fa051809ad299b48d42cd0fdc4ce0caab95ca", "ref_doc_id": "f3b49f9e-2822-4406-a716-d2d1618425b1"}, "b7a0c283-7fdd-4d0b-89bd-49b1f60b0b6c": {"doc_hash": "4e9743941c1c4c71c3ff076b2cdbfc8e64050c5871ee7be6cdb9e10cb9240310", "ref_doc_id": "f3b49f9e-2822-4406-a716-d2d1618425b1"}, "171f228c-c353-45aa-ab27-2bf576a49b91": {"doc_hash": "204db87b9b114a3e4d811691b0198a4a042266bb00ca26155a8c925d8ba63217", "ref_doc_id": "812560f0-129a-4f4f-a873-18407f47654d"}, "06f082e4-c6de-4192-ba72-c211acc799c3": {"doc_hash": "479cfd6b4feb70babc66a764a7882608eda4f68f402a27623b46abd70f30b9cd", "ref_doc_id": "812560f0-129a-4f4f-a873-18407f47654d"}, "4be7f25d-a903-4266-bb05-6b94877242ba": {"doc_hash": "8d0c9215727f0ac84eb56f1a020cd3d651e4725f7b0887ebde054bd6f448f3bb", "ref_doc_id": "7ae5bda9-3fc3-4f5e-9676-3e3a5b04ada3"}, "b8b98277-fd86-4384-b942-6a453fcd0e41": {"doc_hash": "7b353fa6a18fe3acf0ce2b9f4548d96a6ce70dbef0713089ea00c9df58fdd559", "ref_doc_id": "7ae5bda9-3fc3-4f5e-9676-3e3a5b04ada3"}, "49b0ae62-4ef7-49c3-83d2-8ed6e31719e5": {"doc_hash": "861e177920241575162cc7d902c461444f20fba15ebbd5b602d9c769a33525b9", "ref_doc_id": "2cacf691-112c-49b8-917c-4b95010d0871"}, "77b2e161-194b-4975-8bb8-f55d1e71101a": {"doc_hash": "b0f1be2d4a302a0f62f3df7e81ae4d76fcf7019c7776d6df1d2eb76bd8f4da2a", "ref_doc_id": "2cacf691-112c-49b8-917c-4b95010d0871"}, "827634ea-0225-4226-ae31-9d1a6190ef4b": {"doc_hash": "b35aa15e066250979db00e52f9f9141c990c0d2d982329d2f2d70fd753ad12e5", "ref_doc_id": "2cacf691-112c-49b8-917c-4b95010d0871"}, "f38875ec-8395-4ee5-86b3-0510203e20ce": {"doc_hash": "b724aeec0f2fc292a43d415333d5c611d342258b0c88a0d22037f3de6921716d", "ref_doc_id": "f122079e-0696-43e7-954d-3c9ab0837715"}, "2a10c853-f117-46c1-a02c-362a5f771083": {"doc_hash": "492f449d2ddf4bd155293535e560d63fb7d829eb8596fb5bbaf7a22df5b94e97", "ref_doc_id": "f122079e-0696-43e7-954d-3c9ab0837715"}, "38bb7438-28de-4116-82bb-858ae992f43d": {"doc_hash": "9323236964db72c205acd00a8b477e6dbe7ed0e28ff7589d14d99958cd504d37", "ref_doc_id": "f122079e-0696-43e7-954d-3c9ab0837715"}, "41b160e8-3c5d-4fd5-af1f-cedffa097bd1": {"doc_hash": "7d8bb68825ebd88d1666b5bd335e6b96a97b027bcec335176199610e0557fb98", "ref_doc_id": "f122079e-0696-43e7-954d-3c9ab0837715"}, "28951f6e-67ce-44c5-89d6-f5e16fdeeff2": {"doc_hash": "6ff6d10ca592576b3789465c49111a912da49a7a29e421f408f4e0b360e26df3", "ref_doc_id": "a0776b31-c3ac-4c62-b9e9-39ec3249ddb5"}, "31a64274-4d4e-4171-b86a-e2a192f7be00": {"doc_hash": "2dedb41e172344044b153bf94dca4d2edc03be447ae945d0e165c43d3befabc1", "ref_doc_id": "a0776b31-c3ac-4c62-b9e9-39ec3249ddb5"}, "e39dcace-5031-47a8-be55-c6220ca61f55": {"doc_hash": "c015a003271074d6406f03bfdfaf158b7668c5e9827b00d27fe591ec7574f733", "ref_doc_id": "a0776b31-c3ac-4c62-b9e9-39ec3249ddb5"}, "860f5b32-d621-4ae9-8170-87db736895d0": {"doc_hash": "f1471d0a5768b500aa84910c0e02974b328059576d43095eb285212c47f2f7a5", "ref_doc_id": "a0776b31-c3ac-4c62-b9e9-39ec3249ddb5"}, "72a2e743-a08d-4029-a42d-7cbef763d51e": {"doc_hash": "ac057a75e2b40a9d9f2ba77d3a42fb208d12209cb41a0840ce73f3980211f3c5", "ref_doc_id": "6d1b1009-9f31-49f1-b1ee-4f26dc589405"}, "1a787cf3-587f-43ab-a92f-04834985d2c8": {"doc_hash": "20ee85c1572cd4cb11d04f20c7730440b10e0bda309b5bf11b07604249fd10d6", "ref_doc_id": "6d1b1009-9f31-49f1-b1ee-4f26dc589405"}, "75a1ecaf-4e1e-439d-b1b8-324643db379f": {"doc_hash": "50c947eb2b5fe982f020ba2b9b57266f3df4db58d56c65a96f99fb8e88801f17", "ref_doc_id": "6d1b1009-9f31-49f1-b1ee-4f26dc589405"}, "a3639e37-007e-4971-bf01-3b76407111bf": {"doc_hash": "09b30f53b6117a99203c1d01fb2efe511be0fce2574126dbbbd7e17e3c96eb6f", "ref_doc_id": "6d1b1009-9f31-49f1-b1ee-4f26dc589405"}, "6895513c-ddd0-43ba-8ade-7aa34d346c88": {"doc_hash": "c5153e9034dbc4d45542463bc30c44515bba86fc35a884e21790b0917e68b083", "ref_doc_id": "042dc8e1-50a3-48aa-8025-e59c1e3d54f6"}}}